WO2020065613A1 - Monoacylglycerol lipase modulators - Google Patents

Monoacylglycerol lipase modulators Download PDF

Info

Publication number
WO2020065613A1
WO2020065613A1 PCT/IB2019/058240 IB2019058240W WO2020065613A1 WO 2020065613 A1 WO2020065613 A1 WO 2020065613A1 IB 2019058240 W IB2019058240 W IB 2019058240W WO 2020065613 A1 WO2020065613 A1 WO 2020065613A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridin
pyrazolo
methanone
dimethyl
dihydro
Prior art date
Application number
PCT/IB2019/058240
Other languages
French (fr)
Inventor
Michael K. Ameriks
Gang Chen
Chaofeng Huang
Brian Ngo LAFORTEZA
Suchitra Ravula
Emma Helen SOUTHGATE
Wei Zhang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020217012874A priority Critical patent/KR20210069080A/en
Priority to CA3111380A priority patent/CA3111380A1/en
Priority to EA202190886A priority patent/EA202190886A1/en
Priority to CN201980078969.1A priority patent/CN113164459A/en
Priority to MX2021003737A priority patent/MX2021003737A/en
Priority to PE2021000405A priority patent/PE20211773A1/en
Priority to JOP/2021/0058A priority patent/JOP20210058A1/en
Priority to AU2019350624A priority patent/AU2019350624A1/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority to CR20210153A priority patent/CR20210153A/en
Priority to EP19780427.1A priority patent/EP3856178A1/en
Priority to JP2021517202A priority patent/JP2022502424A/en
Priority to BR112021005896-6A priority patent/BR112021005896A2/en
Priority to SG11202102281VA priority patent/SG11202102281VA/en
Publication of WO2020065613A1 publication Critical patent/WO2020065613A1/en
Priority to PH12021550659A priority patent/PH12021550659A1/en
Priority to IL281812A priority patent/IL281812A/en
Priority to CONC2021/0003944A priority patent/CO2021003944A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention is related to certain fused chemical entities having MGL modulating properties, pharmaceutical compositions comprising these chemical entities, chemical processes for preparing these chemical entities and their use in the treatment of diseases, disorders or conditions associated with MGL receptor activity in subjects, in particular humans.
  • Cannabis Sativa and analogs of A 9 -tetrahydrocannabinol have been used since the days of folk medicine for therapeutic purposes.
  • the endocannabinoid system consists of two G-protein coupled receptors, cannabinoid receptor type 1 (CB1) (Matsuda et al, Nature, 1990, 346, 561-4) and cannabinoid receptor type 2 (CB2) (Munro et al, Nature, 1993, 365, 61-5).
  • CB1 receptor is one of the most abundant G-protein coupled receptor expressed in the brain (Herkenam et al., Proc. Nat. Acad. Sci., 1990, 87 (5), 1932-1936).
  • CB1 is also expressed peripherally in the liver, gastrointestinal tract, pancreas, adipose tissue and skeletal muscles (Di Marzo et al, Curr Opin Lipidol, 2007, 18, 129-140).
  • CB2 is predominantly expressed in immune cells such as monocytes (Pacher et al., Amer J Physiol, 2008, 294, Hl 133-H1134) and under certain conditions (inflammation) in the brain ((Benito et al.
  • N-arachidonoylethanolamine (AEA or anandamide) was found to be an endogenous ligand for cannabinoid receptors (Devane et al, Science, 1992, 258, 1946-9).
  • 2-arachidonoylglycerol (2- AG) was also identified as an additional endogenous ligand for the cannabinoid receptors (Mechoulam et al. , Biochem Pharmacol, 1995, 50, 83-90; Sugiura et al. , Biochem Biophys Res Commun, 1995, 215, 89-97).
  • Concentrations of 2-AG were reported to be at least 100 times higher than these of anandamide in the rat brain (Buczynski and Parsons, Brit J Pharmacol, 2010, 160 (3), 423-42). Therefore 2-AG may play more essential physiological roles than anandamide in the brain endocannabinoid system (Sugiura et al.
  • endocannabinoid 2- AG is a full agonist for CB1 and CB2 receptors, while anandamide is a partial agonist for both receptors (Suguira et al, Prog Lipid Res, 2006, 45(5):405-46).
  • endocannabinoids signal through a retrograde mechanism. They are synthesized on demand in postsynaptic neurons and then rapidly degraded following binding to presynaptic cannabinoid receptors (Ahn et ah, Chem Rev. 2008, 108(5): 1687-707).
  • Monoacylglycerol lipase (MGLL, also known as MAG lipase and MGL) is the serine hydrolase responsible for the degradation of 2- AG into arachidonic acid and glycerol in the central nervous system (Mechoulam et al., Biochem Pharmacol, 1995, 50, 83-90; Sugiura et al., Biochem Biophys Res Commun, 1995, 215, 89-97; Long et al, Nat Chem Biol.
  • MGL is located in presynaptic neurons (Straiker et al, Mol Pharmacol. , 2009, Dec;76(6): 1220-7) and astrocytes (Walter et al, J Neurosci., 2004, Sep 15;24(37): 8068-74) within regions associated with high CB1 receptor density.
  • genetic ablation of MGL expression produces 10-fold increase in brain 2- AG levels without affecting anandamide concentration (Schlosburg et al, Nat Neurosci., 2010, Sep;l3(9): l l l3-9).
  • MGL modulation offers an interesting strategy for potentiating the cannabinoid system.
  • the primary advantage of this approach is that only brain regions where
  • endocannabinoids are actively produced will be modulated, potentially minimizing the side effects associated with exogenous CB1 agonists.
  • Pharmacological inactivation of MGL by covalent inhibitors in animals increase 2- AG content in brain and peripheral tissues and has been found to produce antinociceptive, anxiolytic and anti-inflammatory effects that are dependent on CB1 and/or CB2 receptors (Long et al, Nat Chem Biol., 2009, Jan, 5(l):37-44; Ghosh et al, Life Sci., 2013, Mar 19, 92(8-9):498-505; Bedse et al, Biol Psychiatry., 2017, Oct 1, 82(7):488-499; Bernal-Chico et al, Glia., 2015, Jan, 63( 1 ): 163-76 _Patel et al.
  • MGL modulation including MGL inhibition also promotes CB1 /2-independent effects on neuroinflammation (Nomura et al, Science., 2011, Nov 11;334(6057):809-13).
  • MGL modulation leads to reduction in proinflammatory prostanoid signaling in animal models of traumatic brain injury (Katz et al, J Neurotrauma., 2015, Mar l;32(5):297-306; Zhang et ah, J Cereb Blood Flow Metab., 2015, Mar 3l;35(4):706), neurodegeneration including Alzheimer’s disease ⁇ Piro et ah, Cell Rep., 2012, Jun 28, 1(6):617-23; Wenzel et al, Life Sci., 2018, Aug 15, 207:314-322; Chen et al, Cell Rep.,
  • MGL modulation including MGL inhibition offers a compelling therapeutic approach for the treatment of a vast array of complex diseases.
  • MGL modulation, including MGL inhibition in animals does not produces the full spectrum of neurobehavioral effects observed with A 9 -tetrahydrocannabinol and other CB1 agonists (Tuo et al, J Med Chem., 2017, Jan 12, 60(1), 4-46; Mulvihill et al, Life Sci., 2013, Mar 19, 92(8-9), 492-7).
  • Endocannabinoid hypoactivity is a risk factor for the treatment of depression, anxiety and post-traumatic stress disorders. Millennia of human use of cannabis sativa, and a brief period in which humans were treated with the endocannabinoid antagonist, rimonabant, provide support for that hypothesis.
  • 2-AG levels are decreased in individuals with major depression (Hill et al, Pharmacopsychiatry., 2008, Mar; 41(2): 48-53; Hill et al, Psychoneuroendocrinology., 2009, Sep; 34(8): 1257-1262.). Low circulating 2-AG levels predict rates of depression (Hauer et al, Rev Neurosci., 2012, 23(5-6):68l-90).
  • Cannabinoid receptor agonists are clinically used to treat pain, spasticity, emesis and anorexia (Di Marzo, et ah, Annu Rev Med., 2006, 57:553-74; Ligresti et al, Curr Opin Chem Biol., 2009, Jun;l3(3):32l-3 l). Therefore, MGL modulators, including MGL inhibitors are also potentially useful for these indications.
  • MGL exerts CB1 -dependant antinociceptive effects in animal models of noxious chemical, inflammatory, thermal and neuropathic pain (Guindon et al, Br J Pharmacol., 2011, Aug;l63(7): 1464-78; Kinsey et al., J Pharmacol Exp Ther., 2009, Sep;330(3):902-l0; Long et al, Nat Chem Biol., 2009, Jan;5(l):37-44).
  • MGL blockade reduces mechanical and acetone induced cold allodynia in mice subjected to chronic constriction injury of the sciatic nerve (Kinsey et al, J Pharmacol Exp Ther., 2009, Sep;330(3):902-l0).
  • MGL inhibition produces opiate- sparing events with diminished tolerance, constipation, and cannabimimetic side effects (Wilkerson et al, J Pharmacol Exp Ther., 2016, Apr;357(l): l45- 56).
  • MGL blockade is protective in model of inflammatory bowel disease (Alhouayek et al, FASEB J., 2011, Aug;25(8):27l 1-21).
  • MGL inhibition also reverse Paclitaxel-induced nociceptive behavior and proinflammatory markers in a mouse model of chemotherapy-induced neuropathy (Curry et al, J Pharmacol Exp Ther., 2018, Jul;366(l): 169-18).
  • MGL inhibitors are also potentially useful for the treatment of chronic inflammatory condition of the urinary bladder like interstitial cystitis (Chinnadurai et al, Med Hypotheses 2019, Oct; 131 : 109321).
  • MGL is upregulated in aggressive human cancer cells and primary tumors where it has a unique role of providing lipolytic sources of free fatty acids for synthesis of oncogenic signaling lipids that promote cancer aggressiveness.
  • MGL in cancer plays a distinct role in modulating the fatty acid precursor pools for synthesis of protumorigenic signaling lipids in malignant human cancer cells.
  • MGL blockade shows anti-emetic and anti-nausea effects in a lithium chloride model of vomiting in shrews (Sticht el al, Br J Pharmacol., 2012, Apr, l65(8):2425-35).
  • MGL modulators including MGL inhibitors may have utility in modulating drug dependence of opiates.
  • MGL blockade reduce the intensity of naloxone-precipitated morphine withdrawal symptoms in mice.
  • MGL blockade also attenuated spontaneous withdrawal signs in morphine- dependent mice (Ramesh et al, J Pharmacol Exp Ther., 2011, Oct, 339(l): l73-85).
  • MGL modulators are also potentially useful for the treatment of eye conditions, including but not limited to, glaucoma and disease states arising from elevated intraocular pressure (Miller et al., Pharmaceuticals, 2018, 11, 50).
  • Embodiments of the present invention relate to chemical entities, pharmaceutical compositions containing them, methods of making and purifying them, and methods for using them the treatment of diseases, disorders, and conditions associated with the MGL modulation.
  • An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition associated with the MGL modulation using at least one chemical entity of the invention.
  • Embodiments of this invention are compounds of Formula (I),
  • R 2 is selected from the group consisting of: (a)
  • X is selected from the group consisting of: O, S, NH, and NCH3; R a is H or halo;
  • R b is selected from the group consisting of: H, halo and CH3;
  • R c is H or CF3
  • R d is H or CH3
  • R 3 is selected from the group consisting of:
  • R 4 is selected from the group consisting of: Ci- 4 alkyl
  • R 3 is cyclopropyl
  • Embodiments of this invention are also compounds of Formula (II),
  • R 1 is Ci- 4 alkyl
  • R 2a is selected from the group consisting of:
  • R 3a is selected from the group consisting of:
  • Phenyl or phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, Ci- 4 alkyl, Ci- 4 haloalkyl, OCi- 4 alkyl, and
  • R f is selected from the group consisting of: H, halo, Ci- 4 alkyl, Ci- 4 haloalkyl, OCi- 4 alkyl, and OCi- 4 haloalkyl;
  • R g is selected from the group consisting of: OCi- 4 alkyl, OCi- 4 haloalkyl, CH2OCH3, CH2OH,
  • R h is selected from the group consisting of: H, Ci- 4 alkyl, Ci- 4 haloalkyl, and C3-6cycloalkyl;
  • R 1 is selected from the group consisting of: H, halo, Ci- 4 alkyl, Ci- 4 haloalkyl, OCi- 4 alkyl,
  • R 1 is selected from the group consisting of: H, halo, Ci- 4 alkyl and Ci- 4 haloalkyl;
  • R k is selected from the group consisting of: H, halo, OH, Ci- 4 alkyl, Ci- 4 haloalkyl, OCi- 4 alkyl, and OCi- 4 haloalkyl;
  • R m is H or Ci- 4 alkyl
  • R n is selected from the group consisting of: H, halo and OCi- 4 alkyl;
  • R° is selected from the group consisting of: H, Ci- 4 alkyl, and Ci- 4 haloalkyl;
  • R p is selected from the group consisting of: H, Ci- 4 alkyl, and OCi- 4 alkyl;
  • Y is CH or N
  • R 4a is selected from the group consisting of: CH3, CF2H, CF3, C3-6cycloalkyl, and phenyl;
  • alkyl refers to a straight- or branched-chain alkyl group having from 1 to 8 carbon atoms in the chain.
  • alkyl groups include methyl (Me), ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples.
  • Ci-C 4 alkyl refers to straight- or branched-chain alkyl group having from 1 to 4 carbon atoms in the chain.
  • cycloalkyl refers to a saturated or partially saturated, monocyclic, fused polycyclic, or spiro polycyclic carbocycle having from 3 to 12 ring atoms per carbocycle.
  • cycloalkyl groups include the following entities, in the form of properly bonded moieties:
  • the term“halogen” or“halo” represents chlorine, fluorine, bromine, or iodine.
  • haloalkyl refers to a straight- or branched-chain alkyl group having from 1 to 6 carbon atoms in the chain optionally substituting hydrogens with halogens.
  • C1-C4 haloalkyl refers to a straight- or branched-chain alkyl group having from 1 to 4 carbon atoms in the chain, optionally substituting hydrogens with halogens.
  • haloalkyl groups include trifluoromethyl (CF3), difluoromethyl (CF2H), monofluoromethyl (CH2F), pentafluoroethyl (CF2CF3), tetrafluoroethyl (CHFCF3), monofluoroethyl (CH2CH2F), trifluoroethyl (CH2CF3), tetrafluorotrifluoromethylethyl (CF(CF3)2), and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples.
  • aryl refers to a monocyclic, aromatic carbocycle (ring structure having ring atoms that are all carbon) having 6 atoms per ring (Carbon atoms in the aryl groups are sp2 hybridized.)
  • phenyl represents the following moiety:
  • heteroaryl refers to an aromatic monocyclic or multicyclic ring system comprising 5 to 14 ring atoms, wherein from 1 to 4 of the ring atoms is
  • a heteroaryl group has 5 to 10 ring atoms.
  • a heteroaryl group is monocyclic and has 5 or 6 ring atoms.
  • a heteroaryl group is monocyclic and has 5 or 6 ring atoms and at least one nitrogen ring atom.
  • a heteroaryl group is joined via a ring carbon atom and any nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide.
  • heteroaryl also encompasses a heteroaryl group, as defined above, which has been fused to a benzene ring.
  • the term "5-membered heteroaryl” as used herein, refers to a heteroaryl group, as defined above, which has 5 ring atoms.
  • 6-membered heteroaryl refers to a heteroaryl group, as defined above, which has 6 ring atoms.
  • Non-limiting examples of illustrative 6-membered heteroaryls include:
  • 5,6-fused bicyclic heteroaryl or 6,5-fused bicyclic heteroaryl refers to a heteroaryl group, as defined above, which has 9 ring atoms.
  • Non-limiting examples of illustrative 5,6-fused bicyclic heteroaryl or 6,5-fused bicyclic heteroaryl include:
  • 6,6-fused bicyclic heteroaryl refers to a heteroaryl group, as defined above, which has 9 ring atoms.
  • Non-limiting examples of illustrative 6,6-fused bicyclic heteroaryl include:
  • heterocycloalkyl refers to a ring system which is non aromatic, 1 to 4 of the ring atoms is independently O, N or S and the remaining ring atoms are carbon atoms, which may optionally be fused to another ring (aromatic or heteroaromatic).
  • Non- limiting examples of illustrative 6,6-fused bicyclic heteroaryl include:
  • substituted means that the specified group or moiety bears one or more substituents.
  • unsubstituted means that the specified group bears no substituents.
  • optionally substituted means that the specified group is unsubstituted or substituted by one or more substituents. Where the term“substituted” is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system.
  • variable point of attachment means that a group is allowed to be attached at more than one alternative position in a structure.
  • the attachment will always replace a hydrogen atom on one of the ring atoms.
  • all permutations of bonding are represented by the single diagram, as shown in the illustrations below.
  • substituted means that the specified group or moiety bears one or more substituents.
  • unsubstituted means that the specified group bears no substituents.
  • optionally substituted means that the specified group is unsubstituted or substituted by one or more substituents. Where the term“substituted” is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system.
  • any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms.
  • compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers and stereoisomers of the compounds of the general formula, and mixtures thereof, are considered within the scope of such formula.
  • the compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual ( R )- or (A)-stereoisomers or as mixtures thereof.
  • any formula given herein is intended to represent a racemate, one or more of its enantiomeric forms, one or more of its diastereomeric forms, and mixtures thereof.
  • any formula given herein is intended to refer also to any one of hydrates, solvates, polymorphs and of such compounds, and mixtures thereof, even if such forms are not listed explicitly.
  • the term“R” at a stereocenter designates that the stereocenter is purely of the R- configuration as defined in the art; likewise, the term“S” means that the stereocenter is purely of the L-configuration.
  • the term“RS” refers to a stereocenter that exists as a mixture of the R- and L-configurations.
  • Compounds containing one stereocenter drawn without a stereo bond designation are a mixture of 2 enantiomers.
  • Compounds containing 2 stereocenters both drawn without stereo bond designations are a mixture of 4 diaster eomers.
  • Compounds with 2 stereocenters both labeled“RS” and drawn with stereo bond designations are a 2-component mixture with relative stereochemistry as drawn.
  • Unlabeled stereocenters drawn without stereo bond designations are a mixture of the R- and L-configurations. For unlabeled stereocenters drawn with stereo bond designations, the absolute stereochemistry is as depicted.
  • references to a compound herein stands for a reference to any one of: (a) the actually recited form of such compound, and (b) any of the forms of such compound in the medium in which the compound is being considered when named.
  • reference herein to a compound such as R-COOH encompasses reference to any one of, for example, R-COOH(s), R- COOH(sol), and R-COO-(sol).
  • R-COOH(s) refers to the solid compound, as it could be for example in a tablet or some other solid pharmaceutical composition or preparation
  • R-COOH(sol) refers to the undissociated form of the compound in a solvent
  • R-COO-(sol) refers to the dissociated form of the compound in a solvent, such as the dissociated form of the compound in an aqueous environment, whether such dissociated form derives from R-COOH, from a salt thereof, or from any other entity that yields R-COO- upon dissociation in the medium being considered.
  • an expression such as“exposing an entity to compound of formula R-COOH” refers to the exposure of such entity to the form, or forms, of the compound R-COOH that exists, or exist, in the medium in which such exposure takes place.
  • an expression such as“reacting an entity with a compound of formula R-COOH” refers to the reacting of (a) such entity in the chemically relevant form, or forms, of such entity that exists, or exist, in the medium in which such reacting takes place, with (b) the chemically relevant form, or forms, of the compound R-COOH that exists, or exist, in the medium in which such reacting takes place.
  • any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
  • Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number in an enriched form.
  • isotopes that can be incorporated into compounds of the invention in a form that exceeds natural abundances include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2 H (or chemical symbol D), 3 ⁇ 4 (or chemical symbol T), n C, 13 C, 14 C, 15 N, 18 0, 17 0, 31 P, 32 P, 35 S, 18 F, 36 Cl, and 125 I, respectively.
  • Such isotopically labelled compounds are useful in metabolic studies (preferably with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques [such as positron emission tomography (PET) or single photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
  • PET positron emission tomography
  • SPECT single photon emission computed tomography
  • an 18 F or n C labeled compound may be particularly preferred for PET or SPECT studies.
  • substitution with heavier isotopes such as deuterium (i.e., 2 H, or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage
  • Isotopically labeled compounds of this invention can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non- isotopically labeled reagent.
  • Cn-m alkyl refers to an aliphatic chain, whether straight or branched, with a total number N of carbon members in the chain that satisfies n ⁇ N ⁇ m, with m > n.
  • each of groups Q and R can be H or F
  • the choice of H or F for Q is made independently of the choice of H or F for R, so the choice of assignment for Q does not determine or condition the choice of assignment for R, or vice-versa, unless it is expressly indicated otherwise.
  • Illustrative claim recitation in this regard would read as“each of Q and R is independently H or F”, or“each of Q and R is independently selected from the group consisting of H and F”.
  • a zwitterionic compound would be encompassed herein by referring to a compound that is known to form a zwitterion, even if it is not explicitly named in its zwitterionic form.
  • Terms such as zwitterion, zwitterions, and their synonyms zwitterionic compound(s) are standard IUP AC-endorsed names that are well known and part of standard sets of defined scientific names. In this regard, the name zwitterion is assigned the name
  • a zwitterion or zwitterionic compound is a neutral compound that has formal unit charges of opposite sign. Sometimes these compounds are referred to by the term“inner salts”. Other sources refer to these compounds as“dipolar ions”, although the latter term is regarded by still other sources as a misnomer.
  • aminoethanoic acid the amino acid glycine
  • H2NCH2COOH the amino acid glycine
  • Zwitterions, zwitterionic compounds, inner salts and dipolar ions in the known and well- established meanings of these terms are within the scope of this invention, as would in any case be so appreciated by those of ordinary skill in the art. Because there is no need to name each and every embodiment that would be recognized by those of ordinary skill in the art, no structures of the zwitterionic compounds that are associated with the compounds of this invention are given explicitly herein. They are, however, part of the embodiments of this invention. No further examples in this regard are provided herein because the interactions and transformations in a given medium that lead to the various forms of a given compound are known by any one of ordinary skill in the art.
  • embodiments of this invention comprise the various groupings that can be made from the listed assignments, taken independently, and equivalents thereof.
  • substituent Sexampie is one of S i, S2, and S3
  • this listing refers to embodiments of this invention for which Sexampie is S i; Sexampie is S2; Sexampie IS S3 ; Sexampie IS One of Si and S 2 ; Sexampie IS One of Si and S3; Sexampie IS One of S2 and S3; Sexampie is one of S i, S2 and S3; and Sexampie is any equivalent of each one of these choices.
  • embodiments that have two carbon members (C2), and embodiments that have three carbon members (C3) are possible.
  • a “pharmaceutically acceptable salt” is intended to mean a salt of an acid or base of a compound represented by Formula (I) (as well as compounds of Formula (II)) that is non- toxic, biologically tolerable, or otherwise biologically suitable for administration to the subject. See, generally, S.M. Berge, et al,“Pharmaceutical Salts”, J. Pharm. Sci., 1977, 66: 1-19, and
  • Preferred pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response.
  • a compound of Formula (I) (as well as compounds of Formula (II)) may possess a sufficiently acidic group, a sufficiently basic group, or both types of functional groups, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
  • Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates,
  • metaphosphates pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-l,4-di oates, hexyne-l,6- dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, g-hydroxybutyrates, glycolates, tartrates, methane-sulfonates, propanesulfonates
  • Compounds of Formula (I) may contain at least one nitrogen of basic character, so desired pharmaceutically acceptable salts may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid,
  • an inorganic acid such as hydrochlor
  • Compounds of Formula (I) may contain a carboxylic acid moiety, a desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases such as those given as examples herein, and any other base and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology.
  • an inorganic or organic base such as an amine (primary, secondary or tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases such as those given as examples herein, and any other base and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology.
  • suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonia, carbonates, bicarbonates, primary, secondary, and tertiary amines, and cyclic amines, such as benzylamines, pyrrolidines, piperidine, morpholine, piperazine, /V-methyl-glucamine and tromethamine and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
  • amino acids such as glycine and arginine
  • ammonia carbonates, bicarbonates, primary, secondary, and tertiary amines
  • cyclic amines such as benzylamines, pyrrolidines, piperidine, morpholine, piperazine, /V-methyl-glucamine and tromethamine
  • inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum,
  • the compounds of the invention including their pharmaceutically acceptable salts, whether alone or in combination, (collectively,“active agent” or “active agents”) of the present invention are useful as MGL-modulators in the methods of the invention.
  • Such methods for modulating MGL comprise the use of a therapeutically effective amount of at least one chemical entity of the invention.
  • the MGL modulator is an inhibitor and is used in a subject diagnosed with or suffering from a disease, disorder, or condition associated with MGL receptor activity, such as those described herein. Symptoms or disease states are intended to be included within the scope of "disease, disorders or conditions.”
  • the invention relates to methods of using the active agents described herein to treat subjects diagnosed with or suffering from a disease, disorder, or condition associated with the MGL receptor activity.
  • treat or “treating” as used herein is intended to refer to administration of an active agent or composition of the invention to a subject for the purpose of effecting a therapeutic or prophylactic benefit through modulation of MGL receptor activity. Treating includes reversing, ameliorating, alleviating, inhibiting the progress of, lessening the severity of, or preventing a disease, disorder, or condition, or one or more symptoms of such disease, disorder or condition associated with the MGL modulation.
  • subject refers to a mammalian patient in need of such treatment, such as a human.
  • composition refers to a product that includes the specified ingredients in therapeutically effective amounts, as well as any product that results, directly, or indirectly, from combinations of the specified ingredients in the specified amounts.
  • MGL inhibitor is intended to encompass a compound that interacts with MGL to substantially reduce or eliminate its catalytic activity, thereby increasing the concentrations of its substrate(s).
  • MGL-modulated is used to refer to the condition of being affected by the modulation of the MGL enzyme including the condition of being affected by the inhibition of the MGL enzyme.
  • the disclosure is directed to methods for treating, ameliorating and / or preventing diseases, conditions, or disorders associated with pain (including inflammatory pain), and also psychiatric disorders, neurological disorders, cancers and eye conditions by the administration of therapeutically effective amounts of MGL modulators to subjects in need thereof.
  • moduleators include both inhibitors and activators, where “inhibitors” refer to compounds that decrease, prevent, inactivate, desensitize, or down-regulate the MGL expression or activity, and“activators” are compounds that increase, activate, facilitate, sensitize, or up- regulate MGL expression or activity.
  • the term“affect” or“affected” when referring to a disease, condition or disorder that is affected by inhibition of MGL) includes a reduction in the frequency and / or severity of one or more symptoms or manifestations of said disease, condition or disorder; and / or include the prevention of the development of one or more symptoms or manifestations of said disease, condition or disorder or the development of the disease, condition or disorder.
  • a therapeutically effective amount of at least one active agent according to the invention is administered to a subject suffering from or diagnosed as having such a disease, disorder, or condition.
  • a "therapeutically effective amount” means an amount or dose sufficient to generally bring about the desired therapeutic or prophylactic benefit in subjects in need of such treatment for the designated disease, disorder, or condition.
  • Effective amounts or doses of the active agents of the present invention may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician.
  • routine factors e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician.
  • routine factors e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician.
  • the dose may be adjusted for preventive or maintenance treatment.
  • the dosage or the frequency of administration, or both may be reduced as a function of the symptoms, to a level at which the desired therapeutic or prophylactic effect is maintained.
  • treatment may cease.
  • Subjects may, however, require intermittent treatment on a long-term basis upon any recurrence of symptoms.
  • the compounds of the invention are envisaged for use alone, in combination with one or more of other compounds of this invention, or in combination with additional active ingredients in the treatment of the conditions discussed below.
  • the additional active ingredients may be co-administered separately with at least one compound of the invention, with active agents of the invention or included with such an agent in a pharmaceutical composition according to the invention.
  • additional active ingredients are those that are known or discovered to be effective in the treatment of conditions, disorders, or diseases associated with the MGF modulation, such as another MGF inhibitor or a compound active against another target associated with the particular condition, disorder, or disease.
  • the combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of an agent according to the invention), decrease one or more side effects, or decrease the required dose of the active agent according to the invention.
  • an“effective amount” means an amount sufficient to affect MGL modulation.
  • a pharmaceutical composition of the invention comprises a therapeutically effective amount of at least one active agent in accordance with the invention.
  • compositions commonly used in pharmaceutical compositions are substances that are non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith.
  • excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
  • Delivery forms of the pharmaceutical compositions containing one or more dosage units of the active agents may be prepared using pharmaceutically acceptable excipients and compounding techniques known or that become available to those of ordinary skill in the art.
  • compositions may be administered in the inventive methods by a suitable route of delivery, e.g., oral, parenteral, rectal, topical, or ocular routes, or by inhalation.
  • a suitable route of delivery e.g., oral, parenteral, rectal, topical, or ocular routes, or by inhalation.
  • the preparation may be in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, powders for reconstitution, liquid preparations, or suppositories.
  • the compositions may be formulated for any one of a plurality of administration routes, such as intravenous infusion, topical administration, or oral administration.
  • the compositions may be formulated for oral administration.
  • the active agents of the invention can be provided in the form of tablets or capsules, or as a solution, emulsion, or suspension.
  • the active agents may be formulated to yield a dosage of, e.g., for a 70-kg human, an illustrative range for a suitable dosage amount is from about 1 to 1000 mg/day in single or multiple dosage units.
  • Oral tablets may include the active ingredient(s) mixed with compatible pharmaceutically acceptable excipients such as diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents.
  • suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like.
  • Exemplary liquid oral excipients include ethanol, glycerol, water, and the like.
  • Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are exemplary disintegrating agents.
  • Binding agents may include starch and gelatin.
  • the lubricating agent if present, may be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.
  • Capsules for oral administration include hard and soft gelatin or (hydroxypropyl)methyl cellulose capsules.
  • active ingredient(s) may be mixed with a solid, semi-solid, or liquid diluent.
  • Liquids for oral administration may be in the form of suspensions, solutions, emulsions or syrups or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose,
  • non-aqueous vehicles e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.
  • compositions may be formulated for rectal administration as a suppository, enema or foam.
  • parenteral use including intravenous, intramuscular, intraperitoneal, or subcutaneous routes, the agents of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil.
  • Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride.
  • Such forms may be presented in unit-dose form such as ampules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre- concentrate that can be used to prepare an injectable formulation.
  • Illustrative infusion doses range from about 1 to 1000 mg/kg/minute of agent admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.
  • the agents may be mixed with a pharmaceutical carrier at a concentration of about 0.01% to about 20% of drug to vehicle, preferably 0.1% to 10%.
  • a pharmaceutical carrier for topical administration, may be mixed with a pharmaceutical carrier at a concentration of about 0.01% to about 20% of drug to vehicle, preferably 0.1% to 10%.
  • Another mode of administering the agents of the invention may utilize a patch formulation to affect transdermal delivery.
  • Active agents may alternatively be administered in methods of this invention by inhalation, via the nasal or oral routes, e.g., in a spray formulation also containing a suitable carrier.
  • the invention is directed to a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition associated with MGL modulation, comprising administering to the subject in need of such treatment a therapeutically effective amount of the active agent.
  • the compounds of Formula (I) and Formula (II) are useful in methods for treating, ameliorating and / or preventing a disease, a condition or a disorder that is affected by the inhibition of MGL.
  • Such methods comprise administering to a subject, including an animal, a mammal, and a human in need of such treatment, amelioration and / or prevention, a
  • the compounds of Formula (I), Formula (II), or pharmaceutically acceptable salts, isotopes, N-oxides, solvates and stereoisomers thereof are useful for treating, ameliorating and / or preventing diseases, conditions, or disorders causing pain, psychiatric disorders, neurological disorders, cancers and eyes conditions.
  • the compounds of Formula (I), Formula (II), or pharmaceutically acceptable salts, isotopes, N-oxides, solvates and stereoisomers thereof are useful for treating, ameliorating and / or preventing inflammatory pain, major depressive disorder, treatment resistant depression, anxious depression or bipolar disorder by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I), Formula (II), or a pharmaceutically acceptable salt, isotope, N-oxide, solvate or stereoisomer thereof as herein defined.
  • Pain Examples of inflammatory pain include, but are not limited to, pain due to a disease, condition, disorder, or a pain state including inflammatory bowel disease, visceral pain, migraine, post-operative pain, osteoarthritis, rheumatoid arthritis, back pain, lower back pain, joint pain, abdominal pain, chest pain, labor, musculoskeletal diseases, skin diseases, toothache, pyresis, burn, sunburn, snake bite, venomous snake bite, spider bite, insect sting, neurogenic bladder, interstitial cystitis, urinary tract infection, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, pharyngitis, mucositis, enteritis, irritable bowel syndrome, cholecystitis, pancreatitis, postmastectomy pain syndrome, menstrual pain, endometriosis, pain due to physical trauma, headache, sinus headache, tension headache, or arachnoiditis.
  • One type of inflammatory pain is inflammatory hyperalgesia / hypersensitivity.
  • inflammatory hyperalgesia examples include a disease, condition, disorder, or pain state including inflammation, osteoarthritis, rheumatoid arthritis, back pain, joint pain, abdominal pain, musculoskeletal diseases, skin diseases, post-operative pain, headaches, toothache, burn, sunburn, insect sting, neurogenic bladder, urinary incontinence, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact
  • a disease, condition, disorder, or pain state including inflammation, osteoarthritis, rheumatoid arthritis, back pain, joint pain, abdominal pain, musculoskeletal diseases, skin diseases, post-operative pain, headaches, toothache, burn, sunburn, insect sting, neurogenic bladder, urinary incontinence, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact
  • dermatitis/hypersensitivity and/or dermal allergy itch, eczema, pharyngitis, enteritis, irritable bowel syndrome, inflammatory bowel diseases including Crohn's Disease, ulcerative colitis, benign prostatic hypertrophy, and nasal hypersensitivity.
  • the present invention is directed to a method for treating, ameliorating and / or preventing inflammatory visceral hyperalgesia in which an enhanced visceral irritability exists, comprising, consisting of, and/or consisting essentially of the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula (I) (as well as compounds of Formula (II)) or a pharmaceutically acceptable salt, isotope, N- oxide, solvate or stereoisomer thereof.
  • the present invention is directed to a method for treating inflammatory somatic hyperalgesia in which a hypersensitivity to thermal, mechanical and/or chemical stimuli exists, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula (I) (as well as compounds of Formula (II)), or a pharmaceutically acceptable salt, isotope, N-oxide, solvate or stereoisomer thereof.
  • a further embodiment of the present invention is directed to a method for treating, ameliorating and / or preventing neuropathic pain.
  • a neuropathic pain include pain due to a disease, condition, disorder, or pain state including cancer, neurological disorders, spine and peripheral nerve surgery, brain tumor, traumatic brain injury (TBI), spinal cord trauma, chronic pain syndrome, fibromyalgia, chronic fatigue syndrome, lupus, sarcoidosis, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, central pain, neuropathies associated with spinal cord injury, stroke, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, multiple sclerosis, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, oral neuropathic pain, Charcot's pain, complex regional pain syndrome I and II (CRPS I/II), radiculopathy, Guillain-Barre syndrome, meralgia paresthetica
  • neuropathic cold allodynia which can be characterized by the presence of a neuropathy-associated allodynic state in which a hypersensitivity to cooling stimuli exists.
  • neuropathic cold allodynia include allodynia due to a disease, condition, disorder or pain state including neuropathic pain (neuralgia), pain arising from spine and peripheral nerve surgery or trauma, traumatic brain injury (TBI), trigeminal neuralgia, postherpetic neuralgia, causalgia, peripheral neuropathy, diabetic neuropathy, central pain, stroke, peripheral neuritis, polyneuritis, complex regional pain syndrome I and II (CRPS I/II) and radiculopathy.
  • neuropathic pain neuralgia
  • TBI traumatic brain injury
  • trigeminal neuralgia postherpetic neuralgia
  • causalgia peripheral neuropathy
  • diabetic neuropathy central pain
  • stroke peripheral neuritis
  • polyneuritis complex regional pain syndrome I and II (CRPS I/II
  • the present invention is directed to a method for treating, ameliorating and / or preventing neuropathic cold allodynia in which a hypersensitivity to a cooling stimuli exists, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula (I) (as well as compounds of Formula (II)) or a pharmaceutically acceptable salt, isotope, N-oxide, solvate or stereoisomer thereof.
  • Psychiatric disorders include, but are not limited to, anxieties such as, social anxiety, post-traumatic stress disorder, phobias, social phobia, special phobias, panic disorder, obsessive-compulsive disorder, acute stress disorder, separation anxiety disorder, and generalized anxiety disorder, as well as depression such as, major depression, bipolar disorder, seasonal affective disorder, post-natal depression, manic depression, and bipolar depression, mood disorders and mood affective disorders that can be treated according to the present invention include, but are not limited to, bipolar disorder I depressed, hypomanic, manic and mixed form; bipolar disorder II; depressive disorders, such as single depressive episode or recurrent major depressive disorder, minor depressive disorder, treatment-resistant depression, anxious depression, bipolar disorder, depressive disorder with postpartum onset, depressive disorders with psychotic symptoms; persistent mood disorders, such as cyclothymia, dysthymia, euthymia; and premenstrual dysphoric disorder;psycho
  • neurological disorder examples include, but are not limited to, tremors, dyskinesias, dystonias, spasticity, Tourette’s Syndrome; neuromyelitis optica, Parkinson’s disease;
  • Alzheimer’s disease senile dementia
  • Huntington’s disease Epilepsy/seizure disorders and sleep disorders.
  • cancers include, but are not limited to, benign skin tumors, prostate tumors, ovarian tumors and cerebral tumors (glioblastomas, medulloepithebomas, medulloblastomas, neuroblastomas, tumors of embryonic origin, astrocytomas, astroblastomas, ependymomas, oligodendrogliomas, neuroepitheliomas, epiphyseal tumor, ependymoblastomas, malignant meningiomas, sarcomatosis, malignant melanomas, schwannomas).
  • Examples of eye conditions include, but are not limited to, ocular hypertension, glaucoma, degeneration and apoptosis of retinal ganglion cells and neuroretinal cells.
  • Other embodiments of this invention provide for a method for modulating MGL receptor activity, including when such receptor is in a subject, comprising exposing MGL receptor to a therapeutically effective amount of at least one compound selected from compounds of the invention.
  • Embodiments of this invention are compounds of Formula (I),
  • R 2 is selected from the group consisting of: (a)
  • X is selected from the group consisting of: O, S, NH, and NCH3; R a is H or halo;
  • R b is selected from the group consisting of: H, halo and CH3;
  • R c is H or CF3
  • R d is H or CH3
  • R 3 is selected from the group consisting of: (h) Phenyl; or phenyl independently substituted with one or two members selected from
  • R 4 is selected from the group consisting of: Ci- 4 alkyl
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 3 is phenyl, 3,5-difluorophenyl, 3-chlorophenyl, 3 -fluorophenyl, or 3-(difluoromethoxy)phenyl.
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 3 is cyclopropyl.
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 4 is CFE.
  • An additional embodiment of the invention is a compound of Formula (I) wherein X is O.
  • An additional embodiment of the invention is a compound of Formula (I) wherein X is S.
  • An additional embodiment of the invention is a compound of Formula (I) wherein X is NH or
  • a further embodiment of the current invention is a compound as shown below in Table 1.
  • R 2 is selected from the group consisting of: (a)
  • X is selected from the group consisting of: O, S, NH, and NCH3;
  • R a is H or halo
  • R b is selected from the group consisting of: H, halo and CH3;
  • R c is H or CF3
  • R d is H or CH3
  • R 3 is selected from the group consisting of:
  • R 4 is selected from the group consisting of: Ci- 4 alkyl
  • R 3 is cyclopropyl
  • An additional embodiment of the invention is a pharmaceutical composition comprising a therapeutically effective amount of at least one compound in Table 1 , as well as and
  • An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by MGL receptor activity, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one compound selected from compounds of Formula (I):
  • R 2 is selected from the group consisting of:
  • X is selected from the group consisting of: O, S, NH, and NCH3; R a is H or halo;
  • R b is selected from the group consisting of: H, halo and CH3;
  • R c is H or CF3
  • R d is H or CH3
  • R 3 is selected from the group consisting of: (h) Phenyl; or phenyl independently substituted with one or two members selected from
  • R 4 is selected from the group consisting of: Ci- 4 alkyl
  • R 3 is cyclopropyl; and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, to a subject in need thereof.
  • An additional embodiment of the invention is a compound of Formula (II) wherein
  • R 1 is Ci- 4 alkyl
  • R 2a is selected from the group consisting of:
  • R a is selected from the group consisting of:
  • Phenyl or phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, Ci- 4 alkyl, Ci- 4 haloalkyl, OCi- 4 alkyl, and OCi-6haloalkyl;
  • Heterocycloalkyl selected from the group consisting of:
  • R f is selected from the group consisting of: H, halo, Ci- 4 alkyl, Ci- 4 haloalkyl, OCi- 4 alkyl, and OCi- 4 haloalkyl;
  • R g is selected from the group consisting of: OCi- 4 alkyl, OCi- 4 haloalkyl, CH2OCH3,
  • R h is selected from the group consisting of: H, Ci- 4 alkyl , Ci- 4 haloalkyl, and
  • R 1 is selected from the group consisting of: H, halo, Ci- 4 alkyl, Ci- 4 haloalkyl, OCi- 4 alkyl, C3-6cycloalkyl, and C3-6cycloalkyl substituted with one or two members
  • R 1 is selected from the group consisting of: H, halo, Ci- 4 alkyl and Ci- 4 haloalkyl;
  • R k is selected from the group consisting of: H, halo, OH, Ci- 4 alkyl, Ci- 4 haloalkyl, OCi-
  • R m is H or Ci- 4 alkyl
  • R n is selected from the group consisting of: H, halo and OCi- 4 alkyl;
  • R° is selected from the group consisting of: H, Ci- 4 alkyl, and Ci- 4 haloalkyl;
  • R p is selected from the group consisting of: H, Ci- 4 alkyl, and OCi- 4 alkyl; Y is CH or N; and
  • R 4a is selected from the group consisting of: CH3, CF2H, CF3, C3-6cycloalkyl, and phenyl; and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 1 is CH3.
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 1 is CH2CH3
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R e is ' ⁇ t“ ,
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 3a is phenyl; or phenyl substituted with one member selected from the group consisting of: F, Cl, OCH3, OCH2CH3, OCH(CH3)2, OCHF2, CF3, CF2CH3, OCF2H, and OCF3.
  • R 3a is phenyl substituted with two or three members independently selected from the group consisting of: F, Cl, CH 3 , CF 2 H, OCF2H and OCH3.
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 3a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 3a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 4a is CH3.
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 4a is CF3.
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 4a is CF2H.
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 4a is phenyl.
  • An additional embodiment of the invention is a compound of Formula (II) having the Formula
  • R 1 is CH 3 ;
  • R 2a is selected from the group consisting of:
  • R 4a is CH3 or phenyl
  • each R n is independently selected from the group consisting of: H, Cl and F; and m is 1,2, or 3.
  • An additional embodiment of the invention is a compound of Formula (II) having the Formula
  • R 1 is CH 3 or CH 2 CH 3
  • R f is selected from the group consisting of: H, halo, Ci- 4 alkyl, Ci- 4 haloalkyl, OCi- 4 alkyl, and OCi- 4 haloalkyl;
  • R 3a is phenyl substituted with one, two, or three members independently selected from halo or Ci- 4 alkyl;
  • R 4a is CH 3 .
  • An additional embodiment of the invention is a compound of Formula (II) having the Formula
  • R 1 is CH 3 ;
  • R f is selected from the group consisting of: H, halo, Ci- 4 alkyl, Ci- 4 haloalkyl,
  • R 3a is 3-chlorophenyl, 3,5-difluorophenyl, 3-fluoro-5-methyl-phenyl, or 3,4,5- trifluorophenyl;
  • R 4a is CH 3 .
  • An additional embodiment of the invention is a compound of Formula (II) having the Formula
  • R 1 is CH 3 ;
  • R 2a is selected from the group consisting of:
  • R 1 is selected from the group consisting of: H, F, CH3, CF3, CF2H, OCH3, and cyclopropyl; R 1 is selected from the group consisting of: H, Br, F, CH3, and CF3;
  • R m is H or CH3
  • R n is selected from the group consisting of: H, halo and OCH3;
  • R° is selected from the group consisting of: H, CH3, CF3, CF2H, and CH2CH2F;
  • Y is CH or N
  • R 3a is phenyl substituted with one, two or three members each independently selected from the group consisting of: Cl, F, CH3, and OCH3.
  • An additional embodiment of the invention is a compound of Formula (II) having the Formula (IIC), wherein
  • R 1 is CH 3 ;
  • R 3a is 3-chlorophenyl, 3,5-difluorophenyl, 3,5-dichlorophenyl, 3-fluoro-5-methylphenyl, 3- chloro-5-methoxy-phenyl, or 3,4,5-trifluorophenyl.
  • An additional embodiment of the invention is a compound of Formula (II) having the Formula
  • R 2a is selected from the group consisting of:
  • R f is selected from the group consisting of: H, F and OCFb;
  • R J is selected from the group consisting of: H, Cl, F and CF 3;
  • R k is selected from the group consisting of: H, Br, CFF, CF3, OH, and OCH2CH2F;
  • R m is H or CH3;
  • R p is selected from the group consisting of: H, CH3, and OCH3;
  • R 3a is selected from the group consisting of:
  • phenyl phenyl substituted with one, two or three members each independently selected from the group consisting of: Cl, F, Ci- 4 alkyl, CF3, OCi- 4 alkyl, OCF3, and OCF2H; and
  • R f is H, F, CH 3 , CF 2 H, CF 3 , OCH 3 , OCF 2 H;
  • R 4a is CH 3 or CF2H.
  • An additional embodiment of the invention is a compound of Formula (II) having the Formula (IID), wherein:
  • R 3a is 5-methylfuran-2-yl, 5-(trifluoromethyl)furan-2-yl, pyridin-3-yl, 5-fluoropyridin-3-yl, 5- (trifluoromethyl)pyridin-3-yl, phenyl, 3-chlorophenyl, 3,5-difluorophenyl, 3,5- dichlorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-4-methoxyphenyl, 4- (difluoromethoxy)-3-fluorophenyl, 3-fluoro-5-(trifluoromethyl)phenyl, 3-chloro-4- methoxyphenyl, 3-fluoro-5-methoxyphenyl, 3-chloro-4-methylphenyl, 3,5-difluoro-4- methylphenyl, or 3,4,5-trifluorophenyl; and
  • R 4a is CH 3 .
  • An additional embodiment of the invention is a compound of Formula (II) having the Formula (HE):
  • Y is CH or N
  • R f is H or F
  • R g is selected from the group consisting of: OCi- 4 alkyl, CH2OCH3, CH2OH,
  • R h is selected from the group consisting of: Ci -4 alkyl, CF3, and cyclopropyl;
  • R 1 is selected from the group consisting of: H, halo, Ci- 4 alkyl, CF2H, CF3, OCH3, cyclopropyl, cyclobutyl, and cyclopropyl substituted with one or two members independently selected from: F and CH3;
  • R is selected from the group consisting of: H, Cl, F, and CH3;
  • R m is H, CH3, or CH2CH3;
  • R 3a is selected from the group consisting of: phenyl, 3, 3-chlorophenyl, 5-difluorophenyl,
  • R 4a is selected from the group consisting of: CH3, C3-6cycloalkyl, and phenyl.
  • An additional embodiment of the invention is a compound of Formula (II) having the Formula
  • R h is CH 3 ;
  • R j is H or CF 2 H
  • R m is H or CH 3 ;
  • R 3a is 3-chlorophenyl or 3,4,5-trifluorophenyl.
  • a further embodiment of the current invention is a compound as shown below in Table 2.
  • An additional embodiment of the invention is a compound selected from the group consisting of compounds of Formula (I), Formula (II), Formula (IIA), Formula (IIB), or Formula (IIC), or Formula (IID), or Formula (HE), or Formula (IIF), or a combination thereof.
  • R 1 is Ci- 4 alkyl
  • R 2a is selected from the group consisting of:
  • R a is selected from the group consisting of:
  • halo selected from the group consisting of: halo, Ci- 4 alkyl, Ci- 4 haloalkyl, OCi- 4 alkyl, and OCi-6haloalkyl;
  • R f is selected from the group consisting of: H, halo, Ci- 4 alkyl, Ci- 4 haloalkyl, OCi- 4 alkyl, and OCi- 4 haloalkyl;
  • R g is selected from the group consisting of: OCi- 4 alkyl, OCi- 4 haloalkyl, CH2OCH3,
  • R h is selected from the group consisting of: H, Ci- 4 alkyl , Ci- 4 haloalkyl, and
  • R 1 is selected from the group consisting of: H, halo, Ci- 4 alkyl, Ci- 4 haloalkyl, OCi- 4 alkyl, C3-6cycloalkyl, and C3-6cycloalkyl substituted with one or two members
  • R 1 is selected from the group consisting of: H, halo, Ci- 4 alkyl and Ci- 4 haloalkyl
  • R k is selected from the group consisting of: H, halo, OH, Ci- 4 alkyl, Ci- 4 haloalkyl, OCi- 4alkyl, and OCi- 4 haloalkyl;
  • R m is H or Ci- 4 alkyl
  • R n is selected from the group consisting of: H, halo and OCi- 4 alkyl;
  • R° is selected from the group consisting of: H, Ci- 4 alkyl, and Ci- 4 haloalkyl;
  • R p is selected from the group consisting of: H, Ci- 4 alkyl, and OCi- 4 alkyl;
  • Y is CH or N
  • R 4a is selected from the group consisting of: CH3, CF2H, CF3, C3-6cycloalkyl, and phenyl; and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers of
  • An additional embodiment of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (II A), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IIA), pharmaceutically acceptable prodrugs of compounds of Formula (IIA), and pharmaceutically active metabolites of Formula (IIA); and at least one pharmaceutically acceptable excipient.
  • An additional embodiment of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (IIB), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IIB), pharmaceutically acceptable prodrugs of compounds of Formula (IIB), and pharmaceutically active metabolites of Formula (IIB); and at least one pharmaceutically acceptable excipient.
  • An additional embodiment of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (II C), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IIC), pharmaceutically acceptable prodrugs of compounds of Formula (IIC), and pharmaceutically active metabolites of Formula (IIC); and at least one pharmaceutically acceptable excipient.
  • An additional embodiment of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (IID), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IID), pharmaceutically acceptable prodrugs of compounds of Formula (IID), and pharmaceutically active metabolites of Formula (IID); and at least one pharmaceutically acceptable excipient.
  • An additional embodiment of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (HE), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (HE), pharmaceutically acceptable prodrugs of compounds of Formula (HE), and pharmaceutically active metabolites of Formula (HE); and at least one pharmaceutically acceptable excipient.
  • An additional embodiment of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (IIF), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IIF), pharmaceutically acceptable prodrugs of compounds of Formula (IIF), and pharmaceutically active metabolites of Formula (IIF); and at least one pharmaceutically acceptable excipient.
  • An additional embodiment of the invention is a pharmaceutical composition comprising a therapeutically effective amount of at least one compound in Table 2, as well as
  • compositions of Formula (I) are also within the scope of the invention.
  • pharmaceutically acceptable prodrugs of compounds of Formula (I) as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (HE) and (IIF)
  • pharmaceutically active metabolites of the compounds of Formula (I) as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (HE) and (IIF)
  • pharmaceutically acceptable prodrugs of compounds of Formula (I) as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (HE) and (IIF)
  • pharmaceutically active metabolites of the compounds of Formula (I) as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (HE) and (IIF)
  • isotopic variations of compounds of Formula (I) (as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (HE) and (IIF)), such as, e.g., deuterated compounds of Formula (I), or Formula (II).
  • pharmaceutically acceptable salts, N-oxides or solvates of the isotopic variations of the compounds of Formula (I) (as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (HE) and (IIF)).
  • compositions of Formula (I) are also within the scope of the invention.
  • pharmaceutically acceptable prodrugs of the isotopic variations of the compounds of Formula (I) as well as Formulas (II), (IIA), (IIB), (II C), (IID), (HE) and (IIF)
  • pharmaceutically active metabolites of the isotopic variations of the compounds of Formula (I) as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (HE) and (IIF)).
  • An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by MGL receptor activity, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one compound selected from compounds of Formula (II):
  • R 1 is Ci- 4 alkyl
  • R 2a is selected from the group consisting of:
  • R a is selected from the group consisting of:
  • halo selected from the group consisting of: halo, Ci- 4 alkyl, Ci- 4 haloalkyl, OCi- 4 alkyl, and OCi-6haloalkyl;
  • R f is selected from the group consisting of: H, halo, Ci- 4 alkyl, Ci- 4 haloalkyl,
  • R g is selected from the group consisting of: OCi- 4 alkyl, OCi- 4 haloalkyl, CH2OCH3,
  • R h is selected from the group consisting of: H, Ci- 4 alkyl , Ci- 4 haloalkyl, and
  • R 1 is selected from the group consisting of: H, halo, Ci- 4 alkyl, Ci- 4 haloalkyl, OCi- 4 alkyl, C3-6cycloalkyl, and C3-6cycloalkyl substituted with one or two members
  • R 1 is selected from the group consisting of: H, halo, Ci- 4 alkyl and Ci- 4 haloalkyl;
  • R k is selected from the group consisting of: H, halo, OH, Ci- 4 alkyl, Ci- 4 haloalkyl, OCi- 4alkyl, and OCi- 4 haloalkyl;
  • R m is H or Ci- 4 alkyl
  • R n is selected from the group consisting of: H, halo and OCi- 4 alkyl;
  • R° is selected from the group consisting of: H, Ci- 4 alkyl, and Ci- 4 haloalkyl;
  • R p is selected from the group consisting of: H, Ci- 4 alkyl, and OCi- 4 alkyl; Y is CH or N; and
  • R 4a is selected from the group consisting of: CH3, CF2H, CF3, C3-6cycloalkyl, and phenyl; and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, to a subject in need thereof.
  • An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by MGL receptor activity, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one compound selected from compounds of Formula (I) (as well as Formulas (II), (PA), (PB), (II C), (IID), (HE) and (IIF)), enantiomers and diastereomers of the compounds of Formula (I) (as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (HE) and (IIF)), isotopic variations of the compounds of Formula (I) (as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (HE) and (IIF)), and pharmaceutically acceptable salts of all of the foregoing.
  • compounds of Formula (I) as well as Formulas (II), (PA), (PB), (II C), (I
  • a compound of formula (III) is prepared by condensation of commercially available or synthetically accessible 2-amino-4-aminobenzoic acid; with 1,2- dioxoalkanes such as 2-oxopropanal, 2,3-butanedione, and the like; in a suitable solvent such as EtOH and the like; at a temperature of 80 °C; for a period of about 1-16 hours; to provide a compound of formula (III), where R f is H or CH3.
  • methyl 2-hydroxy quinoxaline-6-carboxylate is prepared by condensation of commercially available or synthetically accessible 2-amino-4-aminobenzoic acid; with ethyl 2-oxoacetate; in a suitable solvent such as ethanol (EtOH) and the like; at room temperature; for a period of 1 hour.
  • Halogenation of methyl 2-hydroxyquinoxaline-6- carboxylate is achieved with a chlorinating reagent, such as thionyl chloride; neat, or in a suitable solvent such as toluene, and the like; followed by catalytic amount of NN- dimethylformamide (DMF); at reflux temperature; to provide methyl 2-chloroquinoxaline-6- carboxylate.
  • a compound of formula (IV) is prepared in two steps.
  • a first step palladium catalyzed reductive deuteration of methyl 2-chloroquinoxaline-6-carboxylate; using a commercially available deuterated reagent such as sodium borodeuteride; in presence of a palladium catalyst such as [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (PdCl2(dppf)), and the like; a base such as tetramethylethylenediamine (TMEDA or TEMED); in a suitable solvent such as tetrahydrofuran (THF), and the like; at room temperature; for a period of 1 hour.
  • TMEDA or TEMED tetramethylethylenediamine
  • THF tetrahydrofuran
  • a second step saponification of the ester to the acid is achieved employing conditions known to one skilled in the art. For example, employing a suitable base such as NaOH, LiOH, and the like; in a suitable solvent such as water, THF, methanol (MeOH), or a mixture thereof; at room temperature; for a period of about 1 h; provides a compound of formula (IV), where M is lithium.
  • a suitable base such as NaOH, LiOH, and the like
  • a suitable solvent such as water, THF, methanol (MeOH), or a mixture thereof
  • methyl quinoline-6-carboxylate is halogenated under conditions known to one skilled in the art.
  • a halogenating agent such as N-bromosuccinimide (NBS), N-iodosuccinimide (NIS), and the like
  • NBS N-bromosuccinimide
  • NMS N-iodosuccinimide
  • AcOH acetic acid
  • the halogenating agent is NIS, for a compound of formula (V), where Hal is I.
  • the iodo-substituent allows the insertion of the trifluoromethyl moiety via (trifluoromethyl)copper-mediated trifluoromethylation, employing a trifluormethylating agent such as trifluoromethyl iodide, sodium trifluoroacetate, methyl 2,2-difluoro-2- (fluorosulfonyl)acetate, trifluoromethyl-trimethylsilane, trifluoromethyl- triethylsilane, methyl chlorodifluoroacetate-potassium fluoride, and the like, (methyl2,2- difluoro-2-(fluorosulfonyl)acetate is preferred); a catalyst such as copper iodide, copper bromide, or other such copper salts, and copper powder (copper iodide is preferred), in an inert solvent such as V,V-dimethylformamide, V, V-dimethylacetamide, dimethyl sulfoxide, N-
  • Saponification of the ester to the acid is achieved employing conditions known to one skilled in the art, for example, using a suitable base such as NaOH, LiOH, and the like, in a suitable solvent such as water/THF/MeOH, at a temperature of about 60 °C, for a period of about 2 h, to provide 3-(trifluoromethyl)quinoline-6-carboxylic acid.
  • a suitable base such as NaOH, LiOH, and the like
  • a suitable solvent such as water/THF/MeOH
  • a compound of formula (VI), where R a is H or halo, is alkylated with a suitable alkyl halide such as l-iodoethane, fluoro-2-iodoethane, and the like; a suitable base such as CS2CO3, K2CO3, and the like; in a suitable solvent such as N,N- dimethylformamide.
  • a suitable alkyl halide such as l-iodoethane, fluoro-2-iodoethane, and the like
  • a suitable base such as CS2CO3, K2CO3, and the like
  • a suitable solvent such as N,N- dimethylformamide
  • compounds of formulas (IXa), (IXb) and (IXc) are prepared under conditions known to one skilled in the art, by condensation of commercially available or synthetically accessible substituted pyridine, pyridazine and pyrazine amines of formulas (Villa), (Vlllb) and (VIIIc) where R 1 is independently H, Ci- 4 alkyl, Ci- 4 haloalkyl, OCi- 4 alkyl, and
  • Saponification of the esters (IXa), (IXb) and (IXc) to the corresponding acid is achieved employing conditions known to one skilled in the art, for example, using a suitable base such as potassium trimethylsilanolate (TMSOK), NaOH, LiOH, and the like, in a suitable solvent such as water/THF/MeOH, at a temperature of about 60 °C, for a period of about 24 h, to provide compounds of formulas (Xa), (Xb), and (Xc), where M is potassium, Na, or Li, preferably potassium.
  • a suitable base such as potassium trimethylsilanolate (TMSOK), NaOH, LiOH, and the like
  • TMSOK potassium trimethylsilanolate
  • NaOH NaOH
  • LiOH LiOH
  • a suitable solvent such as water/THF/MeOH
  • Saponification employing basic conditions, using a suitable base such as TMSOK, NaOH, LiOH, and the like; in a suitable solvent such as water, THF, MeOH, or a mixture thereof; at a temperature of about 60 °C; for a period of about 24 h; provides a compound of formula (XHIb) where M is potassium, Na, or Li; preferably potassium.
  • a suitable base such as TMSOK, NaOH, LiOH, and the like
  • a suitable solvent such as water, THF, MeOH, or a mixture thereof
  • a compound of formula (XlVb), where R 1 is an optionally substituted C3-6cycloalkyl is reacted with oxalyl chloride; ethyl potassium malonate; in the presence of magnesium chloride; a suitable base such as triethylamine, and the like; in a suitable solvent such as ethyl acetate, THF, or a mixture thereof; to provide a compound of formula (XV), where R m is ethyl.
  • ACN acetonitrile
  • corresponding acid is achieved employing conditions known to one skilled in the art.
  • a suitable base such as NaOH, LiOH, KOH, and the like, preferably LiOH
  • a suitable solvent such as water, THF, MeOH, or a mixture thereof; at a temperature of about 60 °C; for a period of about 24 h; to provide compounds of formulas (XXa), (XXb), and (XXc), where M is potassium, Na, or Li, preferably potassium.
  • a suitable alkylating agent such as methyl iodide (Mel)
  • a suitable base such as NaH, and the like
  • THF a suitable solvent
  • hydrolysis of methyl 5,7- dimethyl-7H-pyrrolo[2,3-d]pyrimidine-4-carboxylate is achieved employing conditions previously described, to provide potassium 5,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-4- carboxylate.
  • Oxidation of 4-( 1 -ethoxy vinyl)- 1, 6-dimethyl- lH-pyrazolo [3, 4- d]pyrimidine employing oxidation conditions such as sodium periodate; potassium
  • permanganate in suitable solvent such as 1,4 dioxane, and the like; at a temperature of about room temperature; for a period of 18h; and neutralized with aqueous potassium carbonate solution; provides a mixture of ethyl l,6-dimethyl-lH-pyrazolo[3,4-d]pyrimidine-4-carboxylate and 1, 6-dimethyl- lH-pyrazolo [3, 4-d]pyrimidine-4-carboxylic acid (WO 2015/025026; Page-96).
  • suitable solvent such as 1,4 dioxane, and the like
  • 6, 6-dimethylmorpholine-3 -carboxylic acid is prepared in two steps from 4-(tert-butyl) 3-methyl 6,6-dimethylmorpholine-3,4-dicarboxylate.
  • deprotection of BOC group is achieved according to procedures known to one skilled in the art and employing established methodologies, such as those described in T. W. Greene and P. G. M. Wuts,“Protective Groups in Organic Synthesis,” 3 ed., John Wiley & Sons, 1999, pgs 518-525.
  • deprotection under acidic conditions such as trifluoroacetic acid (TFA)/CH2Ch, HCl/Dioxane, and the like, at room temperature for a period of 2 h.
  • acidic conditions such as trifluoroacetic acid (TFA)/CH2Ch, HCl/Dioxane, and the like
  • suitable base such as NaOH and the like
  • MeOH/water a solvent such as MeOH/water
  • Diazotization of 6,6-dimethylmorpholine-3- carboxylic acid is achieved employing sodium nitrite; in water; under acidic conditions such as cone. HC1; at temperatures ranging from 0 °C to room temperature; for a period of 16 h.
  • TFAA trifluoroacetic anhydride
  • ACN acetonitrile
  • a suitable base such as NaOH, LiOH, KOH, and the like
  • a suitable solvent such as water, THF, MeOH, or a mixture thereof; at a temperature of about 60 °C; for a period of about 24 h; to provide compounds of formulas (XXIa) and (XXIb), where M is K, Na, or Li.
  • a keto-ester compound of formula (XXV), where PG is a suitable protecting group such as BOC (tert-butyloxycarbonyl), and R 1 is Ci- 4 alkyl is prepared from a commercially available or synthetically accessible compound of formula (XXIV).
  • a compound of formula (XXIV), where PG is BOC is converted to compound (XXV), by treatment with a strong base such as LHMDS, in a suitable solvent such as THF, and the like, at a temperature of about -78 °C; for 30 minutes, followed by treatment with ethyl cyanoformate at -78 °C, for a period of about 2 hours.
  • a compound of formula (XXIII) is prepared in two steps from a compound of formula (XXII), where R 1 is Ci- 4 alkyl.
  • a compound of formula (XXII) is alkylated with ethyl 4-bromobutanoate; employing potassium iodide; a suitable base such as dibasic potassium phosphate.
  • BOC protection employing established methodologies, such as those described in T. W. Greene and P. G. M. Wuts,“Protective Groups in Organic Synthesis,” 3 ed., lohn Wiley & Sons, 1999, pgs 518-525, provides a compound of formula (XXIII).
  • ethyl L-alaninate hydrochloride is alkylated by treatment with bromobutanoate and potassium iodide in the presence of a suitable base such as dibasic potassium phosphate in a suitable solvent such as DMF.
  • a suitable base such as dibasic potassium phosphate
  • a suitable solvent such as DMF.
  • the amine moiety is protected with a carbamate protecting group such as tert-butyloxycarbonyl (BOC). Cyclization of the diester occurs under Dieckmann condensation conditions known to one skilled in the art.
  • ethyl (S)-4-((tert-butoxycarbonyl)(l -ethoxy- l-oxopropan-2-yl)amino)butanoate is treated with lithium bis(trimethylsilyl)amide (LiHMDS) at a suitable temperature range such as between -40 °C to 20 °C to provide l-(tert- butyl) 4-ethyl (2S)-2-methyl-3-oxopiperidine-l,4-dicarboxylate.
  • LiHMDS lithium bis(trimethylsilyl)amide
  • a commercially available or synthetically accessible compound of formula (XXV), where R 1 is H, and PG is BOC (tert-butyloxycarbonyl) is reacted with a commercially available or synthetically accessible hydrazine compound of formula R 4 NHNH2, where R 4 is Ci- 4 alkyl, in AcOH, at a temperature of about 80 °C, to provide a pyrazolone compound of formula (XXVIa), where R 4 is Ci- 4 alkyl.
  • a commercially available or synthetically accessible compound of formula (XXV), where R 1 is Ci- 4 alkyl, and PG is BOC (tert-butyloxycarbonyl) is reacted with a commercially available or synthetically accessible hydrazine compound of formula R 4a NHNH2, or salt thereof, where R 4a is Ci- 4 alkyl,
  • C3-6cycloalkyl or phenyl in a suitable solvent such as toluene or ethanol with a suitable base such as A, A-diisopropylethylamine (Hiinig's base or DIEA), at a temperature of between 80 and 110 °C, to provide a pyrazolone compound of formula (XXVIb), where R 4a is Ci- 4 alkyl, C3-6cycloalkyl or phenyl.
  • a sulfonate-based leaving group such as trifluoromethanesulfonyl (triflate)
  • triflate trifluoromethanesulfonic anhydride
  • a base such as triethylamine (TEA), pyridine, N-ethyldiisopropylamine (DIEA, DIPEA), and the like; in a suitable solvent such as DCM and the like.
  • Milder triflating agents such as A- phenylbis(trifluoromethanesufonimide) (Tf2NPh), a base such as TEA, DIEA, and the like, in a suitable solvent such as DCM, and the like; are used for better selectivity, to provide compounds of formulas (XXVIIa) and (XXVIIb).
  • a compound of formula (XXV), where PG is BOC is reacted with hydrazine hydrate, to provide tert-butyl 7-methyl-3-oxo-l,2,3,4,5,7-hexahydro-6H-pyrazolo[3,4- c]pyridine-6-carboxylate.
  • tert-Butyl 7-methyl-3-oxo- l ,2,3,4,5,7-hexahydro-6H-pyrazolo[3,4- c]pyridine-6-carboxylate is reacted with a triflating agent as previously described to provide tert- butyl 7-methyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridine-6-carboxylate.
  • 3- iodobenzoic acid is reacted with 3-(trifluoromethyl)pyrazole, a base such as cesium carbonate, a copper catalyst such as Cul, a ligand such as /ra «.s-A,A'-dimethylcyclohexane- 1 ,2-diamine, in a suitable solvent such as DMF, at temperatures ranging from 100-140° C, under microwave irradiation, to provide 3-[3-(trifluoromethyl)pyrazol-l-yl]benzoic acid.
  • a base such as cesium carbonate
  • a copper catalyst such as Cul
  • a ligand such as /ra «.s-A,A'-dimethylcyclohexane- 1 ,2-diamine
  • a compound of formula (XXXI) where R f is halo, Ci- 4 alkyl, Ci- 4 haloalkyl or OCi- 4 alkyl is reacted with diformylhydrazine, in the presence of trimethylsilyl chloride as a Lewis acid, triethylamine, in a suitable solvent such as pyridine, at a temperature of about 100 °C, for a period of about 16 h, to provide the 1 ,2,4-triazol-4-yl intermediate; in a second step, saponification is achieved according to conditions known to one skilled in the art, or as previously described.
  • 5,8-dihydro-6H-pyrano[3,4-b]pyridine 1 -oxide is prepared by oxidizing 5,8-dihydro-6H-pyrano[3,4-b]pyridine (prepared according to procedures described in Tetrahedron, 45(19), 6211-20; 1989) employing conditions known to one skilled in the art.
  • 5,8-dihydro-6H-pyrano[3,4-b]pyridine is reacted with an oxidizing agent such as meta- chloroperoxybenzoic acid (/ «CPBA), in a suitable solvent such as DCM, at a temperature ranging from 0 °C to 25 °C to provide 5,8-dihydro-6H-pyrano[3,4-b]pyridine 1 -oxide.
  • an oxidizing agent such as meta- chloroperoxybenzoic acid (/ «CPBA)
  • a suitable solvent such as DCM
  • Halogenation employing a chlorinating agent such as POCb, and the like, in a suitable solvent such as chloroform, and the like, at temperatures ranging from 70-90 °C, to affords a mixture of compounds of formula (XXXII) and (XXXIII), where HAL is Cl.
  • Palladium-catalyzed cyanation of (hetero)aryl halide compounds of formula (XXXII) and (XXXIII) is achieved employing zinc cyanide as the nucleophile, zinc, tris(dibenzylideneacetone)dipalladium(0), and I,G- bis(diphenylphosphino)ferrocene, in a suitable solvent, at a temperature of about 90 °C, for a period of 4 days, to provide 5,8-dihydro-6H-pyrano[3,4-b]pyridine-4-carbonitrile and 5,8- dihydro-6H-pyrano[3,4-b]pyridine-2-carbonitrile.
  • 3,4-Dihydro-2H-pyrano[2,3-b]pyridine-5-carboxylic acid is prepared according to methods previously described starting from 3,4-dihydro-2H-pyrano[2,3-b]pyridine.
  • a compound of formula (XXVIIa), where R 4 is Ci- 4 alkyl and PG is BOC; is reacted with a suitably substituted commercially available or synthetically accessible alkyl, cycloalkyl, aryl or heteroaryl boronic acid, boro
  • palladium(II)bis(triphenylphosphine) dichloride Pd(PPh3)2Cl2
  • XPhos-Pd-G2 precatalyst chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-l,l '-biphenyl)[2-(2'-amino-l,l'- biphenyl)]palladium(II)
  • a base such as K 3 P0 4 , aq.
  • a compound of formula (XLa), where R 4 is Ci- 4 alkyl; and R 2 is quinoline; is prepared by conventional amide bond forming techniques such as coupling reactions which are well known to those skilled in the art (such as HATU (1- [bis(dimethylamino)methylene]- l H- 1 ,2,3-triazolo[4,5-/i]pyridinium 3-oxid
  • a suitable pyridinium salt such as 2-chloro-l -methyl pyridinium chloride; or another suitable coupling agent such as /V,/V,/V',/V'-tetramethyl- -( 1 //-benzotriazol- 1 -yl)uronium hexafluorophosphate (HBTU), 1 - [bis(dimethylamino)methylene] - 1 H- 1 ,2,3 -triazolo [4, 5 - Ajpyridinium 3-oxid hexafluorophosphate (HATU), 2,4,6-tripropyl-l,3,5,2,4,6- trioxatriphosphorinane-2, 4, 6-trioxide (T3P ® ) and the like.
  • Coupling reactions are conducted in a suitable solvent such as DCM, THF, DMF and the like, optionally in the presence of a tertiary amine such as N-methylmorpholine, N-ethyldiisopropylamine (DIEA, DIPEA), or triethylamine (TEA), at a temperature ranging from about 0 °C to rt, to provide compound a of formula (XLa).
  • a compound of (XXXIXb) is reacted in the same fashion as described above to provide compounds of formula (XLb).
  • a compound of formula (XLI), where R 1 is Ci- 4 alkyl, and R 3a is phenyl substituted with one, two, or three halo members is prepared by reacting tert-butyl 7- methyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate is in metal-mediated cross coupling reaction employing conditions previously described with a commercially available or synthetically accessible suitably substituted phenyl boronic acid.
  • Diflouromethylation of a compound of formula (XLI) is achieved employing sodium 2- chloro-2,2-difluoroacetate, a suitable base such as NaH, in a solvent such as DMF, and the like, to provide a compound of formula (XLII), where R 4a is CF2H.
  • Trifluoromethylation of a compound of formula (XLI) is achieved in two steps.
  • a first step reaction with dibromodifluoromethane, in a suitable solvent such as DMF, in the presence of a suitable base such as NaH, at elevated temperature, provides the l-bromodifluoromethylated intermediate.
  • a suitable solvent such as DMF
  • silver(I) tetrafluoroborate in a suitable solvent such as DCM, at temperatures ranging from 0 °C to room temperature, provides a compound of formula (XLII), where R 4a is CF3.
  • R 2a , R 3 , R 3a , R 4 and R 4a are as defined in claim 1 and claim 28, are prepared from compounds of formula (XLV) or (XLIII), according to conventional amide bond forming techniques such as coupling reactions with a suitably substituted aryl or heteroaryl carboxylic acid, which are previously described, or by reaction of suitably substituted aryl or heteroaryl acid chlorides (conversion of the acid to an acid chloride), employing a base such as TEA (triethylamine), and the like, in a suitable solvent such as DCM, THF, ethyl acetate (EtOAc), and the like.
  • a base such as TEA (triethylamine)
  • EtOAc ethyl acetate
  • T2O toluene-p-sulphonic anhydride
  • TEA triethylamine
  • R 2a is l-methyl-lH-indol-7-yl, l-methyl-lH-pyrrolo[2,3-c]pyridin-3-yl, l-methyl-lH- pyrrolo[2,3-c]pyridin-4-yl, l-methyl-lH-pyrrolo[3,2-c]pyridin-4-yl, 1 -methyl- lH-pyrrolo [3,2- c]pyridin-3-yl, 2-methylpyrazolo[3,4-c]pyridin-7-yl, l-methylpyrazolo[3,4-c]pyridin-7-yl, or 3- methyl- 1 ,3-benzoxazol-2-one.
  • a compound of Formula (II), where R 2a is 3-bromopyrazolo[l,5-a]pyridin-4-yl is reacted with trimethylboroxine, a suitable catalyst such as tetrakis(triphenylphosphine)palladium(0), and a suitable base such as potassium carbonate, in a suitable solvent such as A, A- dimethylformamide at 100 °C to provide a compound of Formula (II), where R 2a is 3- methy lpyrazolo [ 1 , 5 -a] pyr idin-4-y 1.
  • tert-butyl (L')-(1 -oxopropan-2-yl)carbamate and methylhydrazine can be condensed in a suitable solvent such as THF to afford tert-butyl (S,E)- (l-(2-methylhydrazineylidene)propan-2-yl)carbamate.
  • a commercially available or synthetically accessible suitably substituted aryl aldehyde of formula (XL VI) is treated with 2-(2-nitroethyl)- l,3-dioxolane in the presence of a catalytic amount of suitable base such as piperidine; in a suitable solvent such as toluene; at a temperature of 110 °C to provide a compound of formula (XL VII), where R 3a and R 4a are as defined in Formula (II).
  • Compounds of Formula (I) may be converted to their corresponding salts using methods known to one of ordinary skill in the art.
  • an amine of Formula (I) (as well as compounds of Formula (II)) is treated with trifluoroacetic acid, HC1, or citric acid in a solvent such as Et 2 0, CH2CI2, THF, MeOH, chloroform, or isopropanol to provide the corresponding salt form.
  • trifluoroacetic acid or formic acid salts are obtained as a result of reverse phase HPLC purification conditions.
  • Crystalline forms of pharmaceutically acceptable salts of compounds of Formula (I) may be obtained in crystalline form by recrystallization from polar solvents (including mixtures of polar solvents and aqueous mixtures of polar solvents) or from non-polar solvents (including mixtures of non-polar solvents).
  • the compounds according to this invention may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diaster eomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.
  • reaction mixtures were magnetically stirred at room temperature (rt) under a nitrogen atmosphere. Where solutions were“dried,” they were generally dried over a drying agent such as Na 2 S0 4 or MgS0 4 . Where mixtures, solutions, and extracts were “concentrated”, they were typically concentrated on a rotary evaporator under reduced pressure. Reactions under microwave irradiation conditions were carried out in a Biotage Initiator or CEM (Microwave Reactor) Discover instrument.
  • SFC supercritical fluid high performance liquid chromatography
  • Mass spectra were obtained on an Agilent series 1100 MSD using electrospray ionization (ESI) in positive mode unless otherwise indicated. Calculated (calcd.) mass corresponds to the exact mass.
  • NMR Nuclear magnetic resonance
  • Step A / ⁇ /7-Butyl 2-methyl-3-oxo- 1 5.7-tetrahvdropyrazolo 6lpyridine-6-carboxylate.
  • Step B fer/-Butyl 2-methyl-3-( ' trifluoromethylsulfonyloxy)-5.7-dihvdro- razoloi3.4-
  • Step D 2-Methyl-3-phenyl-4.5.6.7-tetrahvdropyrazolo[3.4-61pyridine.
  • tert- butyl 2-methyl-3-phenyl-5,7-dihydro-4//-pyrazolo[3,4-6]pyridine-6-carboxylate (6.41 g, 20.5 mmol) in dichloromethane (65 mL) was added trifluoroacetic acid (TFA) (15.5 mL, 203 mmol, 1.49 g/mL) at 0 °C and the reaction was stirred at room temperature for 18 h.
  • the reaction mixture was poured into saturated sodium carbonate (250 mL) and the layers were separated.
  • Step A 1 -(tert-Butyl) 4-ethyl 2-methyl-3-oxopiperidine-E4-dicarboxylate.
  • tert-butyl 2-methyl-3 -oxopiperi dine- l-carboxy late 5 g, 23.4 mmol
  • tetrahydrofuran 35 mL
  • lithium bis(trimethylsilyl)amide 1.0 M in THF, 28.1 mL, 28.1 mmol
  • Stirring was maintained at -78 °C for 30 minutes, and then a solution of ethyl cyanoformate (3.0 mL, 30.4 mmol) in THF (15 mL) was added dropwise at -78 °C over a period of 10 minutes.
  • the reaction mixture was allowed to stir at -78 °C for 2 h and then quenched with saturated aqueous NH 4 Cl.
  • Step B tert-Butyl 2.7-dimethyl-3-oxo- l .2.3A5.7-hexahvdro-6H-pyrazolo c1pyridine-6-
  • Step C tert-Butyl-2.7-dimethyl-3-( ' ( ' ( ' trifluoromethyl)sulfonyl)oxy)-2.4.5.7-tetrahvdro-6H-
  • Step A Ethyl (N)-4-((l -ethoxy- 1 -oxopropan-2-yl) amino)butanoate.
  • DMF 21 L, 6 V
  • ethyl L-alaninate hydrochloride 6.13 kg, 2.0 eq. 90 % w/w
  • K2HPO4 10.94 kg, 3.5 eq.
  • KI 2.98 kg, 1.0 eq.
  • Step B Ethyl (S)-4-((tert-butoxycarbonyl)(l-ethoxy-l-oxopropan-2-yl)amino)butanoate.
  • Step C 1 -(tert-Butyl) 4-ethyl (2S)-2-methyl-3-oxopiperidine-l,4-dicarboxylate.
  • LiHMDS lithium bis(trimethylsilyl)amide
  • Step D tert-Butyl (7S)-2,7-dimethyl-3-oxo-2,3,3a,4,5,7-hexahydro-6H-pyrazolo[3,4-c]pyridine-
  • 6-carboxylate 6-carboxylate.
  • methylhydrazine sulfate 360 g, 2.5 mol, 1.5 eq.
  • EtOH 5 L, 10.6 V
  • DIEA 399 mL, 2.4 mol, 1.45 eq.
  • Step A 2-Methyl-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4-c
  • Step B 2-Methyl-6-( ' quinoline-6-carbonyl)-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4-c1pyridin-3-yl trifluoromethanesulfonate.
  • 2-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c]pyridin-3-yl trifluoromethanesulfonate 354 mg, 1.24 mmol
  • quinoline-6-carboxylic acid (236 mg, 1.37 mmol)
  • DIPEA 0.64 mL, 3.72 mmol
  • Step A Methyl 3-iodoquinoline-6-carboxylate.
  • acetic acid AcOH
  • NIS V-iodosuccinimide
  • Step B Methyl 3-ttrifluoromethyl)quinoline-6-carboxylate.
  • a microwave vial was charged with methyl 3-iodoquinoline-6-carboxylate (150 mg, 0.48 mmol), methyl 2,2-difluoro-2- (fluorosulfonyl)acetate (0.15 mL, 1.20 mmol), copper(I) iodide (228 mg, 1.20 mmol), DMPU (0.33 mL, 2.71 mmol), and DMF (3.0 mL).
  • the head space was evacuated under vacuum and refilled with N2 ( c 3), and then the reaction mixture was heated under microwave irradiation at 130 °C for 30 min.
  • Step C 3-(Trifluoromethyl)quinoline-6-carboxylic acid.
  • a mixture of methyl 3- (trifluoromethyl)quinoline-6-carboxylate (25 mg, 98.0 pmol), NaOH (7.8 mg, 0.2 mmol), and H2O (20 pL, 1.11 mmol) in 1 : 1 THF:MeOH (0.4 mL) was heated to 60 °C for 2 h. The reaction was allowed to cool to room temperature and the solvent removed in vacuo. The resulting crude product was dissolved in H2O and the reaction mixture was acidified to pH 5 with 2N HC1. The resulting precipitate was collected via vacuum filtration to afford the title compound as a white solid.
  • Step A tert-Butyl 3-( ' 3.5-difluorophenyl)-7-methyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridine-6-carboxylate.
  • the title compound was prepared in a manner analogous to
  • Step B tert-Butyl 3-(3.5-difluorophenyl)-7-methyl-2-( ' methyl-d3)- tetrahvdro-6H-
  • pyrazolor3.4-c1pyridine-6-carboxylate To an ice-cold solution of tert-butyl 3-(3,5- difluorophenyl)-7-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (200 mg, 0.6 mmol) in THF (2.0 mL) was added 60 wt% sodium hydride/mineral oil (24 mg, 0.6 mmol). The reaction mixture was stirred for 30 min at 0 ° C, and then iodomethane-d3 (40 pL, 0.6 mmol) was added.
  • Step A tert-Butyl 2-(difluoromethyl)-3-(3.5-difluorophenyl)-7-methyl- tetrahvdro-6H-
  • Step B 2-( ' Difluoromethyl)-3-( ' 3.5-difluorophenyl)-7-methyl-4.5.6.7-tetrahvdro-2H- pyrazolor3.4-c1 pyridine.
  • Step A tert-Butyl ( ' S)-7-methyl-3-( ' 3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridine-6-carboxylate.
  • the title compound was prepared in a manner analogous to
  • Step B (S)-2-(Difluoromethyl)-7-methyl-3-(3.4.5-trifluorophenyl)-4.5.6.7-tetrahvdro-2H- pyrazolor3.4-c1 pyridine.
  • the title compound was prepared in a manner analogous to
  • Step B (RV2-(DifluoromethylV7-methyl-3-(3.4.5-trifluorophenylV4.5.6.7-tetrahvdro-2H- pyrazolor3.4-c1 pyridine.
  • the title compound was prepared in a manner analogous to
  • Step A tert-butyl 2-( ' bromodifluoromethyl)-3-( ' 3.5-difluorophenyl)-7-methyl- tetrahvdro-
  • Step B 3-( ' 3.5-Difluorophenyl)-7-methyl-2-( ' trifluoromethyl)-4.5.6.7-tetrahvdro-2H- pyrazolor3.4-cl pyridine.
  • Step A -2-( ' 3-( ' 3.5-Difluorophenyl)-2-nitroallyl)- l 3-dioxolane.
  • 2-(2-nitroethyl)-l,3- dioxolane (20.26 g, 137.72 mmol)
  • 3,5-difluorobenzaldehyde (19.57 g, 137.72 mmol) and catalytic piperidine (2 mL, 20.25 mmol) in toluene (150 mL). Heat to reflux overnight.
  • the reaction mixture was cooled to room temperature then quenched with saturated NaCl solution (150 mL).
  • the extracted organic layer was dried with Na2S0 4 , filtered and concentrated to dark oil to recover quantitative crude yield of the title compound.
  • the compound was used in the next step without further purification.
  • Step B tert-Butyl (L' , / ' -H 1 -(2-methylhydrazineylidene)propan-2-yl)carbamate.
  • ⁇ solution of methylhydrazine (3.04 mL, 57.73 mmol) and tert-butyl (L)-( 1 -oxopropan-2-yl) carbamate (10 g, 57.73 mmol) in THF (150 mL) was stirred for 4 hours at room temperature.
  • the reaction mixture was dried over Na ⁇ SO-i, filtered and evaporated under reduced pressure overnight.
  • the title compound was isolated as a light oil in quantitative crude yield. The crude product was used in the next reaction without further purification.
  • Step C tert-Butyl ( ⁇ S)-(l-(4-((l,3-dioxolan-2-yl)methyl)-5-(3,5-difluorophenyl)-l-methyl-lH- pyrazol-3-yl)ethyl)carbamate.
  • Step D (A)-3-(3,5-Difluorophenvl)-2,7-dimethvl-4,5,6,7-tetrahvdro-2H-pvrazolo[3,4-c]pvridine.
  • Step A tert-butyl 2-( ' bicvclon . 1. 11pentan- l -yl)-7-methyl-3-oxo- l .2.3.4.5.7-hexahydro-6H- pyrazolo[3.4-c1pyridine-6-carboxylate.
  • 1 -(tert-butyl) 4-ethyl 2-methyl-3- oxopiperidine-l,4-dicarboxylate (Intermediate 7, Step A) (224 mg, 0.79 mmol) and
  • Step B 2-(bicyclo[l. l. l]pentan-l-yl)-7-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c]pyridine.
  • the title compound was prepared in a manner analogous to Intermediate 1, Steps B- D using tert-butyl 2-(bicyclo[l. l.
  • Step A 2-(Chloromethyl)pyrazine.
  • a solution of thionyl chloride (30.9 mL, 435.9 mmol) in DCM (250 mL) was added dropwise to a mixture of 2-pyrazinylmethanol (16 g, 145.3 mmol) in DCM (250 mL) under a nitrogen atmosphere at 0 °C.
  • the reaction mixture was stirred at room temperature overnight.
  • Saturated aqueous NaHCC was added and the mixture was extracted with DCM.
  • the organic layer was separated, dried over MgS0 4 , filtered and concentrated under reduced pressure. Purification (LCC, S1O2, 0-50% Et 2 0 in pentane) afforded the title compound (18.7 g, 100%).
  • the title compound is volatile and unstable.
  • Step B 2-((But-3-yn-l-yloxy)methyl)pyrazine.
  • Sodium (4 g, 174.4 mmol) was added to a solution of 3-butyn-l-ol (16.5 mL, 218.0 mmol) in THF (300 mL) under a nitrogen atmosphere at room temperature.
  • a solution of 2-(chloromethyl)pyrazine (18.7 g, 145.3 mmol) in THF (300 mL) was added to the suspension and the reaction mixture was heated to 40 °C for 2 hours. Then, the reaction mixture was stirred at room temperature overnight.
  • Step C 5,8-Dihydro-6H-pyrano[3,4-b]pyridine.
  • a mixture of 2-((but-3-yn-l-yloxy)methyl)pyrazine (8.3 g, 51.0 mmol) in undecane (33 mL) was stirred at 195 °C for 7 days.
  • Purification FCC, SiCh, 0-90% EtOAc in heptane
  • MS MS (ESI): mass calcd. for CsFENC), 135.1 ; m/z found, 136 [M+H] + .
  • Step D 5,8-Dihydro-6H-pyrano[3,4-b]pyridine l-oxide.
  • Step E 4-Chloro-5,8-dihydro-6H-pyrano[3,4-b]pyridine.
  • Phosphorus(V) oxychloride (6.3 mL, 67.6 mmol) was added to a mixture of 5,8-dihydro-6H- pyrano[3,4-b]pyridine l-oxide (1.5 g, 9.7 mmol) in chloroform (55 mL). The reaction mixture was refluxed at 80 °C overnight. Then, iced water and aqueous ammonia was added until basic pH was reached. DCM was added to the mixture. The organic layer was separated, dried over MgS0 4 , filtered and concentrated under reduced pressure.
  • Step F 5,8-Dihydro-6H-pyrano[3,4-b]pyridine-4-carbonitrile.
  • Step G 5.8-Dihvdro-6H-pyranoi3.4-b1pyridine-4-carboxylic acid.
  • a mixture of 5,8-dihydro-6H- pyrano[3,4-b]pyridine-4-carbonitrile (94.4 mg, 0.6 mmol) and LiOH (4N in water, 0.7 mL, 2.9 mmol) in THF (9 mL) was refluxed at 90 °C. After 16 hours, the reaction mixture was concentrated under reduced pressure. Purification (preparative HPLC, METHOD A) afforded the title compound (82 mg, 78%).
  • Step A 5.8-Dihvdro-6H-pyranoi3.4-b1pyridine-2-carbonitrile.
  • the title compound was prepared in a manner analogous to Intermediate 57, Step F, using 2-chloro-5,8-dihydro-6H-pyrano[3,4- b]pyridine (side Product from Intermediate 57, Step E) instead of 4-chloro-5,8-dihydro-6H- pyrano[3,4-b]pyridine (Intermediate 57, Step E).
  • Step B 5.8-Dihvdro-6H-pyranoi3.4-b1pyridine-2-carboxamide.
  • NaOH 48.5 mg, 1.2 mmol
  • EtOH 2 mL
  • the mixture was heated to 50 °C overnight.
  • volatiles were removed and water (3.0 mL) followed by cone.
  • HC1 (0.65 mL) was added to the crude material. After 20 minutes, the solids were filtered off. The filtrate was extracted using EtOAc (3x). The combined organics were dried over MgS0 4 , filtered and concentrated under reduced pressure to afford the title compound.
  • the compound was carried as is to the next step without further purification.
  • Step C 5,8-Dihydro-6H-pyrano[3,4-b]pyridine-2-carboxylic acid.
  • 4N LiOH 0.3 mL, 1.2 mmol
  • 58-dihydro-6H-pyrano[3,4-b]pyridine-2-carboxamide 43.0 mg, 0.2 mmol
  • the mixture was heated to 50 °C for 3 days. Then, volatiles were removed and EtOAc was added. The mixture was stirred at room temperature. The solvent was pipetted out and DCM was added to the crude mixture. The mixture was stirred at room temperature overnight. Then, the solvent was pipetted out and MeOH was added to the crude mixture. The mixture was stirred at room temperature. The solids were filtered off and the filtrate was concentrated under reduced pressure to afford the title compound.
  • Step B 5-Trifluoromethyl)- 1 -((2-(trimethylsilyl)ethoxy)methyl)- 1 H-pyrrolo b1pyridine-4-
  • Step A Methyl 1 -(Y2-( ' trimethylsilyl)ethoxy)methyl)- l H-pyrazolo[3.4-b1pyridine-5-carboxylate.
  • the title compound was prepared in a manner analogous to
  • Step B 1 -(Y2-(Trimethylsilyl)ethoxy)methyl)- l H-pyrazolo[3.4-b1pyridine-5-carboxylic acid.

Abstract

Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. and; Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.

Description

MONOACYLGLYCEROL LIPASE MODULATORS
FIELD OF THE INVENTION
The present invention is related to certain fused chemical entities having MGL modulating properties, pharmaceutical compositions comprising these chemical entities, chemical processes for preparing these chemical entities and their use in the treatment of diseases, disorders or conditions associated with MGL receptor activity in subjects, in particular humans.
BACKGROUND OF THE INVENTION
Cannabis Sativa and analogs of A9-tetrahydrocannabinol have been used since the days of folk medicine for therapeutic purposes. The endocannabinoid system consists of two G-protein coupled receptors, cannabinoid receptor type 1 (CB1) (Matsuda et al, Nature, 1990, 346, 561-4) and cannabinoid receptor type 2 (CB2) (Munro et al, Nature, 1993, 365, 61-5). CB1 receptor is one of the most abundant G-protein coupled receptor expressed in the brain (Herkenam et al., Proc. Nat. Acad. Sci., 1990, 87 (5), 1932-1936). CB1 is also expressed peripherally in the liver, gastrointestinal tract, pancreas, adipose tissue and skeletal muscles (Di Marzo et al, Curr Opin Lipidol, 2007, 18, 129-140). CB2 is predominantly expressed in immune cells such as monocytes (Pacher et al., Amer J Physiol, 2008, 294, Hl 133-H1134) and under certain conditions (inflammation) in the brain ((Benito et al. , Brit J Pharmacol, 2008, 153, 277-285) and in skeletal (Cavuoto et al, Biochem Biophys Res Commun, 2007, 364, 105-110) and cardiac muscles (Hajrasouliha et al, Eur J Pharmacol, 2008, 579, 246-252).
In 1992, N-arachidonoylethanolamine (AEA or anandamide) was found to be an endogenous ligand for cannabinoid receptors (Devane et al, Science, 1992, 258, 1946-9).
Subsequently, 2-arachidonoylglycerol (2- AG) was also identified as an additional endogenous ligand for the cannabinoid receptors (Mechoulam et al. , Biochem Pharmacol, 1995, 50, 83-90; Sugiura et al. , Biochem Biophys Res Commun, 1995, 215, 89-97). Concentrations of 2-AG were reported to be at least 100 times higher than these of anandamide in the rat brain (Buczynski and Parsons, Brit J Pharmacol, 2010, 160 (3), 423-42). Therefore 2-AG may play more essential physiological roles than anandamide in the brain endocannabinoid system (Sugiura et al. Prostaglandins Leukot Essent Fatty Acids., 2002, Feb-Mar, 66(2-3): 173-92). The endocannabinoid 2- AG is a full agonist for CB1 and CB2 receptors, while anandamide is a partial agonist for both receptors (Suguira et al, Prog Lipid Res, 2006, 45(5):405-46). Unlike many classical neurotransmitters, endocannabinoids signal through a retrograde mechanism. They are synthesized on demand in postsynaptic neurons and then rapidly degraded following binding to presynaptic cannabinoid receptors (Ahn et ah, Chem Rev. 2008, 108(5): 1687-707). Monoacylglycerol lipase (MGLL, also known as MAG lipase and MGL) is the serine hydrolase responsible for the degradation of 2- AG into arachidonic acid and glycerol in the central nervous system (Mechoulam et al., Biochem Pharmacol, 1995, 50, 83-90; Sugiura et al., Biochem Biophys Res Commun, 1995, 215, 89-97; Long et al, Nat Chem Biol. 2009 Jan;5(l):37-44; ), Schlosburg et al, Nat Neurosci., 2010, Sep;l3(9): l l l3-9) and peripheral tissues (Long et al, Chem Biol., 2009 Jul 3l ;l6(7):744-53). Anandamide is hydrolyzed by fatty acid amide hydrolase (FAAH) (Piomelli, Nat Rev Neurosci, 2003, 4, 873-884). MGL exists in both soluble and membrane bound forms (Dinh et al, Proc Natl Acad Sci U SA., 2002, Aug 6;99(l6): 10819- 24). In the brain MGL is located in presynaptic neurons (Straiker et al, Mol Pharmacol. , 2009, Dec;76(6): 1220-7) and astrocytes (Walter et al, J Neurosci., 2004, Sep 15;24(37): 8068-74) within regions associated with high CB1 receptor density. Compared to wild-type controls, genetic ablation of MGL expression produces 10-fold increase in brain 2- AG levels without affecting anandamide concentration (Schlosburg et al, Nat Neurosci., 2010, Sep;l3(9): l l l3-9).
Thus, MGL modulation offers an interesting strategy for potentiating the cannabinoid system. The primary advantage of this approach is that only brain regions where
endocannabinoids are actively produced will be modulated, potentially minimizing the side effects associated with exogenous CB1 agonists. Pharmacological inactivation of MGL by covalent inhibitors in animals increase 2- AG content in brain and peripheral tissues and has been found to produce antinociceptive, anxiolytic and anti-inflammatory effects that are dependent on CB1 and/or CB2 receptors (Long et al, Nat Chem Biol., 2009, Jan, 5(l):37-44; Ghosh et al, Life Sci., 2013, Mar 19, 92(8-9):498-505; Bedse et al, Biol Psychiatry., 2017, Oct 1, 82(7):488-499; Bernal-Chico et al, Glia., 2015, Jan, 63( 1 ): 163-76 _Patel et al. Neurosci Biobehav Rev., 2017, May, 76(Pt A):56-66^_Beΐ86 et al, Transl Psychiatry., 2018, Apr 26, 8(l):92). In addition to the role of MGL in terminating 2- AG signaling, MGL modulation, including MGL inhibition also promotes CB1 /2-independent effects on neuroinflammation (Nomura et al, Science., 2011, Nov 11;334(6057):809-13). MGL modulation, including MGL inhibition leads to reduction in proinflammatory prostanoid signaling in animal models of traumatic brain injury (Katz et al, J Neurotrauma., 2015, Mar l;32(5):297-306; Zhang et ah, J Cereb Blood Flow Metab., 2015, Mar 3l;35(4):706), neurodegeneration including Alzheimer’s disease {Piro et ah, Cell Rep., 2012, Jun 28, 1(6):617-23; Wenzel et al, Life Sci., 2018, Aug 15, 207:314-322; Chen et al, Cell Rep.,
2012, Nov 29, 2(5): 1329-39), Parkinson’s disease (Nomura et al., Science, 2011, Nov 11, 334(6057), 809-13; Pasquarelli et al., Neurochem Int., 2017, Nov, 110: 14-24), amyotrophic lateral sclerosis (Pasquarelli et al, Neuropharmacology, 2017, Sep 15, 124: 157-169), multiple sclerosis (Hernadez-Torres et al, Angew Chem Int Ed Engl., 2014, Dec 8, 53(50): 13765-70; Bernal-Chico et al., Glia., 2015, Jan, 63(l): l63-76), Huntington’s disease (Covey et al,
Neuropsychopharmacology, 2018, 43, 2056-2063), Tourette syndrome and status epilepticus (Terrone et al., Epilepsia., 2018, Jan, 59(1), 79-91; von Ruden et al, Neurobiol Dis., 2015, May;77:238-45).
Therefore, by potentiating the cannabinoid system and attenuating proinflammatory cascades, MGL modulation, including MGL inhibition offers a compelling therapeutic approach for the treatment of a vast array of complex diseases. Importantly, MGL modulation, including MGL inhibition in animals does not produces the full spectrum of neurobehavioral effects observed with A9-tetrahydrocannabinol and other CB1 agonists (Tuo et al, J Med Chem., 2017, Jan 12, 60(1), 4-46; Mulvihill et al, Life Sci., 2013, Mar 19, 92(8-9), 492-7).
Endocannabinoid hypoactivity is a risk factor for the treatment of depression, anxiety and post-traumatic stress disorders. Millennia of human use of cannabis sativa, and a brief period in which humans were treated with the endocannabinoid antagonist, rimonabant, provide support for that hypothesis. 2-AG levels are decreased in individuals with major depression (Hill et al, Pharmacopsychiatry., 2008, Mar; 41(2): 48-53; Hill et al, Psychoneuroendocrinology., 2009, Sep; 34(8): 1257-1262.). Low circulating 2-AG levels predict rates of depression (Hauer et al, Rev Neurosci., 2012, 23(5-6):68l-90). Reduced circulating 2-AG has been found in patient with post-traumatic stress disorder (PTSD) (Hill et al., Psychoneuroendocrinology, 2013, 38 (12), 2952-2961). Healthy volunteers exposed to chronic stressors exhibited progressively diminished circulating 2-AG levels which correlated with the onset of reductions in measures of positive emotions (Yi et al, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016,
67 (3), 92-97). The CB1 receptor inverse agonist/antagonist Rimonabant has been withdrawn from the market due to the high incidence of severe depression and suicidal ideation (Christensen et al, The Lancet, 2007, 370, 1706-1713). Therefore, MGL modulators are potentially useful for the treatment of mood disorders, anxiety and PTSD.
Cannabinoid receptor agonists are clinically used to treat pain, spasticity, emesis and anorexia (Di Marzo, et ah, Annu Rev Med., 2006, 57:553-74; Ligresti et al, Curr Opin Chem Biol., 2009, Jun;l3(3):32l-3 l). Therefore, MGL modulators, including MGL inhibitors are also potentially useful for these indications. MGL exerts CB1 -dependant antinociceptive effects in animal models of noxious chemical, inflammatory, thermal and neuropathic pain (Guindon et al, Br J Pharmacol., 2011, Aug;l63(7): 1464-78; Kinsey et al., J Pharmacol Exp Ther., 2009, Sep;330(3):902-l0; Long et al, Nat Chem Biol., 2009, Jan;5(l):37-44). MGL blockade reduces mechanical and acetone induced cold allodynia in mice subjected to chronic constriction injury of the sciatic nerve (Kinsey et al, J Pharmacol Exp Ther., 2009, Sep;330(3):902-l0). MGL inhibition produces opiate- sparing events with diminished tolerance, constipation, and cannabimimetic side effects (Wilkerson et al, J Pharmacol Exp Ther., 2016, Apr;357(l): l45- 56). MGL blockade is protective in model of inflammatory bowel disease (Alhouayek et al, FASEB J., 2011, Aug;25(8):27l 1-21). MGL inhibition also reverse Paclitaxel-induced nociceptive behavior and proinflammatory markers in a mouse model of chemotherapy-induced neuropathy (Curry et al, J Pharmacol Exp Ther., 2018, Jul;366(l): 169-18). MGL inhibitors are also potentially useful for the treatment of chronic inflammatory condition of the urinary bladder like interstitial cystitis (Chinnadurai et al, Med Hypotheses 2019, Oct; 131 : 109321).
Inhibition of 2- AG hydrolysis exerts anti-proliferative activity and reduction in prostate cancer cell invasiveness (Nithipatikom et al, Cancer Res., 2004, Dec 15, 64(24): 8826- 30; Nithipatikom et al, Biochem Biophys Res Commun., 2005, Jul 15,332(4): 1028- 33; Nithipatikom et al, Prostaglandins Other Lipid Mediat., 2011, Feb, 94(1 -2): 34-43). MGL is upregulated in aggressive human cancer cells and primary tumors where it has a unique role of providing lipolytic sources of free fatty acids for synthesis of oncogenic signaling lipids that promote cancer aggressiveness. Thus, beyond the physiological roles of MGL in mediated endocannabinoid signaling, MGL in cancer plays a distinct role in modulating the fatty acid precursor pools for synthesis of protumorigenic signaling lipids in malignant human cancer cells.
MGL blockade shows anti-emetic and anti-nausea effects in a lithium chloride model of vomiting in shrews (Sticht el al, Br J Pharmacol., 2012, Apr, l65(8):2425-35). MGL modulators, including MGL inhibitors may have utility in modulating drug dependence of opiates. MGL blockade reduce the intensity of naloxone-precipitated morphine withdrawal symptoms in mice. MGL blockade also attenuated spontaneous withdrawal signs in morphine- dependent mice (Ramesh et al, J Pharmacol Exp Ther., 2011, Oct, 339(l): l73-85).
MGL modulators are also potentially useful for the treatment of eye conditions, including but not limited to, glaucoma and disease states arising from elevated intraocular pressure (Miller et al., Pharmaceuticals, 2018, 11, 50).
SUMMARY OF THE INVENTION
Embodiments of the present invention relate to chemical entities, pharmaceutical compositions containing them, methods of making and purifying them, and methods for using them the treatment of diseases, disorders, and conditions associated with the MGL modulation. An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition associated with the MGL modulation using at least one chemical entity of the invention.
Additional embodiments, features, and advantages of the invention will be apparent from the following detailed description and through practice of the invention.
Embodiments of this invention are compounds of Formula (I),
Figure imgf000006_0001
wherein:
R2 is selected from the group consisting of: (a)
Figure imgf000007_0001
(b) pyridyl substituted with OCi-4haloalkyl; (c) pyrazole or 1H- 1,2, 4-triazole each substituted with one or two members each
independently selected from the group consisting of: H, Cl, Ci-4alkyl, cyclopropyl and phenyl;
(d)
Figure imgf000007_0002
Figure imgf000008_0003
where X is selected from the group consisting of: O, S, NH, and NCH3; Ra is H or halo;
Rb is selected from the group consisting of: H, halo and CH3;
Rc is H or CF3; and
Rd is H or CH3;
R3 is selected from the group consisting of:
(h) Phenyl; or phenyl independently substituted with one or two members selected from
Figure imgf000008_0001
R4 is selected from the group consisting of: Ci-4alkyl;
with the proviso that when
Figure imgf000008_0002
, then R3 is cyclopropyl; and
pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.
Embodiments of this invention are also compounds of Formula (II),
Figure imgf000009_0001
wherein
R1 is Ci-4alkyl;
R2a is selected from the group consisting of:
(a)
Figure imgf000009_0002
(b) 6-Membered heteroaryl selected from the group consisting of:
Figure imgf000009_0003
(c) 5-Membered heteroaryl selected from the group consisting of:
Figure imgf000009_0004
(d) 5,6-Fused or 6,5-fused heteroaryl selected from the group consisting of:
Figure imgf000009_0005
Figure imgf000010_0001
(e) Fused 6,6 heteroaryl selected from the group consisting of:
Figure imgf000010_0002
Figure imgf000011_0001
(f) Heterocycloalkyl selected from the group consisting of:
Figure imgf000011_0002
R3a is selected from the group consisting of:
(g) Phenyl; or phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, and
OCi-6haloalkyl; (h) 5-Membered heteroaryl selected from the group consisting of:
Figure imgf000012_0001
and
Figure imgf000012_0002
(i) 6-Membered heteroaryl selected from the group consisting of:
Figure imgf000012_0003
and
Figure imgf000012_0004
(j) 5,6-Fused or 6,5-fused heteroaryl selected from the group consisting of:
Figure imgf000012_0005
(k) Heterocycloalkyl selected from the group consisting of:
Figure imgf000012_0006
Re is selected from the group consisting of: OCi-4alkyl, OCi-4haloalkyl, (C=0)NHCH3, and 5- membered heteroaryl ring containing two or three nitrogen members, wherein the 5- membered heteroaryl ring is optionally substituted with one Rf member;
Rf is selected from the group consisting of: H, halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, and OCi-4haloalkyl;
Rg is selected from the group consisting of: OCi-4alkyl, OCi-4haloalkyl, CH2OCH3, CH2OH,
Figure imgf000012_0007
Rh is selected from the group consisting of: H, Ci-4alkyl, Ci-4haloalkyl, and C3-6cycloalkyl; R1 is selected from the group consisting of: H, halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl,
C3-6cycloalkyl, and C3-6cycloalkyl substituted with one or two members independently selected from: F and CH3;
R1 is selected from the group consisting of: H, halo, Ci-4alkyl and Ci-4haloalkyl;
Rk is selected from the group consisting of: H, halo, OH, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, and OCi-4haloalkyl;
Rm is H or Ci-4alkyl;
Rn is selected from the group consisting of: H, halo and OCi-4alkyl;
R° is selected from the group consisting of: H, Ci-4alkyl, and Ci-4haloalkyl;
Rp is selected from the group consisting of: H, Ci-4alkyl, and OCi-4alkyl;
Y is CH or N; and
R4a is selected from the group consisting of: CH3, CF2H, CF3, C3-6cycloalkyl, and phenyl;
and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.
DETAILED DESCRIPTION OF THE INVENTION
As used herein, the terms "including", "containing" and“comprising” are used in their open, non-limiting sense.
Unless qualified specifically in particular instances of use, the term“alkyl” refers to a straight- or branched-chain alkyl group having from 1 to 8 carbon atoms in the chain. Examples of alkyl groups include methyl (Me), ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples. “Ci-C4alkyl” refers to straight- or branched-chain alkyl group having from 1 to 4 carbon atoms in the chain.
The term“cycloalkyl” refers to a saturated or partially saturated, monocyclic, fused polycyclic, or spiro polycyclic carbocycle having from 3 to 12 ring atoms per carbocycle.
Illustrative examples of cycloalkyl groups include the following entities, in the form of properly bonded moieties:
Figure imgf000013_0001
The term“halogen” or“halo” represents chlorine, fluorine, bromine, or iodine.
The term“haloalkyl” refers to a straight- or branched-chain alkyl group having from 1 to 6 carbon atoms in the chain optionally substituting hydrogens with halogens. The term“C1-C4 haloalkyl” as used here refers to a straight- or branched-chain alkyl group having from 1 to 4 carbon atoms in the chain, optionally substituting hydrogens with halogens. Examples of “haloalkyl” groups include trifluoromethyl (CF3), difluoromethyl (CF2H), monofluoromethyl (CH2F), pentafluoroethyl (CF2CF3), tetrafluoroethyl (CHFCF3), monofluoroethyl (CH2CH2F), trifluoroethyl (CH2CF3), tetrafluorotrifluoromethylethyl (CF(CF3)2), and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples.
The term“aryl” refers to a monocyclic, aromatic carbocycle (ring structure having ring atoms that are all carbon) having 6 atoms per ring (Carbon atoms in the aryl groups are sp2 hybridized.)
The term“phenyl” represents the following moiety:
Figure imgf000014_0001
The term "heteroaryl" as used herein, refers to an aromatic monocyclic or multicyclic ring system comprising 5 to 14 ring atoms, wherein from 1 to 4 of the ring atoms is
independently O, N or S and the remaining ring atoms are carbon atoms. In one embodiment, a heteroaryl group has 5 to 10 ring atoms. In another embodiment, a heteroaryl group is monocyclic and has 5 or 6 ring atoms. In another embodiment, a heteroaryl group is monocyclic and has 5 or 6 ring atoms and at least one nitrogen ring atom. A heteroaryl group is joined via a ring carbon atom and any nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide. The term "heteroaryl" also encompasses a heteroaryl group, as defined above, which has been fused to a benzene ring. The term "5-membered heteroaryl" as used herein, refers to a heteroaryl group, as defined above, which has 5 ring atoms. Non-limiting examples of illustrative 5-membered heteroaryls
include:
Figure imgf000015_0001
The term "6-membered heteroaryl" as used herein, refers to a heteroaryl group, as defined above, which has 6 ring atoms. Non-limiting examples of illustrative 6-membered heteroaryls include:
Figure imgf000015_0002
The term "5,6-fused bicyclic heteroaryl or 6,5-fused bicyclic heteroaryl" as used herein, refers to a heteroaryl group, as defined above, which has 9 ring atoms. Non-limiting examples of illustrative 5,6-fused bicyclic heteroaryl or 6,5-fused bicyclic heteroaryl include:
Figure imgf000015_0003
The term "6,6-fused bicyclic heteroaryl" as used herein, refers to a heteroaryl group, as defined above, which has 9 ring atoms. Non-limiting examples of illustrative 6,6-fused bicyclic heteroaryl include:
Figure imgf000016_0001
The term“heterocycloalkyl” as used herein, refers to a ring system which is non aromatic, 1 to 4 of the ring atoms is independently O, N or S and the remaining ring atoms are carbon atoms, which may optionally be fused to another ring (aromatic or heteroaromatic). Non- limiting examples of illustrative 6,6-fused bicyclic heteroaryl include:
Figure imgf000016_0002
Those skilled in the art will recognize that the species of heteroaryl, cycloalkyl, aryl groups listed or illustrated above are not exhaustive, and that additional species within the scope of these defined terms may also be selected.
The term“substituted” means that the specified group or moiety bears one or more substituents. The term "unsubstituted" means that the specified group bears no substituents. The term“optionally substituted” means that the specified group is unsubstituted or substituted by one or more substituents. Where the term“substituted” is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system.
The term“variable point of attachment” means that a group is allowed to be attached at more than one alternative position in a structure. The attachment will always replace a hydrogen atom on one of the ring atoms. In other words, all permutations of bonding are represented by the single diagram, as shown in the illustrations below.
Figure imgf000017_0001
Figure imgf000017_0002
Figure imgf000017_0003
Figure imgf000017_0004
Those skilled in the art will recognize that that if more than one such substituent is present for a given ring, the bonding of each substituent is independent of all of the others. The groups listed or illustrated above are not exhaustive.
The term“substituted” means that the specified group or moiety bears one or more substituents. The term "unsubstituted" means that the specified group bears no substituents. The term“optionally substituted” means that the specified group is unsubstituted or substituted by one or more substituents. Where the term“substituted” is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system.
Any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms. In particular, compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers and stereoisomers of the compounds of the general formula, and mixtures thereof, are considered within the scope of such formula. The compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual ( R )- or (A)-stereoisomers or as mixtures thereof. Thus, any formula given herein is intended to represent a racemate, one or more of its enantiomeric forms, one or more of its diastereomeric forms, and mixtures thereof. Additionally, any formula given herein is intended to refer also to any one of hydrates, solvates, polymorphs and of such compounds, and mixtures thereof, even if such forms are not listed explicitly. The term“R” at a stereocenter designates that the stereocenter is purely of the R- configuration as defined in the art; likewise, the term“S” means that the stereocenter is purely of the L-configuration. As used herein, the term“RS” refers to a stereocenter that exists as a mixture of the R- and L-configurations.
Compounds containing one stereocenter drawn without a stereo bond designation are a mixture of 2 enantiomers. Compounds containing 2 stereocenters both drawn without stereo bond designations are a mixture of 4 diaster eomers. Compounds with 2 stereocenters both labeled“RS” and drawn with stereo bond designations are a 2-component mixture with relative stereochemistry as drawn. Unlabeled stereocenters drawn without stereo bond designations are a mixture of the R- and L-configurations. For unlabeled stereocenters drawn with stereo bond designations, the absolute stereochemistry is as depicted.
Reference to a compound herein stands for a reference to any one of: (a) the actually recited form of such compound, and (b) any of the forms of such compound in the medium in which the compound is being considered when named. For example, reference herein to a compound such as R-COOH, encompasses reference to any one of, for example, R-COOH(s), R- COOH(sol), and R-COO-(sol). In this example, R-COOH(s) refers to the solid compound, as it could be for example in a tablet or some other solid pharmaceutical composition or preparation; R-COOH(sol) refers to the undissociated form of the compound in a solvent; and R-COO-(sol) refers to the dissociated form of the compound in a solvent, such as the dissociated form of the compound in an aqueous environment, whether such dissociated form derives from R-COOH, from a salt thereof, or from any other entity that yields R-COO- upon dissociation in the medium being considered. In another example, an expression such as“exposing an entity to compound of formula R-COOH” refers to the exposure of such entity to the form, or forms, of the compound R-COOH that exists, or exist, in the medium in which such exposure takes place. In still another example, an expression such as“reacting an entity with a compound of formula R-COOH” refers to the reacting of (a) such entity in the chemically relevant form, or forms, of such entity that exists, or exist, in the medium in which such reacting takes place, with (b) the chemically relevant form, or forms, of the compound R-COOH that exists, or exist, in the medium in which such reacting takes place. In this regard, if such entity is for example in an aqueous environment, it is understood that the compound R-COOH is in such same medium, and therefore the entity is being exposed to species such as R-COOH(aq) and/or R-COO-(aq), where the subscript“(aq)” stands for“aqueous” according to its conventional meaning in chemistry and biochemistry. A carboxylic acid functional group has been chosen in these nomenclature examples; this choice is not intended, however, as a limitation but it is merely an illustration. It is understood that analogous examples can be provided in terms of other functional groups, including but not limited to hydroxyl, basic nitrogen members, such as those in amines, and any other group that interacts or transforms according to known manners in the medium that contains the compound. Such interactions and transformations include, but are not limited to, dissociation, association, tautomerism, solvolysis, including hydrolysis, solvation, including hydration, protonation, and deprotonation. No further examples in this regard are provided herein because these interactions and transformations in a given medium are known by any one of ordinary skill in the art.
Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number in an enriched form. Examples of isotopes that can be incorporated into compounds of the invention in a form that exceeds natural abundances include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2H (or chemical symbol D), ¾ (or chemical symbol T), nC, 13C, 14C, 15N, 180, 170, 31P, 32P, 35S, 18F, 36Cl, and 125I, respectively. Such isotopically labelled compounds are useful in metabolic studies (preferably with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques [such as positron emission tomography (PET) or single photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 18F or nC labeled compound may be particularly preferred for PET or SPECT studies. Further, substitution with heavier isotopes such as deuterium (i.e., 2H, or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage
requirements. Isotopically labeled compounds of this invention can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non- isotopically labeled reagent.
When referring to any formula given herein, the selection of a particular moiety from a list of possible species for a specified variable is not intended to define the same choice of the species for such variable appearing elsewhere. In other words, where a variable appears more than once, the choice of the species from a specified list is independent of the choice of the species for the same variable elsewhere in the formula, unless stated otherwise.
The term Cn-m alkyl refers to an aliphatic chain, whether straight or branched, with a total number N of carbon members in the chain that satisfies n < N < m, with m > n.
When the same plurality of substituents is assigned to various groups, the specific individual substituent assignment to each of such groups is meant to be independently made with respect to the specific individual substituent assignments to the remaining groups. By way of illustration, but not as a limitation, if each of groups Q and R can be H or F, the choice of H or F for Q is made independently of the choice of H or F for R, so the choice of assignment for Q does not determine or condition the choice of assignment for R, or vice-versa, unless it is expressly indicated otherwise. Illustrative claim recitation in this regard would read as“each of Q and R is independently H or F”, or“each of Q and R is independently selected from the group consisting of H and F”.
Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art.
In another example, a zwitterionic compound would be encompassed herein by referring to a compound that is known to form a zwitterion, even if it is not explicitly named in its zwitterionic form. Terms such as zwitterion, zwitterions, and their synonyms zwitterionic compound(s) are standard IUP AC-endorsed names that are well known and part of standard sets of defined scientific names. In this regard, the name zwitterion is assigned the name
identification CHEBT27369 by the Chemical Entities of Biological Interest (ChEBI) dictionary of molecular entities. As generally well known, a zwitterion or zwitterionic compound is a neutral compound that has formal unit charges of opposite sign. Sometimes these compounds are referred to by the term“inner salts”. Other sources refer to these compounds as“dipolar ions”, although the latter term is regarded by still other sources as a misnomer. As a specific example, aminoethanoic acid (the amino acid glycine) has the formula H2NCH2COOH, and it exists in some media (in this case in neutral media) in the form of the zwitterion +FFNCFl2COO .
Zwitterions, zwitterionic compounds, inner salts and dipolar ions in the known and well- established meanings of these terms are within the scope of this invention, as would in any case be so appreciated by those of ordinary skill in the art. Because there is no need to name each and every embodiment that would be recognized by those of ordinary skill in the art, no structures of the zwitterionic compounds that are associated with the compounds of this invention are given explicitly herein. They are, however, part of the embodiments of this invention. No further examples in this regard are provided herein because the interactions and transformations in a given medium that lead to the various forms of a given compound are known by any one of ordinary skill in the art.
When referring to any formula given herein, the selection of a particular moiety from a list of possible species for a specified variable is not intended to define the same choice of the species for the variable appearing elsewhere. In other words, where a variable appears more than once, the choice of the species from a specified list is independent of the choice of the species for the same variable elsewhere in the formula, unless stated otherwise.
By way of a first example on substituent terminology, if substituent S1 example is one of Si and S2, and substituent S2examPie is one of S3 and S4, then these assignments refer to embodiments of this invention given according to the choices S Example is S i and S2exampie is S3 ; S Example is S i and S2exampie is S4; S ' xampl is S ' and S2exampie is S3; S ' xampl is S ' and S2exampie is S4; and equivalents of each one of such choices. The shorter terminology“S Example is one of S i and S2, and S2example IS one of S3 and S4” is accordingly used herein for the sake of brevity, but not by way of limitation. The foregoing first example on substituent terminology, which is stated in generic terms, is meant to illustrate the various substituent assignments described herein.
Furthermore, when more than one assignment is given for any member or substituent, embodiments of this invention comprise the various groupings that can be made from the listed assignments, taken independently, and equivalents thereof. By way of a second example on substituent terminology, if it is herein described that substituent Sexampie is one of S i, S2, and S3, this listing refers to embodiments of this invention for which Sexampie is S i; Sexampie is S2; Sexampie IS S3 ; Sexampie IS One of Si and S2; Sexampie IS One of Si and S3; Sexampie IS One of S2 and S3; Sexampie is one of S i, S2 and S3; and Sexampie is any equivalent of each one of these choices. The shorter terminology“Sexampie is one of S i, S2, and S3” is accordingly used herein for the sake of brevity, but not by way of limitation. The foregoing second example on substituent terminology, which is stated in generic terms, is meant to illustrate the various substituent assignments described herein.
The nomenclature“Ci-Q” with j > i, when applied herein to a class of substituents, is meant to refer to embodiments of this invention for which each and every one of the number of carbon members, from i to j including i and j, is independently realized. By way of example, the term C1-C3 refers independently to embodiments that have one carbon member (Ci),
embodiments that have two carbon members (C2), and embodiments that have three carbon members (C3).
A "pharmaceutically acceptable salt” is intended to mean a salt of an acid or base of a compound represented by Formula (I) (as well as compounds of Formula (II)) that is non- toxic, biologically tolerable, or otherwise biologically suitable for administration to the subject. See, generally, S.M. Berge, et al,“Pharmaceutical Salts”, J. Pharm. Sci., 1977, 66: 1-19, and
Handbook of Pharmaceutical Salts, Properties, Selection, and Use, Stahl and Wermuth, Eds., Wiley -VCH and VHCA, Zurich, 2002. Preferred pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response.
A compound of Formula (I) (as well as compounds of Formula (II)) may possess a sufficiently acidic group, a sufficiently basic group, or both types of functional groups, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates,
metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-l,4-di oates, hexyne-l,6- dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, g-hydroxybutyrates, glycolates, tartrates, methane-sulfonates, propanesulfonates, naphthalene- 1 -sulfonates, naphthalene-2-sulfonates, and mandelates.
Compounds of Formula (I) (as well as compounds of Formula (II)) may contain at least one nitrogen of basic character, so desired pharmaceutically acceptable salts may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such as mandelic acid, citric acid, or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid, 2-acetoxybenzoic acid, naphthoic acid, or cinnamic acid, a sulfonic acid, such as laurylsulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, any compatible mixture of acids such as those given as examples herein, and any other acid and mixture thereof that are regarded as equivalents.
Compounds of Formula (I) (as well as compounds of Formula (II)) may contain a carboxylic acid moiety, a desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases such as those given as examples herein, and any other base and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology. Illustrative examples of suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonia, carbonates, bicarbonates, primary, secondary, and tertiary amines, and cyclic amines, such as benzylamines, pyrrolidines, piperidine, morpholine, piperazine, /V-methyl-glucamine and tromethamine and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
The compounds of the invention, including their pharmaceutically acceptable salts, whether alone or in combination, (collectively,“active agent” or "active agents") of the present invention are useful as MGL-modulators in the methods of the invention. Such methods for modulating MGL comprise the use of a therapeutically effective amount of at least one chemical entity of the invention.
In some embodiments, the MGL modulator is an inhibitor and is used in a subject diagnosed with or suffering from a disease, disorder, or condition associated with MGL receptor activity, such as those described herein. Symptoms or disease states are intended to be included within the scope of "disease, disorders or conditions."
Accordingly, the invention relates to methods of using the active agents described herein to treat subjects diagnosed with or suffering from a disease, disorder, or condition associated with the MGL receptor activity. The term "treat" or "treating" as used herein is intended to refer to administration of an active agent or composition of the invention to a subject for the purpose of effecting a therapeutic or prophylactic benefit through modulation of MGL receptor activity. Treating includes reversing, ameliorating, alleviating, inhibiting the progress of, lessening the severity of, or preventing a disease, disorder, or condition, or one or more symptoms of such disease, disorder or condition associated with the MGL modulation. The term "subject" refers to a mammalian patient in need of such treatment, such as a human.
The term“composition” refers to a product that includes the specified ingredients in therapeutically effective amounts, as well as any product that results, directly, or indirectly, from combinations of the specified ingredients in the specified amounts.
The term“MGL inhibitor” is intended to encompass a compound that interacts with MGL to substantially reduce or eliminate its catalytic activity, thereby increasing the concentrations of its substrate(s). The term“MGL-modulated” is used to refer to the condition of being affected by the modulation of the MGL enzyme including the condition of being affected by the inhibition of the MGL enzyme. The disclosure is directed to methods for treating, ameliorating and / or preventing diseases, conditions, or disorders associated with pain (including inflammatory pain), and also psychiatric disorders, neurological disorders, cancers and eye conditions by the administration of therapeutically effective amounts of MGL modulators to subjects in need thereof.
The term“modulators” include both inhibitors and activators, where "inhibitors” refer to compounds that decrease, prevent, inactivate, desensitize, or down-regulate the MGL expression or activity, and“activators” are compounds that increase, activate, facilitate, sensitize, or up- regulate MGL expression or activity.
As used herein, unless otherwise noted, the term“affect” or“affected” (when referring to a disease, condition or disorder that is affected by inhibition of MGL) includes a reduction in the frequency and / or severity of one or more symptoms or manifestations of said disease, condition or disorder; and / or include the prevention of the development of one or more symptoms or manifestations of said disease, condition or disorder or the development of the disease, condition or disorder.
In treatment methods according to the invention, a therapeutically effective amount of at least one active agent according to the invention is administered to a subject suffering from or diagnosed as having such a disease, disorder, or condition. A "therapeutically effective amount" means an amount or dose sufficient to generally bring about the desired therapeutic or prophylactic benefit in subjects in need of such treatment for the designated disease, disorder, or condition. Effective amounts or doses of the active agents of the present invention may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician. For a 70-kg human, an illustrative range for a suitable dosage amount is from about 1 to 1000 mg/day in single or multiple dosage units (e.g., BID, ED, QID or as required by modality).
Once improvement of the subject's disease, disorder, or condition has occurred, the dose may be adjusted for preventive or maintenance treatment. For example, the dosage or the frequency of administration, or both, may be reduced as a function of the symptoms, to a level at which the desired therapeutic or prophylactic effect is maintained. Of course, if symptoms have been alleviated to an appropriate level, treatment may cease. Subjects may, however, require intermittent treatment on a long-term basis upon any recurrence of symptoms.
In addition, the compounds of the invention are envisaged for use alone, in combination with one or more of other compounds of this invention, or in combination with additional active ingredients in the treatment of the conditions discussed below. The additional active ingredients may be co-administered separately with at least one compound of the invention, with active agents of the invention or included with such an agent in a pharmaceutical composition according to the invention. In an illustrative embodiment, additional active ingredients are those that are known or discovered to be effective in the treatment of conditions, disorders, or diseases associated with the MGF modulation, such as another MGF inhibitor or a compound active against another target associated with the particular condition, disorder, or disease. The combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of an agent according to the invention), decrease one or more side effects, or decrease the required dose of the active agent according to the invention.
When referring to inhibiting the target, an“effective amount” means an amount sufficient to affect MGL modulation.
The active agents of the invention are envisaged for use, alone or in combination with one or more additional active ingredients, to formulate pharmaceutical compositions of the invention. A pharmaceutical composition of the invention comprises a therapeutically effective amount of at least one active agent in accordance with the invention.
Pharmaceutically acceptable excipients commonly used in pharmaceutical compositions are substances that are non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith. Examples of such excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
Delivery forms of the pharmaceutical compositions containing one or more dosage units of the active agents may be prepared using pharmaceutically acceptable excipients and compounding techniques known or that become available to those of ordinary skill in the art.
The compositions may be administered in the inventive methods by a suitable route of delivery, e.g., oral, parenteral, rectal, topical, or ocular routes, or by inhalation.
The preparation may be in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, powders for reconstitution, liquid preparations, or suppositories. The compositions may be formulated for any one of a plurality of administration routes, such as intravenous infusion, topical administration, or oral administration. Preferably, the compositions may be formulated for oral administration.
For oral administration, the active agents of the invention can be provided in the form of tablets or capsules, or as a solution, emulsion, or suspension. To prepare the oral compositions, the active agents may be formulated to yield a dosage of, e.g., for a 70-kg human, an illustrative range for a suitable dosage amount is from about 1 to 1000 mg/day in single or multiple dosage units. Oral tablets may include the active ingredient(s) mixed with compatible pharmaceutically acceptable excipients such as diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents. Suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like.
Exemplary liquid oral excipients include ethanol, glycerol, water, and the like. Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are exemplary disintegrating agents. Binding agents may include starch and gelatin. The lubricating agent, if present, may be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.
Capsules for oral administration include hard and soft gelatin or (hydroxypropyl)methyl cellulose capsules. To prepare hard gelatin capsules, active ingredient(s) may be mixed with a solid, semi-solid, or liquid diluent. Liquids for oral administration may be in the form of suspensions, solutions, emulsions or syrups or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose,
carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.
The active agents of this invention may also be administered by non-oral routes. For example, compositions may be formulated for rectal administration as a suppository, enema or foam. For parenteral use, including intravenous, intramuscular, intraperitoneal, or subcutaneous routes, the agents of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Such forms may be presented in unit-dose form such as ampules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre- concentrate that can be used to prepare an injectable formulation. Illustrative infusion doses range from about 1 to 1000 mg/kg/minute of agent admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.
For topical administration, the agents may be mixed with a pharmaceutical carrier at a concentration of about 0.01% to about 20% of drug to vehicle, preferably 0.1% to 10%. Another mode of administering the agents of the invention may utilize a patch formulation to affect transdermal delivery.
Active agents may alternatively be administered in methods of this invention by inhalation, via the nasal or oral routes, e.g., in a spray formulation also containing a suitable carrier.
In a further embodiment, the invention is directed to a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition associated with MGL modulation, comprising administering to the subject in need of such treatment a therapeutically effective amount of the active agent.
The compounds of Formula (I) and Formula (II) are useful in methods for treating, ameliorating and / or preventing a disease, a condition or a disorder that is affected by the inhibition of MGL. Such methods comprise administering to a subject, including an animal, a mammal, and a human in need of such treatment, amelioration and / or prevention, a
therapeutically effective amount of a compound of Formula (I), Formula (II), or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof.
In particular, the compounds of Formula (I), Formula (II), or pharmaceutically acceptable salts, isotopes, N-oxides, solvates and stereoisomers thereof, are useful for treating, ameliorating and / or preventing diseases, conditions, or disorders causing pain, psychiatric disorders, neurological disorders, cancers and eyes conditions. More particularly, the compounds of Formula (I), Formula (II), or pharmaceutically acceptable salts, isotopes, N-oxides, solvates and stereoisomers thereof, are useful for treating, ameliorating and / or preventing inflammatory pain, major depressive disorder, treatment resistant depression, anxious depression or bipolar disorder by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I), Formula (II), or a pharmaceutically acceptable salt, isotope, N-oxide, solvate or stereoisomer thereof as herein defined.
1) Pain Examples of inflammatory pain include, but are not limited to, pain due to a disease, condition, disorder, or a pain state including inflammatory bowel disease, visceral pain, migraine, post-operative pain, osteoarthritis, rheumatoid arthritis, back pain, lower back pain, joint pain, abdominal pain, chest pain, labor, musculoskeletal diseases, skin diseases, toothache, pyresis, burn, sunburn, snake bite, venomous snake bite, spider bite, insect sting, neurogenic bladder, interstitial cystitis, urinary tract infection, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, pharyngitis, mucositis, enteritis, irritable bowel syndrome, cholecystitis, pancreatitis, postmastectomy pain syndrome, menstrual pain, endometriosis, pain due to physical trauma, headache, sinus headache, tension headache, or arachnoiditis.
One type of inflammatory pain is inflammatory hyperalgesia / hypersensitivity.
Examples of inflammatory hyperalgesia include a disease, condition, disorder, or pain state including inflammation, osteoarthritis, rheumatoid arthritis, back pain, joint pain, abdominal pain, musculoskeletal diseases, skin diseases, post-operative pain, headaches, toothache, burn, sunburn, insect sting, neurogenic bladder, urinary incontinence, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact
dermatitis/hypersensitivity and/or dermal allergy, itch, eczema, pharyngitis, enteritis, irritable bowel syndrome, inflammatory bowel diseases including Crohn's Disease, ulcerative colitis, benign prostatic hypertrophy, and nasal hypersensitivity.
In an embodiment, the present invention is directed to a method for treating, ameliorating and / or preventing inflammatory visceral hyperalgesia in which an enhanced visceral irritability exists, comprising, consisting of, and/or consisting essentially of the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula (I) (as well as compounds of Formula (II)) or a pharmaceutically acceptable salt, isotope, N- oxide, solvate or stereoisomer thereof. In a further embodiment, the present invention is directed to a method for treating inflammatory somatic hyperalgesia in which a hypersensitivity to thermal, mechanical and/or chemical stimuli exists, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula (I) (as well as compounds of Formula (II)), or a pharmaceutically acceptable salt, isotope, N-oxide, solvate or stereoisomer thereof.
A further embodiment of the present invention is directed to a method for treating, ameliorating and / or preventing neuropathic pain. Examples of a neuropathic pain include pain due to a disease, condition, disorder, or pain state including cancer, neurological disorders, spine and peripheral nerve surgery, brain tumor, traumatic brain injury (TBI), spinal cord trauma, chronic pain syndrome, fibromyalgia, chronic fatigue syndrome, lupus, sarcoidosis, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, central pain, neuropathies associated with spinal cord injury, stroke, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, multiple sclerosis, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, oral neuropathic pain, Charcot's pain, complex regional pain syndrome I and II (CRPS I/II), radiculopathy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, postherpetic neuralgia, causalgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, trigeminal neuralgia, vulvodynia, vidian neuralgia or chemotherapy-induced neuropathy.
One type of neuropathic pain is neuropathic cold allodynia, which can be characterized by the presence of a neuropathy-associated allodynic state in which a hypersensitivity to cooling stimuli exists. Examples of neuropathic cold allodynia include allodynia due to a disease, condition, disorder or pain state including neuropathic pain (neuralgia), pain arising from spine and peripheral nerve surgery or trauma, traumatic brain injury (TBI), trigeminal neuralgia, postherpetic neuralgia, causalgia, peripheral neuropathy, diabetic neuropathy, central pain, stroke, peripheral neuritis, polyneuritis, complex regional pain syndrome I and II (CRPS I/II) and radiculopathy.
In a further embodiment, the present invention is directed to a method for treating, ameliorating and / or preventing neuropathic cold allodynia in which a hypersensitivity to a cooling stimuli exists, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula (I) (as well as compounds of Formula (II)) or a pharmaceutically acceptable salt, isotope, N-oxide, solvate or stereoisomer thereof.
2) Psychiatric disorders Examples of psychiatric disorders include, but are not limited to, anxieties such as, social anxiety, post-traumatic stress disorder, phobias, social phobia, special phobias, panic disorder, obsessive-compulsive disorder, acute stress disorder, separation anxiety disorder, and generalized anxiety disorder, as well as depression such as, major depression, bipolar disorder, seasonal affective disorder, post-natal depression, manic depression, and bipolar depression, mood disorders and mood affective disorders that can be treated according to the present invention include, but are not limited to, bipolar disorder I depressed, hypomanic, manic and mixed form; bipolar disorder II; depressive disorders, such as single depressive episode or recurrent major depressive disorder, minor depressive disorder, treatment-resistant depression, anxious depression, bipolar disorder, depressive disorder with postpartum onset, depressive disorders with psychotic symptoms; persistent mood disorders, such as cyclothymia, dysthymia, euthymia; and premenstrual dysphoric disorder;psychoses.
3) Neurological disorders
Examples of neurological disorder include, but are not limited to, tremors, dyskinesias, dystonias, spasticity, Tourette’s Syndrome; neuromyelitis optica, Parkinson’s disease;
Alzheimer’s disease; senile dementia; Huntington’s disease; Epilepsy/seizure disorders and sleep disorders.
4) Cancers:
Examples of cancers include, but are not limited to, benign skin tumors, prostate tumors, ovarian tumors and cerebral tumors (glioblastomas, medulloepithebomas, medulloblastomas, neuroblastomas, tumors of embryonic origin, astrocytomas, astroblastomas, ependymomas, oligodendrogliomas, neuroepitheliomas, epiphyseal tumor, ependymoblastomas, malignant meningiomas, sarcomatosis, malignant melanomas, schwannomas).
5) Eye conditions
Examples of eye conditions include, but are not limited to, ocular hypertension, glaucoma, degeneration and apoptosis of retinal ganglion cells and neuroretinal cells. Other embodiments of this invention provide for a method for modulating MGL receptor activity, including when such receptor is in a subject, comprising exposing MGL receptor to a therapeutically effective amount of at least one compound selected from compounds of the invention.
Embodiments of this invention are compounds of Formula (I),
Figure imgf000032_0001
wherein:
R2 is selected from the group consisting of: (a)
Figure imgf000032_0002
(b) pyridyl substituted with OCi-4haloalkyl;
(c) pyrazole or 1H- 1,2, 4-triazole each substituted with one or two members each
independently selected from the group consisting of: H, Cl, Ci-4alkyl, cyclopropyl and phenyl;
(d)
Figure imgf000033_0001
where X is selected from the group consisting of: O, S, NH, and NCH3; Ra is H or halo;
Rb is selected from the group consisting of: H, halo and CH3;
Rc is H or CF3; and
Rd is H or CH3;
R3 is selected from the group consisting of: (h) Phenyl; or phenyl independently substituted with one or two members selected from
Figure imgf000034_0001
R4 is selected from the group consisting of: Ci-4alkyl;
,
with the proviso that when
Figure imgf000034_0002
, then R is cyclopropyl;
and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.
An additional embodiment of the invention is a compound of Formula (I) wherein R2 is
Figure imgf000034_0003
An additional embodiment of the invention is a compound of Formula (I) wherein R2 is
Figure imgf000034_0004
An additional embodiment of the invention is a compound of Formula (I) wherein R2 is
Figure imgf000035_0001
An additional embodiment of the invention is a compound of Formula (I) wherein R2 is
Figure imgf000035_0002
An additional embodiment of the invention is a compound of Formula (I) wherein R2 is
Figure imgf000035_0003
An additional embodiment of the invention is a compound of Formula (I) wherein R2 is
Figure imgf000035_0004
An additional embodiment of the invention is a compound of Formula (I) wherein R2 is
Figure imgf000035_0005
An additional embodiment of the invention is a compound of Formula (I) wherein R2 is
Figure imgf000036_0001
An additional embodiment of the invention is a compound of Formula (I) wherein R2 is
Figure imgf000036_0002
An additional embodiment of the invention is a compound of Formula (I) wherein R2 is
Figure imgf000036_0003
An additional embodiment of the invention is a compound of Formula (I) wherein R2 is
Figure imgf000036_0004
An additional embodiment of the invention is a compound of Formula (I) wherein R2 is
Figure imgf000037_0001
An additional embodiment of the invention is a compound of Formula (I) wherein R2 is
Figure imgf000037_0002
An additional embodiment of the invention is a compound of Formula (I) wherein R3 is phenyl, 3,5-difluorophenyl, 3-chlorophenyl, 3 -fluorophenyl, or 3-(difluoromethoxy)phenyl.
An additional embodiment of the invention is a compound of Formula (I) wherein R3 is cyclopropyl. An additional embodiment of the invention is a compound of Formula (I) wherein R4 is CFE.
An additional embodiment of the invention is a compound of Formula (I) wherein X is O.
An additional embodiment of the invention is a compound of Formula (I) wherein X is S.
An additional embodiment of the invention is a compound of Formula (I) wherein X is NH or
NCH3.
A further embodiment of the current invention is a compound as shown below in Table 1.
Figure imgf000037_0003
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0002
and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.
An additional embodiment of the invention is a pharmaceutical composition comprising:
(A) a therapeutically effective amount of at least one compound selected from
compounds of Formula (I)
Figure imgf000044_0001
wherein:
R2 is selected from the group consisting of: (a)
Figure imgf000045_0001
(b) pyridyl substituted with OCi-4haloalkyl;
(c) pyrazole or 1H- 1,2, 4-triazole each substituted with one or two members each
independently selected from the group consisting of: H, Cl, Ci-4alkyl, cyclopropyl and phenyl;
(d)
Figure imgf000045_0002
Figure imgf000046_0003
where X is selected from the group consisting of: O, S, NH, and NCH3;
Ra is H or halo;
Rb is selected from the group consisting of: H, halo and CH3;
Rc is H or CF3; and
Rd is H or CH3;
R3 is selected from the group consisting of:
(h) Phenyl; or phenyl independently substituted with one or two members selected from
Figure imgf000046_0001
R4 is selected from the group consisting of: Ci-4alkyl;
with the proviso that when
Figure imgf000046_0002
, then R3 is cyclopropyl;
and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers of compounds of Formula (I);
and (B) at least one pharmaceutically acceptable excipient.
An additional embodiment of the invention is a pharmaceutical composition comprising a therapeutically effective amount of at least one compound in Table 1 , as well as and
pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers of compounds of Table 1, pharmaceutically acceptable prodrugs of compounds of Table 1, and pharmaceutically active metabolites of Table 1 ; and at least one pharmaceutically acceptable excipient.
An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by MGL receptor activity, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one compound selected from compounds of Formula (I):
Figure imgf000047_0001
wherein:
R2 is selected from the group consisting of:
(a)
Figure imgf000047_0002
(b) pyridyl substituted with OCi-4haloalkyl;
(c) pyrazole or 1H- 1,2, 4-triazole each substituted with one or two members each
independently selected from the group consisting of: H, Cl, Ci-4alkyl, cyclopropyl and phenyl;
Figure imgf000048_0001
where X is selected from the group consisting of: O, S, NH, and NCH3; Ra is H or halo;
Rb is selected from the group consisting of: H, halo and CH3;
Rc is H or CF3; and
Rd is H or CH3;
R3 is selected from the group consisting of: (h) Phenyl; or phenyl independently substituted with one or two members selected from
Figure imgf000049_0001
R4 is selected from the group consisting of: Ci-4alkyl;
with the proviso that when
Figure imgf000049_0002
, then R3 is cyclopropyl; and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, to a subject in need thereof.
An additional embodiment of the invention is a compound of Formula (II) wherein
Figure imgf000049_0003
wherein
R1 is Ci-4alkyl;
R2a is selected from the group consisting of:
(a)
Figure imgf000049_0004
(b) 6-Membered heteroaryl selected from the group consisting of:
Figure imgf000049_0005
(c) 5-Membered heteroaryl selected from the group consisting of:
Figure imgf000050_0001
(d) 5,6-Fused or 6,5-fused heteroaryl selected from the group consisting of:
Figure imgf000050_0002
Figure imgf000051_0001
(e) Fused 6,6 heteroaryl selected from the group consisting of:
Figure imgf000051_0002
(f) Heterocycloalkyl selected from the group consisting of:
Figure imgf000051_0003
Figure imgf000052_0001
R a is selected from the group consisting of:
(g) Phenyl; or phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, and OCi-6haloalkyl;
(h) 5-Membered heteroaryl selected from the group consisting of:
Figure imgf000052_0002
Figure imgf000052_0003
(i) 6-Membered heteroaryl selected from the group consisting of:
Figure imgf000052_0004
and
Figure imgf000052_0005
(j) 5,6-Fused or 6,5-fused heteroaryl selected from the group consisting of:
Figure imgf000053_0001
Heterocycloalkyl selected from the group consisting of:
Figure imgf000053_0002
Re is selected from the group consisting of: OCi-4alkyl, OCi-4haloalkyl, (C=0)NHCH3, and 5-membered heteroaryl ring containing two or three nitrogen members, wherein the 5-membered heteroaryl ring is optionally substituted with one Rf member;
Rf is selected from the group consisting of: H, halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, and OCi-4haloalkyl;
Rg is selected from the group consisting of: OCi-4alkyl, OCi-4haloalkyl, CH2OCH3,
Figure imgf000053_0003
Rh is selected from the group consisting of: H, Ci-4alkyl , Ci-4haloalkyl, and
C3-6cycloalkyl;
R1 is selected from the group consisting of: H, halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, C3-6cycloalkyl, and C3-6cycloalkyl substituted with one or two members
independently selected from: F and CH3;
R1 is selected from the group consisting of: H, halo, Ci-4alkyl and Ci-4haloalkyl;
Rk is selected from the group consisting of: H, halo, OH, Ci-4alkyl, Ci-4haloalkyl, OCi-
4alkyl, and OCi-4haloalkyl;
Rm is H or Ci-4alkyl;
Rn is selected from the group consisting of: H, halo and OCi-4alkyl;
R° is selected from the group consisting of: H, Ci-4alkyl, and Ci-4haloalkyl;
Rp is selected from the group consisting of: H, Ci-4alkyl, and OCi-4alkyl; Y is CH or N; and
R4a is selected from the group consisting of: CH3, CF2H, CF3, C3-6cycloalkyl, and phenyl; and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof. An additional embodiment of the invention is a compound of Formula (II) wherein R1 is CH3. An additional embodiment of the invention is a compound of Formula (II) wherein R1 is CH2CH3
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000054_0001
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000055_0001
An additional embodiment of the invention is a compound of Formula (II) wherein Re is '~t“ ,
Figure imgf000055_0002
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000055_0003
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000056_0001
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000056_0002
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000057_0001
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000057_0002
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000057_0003
An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
Figure imgf000058_0001
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000058_0002
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000058_0003
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000058_0004
An additional embodiment of the invention is a compound of Formula (II) wherein R
Figure imgf000059_0001
Figure imgf000059_0002
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000059_0003
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000060_0001
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000060_0002
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000060_0003
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000061_0001
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000061_0002
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000061_0003
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000062_0001
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000062_0002
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000062_0003
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000062_0004
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000063_0001
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000063_0002
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000063_0003
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000064_0001
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000064_0002
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000064_0003
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000065_0001
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000065_0002
An additional embodiment of the invention is a compound of Formula (II) wherein R2a is
Figure imgf000065_0003
An additional embodiment of the invention is a compound of Formula (II) wherein R3a is phenyl; or phenyl substituted with one member selected from the group consisting of: F, Cl, OCH3, OCH2CH3, OCH(CH3)2, OCHF2, CF3, CF2CH3, OCF2H, and OCF3. An additional embodiment of the invention is a compound of Formula (II) wherein R3a is phenyl substituted with two or three members independently selected from the group consisting of: F, Cl, CH3, CF2H, OCF2H and OCH3. An additional embodiment of the invention is a compound of Formula (II) wherein R3a is
Figure imgf000066_0001
An additional embodiment of the invention is a compound of Formula (II) wherein R3a is
Figure imgf000066_0002
An additional embodiment of the invention is a compound of Formula (II) wherein R4a is CH3. An additional embodiment of the invention is a compound of Formula (II) wherein R4a is CF3.
An additional embodiment of the invention is a compound of Formula (II) wherein R4a is CF2H. An additional embodiment of the invention is a compound of Formula (II) wherein R4a is phenyl. An additional embodiment of the invention is a compound of Formula (II) having the Formula
Figure imgf000067_0001
wherein
R1 is CH3;
R2a is selected from the group consisting of:
Figure imgf000067_0002
R4a is CH3 or phenyl; and
each Rn is independently selected from the group consisting of: H, Cl and F; and m is 1,2, or 3.
An additional embodiment of the invention is a compound of Formula (II) having the Formula
(PB):
Figure imgf000067_0003
wherein
R1 is CH3 or CH2CH3
Re is selected from the group consisting of: OCi-4alkyl, OCi-4haloalkyl, (C=0)NHCH3, and 5-membered heteroaryl ring containing two or three nitrogen members, wherein the 5-membered heteroaryl ring is optionally substituted with one Rf member; Rf is selected from the group consisting of: H, halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, and OCi-4haloalkyl;
R3a is phenyl substituted with one, two, or three members independently selected from halo or Ci-4alkyl; and
R4a is CH3.
An additional embodiment of the invention is a compound of Formula (II) having the Formula
(IIB), wherein
R1 is CH3;
Re is selected from the group consisting of: OCi-4alkyl, OCi-4haloalkyl, (C=0)NHCH3, and 5-membered heteroaryl ring containing two or three nitrogen members, wherein the 5-membered heteroaryl ring is optionally substituted with one Rf member;
Rf is selected from the group consisting of: H, halo, Ci-4alkyl, Ci-4haloalkyl,
OCi-4alkyl, and OCi-4haloalkyl;
R3a is 3-chlorophenyl, 3,5-difluorophenyl, 3-fluoro-5-methyl-phenyl, or 3,4,5- trifluorophenyl; and
R4a is CH3.
An additional embodiment of the invention is a compound of Formula (II) having the Formula
(IIC):
Figure imgf000068_0001
wherein
R1 is CH3;
R2a is selected from the group consisting of:
Figure imgf000069_0001
Figure imgf000070_0001
R1 is selected from the group consisting of: H, F, CH3, CF3, CF2H, OCH3, and cyclopropyl; R1 is selected from the group consisting of: H, Br, F, CH3, and CF3;
Rm is H or CH3;
Rn is selected from the group consisting of: H, halo and OCH3;
R° is selected from the group consisting of: H, CH3, CF3, CF2H, and CH2CH2F;
Y is CH or N;
and
R3a is phenyl substituted with one, two or three members each independently selected from the group consisting of: Cl, F, CH3, and OCH3.
An additional embodiment of the invention is a compound of Formula (II) having the Formula (IIC), wherein
R1 is CH3;
R2a is
Figure imgf000071_0001
70
Figure imgf000072_0001
Figure imgf000073_0001
R3a is 3-chlorophenyl, 3,5-difluorophenyl, 3,5-dichlorophenyl, 3-fluoro-5-methylphenyl, 3- chloro-5-methoxy-phenyl, or 3,4,5-trifluorophenyl. An additional embodiment of the invention is a compound of Formula (II) having the Formula
(HD):
Figure imgf000074_0001
wherein
R2a is selected from the group consisting of:
Figure imgf000074_0002
Rf is selected from the group consisting of: H, F and OCFb;
RJ is selected from the group consisting of: H, Cl, F and CF3;
Rk is selected from the group consisting of: H, Br, CFF, CF3, OH, and OCH2CH2F; Rm is H or CH3; and
Rp is selected from the group consisting of: H, CH3, and OCH3;
R3a is selected from the group consisting of:
(a) phenyl, phenyl substituted with one, two or three members each independently selected from the group consisting of: Cl, F, Ci-4alkyl, CF3, OCi-4alkyl, OCF3, and OCF2H; and
Figure imgf000075_0001
where Rf is H, F, CH3, CF2H, CF3, OCH3, OCF2H; and
R4a is CH3 or CF2H.
An additional embodiment of the invention is a compound of Formula (II) having the Formula (IID), wherein:
R2a is
Figure imgf000075_0002
Figure imgf000076_0001
R3a is 5-methylfuran-2-yl, 5-(trifluoromethyl)furan-2-yl, pyridin-3-yl, 5-fluoropyridin-3-yl, 5- (trifluoromethyl)pyridin-3-yl, phenyl, 3-chlorophenyl, 3,5-difluorophenyl, 3,5- dichlorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-4-methoxyphenyl, 4- (difluoromethoxy)-3-fluorophenyl, 3-fluoro-5-(trifluoromethyl)phenyl, 3-chloro-4- methoxyphenyl, 3-fluoro-5-methoxyphenyl, 3-chloro-4-methylphenyl, 3,5-difluoro-4- methylphenyl, or 3,4,5-trifluorophenyl; and
R4a is CH3.
An additional embodiment of the invention is a compound of Formula (II) having the Formula (HE):
Figure imgf000076_0002
wherein
Figure imgf000077_0002
is selected from the group consisting of:
Figure imgf000077_0001
Figure imgf000077_0003
where
Y is CH or N;
Rf is H or F;
Rg is selected from the group consisting of: OCi-4alkyl, CH2OCH3, CH2OH,
Figure imgf000077_0004
Rh is selected from the group consisting of: Ci-4alkyl, CF3, and cyclopropyl;
R1 is selected from the group consisting of: H, halo, Ci-4alkyl, CF2H, CF3, OCH3, cyclopropyl, cyclobutyl, and cyclopropyl substituted with one or two members independently selected from: F and CH3;
R is selected from the group consisting of: H, Cl, F, and CH3;
Rm is H, CH3, or CH2CH3;
R3a is selected from the group consisting of: phenyl, 3, 3-chlorophenyl, 5-difluorophenyl,
3-fluoro-5-methyl-phenyl, 3,4,5-trifluorophenyl; and
R4a is selected from the group consisting of: CH3, C3-6cycloalkyl, and phenyl. An additional embodiment of the invention is a compound of Formula (II) having the Formula
(IIF):
Figure imgf000078_0001
wherein
Figure imgf000078_0002
is selected from the group consisting of:
Figure imgf000078_0003
where
Rh is CH3;
Rj is H or CF2H;
Rm is H or CH3;
R3a is 3-chlorophenyl or 3,4,5-trifluorophenyl. A further embodiment of the current invention is a compound as shown below in Table 2.
Table 2.
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000110_0001
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000114_0002
and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.
An additional embodiment of the invention is a compound selected from the group consisting of compounds of Formula (I), Formula (II), Formula (IIA), Formula (IIB), or Formula (IIC), or Formula (IID), or Formula (HE), or Formula (IIF), or a combination thereof.
A further embodiment of the current invention is a compound selected from the group consisting of:
Figure imgf000114_0001
Figure imgf000115_0001
and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.
An additional embodiment of the invention is a pharmaceutical composition comprising:
(A) a therapeutically effective amount of at least one compound selected from compounds of Formula (II):
Figure imgf000115_0002
wherein
R1 is Ci-4alkyl;
R2a is selected from the group consisting of:
Figure imgf000115_0003
(b) 6-Membered heteroaryl selected from the group consisting of:
Figure imgf000116_0001
(c) 5-Membered heteroaryl selected from the group consisting of:
Figure imgf000116_0002
(d) 5,6-Fused or 6,5-fused heteroaryl selected from the group consisting of:
Figure imgf000116_0003
Figure imgf000117_0001
(e) Fused 6,6 heteroaryl selected from the group consisting of:
Figure imgf000117_0002
(f) Heterocycloalkyl selected from the group consisting of:
Figure imgf000118_0001
R a is selected from the group consisting of:
(g) Phenyl; or phenyl substituted with one, two, or three members each independently
selected from the group consisting of: halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, and OCi-6haloalkyl;
(h) 5-Membered heteroaryl selected from the group consisting of:
Figure imgf000118_0002
, and
Figure imgf000118_0003
(i) 6-Membered heteroaryl selected from the group consisting of: u GMI-2 and
Figure imgf000119_0001
(j) 5,6-Fused or 6,5-fused heteroaryl selected from the group consisting of:
Figure imgf000119_0002
(k) Heterocycloalkyl selected from the group consisting of:
Figure imgf000119_0003
Re is selected from the group consisting of: OCi-4alkyl, OCi-4haloalkyl, (C=0)NHCH3, and 5-membered heteroaryl ring containing two or three nitrogen members, wherein the 5-membered heteroaryl ring is optionally substituted with one Rf member;
Rf is selected from the group consisting of: H, halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, and OCi-4haloalkyl;
Rg is selected from the group consisting of: OCi-4alkyl, OCi-4haloalkyl, CH2OCH3,
Figure imgf000119_0004
Rh is selected from the group consisting of: H, Ci-4alkyl , Ci-4haloalkyl, and
C3-6cycloalkyl;
R1 is selected from the group consisting of: H, halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, C3-6cycloalkyl, and C3-6cycloalkyl substituted with one or two members
independently selected from: F and CH3;
R1 is selected from the group consisting of: H, halo, Ci-4alkyl and Ci-4haloalkyl; Rk is selected from the group consisting of: H, halo, OH, Ci-4alkyl, Ci-4haloalkyl, OCi- 4alkyl, and OCi-4haloalkyl;
Rm is H or Ci-4alkyl;
Rn is selected from the group consisting of: H, halo and OCi-4alkyl;
R° is selected from the group consisting of: H, Ci-4alkyl, and Ci-4haloalkyl;
Rp is selected from the group consisting of: H, Ci-4alkyl, and OCi-4alkyl;
Y is CH or N; and
R4a is selected from the group consisting of: CH3, CF2H, CF3, C3-6cycloalkyl, and phenyl; and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers of
compounds of Formula (II); and
(B) at least one pharmaceutically acceptable excipient.
An additional embodiment of the invention is a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (II A), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IIA), pharmaceutically acceptable prodrugs of compounds of Formula (IIA), and pharmaceutically active metabolites of Formula (IIA); and at least one pharmaceutically acceptable excipient.
An additional embodiment of the invention is a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (IIB), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IIB), pharmaceutically acceptable prodrugs of compounds of Formula (IIB), and pharmaceutically active metabolites of Formula (IIB); and at least one pharmaceutically acceptable excipient.
An additional embodiment of the invention is a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (II C), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IIC), pharmaceutically acceptable prodrugs of compounds of Formula (IIC), and pharmaceutically active metabolites of Formula (IIC); and at least one pharmaceutically acceptable excipient.
An additional embodiment of the invention is a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (IID), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IID), pharmaceutically acceptable prodrugs of compounds of Formula (IID), and pharmaceutically active metabolites of Formula (IID); and at least one pharmaceutically acceptable excipient.
An additional embodiment of the invention is a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (HE), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (HE), pharmaceutically acceptable prodrugs of compounds of Formula (HE), and pharmaceutically active metabolites of Formula (HE); and at least one pharmaceutically acceptable excipient.
An additional embodiment of the invention is a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (IIF), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IIF), pharmaceutically acceptable prodrugs of compounds of Formula (IIF), and pharmaceutically active metabolites of Formula (IIF); and at least one pharmaceutically acceptable excipient.
An additional embodiment of the invention is a pharmaceutical composition comprising a therapeutically effective amount of at least one compound in Table 2, as well as
pharmaceutically acceptable salts, N-oxides or solvates of compounds of Table 2,
pharmaceutically acceptable prodrugs of compounds of Table 2, and pharmaceutically active metabolites of Table 2; and at least one pharmaceutically acceptable excipient.
Also within the scope of the invention are enantiomers and diastereomers of the compounds of Formula (I) (as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (HE) and (IIF)) Also within the scope of the invention are the pharmaceutically acceptable salts, N-oxides or solvates of the compounds of Formula (I) (as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (HE) and (IIF)). Also within the scope of the invention are the pharmaceutically acceptable prodrugs of compounds of Formula (I) (as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (HE) and (IIF)), and pharmaceutically active metabolites of the compounds of Formula (I) (as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (HE) and (IIF)).
Also within the scope of the invention are isotopic variations of compounds of Formula (I) (as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (HE) and (IIF)), such as, e.g., deuterated compounds of Formula (I), or Formula (II). Also within the scope of the invention are the pharmaceutically acceptable salts, N-oxides or solvates of the isotopic variations of the compounds of Formula (I) (as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (HE) and (IIF)). Also within the scope of the invention are the pharmaceutically acceptable prodrugs of the isotopic variations of the compounds of Formula (I) (as well as Formulas (II), (IIA), (IIB), (II C), (IID), (HE) and (IIF)), and pharmaceutically active metabolites of the isotopic variations of the compounds of Formula (I) (as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (HE) and (IIF)).
An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by MGL receptor activity, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one compound selected from compounds of Formula (II):
Figure imgf000122_0001
wherein
R1 is Ci-4alkyl;
R2a is selected from the group consisting of:
Figure imgf000122_0002
(b) 6-Membered heteroaryl selected from the group consisting of:
Figure imgf000122_0003
(c) 5-Membered heteroaryl selected from the group consisting of:
Figure imgf000122_0004
(d) 5,6-Fused or 6,5-fused heteroaryl selected from the group consisting of:
Figure imgf000123_0001
Figure imgf000124_0001
(e) Fused 6,6 heteroaryl selected from the group consisting of:
Figure imgf000124_0002
(f) Heterocycloalkyl selected from the group consisting of:
Figure imgf000124_0003
Figure imgf000125_0001
R a is selected from the group consisting of:
(g) Phenyl; or phenyl substituted with one, two, or three members each independently
selected from the group consisting of: halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, and OCi-6haloalkyl;
\
(h) 5-Membered heteroaryl selected from the group consisting of: and
Figure imgf000125_0002
(i) 6-Membered heteroaryl selected from the group consisting of:
Figure imgf000125_0003
and
Figure imgf000125_0004
(j) 5,6-Fused or 6,5-fused heteroaryl selected from the group consisting of:
Figure imgf000126_0001
(k) Heterocycloalkyl selected from the group consisting of:
Figure imgf000126_0002
Re is selected from the group consisting of: OCi-4alkyl, OCi-4haloalkyl, (C=0)NHCH3, and 5-membered heteroaryl ring containing two or three nitrogen members, wherein the 5-membered heteroaryl ring is optionally substituted with one Rf member;
Rf is selected from the group consisting of: H, halo, Ci-4alkyl, Ci-4haloalkyl,
OCi-4alkyl, and OCi-4haloalkyl;
Rg is selected from the group consisting of: OCi-4alkyl, OCi-4haloalkyl, CH2OCH3,
Figure imgf000126_0003
Rh is selected from the group consisting of: H, Ci-4alkyl , Ci-4haloalkyl, and
C3-6cycloalkyl;
R1 is selected from the group consisting of: H, halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, C3-6cycloalkyl, and C3-6cycloalkyl substituted with one or two members
independently selected from: F and CH3;
R1 is selected from the group consisting of: H, halo, Ci-4alkyl and Ci-4haloalkyl;
Rk is selected from the group consisting of: H, halo, OH, Ci-4alkyl, Ci-4haloalkyl, OCi- 4alkyl, and OCi-4haloalkyl;
Rm is H or Ci-4alkyl;
Rn is selected from the group consisting of: H, halo and OCi-4alkyl;
R° is selected from the group consisting of: H, Ci-4alkyl, and Ci-4haloalkyl;
Rp is selected from the group consisting of: H, Ci-4alkyl, and OCi-4alkyl; Y is CH or N; and
R4a is selected from the group consisting of: CH3, CF2H, CF3, C3-6cycloalkyl, and phenyl; and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, to a subject in need thereof.
An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by MGL receptor activity, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one compound selected from compounds of Formula (I) (as well as Formulas (II), (PA), (PB), (II C), (IID), (HE) and (IIF)), enantiomers and diastereomers of the compounds of Formula (I) (as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (HE) and (IIF)), isotopic variations of the compounds of Formula (I) (as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (HE) and (IIF)), and pharmaceutically acceptable salts of all of the foregoing.
Exemplary compounds useful in methods of the invention will now be described by reference to the illustrative synthetic schemes for their general preparation below and the specific examples that follow. Artisans will recognize that, to obtain the various compounds herein, starting materials may be suitably selected so that the ultimately desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product. Alternatively, it may be necessary or desirable to employ, in the place of the ultimately desired substituent, a suitable group that may be carried through the reaction scheme and replaced as appropriate with the desired substituent. Unless otherwise specified, the variables are as defined above in reference to Formula (I) or Formula (II). Reactions may be performed between the melting point and the reflux temperature of the solvent, and preferably between 0 °C and the reflux temperature of the solvent. Reactions may be heated employing conventional heating or microwave heating. Reactions may also be conducted in sealed pressure vessels above the normal reflux temperature of the solvent.
Abbreviations and acronyms used herein include the following:
Table 3:
Figure imgf000128_0001
Figure imgf000129_0001
PREPARATIVE EXAMPLES Exemplary compounds useful in methods of the invention will now be described by reference to the illustrative synthetic schemes for their general preparation below and the specific examples to follow.
SCHEME 1
1 ,2-dioxoalkanes
Figure imgf000130_0001
EtOH
Figure imgf000130_0002
Figure imgf000130_0003
According to SCHEME 1, a compound of formula (III) is prepared by condensation of commercially available or synthetically accessible 2-amino-4-aminobenzoic acid; with 1,2- dioxoalkanes such as 2-oxopropanal, 2,3-butanedione, and the like; in a suitable solvent such as EtOH and the like; at a temperature of 80 °C; for a period of about 1-16 hours; to provide a compound of formula (III), where Rf is H or CH3.
SCHEME 2
Figure imgf000130_0004
According to SCHEME 2, treatment of 4-amino-3-bromobenzoic acid with excess glycerol; under Skraup conditions known to one skilled in the art (R.H.F. Manske and M.Kulka, "The Skraup Synthesis of Quinolines"; Org. Reaction, vol. 7, p. 59-98, 1953); affords 6-carboxy- 8-bromoquinoline. For example, 4-amino-3-bromobenzoic acid is reacted with sulfuric acid; glycerol; an oxidizing agent such as nitrobenzene; in the presence of ferrous sulfate; at a temperature of 140 °C; to provide 6-carboxy-8-bromoquinoline.
SCHEME 3
O
1. Condensation
- MeO' 1. Deuteration
2. Halogenation 2. Saponification
Figure imgf000130_0005
Figure imgf000130_0006
Figure imgf000130_0007
Figure imgf000130_0008
According to SCHEME 3, methyl 2-hydroxy quinoxaline-6-carboxylate is prepared by condensation of commercially available or synthetically accessible 2-amino-4-aminobenzoic acid; with ethyl 2-oxoacetate; in a suitable solvent such as ethanol (EtOH) and the like; at room temperature; for a period of 1 hour. Halogenation of methyl 2-hydroxyquinoxaline-6- carboxylate is achieved with a chlorinating reagent, such as thionyl chloride; neat, or in a suitable solvent such as toluene, and the like; followed by catalytic amount of NN- dimethylformamide (DMF); at reflux temperature; to provide methyl 2-chloroquinoxaline-6- carboxylate. A compound of formula (IV) is prepared in two steps. In a first step, palladium catalyzed reductive deuteration of methyl 2-chloroquinoxaline-6-carboxylate; using a commercially available deuterated reagent such as sodium borodeuteride; in presence of a palladium catalyst such as [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (PdCl2(dppf)), and the like; a base such as tetramethylethylenediamine (TMEDA or TEMED); in a suitable solvent such as tetrahydrofuran (THF), and the like; at room temperature; for a period of 1 hour. In a second step, saponification of the ester to the acid is achieved employing conditions known to one skilled in the art. For example, employing a suitable base such as NaOH, LiOH, and the like; in a suitable solvent such as water, THF, methanol (MeOH), or a mixture thereof; at room temperature; for a period of about 1 h; provides a compound of formula (IV), where M is lithium.
SCHEME 4
Figure imgf000131_0001
Figure imgf000131_0003
Saponification
Figure imgf000131_0002
According to SCHEME 4, methyl quinoline-6-carboxylate is halogenated under conditions known to one skilled in the art. For example, reaction of methyl quinoline-6- carboxylate; with a halogenating agent such as N-bromosuccinimide (NBS), N-iodosuccinimide (NIS), and the like; in a suitable solvent such as acetic acid (AcOH); at a temperature of about 100 °C; for a period of 2-4 h; provides a compound of formula (V). In a preferred method, the halogenating agent is NIS, for a compound of formula (V), where Hal is I. In another approach, the iodo-substituent allows the insertion of the trifluoromethyl moiety via (trifluoromethyl)copper-mediated trifluoromethylation, employing a trifluormethylating agent such as trifluoromethyl iodide, sodium trifluoroacetate, methyl 2,2-difluoro-2- (fluorosulfonyl)acetate, trifluoromethyl-trimethylsilane, trifluoromethyl- triethylsilane, methyl chlorodifluoroacetate-potassium fluoride, and the like, (methyl2,2- difluoro-2-(fluorosulfonyl)acetate is preferred); a catalyst such as copper iodide, copper bromide, or other such copper salts, and copper powder (copper iodide is preferred), in an inert solvent such as V,V-dimethylformamide, V, V-dimethylacetamide, dimethyl sulfoxide, N- methylpyrrolidone, and other such aprotic polar solvents; (V,V-dimethylformamide is preferred) and a base such as V,V'-Dimethylpropyleneurea (DMPU); a temperatures ranging from 100 to 130 °C, employing microwave or conventional heating; to provide methyl 3-
(trifluoromethyl)quinoline-6-carboxylate.
Saponification of the ester to the acid is achieved employing conditions known to one skilled in the art, for example, using a suitable base such as NaOH, LiOH, and the like, in a suitable solvent such as water/THF/MeOH, at a temperature of about 60 °C, for a period of about 2 h, to provide 3-(trifluoromethyl)quinoline-6-carboxylic acid.
SCHEME 5
M
1. Alkylation
2. Saponification
Figure imgf000132_0002
Figure imgf000132_0001
According to SCHEME 5, a compound of formula (VI), where Ra is H or halo, is alkylated with a suitable alkyl halide such as l-iodoethane, fluoro-2-iodoethane, and the like; a suitable base such as CS2CO3, K2CO3, and the like; in a suitable solvent such as N,N- dimethylformamide. Subsequent saponification employing conditions previously described, provides a compound of formula (VII). In a similar fashion, 3-hydroxyquinoline-6-carboxylic acid, and methyl indole-4-carboxylic acid are alkylated and saponified.
SCHEME 6
Figure imgf000133_0001
According to SCHEME 6, compounds of formulas (IXa), (IXb) and (IXc) are prepared under conditions known to one skilled in the art, by condensation of commercially available or synthetically accessible substituted pyridine, pyridazine and pyrazine amines of formulas (Villa), (Vlllb) and (VIIIc) where R1 is independently H, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, and
C3-6cycloalkyl; using ethyl 2-chloro-3-oxobutanoate in suitable solvents such as 1 ,2-dimethoxy ethane (DME), and the like; at temperature of 90 °C, for a period of about 2-16 hours.
Saponification of the esters (IXa), (IXb) and (IXc) to the corresponding acid is achieved employing conditions known to one skilled in the art, for example, using a suitable base such as potassium trimethylsilanolate (TMSOK), NaOH, LiOH, and the like, in a suitable solvent such as water/THF/MeOH, at a temperature of about 60 °C, for a period of about 24 h, to provide compounds of formulas (Xa), (Xb), and (Xc), where M is potassium, Na, or Li, preferably potassium.
SCHEME 7
Figure imgf000134_0001
1 . Esterification
Figure imgf000134_0002
2. Fluorination
Figure imgf000134_0003
Figure imgf000134_0004
Figure imgf000134_0006
Figure imgf000134_0005
Figure imgf000134_0007
According to SCHEME 7, a commercially available or synthetically accessible acid compound of (XI) is converted to its corresponding methyl ester by employing thionyl chloride in methanol, at a temperature of about 65 °C. Subsequent fluorination using 1 -chloromethyl-4- fluoro-l,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (Selectfluor®) provides a compound of formula (XII). Saponification of the ester, employing conditions previously described, then treatment under acidic conditions provides a compound of formula (XHIa). Saponification employing basic conditions, using a suitable base such as TMSOK, NaOH, LiOH, and the like; in a suitable solvent such as water, THF, MeOH, or a mixture thereof; at a temperature of about 60 °C; for a period of about 24 h; provides a compound of formula (XHIb) where M is potassium, Na, or Li; preferably potassium.
SCHEME 8
H
Figure imgf000134_0008
3. Saponification
(XlVb) o o
EtCr X^^ XOK AT
Rh
(XVI b)
According to SCHEME 8, a compound of formula (XlVa), where R1 is C3-6cycloalkyl substituted with Ci-4alkyl, is treated with dimethylcarbonate; and a suitable base such as potassium /er/-butoxide, and the like; in a suitable solvent such as toluene, and the like; at a temperature of about 75 °C; to provide a compound of (XV), where Rm is methyl. Alternatively, a compound of formula (XlVb), where R1 is an optionally substituted C3-6cycloalkyl, is reacted with oxalyl chloride; ethyl potassium malonate; in the presence of magnesium chloride; a suitable base such as triethylamine, and the like; in a suitable solvent such as ethyl acetate, THF, or a mixture thereof; to provide a compound of formula (XV), where Rm is ethyl.
A commercially available or synthetically accessible compound of formula (XV), where R1 is Ci-4haloalkyl, C3-6cycloalkyl optionally substituted with one or two halo, or Ci-4alkyl; is reacted with A, A-dimethylformamide dimethyl acetal or triethyl orthoformate; neat or in a suitable solvent such as acetic anhydride; at temperatures ranging from room temperature or 135 °C. The resulting mixture is then reacted with commercially available or synthetically accessible hydrazine of formula RhNHNH2, where Rh is either Ci-4alkyl or C3-6cycloalkyl; in a suitable solvent such as ethanol, and the like; to afford the pyrazole intermediates which are subsequently saponified under conditions previously described to provides regioisomeric compounds of formula (XVIa) and formula (XVIb). It is known that depending on the saponification conditions and the purification method, the resulting compounds of formula (XVIa) and (XVIb), which may be metal salts, are obtained.
SCHEME 9
Figure imgf000135_0001
According to SCHEME 9, a commercially available or synthetically accessible compound of formula (XVIIa) where Rm is Me; is dissolved in a suitable solvent such as acetonitrile (ACN) and the like; and reacted with an aminating reagent such as 0(2,4- dinitrophenyl)hydroxylamine; at a temperature of 40 °C; for a period of 18 h; to provide a pyridinium compound of formula (XVIIIa).
In an alternate method, commercially available or synthetically accessible compounds of formulas (XVIIb), and (XVIIc), where Rm is Ci-4alkyl; are dissolved in a solvent such as dichloromethane (DCM), and the like; and reacted with an aminating reagent (formed by treatment of (E)-N-((mesitylsulfonyl)oxy)acetimidate; with an acid such as perchloric acid, and the like); in a suitable solvent such as dioxane, water, or a mixture thereof; at a temperature ranging from 0 °C to room temperature; to provide corresponding amino pyrazinium and amino pyridazinium salts of formulas (XVIIIb) and (XVIIIc). Compounds of formulas (XVIIIa), (XVIIIb), and (XVIIIc). undergo a [3+2] cycloaddition; in the presence of an alkynoate of formula (XIX), where R1 is Ci-4alkyl or C3-6cycloalkyl; a suitable base such as K2CO3, and the like; in a solvent such as DMF. Subsequent saponification of the ester moiety to the
corresponding acid is achieved employing conditions known to one skilled in the art. For example, using a suitable base such as NaOH, LiOH, KOH, and the like, preferably LiOH; in a suitable solvent such as water, THF, MeOH, or a mixture thereof; at a temperature of about 60 °C; for a period of about 24 h; to provide compounds of formulas (XXa), (XXb), and (XXc), where M is potassium, Na, or Li, preferably potassium.
SCHEME 10
Figure imgf000136_0002
Figure imgf000136_0001
According to SCHEME 10, alkylation of methyl 5-methyl-7H-pyrrolo[2,3-d]pyrimidine- 4-carboxylate with a suitable alkylating agent such as methyl iodide (Mel); a suitable base such as NaH, and the like; in a suitable solvent such as THF, and the like; provides methyl 5,7- dimethyl-7H-pyrrolo[2,3-d]pyrimidine-4-carboxylate. Subsequent hydrolysis of methyl 5,7- dimethyl-7H-pyrrolo[2,3-d]pyrimidine-4-carboxylate is achieved employing conditions previously described, to provide potassium 5,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-4- carboxylate.
SCHEME 11
Figure imgf000137_0001
Figure imgf000137_0003
According to SCHEME 11, reaction of 4-chloro-l,6-dimethyl-lH-pyrazolo[3,4- d] pyrimidine in a Stille cross coupling reaction with an alkyl stannane such as tributyl(l- ethoxyvinyl)stannane; a palladium catalyst such as bis(triphenylphosphine)palladium(II) dichloride (Pd(PPh3)2Cl2), and the like; in suitable solvent such as DMF, and the like; at a temperature of 60 °C; for a period of 16 h; provides 4-(l-ethoxyvinyl)-l,6-dimethyl-lH- pyrazolo[3,4-d]pyrimidine. Oxidation of 4-( 1 -ethoxy vinyl)- 1, 6-dimethyl- lH-pyrazolo [3, 4- d]pyrimidine employing oxidation conditions such as sodium periodate; potassium
permanganate; in suitable solvent such as 1,4 dioxane, and the like; at a temperature of about room temperature; for a period of 18h; and neutralized with aqueous potassium carbonate solution; provides a mixture of ethyl l,6-dimethyl-lH-pyrazolo[3,4-d]pyrimidine-4-carboxylate and 1, 6-dimethyl- lH-pyrazolo [3, 4-d]pyrimidine-4-carboxylic acid (WO 2015/025026; Page-96).
SCHEME 12
Figure imgf000137_0002
According to SCHEME 12, 6, 6-dimethylmorpholine-3 -carboxylic acid is prepared in two steps from 4-(tert-butyl) 3-methyl 6,6-dimethylmorpholine-3,4-dicarboxylate. In a first step, deprotection of BOC group is achieved according to procedures known to one skilled in the art and employing established methodologies, such as those described in T. W. Greene and P. G. M. Wuts,“Protective Groups in Organic Synthesis,” 3 ed., John Wiley & Sons, 1999, pgs 518-525. For example, deprotection under acidic conditions such as trifluoroacetic acid (TFA)/CH2Ch, HCl/Dioxane, and the like, at room temperature for a period of 2 h. Subsequent hydrolysis in situ, with suitable base such as NaOH and the like, in a solvent such as MeOH/water provides 6,6-dimethylmorpholine-3-carboxylic acid. Diazotization of 6,6-dimethylmorpholine-3- carboxylic acid is achieved employing sodium nitrite; in water; under acidic conditions such as cone. HC1; at temperatures ranging from 0 °C to room temperature; for a period of 16 h. The resulting nitroso acid is treated with trifluoroacetic anhydride (TFAA) in a suitable solvent such as acetonitrile (ACN) and the like; at room temperature; for a period of 2 h; to provide 6,6- dimethyl-6,7-dihydro-4H-[l,2,3]oxadiazolo[4,3-c][l,4]oxazin-8-ium-3-olate ( Reference :
Nikitenko, A. A., et al. Org. Process Res. Dev., 2006, 10 (4), pp 712-716)
6,6-Dimethyl-6,7-dihydro-4H-[l,2,3]oxadiazolo[4,3-c][l,4]oxazin-8-ium-3-olate undergoes a [3+2] cycloaddition reaction with an alkynoate of formula (XIX), where R1 is Ci- 4alkyl; in a suitable solvent such as xylene, and the like; at a temperature of about 140 °C; for a period of 2 h. Subsequent saponification of the resulting two regioisomeric esters to the corresponding acids is achieved employing conditions previously described. For example, employing a suitable base such as NaOH, LiOH, KOH, and the like; in a suitable solvent such as water, THF, MeOH, or a mixture thereof; at a temperature of about 60 °C; for a period of about 24 h; to provide compounds of formulas (XXIa) and (XXIb), where M is K, Na, or Li.
SCHEME 13
Figure imgf000138_0001
THF, -78 °C
(XXIV)
According to SCHEME 13, a keto-ester compound of formula (XXV), where PG is a suitable protecting group such as BOC (tert-butyloxycarbonyl), and R1 is Ci-4alkyl is prepared from a commercially available or synthetically accessible compound of formula (XXIV). For example, a compound of formula (XXIV), where PG is BOC, is converted to compound (XXV), by treatment with a strong base such as LHMDS, in a suitable solvent such as THF, and the like, at a temperature of about -78 °C; for 30 minutes, followed by treatment with ethyl cyanoformate at -78 °C, for a period of about 2 hours.
In an alternate method, a compound of formula (XXIII) is prepared in two steps from a compound of formula (XXII), where R1 is Ci-4alkyl. In a first step, a compound of formula (XXII) is alkylated with ethyl 4-bromobutanoate; employing potassium iodide; a suitable base such as dibasic potassium phosphate. In a second step, BOC protection employing established methodologies, such as those described in T. W. Greene and P. G. M. Wuts,“Protective Groups in Organic Synthesis,” 3 ed., lohn Wiley & Sons, 1999, pgs 518-525, provides a compound of formula (XXIII). Cyclization under Dieckmann condensation conditions of a compound of formula (XXIII) using a suitable base such as LiHMDS or potassium tert-butoxide; in a suitable solvent such as tetrahydrofuran and the like; at temperatures between -40 °C to 20 °C; provides a keto-ester of formula (XXV).
In a similar fashion, ethyl L-alaninate hydrochloride is alkylated by treatment with bromobutanoate and potassium iodide in the presence of a suitable base such as dibasic potassium phosphate in a suitable solvent such as DMF. The amine moiety is protected with a carbamate protecting group such as tert-butyloxycarbonyl (BOC). Cyclization of the diester occurs under Dieckmann condensation conditions known to one skilled in the art. For example ethyl (S)-4-((tert-butoxycarbonyl)(l -ethoxy- l-oxopropan-2-yl)amino)butanoate is treated with lithium bis(trimethylsilyl)amide (LiHMDS) at a suitable temperature range such as between -40 °C to 20 °C to provide l-(tert- butyl) 4-ethyl (2S)-2-methyl-3-oxopiperidine-l,4-dicarboxylate.
SCHEME 14
Figure imgf000140_0001
(XXVI b) (XXVI lb)
According to SCHEME 14, a commercially available or synthetically accessible compound of formula (XXV), where R1 is H, and PG is BOC (tert-butyloxycarbonyl) is reacted with a commercially available or synthetically accessible hydrazine compound of formula R4NHNH2, where R4 is Ci-4alkyl, in AcOH, at a temperature of about 80 °C, to provide a pyrazolone compound of formula (XXVIa), where R4 is Ci-4alkyl. A commercially available or synthetically accessible compound of formula (XXV), where R1 is Ci-4alkyl, and PG is BOC (tert-butyloxycarbonyl) is reacted with a commercially available or synthetically accessible hydrazine compound of formula R4aNHNH2, or salt thereof, where R4a is Ci-4alkyl,
C3-6cycloalkyl or phenyl, in a suitable solvent such as toluene or ethanol with a suitable base such as A, A-diisopropylethylamine (Hiinig's base or DIEA), at a temperature of between 80 and 110 °C, to provide a pyrazolone compound of formula (XXVIb), where R4a is Ci-4alkyl, C3-6cycloalkyl or phenyl.
Derivation of pyrazolone compounds of formulas (XXVIa) and (XXVIb) with a sulfonate-based leaving group such as trifluoromethanesulfonyl (triflate) is achieved by is by reaction with a triflating agent such as trifluoromethanesulfonic anhydride (ΊΪ2O); a base such as triethylamine (TEA), pyridine, N-ethyldiisopropylamine (DIEA, DIPEA), and the like; in a suitable solvent such as DCM and the like. Milder triflating agents such as A- phenylbis(trifluoromethanesufonimide) (Tf2NPh), a base such as TEA, DIEA, and the like, in a suitable solvent such as DCM, and the like; are used for better selectivity, to provide compounds of formulas (XXVIIa) and (XXVIIb). In a similar fashion a compound of formula (XXV), where PG is BOC, is reacted with hydrazine hydrate, to provide tert-butyl 7-methyl-3-oxo-l,2,3,4,5,7-hexahydro-6H-pyrazolo[3,4- c]pyridine-6-carboxylate. tert-Butyl 7-methyl-3-oxo- l ,2,3,4,5,7-hexahydro-6H-pyrazolo[3,4- c]pyridine-6-carboxylate is reacted with a triflating agent as previously described to provide tert- butyl 7-methyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridine-6-carboxylate.
SCHEME 15
Figure imgf000141_0001
According to SCHEME 15, Ullmann-type copper-mediated displacement of an optionally substituted aryl halide compound of formula (XXVIII), where Rf is independently selected from the group consisting of: halo, Ci-4alkyl, Ci-4haloalkyl, and OCi-4alkyl; HAL is I, or Br; and Z is CH or N, wherein only one Z can be N; with an nitrogen containing nucleophile such as a 5 membered heteroaryl containing 2 or 3 nitrogen members of formula (XXIX), where Ra is independently selected from the group consisting of: halo, Ci-4alkyl, Ci-4haloalkyl, and OCi- 4alkyl; in the presence of a copper catalyst such as copper powder, copper (I) iodide, and the like; an inorganic base such as cesium carbonate, potassium carbonate, K3P04, and the like; an auxiliary bidentate amine ligand such as /ra«.v-/V,/V'-dimethylcyclohexane- 1 ,2-diamine; in an inert high boiling solvent such as nitrobenzene, toluene, xylene, /V-methylpyrrolidone (NMP), dimethylformamide (DMF), and the like, at temperatures ranging from 100-200° C; employing conventional or microwave heating; provides a compound of formula (XXX). For example, 3- iodobenzoic acid is reacted with 3-(trifluoromethyl)pyrazole, a base such as cesium carbonate, a copper catalyst such as Cul, a ligand such as /ra«.s-A,A'-dimethylcyclohexane- 1 ,2-diamine, in a suitable solvent such as DMF, at temperatures ranging from 100-140° C, under microwave irradiation, to provide 3-[3-(trifluoromethyl)pyrazol-l-yl]benzoic acid.
SCHEME 16
Figure imgf000142_0001
According to SCHEME 16, a compound of formula (XXX), where Z is CH, and HET1 is l,2,4-triazol-4-yl, is prepared in two steps from a compound of formula (XXXI) where Rf is halo, Ci-4alkyl, Ci-4haloalkyl or OCi-4alkyl. In a first step, a compound of formula (XXXI) where Rf is halo, Ci-4alkyl, Ci-4haloalkyl or OCi-4alkyl is reacted with diformylhydrazine, in the presence of trimethylsilyl chloride as a Lewis acid, triethylamine, in a suitable solvent such as pyridine, at a temperature of about 100 °C, for a period of about 16 h, to provide the 1 ,2,4-triazol-4-yl intermediate; in a second step, saponification is achieved according to conditions known to one skilled in the art, or as previously described.
SCHEME 17
Figure imgf000142_0002
According to SCHEME 17, 5,8-dihydro-6H-pyrano[3,4-b]pyridine 1 -oxide is prepared by oxidizing 5,8-dihydro-6H-pyrano[3,4-b]pyridine (prepared according to procedures described in Tetrahedron, 45(19), 6211-20; 1989) employing conditions known to one skilled in the art. For example, 5,8-dihydro-6H-pyrano[3,4-b]pyridine, is reacted with an oxidizing agent such as meta- chloroperoxybenzoic acid (/«CPBA), in a suitable solvent such as DCM, at a temperature ranging from 0 °C to 25 °C to provide 5,8-dihydro-6H-pyrano[3,4-b]pyridine 1 -oxide.
Halogenation employing a chlorinating agent such as POCb, and the like, in a suitable solvent such as chloroform, and the like, at temperatures ranging from 70-90 °C, to affords a mixture of compounds of formula (XXXII) and (XXXIII), where HAL is Cl. Palladium-catalyzed cyanation of (hetero)aryl halide compounds of formula (XXXII) and (XXXIII) is achieved employing zinc cyanide as the nucleophile, zinc, tris(dibenzylideneacetone)dipalladium(0), and I,G- bis(diphenylphosphino)ferrocene, in a suitable solvent, at a temperature of about 90 °C, for a period of 4 days, to provide 5,8-dihydro-6H-pyrano[3,4-b]pyridine-4-carbonitrile and 5,8- dihydro-6H-pyrano[3,4-b]pyridine-2-carbonitrile. Hydrolysis of 5,8-dihydro-6H-pyrano[3,4- b]pyridine-4-carbonitrile employing a suitable base such as NaOH, LiOH, and the like; in a suitable solvent such as water, THF, MeOH, ethanol (EtOH), or a mixture thereof; at room temperature; for a period of about 16 h; provides 5,8-dihydro-6H-pyrano[3,4-b]pyridine-4- carboxylic acid. Hydrolysis of 5,8-dihydro-6H-pyrano[3,4-b]pyridine-2-carbonitrile employing similar conditions previously described provides 5,8-dihydro-6H-pyrano[3,4-b]pyridine-2- carboxamide, which is subsequently treated with LiOH, in THF to provide 5,8-dihydro-6H- pyrano[3,4-b]pyridine-2-carboxybc acid.
3,4-Dihydro-2H-pyrano[2,3-b]pyridine-5-carboxylic acid is prepared according to methods previously described starting from 3,4-dihydro-2H-pyrano[2,3-b]pyridine.
SCHEME 18
Figure imgf000143_0001
(XXVI la) (XXXVIa) (XXXVI la)
Coupling Deprotection
or or or
Figure imgf000143_0002
(XXVI lb) (XXXVI b) (XXXVI lb)
According to SCHEME 18, a compound of formula (XXVIIa) where R4 is Ci-4alkyl and PG is BOC; is reacted in a metal mediated cross coupling reaction to provide a compound of formula (XXXVIa), where PG is BOC, and R3 is C3-4cycloalkyl, 5-methylthiophen-2-yl, 5- (trifluoromethyl)thiophen-2-yl, lH-indol-2-yl, l-methyl-lH-indol-2-yl phenyl, or phenyl substituted with one or two members independently selected from the group consisting of: halo or OCi-4haloalkyl; For example, a compound of formula (XXVIIa), where R4 is Ci-4alkyl and PG is BOC; is reacted with a suitably substituted commercially available or synthetically accessible alkyl, cycloalkyl, aryl or heteroaryl boronic acid, boronate ester, and the like, in the presence of a palladium catalyst such as [l,l'-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (PdCl2(dtbpf)), tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4), [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(II) (PdCk(dppf)),
palladium(II)bis(triphenylphosphine) dichloride (Pd(PPh3)2Cl2), XPhos-Pd-G2 precatalyst (chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-l,l '-biphenyl)[2-(2'-amino-l,l'- biphenyl)]palladium(II)), and the like, a base such as K3P04, aq. Na2C03, Na2C03, Cs2C03, and the like, in a suitable solvent such as 1 ,2-dimethoxy ethane, l,4-dioxane, DMF, water, or a mixture thereof, at a temperature ranging from 60 to 180 °C, employing microwave or conventional heating, for a period of about 30 min to 16 h, to provide a compound of formula (XXXVIa). In a similar fashion, a compound of formula (XXVIIb), where R1 and R4a are as defined in Claim 28, is reacted with commercially available or synthetically accessible alkyl, cycloalkyl, aryl or heteroaryl boronic acid, boronate ester, and the like, in a metal mediated cross coupling as previously described to provide a compound of formula (XXXVIb), where R3a is as defined in Claim 28.
Cleavage of the BOC protecting group on a compound of formula (XXXVIa) or
(XXXVIb) is achieved according to procedures known to one skilled in the art and employing established methodologies, such as those described in T. W. Greene and P. G. M. Wuts,
“Protective Groups in Organic Synthesis,” 3 ed., lohn Wiley & Sons, 1999, pgs 518-525. For example, under acidic conditions such as TFA/CH2CI2, HCl/Dioxane, and the like, provides compounds of formula (XXXVIIa) and (XXXVIIb).
SCHEME 19
Figure imgf000145_0001
(XXVI la) (XXXIXa) (XLa)
Deprotection Coupling
Figure imgf000145_0002
(XXVI lb) (XXXIXb)
Figure imgf000145_0003
According to SCHEME 19, cleavage of the BOC protecting group on compounds of formulas (XXVIIa) and (XXVIIb) according to methods previously described, provides compounds of formula (XXXIXa) and (XXXIXb). A compound of formula (XLa), where R4 is Ci-4alkyl; and R2 is quinoline; is prepared by conventional amide bond forming techniques such as coupling reactions which are well known to those skilled in the art (such as HATU (1- [bis(dimethylamino)methylene]- l H- 1 ,2,3-triazolo[4,5-/i]pyridinium 3-oxid
hexafluorophosphate), BOP (benzotriazol- l-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate), or conversion of the acid to an acid chloride). For example, reaction of a compound of formula (XXXIXa) where R4 is Ci-4alkyl or phenyl; with a commercially available or synthetically accessible (according to the schemes above) suitably substituted aryl, or heteroaryl carboxylic acid, where the acid is activated with an appropriate activating reagent, for example a carbodiimide, such as N,N'-dicyclohexylcarbodiimide (DCC) or l-ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDC, ED AC or EDCI) optionally in the presence of hydroxybenzotriazole (HOBt) and/or a catalyst such as 4-dimethylaminopyridine (DMAP); a halotrisaminophosphonium salt such as (benzotriazol- l-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), or bromotripyrrolidinophosphonium hexafluorophosphate
(PyBroP®); a suitable pyridinium salt such as 2-chloro-l -methyl pyridinium chloride; or another suitable coupling agent such as /V,/V,/V',/V'-tetramethyl- -( 1 //-benzotriazol- 1 -yl)uronium hexafluorophosphate (HBTU), 1 - [bis(dimethylamino)methylene] - 1 H- 1 ,2,3 -triazolo [4, 5 - Ajpyridinium 3-oxid hexafluorophosphate (HATU), 2,4,6-tripropyl-l,3,5,2,4,6- trioxatriphosphorinane-2, 4, 6-trioxide (T3P®) and the like. Coupling reactions are conducted in a suitable solvent such as DCM, THF, DMF and the like, optionally in the presence of a tertiary amine such as N-methylmorpholine, N-ethyldiisopropylamine (DIEA, DIPEA), or triethylamine (TEA), at a temperature ranging from about 0 °C to rt, to provide compound a of formula (XLa). Similarly, a compound of (XXXIXb) is reacted in the same fashion as described above to provide compounds of formula (XLb).
SCHEME 20
Figure imgf000146_0001
According to SCHEME 20, a compound of formula (XLI), where R1 is Ci-4alkyl, and R3a is phenyl substituted with one, two, or three halo members, is prepared by reacting tert-butyl 7- methyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate is in metal-mediated cross coupling reaction employing conditions previously described with a commercially available or synthetically accessible suitably substituted phenyl boronic acid. Alkylation of a compound of formula (XLI), with a suitable alkylating agent such as CD3I, a suitable base such as NaH, and the like, in a suitable solvent such as THF, and the like, provides a compound of formula (XLII), where R4a is CD3.
Diflouromethylation of a compound of formula (XLI) is achieved employing sodium 2- chloro-2,2-difluoroacetate, a suitable base such as NaH, in a solvent such as DMF, and the like, to provide a compound of formula (XLII), where R4a is CF2H.
Trifluoromethylation of a compound of formula (XLI) is achieved in two steps. In a first step, reaction with dibromodifluoromethane, in a suitable solvent such as DMF, in the presence of a suitable base such as NaH, at elevated temperature, provides the l-bromodifluoromethylated intermediate. Subsequent reaction with silver(I) tetrafluoroborate, in a suitable solvent such as DCM, at temperatures ranging from 0 °C to room temperature, provides a compound of formula (XLII), where R4a is CF3.
Cleavage of the BOC protecting group according to methods previously described, provides a compound of formula (XLIII).
SCHEME 21
Figure imgf000147_0001
According to SCHEME 21, a compound of formula (XXVIIb), is coupled in a metal mediated cross coupling reaction as previously described, with a suitably substituted
commercially available or synthetically accessible aryl, alkyl, or heteroaryl boronic acid, to provide a compound of formula (XLIV), where R3a and R4a are as described in claim 28.
Subsequent deprotection employing methods previously described provides a compound of formula (XLIII).
SCHEME 22
Amide Coupling
Figure imgf000147_0002
Figure imgf000147_0003
Amide Coupling
Figure imgf000147_0005
Figure imgf000147_0004
Figure imgf000147_0006
According to SCHEME 22, compounds of Formula (I), or Formula (II), where R1, R2,
R2a, R3, R3a, R4 and R4a are as defined in claim 1 and claim 28, are prepared from compounds of formula (XLV) or (XLIII), according to conventional amide bond forming techniques such as coupling reactions with a suitably substituted aryl or heteroaryl carboxylic acid, which are previously described, or by reaction of suitably substituted aryl or heteroaryl acid chlorides (conversion of the acid to an acid chloride), employing a base such as TEA (triethylamine), and the like, in a suitable solvent such as DCM, THF, ethyl acetate (EtOAc), and the like.
A compound of Formula (II), where R2a is a phenyl substituted with a reactive functional group such as CH2CH2O-TS, is fluorinated with [18F]fluoride, a base such as K2CO3, in a solvent such as acetonitrile/water, to provide a compound of Formula (II), where R2a is phenyl substituted with CH2CH218F.
A compound of Formula (II), where R2a is an indole substituted with a reactive functional group such as CH2CH2O-THP, is deprotected with HCl/MeOH, to provide the free CH2CH2OH intermediate. Subsequent tosylation of the OH moiety employing toluene-p-sulphonic anhydride (TS2O), a base such as TEA (triethylamine), in a suitable solvent, provides a tosylated compound which is subsequently fluorinated with [18F]fluoride, as previously described, to provide a compound of Formula (II), where R2a is an indole substituted with CH2CH218F.
A compound of Formula (II), where R2a is lH-pyrrolo[2,3-b]pyridin-4-yl, is alkylated with fluoro-2-iodoethane; a suitable base such as CS2CO3, K2CO3, NaH, and the like; in a suitable solvent such as A,A-dimethylfonriaiTiide, and the like, to provide a compound of Formula (II) where R2a is l-(2-fluoroethyl)-lH-pyrrolo[2,3-b]pyridin-4-yl. In a similar fashion a compound of Formula (II), where R2a is lH-indol-7-yl, lH-pyrrolo[2,3-c]pyridin-3-yl, or 1H- pyrrolo[2,3-c]pyridin-4-yl, is alkylated with Mel, NaH, in a suitable solvent such as
tetrahydrofuan, A, A-dimethylformamide, and the like, to provide compounds of Formula (II), where R2a is l-methyl-lH-indol-7-yl, l-methyl-lH-pyrrolo[2,3-c]pyridin-3-yl, l-methyl-lH- pyrrolo[2,3-c]pyridin-4-yl, l-methyl-lH-pyrrolo[3,2-c]pyridin-4-yl, 1 -methyl- lH-pyrrolo [3,2- c]pyridin-3-yl, 2-methylpyrazolo[3,4-c]pyridin-7-yl, l-methylpyrazolo[3,4-c]pyridin-7-yl, or 3- methyl- 1 ,3-benzoxazol-2-one.
A compound of Formula (II), where R2a is 3-bromopyrazolo[l,5-a]pyridin-4-yl is reacted with trimethylboroxine, a suitable catalyst such as tetrakis(triphenylphosphine)palladium(0), and a suitable base such as potassium carbonate, in a suitable solvent such as A, A- dimethylformamide at 100 °C to provide a compound of Formula (II), where R2a is 3- methy lpyrazolo [ 1 , 5 -a] pyr idin-4-y 1.
SCHEME 23
Figure imgf000148_0001
According to SCHEME 23, tert-butyl (L')-(1 -oxopropan-2-yl)carbamate and methylhydrazine can be condensed in a suitable solvent such as THF to afford tert-butyl (S,E)- (l-(2-methylhydrazineylidene)propan-2-yl)carbamate. A commercially available or synthetically accessible suitably substituted aryl aldehyde of formula (XL VI) is treated with 2-(2-nitroethyl)- l,3-dioxolane in the presence of a catalytic amount of suitable base such as piperidine; in a suitable solvent such as toluene; at a temperature of 110 °C to provide a compound of formula (XL VII), where R3a and R4a are as defined in Formula (II).
Pyrazole ring formation is accomplished through [3+2] cycloaddition of tert-butyl (S,E)- (l-(2-methylhydrazineylidene)propan-2-yl)carbamate and a compound of formula (XL VII) at a temperature of 40 °C. Subsequent global deprotection and cyclization by treatment with trifluoroacetic acid and triethylsilane at 55 °C affords a compound of formula (XLIII).
Compounds of Formula (I) (as well as compounds of Formula (II)) may be converted to their corresponding salts using methods known to one of ordinary skill in the art. For example, an amine of Formula (I) (as well as compounds of Formula (II)) is treated with trifluoroacetic acid, HC1, or citric acid in a solvent such as Et20, CH2CI2, THF, MeOH, chloroform, or isopropanol to provide the corresponding salt form. Alternately, trifluoroacetic acid or formic acid salts are obtained as a result of reverse phase HPLC purification conditions. Crystalline forms of pharmaceutically acceptable salts of compounds of Formula (I) (as well as compounds of Formula (II)) may be obtained in crystalline form by recrystallization from polar solvents (including mixtures of polar solvents and aqueous mixtures of polar solvents) or from non-polar solvents (including mixtures of non-polar solvents).
Where the compounds according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diaster eomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.
Compounds prepared according to the schemes described above may be obtained as single forms, such as single enantiomers, by form-specific synthesis, or by resolution.
Compounds prepared according to the schemes above may alternately be obtained as mixtures of various forms, such as racemic (1 : 1) or non-racemic (not 1 : 1) mixtures. Where racemic and non- racemic mixtures of enantiomers are obtained, single enantiomers may be isolated using conventional separation methods known to one of ordinary skill in the art, such as chiral chromatography, recrystallization, diastereomeric salt formation, derivatization into diastereomeric adducts, biotransformation, or enzymatic transformation. Where regioisomeric or diastereomeric mixtures are obtained, as applicable, single isomers may be separated using conventional methods such as chromatography or crystallization.
The following specific examples are provided to further illustrate the invention and various preferred embodiments.
EXAMPLES
In obtaining the compounds described in the examples below and the corresponding analytical data, the following experimental and analytical protocols were followed unless otherwise indicated.
Unless otherwise stated, reaction mixtures were magnetically stirred at room temperature (rt) under a nitrogen atmosphere. Where solutions were“dried,” they were generally dried over a drying agent such as Na2S04 or MgS04. Where mixtures, solutions, and extracts were “concentrated”, they were typically concentrated on a rotary evaporator under reduced pressure. Reactions under microwave irradiation conditions were carried out in a Biotage Initiator or CEM (Microwave Reactor) Discover instrument.
For the reactions conducted under continuous flow conditions,“flowed through a LTF- VS mixer” refers to the use of a Chemyx Fusion 100 Touch Syringe Pump that is in line via 1/16” PTFE tubing to a LTF-VS mixer (Little Things Factory GmbH (http://www.ltf- gmbh.com), unless otherwise indicated.
Normal-phase silica gel chromatography (FCC) was performed on silica gel (SiCh) using prepacked cartridges.
Preparative reverse-phase high performance liquid chromatography (RP HPLC) was performed on either:
METHOD A An Agilent HPLC with an Xterra Prep RP18 column (5 mM, 30 x 100 or 50 x l50mm) or an XBridge Cl 8 OBD column (5 mM, 30 x 100 or 50 x l 50mm), and a mobile phase of 5% ACN in 20mM NH4OH was held for 2 min, then a gradient of 5-99% ACN over 15 min, then held at 99% ACN for 5 min, with a flow rate of 40 or 80 mL/min. or
METHOD B. A Shimadzu LC-8A Series HPLC with an Inertsil ODS-3 column (3 mm,
30 x lOOmm, T = 45 °C), mobile phase of 5% ACN in H2O (both with 0.05% TFA) was held for 1 min, then a gradient of 5-99% ACN over 6 min, then held at 99% ACN for 3 min, with a flow rate of 80 mL/min.
or
METHOD C. A Shimadzu LC-8A Series HPLC with an XBridge Cl 8 OBD column (5 pm, 50 x lOOmm), mobile phase of 5% ACN in H2O (both with 0.05% TFA) was held for 1 min, then a gradient of 5-99% ACN over 14 min, then held at 99% ACN for 10 min, with a flow rate of 80 mL/min.
or
METHOD D A Gilson HPLC with an XBridge C18 column (5pm, 100 x 50mm), mobile phase of 5-99% ACN in 20 mM NH4OH over 10 min and then hold at 99 ACN for 2 min, at a flow rate of 80 mL/min.
or
METHOD E An ACCQ Prep HPLC with an XBridge Cl 8 OBD column (5 pM, 50 x 100), mobile phase of 5% ACN in H2O (both with 0.05% TFA) was held for 1 min, then a gradient of 5-95% ACN over 12 min, then held at 95% ACN for 2 min, with a flow rate of 80 mL/min.
Preparative supercritical fluid high performance liquid chromatography (SFC) was performed either on a Jasco preparative SFC system, an APS 1010 system from Berger instruments, or a SFC-PICLAB-PREP 200 (PIC SOLUTION, Avignon, France). The separations were conducted at 100 to 150 bar with a flow rate ranging from 40 to 60 mL/min. The column was heated to 35 to 40 °C.
Mass spectra (MS) were obtained on an Agilent series 1100 MSD using electrospray ionization (ESI) in positive mode unless otherwise indicated. Calculated (calcd.) mass corresponds to the exact mass.
Nuclear magnetic resonance (NMR) spectra were obtained on Bruker model DRX spectrometers. Definitions for multiplicity are as follows: s = singlet, d = doublet, t= triplet, q = quartet, m = multiplet, br = broad. It will be understood that for compounds comprising an exchangeable proton, said proton may or may not be visible on an NMR spectrum depending on the choice of solvent used for running the NMR spectrum and the concentration of the compound in the solution.
Chemical names were generated using ChemDraw Ultra 17.1 (CambridgeSoft Corp., Cambridge, MA) or OEMetaChem VI.4.0.4 (Open Eye).
Compounds designated as R* or S* are enantiopure compounds where the absolute configuration was not determined.
Intermediate 1 : 2-Methyl-3-phenyl-4.5.6.7-tetrahvdropyrazolo[3.4-6lpyridine.
Figure imgf000152_0001
Step A: /^/7-Butyl 2-methyl-3-oxo- 1 5.7-tetrahvdropyrazolo 6lpyridine-6-carboxylate. To a
Figure imgf000152_0002
mixture of l-/er/-butyl 4-ethyl-3-oxopiperidine-l,4-dicarboxylate (8.89 g, 32.8 mmol) in acetic acid (100 mL) was added methylhydrazine (2.6 mL, 49.7 mmol, 0.88 g/mL) and the reaction was stirred at 80 °C for 1 h. The reaction mixture was concentrated under reduced pressure.
Purification (FCC, silica gel (SiC ) column chromatography, eluting with ethyl acetate
(EtOAc): methanol (MeOH)(lO: 1) afforded the title compound (8.11 g, 32.0 mmol, 97%) as a yellow foam. MS (ESI): mass calcd. for C12H9N3O3, 253.1; m/z found, 254.2 [M+H]+.
Step B: fer/-Butyl 2-methyl-3-('trifluoromethylsulfonyloxy)-5.7-dihvdro- razoloi3.4-
Figure imgf000152_0003
clpyridine-6-carboxylate. To a solution of /cvY-butyl 2-methyl-3-oxo-l,4,5,7- tetrahydropyrazolo[3,4-c]pyridine-6-carboxylate (8.70 g, 34.3 mmol) in dichloromethane (100 mL) was added /V,/V-diisopropylethylamine (DIEA/DIPEA) (6.55 mL, 37.9 mmol, 0.747 g/mL) and A-phenyl /y.v(trifluoromethanesulfonimide) (13.5 g, 37.8 mmol). The reaction mixture was stirred at room temperature (rt) for 8 h and concentrated under reduced pressure. Purification (FCC, silica gel (S1O2) column chromatography, eluting with heptane: ethyl acetate (6: 1 4: 1) afforded the title compound (9.55 g, 24.8 mmol, 72%) as a colorless oil. MS (ESI): mass calcd. for C13H18F3N3O5S, 385.1; m/z found, 330.0 [M+2H-/Bu]+. Step C: Butyl 2-methyl-3-phenyl-5.7-dihvdro-4//-pyrazolo[3.4-6lpyridine-6-carboxylate. To a solution of /tw-butyl 2-methyl-3-(trifluoromethylsulfonyloxy)-5,7-dihydro-4//-pyrazolo[3,4- c]pyridine-6-carboxylate (2.14 g, 5.55 mmol) in l,4-dioxane (60 mL) was added phenylboronic acid (940 mg, 7.71 mmol), aqueous sodium carbonate (2 M, 8.3 mL, 16.6 mmol) and
/£7raA7.v(triphenylphosphine)palladium(0) (320 mg, 0.277 mmol). The reaction mixture was stirred at 65 °C for 18 h under argon and concentrated under reduced pressure. The residue was taken up in ethyl acetate (EtOAc) (50 mL), washed with 1 M sodium hydroxide (2 x 60 mL), brine (1 x 90 mL, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with heptane: ethyl acetate (4: 1) to give the title compound (1.51 g, 4.42 mmol, 86%) as a yellow powder. MS (ESI): mass calcd. for C18H23N3O2, 313.2; m/z found, 314.2 [M+H]+. Ή NMR (300 MHz, DMSO- e) d 7.57 - 7.39 (m, 5H), 4.44 (s, 2H), 3.74 (s, 3H), 3.53 (t, J= 5.8 Hz, 2H), 2.55 - 2.43 (m, 2H), 1.43 (s, 9H).
Step D: 2-Methyl-3-phenyl-4.5.6.7-tetrahvdropyrazolo[3.4-61pyridine. To a mixture of tert- butyl 2-methyl-3-phenyl-5,7-dihydro-4//-pyrazolo[3,4-6]pyridine-6-carboxylate (6.41 g, 20.5 mmol) in dichloromethane (65 mL) was added trifluoroacetic acid (TFA) (15.5 mL, 203 mmol, 1.49 g/mL) at 0 °C and the reaction was stirred at room temperature for 18 h. The reaction mixture was poured into saturated sodium carbonate (250 mL) and the layers were separated. The aqueous layer was extracted with dichloromethane (2 x 200 mL). The combined organic layers were washed with brine (2 x 150 mL). The organic layer was dried over sodium sulfate, filtered and evaporated to give the title compound (4.00 g, 18.8 mmol, 91%) as a yellow powder. MS (ESI): mass calcd. for C13H15N3, 213.1; m/z = 214.3
Figure imgf000153_0001
NMR (500 MHz, DMSO-r/e) d 7.53 - 7.48 (m, 2H), 7.44 - 7.39 (m, 3H), 3.74 - 3.69 (m, 5H), 3.35 - 3.27 (m, 1H), 2.83 (t, J = 5.7 Hz, 2H), 2.41 (t, J= 5.7 Hz, 2H).
Intermediate 2: 3-Cvclopropyl-2-methyl-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4-c1pyridine.
Figure imgf000153_0002
The title compound was prepared in a manner analogous to Intermediate 1, using cyclopropylboronic acid instead of phenylboronic acid in Step C. MS (ESI): mass calcd. for C10H15N3, 177.1 ; m/z found, 178.1 [M+H] +. Intermediate 3 : 2-Methyl-3-('5-methylthiophen-2-yl)-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4- clpyridine.
Figure imgf000154_0001
The title compound was prepared in a manner analogous to Intermediate 1, using 4, 4,5,5- tetramethyl-2-(5-methylthiophen-2-yl)-l,3,2-dioxaborolane instead of phenylboronic acid in Step C. MS (ESI): mass calcd. for C12H15N3S, 233.1; m/z found, 234.1 [M+H]+.
Intermediate 4: 3-('3-Fluorophenyl)-2-methyl-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4-c1pyridine.
Figure imgf000154_0002
The title compound was prepared in a manner analogous to Intermediate 1, using 3- fluorophenylboronic acid instead of phenylboronic acid in Step C. MS (ESI): mass calcd. for C13H14FN3, 231.1 ; m/z found, 232.1 [M+H]+.
Intermediate 5: 3-('3.5-Difluorophenyl)-2-methyl-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4-c1pyridine.
Figure imgf000154_0003
The title compound was prepared in a manner analogous to Intermediate 1, using 3,5- difluorophenylboronic acid instead of phenylboronic acid in Step C. MS (ESI): mass calcd. for C13H13F2N3, 249.1 ; m/z found, 250.1 [M+H]+. Intermediate 6: 2-Ethyl-3-phenyl-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4-c1pyridine.
Figure imgf000155_0001
The title compound was prepared in a manner analogous to Intermediate 1, using ethylhydrazine hydrochloride instead of methylhydrazine in Step A. MS (ESI): mass calcd. for C13H21N3O3, 267.2; m/z found, 268.2 [M+H]+.
Intermediate 7: tert-Butyl 2.7-dimethyl-3-('(Ytrifluoromethyl)sulfonyl)oxy)- tetrahvdro-
Figure imgf000155_0002
6H-pyrazolo[3.4-c1pyridine-6-carboxylate.
Figure imgf000155_0003
Step A: 1 -(tert-Butyl) 4-ethyl 2-methyl-3-oxopiperidine-E4-dicarboxylate. To a cooled (-78 °C) solution of tert-butyl 2-methyl-3 -oxopiperi dine- l-carboxy late (5 g, 23.4 mmol) in
tetrahydrofuran (THF) (35 mL), was added lithium bis(trimethylsilyl)amide (1.0 M in THF, 28.1 mL, 28.1 mmol) dropwise over a period of 10 minutes. Stirring was maintained at -78 °C for 30 minutes, and then a solution of ethyl cyanoformate (3.0 mL, 30.4 mmol) in THF (15 mL) was added dropwise at -78 °C over a period of 10 minutes. The reaction mixture was allowed to stir at -78 °C for 2 h and then quenched with saturated aqueous NH4Cl. The aqueous layer was extracted with EtOAc (2 x 100 mL), the combined organics dried over Na2S04 and concentrated in vacuo. The residue was purified by flash chromatography (S1O2; 0-30% EtO Ac/hexanes) to give the title compound as an oil (3.5g, 52% yield). ¾ NMR (500 MHz, CDCh) d 4.26 - 4.10 (m, 2H), 2.79 (s, 1H), 2.34 - 2.14 (m, 2H), 1.47 (d, J= 27.0 Hz, 2H), 1.40 (s, 9H), 1.36 (s, 1H), 1.29 (d, J= 6.9 Hz, 3H), 1.23 (t, J= 7.1 Hz, 3H).
Step B: tert-Butyl 2.7-dimethyl-3-oxo- l .2.3A5.7-hexahvdro-6H-pyrazolo c1pyridine-6-
Figure imgf000156_0001
carboxylate. To a solution of [l-(tert-butyl) 4-ethyl 2-methyl-3-oxopiperidine-l,4-dicarboxylate] (3.5 g, 12.1 mmol) in toluene (40.0 mL) was added methylhydrazine (0.96 mL, 18.1 mmol). The reaction mixture was refluxed at 110 °C for 3 h. The reaction mixture was cooled to room temperature and the solvent was removed in vacuo. Purification (FCC, SiC ; 0-10% DCM- MeOH) afforded the title compound as an oil (2.7g, 83% yield). MS (ESI): mass calcd. for C13H21N3O3, 267.2; m/z found, 268.1 [M+H]+.
Step C: tert-Butyl-2.7-dimethyl-3-('('('trifluoromethyl)sulfonyl)oxy)-2.4.5.7-tetrahvdro-6H-
Pyrazolol3.4-c1pyridine-6-carboxylate. To a solution of tert-butyl 2,7-dimethyl-3-oxo- l,2,3,4,5,7-hexahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (2.7g, 10.1 mmol) in dichloromethane (45.0 mL) was added diisopropylethylamine (1.9 mL, 11.1 mmol) followed by l,l,l-trifluoro-N-phenyl-N-((trifluoromethyl)sulfonyl)methanesulfonamide (4.0g, 11.1 mmol). The reaction mixture was stirred at room temperature for 5 h and concentrated in vacuo. The crude residue was purified by flash chromatography (S1O2; 0-20% hexanes-EtOAc ) to give the title compound as an oil (3.8g, 86% yield). MS (ESI): mass calcd. for C14H20F3N3O5S, 399.1 ; m/z found, 344.0 [M+2H-¾u]+. ¾ NMR (500 MHz, CDCb) d 5.23 (s, 1H), 4.25 (s, 1H), 3.70 (s, 3H), 2.85 (s, 1H), 2.47 (dtd, J= 30.7, 15.4, 4.0 Hz, 2H), 1.41 (s, 9H), 1.34 (d, J= 6.8 Hz, 3H).
Intermediate 8: (SVtert-Butyl 2.7-dimethyl-3-(Y('trifluoromethyl)sulfonyl) oxyV2.4.5.7- c1 pyridine-6-carboxylate.
Figure imgf000156_0002
Method A:
Purification of racemic tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7- tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate, Intermediate 7 (8. lg, 18.5 mmol) by chiral SFC chromatography (Stationary phase: Whelk-Ol (S, S) 5pm 250*21.2mm, Mobile phase:
90% CO2, 10% iPrOH) provided 3.6g of the title compound. [a]20p = +100.3 (c = 1.0, MeOH). MS (ESI): mass calcd. for C14H20F3N3O5S, 399.1; m/z found, 344.0 [M+2H-lBu]_. Ή NMR (500 MHz, CDCh) d 5.23 (s, 1H), 4.25 (s, 1H), 3.70 (s, 3H), 2.85 (s, 1H), 2.47 (dtd, J= 30.7, 15.4, 4.0 Hz, 2H), 1.41 (s, 9H), 1.34 (d, = 6.8 Hz, 3H).
Method B:
Step A: Ethyl (N)-4-((l -ethoxy- 1 -oxopropan-2-yl) amino)butanoate. Into a 50 L reactor were added DMF (21 L, 6 V), ethyl L-alaninate hydrochloride (6.13 kg, 2.0 eq. 90 % w/w), K2HPO4 (10.94 kg, 3.5 eq.) and KI (2.98 kg, 1.0 eq.) successively at 20-30 °C. The resulting mixture was warmed to 50-55 °C and held at this temperature for 30 min. Then a solution of ethyl 4- bromobutanoate (3.50 kg, 1.0 eq.) in dimethylformamide (DMF) (7 L, 2 V) was added dropwise over 1 h while keeping the temperature at 50-55 °C. The mixture was stirred at 50-55 °C for 3 h. After the completion of the reaction, the reaction mixture was cooled to 20-30 °C and transferred into another reactor followed by adding water (87.5 L, 25 V). The resulting mixture was extracted with tert-butyl methyl ether (MTBE) (17.5 L x 4). The organic phase was collected and washed with brine (17.5 L). The organic phase was combined with the organic phases from other two batches (1.00 kg batch and 2.50 kg batch). Then the solution was concentrated under vacuum at 40-45 °C to give 6.8 kg of the title compound as a light-yellow oil (94% w/w assay by Q-NMR) in the yield of 82.2%. ¾ NMR (CDCh, 300 MHz) d 4.26-4.12 (m, 3H), 4.12 (d, J = 7.1 Hz, 1H), 3.35 (q, = 7.0 Hz, 1H), 2.68 (dt, J= 11.4, 7.0 Hz, 1H), 2.55 (dt, J= 11.4, 7.1 Hz, 1H), 2.38 (t, = 7.3 Hz, 2H), 1.84 (q, = 6.9 Hz, 1H), 1.36-1.17 (m, 9H).
Step B: Ethyl (S)-4-((tert-butoxycarbonyl)(l-ethoxy-l-oxopropan-2-yl)amino)butanoate. Into a
20 L reactor were added crude ethyl (5)-4-((l -ethoxy- 1 -oxopropan-2-yl) amino)butanoate (3.5 kg, 1.0 eq.), tetrahydrofuran (THF) (10 L, 3 V), and di -tert-butyl di carbonate (3.5 kg, 1.05 eq.) at 20-30 °C. The resulting mixture was warmed to 55-60 °C and held at this temperature for 3 h. After the completion of the reaction, the reaction mixture was concentrated under vacuum at 40-45 °C to give 5624 g of the title compound as a yellow oil with purity of 87.2 % (GC) and 99.1 % ee. The crude product was used in the next step without further purification. ' H NMR (CDCh, 400 MHz,) d 4.43-3.92 (m, 5H), 3.53-3.31 (m, 1H), 3.24-3.03 (m, 1H), 2.47-2.28 (m, 2H), 1.98-1.87 (m, 2H), 1.54 (s, 3H), 1.51-1.40 (m, 11H), 1.33-1.22 (m, 7H).
Step C: 1 -(tert-Butyl) 4-ethyl (2S)-2-methyl-3-oxopiperidine-l,4-dicarboxylate. Into a 10 L four necked flask were added crude ethyl(S)-4-((tert-butoxycarbonyl)(l-ethoxy-l-oxopropan-2- yl)amino)butanoate (450 g, 87% pure, 1.9 mol, 1.0 eq.) and THF (2.25 L, 5 V) at 20-30 °C.
After the mixture was cooled to -40 °C to -30 °C, lithium bis(trimethylsilyl)amide (LiHMDS)
(1 M in THF, 2.9 L, 2.9 mol, 1.5 eq.) was added dropwise while keeping the temperature at -40 °C to -30 °C. The resulting reaction mixture was warmed to 10-20 °C and held at this temperature for 1 h. After the completion of the reaction, the reaction mixture was combined with other two batches then poured into aq. citric acid (408.6 g in 2250 mL H2O, 2.9 mol, 1.5 eq.). After phase separation, the aqueous layer was re-extracted with MTBE (12 L, 10 V), the combined organic layers were sequentially washed with brine (9 L x 2). The organic phase was dried over Na2S04, then concentrated under vacuum to give crude product. The crude product was purified by silica gel chromatography (petroleum ether/ethyl acetate = 1/0 to 20/1) to give the title compound (1100 g) with 99 % purity in the yield of 70% over two steps. 'H NMR (500 MHz, CDCh) d 4.26 - 4.10 (m, 2H), 2.79 (s, 1H), 2.34 - 2.14 (m, 2H), 1.47 (d, J= 27.0 Hz, 2H), 1.40 (s, 9H), 1.36 (s, 1H), 1.29 (d, J= 6.9 Hz, 3H), 1.23 (t, J= 7.1 Hz, 3H).
Step D: tert-Butyl (7S)-2,7-dimethyl-3-oxo-2,3,3a,4,5,7-hexahydro-6H-pyrazolo[3,4-c]pyridine-
6-carboxylate. Into a 10 L four-necked flask were added methylhydrazine sulfate (360 g, 2.5 mol, 1.5 eq.), EtOH (5 L, 10.6 V) and DIEA (399 mL, 2.4 mol, 1.45 eq.) at 20-30 °C. The resulting mixture was warmed to 75-80 °C over 30 min. Then a solution of 1 -(tert- butyl) 4-ethyl (2S)-2-methyl-3-oxopiperidine-l,4-dicarboxylate (495 g crude, assay weight 470 g, 1.6 mol, 1.0 eq.) in EtOH (500 mL) was added dropwise over 20 min while keeping the temperature at 75-80 °C. The resulting mixture was stirred at 75-80 °C for 4 h. After the completion of the reaction, the reaction mixture was concentrated under vacuum. The resulting residue was combined with the residue from another 470 g batch. To the combined residues were diluted with DCM (8 L, 8.5 V), H2O (2 L, 2.7 V) and brine (2.5 L, 2.7 V). After phase separation, the aqueous layers were re-extracted with DCM (2 L x 2). The combined organic layers were dried over Na2S04, then concentrated under vacuum to give the title compound, which was used in the next step without further purification. MS (ESI): mass calcd. for C13H21N3O3, 267.2; m/z found, 268.1 [M+H]+. Step E: (S)-tert-Butyl 2,7-dimethyl-3-(trifluoromethylsulfonyloxy)-4,5-dihydro-2H- pyrazolo[3,4-clpyridine-6(7H)-carboxylate. Into a 10 L four-necked flask were added tert-butyl
(7S)-2,7-dimethyl-3-oxo-2,3,3a,4,5,7-hexahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (940g, 3.3 mol, 1.0 eq.), DCM (6 L, 6.4 V) and DIEA (550 mL, 3.3 mol, 1.0 eq.) at 20-30 °C. After the mixture was cooled to 10-20 °C, /V-(5-chloro-2- pyridyl)bis(trifluoromethanesulfonimide) (902 g, 2.3 mol, 0.7 eq.) was added batch-wise while keeping the temperature at 10-20 °C. Additional /V-(5-chloro-2- pyridyl)bis(trifluoromethanesulfonimide) (232 g, 0.6 mol, 0.18 eq.) was added. After stirring overnight, HPLC indicated the reaction was completed. Then the reaction mixture was concentrated under vacuum, followed by purification with silica gel chromatography (petroleum ether/ethyl acetate = 1/0 to 8/1) to give 1106 g of the title compound with a purity of 99 % (84% yield over two steps). ¾ NMR (400 MHz, CDCb) d 5.19 (br, 1H), 4.30 (br, 1H), 3.78 (s, 3H), 2.99-2.85 (m, 1H), 2.59-2.52 (m, 1H), 1.48 (s, 10H), 1.41 (d, J= 6.4 Hz, 3H).
Intermediate 9: ('R)-tert-Butyl 2.7-dimethyl-3-('(Ytrifluoromethyl)sulfonyl) oxy)-
Figure imgf000159_0001
tetrahvdro-6H-pyrazolo[3.4-c1pyridine-6-carboxylate.
Figure imgf000159_0002
Purification of racemic tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7- tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate, Intermediate 7 (8. lg, 18.5 mmol) by chiral SFC chromatography (Stationary phase: Whelk-Ol (S, S) 5pm 250*21.2mm, Mobile phase:
90% CO2, 10% iPrOH) provided 3.8g of the title compound. [a]20p = - 92.6 (c = 1.0, MeOH).
MS (ESI): mass calcd. for C14H20F3N3O5S, 399.1; m/z found, 344.0 [M+2H-lBu]_. Ή NMR (500 MHz, CDCb) d 5.23 (s, 1H), 4.25 (s, 1H), 3.70 (s, 3H), 2.85 (s, 1H), 2.47 (dtd, J= 30.7, 15.4, 4.0 Hz, 2H), 1.41 (s, 9H), 1.34 (d, = 6.8 Hz, 3H).
Intermediate 10: 2-Methyl-6-('quinoline-6-carbonyl)-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4- clpyridin-3-yl trifluoromethanesulfonate.
Figure imgf000159_0003
Step A: 2-Methyl-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4-c|pyridin-3-yl trifluoromethanesulfonate.
To a solution of [tert-butyl 2-methyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridine-6-carboxylate] Intermediate 1, Step C, (1 g, 2.60 mmol) in dichloromethane (7.8 mL) was added trifluoroacetic acid (TFA) (7.8 mL, 101 mmol). The reaction mixture was stirred at room temperature for 30 min, and then concentrated in vacuo.
The residue was purified by preparative HPLC (High Pressure Liquid Chromatography) to afford the title compound as a yellow solid (354 mg, 48% yield). MS (ESI): mass calcd. for
C8H10F3N3O3S, 285.0; m/z found, 286.1 [M+H]+.
Step B: 2-Methyl-6-('quinoline-6-carbonyl)-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4-c1pyridin-3-yl trifluoromethanesulfonate. To a solution of 2-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c]pyridin-3-yl trifluoromethanesulfonate (354 mg, 1.24 mmol) and quinoline-6-carboxylic acid (236 mg, 1.37 mmol) in dichloromethane (5.3 mL) was added HATU (708 mg, 1.86 mmol) followed by DIPEA (0.64 mL, 3.72 mmol). The reaction mixture was stirred at 36 °C for 4.5 h, and then diluted with dichloromethane (DCM) and H2O. The layers were separated, and the aqueous layer extracted with DCM (x2). The combined organics were washed with brine, dried over Na2S04, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (0-20% MeOH in DCM) to afford the title compound as an amorphous solid (241 mg, 44% yield). MS (ESI): mass calcd. for C18H15F3N4O4S, 440.1; m/z found, 441.0
[M+H]+.
Intermediate 11 : 2.7-Dimethyl-6-(quinoline-6-carbonyl)-4.5.6.7-tetrahvdro-2H-pyrazolor3.4- clpyridin-3-yl trifluoromethanesulfonate.
Figure imgf000160_0001
The title compound was prepared in a manner analogous to Intermediate 10, using tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 7) instead of [tert-butyl 2-methyl-3-(((trifluoromethyl)sulfonyl)oxy)- 2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate] in Step A. MS (ESI): mass calcd. for C19H17F3N4O4S, 454.1; m/z found, 455.0 [M+H]+. Intermediate 12: 2-Chloro-3-(2-fluoroethoxy)benzoic acid.
Figure imgf000161_0001
A solution of methyl 2-chloro-3-hydroxybenzoate (150 mg, 0.80 mmol), l-fluoro-2-iodoethane (167 mg, 0.97 mmol) and cesium carbonate (392 mg, 1.2 mmol) in dimethylformamide (DMF)
(3.1 mL) was stirred at rt for 16 h. The reaction mixture was diluted with water and extracted with ethyl acetate (EtOAc) (20 mL x 3). The combined organic layers were washed with brine, dried, filtered and concentrated under reduced pressure. Purification (FCC SiC , EtOAc in hexanes (0 to 25%) afforded a yellow oil (183 mg, 98%). The oil (183 mg, 0.79 mmol) was further diluted in tetrahydrofuran (THF) (6.4 mL) and water (0.28 mL). Lithium hydroxide monohydrate (264 mg, 6.3 mmol) was added. The reaction mixture was sealed and heated to 85°C for 19 h then cooled. The reaction mixture was concentrated under reduced pressure and the resulting crude product was neutralized with HC1 (1M, aq, 6.3 mL, 6.3 mmol). The resulting crude solid was filtered and dried to yield the title product (102 mg, 59%), which was used without further purification. MS (ESI): mass calcd. for CiTLClFCb, 218.0; m/z found, 217.0 [M-
H] .
Intermediate 13: 2-(2-Fluoroethoxy)benzoic acid.
Figure imgf000161_0002
The title compound was prepared in a manner analogous to Intermediate 12, using methyl 2- hydroxybenzoate in place of methyl 2-chloro-3-hydroxybenzoate. The crude product was used directly without purification.
Intermediate 14: 2-Chloro-5-(2-fluoroethoxy)benzoic acid.
Figure imgf000161_0003
The title compound was prepared in a manner analogous to Intermediate 12, using methyl 2- chloro-5-hydroxybenzoate in place of methyl 2-chloro-3-hydroxybenzoate. MS (ESI): mass calcd. for C9H8CIFO3, 218.0; m/z found, 217.0 [M-H] . Intermediate 15: 3-('2-Fluoroethoxy)benzoic acid.
Figure imgf000162_0001
The title compound was prepared in a manner analogous to Intermediate 12, using methyl 3- hydroxybenzoate in place of methyl 2-chloro-3-hydroxybenzoate. MS (ESI): mass calcd. for C9H9FO3, 184.1 ; m/z found, 183.0 [M-H] .
Intermediate 16: 4-('2-Fluoroethoxy)benzoic acid.
Figure imgf000162_0002
The title compound was prepared in a manner analogous to Intermediate 12, using methyl 4- hydroxybenzoate in place of methyl 2-chloro-3-hydroxybenzoate. MS (ESI): mass calcd. for C9H9FO3, 184.1 ; m/z found, 183.0 [M-H] .
Intermediate 17: l-(2-FluoroethylVlH-indole-4-carboxylic acid.
Figure imgf000162_0003
The title compound was prepared in a manner analogous to Intermediate 12, using methyl indole-4-carboxylic acid in place of methyl 2-chloro-3-hydroxybenzoate. MS (ESI): mass calcd. for C11H10FNO2, 207.1 ; m/z found, 208.1 [M+H]+. Intermediate 18: 3-(2-Fluoroethoxy)quinoline-6-carboxylic acid.
Figure imgf000163_0001
The title compound was prepared in a manner analogous to Intermediate 12, using 3- hydroxyquinoline-6-carboxylic acid in place of methyl 2-chloro-3-hydroxybenzoate and NaOH in place of LiOH. MS (ESI): mass calcd. for C12H10FNO3, 235.1; m/z found, 236.2 [M+H]+.
Intermediate 19: 2-Fluoro-3-(2-fluoroethoxy)benzoic acid.
Figure imgf000163_0002
The title compound was prepared in a manner analogous to Intermediate 12, using methyl 2- fluoro-3-hydroxybenzoate in place of methyl 2-chloro-3-hydroxybenzoate and NaOH in place of LiOH. MS (ESI): mass calcd. for C9H8F2O3, 202.0; m/z found, 201.0 [M-H] .
Intermediate 20: 4-Fluoro-3-('2-fluoroethoxy)benzoic acid
Figure imgf000163_0003
The title compound was prepared in a manner analogous to Intermediate 12, using methyl 4- fluoro-3-hydroxybenzoate in place of methyl 2-chloro-3-hydroxybenzoate and NaOH in place of LiOH. MS (ESI): mass calcd. for C9H8F2O3, 202.0; m/z found, 201.0 [M-H] .
Intermediate 21 : 5-Fluoro-3-t2-fluoroethoxy)benzoic acid
Figure imgf000163_0004
The title compound was prepared in a manner analogous to Intermediate 12, using methyl 5- fluoro-3-hydroxybenzoate in place of methyl 2-chloro-3-hydroxybenzoate and NaOH in place of LiOH. MS (ESI): mass calcd. for C9H8F2O3, 202.0; m/z found, 201.0 [M-H] . Intermediate 22: 2-Fluoro-5-(2-fluoroethoxy)benzoic acid.
Figure imgf000164_0001
The title compound was prepared in a manner analogous to Intermediate 12, using methyl 2- fluoro-5-hydroxybenzoate in place of methyl 2-chloro-3-hydroxybenzoate and NaOH in place of FiOH. MS (ESI): mass calcd. for C9H8F2O3, 202.0; m/z found, 201.0 [M-H] .
Intermediate 23: 8-(Trifluoromethyl)quinoline-6-carboxylic acid.
Figure imgf000164_0002
A mixture of 4-amino-3-(trifluoromethyl)benzoic acid (870 mg, 4.24 mmol), glycerol (0.62 mF, 8.49 mmol), and 3-nitrobenzenesulfonic acid sodium salt (4.30 g, 19.1 mmol) in 75% aqueous H2SO4 was heated to 100 °C for 3 h, then 140 °C for an additional 1 h. The reaction mixture was cooled to room temperature, and the pH of the reaction mixture was adjusted to pH 7with careful addition of 20% aqueous NaOH solution. The resulting suspension was filtered, and the solid collected to afford the title compound as a brown solid. The filtrate was extracted with EtOAc (x3), and the combined organics were dried over Na2S04, filtered, and concentrated under reduced pressure to afford additional material as a brown solid. MS (ESI): mass calcd. for C11H6F3NO2, 241.0; m/z found, 242.0 [M+H]+.
Intermediate 24: 3-(Trifluoromethyl)quinoline-6-carboxylic acid.
Figure imgf000164_0003
Step A: Methyl 3-iodoquinoline-6-carboxylate. To a solution of methyl quinoline-6-carboxylate (4.0 g, 21.4 mmol) in acetic acid (AcOH) (35 mL) was added /V-iodosuccinimide (NIS) (7.21 g, 35.1 mmol). The reaction mixture was heated to 100 °C for 2 h. After cooling to room temperature, the reaction mixture was poured into a solution of saturated aqueous Na CCh cooled in an ice bath. The resulting precipitate was collected via vacuum filtration and triturated in hot methanol (MeOH) to afford the title compound as a white solid (2.86 g, 43% yield). MS (ESI): mass calcd. for CnHsINCh, 313.0; m/z found, 314.0 [M+H]+.
Step B: Methyl 3-ttrifluoromethyl)quinoline-6-carboxylate. A microwave vial was charged with methyl 3-iodoquinoline-6-carboxylate (150 mg, 0.48 mmol), methyl 2,2-difluoro-2- (fluorosulfonyl)acetate (0.15 mL, 1.20 mmol), copper(I) iodide (228 mg, 1.20 mmol), DMPU (0.33 mL, 2.71 mmol), and DMF (3.0 mL). The head space was evacuated under vacuum and refilled with N2 (c3), and then the reaction mixture was heated under microwave irradiation at 130 °C for 30 min. The reaction mixture was filtered over a pad of diatomaceous earth (Celite®), eluting with MeOH. The filtrate was concentrated, the residue dissolved in EtOAc, and the solution washed with saturated aqueous NH4Cl. The aqueous layer was extracted with EtOAc (x3) and the combined organics were washed with brine (x3), dried over Na2S04, filtered, and concentrated under reduced pressure. Purification (LCC, S1O2, 0-50% EtOAc in hexanes) afforded the title compound (16 mg, 13% yield). MS (ESI): mass calcd. for C12H8F3NO2, 255.1; m/z found, 256.1 [M+H]+.
Step C: 3-(Trifluoromethyl)quinoline-6-carboxylic acid. A mixture of methyl 3- (trifluoromethyl)quinoline-6-carboxylate (25 mg, 98.0 pmol), NaOH (7.8 mg, 0.2 mmol), and H2O (20 pL, 1.11 mmol) in 1 : 1 THF:MeOH (0.4 mL) was heated to 60 °C for 2 h. The reaction was allowed to cool to room temperature and the solvent removed in vacuo. The resulting crude product was dissolved in H2O and the reaction mixture was acidified to pH 5 with 2N HC1. The resulting precipitate was collected via vacuum filtration to afford the title compound as a white solid. MS (ESI): mass calcd. for C11H6F3NO2, 241.0; m/z found, 242.0 [M+H]+.
Intermediate 25: 2-Methylquinoxaline-6-carboxylic acid.
Figure imgf000165_0001
To a solution of 3,4-diaminobenzoic acid (500 mg, 3.3 mmol) in ethanol (EtOH) (4.0 mL) was added 2-oxopropanal (0.45 mL, 6.6 mmol). The reaction mixture was refluxed at 80 °C for 16 hours (h/hrs). The reaction mixture was cooled to room temperature and the solvent was removed in vacuo. The crude product was used in the next step without further purification. MS (ESI): mass calcd. for C10H8N2O2, 188.0 m/z found, 189.0 [M+H]+. ¾ NMR (500 MHz,
DMSO-r/e) d 13.38 (s, 1H), 8.96 (s, 1H), 8.62 - 8.49 (m, 1H), 8.31 - 8.19 (m, 1H), 8.17 - 7.95 (m, 1H), 2.75 (d, J= 1.6 Hz, 3H).
Intermediate 26: 7-Methyl-2.3-diphenyl-4.5.6.7-tetrahvdro-2H-pyrazolol3.4-c1pyridine.
Figure imgf000166_0001
The title compound was prepared in a manner analogous to Intermediate 1, using l-(tert-butyl) 4- ethyl 2-methyl-3-oxopiperidine-l,4-dicarboxylate instead of 1 - c/7-butyl 4-ethyl-3- oxopiperidine-l,4-dicarboxylate and phenylhydrazine instead of methylhydrazine in Step A. MS(ESI): mass calcd. for C19H19N3, 289.1; m/z found, 290.1 [M+H] +.
Intermediate 27: /V- Butyl 7-ethyl-2-methyl-3-(((trifluoromethyl)sulfonyl) oxy)-2A5.7- tetrahvdro-6H-pyrazolol3.4-c1 pyridine-6-carboxylate.
Figure imgf000166_0002
The title compound was prepared in a manner analogous to Intermediate 7, using tert-butyl 2- ethyl-3-oxopiperidine-l-carboxylate instead of tert-butyl 2-methyl-3-oxopiperidine-l- carboxylate m Step A. ¾ NMR (500 MHz, CDCb) d 5.20 - 4.96 (m, 1H), 4.48 - 4.14 (m, 1H), 3.78 (s, 3H), 3.05 - 2.85 (m, 1H), 2.67 - 2.53 (m, 1H), 2.52 - 2.44 (m, 1H), 1.90 - 1.82 (m, 1H), 1.78 - 1.68 (m, 1H), 1.48 (s, 9H), 1.03 (t, = 7.4 Hz, 3H). Intermediate 28: /V- Butyl 7-methyl-3-(((trifluoromethyl)sulfonyl)oxy)- tetrahvdro-6H-
Figure imgf000167_0001
ridine-6-carboxylate.
Figure imgf000167_0002
The title compound was prepared in a manner analogous to Intermediate 7, using hydrazine hydrate instead of methyl hydrazine in Step B. The crude residue was purified by silica gel chromatography (0-20% EtO Ac/hexanes @ 220 nm wavelength) to give the title compound as an oil (550 mg, 51% yield). MS (ESI): mass calcd. for C13H18F3N3O5S, 385.1; m/z found, 329.1 [M+2H-lBu] +. Intermediate 29: tert-Butyl methyl-3-((YtrifluoromethylIsulfonylIoxyV2A5.7-tetrahvdro-
Figure imgf000167_0003
6H-pyrazolo[3.4-c1pyridine-6-carboxylate.
Figure imgf000167_0004
Purification of tert-butyl 7-methyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridine-6-carboxylate, Intermediate 28, by chiral SFC chromatography (Stationary phase: CHIRALPAK IC 5pm 250*30mm, Mobile phase: 87% CO2, 13% MeOH, retention time = 0.86 min) afforded the title compound as a pure enantiomer. MS (ESI): mass calcd. for C13H18F3N3O5S, 385.1; m/z found, 329.1 [M+2H-¾u]+.
Intermediate 30: tert-Butyl ('R)-7-methyl-3-(Y('trifluoromethyl)sulfonyl)oxy)- tetrahvdro-
Figure imgf000167_0005
6H-pyrazolo[3.4-c1pyridine-6-carboxylate.
Figure imgf000167_0006
Purification of tert-butyl 7-methyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridine-6-carboxylate, Intermediate 28 by chiral SFC chromatography (Stationary phase: CHIRALPAK IC 5pm 250*30mm, Mobile phase: 87% CO2, 13% MeOH, retention time = 1.79 min) afforded the title compound as a pure enantiomer. MS (ESI): mass calcd. for C13H18F3N3O5S, 385.1; m/z found, 329.1 [M+2H-Bu] +.
Intermediate 31 : 3-('3.5-Difluorophenyl)-7-methyl-2-('methyl-d3)-4.5.6.7-tetrahvdro-2H- pyrazolo [3.4-cl pyridine.
Figure imgf000168_0001
Step A: tert-Butyl 3-('3.5-difluorophenyl)-7-methyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridine-6-carboxylate. The title compound was prepared in a manner analogous to
Intermediate 1, using tert-butyl 7-methyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro- 6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 28) instead of tert-butyl 2-methyl-3- (trifluoromethylsulfonyloxy)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-6-carboxylate and 3,5- difluorophenylboronic acid instead of phenylboronic acid in Step C. MS (ESI): mass calcd. for C18H21F2N3O2, 349.1; m/z found, 294.0 [M+2H-lBu] +.
Step B: tert-Butyl 3-(3.5-difluorophenyl)-7-methyl-2-('methyl-d3)- tetrahvdro-6H-
Figure imgf000168_0002
pyrazolor3.4-c1pyridine-6-carboxylate. To an ice-cold solution of tert-butyl 3-(3,5- difluorophenyl)-7-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (200 mg, 0.6 mmol) in THF (2.0 mL) was added 60 wt% sodium hydride/mineral oil (24 mg, 0.6 mmol). The reaction mixture was stirred for 30 min at 0 °C, and then iodomethane-d3 (40 pL, 0.6 mmol) was added. Stirring was maintained at 0 °C for 1 h and the crude mixture was quenched with water then extracted with EtOAc (x3). The combined organic layers were dried over Na2S04, concentrated in vacuo and purified by reverse-phase HPLC (XBridge Cl 8 column (5pm, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH4OH) to afford the title compound as white solid (33 mg, 16% yield). MS (ESI): mass calcd. for C19H20D3F2N3O2, 366.1; m/z found, 311.1 [M+2H-¾u] +. ¾ NMR (500 MHz, DMSO-r/e) d 7.39 - 7.20 (m, 3H), 5.09 (s, 1H), 4.12 (s, 1H), 2.92 (s, 1H), 2.70 - 2.57 (m, 1H), 2.44 - 2.30 (m, 1H), 1.43 (s, 9H), 1.35 (d, J= 6.7 Hz, 3H). Step C: 3-('3.5-Difluorophenyl)-7-methyl-2-('methyl-d3)-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4- clpyridine. To a solution of tert-butyl 3-(3,5-difluorophenyl)-7-methyl-2-(methyl-d3)-2,4,5,7- tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (28 mg, 0.075 mmol) in DCM (1 mL) was added TFA and the mixture was stirred at room temperature for 1 h. The solvent was
concentrated in vacuo and the crude residue taken onto the next step without further purification. MS (ESI): mass calcd. for C14H12D3F2N3, 266.1; m/z found, 267.1 [M+H] +.
Intermediate 32: 2-('Difluoromethyl)-3-('3.5-difluorophenyl)-7-methyl-4.5.6.7-tetrahvdro-2H- pyrazolo [3.4-cl pyridine.
Figure imgf000169_0001
Step A: tert-Butyl 2-(difluoromethyl)-3-(3.5-difluorophenyl)-7-methyl- tetrahvdro-6H-
Figure imgf000169_0002
Pyrazolo[3.4-c1pyridine-6-carboxylate. To an ice-cold solution of tert-butyl 3-(3,5- difluorophenyl)-7-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate, Intermediate 31, Step A, (125 mg, 0.36 mmol) in DMF (5.0 mL) was added 60 wt% sodium hydride/mineral oil (36 mg, 0.9 mmol). The mixture was stirred for 30 minutes at 0 °C, and then sodium 2-chloro-2,2-difluoroacetate (136 mg, 0.9 mmol) was added. The reaction was heated to 80 °C for 2 h, and then cooled to room temperature before quenching with water and extracting the aqueous layer with EtOAc (x3). The combined organic extracts were dried over Na2S04, concentrated in vacuo and purified by reverse-phase HPLC (XBridge Cl 8 column; 5pm, 100 x 4.6mm; mobile phase of 10-100% ACN in 20 mM NH4OH) to afford the title compound as a white solid (47 mg, 33% yield). MS (ESI): mass calcd. for C19H21F4N3O2, 399.1; m/z found,
400.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 7.70 (t, J= 57.6 Hz, 1H), 7.44 (m, 1H), 7.32 - 7.19 (m, 2H), 5.20 (s, 1H), 4.12 (d, J= 22.4 Hz, 1H), 2.97 (s, 1H), 2.62 (q, = 8.5, 4.9 Hz, 1H), 2.39 (d, J= 14.8 Hz, 1H), 1.44 (s, 9H), 1.40 (d, J= 6.8 Hz, 3H).
Step B: 2-('Difluoromethyl)-3-('3.5-difluorophenyl)-7-methyl-4.5.6.7-tetrahvdro-2H- pyrazolor3.4-c1 pyridine. To a solution of tert-butyl 2-(difluoromethyl)-3-(3,5-difluorophenyl)-7- methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (38 mg, 0.05 mmol) in DCM (1 mL) was added TFA (1 mL) and the mixture was stirred at rt for 1 h. The solvent was concentrated in vacuo and the crude residue was taken onto the next step without further purification. MS (ESI): mass calcd. for C14H12D3F2N3, 266.1; m/z found, 267.1 [M+H] +. Intermediate 33: (S)-2-(Difluoromethyl)-7-methyl-3-(3 A5-trifluorophenyl)-4.5.6.7-tetrahvdro- 2H-pyrazolo[3.4-c1pyridine.
Figure imgf000170_0001
Step A: tert-Butyl ('S)-7-methyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridine-6-carboxylate. The title compound was prepared in a manner analogous to
Intermediate 1, using tert-butyl (S)-7-methyl-3-(((trifluoromethyl)sulfonyl)oxy)-2, 4,5,7- tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 29) instead of tert-butyl 2- methyl-3-(trifluoromethylsulfonyloxy)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-6-carboxylate and (3,4,5-trifluorophenyl)boronic acid instead of phenylboronic acid in Step C. MS (ESI): mass calcd. for C18H20F3N3O2, 367.2; m/z found, 312.0 [M+2H-lBu] +.
Step B: (S)-2-(Difluoromethyl)-7-methyl-3-(3.4.5-trifluorophenyl)-4.5.6.7-tetrahvdro-2H- pyrazolor3.4-c1 pyridine. The title compound was prepared in a manner analogous to
Intermediate 32, using tert-butyl (S)-7-methyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridine-6-carboxylate in place of tert-butyl 3-(3,5-difluorophenyl)-7-methyl- 2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate in Step A. MS (ESI): mass calcd. for C14H12F5N3, 317.1 m/z found, 318.1 [M+H] +.
Intermediate 34: (R)-2-(Difluoromethyl)-7-methyl-3-(3.4.5-trifluorophenyl)-4.5.6.7-tetrahvdro-
Figure imgf000171_0003
clpyridine-6-carboxylate. The title compound was prepared in a manner analogous to
Intermediate 1, using tert-butyl (R)-7-methyl-3-(((trifluoromethyl)sulfonyl)oxy)-2, 4,5,7- tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 30) instead of tert-butyl 2- methyl-3-(trifluoromethylsulfonyloxy)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-6-carboxylate and (3,4,5-trifluorophenyl)boronic acid instead of phenylboronic acid in Step C. MS (ESI): mass calcd. for C18H20F3N3O2, 367.2; m/z found, 312.0 [M+2H-lBu] +.
Step B: (RV2-(DifluoromethylV7-methyl-3-(3.4.5-trifluorophenylV4.5.6.7-tetrahvdro-2H- pyrazolor3.4-c1 pyridine. The title compound was prepared in a manner analogous to
Intermediate 32, using tert-butyl (R)-7-methyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridine-6-carboxylate in place of tert-butyl 3-(3,5-difluorophenyl)-7-methyl- 2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate in Step A. MS (ESI): mass calcd. for C14H12F5N3, 317.1 m/z found, 318.1 [M+H] +.
Intermediate 35: 3-('3.5-Difluorophenyl)-7-methyl-2-('trifluoromethyl)-4.5.6.7-tetrahvdro-2H- pyrazolo [3.4-cl pyridine.
Figure imgf000171_0001
Step A: tert-butyl 2-('bromodifluoromethyl)-3-('3.5-difluorophenyl)-7-methyl- tetrahvdro-
Figure imgf000171_0002
6H-pyrazolo[3.4-c1pyridine-6-carboxylate. The title compound was prepared in a manner analogous to Intermediate 32, using dibromo difluoromethane instead of sodium 2-chloro-2,2- difluoroacetate in Step A. MS(ESI): mass calcd. for Ci9H2oBrF4N302, 477.1; m/z found, 423.9 [M+2H-lBu]7
Step B: 3-('3.5-Difluorophenyl)-7-methyl-2-('trifluoromethyl)-4.5.6.7-tetrahvdro-2H- pyrazolor3.4-cl pyridine. To a cooled (-78 °C) solution of tert-butyl 2-(bromodifluoromethyl)-3-
(3,5-difluorophenyl)-7-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (90 mg, 0.2 mmol) in DCM (3.0 mL) was added silver tetrafluoroborate (81 mg, 0.4 mmol) portion- wise. The reaction mixture was then warmed to room temperature and stirred for 20 h. Saturated aqueous NaHCC (5 mL) was added and the mixture filtered. The aqueous layer of the filtrate was extracted with DCM (x 2) and the combined organics were dried over Na2S04 and concentrated in vacuo. Purification by reverse- phase HPLC (XBridge Cl 8 column; 5pm, 100 x 4.6mm; mobile phase of 10-100% ACN in 20 mM NLLOH) provided the title compound as a white solid (25 mg, 42% yield). MS(ESI): mass calcd. for C14H12F5N3, 317.1 ; m/z found, 318.1 [M+H] +.
Intermediate 36: 3-(2-(Tosyloxy)ethoxy)benzoic acid.
Figure imgf000172_0001
The title compound was prepared in a manner analogous to Intermediate 12, using methyl 3- hydroxybenzoate in place of methyl 2-chloro-3-hydroxybenzoate, ethane- 1 ,2-diyl bis(4- methylbenzenesulfonate) in place of l-fluoro-2-iodoethane, and NaOH in place of Li OH. MS (ESI): mass calcd. for C16H16O6S, 336.1; m/z found, 337.1 [M+H]+.
Intermediate 37: 1 -(2-(YTetrahvdro-2H-pyran-2-yl)oxy)ethyl)- 1 H-indole-5-carboxylic acid.
Figure imgf000172_0002
The title compound was prepared in a manner analogous to Intermediate 12, using methyl 1H- indole-5-carboxylate in place of methyl 2-chloro-3-hydroxybenzoate and 2-(2- bromoethoxy)tetrahydro-2H-pyran in place of ethane- 1 ,2-diyl bis(4-methylbenzenesulfonate) in place of l-fluoro-2-iodoethane. MS (ESI): mass calcd. for C16H19NO4, 289.1; m/z found, 290.1 [M+H]+.
Intermediate 38: 3-[3-(Trifluoromethyl)pyrazol- l -yllbenzoic acid.
Figure imgf000173_0001
A mixture of 3-iodobenzoic acid (300 mg, 1.21 mmol), 3-(trifluoromethyl)pyrazole (247 mg, 1.82 mmol), cesium carbonate (670 mg, 2.06 mmol), ra«.s-/V,/V'-dimethylcyclohexane- 1 ,2- diamine (32 pL, 0.203 mmol) and copper(I) iodide (25 mg, 0.131 mmol) in N,N- dimethylformamide (1.25 mL) was stirred at 100 °C for 30 min, then at 140 °C for 70 min under microwave irradiation. The reaction mixture was taken up in water (5 mL), acidified to pH 3 with 1 M hydrochloric acid and extracted with ethyl acetate (3 x 5 mL). The combined organic layers were dried over sodium sulfate, filtered and evaporated. The crude product was purified by preparative HPLC to afford the title compound (140 mg, 45% yield) as a tan powder. MS (ESI): mass calcd. for C11H7E3N2O2, 256.0; m/z found, 257.1 [M+H]+.
Intermediate 39: ('S)-3-('3.5-Difluorophenyl)-2.7-dimethyl-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4- clpyridine. Hydrochloride salt.
Figure imgf000173_0002
Step A: -2-('3-('3.5-Difluorophenyl)-2-nitroallyl)- l 3-dioxolane. Dilute 2-(2-nitroethyl)-l,3- dioxolane (20.26 g, 137.72 mmol), 3,5-difluorobenzaldehyde (19.57 g, 137.72 mmol) and catalytic piperidine (2 mL, 20.25 mmol) in toluene (150 mL). Heat to reflux overnight. The reaction mixture was cooled to room temperature then quenched with saturated NaCl solution (150 mL). The extracted organic layer was dried with Na2S04, filtered and concentrated to dark oil to recover quantitative crude yield of the title compound. The compound was used in the next step without further purification.
Step B: tert-Butyl (L',/'-H 1 -(2-methylhydrazineylidene)propan-2-yl)carbamate. ^ solution of methylhydrazine (3.04 mL, 57.73 mmol) and tert-butyl (L)-( 1 -oxopropan-2-yl) carbamate (10 g, 57.73 mmol) in THF (150 mL) was stirred for 4 hours at room temperature. The reaction mixture was dried over Na^SO-i, filtered and evaporated under reduced pressure overnight. The title compound was isolated as a light oil in quantitative crude yield. The crude product was used in the next reaction without further purification.
Step C: tert-Butyl (<S)-(l-(4-((l,3-dioxolan-2-yl)methyl)-5-(3,5-difluorophenyl)-l-methyl-lH- pyrazol-3-yl)ethyl)carbamate. To a solution of tert-Butyl (L', /7)-( 1 -(2- methylhydrazineylidene)propan-2-yl)carbamate (11.62 g, 57.73 mmol) in EtOH (500 mL) was added (E)-2-(3-(3,5-difluorophenyl)-2-nitroallyl)-l,3-dioxolane (16.27 g, 59.98 mmol). The reaction was stirred overnight at room temperature under open air. The reaction mixture was mildly heated to 40 °C overnight to drive the reaction to completion. The reaction was concentrated to an oil then quenched with EtOAc (250 mL) and NaCl solution (250 mL). The extracted organic layer was washed with water then dried with Na^SO-i, filtered and concentrated to dark orange oil. Purification (FCC, SiCh, 7/3 hexane/EtOAc) afforded the title compound (13.32 g, 54.5%).
Step D: (A)-3-(3,5-Difluorophenvl)-2,7-dimethvl-4,5,6,7-tetrahvdro-2H-pvrazolo[3,4-c]pvridine.
A solution of tert-Butyl (L)-( 1 -(4-(( 1 ,3-dioxolan-2-yl)methyl)-5-(3,5-difluorophenyl)- l -methyl- lH-pyrazol-3-yl)ethyl)carbamate (4 g, 9.446 mmol) in CH2CI2 (30 mL), TFA (8 mL, 104.54 mmol) and triethylsilane (23 mL, 144.0 mmol) was stirred for 30 minutes then heated to 55 °C overnight. The reaction mixture was concentrated to an oil then quenched with EtOAc and 1 N NaOH to pH 11-12. The extracted organic layer was dried with Na2S04, filtered and evaporated to light brown oil. The crude product was diluted in EtOH and 1.1 equivalents of 1 N HC1 (10 mL, 10 mmol) was added. The mixture was stirred over weekend without any formation of the HC1 salt. The mixture was concentrated to a light brown solid then slurried in minimum 9/1 CH3CN/TBME overnight. The solids were filtered to recover the HC1 salt of the title compound (1.92 g, 68%). Intermediate 40: (SV2.7-dimethyl-3-(3.4.5-trifluorophenylV4.5.6.7-tetrahvdro-2H-pyrazolor3.4- clpyridine.
Figure imgf000175_0001
The title compound was prepared in a manner analogous to Intermediate 1, using (S)-tert-Butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine- 6-carboxylate (Intermediate 8) instead of / -butyl 2-methyl-3-(trifluoromethylsulfonyloxy)-5,7- dihydro-4//-pyrazolo[3,4-6]pyridine-6-carboxylate, 3,4,5-trifluorophenylboronic acid instead of phenylboronic acid, and XPhos-Pd-G2 instead of /£7ra /.v(triphenylphosphine)palladium(0) in Step C. MS (ESI): mass calcd. for C14H14F3N3, 281.1; m/z found, 282.0 [M+H] +. ¾ NMR (600 MHz, CDCb) d 7.00 - 6.92 (m, 2H), 4.04 (q, J= 6.6 Hz, 1H), 3.80 (s, 3H), 3.31 - 3.23 (m, 1H), 2.96 - 2.86 (m, 1H), 2.64 - 2.54 (m, 1H), 2.47 - 2.38 (m, 1H), 1.49 (d, = 6.6 Hz, 3H).
Intermediate 41 : (S)-3-(3-Chloro-5-methoxyphenyl)-2.7-dimethyl-4.5.6.7-tetrahvdro-2H- pyrazolor3.4-c1 pyridine.
Figure imgf000175_0002
The title compound was prepared in a manner analogous to Intermediate 40, using (3-chloro-5- methoxy phenyl) boronic acid instead of (3,4,5-trifluorophenyl) boronic acid. MS (ESI): mass calcd. for CisHisClNsO, 291.1 ; m/z found, 292.0 [M+H] +. Intermediate 42: ('S)-3-('3-fluoro-5-methylphenyl)-2.7-dimethyl-4.5.6.7-tetrahvdro-2H- pyrazolor3.4-c1 pyridine.
Figure imgf000176_0001
The title compound was prepared in a manner analogous to Intermediate 40, using (3-fluoro-5- methyl phenyl) boronic acid instead of (3,4,5-trifluorophenyl) boronic acid. MS (ESI): mass calcd. for CisHisFNs, 259.2; m/z found, 260.1 [M+H] +.
Intermediate 43: ('S)-3-('2.2-difluorobenzo[din .31dioxol-4-yl)-2.7-dimethyl-4.5.6.7-tetrahvdro- 2H-pyrazolo[3.4-c1pyridine.
Figure imgf000176_0002
The title compound was prepared in a manner analogous to Intermediate 40 using (2,2- difluorobenzo[d][l,3]dioxol-4-yl)boronic acid instead of (3,4,5-trifluorophenyl) boronic acid. MS (ESI): mass calcd. for C15H15F2N3O2, 307.1.1; m/z found, 308.1 [M+H] +. Intermediate 44: (SV2.7-dimethyl-3-(3-(trifluoromethoxy)phenylV4.5.6.7-tetrahvdro-2H- pyrazolo G3 ,4-cl pyridine.
Figure imgf000176_0003
The title compound was prepared in a manner analogous to Intermediate 40 using (3- (trifluoromethoxy)phenyl)boronic acid instead of (3,4,5-trifluorophenyl) boronic acid. MS (ESI): mass calcd. for C15H16F3N3O, 311.1; m/z found, 312.0 [M+H] +. Intermediate 45: (S)-3-(3-(difluoromethoxy)phenyl)-2.7-dimethyl- tetrahvdro-2H-
Figure imgf000177_0001
pyrazolo [3.4-cl pyridine.
Figure imgf000177_0002
The title compound was prepared in a manner analogous to Intermediate 40 using (3- (difluoromethoxy)phenyl)boronic acid instead of (3,4,5-trifluorophenyl) boronic acid. MS (ESI): mass calcd. for C15H17F2N3O, 293.1; m/z found, 294.1 [M+H] +.
Intermediate 46: (S)-3-(3-isopropoxyphenyl)-2.7-dimethyl-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4- clpyridine.
Figure imgf000177_0003
The title compound was prepared in a manner analogous to Intermediate 40 using (3- isopropoxyphenyl)boronic acid instead of (3,4,5-trifluorophenyl) boronic acid. MS (ESI): mass calcd. for C15H23N3O, 285.2; m/z found, 286.1 [M+H] +.
Intermediate 47: ('S)-3-('2-methoxyphenyl)-2.7-dimethyl-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4- clpyridine.
Figure imgf000178_0001
The title compound was prepared in a manner analogous to Intermediate 40 using (2- methoxyphenyl)boronic acid instead of (3,4,5-trifluorophenyl) boronic acid. MS (ESI): mass calcd. for C15H19N3O, 257.2; m/z found, 258.1 [M+H] +.
Intermediate 48: ('S)-3-('3-methoxyphenyl)-2.7-dimethyl-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4- clpyridine.
Figure imgf000178_0002
The title compound was prepared in a manner analogous to Intermediate 40 using (3-methoxy phenyl)boronic acid instead of (3,4,5-trifluorophenyl) boronic acid. MS (ESI): mass calcd. for C15H23N3O, 285.2; m/z found, 286.1 [M+H] +.
Intermediate 49: ('S)-2.7-Dimethyl-6-('quinoline-6-carbonyl)-4.5.6.7-tetrahvdro-2H-pyrazolol3.4- clpyridin-3-yl trifluoromethanesulfonate.
Figure imgf000178_0003
The title compound was prepared in a manner analogous to Intermediate 10, using (S)-tert-butyl
2.7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine- 6-carboxylate (Intermediate 8) instead of [tert-butyl 2-methyl-3-(((trifluoromethyl)sulfonyl)oxy)-
2.4.5.7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate] in Step A, and 1- propanephosphonic anhydride (T3P®, 50% in ethyl acetate) instead of HATU in Step B. MS (ESI): mass calcd. for C19H17F3N4O4S, 454.1; m/z found, 455.1 [M+H]+.
Intermediate 50: (SV2.7-dimethyl-3-(3-(trifluoromethvB phenyl )-4.5.6.7-tetrahydro-2H- pyrazolo[3.4-c1 pyridine.
Figure imgf000179_0001
The title compound was prepared in a manner analogous to Intermediate 40 using (3- (trifluoromethyl) phenyl) boronic acid instead of (3,4,5-trifluorophenyl) boronic acid. MS (ESI): mass calcd. for C15H16F3N3, 295.1; m/z found, 296.1 [M+H] +.
Intermediate 51 : 2-(Bicvclor 1.1.11pentan- l -yl)-7-methyl-3-phenyl-4.5.6.7-tetrahvdro-2H- pyrazolor3.4-c1pyridine.
Figure imgf000179_0002
Step A: tert-butyl 2-('bicvclon . 1. 11pentan- l -yl)-7-methyl-3-oxo- l .2.3.4.5.7-hexahydro-6H- pyrazolo[3.4-c1pyridine-6-carboxylate. To a solution of 1 -(tert-butyl) 4-ethyl 2-methyl-3- oxopiperidine-l,4-dicarboxylate (Intermediate 7, Step A) (224 mg, 0.79 mmol) and
bicyclo[l. l . l]pentan-l-ylhydrazine dihydrochloride (148 mg, 0.87 mmol) in EtOH (1.5 mL) was added triethylamine (0.24 mL, 1.73 mmol), and the reaction stirred at 80 °C overnight. After cooling to room temperature, the mixture was diluted in hexanes, the solids filtered away, and the filtrate concentrated in vacuo. The crude residue was purified by silica gel chromatography (0-20% MeOH/DCM) to afford the title compound as a yellow oil (164 mg, 65% yield). MS (ESI): mass calcd. for C17H25N3O3, 319.2; m/z found, 320.1 [M+H] +. Step B: 2-(bicyclo[l. l. l]pentan-l-yl)-7-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c]pyridine. The title compound was prepared in a manner analogous to Intermediate 1, Steps B- D using tert-butyl 2-(bicyclo[l. l. l]pentan-l-yl)-7-methyl-3-oxo-l,2,3,4,5,7-hexahydro-6H- pyrazolo[3,4-c]pyridine-6-carboxylate instead of tert-butyl 2-methyl-3-oxo-l,4,5,7- tetrahydropyrazolo[3,4-c]pyridine-6-carboxylate in Step B, and XPhos-Pd-G2 instead of tetrakis(triphenylphosphine)palladium(0) in Step C. MS (ESI): mass calcd. for C18H21N3, 279.2; m/z found, 280.2 [M+H] +.
Intermediate 52: tert-Butyl 7-methyl-2-phenyl-3-(((trifluoromethyl)sulfonyl) oxy)-2, 4,5,7- tetrahydro-6H-pyrazolo[3,4-cl pyridine-6-carboxylate.
Figure imgf000180_0001
The title compound was prepared in a manner analogous to Intermediate 7, using
phenylhydrazine instead of methylhydrazine in Step B. MS(ESI): mass calcd. for
C19H22F3N3O5S, 461.5; m/z found, 406.0 [M+2H-tBu] +.
Intermediate 53: tert-Butyl (S)-7-methyl-2-phenyl-3-(((trifluoromethyl)sulfonyl) oxy)-2, 4,5,7- tetrahydro-6H-pyrazolo[3,4-c] pyridine-6-carboxylate.
Figure imgf000180_0002
Purification of racemic tert-butyl 7-methyl-2-phenyl-3-(((trifluoromethyl)sulfonyl) oxy)-2, 4,5,7- tetrahydro-6H-pyrazolo[3,4-c] pyridine-6-carboxylate (Intermediate 52) (2.4 g, 5.2 mmol) by chiral SFC chromatography (Stationary phase: Whelk-Ol (S, S) 3 pm 100*4.6 mm, 10% iPrOH, neat, 3.5 ml/min) provided 861 mg of the title compound. (ESI): mass calcd. for C19H22F3N3O5S, 461.5; m/z found, 406.0 [M+2H-lBu] +. Ή NMR (400 MHz, DMSO-r/e) d 7.64 - 7.45 (m, 5H), 5.17 (s, 1H), 4.20 (s, 1H), 3.03 (s, 1H), 2.69 - 2.57 (m, 1H), 2.54 (d, = 5.4 Hz, 1H), 1.45 (s, 9H), 1.40 (d, = 6.8 Hz, 3H). Intermediate 54: tert-Butyl tR)-7-methyl-2-Dhenyl-3-ttttrifluoromethyl)sulfonyl) oxyV2.4.5.7- tetrahvdro-6H-pyrazolo[3.4-c1 pyridine-6-carboxylate.
Figure imgf000181_0001
Purification of racemic tert-butyl 7-methyl-2-phenyl-3-(((trifluoromethyl)sulfonyl) oxy)-2, 4,5,7- tetrahydro-6H-pyrazolo[3,4-c] pyridine-6-carboxylate (Intermediate 52) (2.4 g, 5.2 mmol) by chiral SFC chromatography (Stationary phase: Whelk-Ol (S, S) 3 pm 100*4.6 mm, 10% iPrOH, neat, 3.5 ml/min) provided 778 mg of the title compound. (ESI): mass calcd. for C19H22F3N3O5S, 461.5; m/z found, 406.0 [M+2H-lBu] +.
Intermediate 55: ('S)-7-Methyl-2.3-diphenyl-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4-c1 pyridine.
Figure imgf000181_0002
The title compound was prepared in a manner analogous to Intermediate 1, using tert-butyl (S)- 7-methyl-2-phenyl-3-(((trifluoromethyl)sulfonyl) oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c] pyridine-6-carboxylate (Intermediate 53) instead of / /V-butyl 2-methyl-3-
(trifluoromethylsulfonyloxy)-5,7-dihydro-4//-pyrazolo[3,4-6]pyridine-6-carboxylate in Step C. MS(ESI): mass calcd. for C19H19N3, 289.1; m/z found, 290.1 [M+H] +.
Intermediate 56: ('R)-7-Methyl-2.3-diphenyl-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4-cl pyridine.
Figure imgf000181_0003
The title compound was prepared in a manner analogous to Intermediate 1, using tert-butyl (R)- 7-methyl-2-phenyl-3-(((trifluoromethyl)sulfonyl) oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c] pyridine-6-carboxylate (Intermediate 54) instead of tert- butyl 2-methyl-3- (trifl uoromethylsulfony loxy)-5, 7-dihydro-4//-pyrazolo[3, 4-c] pyridine-6-carboxy late in Step C. MS(ESI): mass calcd. for C19H19N3, 289.1; m/z found, 290.1 [M+H] +.
:-4-carboxybc acid.
Figure imgf000182_0001
Step A: 2-(Chloromethyl)pyrazine. A solution of thionyl chloride (30.9 mL, 435.9 mmol) in DCM (250 mL) was added dropwise to a mixture of 2-pyrazinylmethanol (16 g, 145.3 mmol) in DCM (250 mL) under a nitrogen atmosphere at 0 °C. The reaction mixture was stirred at room temperature overnight. Saturated aqueous NaHCC was added and the mixture was extracted with DCM. The organic layer was separated, dried over MgS04, filtered and concentrated under reduced pressure. Purification (LCC, S1O2, 0-50% Et20 in pentane) afforded the title compound (18.7 g, 100%). The title compound is volatile and unstable. MS (ESI): mass calcd. for
C5H5CIN2, 128.0; m/z found, 129 [M+H]+. ¾ NMR (300 MHz, CDCb) d 8.75 (s, 1H), 8.55 (s, 2H), 4.70 (s, 2H).
Step B: 2-((But-3-yn-l-yloxy)methyl)pyrazine. Sodium (4 g, 174.4 mmol) was added to a solution of 3-butyn-l-ol (16.5 mL, 218.0 mmol) in THF (300 mL) under a nitrogen atmosphere at room temperature. After 2 hours, a solution of 2-(chloromethyl)pyrazine (18.7 g, 145.3 mmol) in THF (300 mL) was added to the suspension and the reaction mixture was heated to 40 °C for 2 hours. Then, the reaction mixture was stirred at room temperature overnight. A mixture of EtOAc and water (5: 1) was added to the reaction mixture. The organic layer was separated, dried over MgS04, filtered and concentrated under reduced pressure. Purification (FCC, S1O2, 0-40% EtOAc in heptane) afforded the title compound (14.7 g, 62%). MS (ESI): mass calcd. for C9H10N2O, 162.1; m/z found, 163 [M+H]+. ¾ NMR (300 MHz, CDCb) d 8.76 (s, 1H), 8.50 (s, 2H), 4.73 (s, 2H), 3.73 (t, J= 6.8 Hz, 2H), 2.56 (td, J= 6.7, 2.5 Hz, 2H), 2.01 (t, J= 2.1 Hz, 1H). Step C: 5,8-Dihydro-6H-pyrano[3,4-b]pyridine. A mixture of 2-((but-3-yn-l-yloxy)methyl)pyrazine (8.3 g, 51.0 mmol) in undecane (33 mL) was stirred at 195 °C for 7 days. Purification (FCC, SiCh, 0-90% EtOAc in heptane) afforded the title compound (1.5 g, 22%). MS (ESI): mass calcd. for CsFENC), 135.1 ; m/z found, 136 [M+H]+. 'H NMR (300 MHz, CDCb) d 8.38 (d, J= 4.5 Hz, 1H), 7.42 (d, J= 7.7 Hz, 1H), 7.10 (dd, J= 7.4, 5.0 Hz, 1H), 4.79 (s, 2H), 3.98 (t, J= 5.6 Hz, 2H), 2.88 (t, J= 5.6 Hz, 2H).
Step D: 5,8-Dihydro-6H-pyrano[3,4-b]pyridine l-oxide.
«r-CPBA (3.1 g, 18.0 mmol) was added to mixture of 5,8-dihydro-6H-pyrano[3,4-b]pyridine (1.5 g, 11.2 mmol) in DCM (22 mL). The reaction mixture was stirred overnight at room temperature. Purification (FCC, SiCh, 0-3% MeOH in DCM) afforded the title compound (1.5 g, 86%). MS (ESI): mass calcd. for CsHgNCh, 151.1 ; m/z found, 152 [M+Hf. ¾ NMR (300 MHz, CDCb) d 8.12 (d, J= 6.2 Hz, 1H), 7.20 - 6.96 (m, 2H), 4.89 (s, 2H), 3.93 (t, J= 5.5 Hz, 2H), 2.87 (t, J = 5.3 Hz, 2H).
Step E: 4-Chloro-5,8-dihydro-6H-pyrano[3,4-b]pyridine.
Phosphorus(V) oxychloride (6.3 mL, 67.6 mmol) was added to a mixture of 5,8-dihydro-6H- pyrano[3,4-b]pyridine l-oxide (1.5 g, 9.7 mmol) in chloroform (55 mL). The reaction mixture was refluxed at 80 °C overnight. Then, iced water and aqueous ammonia was added until basic pH was reached. DCM was added to the mixture. The organic layer was separated, dried over MgS04, filtered and concentrated under reduced pressure. Purification (FCC, SiCh, 0-20% EtOAc in heptane) afforded the title compound (860 mg, 52%) and 2-chloro-5,8-dihydro-6H- pyrano[3,4-b]pyridine (370 mg, 23%). MS (ESI): mass calcd. for CxHxONO, 169.0; m/z found, 170
Figure imgf000183_0001
8.29 (d, J= 5.2 Hz, 1H), 7.20 (d, J= 5.2 Hz, 1H), 4.77 (s, 2H), 4.02 (t, J= 5.7 Hz, 2H), 2.88 (t, J= 5.6 Hz, 2H).
Step F: 5,8-Dihydro-6H-pyrano[3,4-b]pyridine-4-carbonitrile.
A mixture of 4-chloro-5,8-dihydro-6H-pyrano[3,4-b]pyridine (100 mg, 0.6 mmol), zinc cyanide (69 mg, 0.6 mmol), 1 , l'-bis(diphenylphosphino)ferrocene (26.1 mg, 0.05 mmol),
tris(dibenzylideneaeetone)dipalladium(0) (27 mg, 0.03 mmol) and zinc (19 mg, 0.3 mmol) in DMF (5 mL) was stirred at 90 °C under a nitrogen atmosphere. After l6h, zinc cyanide (69 mg, 0.6 mmol), zinc (19 mg, 0.3 mmol), l,l'-bis(diphenylphosphino)ferrocene (26.1 mg, 0.05 mmol) and tris(dibenzylideneaeetone)dipalladium(0) (27 mg, 0.03 mmol) were added to the reaction mixture. The reaction mixture was heated to 90 °C for 4 days. Then, the reaction mixture was cooled to room temperature. Saturated aqueous NaHCCb (20 mL) was added and the mixture was extracted using EtOAc (3 x 30 mL). The combined organics were dried over MgS04, filtered and concentrated under reduced pressure to afford the crude title product 1-P1. The title compound was carried as is to the next step. MS (ESI): mass calcd. for C9H8N2O, 160.1 ; m/z found, 161.1 [M+H]+.
Step G: 5.8-Dihvdro-6H-pyranoi3.4-b1pyridine-4-carboxylic acid. A mixture of 5,8-dihydro-6H- pyrano[3,4-b]pyridine-4-carbonitrile (94.4 mg, 0.6 mmol) and LiOH (4N in water, 0.7 mL, 2.9 mmol) in THF (9 mL) was refluxed at 90 °C. After 16 hours, the reaction mixture was concentrated under reduced pressure. Purification (preparative HPLC, METHOD A) afforded the title compound (82 mg, 78%). MS (ESI): mass calcd. for C9H9NO3, 179.1; m/z found, 180.1 [M+H]+.
Intermediate 58: 3.4-Dihvdro-2H-pyranoi2.3-b1pyridine-5-carboxylic acid.
Figure imgf000184_0001
The title compound was prepared in a manner analogous to Intermediate 57, Steps D-G, using 3,4-dihydro-2H-pyrano[2,3-B]pyridine in Step D instead of 5,8-dihydro-6H-pyrano[3,4- b]pyridine; and MeOH was used instead of THF in Step G. MS (ESI): mass calcd. for C9H9NO3, 179.1 ; m/z found, 180.1 [M+H]+.
Intermediate 59: 5.8-Dihvdro-6H-pyranoi3.4-b1pyridine-2-carboxylic acid.
Figure imgf000184_0002
Step A: 5.8-Dihvdro-6H-pyranoi3.4-b1pyridine-2-carbonitrile. The title compound was prepared in a manner analogous to Intermediate 57, Step F, using 2-chloro-5,8-dihydro-6H-pyrano[3,4- b]pyridine (side Product from Intermediate 57, Step E) instead of 4-chloro-5,8-dihydro-6H- pyrano[3,4-b]pyridine (Intermediate 57, Step E). MS (ESI): mass calcd. for C9H8N2O, 160.1 ; m/z found, 161.1 [M+H]+.
Step B: 5.8-Dihvdro-6H-pyranoi3.4-b1pyridine-2-carboxamide. NaOH (48.5 mg, 1.2 mmol) was added to a mixture of 5,8-dihydro-6H-pyrano[3,4-b]pyridine-2-carbonitrile (38.9 mg, 0.2 mmol) in EtOH (2 mL). The mixture was heated to 50 °C overnight. Then, volatiles were removed and water (3.0 mL) followed by cone. HC1 (0.65 mL) was added to the crude material. After 20 minutes, the solids were filtered off. The filtrate was extracted using EtOAc (3x). The combined organics were dried over MgS04, filtered and concentrated under reduced pressure to afford the title compound. The compound was carried as is to the next step without further purification.
Step C: 5,8-Dihydro-6H-pyrano[3,4-b]pyridine-2-carboxylic acid. 4N LiOH (0.3 mL, 1.2 mmol) was added to a mixture of 5,8-dihydro-6H-pyrano[3,4-b]pyridine-2-carboxamide (43.0 mg, 0.2 mmol) in THE (2 mL). The mixture was heated to 50 °C for 3 days. Then, volatiles were removed and EtOAc was added. The mixture was stirred at room temperature. The solvent was pipetted out and DCM was added to the crude mixture. The mixture was stirred at room temperature overnight. Then, the solvent was pipetted out and MeOH was added to the crude mixture. The mixture was stirred at room temperature. The solids were filtered off and the filtrate was concentrated under reduced pressure to afford the title compound. MS (ESI): mass calcd. for C9H9NO3, 179.1 ; m/z found, 180.1 [M+H]+.
Intermediate 60: 5-Trifluoromethyl)- 1 -((2-(trimethylsilyl)ethoxy)methyl)- 1 H-pyrrolo
Figure imgf000185_0001
blpyridine-4-carboxylic acid.
Figure imgf000185_0002
xy)methyl 5-(trifluoromethyl)-l-((2-
(trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[2,3-b]pyridine-4-carboxylate. 5-(Trifluoromethyl)- lH-pyrrolo[2,3-b]pyridine-4-carboxylic acid (150 mg, 0.7 mmol) was added to a suspension of NaH (60% dispersion in mineral oil, 65.2 mg, 1.6 mmol) in THE (7 mL) under a nitrogen atmosphere at room temperature. After 5 minutes, 2-(trimethylsilyl)ethoxymethyl chloride (0.36 mL, 2.0 mmol) was added to the reaction mixture. After 16 hours, water (20 mL) was added to the reaction mixture. The mixture was extracted with EtOAc (3 x 30 mL). The combined organics were dried over MgS04, filtered and concentrated under reduced pressure to afford the title compound. The compound was carried as is to the next step without further purification. Step B: 5-Trifluoromethyl)- 1 -((2-(trimethylsilyl)ethoxy)methyl)- 1 H-pyrrolo b1pyridine-4-
Figure imgf000186_0001
carboxylic acid. Lithium hydroxide (4N in water, 1.6 mL, 6.5 mmol) was added to a mixture of (2-(trimethylsilyl)ethoxy)methyl 5-(trifluoromethyl)-l-((2-(trimethylsilyl)ethoxy)methyl)-lH- pyrrolo[2,3-b]pyridine-4-carboxylate (320 mg, 0.7 mmol) in THF (5 mL) at room temperature. After completion, the reaction mixture was concentrated under reduced pressure. Purification (preparative HPLC, METHOD A) afforded the title compound (65 mg, 28%). MS (ESI): mass calcd. for C15H19F3N2O3S1, 360.1 ; m/z found, 361.2 [M+H]+.
Intermediate 61 : 1 -(Y2-(Trimethylsilyl)ethoxy)methyl)- l H-pyrazolo[3.4-b1pyridine-5-carboxylic acid.
Figure imgf000186_0002
Step A: Methyl 1 -(Y2-('trimethylsilyl)ethoxy)methyl)- l H-pyrazolo[3.4-b1pyridine-5-carboxylate. The title compound was prepared in a manner analogous to
Intermediate 60, Step A, using methyl lH-pyrazolo[3,4-b]pyridine-5-carboxylate instead of 5- (trifluoromethyl)-lH-pyrrolo[2,3-b]pyridine-4-carboxylic acid. MS (ESI): mass calcd. for C14H21N3O3S1, 307.1; m/z found, 308.2 [M+H]+.
Step B: 1 -(Y2-(Trimethylsilyl)ethoxy)methyl)- l H-pyrazolo[3.4-b1pyridine-5-carboxylic acid.
The title compound was prepared in a manner analogous to
Intermediate 60, Step B, using methyl l-((2-(trimethylsilyl)ethoxy)methyl)-lH-pyrazolo[3,4- b]pyridine-5-carboxylate instead of (2-(trimethylsilyl)ethoxy)methyl 5-(trifluoromethyl)-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[2,3-b]pyridine-4-carboxylate. MS (ESI): mass calcd. for C14H21N3O3S1, 293.1 ; m/z found, 294.1 [M+H]+.
Intermediate 62: 3-Fluoro-l - (trimethylsilvBethoxylmethylVlH- blpyridine-d-
Figure imgf000186_0003
Figure imgf000186_0004
carboxylic acid.
Figure imgf000187_0001
The title compound was prepared in a manner analogous to Intermediate 60, Step A-B, using 3- fluoro-lH-pyrrolo[2,3-b]pyridine-4-carboxylic acid instead of 5-(trifluoromethyl)-lH- pyrrolo[2,3-b]pyridine-4-carboxybc acid, and using DMF instead of THF in Step A. MS (ESI): mass calcd. for C14H19FN2O3 Si, 310.1; m/z found, 311.1 [M+H]+.
Intermediate 63: 5-Methoxy-2-(2H-l.2.3-triazol-2-vBbenzoic acid.
Figure imgf000187_0002
The title compound was prepared in a manner analogous to Intermediate 38 using 2-iodo-5- methoxybenzoic acid instead of 3-iodobenzoic acid and 1,2, 3-triazole instead of 3-
(trifluoromethyl)pyrazole. MS (ESI): mass calcd. for C10H9N3O3, 219.1; m/z found, 220.1
[M+H] +.
I acid.
Figure imgf000187_0003
The title compound was prepared in a manner analogous to Intermediate 38, using 2-iodobenzoic acid instead of 3-iodobenzoic acid and 1,2, 3 -triazole instead of 3-(trifluoromethyl)pyrazole. MS (ESI): mass calcd. for C9H7N3O2, 189.1 ; m/z found, 190.1 [M+H]+. (prepared according to methods described in Pat. Pub. No. W02016040789, March 17, 2016)
Intermediate 65: 3-(2H- 1.2.3-Triazol-2-yl)benzoic acid.
Figure imgf000188_0001
The title compound was prepared in a manner analogous to Intermediate 38 using 1,2, 3 -triazole instead of 3-(trifluoromethyl)pyrazole. MS (ESI): mass calcd. for C9H7N3O2, 189.1; m/z found, 190.1 [M+H] +. Intermediate 66: 2-('3-(Trifluoromethyl)- l H- l .2.4-triazol- l -vQbenzoic acid.
Figure imgf000188_0002
The title compound was prepared in a manner analogous to Intermediate 38 using 2-iodobenzoic acid instead of 3-iodobenzoic acid and 3-(trifluoromethyl)-lH-l, 2, 4-triazole instead of 3- (trifluoromethyl)pyrazole. MS (ESI): mass calcd. for C10H6F3N3O2, 257.0; m/z found, 258.1 [M+H] +.
Intermediate 67: 5-Fluoro-2-n H- l .2.4-triazol- l -vDbenzoic acid.
Figure imgf000188_0003
The title compound was prepared in a manner analogous to Intermediate 38 using 5-fluoro-2- iodobenzoic acid instead of 3-iodobenzoic acid and 1,2, 4-triazole instead of 3- (trifluoromethyl)pyrazole. MS (ESI): mass calcd. for C9H6FN3O2, 207.0; m/z found, 208.1
[M+H] +.
Intermediate 68: 3-(4-Fluoro- 1 H-pyrazol- 1 -vDbenzoic acid.
Figure imgf000189_0001
The title compound was prepared in a manner analogous to Intermediate 38 using 4- fluoropyrazole instead of 3-(trifluoromethyl)pyrazole. MS (ESI): mass calcd. for C10H7F1N2O2, 206.0; m/z found, 207.1 [M+H]+. Intermediate 69: 3-FluoropyrazolorE5-a1pyridine-4-carboxylic acid.
Figure imgf000189_0002
Step A: Methyl pyrazolorE5-a1pyridine-4-carboxylate. To a suspension of pyrazolo[l,5- a]pyridine-4-carboxylic acid (500 mg, 3.08 mmol) in MeOH (4.8 mL) at 0 °C was added thionyl chloride (0.9 mL, 12.3 mmol) carefully dropwise via syringe. The reaction was stirred at reflux overnight, then cooled to room temperature and diluted with EtOAc. The mixture was carefully basified with sat. aq. NaHCC and the layers separated. The aqueous layer was separated and extracted with EtOAc (x3), then the combined organic layers washed with brine, dried over Na2S04, filtered, and concentrated in vacuo. MS (ESI): mass calcd. for C9H8N2O2, 176.1 ; m/z found, 177.0 [M+H]+.
Step B: Methyl 3-fluoropyrazolorE5-a1pyridine-4-carboxylate. Methyl pyrazolo[l,5-a]pyridine- 4-carboxylate (200 mg, 1.14 mmol) and Selectfluor (442 mg, 1.25 mmol) were stirred in MeCN (4.4 mL) at room temperature for 1 h. The reaction was diluted with EtOAc and H2O, then the aqueous layer separated and extracted with EtOAc (x3). The combined organics were washed with brine, dried over Na2S04, filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography (0-100% EtOAc in hexanes) to afford a yellow solid. MS (ESI): mass calcd. for C9H7FN2O2, 194.0; m/z found, 195.0 [M+H]+. 'H NMR (600 MHz, Chlorofornw/) d 8.44 - 8.41 (m, 1H), 7.94 (d, J= 3.5 Hz, 1H), 7.83 (dd, J= 7.1, 1.1 Hz, 1H), 6.75 (t, = 7. l Hz, 1H), 3.99 (s, 3H).
Step C: 3-FluoropyrazolorE5-alpyridine-4-carboxylic acid. A mixture of methyl 3- fluoropyrazolo[l,5-a]pyridine-4-carboxylate (55 mg, 0.28 mmol), NaOH (22.7 mg, 0.57 mmol), and H2O (58 pL, 3.21 mmol) in 1 : 1 THF/MeOH (1.2 mL) was stirred at 60 °C for 30 min. The reaction was then cooled to room temperature, concentrated in vacuo and re-dissolved in H2O. The mixture was acidified to pH 5 with 2 N HC1, and the precipitate collected via vacuum filtration to afford the title compound as a white solid. MS (ESI): mass calcd. for C8H5FN2O2, 180.0; m/z found, 181.1 [M+H]+.
Intermediate 70: Potassium 3-fluoropyrazolorE5-al pyridine-5-carboxylate.
Figure imgf000190_0001
Step A: Methyl pyrazolorE5-al pyridine- 5 -carboxylate. The title compound was prepared in a manner analogous Intermediate 69 Step A, using pyrazolo[l,5-a] pyridine-5-carboxylic acid instead of pyrazolo[l,5-a] pyridine-4-carboxylic acid. MS(ESI): mass calcd. for C9H8N2O2, 176.1; m/z found, 177.0 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 8.78 (dt, J= 7.3, 1.0 Hz, 1H), 8.41 (dd, J= 1.9, 1.0 Hz, 1H), 8.14 (d, = 2.3 Hz, 1H), 7.26 (ddd, = 7.3, 1.9, 0.4 Hz, 1H), 6.93 (dd, = 2.4, 1.0 Hz, 1H), 3.90 (s, 3H).
Step B: Methyl 3-fluoropyrazolorE5-al pyridine-5-carboxylate. The title compound was prepared in a manner analogous Intermediate 69 Step B, using methyl pyrazolo[l,5-a] pyridine- 5-carboxylate instead of methyl pyrazolo[l,5-a] pyridine-4-carboxylate. MS(ESI): mass calcd. for C9H7FN2O2, 194.1 ; m/z found, 195.0 [M+H] +. Ή NMR (500 MHz, DMSO-r/e) d 8.68 (ddd, J= 7.4, 1.6, 1.0 Hz, 1H), 8.33 - 8.18 (m, 2H), 7.25 (dd, = 7.3, 1.9 Hz, 1H), 3.90 (s, 3H).
Step C: Potassium 3-fluoropyrazolorE5-al pyridine-5-carboxylate. To a solution of methyl 3- fluoropyrazolo[l,5-a] pyridine-5-carboxylate (50 mg, 0.26 mmol) in THF (2.0 mL) was added potassium trimethylsilanolate (50 mg, 0.40 mmol) and the resulting mixture was heated to 60 °C for 24h. The reaction mixture was then filtered and washed with THF to obtain the title compound as white solid which was taken to next step without purification. MS (ESI): mass calcd. for C8H4KFN2O2, 218.0; m/z found, 181.0[M-K+2H] +.
Intermediate 71 : 1 -Methyl-5-P -methylcyclopropyl)- ! H-pyrazole-4-carboxylic acid.
Figure imgf000191_0001
Step A: Methyl l-methyl-5-(T-methylcvclopropylVlH-pyrazole-4-carboxylate and Methyl 1- methyl-3-(l -methylcvclopropylV lH-pyrazole-4-carboxylate. Methyl 3-(l-methylcyclopropyl)-3- oxopropanoate (500 mg, 3.20 mmol) and /V./V-dimethylformamide dimethyl acetal (0.51 mL,
3.84 mmol) were stirred together for 1.5 h, then the mixture concentrated in vacuo. EtOH (3.0 mL) and methylhydrazine (0.17 mL, 3.20 mmol) were then added, and the reaction heated to reflux for 1 h before being allowed to stir overnight at room temperature. The mixture was diluted with EtOAc and H2O, then the aqueous layer separated and extracted with EtOAc (x2). The combined organics were washed with brine, dried over Na2S04, filtered, and concentrated in vacuo, then the crude residue purified by silica gel chromatography (0-25% EtOAc in hexanes) to afford methyl l-methyl-5-(l-methylcyclopropyl)-lH-pyrazole-4-carboxylate (183 mg, 29% yield). MS (ESI): mass calcd. for C10H14N2O2, 194.1; m/z found, 195.2 [M+H]+. ¾ NMR (500 MHz, Chlorofornw/) d 7.79 (s, 1H), 3.92 (s, 3H), 3.82 (s, 3H), 1.35 (s, 3H), 0.95 - 0.86 (m, 4H). Methyl l-methyl-3-(l-methylcyclopropyl)-lH-pyrazole-4-carboxylate was isolated as a second regioisomer (200 mg, 32% yield): MS (ESI): mass calcd. for C10H14N2O2, 194.1; m/z found, 195.2 [M+H]+. ¾ NMR (500 MHz, Chlorofornw/) d 7.77 (s, 1H), 3.83 - 3.81 (m, 6H), 1.41 (s, 3H), 0.95 - 0.91 (m, 2H), 0.72 - 0.69 (m, 2H)
Step B: 1 -Methyl-5-P -methylcyclopropyl )- l H-pyrazole-4-carboxylic acid. To a solution of methyl l-methyl-5-(l-methylcyclopropyl)-lH-pyrazole-4-carboxylate (169 mg, 0.87 mmol) in EtOH (1.8 mL) was added 10 N NaOH (0.35 mL), and the reaction stirred at room temperature overnight. The mixture was concentrated in vacuo, the crude residue re-dissolved in a small amount of H2O, and the mixture acidified with 6 N HC1. The product was collected via vacuum filtration as a white solid, and the filtrate extracted with 20% /-PrOH/DCM (/2). The combined organics were dried over Na2S04, filtered and concentrated in vacuo to afford additional product. The combined material afforded the title compound in 82% yield. MS (ESI): mass calcd. for C9H12N2O2, 180.1 ; m/z found, 181.1 [M+H]+.
Intermediate 72: 1 -Methyl-3-P -methylcvclopropyl)- l H-pyrazole-4-carboxylic acid.
Figure imgf000192_0001
The title compound was prepared in a manner analogous to Intermediate 71, Step B, using methyl l-methyl-3-(l-methylcyclopropyl)-lH-pyrazole-4-carboxylate (isolated as a second regioisomer in Step A) instead of methyl l-methyl-5-(l-methylcyclopropyl)-lH-pyrazole-4- carboxylate. MS (ESI): mass calcd. for C9H12N2O2, 180.1 ; m/z found, 181.1 [M+H]+.
Intermediate 73: Potassium 5-P -fluorocvclopropyl)- l -methyl- 1 H-pyrazole-4-carboxylate.
Figure imgf000192_0002
Step A: Ethyl 3-(T-fluorocvclopropylV3-oxopropanoate. To a solution of ethyl potassium malonate (0.82 g, 4.80 mmol) in EtOAc (5 mL) at 0 °C was added MgCh (1.37 g, 14.4 mmol) followed by triethylamine (3.3 mL, 24.0 mmol). The heterogenous mixture was allowed to warm to room temperature and stirred overnight. In a separate flask, oxalyl chloride (0.41 mL, 4.80 mmol) and DMF (0.4 pL, 5.1 pmol) were added to a 0 °C solution of 1- fluorocyclopropanecarboxylic acid (500 mg, 4.80 mmol) in THF (5.1 mL). The mixture was then maintained at 0 °C for 1 h, then the ice bath was removed and the reaction allowed to warm to room temperature and stirred for an additional 2 h. Afterwards, the solution was carefully added dropwise to the reaction vessel containing ethyl potassium malonate at 0 °C. The combined mixtures were then stirred at room temperature overnight before being carefully quenched with a 10% aq. citric acid solution. The layers were separated and the aqueous layer extracted with CH2CI2 (x2), after which the combined organic layers were washed once with sat. aq. NaHCC , dried over Na2S04, filtered, and concentrated in vacuo at ca. 90 torr, 23 °C. The crude residue was purified by silica gel chromatography (0-100% CH2CI2 in hexanes) to afford a pale brown oil (674 mg, 81% yield).
Step B: Ethyl 5-P -fluorocvclopropyl)- l -methyl- 1 H-pyrazole-4-carboxylate and Ethyl 3-(T- fluorocvclopropylVl -methyl- lH-pyrazole-4-carboxylate. The title compounds were prepared in a manner analogous to Intermediate 71, Step A, using ethyl 3-(l-fluorocyclopropyl)-3- oxopropanoate instead of methyl 3-(l-methylcyclopropyl)-3-oxopropanoate.
Ethyl 5-(l-fluorocyclopropyl)-l-methyl-lH-pyrazole-4-carboxylate: MS (ESI): mass calcd. for C10H13FN2O2, 212.1; m/z found, 213.1 [M+H]+. 1H NMR (600 MHz, Chloroform-^ d 7.88 (s, 1H), 4.31 (q, = 7.1 Hz, 2H), 4.04 (d, = 0.5 Hz, 3H), 1.67 - 1.57 (m, 2H), 1.36 (t, = 7.1 Hz, 3H), 1.19 - 1.14 (m, 2H).
Ethyl 3-(l-fluorocyclopropyl)-l-methyl-lH-pyrazole-4-carboxylate: MS (ESI): mass calcd. for C10H13FN2O2, 212.1; m/z found, 213.1 [M+H]+. ¾ NMK (600 MHz, Chloroform-^ d 7.87 (s, 1H), 4.30 (q, J= 7.1 Hz, 2H), 3.88 (d, J= 0.7 Hz, 3H), 1.43 - 1.37 (m, 2H), 1.34 (t, J= 7.1 Hz, 3H), 1.18 - 1.13 (m, 2H).
Step C: Potassium 5-P -fluorocyclopropyD- l -methyl- 1 H-pyrazole-4-carboxylate. To a solution of ethyl 5-(l-fluorocyclopropyl)-l-methyl-lH-pyrazole-4-carboxylate (50 mg, 0.24 mmol) in THF (1.6 mL) was added potassium trimethylsilanoate (67.2 mg, 0.47 mmol), and the reaction stirred at room temperature overnight. The mixture was then diluted with hexanes, and the white solid collected by vacuum filtration, washing with additional hexanes. MS (ESI): mass calcd. for C8H8FKN2O2, 222.0; m/z found, 185.1 [M-K+2H]+.
Intermediate 74: Potassium 3-P -fluorocvclopropyl)- l -methyl- 1 H-pyrazole-4-carboxylate.
Figure imgf000193_0001
The title compound was prepared in a manner analogous to Intermediate 73, Step C, using ethyl 3-(l-fluorocyclopropyl)-l-methyl-lH-pyrazole-4-carboxylate (isolated as a second regioisomer in Step B) instead of ethyl 5-(l-fluorocyclopropyl)-l-methyl-lH-pyrazole-4-carboxylate. MS (ESI): mass calcd. for C8H8FKN2O2, 222.0; m/z found, 185.1 [M-K+2H]+.
Intermediate 75: 5-(2.2-Difluorocvclopropyl)- 1 -methyl- 1 H-pyrazole-4-carboxylic acid.
Figure imgf000194_0001
The title compound was prepared in a manner analogous to Intermediate 73, using 2,2- difluorocyclopropane-l -carboxylic acid instead of l-fluorocyclopropanecarboxylic acid in Step A. MS (ESI): mass calcd. for C8H8F2N2O2, 202.1; m/z found, 203.1 [M+H]+.
Intermediate 76: Potassium 1 -methyl-67.s-5-('2-methylcvclopropyl)- l H-pyrazole-4-carboxylate.
Figure imgf000194_0002
Step A: Methyl 3-('2-methylcvclopropyl)-3-oxopropanoate. To a solution dimethyl carbonate (1.35 mL, 16.0 mmol) in PhMe (5 mL) was added 1 -(2-methylcyclopropyl)ethan- 1 -one (0.5 g, 5.10 mmol), and the mixture stirred at room temperature for 15 min. After cooling to 0 °C, potassium / -butoxide (0.4 g, 3.57 mmol) was added in one portion, and the reaction heated to 75 °C overnight. After cooling to room temperature, the mixture was poured into cooled (0 °C) H2O, and the pH was adjusted to 2-3 with 6 N HC1. The layers were separated, the aqueous layer extracted with EtOAc, then the combined organics washed with H2O, dried over Na2S04, filtered and concentrated in vacuo (ca. 65 torr, 28 °C) to afford the title compound, which was used directly in the next step without further purification.
Step B: Potassium l-methyl-cA-5-(2-methylcvclopropylj-lH-pyrazole-4-carboxylate. The title compound was prepared in the same manner as Intermediate 73, Steps B-C, using methyl 3-(2- methylcyclopropyl)-3-oxopropanoate instead of ethyl 3-(l-fluorocyclopropyl)-3-oxopropanoate in Step B. MS (ESI): mass calcd. for C9H11KN2O2, 218.0; m/z found, 181.1 [M-K+2H]+.
(Mixture of isomers with relative c .s-configuration at starred stereocenters). Intermediate 77: Potassium cA-5-(2-fluorocvclopropyr)-l-methyl-lH-pyrazole-4-carboxylate.
Figure imgf000195_0001
The title compound was prepared in the same manner as Intermediate 73, Steps B-C, using ethyl cis-3-(-2-fluorocyclopropyl)-3-oxopropanoate instead of ethyl 3-(l-fluorocyclopropyl)-3- oxopropanoate in Step B. MS (ESI): mass calcd. for CsHsFIGNhCh, 222.0; m/z found, 185.1 [M-K+2H]+. (Mixture of isomers with relative cv.s-configuration at starred stereocenters).
Intermediate 78: Potassium /r<mv-5-(2-fluorocvclopropyl)- 1 -methyl- 1 H-pyrazole-4-carboxylate.
Figure imgf000195_0002
The title compound was prepared in the same manner as Intermediate 73, Steps B-C, using ethyl trans-3-(-2-fluorocyclopropyl)-3-oxopropanoate instead of ethyl 3-(l-fluorocyclopropyl)-3- oxopropanoate in Step B. MS (ESI): mass calcd. for CsHsFIGNhCh, 222.0; m/z found, 185.1 [M-K+2H]+. (Mixture of isomers with relative /ram-configuration at starred stereocenters).
Intermediate 79: /r< v-5-(2-fluorocvclopropyl)- 1 -methyl- 1 H-pyrazole-4-carboxylic acid.
Figure imgf000195_0003
The title compound was prepared in the same manner as Intermediate 73 Steps B-C, using ethyl trans-3-(-2-fluorocyclopropyl)-3-oxopropanoate instead of ethyl 3-(l-fluorocyclopropyl)-3- oxopropanoate in Step B, and then purifying under acidic conditions: ACCQPrep HPLC system with XBridge Cl 8 OBD column (5 pm, 50 x 100 mm); mobile phase of 5% MeCN in H2O (both phases containing 0.05% TFA) was held for 1 min, then gradient of 5-95% MeCN in H2O (both containing 0.05% TFA) over 12 min with a flow rate of 80 mF/min. MS (ESI): mass calcd. for C8H9FN2O2, 184.1 ; m/z found, 185.1 [M+H]+. (Mixture of isomers with relative trans- configuration at starred stereocenters).
Intermediate 80: Potassium 5-cyclobutyl- 1 -methyl- 1H-
Figure imgf000196_0001
!-4-carboxylate.
Figure imgf000196_0002
The title compound was prepared in the same manner as Intermediate 73, Steps B-C using ethyl 3 -cyclobutyl-3 -oxopropanoate instead of ethyl 5-(l-fluorocyclopropyl)-l-methyl-lH-pyrazole-4- carboxylate in Step B. MS (ESI): mass calcd. for C9H11KN2O2, 218.0; m/z found, 181.1
[M-K+2H]+.
I -5 -(trifluoromethyl)- 1 H-
Figure imgf000196_0003
:-4-carboxylate.
Figure imgf000196_0004
Step A: Ethyl l-cyclopropyl-5-(trifluoromethyl)-lH-pyrazole-4-carboxylate and Ethyl 1- cyclopropyl-3-(trifluoromethyl)-lH-pyrazole-4-carboxylate. To a solution of triethyl orthoformate (0.34 mL, 2.05 mmol) in acetic anhydride (0.63 mL, 6.66 mmol) was added ethyl 4,4,4-trifluoroacetoacetate (0.1 mL, 0.68 mmol), and the reaction heated to 135 °C overnight. After cooling to room temperature, the mixture was concentrated in vacuo and then re-dissolved in EtOH (0.63 mL). Cyclopropylhydrazine hydrochloride (164 mg, 0.68 mmol) was then added, and the reaction heated to 78 °C for 1 h, then room temperature overnight. The mixture was diluted with EtOAc and H2O, then the aqueous layer separated and extracted with EtOAc (x2). The combined organics were washed with brine, dried over Na2S04, filtered, and concentrated in vacuo, and the crude residue was purified by silica gel chromatography (0-50% EtOAc in hexanes) to afford ethyl l-cyclopropyl-5-(trifluoromethyl)-lH-pyrazole-4-carboxylate (38 mg, 22% yield)MS (ESI): mass calcd. for C10H11F3N2O2, 248.1 ; m/z found, 249.0 [M+H]+. Ή NMR (600 MHz, Chloroform-^ d 7.83 (s, 1H), 4.31 (q, J= 7.1 Hz, 2H), 3.75 - 3.69 (m, 1H), 1.36 - 1.29 (m, 5H), 1.15 - 1.10 (m, 2H). Ethyl 1 -cyclopropyl-3 -(trifluoromethyl)- lH-pyrazole-4- carboxylate was also isolated as a second regioisomer (39 mg, 27% yield): MS (ESI): mass calcd. for C10H11F3N2O2, 248.1; m/z found, 249.0 [M+H]+. Ή NMR (600 MHz, Chloroform-^/) 5 8.03 (s, 1H), 4.31 (q, = 7. l Hz, 2H), 3.69 - 3.64 (m, 1H), 1.34 (t, = 7.1 Hz, 3H), 1.21 - 1.17
(m, 2H), 1.14 - 1.09 (m, 2H).
Step B: Potassium l-cvclopropyl-5-(trifluoromethylVlH-pyrazole-4-carboxylate. The title compound was prepared in a manner analogous to Intermediate 73, Step C using ethyl 1- cyclopropyl-5-(trifluoromethyl)-lH-pyrazole-4-carboxylate instead of ethyl 5-(l- fluorocyclopropyl)-l-methyl-lH-pyrazole-4-carboxylate. MS (ESI): mass calcd. for
C8H6F3KN2O2, 258.0; m/z found, 220.1 [M-K+2H]+.
Intermediate 82: Potassium l-cvclopropyl-3-(trifluoromethylVlH-pyrazole-4-carboxylate.
Figure imgf000197_0001
The title compound was prepared in the same manner as Intermediate 73, Step C, using ethyl 1- cyclopropyl-3-(trifluoromethyl)-lH-pyrazole-4-carboxylate (Intermediate 81, isolated as a second regioisomer in Step A) instead of ethyl 5-(l-fluorocyclopropyl)-l-methyl-lH-pyrazole-4- carboxylate. MS (ESI): mass calcd. for C8H6F3KN2O2, 258.0; m/z found, 220.1 [M-K+2H]+. Intermediate 83: Potassium 2-cvclopropyl-7-methylpyrazolorE5-a1 pyridine-3-carboxylate.
Figure imgf000197_0002
Step A: Ethyl 2-cvclopropyl-7-methylpyrazolorE5-a1 pyridine-3 -carboxy late. To a solution of 0-(2,4-dinitrophenyl) hydroxylamine in acetonitrile (25 mL) was added 2-methylpyridine (466 mg, 5.0 mmol) and the resulting mixture was heated to 40 °C for 18 h. The solution mixture was evaporated to dryness using rotary evaporator and re-dissolved in DMF (25 mL). To this mixture was then added ethyl 3-cyclopropylpropiolate (1.0 g, 7.5 mmol) and potassium carbonate (2.1 g, 15 mmol) and was stirred for another 24h at room temperature. The crude mixture was then diluted with EtOAc (2 x), and the combined organics washed with brine (4 x), dried over Na2S04, filtered, and concentrated. The residue was purified by silica gel chromatography (0-50% EtO Ac/hexanes) to afford the title compound as yellow solid (470 mg, 38.5% yield). MS(ESI): mass calcd. for C14H16N2O2, 244.1; m/z found, 245.1 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 7.95 - 7.86 (m, 1H), 7.46 (dd, J= 8.9, 7.0 Hz, 1H), 6.98 (dt, J = 7.0, 1.2 Hz, 1H), 4.32 (q, J= 7.1 Hz, 2H), 2.82 (tt, J= 7.9, 5.4 Hz, 1H), 2.63 (s, 3H), 1.36 (t, J = 7.1 Hz, 3H), 1.11 - 0.99 (m, 4H).
Step B: Potassium 2-cvclopropyl-7-methylpyrazolorE5-al pyridine-3-carboxylate. The title compound was prepared in a manner analogous to Intermediate 70, Step C using ethyl 2- cyclopropyl-7-methylpyrazolo[l,5-a] pyridine-3-carboxylate instead of methyl 3- fluoropyrazolo[l,5-a] pyridine-5-carboxylate. MS (ESI): mass calcd. for C12H11KN2O2, 254.1 ; m/z found, 217.1 [M-K+2H] +.
Intermediate 84: Potassium 7-fluoroimidazorE2-alpyridine-3-carboxylate.
Figure imgf000198_0001
To a solution of ethyl 7-fluoroimidazo[l,2-a] pyridine-3 -carboxylate (100 mg, 0.5 mmol) in THF (4.0 mL) was added potassium trimethylsilanolate (92.4 mg, 0.72 mmol) and the resulting mixture was stirred at rt for l6h. The reaction mixture was then filtered and washed with THF to obtain the title compound as white solid which was taken to next step without purification. MS (ESI): mass calcd. for C8H4FKN2O2, 218.0; m/z found, 181.1 [M+H] +.
Intermediate 85: Potassium 7-fluoro-2-methylimidazorE2-alpyridine-3-carboxylate.
Figure imgf000198_0002
Step A: ethyl 7-fluoro-2-methylimidazo[ l 2-al pyridine-3-carboxylate. To a solution of 4- fluoropyridin-2-amine (250 mg, 2.2 mmol) in 1 ,2-dimethoxy ethane (2.1 mL, 20. 2 mmol) was added ethyl 2-chloro-3-oxobutanoate (2.3 mL, 2.7 mmol) and the mixture was heated to 90 °C for l6h. The reaction mixture was concentrated under reduced pressure, diluted with EtOAc, washed the organic layer with water (x2). The combined organic extracts were dried over anhydrous Na2S04 and concentrated under vacuo. Purification by flash chromatography (SiCh;
0 - 100% EtO Ac/hexanes) afforded the title compound as a white solid (66.4 mg, 14% yield).
MS (ESI): mass calcd. for C11H11FN2O2, 222.2; m/z found, 223.1 [M+H] +.
Step B: Potassium 7-fluoro-2-methylimidazorL2-al pyridine-3-carboxylate. The title compound was prepared in a manner analogous to Intermediate 70, Step C, using ethyl 7-fluoro-2- methylimidazo[l,2-a] pyridine-3-carboxylate instead of methyl 3-fluoropyrazolo[l,5-a] pyridine- 5-carboxylate. MS (ESI): mass calcd. for C9H6FKN2O2, 232.0; m/z found, 195.1 [M-K+2H] +.
Intermediate 86: Potassium 6-fluoro-2.8-dimethylimidazon 2-al pyridine-3 -carboxylate.
Figure imgf000199_0001
The title compound was prepared in a manner analogous to Intermediate 85, using 5-fluoro-3- methylpyridin-2-amine instead of 4-fluoropyridin-2-amine in step A. MS (ESI): mass calcd. for C10H8FKN2O2, 246.0; m/z found, 209.1 [M-K+2H] +.
Intermediate 87: Potassium 6-fluoro-2.7-dimethylimidazon 2-al pyridine-3 -carboxylate.
Figure imgf000199_0002
The title compound was prepared in a manner analogous to Intermediate 85 using 5-fluoro-4- methylpyridin-2-amine instead of 4-fluoropyridin-2-amine in step A. MS (ESI): mass calcd. for C10H8FKN2O2, 246.0; m/z found, 209.1 [M-K+2H] +. Intermediate 88: Potassium 6.8-difluoro-2-methylimidazo[ l 2-al pyridine-3 -carboxylate.
Figure imgf000200_0001
The title compound was prepared in a manner analogous to Intermediate 85 using 3,5- difluoropyridin-2-amine instead of 4-fluoropyridin-2-amine and heating at 90 °C for 3h in Step A. MS (ESI): mass calcd. for C9H5F2KN2O2, 250.0; m/z found, 213.1 [M-K+2H] +.
Intermediate 89: Potassium 7-methoxy-2-methylimidazorE2-al pyridine-3 -carboxylate.
Figure imgf000200_0002
The title compound was prepared in a manner analogous to Intermediate 85 using 5- methoxypyridin-2-amine instead of 4-fluoropyridin-2-amine in Step A. MS (ESI): mass calcd. for C10H9KN2O3, 244.0; m/z found, 207.0 [M-K+2H] +.
Intermediate 90: Potassium 6-cvclopropyl-2-methylimidazorE2-al pyridine-3-carboxylate.
Figure imgf000200_0003
The title compound was prepared in a manner analogous to Intermediate 85 using 5- cyclopropylpyridin-2-amine instead of 4-fluoropyridin-2-amine and heating at 90 °C for 2h in Step A. MS (ESI): mass calcd. for C12H11KN2O2, 254.0; m/z found, 217.1 [M-K+2H] +.
Intermediate 91 : Potassium pyrrolorE2-al pyrazine- 1 -carboxylate.
Figure imgf000200_0004
The title compound was prepared in a manner analogous to Intermediate 70, Step C, using ethyl pyrrolo[l,2-a] pyrazine-l-carboxylate instead of methyl 3-fluoropyrazolo[l,5-a] pyridine-5- carboxylate. MS (ESI): mass calcd. for C8H5KN2O2, 200.0; m/z found, 163.1 [M-K+2H] +.
I triazolo[4.3-a1 pyridine-3 -carboxylate.
Figure imgf000201_0001
The title compound was prepared in a manner analogous to Intermediate 84, using ethyl [1,2,4] triazolo[4,3-a] pyridine-3 -carboxylate instead of ethyl 7-fluoroimidazo[l,2-a] pyridine-3- carboxylate and stirred for lh at rt. MS (ESI): mass calcd. for C7H4KN3O2, 201.0; m/z found, 164.1 [M-K+2H] +.
Intermediate 93: Potassium 5-methylpyrazolorE5-bl pyridazine-3-carboxylate.
Figure imgf000201_0002
The title compound was prepared in a manner analogous to Intermediate 70, Step C, using methyl 5-methylpyrazolo[l,5-b] pyridazine-3 -carboxylate instead of methyl 3- fluoropyrazolo[l,5-a] pyridine-5-carboxylate. MS (ESI): mass calcd. for C8H6KN3O2, 215.0; m/z found, 178.1 [M-K+2H] +.
Intermediate 94: Potassium 2.4-dimethylpyrazolon 5-al pyrazine-3 -carboxylate.
Figure imgf000201_0003
Step A: 1 -Amino-2-methylpyrazin- 1 -ium 2.4.6-trimethylbenzenesulfonate. To a cooled (0 °C) solution of ethyl (E)-N-((mesitylsulfonyl)oxy) acetimidate (3.9 g, 13.8 mmol) in dioxane (6.0 mL) was added 70% perchloric acid (2.8 mL, 33.3 mmol) dropwise. Following the addition, the temperature was maintained at 0 °C for 10 minutes and then ice-cold water (13 mL) was added at once. The resulting precipitate was collected by vacuum filtration and washed with water (caution: this compound has been reported to be potentially explosive when dry). The white solid was immediately dissolved in DCM (5.0 mL), dried over Na2S04, and filtered. The filtrate was then added dropwise to a cooled (0 °C) solution of 2-methylpyrazine (1.0 g, 11.0 mmol) in DCM (10 mL). The reaction was allowed to warm to room temperature and stirred for 2 h. The resulting
crude mixture was concentrated in vacuo to afford the title compound as a yellow oil. MS (ESI): mass calcd. for CsFMNb, 110.1 ; m/z found, 111.1 [M+H] +.
Step B: Ethyl 2.4-dimethylpyrazolo[L5-a1 pyrazine-3-carboxylate. To the crude solution of a l-amino-2-methylpyrazin-l-ium 2,4,6-trimethylbenzenesulfonate (0.5 g, 1.6 mmol) in DMF (8.0 mL) was added ethyl but-2-ynoate (0.27 g, 2.4 mmol) and potassium carbonate (0.67 g, 4.8 mmol) and the resulting mixture was stirred for l6h at rt. The crude mixture was then diluted with EtOAc (2 x), and the combined organics washed with brine (4 x), dried over Na2S04, filtered, and concentrated. The residue was purified by silica gel chromatography (0-50%
EtO Ac/hexanes) to afford the title compound as yellow solid (65 mg, 18% yield). MS(ESI): mass calcd. for CnHi3N302, 219.1; m/z found, 220.1 [M+H] +.
Step C: Potassium 2.4-dimethylpyrazolon 5-al pyrazine-3-carboxylate. The title compound was prepared in a manner analogous to Intermediate 70, Step C, using ethyl 2,4- dimethylpyrazolo[l,5-a] pyrazine-3-carboxylate instead of methyl 3-fluoropyrazolo[l,5-a] pyridine-5-carboxylate. MS (ESI): mass calcd. for CiHsKELCh, 229.0; m/z found, 192.0
[M-K+2H] +.
Intermediate 95: Potassium 2-cvclopropyl-4-methylpyrazolorL5-al pyrazine-3-carboxylate.
Figure imgf000202_0001
The title compound was prepared in a manner analogous to Intermediate 94, using ethyl 3- cyclopropylpropiolate instead of ethyl but-2-ynoate in Step B. MS (ESI): mass calcd. for C11H10KN3O2, 255.0; m/z found, 218.1 [M-K+2H]
Intermediate 96: Potassium 2-methylimidazorE2-blpyridazine-6-carboxylate.
Figure imgf000203_0001
The title compound was prepared in a manner analogous to Intermediate 70, Step C, using methyl 2-methylimidazo[l,2-b] pyridazine-6-carboxylate instead of ethyl 7-fluoroimidazo[l,2-a] pyridine-3 -carboxy late. MS (ESI): mass calcd. for C8H6KN3O2, 215.0; m/z found, 178.1
[M-K+2H] +.
Intermediate 97: Potassium 2.8-dimethylimidazon 2-bl pyridazine-3-carboxylate.
Figure imgf000203_0002
The title compound was prepared in a manner analogous to Intermediate 85 using 4- methylpyridazin-3-amine instead of 4-fluoropyridin-2-amine in Step A. MS (ESI): mass calcd. for C9H8KN3O2, 229.1 ; m/z found, 192.0 [M-K+2H] +.
Intermediate 98: Potassium 2.7-dimethylimidazon 2-bl pyridazine-3-carboxylate.
Figure imgf000203_0003
The title compound was prepared in a manner analogous to Intermediate 85 using 5- methylpyridazin-3-amine instead of 4-fluoropyridin-2-amine in Step A. MS (ESI): mass calcd. for C9H8KN3O2, 229.1 ; m/z found, 192.0 [M-K+2H] +. Intermediate 99: Potassium 2.5.8-trimethylimidazon 2-al pyrazine-3-carboxylate.
Figure imgf000204_0001
The title compound was prepared in a manner analogous to Intermediate 85 using 3,6- dimethylpyrazin-2-amine instead of 4-fluoropyridin-2-amine in Step A. MS (ESI): mass calcd. for C10H10KN3O2, 243.1 ; m/z found, 206.1 [M-K+2H] +.
Intermediate 100: Sodium 3-methylimidazorE5-al pyrazine-l-carboxylate.
Figure imgf000204_0002
To a stirred solution of methyl 3-methylimidazo[l,5-a] pyrazine-l-carboxylate (53 mg, 0.275 mmol) in ethanol (3.0 mL) and water (1.0 mL) were added sodium hydroxide (33 mg, 0.82 mmol) and the resulting mixture was heated at 80 °C for l6h. The mixture was then cooled and filtered to obtain the title compound as white solid which was taken to next step without purification. MS (ESI): mass calcd. for CxHeN^NaCb, 199.0; m/z found, 178.1 [M-Na+2H]
Intermediate 101 : Potassium 2-cvclopropyl-4-methylpyrazolorE5-a1 pyrazine-3-carboxylate.
Figure imgf000204_0003
The title compound was prepared in a manner analogous to Intermediate 70, Step C, using methyl 5-methyl-7H-pyrrolo[2,3-d] pyrimidine-4-carboxylate instead of ethyl 7- fluoroimidazo[l,2-a] pyridine-3 -carboxylate. MS (ESI): mass calcd. for C8H6KN3O2, 215.0; m/z found, 178.1 [M-K+2H] +.
Intermediate 102: Potassium 5-methyl-7H-pyrrolor2.3-d1pyrimidine-4-carboxylate.
Figure imgf000205_0001
Step A: methyl 5.7-dimethyl-7H-pyrrolo d1 pyrimidine-4-carboxylate. To a cooled (0 °C)
Figure imgf000205_0002
solution of methyl 5-methyl-7H-pyrrolo[2,3-d] pyrimidine-4- carboxy late (0.25 g, 1.3 mmol) in THF (7.5 mL) was added sodium hydride (60% in mineral oil, 105 mg, 2.62 mmol). The reaction mixture was warmed to rt and stirred for lh. After lh, the mixture was cooled to 0 °C, then iodomethane (0.25 mL, 4.0 mmol) was added, and the reaction mixture was stirred for l6h. The reaction was then quenched with water, diluted with EtOAc (2 x), and the combined organics washed with brine (4 x), dried over Na2S04, filtered, and concentrated. The crude residue was taken to next step without further purification. MS(ESI): mass calcd. for
C10H11N3O2, 205.1; m/z found, 206.1 [M+H] +.
Step B: Potassium 5.7-dimethyl-7H-pyrrolo[2.3-d1 pyrimidine-4-carboxylate. The title compound was prepared in a manner analogous to Intermediate 70, Step C, using methyl 5- methyl-7H-pyrrolo[2,3-d] pyrimidine-4-carboxylate instead of methyl 3-fluoropyrazolo[l,5-a] pyridine-5-carboxylate. MS (ESI): mass calcd. for C9H8KN3O2, 229.0; m/z found, 192.0
[M-K+2H] +.
Intermediate 103: 2.3-Dimethylquinoxaline-6-carboxylic acid.
Figure imgf000205_0003
To a stirred solution of 3,4-diaminobenzoic acid (0.25 g, 1.64 mmol) in ethanol (2.0 mL) was added 2,3-butanedione (0.2 mL, 2.0 mmol) and the resulting mixture was heated at 80 °C for lh. The mixture was then cooled and concentrated the solvent to obtain the title compound as brown solid which was taken to next step without further purification. MS (ESI): mass calcd. for C11H10N2O2, 202.2; m/z found, 202.9 [M+H] +.
Intermediate 104: Lithium/! ) quinoxaline-6-carboxylate-2-<7.
Figure imgf000206_0001
Step A: Methyl 2-hvdroxyquinoxaline-6-carboxylate. A solution of methyl 3,4- diaminobenzoate (2.0 g, 12 mmol) in ethanol (6.0 mL) was added ethyl 2-oxoacetate (1.4 mL, 14.4 mmol) and the mixture was stirred at rt for lh. Concentrated the solvent and recrystallized the crude mixture with ethyl acetate (10.0 mL). The resulting yellow solid was filtered and dried on vacuum to afford the title compound (1.5 g, 63% yield). MS (ESI): mass calcd. for
C10H8N2O3, 204.2; m/z found, 205.1 [M+H]+.
Step B: Methyl 2-chloroquinoxaline-6-carboxylate. To a solution of methyl 2- hydroxyquinoxaline-6-carboxylate (655 mg, 3.2 mmol) in toluene (20.0 mL) was added thionyl chloride (5.0 mL, 64.1 mmol) followed by N, N-dimethylformamide (0.3 mL, 3.8 mmol). The resulting solution was heated to reflux temperature for 3h. After cooling the mixture, concentrated the solvent under vacuum and triturated with ethyl acetate. The resulting brown solid was filtered and dried on vacuum to afford the title compound (426 mg, 60% yield). MS (ESI): mass calcd. for C10H7CIN2O2, 222.1; m/z found, 222.9 [M+H] +.
Step C: methyl quinoxaline-6-carboxylate-2-c/. To a solution of methyl 2-chloroquinoxaline-6- carboxylate (225 mg, 1.0 mmol) in THE (20.0 mL) was added PdCl2(dppf) (37 mg, 0.05 mmol), N1, N1, N2, N2-tetramethylethane-l, 2-diamine (0.26 mL, 1.72 mmol) and sodium borodeuteride (72 mg, 1.72 mmol). The mixture was degassed with nitrogen and then stirred at rt for 2h. The reaction mixture was diluted with water and extracted with ethyl acetate (x2). The combined organic extracts were dried over Na2S04 and concentrated. Purification by flash chromatography (S1O2; 0-100% EtO Ac/hexanes) afforded the title compound as a white solid (130 mg, 68% yield). MS (ESI): mass calcd. for C10H7DN2O2, 189.2; m/z found, 190.1 [M+H] +. Ή NMR (400 MHz, DMSO-r/e) d 9.08 (d, J= 1.2 Hz, 1H), 8.64 (dd, J= 2.0, 0.6 Hz, 1H), 8.32 (dd, J = 8.7, 1.9 Hz, 1H), 8.22 (dd, J= 8.7, 0.6 Hz, 1H), 3.97 (s, 3H).
Step D: Lithium(T) quinoxaline-6-carboxylate-2-d. To a solution of methyl quinoxaline-6- carboxylate-2-d (100 mg, 0.53 mmol) in THF (3.5 mL) was added a solution of lithium hydroxide (25.0 mg, 1.05 mmol) in water (1.5 mL). The mixture was stirred at rt for lh, then concentrated the solvent to afford the title compound as white solid which was further taken to next step without purification (quantitative yield). MS (ESI): mass calcd. for CgHrDLfNbO, 181.1 m/z found, 176.0 [M-Li+2H] +.
Intermediate 105: Potassium 2.6.6-trimethyl-6.7-dihvdro-4H-pyrazolo[5/l -c][ 1 4loxazine-3- carboxylate.
Figure imgf000207_0001
A: 6,6- methylmorpholine-3-carboxylic acid. To a solution of 4-(tert-butyl) 3-methyl 6,6-dimethylmorpholine-3,4-dicarboxylate (5g, 18.3 mmol) in DCM (18.3 mL) was added trifluoroacetic acid (6.0 mL) and the mixture was stirred at rt for 2h. Concentrated the solvent, dissolved the crude residue in MeOH (9.2 mL) followed by addition of sodium hydroxide (3.0 g,
73.2 mmol) in water. Concentrated solvent using a rotary evaporator and the crude product was taken to next step without purification. MS (ESI): mass calcd. for C7H13NO3, 159.1 ; m/z found,
160.2 [M+H] +.
Step B: 6,6-Dimethyl-6,7-dihydro-4H- [1,2,3] oxadiazolo[4,3-c][l,4]oxazin-8-ium-3-olate. To a solution of 6,6-dimethylmorpholine-3-carboxylic acid (2.9 g, 18.3 mmol) in water (1.8 mL, 95.2 mmol) was added sodium nitrite (1.9 g, 27.4 mmol) and hydrochloric acid (37% in water) (1.24 mL, 14.8 mmol). The mixture was stirred at rt for l6h, diluted with water and extracted 3X with 20% iPrOH/chloroform mixture. The combined organic extracts were dried over anhydrous Na2S04 and concentrated under vacuo. The crude residue was then dissolved in acetonitrile (7.5 mL) followed by addition of 2,2,2-trifluoroacetic anhydride (1.5 mL, 11.1 mmol). The resulting mixture was stirred at rt for 2h. The reaction mixture was quenched with potassium carbonate (2.0 g, 14.8 mmol), added water and filtered to obtain the title compound as crystalline precipitate extracted 3x with 20% iPrOH/chloroform. The solid was used in next step without further purification. MS (ESI): mass calcd. for C7H12N2O4, 170.2; m/z found, 171.1 [M+H] +.
¾ NMR (500 MHz, DMSO-r/e) d ppm 4.6 (s, 2 H) 4.3 (s, 2 H) 1.3 (s, 6 H).
Step C: Ethyl 2,6,6-trimethyl-6,7-dihydro-4H-pyrazolo[5,l-cl [1,41 oxazine-3-carboxylate and ethyl 3,6,6-trimethyl-6,7-dihydro-4H-pyrazolo[ 5, 1 -cl [1 ,41oxazine-2-carboxylate: To a solution of 6,6-dimethyl-6,7-dihydro-4H- [1,2,3] oxadiazole[4,3-c] [l,4]oxazin-8-ium-3- olate (200 mg, 1.2 mmol) in xylene (4.0 mL) was added ethyl but-2-ynoate (0.28 mL, 2.4 mmol) and the mixture was stirred at 145 °C for 16 h. Concentrated the solvent and purified by flash chromatography (SiC ; 0 - 100% EtO Ac/hexanes) to obtain mixture of regio isomers (91 mg ; 52 mg, 33%; 18% yield). MS (ESI): mass calcd. for C12H18N2O3, 238.3; m/z found, 239.1
[M+H] +.
Step D: (AT Potassium 2.6.6-trimethyl-6.7-dihvdro-4H-pyrazolo[5/l -c][ 1 ,41oxazine-3- carboxylate and (BY Potassium 3.6.6-trimethyl-6.7-dihvdro-4H-pyrazolor5.l-cirl.41oxazine-2- carboxylate: The title compound was prepared in a manner analogous to Intermediate 6 using ethyl 2,6,6-trimethyl-6,7-dihydro-4H-pyrazolo[5,l-c] [1,4] oxazine-3-carboxylate and ethyl 3,6,6-trimethyl-6,7-dihydro-4H-pyrazolo[5,l-c][l,4]oxazine-2-carboxylate (Step C) instead of methyl 3-fluoropyrazolo[l,5-a] pyridine-5-carboxylate. MS (ESI): mass calcd. for
C10H13KN2O3, 248.2; m/z found, 211.1 [M-K+2H] +.
Intermediate 106: Potassium 3.6.6-trimethyl-6.7-dihvdro-4H-pyrazolor5.l-cirl.41oxazine-2- carboxylate.
Figure imgf000208_0001
The title compound was isolated from Intermediate 105, Step C. MS (ESI): mass calcd. for C10H13KN2O3, 248.2; m/z found, 211.1 [M-K+2H] +.
Intermediate 107: 3-Fluoro-5-methoxyisonicotinic acid.
Figure imgf000208_0002
Under a nitrogen atmosphere was added n-BuLi (2.5M in hexanes, 0.21 mL, 0.53 mmol) to a mixture of 4-bromo-3-fluoro-5-methoxypyridine (100 mg, 0.5 mmol) in THF (2.3 mL) at -78C. After 1 hour, CO2 was cannulated and bubbled through the reaction mixture from dry ice. Then, the reaction mixture slowly warmed to room temperature. After 16 hours, water (20 mL) was added and the mixture was acidified using 6N HC1. The mixture was extracted using DCM (3 x 30 mL). The combined organics were discarded. The aqueous layer was concentrated under reduced pressure. Purification (preparative HPLC, METHOD A) afforded the title compound (133 mg, 64%). MS (ESI): mass calcd. for CvHeFNCb, 171.0; m/z found, 172.1 [M+H]+.
Intermediate 108: Potassium 2-cvclopropyl-4-methylpyrazolo[ l .5-blpyridazine-3-carboxylate.
Figure imgf000209_0001
The title compound was prepared in a manner analogous to Intermediate 94, using 4-methyl pyridazine in Step A and ethyl 3-cyclopropylpropiolate instead of ethyl but-2-ynoate in Step B. MS (ESI): mass calcd. for C11H10KN3O2, 255.0; m/z found, 218.1 [M-K+2H]+.
Intermediate 109: Potassium 2-cvclopropyl-5-methylpyrazolorE5-blpyridazine-3-carboxylate.
Figure imgf000209_0002
The title compound was prepared in a manner analogous to Intermediate 94, using 4-methyl pyridazine in Step A and ethyl 3-cyclopropylpropiolate instead of ethyl but-2-ynoate in Step B. MS (ESI): mass calcd. for C11H10KN3O2, 255.0; m/z found, 218.1 [M-K+2H]+.
Intermediate 110: 1.6-Dimethyl- 1 H-pyrazolo[3.4-d1pyrimidine-4-carboxylic acid.
Figure imgf000209_0003
Step A: 4-(l-Ethoxyvinyl)-l,6-dimethyl-lH-pyrazolo[3,4-d]pyrimidine. To a solution of 4- chloro-l,6-dimethyl-lH-pyrazolo[3,4-d]pyrimidine (500 mg, 2.74 mmol) in /V, N- dimethylformamide (4.0 mL) was added tributyl(l -ethoxy vinyl)stannane (0.92 mL, 2.74 mmol), and bis(triphenylphosphine)palladium chloride (192 mg, 0.27 mmol). The reaction mixture was stirred at 60 °C for 18 h under nitrogen and concentrated under reduced pressure. After cooling, the reaction was quenched by saturated potassium fluoride aqueous solution and diluted with ethyl acetate (EtOAc). The resulting precipitate was filtered off and filtrate was collected and washed with water and brine solution. The organic layer is dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with hexanes:ethyl acetate (4: 1) to give the title compound (177 mg, 30% yield) as white solid. MS (ESI): mass calcd. for C11H14N4O, 218.1; m/z found, 219.1
Figure imgf000210_0001
8.27 (s, 1H), 5.74 (d, J= 2.0 Hz, 1H), 4.76 (d, J = 2.0 Hz, 1H), 4.05 (t, J= 6.9 Hz, 2H), 3.99 (s, 3H), 2.71 (s, 3H), 1.48 (t, J= 7.0 Hz, 3H).
Step B: l,6-Dimethyl-lH-pyrazolo[3,4-d]pyrimidine-4-carboxylic acid. To a solution of 4-(l- ethoxyvinyl)-l,6-dimethyl-lH-pyrazolo[3,4-d]pyrimidine (50 mg, 0.23 mmol) in 1,4 dioxane (1.5 mL) was added a solution of sodium periodate (98 mg, 0.46 mmol) in water (0.5 mL) followed by addition of potassium permanganate (18.1 mg, 0.11 mmol) and the mixture was stirred at room temperature for 16 h. After completion, the reaction mixture was adjusted to pH 7-8 with saturated potassium carbonate solution. The precipitate was filtered off and washed with dichloromethane to afford the title compound as white solid. (28 mg, 64% yield). MS (ESI): mass calcd. for C8H8N4O2, 192.1; m/z found, 193.1 [M+H]+.
Intermediate 111 : 3-Fluoro-5-(triazol-2-yljbenzoic acid.
Figure imgf000210_0002
To a mixture of 3-fluoro-5-iodobenzoic acid (270 mg, 1.02 mmol) in /V,/V-dimethylformamide (2.7 mL) was added 1H-1, 2, 3-triazole (88 pL, 1.52 mmol, 1.192 g/mL), cesium carbonate (562 mg, 1.72 mmol), trans-A/M-dimethylcyclohexane-l, 2-diamine (27 pL, 0.171 mmol, 0.902 g/mL) and copper(I) iodide (19 mg, 0.0998 mmol). The reaction mixture was stirred at 140 °C for 80 min under microwave irradiation. The reaction mixture was filtered through a pad of Celite® and the Celite® was washed with ethyl acetate (2 x 5 mL). The combined filtrates were extracted with water (1 x 5 mL). The aqueous layer was acidified to pH 3 with 1 M hydrochloric acid. The aqueous layer was extracted with ethyl acetate (2 x 5 mL). The combined organic layers were dried over magnesium sulfate, filtered and evaporated. The crude product was purified by preparative HPLC to afford the title compound (57 mg, 27% yield) as an off-white powder.
MS (ESI): mass calcd. for C9H6FN3O2, 207.0; m/z found, 208.1 [M+H]+. Ή NMR (500 MHz, DMSO-d6) 5 13.75 (br s, 1H), 9.01 (d, J= 1.2 Hz, 1H), 8.38 - 8.30 (m, 1H), 8.16 (dt, J= 9.4, 2.2 Hz, 1H), 8.03 (d, J= 1.2 Hz, 1H), 7.82 - 7.74 (m, 1H).
Intermediate 112: 3-(3-methyl-lH-L2.4-triazol-l-vnbenzoic acid.
Figure imgf000211_0001
The compound was made in a manner analogous to Intermediate 111 (3-fluoro-5-(triazol-2- yl)benzoic acid) using 3-iodobenzoic acid instead of 3-fluoro-5-iodobenzoic acid and 3-methyl- 1H- 1,2, 4-triazole instead of 1H-1, 2, 3-triazole. MS (ESI): mass calcd. for C10H9N3O2, 203.1; m/z found, 204.1 [M+H]+.
Intermediate 113: 3-fluoro-5-n H- l .2.4-triazol- l -vQbenzoic acid.
Figure imgf000211_0002
The compound was made in a manner analogous to Intermediate 111 (3-fluoro-5-(triazol-2- yl)benzoic acid) using 1H- 1,2, 4-triazole instead of 1H-1, 2, 3-triazole. MS (ESI): mass calcd. for C9H6FN3O2, 207.0; m/z found, 208.1 [M+H]+.
Intermediate 114: 3-methoxy-5-ri H- l .2.4-triazol- l -vQbenzoic acid.
Figure imgf000212_0001
The compound was made in a manner analogous to Intermediate 111 (3-fluoro-5-(triazol-2- yl)benzoic acid) using 3-iodo-5-methoxybenzoic acid instead of 3-fluoro-5-iodobenzoic acid and 1 H-l, 2, 4-triazole instead of 1H-1, 2, 3-triazole. MS (ESI): mass calcd. for C10H9N3O3, 219.1; m/z found, 220.1 [M+H]+. triazol- l -vQbenzoic acid.
Figure imgf000212_0002
The compound was made in a manner analogous to Intermediate 111 (3-fluoro-5-(triazol-2- yl)benzoic acid) using 2-fluoro-6-iodobenzoic acid instead of 3-fluoro-5-iodobenzoic acid and 1 H-l, 2, 4-triazole instead of 1H-1, 2, 3-triazole. MS (ESI): mass calcd. for C9H6FN3O2, 207.0; m/z found, 208.1 [M+H]+.
Intermediate 116: 2-fluoro-5-('2H- 1.2.3-triazol-2-yl)benzoic acid.
Figure imgf000212_0003
The compound was made in a manner analogous to Intermediate 111 (3-fluoro-5-(triazol-2- yl)benzoic acid) using 2-fluoro-5-iodobenzoic acid instead of 3-fluoro-5-iodobenzoic acid. MS (ESI): mass calcd. for C9H6FN3O2, 207.0; m/z found, 208.1 [M+H]+. Intermediate 117: 3-methyl-5-t2H- l .2.3-triazol-2-yl)benzoic acid.
Figure imgf000213_0001
The compound was made in a manner analogous to Intermediate 111 (3-fluoro-5-(triazol-2- yl)benzoic acid) using 3-iodo-5-methylbenzoic acid instead of 3-fluoro-5-iodobenzoic acid. MS (ESI): mass calcd. for C9H6FN3O2, 203.1; m/z found, 204.1 [M+H]+.
Intermediate 118: 3-(2H- 1 2.3-triazol-2-yl )-5-(trifluoromethyl ibenzoic acid.
Figure imgf000213_0002
The compound was made in a manner analogous to Intermediate 111 (3-fluoro-5-(triazol-2- yl)benzoic acid) using 3-iodo-5-(trifluoromethyl)benzoic acid instead of 3-fluoro-5-iodobenzoic acid. MS (ESI): mass calcd. for C10H6F3N3O2, 257.0; m/z found, 256.1 [M-H] .
Intermediate 119: 5-(lH-pyrazol-l-yl1nicotinic acid.
Figure imgf000213_0003
The compound was made in a manner analogous to Intermediate 111 (3-fluoro-5-(triazol-2- yl)benzoic acid) using 5-iodonicotinic acid instead of 3-fluoro-5-iodobenzoic acid and 1H- pyrazole instead of 1H-1, 2, 3-triazole. MS (ESI): mass calcd. for C9H7N3O2, 189.1; m/z found, 190.1 [M+H]+.
Intermediate 120: 3-Fluoro-5-(4H-E2.4-triazol-4-yl1benzoic acid.
Figure imgf000214_0001
Step A: Methyl 3-fluoro-5-(l.2.4-triazol-4-v0benzoate. To a solution of methyl 3-amino-5- fluorobenzoate (250 mg, 1.48 mmol) in pyridine (8 mL) was added 1 ,2-diformylhydrazine (325 mg, 3.69 mmol) and triethylamine (1 mL, 7.16 mmol). To the mixture was added
chlorotrimethylsilane (375 pL, 2.96 mmol) dropwise. The reaction mixture was stirred at 100 °C for 16 h and evaporated. The residue was diluted with dichloromethane (8 mL) and water (10 mL). The aqueous layer was extracted with dichloromethane (2 x 10 mL). The combined organic layers were washed with 10% potassium bisulfate (1 x 15 mL) and 1 M sodium hydroxide (1 x 15 mL), dried over sodium sulfate, filtered and evaporated to give the title compound (131 mg, 0.592 mmol, 40%) as a white powder. MS (ESI): mass calcd. for C10H8FN3O2, 221.1 m/z found, 222.1 [M+H]+.
Step B: 3-Fluoro-5-n .2.4-triazol-4-yl)benzoic acid. To a solution of methyl 3-fluoro-5-(l,2,4- triazol-4-yl)benzoate (130 mg, 0.588 mmol) in l,4-dioxane (1 mL) and water (1 mL) was added sodium hydroxide (48 mg, 1.20 mmol) and the reaction was stirred at room temperature for 16 h. The reaction was quenched with 6 M hydrochloric acid (0.20 mL). The precipitate was collected and washed with water (l x l mL) to afford the title compound (80 mg, 0.386 mmol, 65%) as a white powder. MS (ESI): mass calcd. for C9FLFN3O2, 207.0; m/z found, 208.1 [M+H]+.
Intermediate 121 : 4-Fluoro-3-(4H-L2.4-triazol-4-yl1benzoic acid.
Figure imgf000214_0002
The title compound was prepared in a manner analogous to Intermediate 120 using methyl 3- amino-4-fluorobenzoate instead of methyl 3-amino-5-fluorobenzoate in Step A. MS (ESI): mass calcd. for C9H6FN3O2, 207.0; m/z found, 206.0 [M-H] . Intermediate 122: 3-Methyl-5-('4H- l .2.4-triazol-4-yl)benzoic acid.
Figure imgf000215_0001
The title compound was prepared in a manner analogous to Intermediate 120 using methyl 3- amino-5-methylbenzoate instead of methyl 3-amino-5-fluorobenzoate in Step A. MS (ESI): mass calcd. for C10H9N3O2, 203.1 ; m/z found, 204.1 [M+H] +.
Intermediate 123: 4-Methyl-3-(4H- 1.2.4-triazol-4-yl)benzoic acid.
Figure imgf000215_0002
The title compound was prepared in a manner analogous to Intermediate 120 using methyl 3- amino-4-methylbenzoate instead of methyl 3-amino-5-fluorobenzoate in Step A. MS (ESI): mass calcd. for C10H9N3O2, 203.1; m/z found, 204.1 [M+H] +.
Intermediate 124: 4-Methoxy-3-n .2.4-triazol-4-yl)benzoic acid.
Figure imgf000215_0003
The title compound was prepared in a manner analogous to Intermediate 120 using methyl 3- amino-4-methoxybenzoate instead of methyl 3-amino-5-fluorobenzoate in Step A. MS (ESI): mass calcd. for C10H9N3O3, 219.1; m/z found 220.1 [M+H]+. Intermediate 125: 3-methoxy-5-(4H-E2.4-triazol-4-vnbenzoic acid.
Figure imgf000216_0001
The title compound was prepared in a manner analogous to Intermediate 120 using methyl 3- amino-5-methoxybenzoate instead of methyl 3-amino-5-fluorobenzoate in Step A. MS (ESI): mass calcd. for C10H9N3O3, 219.1; m/z found 220.1 [M+H]+.
Intermediate 126: 3-(4H- 1 ,2.4-triazol-4-yl )-4-(trifluoromethyl ibenzoic acid.
Figure imgf000216_0002
The title compound was prepared in a manner analogous to Intermediate 120 using methyl 3- amino-4-(trifluoromethyl)benzoic acid instead of methyl 3-amino-5-fluorobenzoate in Step A. MS (ESI): mass calcd. for C10H6F3N3O2, 257.1; m/z found 258.1 [M+H]+.
Intermediate 127: 3-(4H- 1 ,2.4-triazol-4-yl )-5-(trifluoromethyl ibenzoic acid.
Figure imgf000216_0003
The title compound was prepared in a manner analogous to Intermediate 120 using methyl 3- amino-5-(trifluoromethyl)benzoate instead of methyl 3-amino-5-fluorobenzoate in Step A. MS (ESI): mass calcd. for C10H6F3N3O2, 257.1; m/z found 258.1 [M+H]+.
Intermediate 128: 2-Fluoro-3-(2-(tosyloxy)ethoxy)benzoic acid.
Figure imgf000216_0004
The title compound was prepared in a manner analogous to Intermediate 12, using methyl 2- fluoro-3-hydroxybenzoate in place of methyl 2-chloro-3-hydroxybenzoate, ethane- 1 ,2-diyl bis(4- methylbenzenesulfonate) in place of 1 -fluoro-2-iodoethane, and NaOH in place of Li OH. MS (ESI): mass calcd. for C16H15FO6S, 354.1; m/z found, 376.9 [M-H+Na]+.
Intermediate 129: 2-chloro-3-(2-((Tetrahvdro-2H-pyran-2-yl)oxy)ethoxy)benzoic.
Figure imgf000217_0001
The title compound was prepared in a manner analogous to Intermediate 12, using 2-(2- bromoethoxy)tetrahydro-2H-pyran in place of 1 -fluoro-2-iodoethane.
Intermediate 130: 3-Fluoro-5-(2-(tosyloxy)ethoxy)benzoic acid.
Figure imgf000217_0002
The title compound was prepared in a manner analogous to Intermediate 12, using methyl 3- fluoro-5-hydroxybenzoate in place of methyl 2-chloro-3-hydroxybenzoate, ethane- 1 ,2-diyl bis(4- methylbenzenesulfonate) in place of l-fluoro-2-iodoethane, and NaOH in place of FiOH. MS (ESI): mass calcd. for C16H15FO6S, 354.1; m/z found, 354.9 [M+H]+.
Intermediate 131 : (SV2-(4-(3-(3.5-DifluorophenylV2.7-dimethyl-4.5.6.7-tetrahvdro-2H- Pyrazolo[3.4-c1pyridine-6-carbonyl)- l H-pyrrolo[2.3-b1pyridin- l -vOethyl 4- methylbenzenesulfonate.
Figure imgf000217_0003
Step A: (S)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-
6-yl)(lH-pyrrolo[2,3-b]pyridin-4-yl)methanone. To a solution of (S)-3-(3,5-difluorophenyl)-2,7- dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine, Intermediate 39, (50 mg, 0.19 mmol) in dichloromethane (DCM) (1.5 mL) was added HATU (144 mg, 0.38 mmol), followed by DIPEA (0.1 mL, 0.66 mmol) and lH-pyrrolo[2,3-b]pyridine-4-carboxylic acid (62 mg, 0.38 mmol), and the mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with water and the aqueous layer extracted with DCM (x2). The combined organics were washed with brine, dried over Na2S04, filtered, and concentrated in vacuo. The crude residue was purified by flash column chromatography (SiCh; 0-15% MeOH in DCM) to afford the title compound (76 mg, 99% yield). MS (ESI): mass calcd. for C22H19F2N5O, 407.2; m/z found, 408.2 [M+H]+.
Step B: (S)-2-(4-(3-(3,5-Difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c]pyridine-6-carbonyl)-lH-pyrrolo[2,3-b]pyridin-l -yl)ethyl 4-methylbenzenesulfonate. A solution of (S)-(3-(3,5-difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)(lH-pyrrolo[2,3-b]pyridin-4-yl)methanone (140 mg, 0.34 mmol), ethane- 1 ,2-diyl bis(4-methylbenzenesulfonate) (255 mg, 0.69 mmol) and cesium carbonate (230 mg, 0.70 mmol) in DMF (2.7 mL) was stirred at rt for 30 minutes. The reaction mixture was diluted with saturated aq. NaHCCh and extracted with EtOAc (x3). The combined organic layers were concentrated under reduced pressure and purified by flash column chromatography (S1O2, 0-5% MeOH in DCM) to afford the title compound. MS (ESI): mass calcd. for C31H29F2N5O4S, 605.2; m/z found, 606.0 [M+H]+.
Example 1 : (2-Methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolol3,4-clpyridin-6-yl)(naphthalen-
1 -yl)methanone.
Figure imgf000218_0001
To a solution of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine, Intermediate 1, (150 mg, 0.7 mmol) in dichloromethane (DCM) (5.0 mL) was added HATU (348 mg, 0.91 mmol), followed by DIPEA (0.6 mL, 3.5 mmol) and 1 -naphthoic acid (222 mg, 1.3 mmol), and the mixture stirred at room temperature for 1 h. The reaction mixture was diluted with water and the aqueous layer extracted with DCM (x2). The combined organics were washed with brine, dried over Na^SOr, filtered, and concentrated in vacuo. The crude residue was purified by reverse-phase HPLC (Method A) to afford the title compound as a white solid (94 mg, 36% yield). MS (ESI): mass calcd. for C24H21N3O, 367.1 ; m/z found, 368.1
Figure imgf000219_0001
NMR (400 MHz, Methanol-r/r) d 8.12 - 7.93 (m, 2H), 7.89 - 7.74 (m, 1H), 7.67 - 7.35 (m, 9H), 5.20 - 4.92 (m, 2H), 4.46 - 4.22 (m, 1H), 4.13 - 3.98 (m, 0.3H), 3.76 (d, J= 54.9 Hz, 3H), 3.52 - 3.41 (m, 1H), 2.93 - 2.75 (m, 0.7H), 2.57 - 2.30 (m, 1H). Example 2: ('3-Cvclopropyl-2-methyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-c1pyridin-6-yl)('2.3- dichlorophenyQmethanone.
Figure imgf000219_0002
The title compound was prepared in a manner analogous to Example 1, using 3-cyclopropyl-2- methyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 2) and 2,3-dichlorobenzoic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C17H17CI2N3O, 349.0; m/z found,
350.0 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 7.82 - 7.69 (m, 1H), 7.52 - 7.24 (m, 2H), 4.64 (dd, J= 116.8, 16.1 Hz, 2H), 4.13 (s, 0.5H), 3.91 - 3.82 (m, 0.5H), 3.74 (d, J= 31.1 Hz, 3H), 3.33 - 3.27 (m, 1H), 2.64 - 2.57 (m, 1H), 2.45 (t, J= 5.8 Hz, 1H), 1.74 (td, = 8.4, 4.3 Hz, 1H), 0.97 - 0.85 (m, 2H), 0.69 - 0.56 (m, 2H).
Example 3 : ('3-Cvclopropyl-2-methyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-c1pyridin-6- vDtnaphthalen- 1 -vDmethanone.
Figure imgf000219_0003
The title compound was prepared in a manner analogous to Example 1, using 3-cyclopropyl-2- methyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 2) instead of 3-(phenyl)-2- methyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 1). MS (ESI): mass calcd. for C21H21N3O, 331.1 ; m/z found, 332.1 [M+H]+.
Figure imgf000220_0001
NMR (400 MHz, Methanol-r/4) d 8.06 - 7.91 (m, 2H), 7.87 - 7.66 (m, 1H), 7.63 - 7.40 (m, 4H), 5.06 - 4.90 (m, 1H), 4.41 - 3.94 (m,
2H), 3.82 (d, J= 54.2 Hz, 3H), 3.46 - 3.38 (m, 1H), 2.91 - 2.76 (m, 1H), 2.56 - 2.33 (m, 1H), 1.82 - 1.69 (m, 1H), 1.09 - 0.91 (m, 2H), 0.84 - 0.60 (m, 2H).
Example 4: (2-Fluoro-3-(trifluoromethoxy)phenyl)(2-methyl-3-phenyl- tetrahvdro-6H-
Figure imgf000220_0002
pyrazolo[3.4-c1pyridin-6-yl)methanone.
Figure imgf000220_0003
The title compound was prepared in a manner analogous to Example 1, using 2-fluoro-3- (trifluoromethoxy) benzoic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for
C21H17F4N3O2, 419.1; m/z found, 420.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 7.79 - 7.62 (m, 1H), 7.62 - 7.37 (m, 7H), 4.77 (s, 1H), 4.38 (s, 1H), 3.97 - 3.86 (m, 1H), 3.81 - 3.69 (m,
3H), 3.45 (t, = 5.8 Hz, 1H), 2.63 (t, = 5.8 Hz, 1H), 2.55 - 2.52 (m, 1H).
Example 5: (2-Methoxy-6-(trifluoromethyl1phenyl¥2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-
Pyrazolo[3.4-c1pyridin-6-yl)methanone.
Figure imgf000220_0004
The title compound was prepared in a manner analogous to Example 1, using 2-methoxy-6- trifluoromethylbenzoic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C22H20F3N3O2, 415.2; m/z found, 416.3 [M+H]+. (500 MHz, DMSO- ck) d 7.66 - 7.60 (m, 1H), 7.55 - 7.48 (m, 2H), 7.48 - 7.40 (m, 4H), 7.40 - 7.34 (m, 1H), 4.86 (d, J= 16.3 Hz, 1H), 4.56 (d, J= 16.3 Hz, 1H), 3.85 (s, 3H), 3.78 (s, 3H), 3.38-3.30 (m, 2H), 2.51-2.34 (m, 2H).
Example 6: (3 -Methoxy-5-(trifluoromethyl)phenyl)(2-methyl-3 -phenyl-2 A5,7-tetrahydro-6H- thanone.
Figure imgf000221_0001
The title compound was prepared in a manner analogous to Example 1, using 3-methoxy-5- trifluoromethylbenzoic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C22H20F3N3O2, 415.2; m/z found, 416.2 [M+H]+. ¾ NMR (500 MHz, DMSO- ek) d 7.56 - 7.49 (m, 2H), 7.49 - 7.41 (m, 3H), 7.39 - 7.28 (m, 3H), 4.72 (s, 2H), 3.88 (s, 3H), 3.79 (s, 3H), 3.55 - 3.41 (m, 2H), 2.61-2.53 (m, 2H).
Example 7: (2-Methoxy-3-methylphenyl¥2-methyl-3-phenyl- tetrahvdro-6H-
Figure imgf000221_0002
Pyrazolo[3.4-c1pyridin-6-yl)methanone.
Figure imgf000221_0003
The title compound was prepared in a manner analogous to Example 1, using 2-methoxy-3- methylbenzoic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C22H23N3O2, 361.2; m/z found, 362.2
[M+H]+. ¾ NMR (300 MHz, DMSO- ek) d 7.58 - 7.35 (m, 5H), 7.31 - 7.19 (m, 1H), 7.06 - 6.95 (m, 1H), 6.81 (d, J= 7.5 Hz, 1H), 4.90 (d, J= 16.2 Hz, 1H), 4.61 (d, J= 16.2 Hz, 1H), 3.81 (s, 3H), 3.78 (s, 3H), 3.46 - 3.21 (m, 2H), 2.57 - 2.29 (m, 2H), 2.05 (s, 3H). Example 8: ('2-Ethyl-3-methoxyphenyl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000222_0001
The title compound was prepared in a manner analogous to Example 1, using 2-ethyl-3- methoxybenzoic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C23H25N3O2, 375.2; m/z found, 376.2
[M+H]+. ¾ NMR (500 MHz, DMSO- ek) d 7.55 - 7.40 (m, 5H), 7.26-7.22 (m, 1H), 7.03-6.99 (m, 1H), 6.80 (dd, = 7.6, 1.1 Hz, 1H), 4.95 (d, J= 16.1 Hz, 1H), 4.55 (d, J= 16.2 Hz, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 3.41-3.34 (m, 1H), 3.33-3.24 (m, 1H), 2.69-2.52 (m, 2H), 2.42-2.28 (m, 2H), 1.05 (t, = 7.4 Hz, 3H).
Example 9: ('3.4-Dimethoxyphenyl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000222_0002
The title compound was prepared in a manner analogous to Example 1, using 3,4- dimethoxybenzoic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C22H23N3O3, 377.2; m/z found, 378.3
[M+H]+. (300 MHz, DMSO- ek) d 7.59 - 7.39 (m, 5H), 7.09 - 6.96 (m, 3H), 4.62 (s, 2H), 3.80 (s, 3H), 3.78 (s, 3H), 3.75 (s, 3H), 3.74 - 3.46 (m, 2H), 2.67 - 2.54 (m, 2H). Example 10: ('2.6-Dimethoxyphenyl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000223_0001
The title compound was prepared in a manner analogous to Example 1, using 2,6- dimethoxybenzoic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C22H23N3O3, 377.2; m/z found, 378.2
[M+H]+. ¾ NMR (500 MHz, DMSO- ek) d 7.55-7.48 (m, 2H), 7.48-7.40 (m, 3H), 7.33 (t, J = 8.4 Hz, 1H), 6.72 (d, J= 8.5 Hz, 2H), 4.70 (s, 2H), 3.74 (s, 6H), 3.67 (s, 3H), 3.35-3.30 (m, 2H), 2.44-2.37 (m, 2H).
Example 11 : ('3.5-Dimethoxyphenyl)-('2-methyl-3-phenyl-5.7-dihvdro-4//-pyrazolo[3.4-
Figure imgf000223_0002
To a suspension of 2-methyl-3-phenyl-4,5,6,7-tetrahydropyrazolo[3,4-c]pyridine, Intermediate 1, (60 mg, 0.281 mmol) in ethyl acetate (1 mL) was added triethylamine (87 pL, 0.624 mmol,
0.726 g/mL) and 3,5-dimethoxybenzoyl chloride (67 mg, 0.334 mmol). The reaction mixture was stirred at room temperature for 1 h and diluted with ethyl acetate (5 mL). The organic layer was washed with water (2 x 3 mL), dried over magnesium sulfate, filtered and evaporated. The residue was purified by preparative HPLC to afford the title compound (38 mg, 0.101 mmol, 36%) as an off-white powder. MS (ESI): mass calcd. for C22H23N3O3, 377.2; m/z found, 378.2
[M+H]+. (500 MHz, DMSO-r/e) d 7.56 - 7.40 (m, 5H), 6.62 - 6.55 (m, 1H), 6.57 - 6.53 (m, 2H), 4.68 (br s, 2H), 3.77 (s, 9H), 3.54 - 3.43 (m, 2H), 2.63 - 2.53 (m, 2H). Example 12: (2-Chloro-3-hvdroxyphenyl¥2-methyl-3-phenyl- tetrahvdro-6H-
Figure imgf000224_0001
Pyrazoloi3.4-c1pyridin-6-yl)methanone.
Figure imgf000224_0002
The title compound was prepared in a manner analogous to Example 1, using 2-chloro-3- hydroxybenzoic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C20H18CIN3O2, 367.1; m/z found, 368.2
[M+H]+. ¾ NMR (500 MHz, DMSO- ek) d 10.48 (br s, 1H), 7.56-7.40 (m, 5H), 7.23-7.18 (m, 1H), 7.01 (dd, = 8.1, 1.4 Hz, 1H), 6.80 (dd, = 7.5, 1.4 Hz, 1H), 4.87 (d, = 16.2 Hz, 1H), 4.61 (d, J= 16.2 Hz, 1H), 3.78 (s, 3H), 3.41-3.31 (m, 2H), 2.51-2.40 (m, 2H).
Example 13 : (2-Chloro-3-methoxyphenyl¥2-methyl-3-phenyl-2A5.7-tetrahvdro-6H- Pyrazolo[3.4-c1pyridin-6-yl)methanone.
Figure imgf000224_0003
The title compound was prepared in a manner analogous to Example 1, using 2-chloro-3- methoxybenzoic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C21H20CIN3O,
381.1; m/z found, 382.0 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 7.61 - 7.33 (m, 6H), 7.28 - 7.18 (m, 1H), 7.07 - 6.85 (m, 1H), 4.96 - 4.78 (m, 1H), 4.69 - 4.58 (m, 1H), 4.24 (s, 1H), 3.94 - 3.85 (m, 3H), 3.81 - 3.69 (m, 3H), 3.39 - 3.34 (m, 1H), 2.70 - 2.58 (m, 1H), 2.48 - 2.40 (m, m). Example 14: ('3-Chloro-2-methoxy-phenyl)-('2-methyl-3-phenyl-5.7-dihvdro-4//-pyrazolo[3.4- 61pyridin-6-yl imethanone.
Figure imgf000225_0001
The title compound was prepared in a manner analogous to Example 1, using 3-chloro-2- methoxybenzoic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H20CIN3O2, 381.1; m/z found, 382.1 [M+H]+. ¾ NMR (300 MHz, DMSO-r/e) d 7.63 - 7.38 (m, 6H), 7.34 - 7.17 (m, 2H), 4.91 (d, J = 16.3 Hz, 1H), 4.61 (d, J= 16.2 Hz, 1H), 3.78 (s, 6H), 3.45 - 3.28 (m, 2H), 2.66 - 2.37 (m, 2H). Example 15: (2-Chloro-6-methoxyphenyl¥2-methyl-3-phenyl-2A5.7-tetrahvdro-6H- Pyrazolo[3.4-c1pyridin-6-yl)methanone.
Figure imgf000225_0002
The title compound was prepared in a manner analogous to Example 1, using 2-chloro-6- methoxybenzoic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C21H20CIN3O, 381.1; m/z found, 382.0 [M+H] +. ¾ NMR (600 MHz, DMSO-r/e) d 7.54 - 7.33 (m, 6H), 7.07
(d, J= 8.2 Hz, 2H), 4.82 - 4.66 (m, 1H), 4.21 (s, 1H), 3.79 (d, J= 3.3 Hz, 2H), 3.76 - 3.71 (m, 3H), 3.68 (s, 1H), 3.36 (t, J= 5.8 Hz, 1H), 2.59 (t, J= 5.8 Hz, 1H), 2.50 (t, J= 5.7 Hz, 1H), 2.45 (d, J= 5.9 Hz, 1H). Example 16: (3-Chloro-5-methoxyphenyl¥2-methyl-3-phenyl-2A5.7-tetrahvdro-6H- Pyrazoloi3.4-c1pyridin-6-yl)methanone.
Figure imgf000226_0001
The title compound was prepared in a manner analogous to Example 1, using 3-chloro-5- methoxybenzoic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C21H20CIN3O2, 381.1; m/z found, 382.1 [M+H]+. Ή NMR (600 MHz, Methanol-A) d 7.53 (t, J= 7.5 Hz, 2H), 7.49 - 7.42 (m, 3H), 7.08 (d, J= 27.0 Hz, 2H), 6.96 (s, 1H), 4.61 - 4.51 (m, 1.5H), 3.98 (s, 0.73H), 3.89 - 3.74 (m, 6.24H), 3.63 (s, 1H), 3.37 - 3.33 (m, 0.53H), 2.76 - 2.61 (m, 2H). Example 17: (2- Amino-3-methylphenyl )('2-methyl-3 -phenyl-2.4.5.7-tetrahydro-6H-pyrazolo[3.4- clpyridin-6-yl jmethanone.
Figure imgf000226_0002
The title compound was prepared in a manner analogous to Example 1, using 2-amino-3- methylbenzoic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H22N4O, 346.2; m/z found, 347.3
Figure imgf000226_0003
7.49 (m, 2H), 7.48-7.41 (m, 3H), 7.06-7.01 (m, 1H), 6.96-6.91 (m, 1H), 6.55 (t, J= 7.5 Hz, 1H), 4.88 (s, 2H), 4.76-4.42 (m, 2H), 3.75 (s, 3H), 3.73-3.45 (m, 2H), 2.62-2.53 (m, 2H), 2.12 (s, 3H). Example 18: (2-( \ H- l .2.4-Triazol- l -yl)phenyl)(2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H- Pyrazoloi3.4-clpyridin-6-yl)methanone.
Figure imgf000227_0001
The title compound was prepared in a manner analogous to Example 1, using 2-(lH- 1,2,4- triazol-l-yl) benzoic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C22H20N6O, 384.1; m/z found, 385.1 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 8.87 (d, = 28. l Hz, 1H), 8.11 (d, = 56.1 Hz, 1H), 7.80 - 7.41 (m, 9H), 4.81 (d, = l6.8 Hz, 1H), 4.35 (dd, J= 45.8, 16.1 Hz, 2H), 4.05 (d, J= 16.1 Hz, 1H), 3.84 - 3.64 (m, 3H), 2.46 - 2.14 (m, 2H).
Example 19: (2-Methyl-3-morpholinophenyl¥2-methyl-3-phenyl-2A5.7-tetrahvdro-6H-
Pyrazolo[3.4-c1pyridin-6-yl)methanone.
Figure imgf000227_0002
The title compound was prepared in a manner analogous to Example 1, using 2-methyl-3- morphilinobenzoic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C25H28N4O2, 416.2; m/z found, 417.3
Figure imgf000227_0003
7.39 (m, 5H), 7.26-7.22 (m, 1H), 7.12-7.08 (m, 1H), 6.96-6.92 (m, 1H), 4.92 (d, J= 16.1 Hz, 1H), 4.59 (d, J= 16.2 Hz, 1H), 3.80-3.76 (m, 2H), 3.76-3.71 (m, 4H), 3.72-3.69 (m, 1H), 3.36-3.31 (m, 2H), 2.92-2.77 (m, 3H), 2.57-2.48 (m, 2H), 2.43-2.32 (m, 1H), 2.17 (s, 3H). Example 20: (5-Chloro-l -methyl- lH-pyrazol-4-yr)(2-methyl-3-phenyl- tetrahvdro-6H-
Figure imgf000228_0001
pyrazoloD .4-c1pyridin-6-yl imethanone.
Figure imgf000228_0002
The title compound was prepared in a manner analogous to Example 1, using 5-chloro-l-methyl- lH-pyrazole-4-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for
CisHisClNsO, 355.1; m/z found, 356.1 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 7.79 (s, 1H), 7.58 - 7.37 (m, 5H), 4.64 (s, 2H), 3.84 (s, 3H), 3.76 (s, 3H), 3.66 (s, 2H), 2.62 (s, 2H).
Example 21 : (Ί .5-Dimethyl- 1 H-pyrazol-4-yl)(2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H- pyrazoloP .4-c1pyridin-6-yl imethanone.
Figure imgf000228_0003
The title compound was prepared in a manner analogous to Example 1, using l,5-dimethyl-lH- pyrazole-4-carboxylic acid instead of l-naphthoic acid. MS (ESI): mass calcd. for C19H21N5O, 335.1; m/z found, 336.1 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 7.60 - 7.39 (m, 6H), 4.64 (s, 2H), 3.75 (s, 6H), 3.71 (d, J= 6.0 Hz, 2H), 2.61 (d, J= 5.4 Hz, 2H), 2.32 (s, 3H).
Example 22: (5-Cvclopropyl-l -methyl- lH-pyrazol-4-yr)(2-methyl-3-phenyl-2.4.5.7-tetrahvdro- l)methanone.
Figure imgf000228_0004
The title compound was prepared in a manner analogous to Example 1, using 5 -cyclopropyl- 1- methyl-lH-pyrazole-4-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C21H23N5O, 361.1; m/z found, 362.1 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 7.57 - 7.34 (m, 6H), 4.63 (s, 2H), 3.84 (s, 3H), 3.75 (s, 3H), 3.57 (s, 2H), 2.56 (t, J= 5.8 Hz, 2H), 1.98 - 1.81 (m, 1H), 0.89 (d, J= 8.2 Hz, 2H), 0.59 (s, 2H).
Example 23: ('2-Methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-c1pyridin-6-yl)(' l -phenyl- 1 H- l .2.4-triazol-3-yl)methanone.
Figure imgf000229_0001
The title compound was prepared in a manner analogous to Example 1, using 1 -phenyl- 1 H-l, 2,4- triazole-3 -carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C22H20N6O, 384.1; m/z found, 385.1 [M+H] +. ¾ NMR (600 MHz, DMSO-r/e) d 9.42 (d, J= 4.3 Hz, 1H), 7.96 - 7.87 (m, 2H), 7.64 - 7.56 (m, 2H), 7.57 - 7.40 (m, 6H), 4.79 (d, J= 16.5 Hz, 2H), 3.92 (t, J= 5.8 Hz, 1H), 3.81 - 3.78 (m, 3H), 3.73 (s, 1H), 2.71 - 2.60 (m, 2H).
Example 24: ('6-('Difluoromethoxy)pyridin-2-yl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H- Pyrazolo[3.4-c1pyridin-6-yl)methanone.
Figure imgf000229_0002
The title compound was prepared in a manner analogous to Example 1, using 6- (difluoromethoxy)picolinic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for
C20H18F2N4O2, 384.1; m/z found, 385.0 [M+H] +.
Figure imgf000229_0003
(400 MHz, DMSO-r/e) d 8.12 - 8.00 (m, 1H), 7.92 - 7.67 (m, 1H), 7.59 - 7.42 (m, 6H), 7.29 - 7.18 (m, 1H), 4.65 (d, J= 58.2 Hz, 2H), 3.87 (t, J= 5.8 Hz, 1H), 3.82 - 3.70 (m, 3H), 3.57 (t, J= 5.7 Hz, 1H), 2.67 - 2.57 (m, 2H). Example 25: (2-Methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolor3.4-c1pyridin-6-yl¥6- (trifluoromethoxy)pyridin-2-yl)methanone.
Figure imgf000230_0001
The title compound was prepared in a manner analogous to Example 1, using 6-
(trifluoromethoxy)picolinic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for
C20H17F3N4O2, 402.1; m/z found, 403.0 [M+H] +.
Figure imgf000230_0002
(400 MHz, DMSO-r/e) d 8.19 (dd, J = 8.2, 7.5 Hz, 1H), 7.70 (dd, J= 7.6, 0.9 Hz, 1H), 7.59 - 7.40 (m, 6H), 4.74 (s, 1H), 4.58 (s, 1H), 3.89 (t, = 5.8 Hz, 1H), 3.79 - 3.70 (m, 3H), 3.57 (t, J= 5.7 Hz, 1H), 2.61 (dt, = l 5.5, 5.8 Hz, 2H).
Example 26: 5-('2-Methyl-3-phenyl-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4-c1pyridine-6-carbonyl)- 2H-benzorb1 G 1.41oxazin-3(4HVone.
Figure imgf000230_0003
The title compound was prepared in a manner analogous to Example 1, using 3-oxo-3,4-dihydro- 2H-benzo[b][l,4]oxazine-5-carboxylic acid instead of l-naphthoic acid. MS (ESI): mass calcd. for C22H20N4O3, 388.1; m/z found, 389.1 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 10.36 (s, 1H), 7.67 - 7.34 (m, 5H), 7.24 - 6.81 (m, 3H), 4.65 (d, J= 26.7 Hz, 3H), 4.41 (s, 1H), 3.95 - 3.64 (m, 3H), 3.42 (s, 2H), 2.66 (d, J= 10.9 Hz, 1H), 2.49 (s, 1H). Example 27: ('4-Methyl-3.4-dihvdro-2H-benzo[bli l .4loxazin-7-yl)('2-methyl-3-phenyl-
Figure imgf000231_0001
tetrahvdro-6H-pyrazoloi3.4-clpyridin-6-yl)methanone.
Figure imgf000231_0002
The title compound was prepared in a manner analogous to Example 1, using 4-methyl-3,4- dihydro-2H-benzo[b][l,4]oxazine-7-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H24N4O2, 388.2; m/z found, 389.1 [M+H] +. ¾ NMR (600 MHz, DMSO-r/e) d 7.57 - 7.39 (m, 5H), 6.94 (dt, J= 8.3, 1.5 Hz, 1H), 6.83 - 6.66 (m, 2H), 4.59 (s, 2H), 4.28 - 4.21 (m, 2H), 3.75 (s, 3H), 3.65 (s, 2H), 3.30 (d, J= 4.3 Hz, 2H), 2.89 (d, J= 1.1 Hz, 3H), 2.59 (t, J= 5.8 Hz, 2H).
Example 28: 1dioxol-4-yl('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-
Figure imgf000231_0003
clpyridin-6-yl jmethanone.
Figure imgf000231_0004
The title compound was prepared in a manner analogous to Example 1, using
benzo[d][l,3]dioxole-4-carboxylic acid instead of l-naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H19N3O3, 361.1 ; m/z found, 362.2 [M+H]+. ¾ NMR (500 MHz, DMSO- de) d 7.59-7.37 (m, 5H), 7.03-7.00 (m, 1H), 6.92 (t, J= 7.7 Hz, 1H), 6.89-6.86 (m, 1H), 6.08 (s, 2H), 4.69 (s, 2H), 3.78 (s, 3H), 3.56-3.47 (m, 2H), 2.63-2.52 (m, 2H). Example 29: dioxol-5-yl(2-methyl-3 -phenyl-2 A5.7-tetrahvdro-6H-pyrazolor3.4-
Figure imgf000232_0001
clpyridin-6-yl imethanone.
Figure imgf000232_0002
The title compound was prepared in a manner analogous to Example 1, using
benzo[d][l,3]dioxole-5-carboxylic acid instead of l-naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H19N3O3, 361.1 ; m/z found, 362.2 [M+H]+. ¾ NMR (300 MHz, DMSO- de) d 7.63-7.37 (m, 5H), 7.06-7.01 (m, 1H), 7.00-6.94 (m, 2H), 6.09 (s, 2H), 4.60 (br s, 2H), 3.76 (s, 3H), 3.77-3.39 (m, 2H), 2.70-2.52 (m, 2H).
Example 30: ('2.2-Difluorobenzo[din .31dioxol-4-yl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H- Pyrazolo[3.4-c1pyridin-6-yl)methanone.
Figure imgf000232_0003
The title compound was prepared in a manner analogous to Example 1, using 2,2- difluorobenzo[d][l,3]dioxole-4-carboxylic acid instead of l-naphthoic acid. MS (ESI): mass calcd. for C21H17F2N3O3, 397.1 ; m/z found, 398.1 [M+H] +. ¾ NMR (400 MHz, DMSO- e) d 7.58 - 7.40 (m, 6H), 7.36 - 7.23 (m, 2H), 4.79 - 4.47 (m, 2H), 3.89 (s, 1H), 3.75 (d, J= 25.6 Hz, 3H), 3.53 (t, J= 5.8 Hz, 1H), 2.70 - 2.54 (m, 2H). Example 31 : ('2-Methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-clpyridin-6-yl)('4H- thienoi3.2-blpyrrol-2-yl)methanone.
Figure imgf000233_0001
The title compound was prepared in a manner analogous to Example 1, using 4H-thieno[3,2- b]pyrrole-2-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C20H18N4OS, 362.1; m/z found, 363.1 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 11.32 (s, 1H), 7.57 - 7.39 (m, 6H), 7.24 (d, J= 3.0 Hz, 1H), 6.41 (d, J= 3.0 Hz, 1H), 4.78 (s, 2H), 3.88 (t, J= 5.7 Hz, 2H), 3.76 (s, 3H), 2.68 (t, J= 5.5 Hz, 2H). Example 32: ('2-Methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-c1pyridin-6-yl)('6- methylimidazo[2.1 -blthiazol-5-yl jmethanone.
Figure imgf000233_0002
The title compound was prepared in a manner analogous to Example 1, using 6- methylimidazo[2,l-b]thiazole-5-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C20H19N5OS, 377.1 ; m/z found, 378.1 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d
7.78 (d, J= 4.4 Hz, 1H), 7.54 - 7.41 (m, 5H), 7.30 (d, J= 4.4 Hz, 1H), 4.67 (s, 2H), 3.77 (s, 1H), 3.75 (s, 3H), 3.27 (s, 1H), 2.70 - 2.59 (m, 2H), 2.35 (s, 3H).
Example 33: Benzofuran-7-yl('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-clpyridin- 6-yl)methanone.
Figure imgf000234_0001
The title compound was prepared in a manner analogous to Example 1, using benzofuran-7- carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C22H19N3O2, 357.1; m/z found, 358.1 [M+H]+. 'H NMR (500 MHz, DMSO-r/e) d 8.07 (d, J= 2.2 Hz, 1H), 7.80 - 7.75 (m, 1H), 7.56 - 7.40 (m, 5H), 7.39 - 7.30 (m, 2H), 7.07 - 7.03 (m, 1H), 4.81 (s, 2H), 3.79 (s, 3H), 3.48 - 3.36 (m, 2H), 2.58 - 2.44 (m, 2H).
Example 34: Benzofuran-4-yl('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-c1pyridin- 6-yl)methanone.
Figure imgf000234_0002
The title compound was prepared in a manner analogous to Example 1, using benzofuran-4- carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C22H19N3O2, 357.1; m/z found, 358.3 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.09 (d, J= 2.2 Hz, 1H), 7.77-7.67 (m, 1H), 7.58-7.38 (m, 6H), 7.36-7.30 (m, 1H), 7.01-6.84 (m, 1H), 4.89-4.71 (m, 2H), 3.78 (br s, 3H), 3.58-3.38 (m, 2H), 2.76-2.48 (m, 2H). Example 35: Benzofuran-5-yl(2-methyl-3-phenyl-2 5.7-tetrahvdro-6H-pyrazolo[3.4-
Figure imgf000235_0001
6-yl)methanone.
Figure imgf000235_0002
The title compound was prepared in a manner analogous to Example 1, using benzofuran-5- carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C22H19N3O2, 357.1; m/z found, 358.2 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) d 8.09 (d, J= 2.2 Hz, 1H), 7.80 - 7.77 (m, 1H), 7.71 - 7.66 (m, 1H), 7.55 - 7.39 (m, 6H), 7.05 - 7.01 (m, 1H), 4.79 - 4.61 (m, 2H), 3.76 (br s, 3H), 3.64 - 3.42 (m,
2H), 2.69 - 2.55 (m, 2H).
Example 36: Benzofuran-3-yl('2-niethyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-c1pyridin- 6-yl)methanone.
Figure imgf000235_0003
The title compound was prepared in a manner analogous to Example 1, using benzofuran-3- carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C22H19N3O2, 357.1; m/z found, 358.2 [M+H]+. ¾ NMR (300 MHz, DMSO-r/e) d 8.44 (s, 1H), 7.77 - 7.71 (m, 1H), 7.72 - 7.65 (m, 1H), 7.59 - 7.30 (m, 7H), 4.76 (s, 2H), 3.93 - 3.59 (m, 2H), 3.76 (s, 3H), 2.72 - 2.58 (m, 2H). Example 37: Benzo[b1thiophen-7-yl('2-niethyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- c|pyridin-6-yl imethanone.
Figure imgf000236_0001
The title compound was prepared in a manner analogous to Example 1, using benzo[b]thiophene- 7-carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C22H19N3OS, 373.1; m/z found, 374.2 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) d 8.04 - 7.97 (m, 1H), 7.83 (d, J= 5.4 Hz, 1H), 7.57 - 7.40 (m, 8H), 4.96 - 4.45 (m, 2H), 3.76 (br s, 3H), 4.00 - 3.38 (m, 2H), 2.71 - 2.55 (m, 2H). Example 38: Benzo[b1thiophen-4-yl('2-niethyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl jmethanone.
Figure imgf000236_0002
The title compound was prepared in a manner analogous to Example 1, using benzo[b]thiophene- 4-carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C22H19N3OS, 373.1; m/z found, 374.3 [M+H]+. ¾
NMR (300 MHz, DMSO-r/e) d 8.19-8.02 (m, 1H), 7.87 (d, J= 5.5 Hz, 1H), 7.60-7.23 (m, 8H), 4.84 (s, 2H), 3.80 (s, 3H), 3.49-3.30 (m, 2H), 2.81-2.46 (m, 2H).
Example 39: Benzo[blthiophen-5-yl('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000237_0001
The title compound was prepared in a manner analogous to Example 1, using benzo[b]thiophene- 5-carboxybc acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C22H19N3OS, 373.1; m/z found, 374.2 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) d 8.13 - 8.08 (m, 1H), 8.02 - 7.98 (m, 1H), 7.87 (d, J= 5.4 Hz, 1H), 7.56 - 7.53 (m, 1H), 7.53 - 7.47 (m, 4H), 7.47 - 7.41 (m, 2H), 4.84 - 4.62 (m, 2H), 3.77 (s, 3H), 3.64 - 3.43 (m, 2H), 2.67 - 2.54 (m, 2H).
Example 40: Benzo[b1thiophen-3-yl('2-niethyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000237_0002
The title compound was prepared in a manner analogous to Example 1, using benzo[b]thiophene- 3-carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C22H19N3O2S, 373.1 ; m/z found, 374.3 [M+H]+. ¾ NMR (300 MHz, DMSO-r/e) d 8.14-8.04 (m, 1H), 8.06 (s, 1H), 7.87-7.73 (m, 1H), 7.62-7.35 (m, 7H), 4.93-4.59 (m, 2H), 3.76 (br s, 3H), 3.70-3.41 (m, 2H), 2.71-2.53 (m, 2H). Example 41 : ('3-Chlorobenzo[blthiophen-2-yl)('2-methyl-3-phenyl- tetrahvdro-6H-
Figure imgf000238_0001
Pyrazoloi3.4-c1pyridin-6-yl)methanone.
Figure imgf000238_0002
The title compound was prepared in a manner analogous to Example 1, using 3- chlorobenzo[b]thiophene-2-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C22H18CIN3OS, 407.0; m/z found, 408.0 [M+H] +. ¾ NMR (600 MHz, DMSO-r/e) 5 8.17 - 8.09 (m, 1H), 7.88 (d, J= 7.6 Hz, 1H), 7.66 - 7.38 (m, 7H), 4.85 - 4.52 (m, 2H), 3.78 (s, 3H), 3.63 (s, 1H), 2.61 (d, J= 10.5 Hz, 2H), 3.98 - 3.87 (m, 1H). Example 42: (Ί H-Indol-4-yl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-c1pyridin- 6-yl)methanone.
Figure imgf000238_0003
The title compound was prepared in a manner analogous to Example 1, using lH-indole-4- carboxylic acid instead of l-naphthoic acid. MS (ESI): mass calcd. for C22H20N4O, 356.1; m/z found, 357.1 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) 5 11.34 (s, 1H), 7.59 - 7.38 (m, 8H), 7.16 (d, J= 7.4 Hz, 1H), 7.04 (dd, J= 7.2, 0.9 Hz, 1H), 6.36 (s, 1H), 4.79 (s, 2H), 3.99 - 3.64 (m, 4H), 3.44 (s, 1H), 2.67 (dd, J= 3.8, 1.8 Hz, 1H).
Example 43: (Ί H-Indol-5-yl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-clpyridin- 6-yl)methanone.
Figure imgf000239_0001
The title compound was prepared in a manner analogous to Example 1, using lH-indole-5- carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C22H20N4O, 356.2; m/z found, 357.3 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 11.30 (br s, 1H), 7.71-7.67 (m, 1H), 7.57-7.39 (m, 7H), 7.20 (dd, J= 8.3, 1.6 Hz, 1H), 6.55-6.48 (m, 1H), 4.65 (s, 2H), 3.75 (s, 3H), 3.90-3.49 (m, 2H), 2.69-2.56 (m, 2H).
Example 44: (Ί H-Indol-3-yl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-c1pyridin- 6-yl)methanone.
Figure imgf000239_0002
The title compound was prepared in a manner analogous to Example 1, using 1H- indole-3 - carboxylic acid instead of l-naphthoic acid. MS (ESI): mass calcd. for C22H20N4O, 356.1; m/z found, 357.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 11.64 (s, 1H), 7.73 (d, J= 7.9 Hz, 1H), 7.58 - 7.42 (m, 7H), 7.23 - 7.06 (m, 2H), 4.75 (s, 2H), 3.83 (t, J= 5.7 Hz, 2H), 3.75 (s, 3H), 2.67 (q, = 7.1, 5.7 Hz, 2H). Example 45: (Ί H-Indol-7-yl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-clpyridin- 6-yl)methanone.
Figure imgf000240_0001
The title compound was prepared in a manner analogous to Example 1, using lH-indole-7- carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and DMA instead of DCM. MS (ESI): mass calcd. for C22H20N4O, 356.2; m/z found, 357.3 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) d 11.11 (br s, 1H), 7.70-7.63 (m, 1H), 7.55-7.48 (m, 2H), 7.48-7.40 (m, 3H), 7.39-7.32 (m, 1H), 7.18-7.12 (m, 1H), 7.06 (t, J= 7.5 Hz, 1H), 6.54-6.49 (m, 1H), 4.93-4.40 (m, 2H), 4.09-3.40 (m, 2H), 3.75 (br s, 3H), 2.69-2.49 (m, 2H).
Example 46: (Ί H-Indol-6-yl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-c1pyridin- 6-yl)methanone.
Figure imgf000240_0002
The title compound was prepared in a manner analogous to Example 1, using lH-indole-6- carboxylic acid instead of l-naphthoic acid. MS (ESI): mass calcd. for C22H20N4O, 356.1; m/z found, 357.1 [M+H] +. ¾ NMR (600 MHz, DMSO-r/e) d 11.26 (s, 1H), 7.60 (d, J= 8.1 Hz, 1H), 7.57 - 7.40 (m, 6H), 7.10 (dd, J= 8.1, 1.5 Hz, 1H), 6.59 - 6.43 (m, 1H), 5.75 (s, 2H), 4.65 (s, 2H), 3.75 (s, 4H), 2.62 (t, J= 5.7 Hz, 2H). Example 47: (5-Fluoro- 1 H-indol-4-yl )('2-methyl-3 -phenyl-2 4.5.7-tetrahydro-6H-pyrazolo
Figure imgf000241_0001
clpyridin-6-yl imethanone.
Figure imgf000241_0002
The title compound was prepared in a manner analogous to Example 1, using 5-fluoro-lH- indole-4-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C22H19FN4O, 374.1; m/z found, 375.1 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 11.41 (s, 1H), 7.59 - 7.37 (m, 6H), 7.07 - 6.95 (m, 1H), 6.34 - 6.20 (m, 1H), 4.94 - 4.75 (m, 1H), 4.34 (s, 1H), 4.19 - 4.06 (m, 1H), 3.85 - 3.66 (m, 3H), 3.50 - 3.39 (m, 1H), 3.17 (d, J= 4.9 Hz, 1H), 2.78 - 2.55 (m, 1H), 2.46 - 2.31 (m, 1H).
Example 48: (7-Chloro- 1 H-indol-3-yl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000241_0003
The title compound was prepared in a manner analogous to Example 1, using 7-chloro-lH- indole-3 -carboxylic acid instead of l-naphthoic acid. MS (ESI): mass calcd. for C22H19CIN4O,
390.1; m/z found, 391.0 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 12.15 - 11.94 (m, 1H), 7.82 (d, J= 2.4 Hz, 1H), 7.71 (dd, J= 8.0, 0.9 Hz, 1H), 7.60 - 7.40 (m, 5H), 7.27 (dd, J= 7.6, 0.9 Hz, 1H), 7.12 (t, J= 7.8 Hz, 1H), 4.76 (s, 2H), 3.83 (t, J= 5.7 Hz, 2H), 3.75 (s, 3H), 2.66 (t, J= 5.8 Hz, 2H). Example 49: (4-Chloro- 1 H-indol-3-yl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000242_0001
The title compound was prepared in a manner analogous to Example 1, using 4-chloro-lH- indole-3 -carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C22H19CIN4O, 390.1; m/z found, 391.1 [M+H]+. ¾ NMR (300 MHz, DMSO-r/e) d 11.76 (br s, 1H), 7.62 (s, 1H), 7.56 - 7.36 (m, 6H), 7.16 (t, = 7.6 Hz, 1H), 7.11 (dd, = 7.6, 1.3 Hz, 1H), 4.88 - 4.62 (m, 2H), 3.76 (br s, 3H), 3.59 - 3.37 (m, 2H), 2.68 - 2.44 (m, 2H).
Example 50: ('7-Methyl- l H-indol-2-yl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000242_0002
The title compound was prepared in a manner analogous to Example 1, using 7-methyl- 1H- indole-2-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H22N4O,
370.1; m/z found, 371.1 [M+H] +. ¾ NMR (600 MHz, DMSO-r/e) d 11.46 (s, 1H), 7.56 - 7.43 (m, 6H), 7.02 - 6.83 (m, 3H), 4.83 (s, 2H), 3.93 (t, J= 5.7 Hz, 2H), 3.77 (s, 3H), 3.33 (s, 3H), 2.70 (s, 2H). Example 51 : (Ί -Methyl- 1 H-indol-4-yl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000243_0001
The title compound was prepared in a manner analogous to Example 1, using 1 -methyl- 1H- indole-4-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H22N4O, 370.1; m/z found, 371.1 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 7.59 - 7.35 (m, 7H), 7.22 (dd, J= 8.2, 7.1 Hz, 1H), 7.07 (dd, J= 7.2, 0.9 Hz, 1H), 6.35 (s, 1H), 4.91 - 4.22 (m, 2H), 3.83 (s, 3H), 3.78 (s, 3H), 3.42 (s, 1H), 2.72 - 2.53 (m, 2H), 2.47 - 2.30 (m, 1H). Example 52: (Ί -Methyl- 1 H-indol-3-yl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000243_0002
The title compound was prepared in a manner analogous to Example 1, using 1 -methyl- 1H- indole-3 -carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H22N4O, 370.1; m/z found, 371.1 [M+H] +. ¾ NMR (600 MHz, DMSO-r/e) d 7.84 - 7.74 (m, 2H), 7.56 -
7.41 (m, 6H), 7.29 - 7.12 (m, 2H), 4.75 (s, 2H), 3.85 (s, 3H), 3.84 (d, J= 5.9 Hz, 2H), 3.75 (s, 3H), 2.67 (t, = 5.8 Hz, 2H).
Example 53: Benzo[dlisoxazol-3-yl('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000244_0001
The title compound was prepared in a manner analogous to Example 1, using benzo[d]isoxazole- 3-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C21H18N4O2, 358.1; m/z found, 359.1 [M+H]+. ¾ NMR (600 MHz, Methanol-i 4) d 7.97 - 7.89 (m, 1H), 7.76 - 7.69 (m, 2H), 7.56 - 7.50 (m, 2H), 7.49 - 7.41 (m, 4H), 4.97 (d, J= 4.7 Hz, 2H), 4.17 - 3.96 (m, 2H),
3.85 - 3.74 (m, 3H), 2.81 - 2.70 (m, 2H). Example 54: ('6-Chlorobenzo[d1isoxazol-3-yl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H- pyrazoloP .4-c1pyridin-6-yl imethanone.
Figure imgf000244_0002
To a solution of 6-chlorobenzo[</]isoxazole-3-carboxylic acid (52 mg, 0.263 mmol) in dichloromethane (600 pL) was added /V,/V-dimethylformamide (10 pL, 0.13 mmol, 0.948 g/mL) and oxalyl chloride (25 pL, 0.287 mmol, 1.45 g/mL) at 0 °C. The reaction mixture was stirred at 0 °C for 5 min. To the reaction mixture was added 2-methyl-3-phenyl-4,5,6,7- tetrahydropyrazolo [3, 4-c] pyridine, Intermediate 1 (55 mg, 0.258 mmol) at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred for 18 h. The reaction mixture was diluted with water (2 mL) and extracted with ethyl acetate (2 x 5 mL). The combined organic layers were washed with 10% potassium bisulfate (1 x 5 mL), 1 M sodium carbonate (1 x 5 mL) and brine (1 x 5 mL), dried over magnesium sulfate, filtered and evaporated. The residue was purified by reverse phase HPLC to afford the title compound (14 mg, 0.036 mmol, 13%) as an off-white powder. MS (ESI): mass calcd. for C21H17CIN4O2, 392.1 ; m/z found, 393.1 58 -
Figure imgf000245_0002
The title compound was prepared in a manner analogous to Example 1, using benzo[c]isoxazole- 3-carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H18N4O2, 358.1; m/z found, 359.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 7.88 - 7.80 (m, 1H), 7.80 - 7.74 (m, 1H), 7.56 - 7.43 (m, 6H),
7.30 - 7.24 (m, 1H), 4.83 (s, 2H), 3.96 - 3.87 (m, 2H), 3.79 (s, 3H), 2.78 - 2.69 (m, 2H).
Example 56: Benzoid1oxazol-6-vh2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazoloi3.4- clpyridin-6-yl jmethanone.
Figure imgf000245_0001
The title compound was prepared in a manner analogous to Example 1, using benzo[d]oxazole-6- carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H18N4O2, 358.1; m/z found, 359.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.86 (s, 1H), 7.95 - 7.91 (m, 1H), 7.89 (d, = 8. l Hz, 1H), 7.58 - 7.41 (m, 6H), 4.79 - 4.62 (m, 2H), 3.78 (br s, 3H), 3.59 - 3.42 (m, 2H), 2.68 - 2.55 (m, 2H). Example 57: Benzo[dloxazol-2-yl('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000246_0001
The title compound was prepared in a manner analogous to Example 1, using benzo[d]oxazole-2- carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H18N4O2, 358.1; m/z found, 359.1 [M+H]+. 'H NMR (500 MHz, DMSO-r/e) d 7.94 - 7.91 (m, 1H), 7.90 - 7.86 (m, 1H), 7.61 - 7.43 (m, 7H),
4.82 (s, 2H), 4.14 - 4.05 (m, 2H), 3.79 (s, 3H), 2.77 - 2.71 (m, 2H). Example 58: Benzo[d1oxazol-5-yl('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000246_0002
The title compound was prepared in a manner analogous to Example 1, using benzo[d]oxazole-5- carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H18N4O2, 358.1; m/z found, 359.1 [M+H]+. ¾ NMR (300 MHz, DMSO-r/e) d 8.86 (s, 1H), 7.94 - 7.89 (m, 1H), 7.87 (d, J= 8.4 Hz, 1H), 7.60 - 7.38 (m, 6H), 4.86 - 4.61 (m, 2H), 3.77 (br s, 3H), 3.63 - 3.40 (m, 2H), 2.71 - 2.53 (m, 2H).
Example 59: Benzo[dlthiazol-7-yl('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000247_0001
The title compound was prepared in a manner analogous to Example 1, using benzo[d]thiazole- 7-carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H18N4OS, 374.1; m/z found, 375.1 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) d 9.47 (s, 1H), 8.25 - 8.20 (m, 1H), 7.69 - 7.63 (m, 2H), 7.55 - 7.42 (m, 5H), 4.71 (br s, 2H), 3.94 - 3.47 (m, 2H), 3.76 (br s, 3H), 2.70 - 2.60 (m, 2H).
Example 60: Benzo[d1thiazol-5-yl('2-niethyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000247_0002
The title compound was prepared in a manner analogous to Example 1, using benzo[d]thiazole- 5-carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H18N4OS, 374.1; m/z found, 375.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 9.50 (s, 1H), 8.28 (d, J= 8.2 Hz, 1H), 8.16 (d, J= 1.5 Hz, 1H), 7.61 - 7.55 (m, 1H), 7.55 - 7.47 (m, 4H), 7.47 - 7.41 (m, 1H), 4.75 (br s, 2H), 3.79 (br s, 3H), 3.63 - 3.44 (m, 2H), 2.68 - 2.55 (m, 2H). Example 61 : Benzo[dlthiazol-4-yl('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000248_0001
The title compound was prepared in a manner analogous to Example 1, using benzo[d]thiazole- 4-carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H18N4OS, 374.1; m/z found, 375.2 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) d 9.45 (s, 1H), 8.26 (dd, J= 7.8, 1.5 Hz, 1H), 7.62 - 7.37 (m, 7H), 4.96 - 4.71 (m, 2H), 3.79 (s, 3H), 3.36 - 3.28 (m, 2H), 2.47 - 2.40 (m, 2H). Example 62: Benzo[d1thiazol-2-yl('2-niethyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000248_0002
The title compound was prepared in a manner analogous to Example 1, using benzo[d]thiazole- 2-carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H18N4OS, 374.1; m/z found, 375.3 [M+H]+. ¾ NMR (300 MHz, DMSO-r/e) d 8.30-8.06 (m, 2H), 7.72-7.35 (m, 7H), 4.82 (s, 2H), 4.49-4.31 (m, 2H), 3.79 (s, 3H), 2.80-2.69 (m, 2H).
Example 63: Benzo[dlisothiazol-3-yl('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000249_0001
The title compound was prepared in a manner analogous to Example 1, using
benzo[d]isothiazole-3 -carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H18N4OS, 374.1; m/z found, 375.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.33 - 8.30 (m, 1H), 8.17 - 8.11 (m, 1H), 7.71 - 7.65 (m, 1H), 7.60 - 7.41 (m, 6H), 4.87 (s, 2H), 3.80 (s, 3H), 3.69 - 3.60 (m, 2H), 2.64 - 2.56 (m, 2H).
Example 64: (Ί H-Indazol-5-yl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000249_0002
The title compound was prepared in a manner analogous to Example 1, using lH-indazole-5- carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and DMA instead of DCM. MS (ESI): mass calcd. for C21H19N5O, 357.2; m/z found, 358.3 [M+H]+. 1H NMR (300 MHz, DMSO-r/e) d 13.26 (br s, 1H), 8.16 (s, 1H), 7.99-7.86 (m, 1H), 7.61 (d, J= 8.6 Hz, 1H), 7.56-7.39 (m, 6H), 4.66 (s, 2H), 3.96-3.45 (m, 2H), 3.76 (s, 3H), 2.69-2.56 (m, 2H). Example 65: (Ί H-Indazol-4-yl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000250_0001
The title compound was prepared in a manner analogous to Example 1, using lH-indazole-4- carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H19N5O, 357.2; m/z found, 358.3 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 13.31 (br s, 1H), 8.02 (br s, 1H), 7.72-7.60 (m, 1H), 7.60-7.34 (m, 6H), 7.19 (d, J= 6.9 Hz, 1H), 4.94-4.65 (m, 2H), 3.84-3.70 (m, 3H), 3.61-3.39 (m, 2H), 2.75- 2.48 (m, 2H).
Example 66: (Ί H-Indazol-3-yl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000250_0002
The title compound was prepared in a manner analogous to Example 1, using lH-indazole-3- carboxylic acid instead of l-naphthoic acid. MS (ESI): mass calcd. for C21H19N5O, 357.1; m/z found, 358.1 [M+H] +. ¾ NMR (600 MHz, DMSO-r/e) d 13.55 (s, 1H), 8.00 (d, J= 8.2 Hz, 1H), 7.62 (d, J= 8.5 Hz, 1H), 7.57 - 7.39 (m, 6H), 7.27 - 7.20 (m, 1H), 5.20 (s, 1H), 4.81 (s, 1H),
4.16 (s, 1H), 3.95 (s, 1H), 3.81 - 3.71 (m, 3H), 2.68 (s, 2H). Example 67: (Ί H-Indazol-7-yl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000251_0001
The title compound was prepared in a manner analogous to Example 1, using lH-indazole-7- carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H19N5O, 357.2; m/z found, 358.3 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 13.25 (br s, 1H), 8.17 (s, 1H), 7.93-7.84 (m, 1H), 7.56-7.48 (m, 2H), 7.49-7.37 (m, 4H), 7.24-7.15 (m, 1H), 4.98-4.61 (m, 2H), 3.76 (s, 3H), 3.67-3.42 (m, 2H), 2.73-2.48 (m, 2H).
Example 68: (Ί H-Indazol-6-yl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000251_0002
The title compound was prepared in a manner analogous to Example 1, using lH-indazole-6- carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H19N5O, 357.2; m/z found, 358.3 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 13.22 (br s, 1H), 8.18 - 8.11 (m, 1H), 7.85 (d, = 8.2 Hz, 1H), 7.61 (s, 1H), 7.55 - 7.50 (m, 2H), 7.50 - 7.41 (m, 3H), 7.22 - 7.11 (m, 1H), 4.88 - 4.59 (m, 2H), 3.77 (br s, 3H), 3.65 - 3.45 (m, 2H), 2.67 - 2.53 (m, 2H). Example 69: (7-Chloro- 1 H-indazol-3-yl)(2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H- Pyrazoloi3.4-clpyridin-6-yl)methanone.
Figure imgf000252_0001
The title compound was prepared in a manner analogous to Example 1, using 7-chloro-lH- indazole-3-carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and DMA instead of DCM. MS (ESI): mass calcd. for C21H18CIN5O, 391.1 ; m/z found, 392.3
[M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 14.10 (s, 1H), 8.01-7.92 (m, 1H), 7.57-7.49 (m, 3H), 7.50-7.41 (m, 3H), 7.27-7.20 (m, 1H), 4.82 (s, 2H), 4.21-4.07 (m, 2H), 3.79 (s, 3H), 2.73-2.60 (m, 2H).
Example 70: (Ί -Methyl- 1 H-indazol-3-yl )(2-methyl-3 -phenyl-2 A5 7-tetrahydro-6H- Pyrazolo[3.4-c1pyridin-6-yl)methanone.
Figure imgf000252_0002
The title compound was prepared in a manner analogous to Example 1, using 1 -methyl- 1H- indazole-3-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C22H21N5O,
371.1; m/z found, 372.1 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 8.01 (d, J= 8.2 Hz, 1H), 7.74 (d, J= 8.5 Hz, 1H), 7.59 - 7.38 (m, 5H), 7.34 - 7.21 (m, 1H), 5.20 (s, 1H), 4.81 (s, 1H), 4.20 - 4.11 (m, 3H), 3.95 (s, 1H), 3.86 - 3.70 (m, 3H), 3.41- 3.35 (m, 1H), 3.30 (s, 1H), 2.68 (s, 2H). Example 71 : (Ί H-Benzo[dlimidazol-5-yl)('2-methyl-3-phenyl- tetrahvdro-6H-
Figure imgf000253_0001
Pyrazoloi3.4-clpyridin-6-yl)methanone.
Figure imgf000253_0002
The title compound was prepared in a manner analogous to Example 1, using 1H- benzo[d]imidazole-5-carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of
DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H19N5O, 357.2; m/z found, 358.2 [M+H]+. ¾ NMR (300 MHz, DMSO-r/e) d 13.15 - 12.02 (m, 1H), 8.32 (s, 1H), 7.72 - 7.67 (m, 1H), 7.65 (d, J= 8.3 Hz, 1H), 7.57 - 7.39 (m, 5H), 7.30 (dd, J= 8.3, 1.6 Hz, 1H), 4.66 (s, 2H), 3.76 (s, 3H), 3.80 - 3.47 (m, 2H), 2.68 - 2.52 (m, 2H).
Example 72: ('2-Methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-c1pyridin-6-yl)('2- (trifluoromethyl V 1 H-benzo G dl imidazol-4-yl)methanone.
Figure imgf000253_0003
The title compound was prepared in a manner analogous to Example 1, using 2- (trifluoromethyl)-lH-benzo[d]imidazole-4-carboxylic acid instead of l-naphthoic acid. MS (ESI): mass calcd. for C22H18F3N5O, 425.1 ; m/z found, 426.1 [M+H] +. Ή NMR (400 MHz, DMSO-r/e) d 14.18 (s, 1H), 7.79 (s, 1H), 7.61 - 7.20 (m, 7H), 4.82 (s, 1H), 4.36 (s, 1H), 3.97 (s, 1H), 3.86 - 3.59 (m, 3H), 3.40 (s, 1H), 2.74 - 2.62 (m, 1H), 2.49 (s, 1H). Example 73: ('2-Methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-clpyridin-6- yl) (pyrazolo G 1.5 -al pyridin- 5 -vDmethanone.
Figure imgf000254_0001
The title compound was prepared in a manner analogous to Example 1, using pyrazolo[l,5- a]pyridine-5-carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H19N5O, 357.2; m/z found, 358.2 [M+H]+. ¾ NMR (300 MHz, DMSO-r/e) d 8.75 (d, J= 7.1 Hz, 1H), 8.08 (d, J= 2.3 Hz, 1H), 7.92 - 7.81 (m, 1H), 7.60 - 7.37 (m, 5H), 6.93 (dd, J= 7.2, 1.9 Hz, 1H), 6.78 - 6.70 (m, 1H), 4.89 - 4.44 (m, 2H), 3.77 (br s, 3H), 3.70 - 3.49 (m, 2H), 2.70 - 2.56 (m, 2H).
Example 74: (2-Methyl-3-phenyl-2A5.7-tetrahvdro-6H-pyrazolo c1pyridin-6-
Figure imgf000254_0002
yl) (pyrazolo G E 5 -al pyridin- 3 -vDmethanone.
Figure imgf000254_0003
The title compound was prepared in a manner analogous to Example 1, using pyrazolo[l,5- a]pyridine-3-carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H19N5O, 357.2; m/z found, 358.2 [M+H]+. (500 MHz, DMSO-r/e) d 8.83 - 8.77 (m, 1H), 8.37 (s, 1H), 7.97 - 7.90 (m, 1H), 7.55 - 7.47 (m, 4H), 7.48 - 7.42 (m, 2H), 7.07 (td, J= 6.9, 1.4 Hz, 1H), 4.77 (s, 2H), 3.89 - 3.81 (m, 2H), 3.76 (s, 3H), 2.76 - 2.65 (m, 2H). Example 75: ('2-Methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-clpyridin-6- yl) (pyrazolo G 1.5 -al pyridin- 7 -ylimethanone.
Figure imgf000255_0001
The title compound was prepared in a manner analogous to Example 1, using pyrazolo[l,5- a]pyridine-7-carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H19N5O, 357.2; m/z found, 358.3 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.05 (d, J= 2.3 Hz, 1H), 7.79 (dd, J= 8.9, 1.3 Hz, 1H), 7.57 - 7.45 (m, 3H), 7.46 - 7.41 (m, 2H), 7.32 - 7.25 (m, 1H), 7.02 (dd, J= 6.8, 1.3 Hz, 1H), 6.73 (d, J= 2.3 Hz, 1H), 4.94 (d, J= 16.2 Hz, 1H), 4.73 (d, J= 16.1 Hz, 1H), 3.79 (s, 3H), 3.37 - 3.19 (m, 2H), 2.56 - 2.41 (m, 2H).
Example 76: Imidazoi l .5-alpyridin- 1 -yl('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl jmethanone.
Figure imgf000255_0002
The title compound was prepared in a manner analogous to Example 1, using imidazo[l,5- a]pyridine-l -carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H19N5O, 357.2; m/z found, 358.2 [M+H]+. (300 MHz, DMSO-r/e) d 8.58 - 8.41 (m, 2H), 8.13 - 7.98 (m, 1H), 7.60 - 7.34 (m, 5H), 7.18 - 7.04 (m, 1H), 6.95 - 6.83 (m, 1H), 5.73 - 5.11 (m, 1H), 4.98 - 4.55 (m, 1H), 4.59 - 4.22 (m, 1H), 4.15 - 3.61 (m, 1H), 3.76 (s, 3H), 2.81 - 2.58 (m, 2H). Example 77: Imidazoj 1.5-alpyridin-6-yl('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000256_0001
The title compound was prepared in a manner analogous to Example 1, using imidazo[l,5- a]pyridine-6-carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H19N5O, 357.2; m/z found, 358.2 [M+H]+. ¾ NMR (300 MHz, DMSO-r/e) d 8.60 (br s, 1H), 8.44 (s, 1H), 7.68 - 7.57 (m, 1H),
7.57 - 7.39 (m, 6H), 6.88 - 6.79 (m, 1H), 4.67 (s, 2H), 3.77 (s, 3H), 3.90 - 3.58 (m, 2H), 2.74 -
2.57 (m, 2H).
Example 78: Imidazor 1.5-a1pyridin-7-yl('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000256_0002
The title compound was prepared in a manner analogous to Example 1, using imidazo[l,5- a]pyridine-7-carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H19N5O, 357.2; m/z found, 358.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.47 (s, 1H), 8.39 (d, J= 7.2 Hz, 1H), 7.74 (s, 1H),
7.58 - 7.38 (m, 6H), 6.75 - 6.68 (m, 1H), 4.66 (s, 2H), 3.76 (s, 3H), 3.75 - 3.51 (m, 2H), 2.70 - 2.57 (m, 2H). Example 79: Imidazoj 1.5-alpyridin-5-yl('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000257_0001
The title compound was prepared in a manner analogous to Example 1, using imidazo[l,5- a]pyridine-5-carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H19N5O, 357.2; m/z found, 358.2 [M+H]+. ¾ NMR (300 MHz, DMSO-r/e) d 8.29 (br s, 1H), 7.77 - 7.65 (m, 1H), 7.59 - 7.38 (m, 6H), 6.95 - 6.81 (m, 2H), 4.94 - 4.46 (m, 2H), 4.06 - 3.43 (m, 2H), 3.77 (s, 3H), 2.73 - 2.58 (m, 2H).
Example 80: Imidazor 1.2-a1pyridin-5-yl('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000257_0002
The title compound was prepared in a manner analogous to Example 1, using imidazo[l,2- a]pyridine-5-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C21H19N5O, 357.1; m/z found, 358.1 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 7.84 (s, 1H), 7.75 - 7.65 (m, 2H), 7.60 - 7.42 (m, 5H), 7.33 (dd, = 9. l, 6.9 Hz, 1H), 7.12 (dd, J= 6.9, 1.1 Hz, 1H), 4.94 - 4.53 (m, 2H), 4.15 - 3.95 (m, 1H), 3.78 (s, 3H), 3.54 (s, 1H), 2.61 (s, 2H). Example 81 : Imidazoi l .2-alpyridin-3-yl('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl imethanone.
Figure imgf000258_0001
The title compound was prepared in a manner analogous to Example 1, using imidazo[l,2- a]pyridine-3-carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H19N5O, 357.2; m/z found, 358.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.97 - 8.92 (m, 1H), 8.13 (s, 1H), 7.74 - 7.70 (m, 1H), 7.56 - 7.48 (m, 4H), 7.48 - 7.43 (m, 2H), 7.09 (td, J= 6.9, 1.3 Hz, 1H), 4.84 (s, 2H), 3.98 - 3.88 (m, 2H), 2.80 - 2.69 (m, 2H).
Example 82: (5-Chloro-2-methylimidazon .2-alpyridin-3-yl)(2-methyl-3-phenyl-
Figure imgf000258_0002
tetrahvdro-6H-pyrazolo[3.4-c1pyridin-6-yl)methanone.
Figure imgf000258_0003
The title compound was prepared in a manner analogous to Example 1, using 5-chloro-2- methylimidazo[l,2-a]pyridine-3 -carboxylic acid instead of l-naphthoic acid. MS (ESI): mass calcd. for C22H20CIN5O, 405.1 ; m/z found, 406.1 [M+H] +.
Figure imgf000258_0004
(400 MHz, DMSO-r/e) d 8.60 - 8.52 (m, 1H), 7.68 - 7.59 (m, 1H), 7.58 - 7.38 (m, 6H), 4.71 (s, 2H), 3.80 - 3.72 (m, 4H), 3.18 (s, 1H), 2.71 - 2.60 (m, 2H), 2.43 (s, 3H). Example 83: ('2-Methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-clpyridin-6-yl)(' l H- pyrroloi3.2-clpyridin-3-yl)methanone.
Figure imgf000259_0001
The title compound was prepared in a manner analogous to Example 1, using lH-pyrrolo[3,2- c]pyridine-3-carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C21H19N5O, 357.2; m/z found, 358.3 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 12.51 - 11.44 (m, 1H), 9.02 - 8.91 (m, 1H), 8.25 - 8.14 (m, 1H), 7.94 - 7.79 (m, 1H), 7.56 - 7.36 (m, 6H), 4.75 (s, 2H), 3.93 - 3.77 (m, 2H), 3.73 (s, 3H), 2.72 - 2.59 (m, 2H).
Example 84: (Ί -Methyl- 1 H-pyrrolo[2.3-b1pyridin-4-yl)('2-methyl-3-phenyl-2.4.5.7-tetrahvdro- ethanone.
Figure imgf000259_0002
The title compound was prepared in a manner analogous to Example 1, using 1 -methyl- 1H- pyrrolo[2,3-b]pyridine-4-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C22H21N5O, 371.1; m/z found, 372.1 [M+H] +. Ή NMR (400 MHz, DMSO- e) d 8.35 (d, J = 4.7 Hz, 1H), 7.67 - 7.36 (m, 4H), 7.30 (t, J= 7.8 Hz, 1H), 7.22 - 7.02 (m, 2H), 6.47 - 6.29 (m, 1H), 4.82 (s, 1H), 4.46 (d, J= 85.4 Hz, 1H), 3.91 - 3.75 (m, 3H), 3.74 - 3.51 (m, 1H), 3.40 (d, J = 5.6 Hz, 1H), 2.49 - 2.31 (m, 1H), 1.41 (d, = 3.8 Hz, 1H), 1.29 - 1.21 (m, 3H). Example 85: [ 1.2.4lTriazolo[ l .5-a1pyridin-5-vK2-methyl-3-phenyl-2A5.7-tetrahvdro-6H- Pyrazoloi3.4-clpyridin-6-yl)methanone.
Figure imgf000260_0001
The title compound was prepared in a manner analogous to Example 1, using [l,2,4]triazolo[l,5- a]pyridine-5-carboxylic acid instead of 1 -naphthoic acid, triethylamine instead of DIPEA, and ethyl acetate instead of DCM. MS (ESI): mass calcd. for C20H18N6O, 358.2; m/z found, 359.2 [M+H]+. ¾ NMR (300 MHz, DMSO-r/e) d 8.56 (br s, 1H), 8.02 - 7.91 (m, 1H), 7.83 - 7.70 (m, 1H), 7.60 - 7.29 (m, 6H), 5.05 - 4.66 (m, 2H), 3.80 (s, 3H), 3.48 - 3.25 (m, 2H), 2.63 - 2.40 (m, 2H).
Example 86: ('2-Methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-c1pyridin-6-yl)('quinolin-4- vDmethanone.
Figure imgf000260_0002
The title compound was prepared in a manner analogous to Example 1, using quinoline-4- carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H20N4O, 368.2; m/z found, 369.2 [M+H]+. ¾ NMR (600 MHz, Methanol-i/4) d 8.96 (dd, J= 8.6, 4.4 Hz, 1H), 8.17 - 8.11 (m, 1H), 7.93 - 7/ 79 (m, 2H), 7.73 - 7.64 (m, 1H), 7.58 - 7.37 (m, 6H), 5.18 - 4.94 (m, 1.55H), 4.43 - 4.21 (m, 1H), 4.04 (m, 0.35H), 3.87 - 3.67 (m, 3H), 3.48 - 3.44 (m, 1.1H), 2.91 - 2.37 (m, 2H). Example 87: Isoquinolin-4-yl('2-methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-clpyridin- 6-yl)methanone.
Figure imgf000261_0001
The title compound was prepared in a manner analogous to Example 1, using isoquinoline-4- carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H20N4O, 368.2; m/z found, 369.2 [M+H]+. ¾ NMR (600 MHz, Methanol-i 4) d 9.36 (d, J= 10.0 Hz, 1H), 8.49 (d, J = 19.7 Hz, 1H), 8.25 - 8.20 (m, 1H), 7.94 - 7.77 (m, 3H), 7.57 - 7.38 (m, 5H), 5.19 - 4.94 (m, 1.2H), 4.48 - 4.25 (m, 1.21H), 4.03 (s, 0.44H), 3.86 - 3.68 (m, 3H), 3.55 - 3.48 (m, 1.14H), 2.91 - 2.38 (m, 2H).
Example 88: Isoquinolin-l -yl(2-methyl-3-phenyl-2A5.7-tetrahvdro-6H-pyrazolor3.4-clpyridin- 6-yl)methanone.
Figure imgf000261_0002
The title compound was prepared in a manner analogous to Example 1, using isoquinoline-l- carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H20N4O, 368.2; m/z found, 369.2 [M+H]+. Ή NMR (600 MHz, MethanoW/4) d 8.51 (m, , 1H), 8.07 - 7.91 (m, 3H), 7.87 - 7.81 (m, 1H), 7.76 - 7.69 (m, 1H), 7.56 - 7.38 (m, 5H), 5.06 (s, 1.28H), 4.33 - 4.15 (m, 1.45H), 3.86 - 3.68 (m, 3H), 3.42 (t, J= 5.8 Hz, 1.27H), 2.88 - 2.49 (m, 2H). Example 89: ('2-Methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-clpyridin-6-yl)('quinolin-5- ylimethanone.
Figure imgf000262_0001
The title compound was prepared in a manner analogous to Example 1, using quinoline-5- carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H20N4O, 368.2; m/z found, 369.2 [M+H]+. Ή NMR (600 MHz, Methanol-i 4) d 8.93 (td, J= 4.6, 1.6 Hz, 1H), 8.37 - 8.25 (m, 1H), 8.19 - 8.14 (m, 1H), 7.87 (m, 1H), 7.71 - 7.38 (m, 7H), 5.22 - 4.91 (m, 1.54H), 4.48 - 3.94 (m, 1.41H), 3.76 (m, 3H), 3.48 (d, J= 15.2 Hz, 1.24H), 2.93 - 2.30 (m, 1.81H). Example 90: ('2-Methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-c1pyridin-6-yl)('quinolin-6- vDmethanone.
Figure imgf000262_0002
The title compound was prepared in a manner analogous to Example 1, using quinoline-6- carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H20N4O, 368.2; m/z found, 369.2 [M+H]+. ¾ NMR (600 MHz, Methanol-i/4) d 8.96 (s, 1H), 8.49 (d, J= 8.3 Hz, 1H), 8.17 (d, J= 8.7 Hz, 1H), 8.13 (d, J= 1.8 Hz, 1H), 7.88 (d, = 8.6 Hz, 1H), 7.68 - 7.61 (m, 1H), 7.57 - 7.43 (m, 5H), 4.93 (s, 1.23H), 4.66 (s, 0.81H), 4.08 (s, 0.72H), 3.89 - 3.64 (m, 4.24H), 2.80 - 2.65 (m, 2H). Example 91 : ('2-Ethyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-clpyridin-6-yl)('quinolin-6- ylimethanone.
Figure imgf000263_0001
The title compound was prepared in a manner analogous to Example 1, using 2-ethyl-3-phenyl- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 6) instead of 3-(phenyl)-2-methyl- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 1) and quinoline-6-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C24H22N4O, 382.2; m/z found, 383.1
Figure imgf000263_0002
The title compound was prepared in a manner analogous to Example 1, using isoquinoline-5- carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H20N4O, 368.2; m/z found, 369.2 [M+H]+. ¾ NMR (600 MHz, Methanol-i 4) d 9.35 (d, J= 5.8 Hz, 1H), 8.51 (dd, J = 24.1, 6.0 Hz, 1H), 8.31 - 8.23 (m, 1H), 7.89 - 7.70 (m, 3H), 7.57 - 7.39 (m, 5H), 5.19 - 4.91 (m, 1.51H), 4.44 - 3.98 (m, 1.52H), 3.87 - 3.69 (m, 3H), 3.48 (s, 1.13H), 2.95 - 2.36 (m, 1.84H). Example 93: ('2-Methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-clpyridin-6-yl)('quinolin-8- ylimethanone.
Figure imgf000264_0001
The title compound was prepared in a manner analogous to Example 1, using quinoline-8- carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H20N4O, 368.2; m/z found, 369.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 8.96 - 8.91 (m, 1H), 8.51 - 8.43 (m, 1H), 8.12 - 8.03 (m, 1H), 7.78 - 7.59 (m, 3H), 7.56 - 7.39 (m, 5H), 4.95 (d, J= 16.1 Hz, 1H), 4.79 (d, J= 16.1 Hz, 1H), 4.38 (dt, J= 12.5, 4.8 Hz, 0.3H), 4.26 - 3.95 (m, 0.7H), 3.80 (s, 2H), 3.66 (s, 1H), 3.25 (t, J= 5.8 Hz, 1H), 2.77 - 2.59 (m, 0.6H), 2.39 (q, J= 5.5 Hz, 1.4H).
Example 94: t2-Methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazoloi3.4-c1pyridin-6-yl)tauinolin-2- vDmethanone.
Figure imgf000264_0002
The title compound was prepared in a manner analogous to Example 1, using quinoline-2- carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H20N4O, 368.2; m/z found, 369.2 [M+H]+. ¾ NMR (600 MHz, Methanol-i 4) d 8.52 - 8.47 (m, 1H), 8.12 - 8.06 (m, 1H), 8.01 (t, = 8.9, 8.2, 1.5 Hz, 1H), 7.89 - 7.82 (m, 1H), 7.75 - 7.67 (m, 2H), 7.56 - 7.50 (m, 2H), 7.49 - 7.42 (m, 3H), 4.95 (s, 1.4H), 4.73 (s, 0.7H), 4.09 (t, J= 5.9 Hz, 0.73H), 3.83 (s, 1.8H), 3.76 - 3.69 (m, 2.37H), 2.80 - 2.72 (m, 2H). Example 95: ('2-Methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-clpyridin-6-yl)('quinolin-3- ylimethanone.
Figure imgf000265_0001
The title compound was prepared in a manner analogous to Example 1, using quinoline-3 - carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H20N4O, 368.2; m/z found, 369.2 [M+H]+. ¾ NMR (600 MHz, Methanol-i/4) d 8.96 (d, J= 2.1 Hz, 1H), 8.55 - 8.51 (m, 1H), 8.11 (d, = 8.5 Hz, 1H), 8.08 - 8.05 (m, 1H), 7.89 (t, J= 7.7 Hz, 1H), 7.71 (t, = 7.5 Hz, 1H), 7.53 (t, J= 7.5 Hz, 2H), 7.45 (t, J= 5.2 Hz, 3H), 4.93 (s, 1.4H), 4.73 (s, 0.6H), 4.17 - 3.66 (m, 5H), 2.82 - 2.67 (m, 2H).
Example 96: ('8-Fluoroquinolin-4-yl)('2-methyl-3-phenyl-2 5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl )methanone.
Figure imgf000265_0002
The title compound was prepared in a manner analogous to Example 1, using 8-fluoroquinoline- 4-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H19FN4O, 386.1 ; m/z found, 387.1 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 9.04 (dd, J= 5.6, 4.2 Hz, 1H), 7.77 - 7.36 (m, 9H), 5.12 - 4.68 (m, 2H), 4.37 - 4.05 (m, 1H), 4.02 - 3.83 (m, 1H), 3.85 - 3.62 (m, 3H), 2.85 - 2.55 (m, 1H), 2.33 (s, 1H). Example 97: ('2-Methyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-clpyridin-6-yl)('quinoxalin- 5-yl)methanone.
Figure imgf000266_0001
The title compound was prepared in a manner analogous to Example 1, using quinoxaline-5- carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C22H19N5O, 369.1; m/z found, 370.1 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 9.09 - 8.94 (m, 2H), 8.19 (td, J= 8.6, 1.4 Hz, 1H), 7.99 - 7.77 (m, 2H), 7.67 - 7.32 (m, 5H), 4.97 - 4.78 (m, 1H), 4.37 - 4.08 (m, 1H), 3.82 - 3.65 (m, 3H), 3.27 (t, J= 5.7 Hz, 1H), 2.80 - 2.53 (m, 1H), 2.49 - 2.28 (m, 2H). Example 98: ('3-('3-('Difluoromethoxy)phenyl)-2-methyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl)(quinolin-6-yl)methanone.
Figure imgf000266_0002
A microwave vial was charged with [2-methyl-6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H- pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10, 30 mg, 68.1 pmol), 3- (difluoromethoxy)phenylboronic acid (15.4 mg, 81.7 pmol), XPhos-Pd-G2 precatalyst (5.4 mg, 6.81 pmol), saturated aqueous Na2CC (0.23 mL), and l,4-dioxane (0.93 mL). The head space was evacuated under vacuum and refilled with N2 (c3), and then the reaction stirred in a microwave reactor at 110 °C for 30 min. After cooling to room temperature, the mixture was diluted with DCM and H2O, the layers separated, and the aqueous layer extracted with DCM (x2). The combined organics were washed with brine, dried over Na2S04, filtered, and concentrated in vacuo. The residue was purified by preparative HPLC to afford a white foam (13.7 mg, 46% yield). MS (ESI): mass calcd. for C24H20F2N4O2, 434.2; m/z found, 435.2
[M+H]+. (500 MHz, Methanol-i/4) d 8.93 (dd, J= 4.3, 1.7 Hz, 1H), 8.43 (d, J= 8.4 Hz, 1H), 8.15 (d, = 8.6 Hz, 1H), 8.07 (d, J= 1.9 Hz, 1H), 7.83 (dd, = 8.7, 1.9 Hz, 1H), 7.61 - 7.53 (m, 2H), 7.31 - 7.19 (m, 3H), 6.85 (t, J= 73.8 Hz, 1H), 4.79 (s, 2H), 4.10 - 3.58 (m, 5H), 2.70 (s, 2H). Example 99: ('3-('3-Chlorophenyl)-2-methyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-clpyridin-6- yl )(ciuinolin-6-yl )methanone.
Figure imgf000267_0001
The title compound was prepared in a manner analogous to Example 98, using 3- chlorophenylboronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C23H19CIN4O, 402.1 ; m/z found, 403.1 [M+H]+. Ή NMR (500 MHz, Methanol -ί/4) d 8.93 (dd, = 4.3, 1.7 Hz, 1H), 8.44 (d, = 8.3 Hz, 1H), 8.15 (d, = 8.7 Hz, 1H), 8.07 (d, J= 1.9 Hz, 1H), 7.84 (dd, = 8.7, 1.9 Hz, 1H), 7.62 - 7.58 (m, 1H), 7.52 - 7.44 (m, 3H), 7.36 (d, = 7.4 Hz, 1H), 4.79 (s, 2H), 3.77 (s, 5H), 2.69 (s, 2H).
Example 100: ('3-('3-Fluorophenyl)-2-methyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-c1pyridin-6- yl )('quinolin-6-yl jmethanone.
Figure imgf000267_0002
The title compound was prepared in a manner analogous to Example 1, using quinoline-6- carboxylic acid instead of l-naphthoic acid and 3-(3-fluorophenyl)-2-methyl-4,5,6,7-tetrahydro- 2H-pyrazolo[3,4-c]pyridine (Intermediate 4) instead of 3-(phenyl)-2-methyl-4,5,6,7-tetrahydro- 2H-pyrazolo[3,4-c]pyridine (Intermediate 1). MS (ESI): mass calcd. for C23H19FN4O, 386.2; m/z found, 387.2 [M+H]+. ¾ NMR (400 MHz, CDCh) d 8.98 (dd, J= 4.3, 1.7 Hz, 1H), 8.24 (d, J = 8.3 Hz, 1H), 8.19 (d, J= 8.6 Hz, 1H), 7.99 (d, = l.8 Hz, 1H), 7.80 (dd, = 8.7, 1.9 Hz, 1H), 7.52 - 7.41 (m, 2H), 7.17 - 7.09 (m, 2H), 7.05 (ddd, = 9.4, 2.6, 1.6 Hz, 1H), 4.95 (s, 1H), 4.67 (s, 1H), 4.11 - 3.43 (m, 5H), 2.69 (d, J= 37.1 Hz, 2H). Example 101 : ('3-('3.5-Difluorophenyl)-2-methyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-clpyridin-
Figure imgf000268_0001
The title compound was prepared in a manner analogous to Example 1, using quinoline-6- carboxylic acid instead of l-naphthoic acid and 3-(3,5-difluorophenyl)-2-methyl-4, 5,6,7- tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 5) instead of 3-(phenyl)-2-methyl-4, 5,6,7- tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 1). MS (ESI): mass calcd. for
C23H18F2N4O, 404.1; m/z found, 404.9 [M+H]+. ¾ NMR (500 MHz, CDCb) d 8.99 (dd, J =
4.2, 1.7 Hz, 1H), 8.21 (d, = 8.3 Hz, 1H), 8.17 (d, J= 8.7 Hz, 1H), 7.98 (d, = l .8 Hz, 1H), 7.79 (dd, = 8.6, 1.9 Hz, 1H), 7.47 (dd, = 8.3, 4.2 Hz, 1H), 6.91 - 6.83 (m, 3H), 5.06 - 4.56 (m, 2H), 4.08 - 3.56 (m, 5H), 2.70 (d, J= 48.8 Hz, 2H).
Example 102: Benzo[d1isoxazol-3-yl('2-methyl-3-('5-methylthiophen-2-yl)-2.4.5.7-tetrahvdro- 6H-pyrazolo[3.4-c1pyridin-6-yl)methanone.
Figure imgf000268_0002
The title compound was prepared in a manner analogous to Example 1, using benzo[d]isoxazole- 3-carboxylic acid instead of 1 -naphthoic acid and 2-methyl-3-(5-methylthiophen-2-yl)-4, 5,6,7- tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 3) instead of 3-(phenyl)-2-methyl-4, 5,6,7- tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 1). MS (ESI): mass calcd. for C20H18N4O2S, 378.1; m/z found, 379.1 [M+H]+. ¾ NMR (600 MHz, Methanol-i 4) d 7.95 - 7.88 (m, 1H), 7.77 - 7.68 (m, 2H), 7.49 - 7.43 (m, 1H), 7.04 (t, J= 3.3 Hz, 1H), 6.90 - 6.85 (m, 1H), 4.94 (s, 2H), 4.16 - 3.96 (m, 2H), 3.92 - 3.82 (m, 3H), 2.81 (dt, J= 22.4, 5.8 Hz, 2H), 2.56 - 2.51 (m, 3H).
Example 103: (2-Methyl-3-(5-(trifluoromethyl)thiophen-2-yl)- tetrahvdro-6H-
Figure imgf000269_0001
Pyrazoloi3.4-c1pyridin-6-yl)tauinolin-6-yl)methanone.
Figure imgf000269_0002
The title compound was prepared in a manner analogous to Example 98, using 5-trifluoromethyl- thiophene-2-boronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C22H17F3N4OS, 442.1 ; m/z found, 443.1 [M+H]+. Ή NMR (600 MHz, Methanol-A) d 8.95 (dd, = 4.4, 1.7 Hz, 1H), 8.48 (d, = 7.7 Hz, 1H), 8.18 - 8.09 (m, 2H), 7.86 (s, 1H), 7.68 - 7.61 (m, 2H), 7.34 (d, J= 3.8 Hz, 1H), 4.90 (s, 1.15H), 4.64 (s, 0.67H), 4.18 - 3.62 (m, 5.2H), 2.94 - 2.69 (m, 2H).
Example 104: (3-P H-Indol-2-yl)-2-methyl-2A5.7-tetrahvdro-6H-pyrazolo c1pyridin-6-
Figure imgf000269_0003
yl )(ciuinolin-6-yl jmethanone.
Figure imgf000269_0004
The title compound was prepared in a manner analogous to Example 98, using 2-(4, 4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indole instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C25H21N5O, 407.2; m/z found, 408.2
Figure imgf000269_0005
NMR (600 MHz, Methanol-i/4) d 8.93 (d, J= 4.3 Hz, 1H), 8.44 (d, J= 8.3 Hz, 1H), 8.14 (d, J= 8.7 Hz, 1H), 8.09 (s, 1H), 7.85 (s, 1H), 7.64 - 7.57 (m, 2H), 7.42 (s, 1H), 7.16 (t, J= 7.6 Hz, 1H), 7.06 (t, J = 7.5 Hz, 1H), 6.65 (s, 1H), 4.91 (s, 1.1H), 4.63 (s, 0.63H), 4.14 - 3.84 (m, 4.3H), 3.67 (s, 1H), 2.95 - 2.73 (m, 2H).
Example 105: (2-Methyl-3-(T -methyl-lH-indol-2-ylV2A5.7-tetrahydro-6H-pyrazolor3.4- c|pyridin-6-yr)(quinolin-6-yr)methanone.
Figure imgf000270_0001
The title compound was prepared in a manner analogous to Example 98, using l-methyl-2- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indole instead of 3-
(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C26H23N5O, 421.2; m/z found, 422.1 [M+H]+. ¾ NMR (600 MHz, Methanol-i 4) d 8.93 (s, 1H), 8.48 - 8.43 (m, 1H), 8.18 - 8.10 (m, 2H), 7.86 (dd, J= 8.7, 1.9 Hz, 1H), 7.60 (d, J= 7.5 Hz, 2H), 7.44 (d, J= 8.1 Hz, 1H), 7.25 (t, = 7.5 Hz, 1H), 7.11 (t, = 7.3 Hz, 1H), 6.61 (d, = 0.8 Hz, 1H), 4.95 (s, 1H), 4.68 (s, 1H), 4.07 (s, 0.64H), 3.82 - 3.63 (m, 7.36H), 2.75 - 2.55 (m, 2H).
Example 106: ('3-('3.5-Difluorophenyl)-2.7-dimethyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- c1pyridin-6-yl)('quinolin-6-yl)methanone.
Figure imgf000270_0002
Step A: tert-Butyl 3-('3.5-difluorophenyl)-2.7-dimethyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridine-6-carboxylate. A microwave vial was charged with racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) (1.0 g, 2.5 mmol), 3,5-difluorophenylboronic acid (475 mg, 3.0 mmol), XPhos- Pd-G2 precatalyst (197 mg, 0.25 mmol), saturated aqueous Na2CCb (2 mL), and l,4-dioxane (8 mL). The head space was evacuated under vacuum and refilled with N2 (x3), and then the reaction stirred in a microwave reactor at 110 °C for 30 min. After cooling to room temperature, the mixture was diluted with DCM and H2O, the layers separated, and the aqueous layer extracted with DCM (c2). The combined organics were washed with brine, dried over Na2S04, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (S1O2; 0- 50% hexanes-EtOAc) to yield the title compound (538 mg, 60% yield). MS (ESI): mass calcd. for C19H23F2N3O2, 363.2; m/z found, 308.1 [M+H-lBu]_.
Step B: racemic 3-('3.5-Difluorophenyl)-2.7-dimethyl-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4- c]pyridine. A solution of tert-butyl 3-(3,5-difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridine-6-carboxylate (538 mg, 1.48 mmol) in 1 : 1 CH2Ch:TFA (4 mL) was stirred at room temperature for 1 h and then concentrated in vacuo. The residue was purified by preparative HPLC (XB ridge Cl 8 column (5pm, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH4OH) to afford the title compound as a white solid (312 mg, 80% yield). MS (ESI): mass calcd. for C14H15F2N3, 263.1; m/z found, 264.1 [M+H]+.
Step C: ('3-('3.5-Difluorophenyl)-2.7-dimethyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-c1pyridin-6- yl)(quinolin-6-yl)methanone. To a solution of racemic 3-(3,5-difluorophenyl)-2,7-dimethyl- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (50 mg, 0.19 mmol) in DCM (2.0 mL) was added HATU (94 mg, 0.25 mmol), followed by DIPEA (0.098 mL, 0.57 mmol) and quinoline-6- carboxylic acid (36 mg, 0.21 mmol), and the mixture was stirred at room temperature for 1 h.
The reaction mixture was diluted with water and the aqueous layer extracted with DCM (c2). The combined organics were washed with brine, dried over Na2S04, filtered, and concentrated in vacuo. The crude residue was purified by reverse-phase HPLC (XBridge Cl 8 column; 5pm, 100 x 4.6mm; mobile phase of 10-100% ACN in 20 mM NH4OH) to afford the title compound as a white solid (45 mg, 56% yield). MS (ESI): mass calcd. for C24H20F2N4O, 418.1; m/z found,
419.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 8.98 (dd, = 4.2, 1.8 Hz, 1H), 8.49 (dd, J = 8.3, 1.7 Hz, 1H), 8.16 - 8.06 (m, 2H), 7.80 (d, = 8.3 Hz, 1H), 7.62 (dd, = 8.3, 4.2 Hz, 1H), 7.46 - 7.23 (m, 3H), 5.69 (d, J= 63.7 Hz, 1H), 4.75 (s, 1H), 3.85 (s, 3H), 3.71 (s, 1H), 2.91 (s, 1H), 2.35 (s, 1H), 1.51 (s, 3H). Example 107: ('S)-('2.7-Dimethyl-3-('5-methylfuran-2-yl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-e-vDlauinoxalin-e-vDmethanone.
Figure imgf000272_0001
The title compound was prepared in a manner analogous to Example 106, using 4, 4,5,5- tetramethyl-2-(5-methylfuran-2-yl)-l,3,2-dioxaborolane instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 7) in Step A, and quinoxaline-6-carboxylic acid instead of quinoline 6-carboxybc acid in Step C. MS (ESI): mass calcd. for C22H21N5O2, 387.2; m/z found, 388.1 [M+H] +. NMR (500 MHz, CDCb) d 8.91 (s, 2H), 8.24 - 8.13 (m, 2H), 7.85 (s, 1H), 6.45 - 5.80 (m, 2.13H), 4.94 (s, 0.76H), 4.23 - 3.80 (m, 3.67H), 3.47 - 3.13 (m, 1H), 3.04 - 2.60 (m, 1H), 2.37 (s, 2.7H), 1.85 - 1.49 (m, 4.74H). Example 108: ('S)-('2.7-Dimethyl-3-('pyridin-3-yl)-2 5.7-tetrahvdro-6H-pyrazolo[3.4-c|pyridin-
6-yl)(quinoxalin-6-yl)methanone.
Figure imgf000272_0002
The title compound was prepared in a manner analogous to Example 106, using pyri din-3 - ylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)- 2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and quinoxaline-6-carboxylic acid instead of quinoline 6-carboxybc acid in Step C. MS (ESI): mass calcd. for C22H20N6O, 384.1; m/z found, 385.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 9.03 (d, J= 1.0 Hz, 2H), 8.81 - 8.55 (m, 2H), 8.28 - 8.08 (m, 2H), 8.06 - 7.86 (m, 2H), 7.55 (dd, J = 7.8, 4.8 Hz, 1H), 5.67 (s, 1H), 4.73 (s, 1H), 3.79 (d, J= 44.9 Hz, 3H), 3.67 (d, J= 13.4 Hz, 1H), 2.88 (s, 1H), 2.32 (s, 1H), 1.54 (s, 3H).
Example 109: ('S)-('3-('5-Fluoropyridin-3-yl)-2.7-dimethyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- vEmethanone.
Figure imgf000273_0001
The title compound was prepared in a manner analogous to Example 106, using (5-fluoropyridin- 3-yl)boronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)- 2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and quinoxaline-6-carboxylic acid instead of quinoline 6-carboxybc acid in Step C. MS (ESI): mass calcd. for C22H19FN6O, 402.1 ; m/z found, 403.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 9.03 (d, J= 0.7 Hz, 2H), 8.72 - 8.56 (m, 2H), 8.25 - 8.09 (m, 2H), 8.04 - 7.83 (m, 2H), 5.71 (d, J= 44.2 Hz, 1H), 4.67(s, 1H), 3.86 (s, 3H), 3.66 (s, 1H), 2.92 (s, 1H), 2.41 - 2.33 (m, 1H), 1.54 (s, 3H). Example 110: (2 7-Dimethyl-3 -phenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-c1pyridin-6- yl )(quinolin-6-yl jmethanone.
Figure imgf000273_0002
The title compound was prepared in a manner analogous to Example 106, using phenylboronic acid instead of 3,5-difluorophenylboronic acid in Step A. MS (ESI): mass calcd. for C24H22N4O, 382.2; m/z found, 383.1 [M+H]+.
Figure imgf000274_0001
NMR (500 MHz, DMSO-r/e) d 8.97 (d, J= 4.3 Hz, 1H), 8.48 (d, J= 8.1 Hz, 1H), 8.13 - 8.07 (m, 2H), 7.80 (d, J= 8.6 Hz, 1H), 7.63 - 7.58 (m, 1H), 7.56 - 7.40 (m, 5H), 5.74 - 4.54 (m, 1H), 3.80 (s, 4H), 3.34 - 3.05 (m, 1H), 2.85 (s, 1H), 2.33 (d, J =
15.4 Hz, 1H), 1.52 (s, 3H).
Example 111 : (RV(2.7-Dimethyl-3-phenyl-2.4.5.7-tetrahvdro-6H-pyrazolor3.4-c1pyridin-6- yl )(ciuinolin-6-yl jmethanone.
Figure imgf000274_0002
The title compound was obtained as a single enantiomer by chiral SFC purification of racemic (2,7-dimethyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin-6- yl)methanone, Example 110 (Stationary phase: Chiralcel OD-H 5um 250 x 20 mm, Mobile phase: 30% methanol, 70% CO2, retention time = 5.90 min). MS (ESI): mass calcd. for
C24H22N4O, 382.2; m/z found, 383.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.97 (d, J= 4.3
Hz, 1H), 8.48 (d, J= 8.1 Hz, 1H), 8.13 - 8.07 (m, 2H), 7.80 (d, = 8.6 Hz, 1H), 7.63 - 7.58 (m,
1H), 7.56 - 7.40 (m, 5H), 5.74 - 4.54 (m, 1H), 3.80 (s, 4H), 3.34 - 3.05 (m, 1H), 2.85 (s, 1H), 2.33 (d, J= 15.4 Hz, 1H), 1.52 (s, 3H).
Example 112: ('S)-('2.7-Dimethyl-3-phenyl-2 5.7-tetrahvdro-6H-pyrazolo[3.4- 6-
Figure imgf000275_0001
yl )(ciuinolin-6-yl )methanone.
Figure imgf000275_0002
The title compound was obtained as a single enantiomer by chiral SFC purification of racemic (2,7-dimethyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin-6- yl)methanone, Example 110 (Stationary phase: Chiralcel OD-H 5um 250 x 20 mm, Mobile phase: 30% methanol, 70% CO2, retention time = 4.58 min). MS (ESI): mass calcd. for
C24H22N4O, 382.2; m/z found, 383.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.97 (d, J= 4.3 Hz, 1H), 8.48 (d, J= 8.1 Hz, 1H), 8.13 - 8.07 (m, 2H), 7.80 (d, = 8.6 Hz, 1H), 7.63 - 7.58 (m, 1H), 7.56 - 7.40 (m, 5H), 5.74 - 4.54 (m, 1H), 3.80 (s, 4H), 3.34 - 3.05 (m, 11H), 2.85 (s, 1H), 2.33 (d, J= 15.4 Hz, 1H), 1.52 (s, 3H).
Example 113: ('7-Methyl-2.3-diphenyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-c1pyridin-6- yl )(ciuinolin-6-yl jmethanone.
Figure imgf000275_0003
The title compound was prepared in a manner analogous to Example 1, using 7-methyl-2,3- diphenyl-4, 5, 6, 7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 26) and quinoline-6- carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C29H24N4O, 444.2; m/z found, 445.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 8.99 (dd, J= 4.2, 1.7 Hz, 1H), 8.50 (dd, = 8.4, 1.7 Hz, 1H), 8.26 - 8.06 (m, 2H), 7.84 (dd, = 8.6, 1.9 Hz, 1H), 7.62 (dd, = 8.3, 4.2 Hz, 1H), 7.46 - 7.10 (m, 10H), 5.76 (s, 1H), 4.13 - 3.39 (m, 2H), 2.95 (s, 1H), 2.21 (s, 1H), 1.61 (d, J = 6.1 Hz, 3H).
Example 114: ('R)-('7-Methyl-2.3-diphenyl-2 5.7-tetrahvdro-6H-pyrazolo[3.4- 6-
Figure imgf000276_0001
ylKquinolin-O-yllmethanone.
Figure imgf000276_0002
The title compound was obtained as a single enantiomer by chiral SFC purification (Chiralcel OD, 5um, 250 x 20 mm, Mobile phase: 40% methanol, 60% CO2; 100% single (R) enantiomer; 9.0 min retention time) of Example 113 [(7-methyl-2,3-diphenyl-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridin-6-yl)(quinolin-6-yl)methanone]. MS (ESI): mass calcd. for C29H24N4O, 444.2; m/z found, 445.1 [M+H]+.
Figure imgf000276_0003
NMR (400 MHz, DMSO-r/e) d 8.99 (dd, J= 4.2, 1.7 Hz, 1H), 8.50 (dd, J= 8.4, 1.7 Hz, 1H), 8.26 - 8.06 (m, 2H), 7.84 (dd, J= 8.6, 1.9 Hz, 1H), 7.62 (dd, J= 8.3, 4.2 Hz, 1H), 7.46 - 7.10 (m, 1 OH), 5.76 (s, 1H), 4.13 - 3.39 (m, 2H), 2.95 (s, 1H), 2.21 (s, 1H), 1.61 (d, = 6.7 Hz, 3H).
Example 115: -('7-Methyl-2.3-diphenyl-2.4.5.7-tetrahvdro-6H-pyrazoloi3.4-c1pyridin-6- yl )(quinolin-6-yl jmethanone.
Figure imgf000276_0004
The title compound was obtained as a single enantiomer by chiral SFC purification (Chiralcel OD, 5um, 250 x 20 mm, Mobile phase: 40% methanol, 60% CO2; 100% single (S) enantiomer; 4.6 min retention time) of Example 113 [(7-methyl-2,3-diphenyl-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridin-6-yl)(quinolin-6-yl)methanone]. MS (ESI): mass calcd. for C29H24N4O, 444.2; m/z found, 445.1 [M+H] +. Ή NMR (400 MHz, DMSO- e) d 8.99 (dd, J= 4.2, 1.7 Hz, 1H), 8.50 (dd, J= 8.4, 1.7 Hz, 1H), 8.26 - 8.06 (m, 2H), 7.84 (dd, J= 8.6, 1.9 Hz, 1H), 7.62 (dd, J= 8.3, 4.2 Hz, 1H), 7.46 - 7.10 (m, 1 OH), 5.76 (s, 1H), 4.13 - 3.39 (m, 2H), 2.95 (s, 1H), 2.21 (s, 1H), 1.61 (d, = 6.7 Hz, 3H). Example 116: (S)-(3-Chloro-5-(trifluoromethoxy)phenyl)(3-(3-chlorophenyl)-2.7-dimethyl- 2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-clpyridin-6-yl)methanone.
Figure imgf000277_0001
The title compound was prepared in a manner analogous to Example 106, using 3- chlorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 3-chloro-5-(trifluoromethoxy)benzoic acid instead of quinoline 6-carboxybc acid in Step C. MS (ESI): mass calcd. for C22H18CI2F3N3O2, 484.1; m/z found, 485.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 7.69 (s, 1H), 7.60 (s, 1H), 7.58 - 7.50 (m,
3H), 7.50 - 7.41 (m, 2H), 5.54 (d, J= 7.5 Hz, 1H), 4.58 (s, 1H), 3.77 (d, J= 29.7 Hz, 3H), 3.23 - 2.68 (m, 2H), 2.31 (d, J= 15.3 Hz, 1H), 1.47 (d, J= 6.7 Hz, 3H).
Example 117: ('S)-('3-('3-Chlorophenyl)-2.7-dimethyl-2 5.7-tetrahvdro-6H-pyrazolo[3.4- c1pyridin-6-vQ( 1 -phenyl- 1 H- 1.2.4-triazol-3-yl)methanone.
Figure imgf000277_0002
The title compound was prepared in a manner analogous to Example 106, using 3- chlorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 1 -phenyl- 1H-1, 2, 4-triazole-3 -carboxylic acid instead of quinoline 6-carboxybc acid in Step C. MS (ESI): mass calcd. for C23H21CIN6O, 432.15; m/z found, 433.2 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 9.42 (d, J= 3.4 Hz, 1H), 7.96 - 7.84 (m, 2H), 7.65 - 7.42 (m, 8H), 5.59 (q, J= 6.7 Hz, 1H), 3.77 (d, J= 31.8 Hz, 3H), 3.35 - 3.08 (m, 1H), 2.87 - 2.66 (m, 1H), 2.47 - 2.33 (m, 1H), 1.53 (dd, = 34.2, 6.8 Hz, 3H).
Example 118: ('S)-('3-('3-Chlorophenyl)-2.7-dimethyl-2 5.7-tetrahvdro-6H-pyrazolo[3.4- rophenyl )- l H- l .2.4-triazol-3-yl)methanone.
Figure imgf000278_0001
The title compound was prepared in a manner analogous to Example 106, using 3- chlorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 5 -ethyl- l-(2-fluorophenyl)-l H-l, 2, 4-triazole-3 -carboxylic acid instead of quinoline 6-carboxylic acid in Step C. MS (ESI): mass calcd. for C25H24CIFN6O, 478.1; m/z found, 479.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 7.82 - 7.65 (m, 2H), 7.63 - 7.41 (m, 6H), 5.57 (q, J= 6.8 Hz, 1H), 3.77 (d, J= 22.4 Hz, 3H), 3.38 - 3.01 (m, 2H), 2.79 - 2.61 (m, 3H), 2.48 - 2.29 (m, 1H), 1.50 (dd, = 27.7, 6.7 Hz, 3H), 1.20 (td, J= 7.5, 4.9 Hz, 3H). Example 119: ('S)-('3-('3-Chlorophenyl)-2.7-dimethyl-2 5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl )('4-('hvdroxymethyl )pyridin-2-yl imethanone.
Figure imgf000279_0001
The title compound was prepared in a manner analogous to Example 106, using 3- chlorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 4-(hydroxymethyl)picobnic acid instead of quinoline 6- carboxylic acid in Step C. MS (ESI): mass calcd. for C21H21CIN4O2, 396.1; m/z found, 397.0 [M+H] +. NMR (500 MHz, DMSO-r/e) d 8.58 - 8.44 (m, 1H), 7.64 - 7.37 (m, 6H), 5.58 (q, J = 6.7 Hz, 1H), 4.59 (s, 2H), 3.83 - 3.69 (m, 4H), 3.31 - 3.01 (m, 2H), 2.86 - 2.59 (m, 1H), 2.47 - 2.25 (m, 1H), 1.46 (dd, = 9.6, 6.8 Hz, 3H). Example 120: ('S)-('3-('3-Chlorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000279_0002
c1pyridin-6-yl)('5-('methoxymethyl)pyridin-3-yl)methanone.
Figure imgf000279_0003
The title compound was prepared in a manner analogous to Example 106, using 3- chlorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 5-(methoxymethyl)nicotinic acid instead of quinoline 6- carboxylic acid in Step C. MS (ESI): mass calcd. for C22H23CIN4O2, 410.1; m/z found, 411.1 [M+H] +. NMR (500 MHz, DMSO-r/e) d 8.65 - 8.54 (m, 2H), 7.79 (s, 1H), 7.64 - 7.42 (m, 4H), 5.57 (d, J= 6.8 Hz, 1H), 4.51 (s, 2H), 3.54 - 3.6 (m, 1H), 3.80 (s, 3H), 3.49 (s, 3H), 3.29 - 2.71 (m, 2H), 2.33 (d, J= 15.6 Hz, 1H), 1.48 (d, J= 6.8 Hz, 3H).
Example 121 : ('S)-('3-('3-Chlorophenyl)-2.7-dimethyl-2 5.7-tetrahvdro-6H-pyrazolo[3.4- c1pyridin-6-yl)t6-isopropoxypyridin-3-yl)methanone.
Figure imgf000280_0001
The title compound was prepared in a manner analogous to Example 106, using 3- chlorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 6-isopropoxynicotinic acid instead of quinoline 6-carboxylic acid in Step C. MS (ESI): mass calcd. for C23H25CIN4O2, 424.1; m/z found, 425.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 8.28 (s, 1H), 7.78 (d, J= 8.2 Hz, 1H), 7.63 - 7.41 (m, 4H), 6.81 (dd, J= 8.5, 0.8 Hz, 1H), 5.46 (d, J= 38.2 Hz, 1H), 5.41 - 5.21 (m, 1H), 3.78 (d, J= 3.9 Hz,
4H), 3.33 - 2.81 (m, 2H), 2.41 - 2.29 (m, 1H), 1.46 (d, = 6.8 Hz, 3H), 1.30 (dd, J= 6.2, 1.8 Hz, 6H).
Example 122: ('S)-('3-('3-Chlorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000281_0001
pyridin-O-ylimethanone.
Figure imgf000281_0002
The title compound was prepared in a manner analogous to Example 106, using 3- chlorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 5-isopropoxynicotinic acid instead of quinoline 6-carboxybc acid in Step C. MS (ESI): mass calcd. for C23H25CIN4O2, 424.1; m/z found, 425.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 8.33 (d, J= 2.8 Hz, 1H), 8.17 (d, J= 17.5 Hz, 1H), 7.63 - 7.37 (m, 5H), 5.56 (d, J= 7.4 Hz, 1H), 4.83 - 4.58 (m, 1H), 3.80 (s, 3H), 3.63 - 3.53 (m, 1H), 3.35 - 2.76 (m, 2H), 2.31 (d, J= 15.2 Hz, 1H), 1.47 (d, J= 6.9 Hz, 3H), 1.28 (dd, J= 6.0, 2.3 Hz, 6H). Example 123: (SVBenzordirE31dioxol-4-yl(3-(3-chlorophenylV2.7-dimethyl-2.4.5.7- tetrahvdro-6H-pyrazolo[3.4-c1pyridin-6-yl)methanone.
Figure imgf000281_0003
The title compound was prepared in a manner analogous to Example 106, using 3- chlorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and benzo[d][l,3]dioxole-4-carboxylic acid instead of quinoline 6- carboxylic acid in Step C. MS (ESI): mass calcd. for C22H20CIN3O3, 409.1; m/z found, 410.1 [M+H] +. NMR (500 MHz, DMSO-r/e) d 7.60 - 7.41 (m, 4H), 7.06 - 6.78 (m, 3H), 6.07 (d, J = 12.4 Hz, 2H), 5.55 (q, J= 6.8 Hz, 1H), 3.76 (d, J= 25.2 Hz, 3H), 3.65 (dd, J= 13.9, 5.1 Hz, 1H), 3.36 - 3.00 (m, 1H), 2.76 - 2.57 (m, 1H), 2.35 (d, J= 14.1 Hz, 1H), 1.42 (dd, J= 23.3, 6.7
Hz, 3H).
Example 124: ('S)-6-('3-('3-Chlorophenyl)-2.7-dimethyl-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4- c1pyridine-6-carbonyl)benzoid1oxazol-2t3H)-one.
Figure imgf000282_0001
The title compound was prepared in a manner analogous to Example 106, using 3- chlorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 2-oxo-2,3-dihydrobenzo[d]oxazole-6-carboxylic acid instead of quinoline 6-carboxylic acid in Step C. MS (ESI): mass calcd. for C22H19CIN4O3, 422.1 ; m/z found, 423.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 7.61 - 7.43 (m, 4H), 7.37 (s, 1H), 7.27 - 7.09 (m, 2H), 5.49 (s, 1H), 3.78 (s, 5H), 2.82 (s, 2H), 2.32 (s, 1H), 1.46 (d, J= 6.8 Hz, 3H).
Example 125: ('S)-('3-('3-Chlorophenyl)-2.7-dimethyl-2 5.7-tetrahvdro-6H-pyrazolo[3.4- c1pyridin-6-yl)t2-methylbenzold1oxazol-6-yl)methanone.
Figure imgf000283_0001
The title compound was prepared in a manner analogous to Example 106, using 3- chlorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 2-methylbenzo[d]oxazole-6-carboxylic acid instead of quinoline 6-carboxybc acid in Step C. MS (ESI): mass calcd. for C23H21CIN4O2, 420.1; m/z found, 421.1 [M+H] +. NMR (500 MHz, DMSO-r/e) d 7.83 - 7.64 (m, 2H), 7.63 - 7.52 (m, 2H), 7.50 -
7.33 (m, 2H), 5.56 (s, 1H), 4.40 (s, 1H), 3.79 (s, 3H), 3.62 (s, 1H), 3.24 (s, 1H), 2.98 - 2.73 (m, 1H), 2.64 (s, 3H), 2.35 (d, J= 42.4 Hz, 1H), 1.47 (d, J= 6.7 Hz, 3H). Example 126: ('3-('3-Chlorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000283_0002
6-yl)('furol3.2-b1pyridin-6-yl)methanone.
Figure imgf000283_0003
The title compound was prepared in a manner analogous to Example 106, using 3-chloroboronic acid instead of 3,5-difluorophenylboronic acid in Step A and furo[3,2-b]pyridine-6-carboxylic acid instead of quinoline-6-carboxylic acid in Step C. MS (ESI): mass calcd. for C22H19CIN4O2, 406.1; m/z found, 407.1 [M+H]+.
Figure imgf000283_0004
NMR (500 MHz, CDCh) d 8.67 (d, J= 1.8 Hz, 1H), 7.95
(d, J= 2.3 Hz, 1H), 7.89 (s, 1H), 7.46 - 7.37 (m, 2H), 7.36 - 7.32 (m, 1H), 7.23 (dt, J= 6.9, 1.8 Hz, 1H), 7.04 (dd, = 2.3, 1.0 Hz, 1H), 5.87 (s, 0.47H), 5.15 - 4.65 (m, 0.72H), 3.81 (s, 3.66H), 3.34 (s, 1H), 2.83 (s, 1H), 2.54 - 2.38 (m, 1H), 1.61 (s, 3.15H).
Example 127: ('R)-('3-('3-Chlorophenyl)-2.7-dimethyl-2 5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl)('furo[3.2-blpyridin-6-yl)methanone.
Figure imgf000284_0001
The title compound was obtained as a single enantiomer by chiral SFC purification of racemic (3-(3-chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(furo[3,2- b]pyridin-6-yl)methanone, Example 126 (Stationary phase: Lux 5m Cellulose-l 5um 250 x 21 mm, Mobile phase: 25% methanol, 75% CO2, retention time = 8.19 min). MS (ESI): mass calcd. for C22H19CIN4O2, 406.1 ; m/z found, 407.1 [M+H]+. ¾ NMR (500 MHz, CDCb) d 8.67 (d, J = 1.8 Hz, 1H), 7.95 (d, J= 2.3 Hz, 1H), 7.89 (s, 1H), 7.46 - 7.37 (m, 2H), 7.36 - 7.32 (m, 1H),
7.23 (dt, = 6.9, 1.8 Hz, 1H), 7.04 (dd, = 2.3, 1.0 Hz, 1H), 5.87 (s, 0.47H), 5.15 - 4.65 (m, 0.72H), 3.81 (s, 3.66H), 3.34 (s, 1H), 2.83 (s, 1H), 2.54 - 2.38 (m, 1H), 1.61 (s, 3.15H).
Example 128: ('S)-('3-('3-Chlorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000284_0002
c1pyridin-6-yl)('furo[3.2-b1pyridin-6-yl)methanone.
Figure imgf000284_0003
The title compound was obtained as a single enantiomer by chiral SFC purification of racemic (3-(3-chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(furo[3,2- b]pyridin-6-yl)methanone, Example 126 (Stationary phase: Lux 5m Cellulose-l 5um 250 x 21 mm, Mobile phase: 25% methanol, 75% CO2, retention time = 5.57 min). MS (ESI): mass calcd for C22H19CIN4O2, 406.1 ; m/z found, 407.1 [M+H]+. ¾ NMR (500 MHz, CDCb) d 8.67 (d, J = 1.8 Hz, 1H), 7.95 (d, J= 2.3 Hz, 1H), 7.89 (s, 1H), 7.46 - 7.37 (m, 2H), 7.36 - 7.32 (m, 1H), 7.23 (dt, = 6.9, 1.8 Hz, 1H), 7.04 (dd, = 2.3, 1.0 Hz, 1H), 5.87 (s, 0.47H), 5.15 - 4.65 (m, 0.72H), 3.81 (s, 3.66H), 3.34 (s, 1H), 2.83 (s, 1H), 2.54 - 2.38 (m, 1H), 1.61 (s, 3.15H).
Example 129: ('S)-('3-('3-Chlorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000285_0001
clpyridin-6-yl)('furo[3.2-blpyridin-2-yl)methanone.
Figure imgf000285_0002
The title compound was prepared in a manner analogous to Example 106, using 3- chlorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and furo[3,2-b]pyridine-2-carboxylic acid instead of quinoline 6- carboxylic acid in Step C. MS (ESI): mass calcd. for C22H19CIN4O2, 406.1; m/z found, 407.0 [M+H]+. (600 MHz, Methanol-i/4) 5 8.61 (d, = 4. l Hz, 1H), 8.12 (d, J= 8.1 Hz, 1H), 7.57 - 7.46 (m, 5H), 7.44 - 7.38 (m, 1H), 5.74 - 5.37 (m, 1H), 4.79 - 4.32 (m, 1.15H), 3.88 - 3.74 (m, 3H), 3.60 - 3.46 (m, 0.64H), 3.08 - 2.77 (m, 1.2H), 2.66 - 2.55 (m, 1H), 1.70 (d, J = 94.5 Hz, 3H).
Example 130: ('S)-('3-('3-Chlorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000286_0001
c1pyridin-6-yl)n H-pyrroloi2.3-b1pyridin-6-yl)methanone.
Figure imgf000286_0002
The title compound was prepared in a manner analogous to Example 106, using 3- chlorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and lH-pyrrolo[2,3-b]pyridine-6-carboxylic acid instead of quinoline 6-carboxybc acid in Step C. MS (ESI): mass calcd. for C22H20CIN5O, 405.1; m/z found, 406.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 11.82 (s, 1H), 8.07 (d, J= 7.8 Hz, 1H), 7.61 - 7.44 (m, 5H), 7.29 (d, J= 8.0 Hz, 1H), 6.54 (d, J= 7.6 Hz, 1H), 5.75 - 5.49 (m, 1H), 5.24 - 5.01 (m, 1H), 3.82 - 3.67 (m, 3H), 3.24 (d, = 12.3 Hz, 1H), 2.95 - 2.67 (m, 1H), 2.34 (d, = 15.4 Hz, 1H), 1.50 (d, J= 6.7 Hz, 3H).
Example 131 : ('S)-('3-('3-Chlorophenyl)-2.7-dimethyl-2 5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl)( 1.5-naphthyridin-2-yl jmethanone.
Figure imgf000286_0003
The title compound was prepared in a manner analogous to Example 106, using 3- chlorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and l,5-naphthyridine-2-carboxybc acid instead of quinoline 6- carboxylic acid in Step C. MS (ESI): mass calcd. for C23H20CIN5O, 417.14; m/z found, 418.2 [M+H] +. NMR (500 MHz, DMSO-r/e) d 9.14 - 9.03 (m, 1H), 8.67 - 8.41 (m, 2H), 8.02 - 7.80 (m, 2H), 7.63 - 7.44 (m, 4H), 5.73 - 5.53 (m, 1H), 3.81 (s, 3H), 3.71 (s, 1H), 3.20 - 3.10
(m, 1H), 2.93 - 2.74 (m, 1H), 2.38 - 2.28 (m, 1H), 1.54 (dd, J= 6.8, 2.1 Hz, 3H).
Example 132: (3-(3-ChlorophenylV2.7-dimethyl-2.4.5.7-tetrahvdro-6H-pyrazolor3.4-c1pyridin-
6-yl )(quinoxalin-6-yl )methanone.
Figure imgf000287_0001
The title compound was prepared in a manner analogous to Example 106, using 3-chloroboronic acid instead of 3,5-difluorophenylboronic acid in Step A and quinoxaline-6-carboxylic acid instead of quinobne-6-carboxylic acid in Step C. MS (ESI): mass calcd. for C23H20CIN5O, 417.1; m/z found, 418.1 [M+H]+. Ή NMR (600 MHz, MethanoW/4) d 8.98 (s, 2H), 8.27 - 8.17 (m, 2H), 7.98 - 7.88 (m, 1H), 7.57 - 7.46 (m, 3H), 7.42 - 7.38 (m, 1H), 5.82 (s, 0.66H), 4.96 - 4.85
(m, 0.75H), 3.81 (m, 3.89H), 3.55 - 3.44 (m, 0.7H), 2.87 (s, 1H), 2.65 - 2.37 (m, 1H), 1.71 - 1.51 (m, 3H).
Example 133: ('R)-('3-('3-Chlorophenyl)-2.7-dimethyl-2 5.7-tetrahvdro-6H-pyrazolo[3.4- c1pyridin-6-yl)tauinoxalin-6-yl)methanone.
Figure imgf000288_0001
The title compound was obtained as a single enantiomer by chiral SFC purification of racemic (3-(3-chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxalin-6-yl)methanone, Example 132 (Stationary phase: Lux 5m Cellulose- 1 5um 250 x 21 mm, Mobile phase: 35% methanol, 65% CO2, retention time = 7.84 min). MS (ESI): mass calcd. for C23H20CIN5O, 417.1 ; m/z found, 418.1 [M+H]+. Ή NMR (600 MHz, Methanol -ah) d 8.98 (s, 2H), 8.27 - 8.17 (m, 2H), 7.98 - 7.88 (m, 1H), 7.57 - 7.46 (m, 3H), 7.42 - 7.38 (m, 1H), 5.82 (s, 0.66H), 4.96 - 4.85 (m, 0.75H), 3.81 (m, 3.89H), 3.55 - 3.44 (m, 0.7H), 2.87 (s, 1H),
2.65 - 2.37 (m, 1H), 1.71 - 1.51 (m, 3H).
Example 134: ('S)-('3-('3-Chlorophenyl)-2.7-dimethyl-2 5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl )('quinoxalin-6-yl jmethanone.
Figure imgf000288_0002
The title compound was obtained as a single enantiomer by chiral SFC purification of racemic (3-(3-chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxalin-6-yl)methanone, Example 132 (Stationary phase: Lux 5m Cellulose- 1 5um 250 x 21 mm, Mobile phase: 35% methanol, 65% CO2, retention time = 5.11 min). MS (ESI): mass calcd. for C23H20CIN5O, 417.1 ; m/z found, 418.1 [M+H]+. Ή NMR (600 MHz, Methanol -ah) d 8.98 (s, 2H), 8.27 - 8.17 (m, 2H), 7.98 - 7.88 (m, 1H), 7.57 - 7.46 (m, 3H), 7.42 - 7.38 (m, 1H), 5.82 (s, 0.66H), 4.96 - 4.85 (m, 0.75H), 3.81 (m, 3.89H), 3.55 - 3.44 (m, 0.7H), 2.87 (s, 1H), 2.65 - 2.37 (m, 1H), 1.71 - 1.51 (m, 3H).
Example 135: (SV(8-Bromoquinoxalin-6-vn(3-(3-chlorophenylV2.7-dimethyl-2.4.5.7- tetrahvdro-6H-pyrazolo[3.4-clpyridin-6-yl)methanone.
Figure imgf000289_0001
The title compound was prepared in a manner analogous to Example 106, using 3- chlorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3-
(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 8-bromoquinoxaline-6-carboxybc acid instead of quinoline 6- carboxylic acid in Step C. MS (ESI): mass calcd. for C23Hi9BrClN50, 495.0; m/z found, 496.0 z,
Figure imgf000289_0002
The title compound was prepared in a manner analogous to Example 106, using tert-butyl 7- ethyl-2-methyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridine-6-carboxylate (Intermediate 27) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) and 3-fluorophenylboronic acid instead of 3,5-difluorophenylboronic acid in Step A. MS (ESI): mass calcd. for C25H23FN4O, 414.2; m/z found, 415.2 [M+H] +.
Figure imgf000290_0001
(500 MHz, CDCb) d 8.96 (dd, J= 4.2, 1.7 Hz, 1H), 8.25 - 8.10 (m, 2H), 7.94 - 7.85 (m, 1H),
7.78 - 7.68 (m, 1H), 7.51 - 7.38 (m, 2H), 7.18 - 6.99 (m, 3H), 5.92 - 5.83 (m, 0.54H), 5.02 -
4.78 (m, 0.79H), 3.91 - 3.64 (m, 3.81H), 3.44 - 3.07 (m, 1H), 2.99 - 2.61 (m, 1H), 2.59 - 2.32 (m, 1H), 2.16 - 1.78 (m, 3H), 1.25 - 1.18 (m, 1H), 0.97 - 0.90 (m, 1H). Example 137: i('7S)-3-('3.5-Difluorophenyl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-[2-('2-fluoroethoxy)phenyl1methanone.
Figure imgf000290_0002
The title compound was prepared in a manner analogous to Example 1, using (S)-3-(3,5- difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine, and 2-(2- fluoroethoxy)benzoic acid (Intermediate 13) instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H22F3N3O2, 429.2; m/z found, 430.1 [M+H]+. ¾ NMR (CDCb): d 7.37-7.27 (m, 2H), 7.07-7.02 (m, 1H), 6.94-6.82 (m, 4H), 5.98-5.91 and 4.99-4.95 (m, 1H), 4.89-4.60 (m, 2H), 4.49- 4.38 and 3.63-3.55 (m, 1H), 4.37-4.05 (m, 2H), 3.86 and 3.79 (s, 3H), 3.39-3.32 and 2.55-2.44 (m, 1H), 3.22-3.16 and 2.32-2.22 (m, 1H), 3.12-2.97 and 2.95-2.88 (m, 1H), 1.62-1.58, 1.47-1.45 and 1.39-1.37 (m, 3H). Example 138: ('S)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000291_0001
c1pyridin-6-yl)('4-('2-fluoroethoxy)phenyl)methanone.
Figure imgf000291_0002
The title compound was prepared in a manner analogous to Example 1, using (S)-3-(3,5- difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine, and 4-(2- fluoroethoxy)benzoic acid (Intermediate 16) instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H22F3N3O2, 429.2; m/z found, 430.3 [M+H]+. ¾ NMR (400 MHz, CDCh) d 7.43 (d, J = 8.7 Hz, 2H), 6.97 (d, J= 8.7 Hz, 2H), 6.94-6.85 (m, 3H), 5.55 (s, 1H), 4.87-4.81 (m, 1H), 4.75- 4.70 (m, 1H), 4.32-4.27 (m, 1H), 4.25-4.21 (m, 1H), 3.85 (s, 3H), 3.21 (s, 1H), 2.87-2.73 (m,
2H), 2.45 (dd, J= 15.2, 3.5 Hz, 1H), 2.31 (s, 1H) 1.59 (d, J= 6.8 Hz, 3H).
Example 139: ('S)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000291_0003
clpyridin-6-yl)(3-(2-fluoroethoxy)phenyl)methanone.
Figure imgf000291_0004
The title compound was prepared in a manner analogous to Example 1, using (S)-3-(3,5- difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine, and 3-(2- fluoroethoxy)benzoic acid (Intermediate 15) instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H22F3N3O2, 429.2; m/z found, 430.3 [M+H]+. ¾ NMR (400 MHz, CDCh) d 7.33-7.26 (m, 1H), 6.99-6.90 (m, 3H), 6.88-6.75 (m, 3H), 5.80 (s, 0.5H), 4.95 (s, 0.5H), 4.82-4.52 (m, 1H), 4.75 (m, 1H), 4.63 (m, 1H), 4.17 (m, 1H), 4.15-4.12 (m, 1H), 3.79 (s, 3H), 3.21-3.05 (m, 1H), 2.76- 2.63 (m, 1H), 2.37 (m, 1H), 1.54 (s, 3H).
Example 140: (' V)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl)(3-(2-(fluoro- ethoxy)phenyl)methanone.
Figure imgf000292_0001
Figure imgf000292_0002
Step A: (SV2-(3-(3-(3.5-DifluorophenylV2.7-dimethyl-4.5.6.7-tetrahvdro-2H-pyrazolor3.4- c|pyridine-6-carbonyl)phenoxy)ethyl 4-methylbenzenesulfonate. The title compound was prepared in a manner analogous to Example 1, using (S)-3-(3,5-difluorophenyl)-2,7-dimethyl-
4.5.6.7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methy 1-3 -phenyl-
4.5.6.7-tetrahydro-2H-pyrazolo[3,4-c]pyridine, and 3-(2-(tosyloxy)ethoxy)benzoic acid
(Intermediate 36) instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C30H29F2N3O5S, 581.2; m/z found, 582.0 [M+H]+.
Step B: (' V)-('3-('3.5-difluorophenyl)-2.7-dimethyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-c1pyridin-
6-yl)(3-(2-(fluoro- ethoxy)phenyl)methanone. [18F]fluoride in a shipping vial from PETNET
Figure imgf000292_0003
Solutions Inc. (San Diego, CA ETSA) is transferred onto and trapped on an ion exchange cartridge. It is then eluted into the reaction vessel (RV1) of the Synthra RNPlus® module with a solution of potassium carbonate (0.75 mg) and Kryptofix 222 (7.2 mg) in 0.8 mL of
acetonitrile/water (6/2, v/v). After the solvent was evaporated under a stream of nitrogen at 85°C and under vacuum, anhydrous CH3CN (0.5 mL) was added, this process was repeated, and the temperature increased to 110 °C for 3.5 min. The reaction vial was then cooled to 70°C before a solution of 3.0 mg of (S)-2-(3-(3-(3,5-difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H- pyrazolo[3,4-c]pyridine-6-carbonyl)phenoxy)ethyl 4-methylbenzenesulfonate in 0.7 mL anhydrous MeCN was added to reaction vessel. The reaction mixture is heated at 95°C for 10 min. The reactor is cooled to 40 °C and diluted with water (4.3 mL) and the contents is transferred into the HPLC injector loop for purification. Purification is performed by HPLC using a semi-preparative Eclipse XDB-C18 column (5 pm, 9.4 mm x 250 mm) with a mixture of 10 mM NELOAc and MeCN (50:50 v/v) at a flow rate of 4 mL/min with UV detection at 254 nm. The purified radiotracer solution was diluted with 30 mL of water and passed through a
SepPak Light C-18 cartridge. The C-18 cartridge was further washed withlO mL of water before 0.5 mL EtOH was used to elute the tracer. The tracer solution was further diluted with 4.5 mL of saline. The final formulation contains an ethanol concentration of 10%, suitable for intravenous (IV) injection.
Example 141 : ('S)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000293_0001
c1pyridin-6-ylj(2-fluoro-3-(2-fluoroethoxyjphenyljmethanone.
Figure imgf000293_0002
The title compound was prepared in a manner analogous to Example 1, using (S)-3-(3,5- difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine, and 2-fluoro-3-(2- fluoroethoxy)benzoic acid (Intermediate 19) instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H22F4N3O2, 447.1 ; m/z found, 448.0 [M+H]+. ¾ NMR (500 MHz, CDCh) d 7.15 (t, J = 7.9 Hz, 1H), 7.09-7.05 (m, 1H), 7.05-6.97 (m, 1H), 6.91-6.86 (m, 3H), 5.93 (d, J= 7.1 Hz,
0.6H), 4.95 (dd, J= 13.1, 5.3 Hz, 0.4H), 4.85 (m, 1H), 4.76-4.73 (m, 1H), 4.36 (t, J= 4.2 Hz, 1H), 4.32-4.27 (m, 1H), 3.89 (s, 1.9H), 3.83 (s, 1.1H), 3.69 (dd, J= 13.9, 5.2 Hz, 0.6H), 3.33 (s, 0.6H), 3.09 (s, 0.4H), 2.56-2.47 (m, 0.4H), 2.41-2.15 (m, 2H), 1.63 (d, J= 6.8 Hz, 1.9H), 1.49 (s,
1.1H). (Fractions of H’s that overlap with solvent are not reported). Example 142: ('S)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000294_0001
c1pyridin-6-yl)t2-fluoro-5-t2-fluoroethoxy)phenyl)methanone.
Figure imgf000294_0003
The title compound was prepared in a manner analogous to Example 1, using (S)-3-(3,5- difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine, and 2-fluoro-5-(2- fluoroethoxy)benzoic acid (Intermediate 22) instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H22F4N3O2, 447.1 ; m/z found, 448.0 [M+H]+. Ή NMR (400 MHz, CDCh) d 7.06 (t, J = 8.7 Hz, 1H), 7.00-6.80 (m, 5H), 5.92 (d, J= 6.9 Hz, 0.5H), 5.04-4.85 (m, 0.5H), 4.73-4.66 (m, 1H), 4.31-4.22 (m, 1H), 4.22-4.16 (m, 1H), 3.89 (s, 1.8H), 3.83 (s, 1.2H), 3.71 (dd, = l3.8, 5.1 Hz, 0.7H), 3.35 (m, 0.7H), 3.10 (t, J= 12.7 Hz, 0.3H), 2.84 (ddd, J= 17.5, 12.3, 5.4 Hz, 0.3H), 2.53 (m, 0.4H), 2.40 (dd, J= 15.4, 3.4 Hz, 0.6H), 2.23 (s, 1H), 1.63 (d, = 6.8 Hz, 1.8H), 1.51 (d, J= 6.8 Hz, 1.2H). (Fractions of H’s that overlap with solvent are not reported). Example 143: (SV(3-(3.5-DifluorophenylV2.7-dimethyl-2.4.5.7-tetrahvdro-6H-pyrazolor3.4- clpyridin-6-yl)(3-fluoro-5-(2-fluoroethoxy)phenyl)methanone.
Figure imgf000294_0002
The title compound was prepared in a manner analogous to Example 1, using (S)-3-(3,5- difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine, and 5-fluoro-3-(2- fluoroethoxy)benzoic acid (Intermediate 21) instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H22F4N3O2, 447.1 ; m/z found, 448.0 [M+H]+. ¾ NMR (400 MHz, CDCh) d 6.95-6.85 (m, 3H), 6.80-6.71 (m, 3H), 5.85 (s, 0.5H), 4.98 (s, 0.5H), 4.88-4.80 (m, 1H), 4.74-4.68 (m, 1H), 4.35-4.25 (m, 1H), 4.24-4.18 (m, 1H), 3.87 (s, 3H), 3.28-3.12 (m, 1H), 3.82-3.72 (m, 1H), 2.82 (s, 0.5H), 2.47 (s, 1H), 2.25 (s, 1H), 1.60 (s, 3H). Example 144: ('S)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000295_0001
clpyridin-6-yl)(4-fluoro-3-(2-fluoroethoxy)phenyl)methanone.
Figure imgf000295_0002
The title compound was prepared in a manner analogous to Example 1, using (S)-3-(3,5- difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine, and 4-fluoro-3-(2- fluoroethoxy)benzoic acid (Intermediate 20) instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H22F4N3O2, 447.1 ; m/z found, 448.0 [M+H]+. ¾ NMR (400 MHz, CDCh) d 7.19-7.11 (m, 2H), 7.04 (m, 1H), 6.94-6.87 (m, 3H), 5.82 (s, 0.6H), 5.06 (s, 0.4H), 4.89-4.81 (m, 1H), 4.80- 4.68 (m, 1H), 4.41-4.33 (m, 1H), 4.33-4.28 (m, 1H), 3.86 (s, 3H), 3.23 (s, 1H), 2.78 (s, 1H), 2.49-2.45 (m, 1H), 2.21 (s, 1H), 1.60 (d, J = 6.8 Hz, 3H). (Fractions of H’s that overlap with solvent are not reported).
Example 145: [2-Chloro-3-('2-fluoroethoxy)phenyl1-i('7S)-3-('3.5-difluorophenyl)-2.7-dimethyl- 5.7-dihvdro-4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000295_0003
The title compound was prepared in a manner analogous to Example 1, using (S)-3-(3,5- difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine, and 2-chloro-3-(2- fluoroethoxy)benzoic acid (Intermediate 12) instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H21CIF3N3O2, 463.1; m/z found, 464.1 [M+H]+. ¾ NMR (CDCh): d 7.33-7.21 (m, 1H), 7.01-6.92 (m, 2H), 6.89-6.81 (m, 3H), 5.96-5.89 and 5.00-4.95 (m, 1H), 4.90-4.72 (m, 2H), 4.70- 4.65 and 3.57-3.49 (m, 1H), 4.37-4.25 (m, 2H), 3.86 and 3.80 (s, 3H), 3.38-3.31 and 2.91-2.78
(m, 1H), 3.26-3.20 and 2.57-2.48 (m, 1H), 3.13-2.99 and 2.33-2.28(m, 1H), 1.64-1.60, 1.49-1.48 and 1.41-1.39 (m, 3H).
Example 146: (2-Chloro-5-(2-fluoroethoxy)phenyl¥3-(3.5-difluorophenylV2.7-dimethyl-2A5.7- tetrahvdro-6H-pyrazolo[3.4-c1pyridin-6-yl)methanone.
Figure imgf000296_0001
The title compound was prepared in a manner analogous to Example 1, using (S)-3-(3,5- difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine, and 2-chloro-5-(2- fluoroethoxy)benzoic acid (Intermediate 14) instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H21CIF3N3O2, 463.1; m/z found, 464.1 [M+H]+. ¾ NMR (CDCh): d 7.37-7.29 (m, 1H), 6.92-6.83 (m, 5H), 5.93-5.87 and 4.97-4.94 (m, 1H), 4.84-4.69 (m, 2H), 4.74-4.64 and 3.60-3.50
(m, 1H), 4.26-4.15 (m, 2H), 3.85 and 3.81 (s, 3H), 3.41-3.33 and 2.87-2.80 (m, 1H), 3.25-3.19 and 2.54-2.47 (m, 1H), 3.14-2.88 (m, 1H), 1.63-1.40 (m, 3H).
Example 147: (SV(2-(2H-E2.3-Triazol-2- phenyl¥3-(3.5-difluorophenv0-2.7-dimethyl- 2.4.5.7-tetrahvdro-6H-pyrazoloi3.4-c1pyridin-6-yl)methanone.
Figure imgf000297_0001
The title compound was prepared in a manner analogous to Example 1, using (S)-3-(3,5- difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine and 2-(2H-l,2,3- triazol-2-yl)benzoic acid (Intermediate 64, prepared according to methods described in Pat. Pub. No. WO2016040789, March 17, 2016) instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H20F2N6O, 434.2; m/z found, 435.1 [M+H]+. ¾ NMR (500 MHz, CDCb) d 8.10 - 7.98 (m, 1H), 7.85 - 7.72 (m, 1.5H), 7.58 - 7.39 (m, 3.5H), 6.93 - 6.70 (m, 3H), 5.95 - 5.76 (m, 0.63H),
5.02 - 4.72 (m, 0.63H), 3.89 - 3.72 (m, 2.96H), 3.62 - 3.52 (m, 0.63H), 3.28 - 2.80 (m, 1.23H), 2.66 - 2.42 (m, 0.78H), 2.35 - 2.26 (m, 0.47H), 2.11 - 1.85 (m, 0.28H), 1.65 - 1.41 (m, 3.15H), 1.07 - 1.03 (m, 0.25H). Example 148: ('3-('3.5-Difluorophenyl)-2.7-dimethyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl)( 1 -phenyl- 1 H- 1.2.4-triazol-3-yl)methanone.
Figure imgf000297_0002
The title compound was prepared in a manner analogous to Example 106, using 1 -phenyl- 1H- l,2,4-triazole-3-carboxylic acid instead of quinoline-6-carboxylic acid in Step C. MS (ESI): mass calcd. for C23H20F2N6O, 434.1 ; m/z found, 435.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d
9.43 (s, 1H), 7.96 - 7.85 (m, 2H), 7.64 - 7.54 (m, 2H), 7.54 - 7.44 (m, 1H), 7.41 - 7.26 (m, 3H), 5.67 - 5.13 (m, 1H), 4.72 - 4.10 (m, 1H), 3.80 (d, J= 30.8 Hz, 3H), 3.20 - 2.72 (m, 2H), 2.47 - 2.41 (m, 1H), 1.53 (dd, J= 32.7, 6.7 Hz, 3H).
Example 149: ('S)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000298_0001
clpyridin-6-yl)(5-ethyl- 1 -phenyl- 1 H- l .2.4-triazol-3-yl)methanone.
Figure imgf000298_0002
The title compound was prepared in a manner analogous to Example 1, using (S)-3-(3,5- difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine and 5-ethyl-l- phenyl-lH-l,2,4-triazole-3-carboxylic acid instead of l-naphthoic acid. MS (ESI): mass calcd. for C25H24F2N6O, 462.2; m/z found, 463.2 [M+H]+. ¾ NMR (600 MHz, Methanol-A) d 7.64 - 7.54 (m, 5H), 7.12 - 7.04 (m, 3H), 5.80 - 5.57 (m, 1H), 4.78 - 4.76 (m, 0.38H), 4.51 - 4.45 (m, 0.55H), 3.86 - 3.78 (m, 3H), 3.50 - 3.40 (m, 0.6H), 3.32 - 3.20 (m, 0.48H), 2.95 - 2.76 (m, 3H), 2.61 - 2.46 (m, 1H), 1.68 - 1.57 (m, 3H), 1.35 - 1.26 (m, 3H).
Example 150: ('S)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000298_0003
c1pyridin-6-yl)n -(2-fluoroethyl)- 1 H-indol-4-yl)methanone.
Figure imgf000298_0004
The title compound was prepared in a manner analogous to Example 1, using (S)-3-(3,5- difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine, and l-(2- fluoroethyl)-lH-indole-4-carboxylic acid (Intermediate 17) instead of l-naphthoic acid. MS (ESI): mass calcd. for C25H23F3N4O, 429.2; m/z found, 430.3 [M+H]+. Ή NMR (400 MHz, Methanol-d4) d 7.51 (d, J= 8.3 Hz, 1H), 7.31-7.27 (m, 1H), 7.21 (dd, J= 8.3, 7.2 Hz, 1H), 7.10- 6.97 (m, 4H), 6.39 (s, 0.6 H), 6.25 (s, 0.4H), 5.84 (s, 0.5H), 4.84 (s, 0.5H), 4.72 (t, J= 4.6 Hz, 1H), 4.60 (t, J= 4.6 Hz, 1H), 4.50 (t, J= 4.7 Hz, 1H), 4.43 (t, J= 4.6 Hz, 1H), 3.81 (s, 2H), 3.71 (s, 1H), 3.35-3.23 (m, 1H), 2.92-2.74 (m, 1 H), 2.58 (m, 1H), 2.30-2.27 (m, 1H), 1.60 (d, J= 6.8 Hz, 2H), 1.35 (s, 1H).
Example 151 : (SV(3-(3.5-DifluorophenylV2.7-dimethyl-2.4.5.7-tetrahvdro-6H-pyrazolor3.4- clpyridin-6-yl)n -('2-('fluoro-l 8F)ethyl)- l H-indol-5-yl)methanone.
Figure imgf000299_0001
Step A: ('('S)-3-('3.5-Difluorophenyl)-2.7-dimethyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-clpyridin-
6-n1)P -('2-('('tetrahvdro-2H-pyran-2-yl)oxy)ethyl)- l H-indol-5-yl)methanone. The title compound was prepared in a manner analogous to Example 1, using (S)-3-(3,5-difluorophenyl)-2,7- dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methyl-3- phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine, and l-(2-((tetrahydro-2H-pyran-2- yl)oxy)ethyl)-lH-indole-5-carboxylic acid (Intermediate 37) instead of 1 -naphthoic acid.
Step B: -('3-('3.5-Difluorophenyl)-2.7-dimethyl-2.4.5.7-tetrahvdro-6H-pyrazoloi3.4-c1pyridin-
6-ylK 1 -(2-hvdroxyethyl)- 1 H-indol-5-yl)methanone. To a solution of ((S)-3-(3,5-difluorophenyl)- 2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(l-(2-((tetrahydro-2H-pyran-2- yl)oxy)ethyl)-lH-indol-5-yl)methanone (150 mg, 0.28 mmol) in methanol (11 mL) was added HC1 (1.25M in EtOH, 0.22 mL, 0.28 mmol). The reaction mixture was stirred overnight and then concentrated in vacuo. The residue was taken up in EtOAc and washed with sat. aq NaHCC .
The organic layer was concentrated and used directly in the next step. MS (ESI): mass calcd. for C25H24F2N4O2, 450.2; m/z found, 451.3 [M+H]+.
Step C: ('S)-2-('5-('3-('3.5-Difluorophenyl)-2.7-dimethyl-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4- clpyridine-6-carbonyl)- 1 H-indol- 1 -vOethyl 4-methylbenzenesulfonate. A solution of (S)-(3-(3,5- difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(l-(2- hydroxyethyl)-lH-indol-5-yl)methanone (200 mg, 0.80 mmol), 4-methylbenzenesulfonic anhydride (217 mg, 0.67 mmol) and triethylamine (0.19 mL, 1.33 mmol) in DCM (2.8 mL) was stirred at rt for 3 h. The reaction mixture was washed with saturated aqueous NaHCC and the organic layer was concentrated in vacuo. Purification (FCC (flash column chromatography),
SiC , MeOH in DCM (0 to 5%) afforded the title compound (60 mg, 22%). MS (ESI): mass calcd. for C32H30CF2N4O4S, 604.2; m/z found, 605.3 [M+H]+.
Step D: (S)-(3-(3,5-difhiorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-
6-yl)(l-(2-(fluoro-18F)ethyl)-lH-indol-5-yl)methanone. [18F]fluoride in a shipping vial from PETNET Solutions Inc. (San Diego, CA EISA) is transferred onto and trapped on an ion exchange cartridge. It is then eluted into the reaction vessel (RV1) of the Synthra RNPlus® module with a solution of potassium carbonate (0.75 mg) and Kryptofix 222 (7.2 mg) in 0.8 mL of acetonitrile/water (6/2, v/v). After the solvent was evaporated under a stream of nitrogen at 85°C and under vacuum, anhydrous CH3CN (0.5 mL) was added, this process was repeated and the temperature increased to 110 °C for 3.5 min. The reaction vial was then cooled to 70°C before a solution of 3.0 mg of (S)-2-(5-(3-(3,5-difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro- 2H-pyrazolo[3,4-c]pyridine-6-carbonyl)-lH-indol-l-yl)ethyl 4-methylbenzenesulfonate in 0.7 ml anhydrous MeCN was added to reaction vessel. The reaction mixture is heated at 95°C for 10 min. The reactor is cooled to 40°C and diluted with water (4.3 mL) and the contents is transferred into the HPLC injector loop for purification. Purification is performed by HPLC using a semi-preparative Eclipse XDB-C18 column (5 pm, 9.4 mm x 250 mm) with a mixture of 10 mM NFEOAc and MeCN (50:50 v/v) at a flow rate of 4 mL/min with LTV detection at 254 nm. The purified radiotracer solution was diluted with 30 mL of water and passed through a SepPak Light C-18 cartridge. The C-18 cartridge was further washed withlO mL of water before 0.5 mL EtOH was used to elute the tracer. The tracer solution was further diluted with 4.5 mL of saline. The final formulation contains an ethanol concentration of 10%, suitable for intravenous injection (IV). Example 152: ('S)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000301_0001
c1pyridin-6-yl)ri -t2-fluoroethyl)- l H-pyrroloi2.3-b1pyridin-4-yl)methanone.
Figure imgf000301_0002
Step A: ('S)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2 5.7-tetrahvdro-6H-pyrazolo[3.4-
Figure imgf000301_0003
6-n1)(Ί H-pyrrolo b1pyridin-4-yl)methanone. The title compound was prepared in a manner
Figure imgf000301_0004
analogous to Example 1 using (S)-3-(3,5-difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H- pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H- pyrazolo [3, 4-c] pyridine, and lH-pyrrolo[2,3-b]pyridine-4-carboxylic acid instead of l-naphthoic acid. MS (ESI): mass calcd. for C22H19F2N5O, 407.2; m/z found, 408.2 [M+H]+.
Step B: ('S)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-c1pyridin- 6-n1)(Ί -('2-fluoroethvD- l H-pyrrolo[2.3-b1pyridin-4-yl)methanone. To an ice-cold solution of (S)- (3-(3,5-difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(lH- pyrrolo[2,3-b]pyridin-4-yl)methanone (82 mg, 0.2 mmol) in DMF (2 mL) was added NaH (24 mg, 0.6 mmol. 60% in mineral oil). The mixture was stirred at 0 °C for 20 min. To this mixture was added l-fluoro-2-iodoethane (52 mg, 0.3 mmol) and the reaction was stirred at rt for 30 min. The reaction was quenched by adding 2 g of dry ice and 3 drops of water and then diluted with ether (30 mL). The mixture was washed with brine (3x20 mL) and the organic layer was dried over Na2S04 and concentrated. The crude product was purified by silica chromatography (0 to 5% MeOH in DCM) to afford the title compound as a clear oil. MS (ESI): mass calcd. for C24H22F3N5O, 453.2; m/z found, 454.3 [M+H]+. ¾ NMR (400 MHz, CDCb) d 8.39 (d, J= 4.9 Hz, 1H), 7.40 (m, 1H), 7.13 (d, J= 4.9 Hz, 1H), 6.85-6.84 (m, 3H), 6.53-6.45 (m, 1H), 6.01 (d, J = 7.0 Hz, 0.5H), 5.03 (d, J= 13.8 Hz, 0.5H), 4.87 (t, J= 4.7 Hz, 1H), 4.76-4.72 (m, 2H), 4.66 (t, J= 4.4 Hz, 1H), 3.89-3.79 (m, 3H), 3.88-3.62 (m, 1H), 3.38-3.07 (m, 1H), 2.70-2.54 (m, 1H), 2.41-2.26 (m, 1H), 1.70 (d, = 6.8 Hz, 1.8H), 1.46 (d, = 6.5 Hz, 1.2H). Example 153: ('S)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000302_0001
c1pyridin-6-yl furor3.2-b1pyridin-6-vnmethanone.
Figure imgf000302_0002
The title compound was prepared in a manner analogous to Example 1, using (S)-3-(3,5- difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine and furo[3,2- b]pyridine-6-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for
C22H18F2N4O2, 408.1; m/z found, 409.1 [M+H]+. ¾ NMR (500 MHz, CDCb) d 8.67 (d, J= 1.7 Hz, 1H), 7.95 (d, J= 2.3 Hz, 1H), 7.89 (s, 1H), 7.04 (dd, J= 2.3, 1.0 Hz, 1H), 6.93 - 6.84 (m, 3H), 5.86 (s, 0.4H), 5.17 - 4.64 (m, 0.68H), 3.83 (s, 3.62H), 3.49 - 3.05 (m, 1H), 2.96 - 2.38 (m,
2H), 1.62 (s, 3.3H).
Example 154: ('R)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000302_0003
c1pyridin-6-yl)('furo[3.2-b1pyridin-6-yl)methanone.
Figure imgf000302_0004
The title compound was prepared in a manner analogous to Example 1, using (R)-3-(3,5- difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 9) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine and furo[3,2- b]pyridine-6-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for
C22H18F2N4O2, 408.1; m/z found, 409.1 [M+H]+. ¾ NMR (500 MHz, CDCb) d 8.67 (d, J= 1.7
Hz, 1H), 7.95 (d, J= 2.3 Hz, 1H), 7.89 (s, 1H), 7.04 (dd, J= 2.3, 1.0 Hz, 1H), 6.93 - 6.84 (m, 3H), 5.86 (s, 0.4H), 5.17 - 4.64 (m, 0.68H), 3.83 (s, 3.62H), 3.49 - 3.05 (m, 1H), 2.96 - 2.38 (m, 2H), 1.62 (s, 3.3H).
Example 155: (2-(Difluoromethyl)-3-(3.5-difluorophenyl)-7-methyl- tetrahvdro-6H-
Figure imgf000303_0001
pyrazolo[3.4-clpyridin-6-yl)('quinolin-6-yl)methanone.
Figure imgf000303_0002
The title compound was prepared in a manner analogous to Example 1, using 2-(difluoromethyl)- 3-(3,5-difluorophenyl)-7-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 32) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine, and quinoline- 6-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C24H18F4N4O, 454.1; m/z found, 455.1 [M+H]+.
Figure imgf000303_0003
(500 MHz, DMSO-r/e) d 8.99 (dd, J= 4.2, 1.8 Hz, 1H), 8.53 - 8.43 (m, 1H), 8.20 - 8.05 (m, 2H), 7.94 - 7.71 (m, 2H), 7.62 (dd, J= 8.3, 4.2 Hz, 1H), 7.52 - 7.42 (m, 1H), 7.34 - 7.25 (m, 2H), 5.74 (s, 1H), 4.79 (d, J= 95.0 Hz, 1H), 3.92 (d, J= 185.0 Hz, 1H), 2.92 (s, 1H), 2.48 - 2.30 (m, 1H), 1.57 (d, J= 6.8 Hz, 3H).
Example 156: (3-(3.5-Difluorophenyl)-7-methyl-2-(trifluoromethyl)- tetrahvdro-6H-
Figure imgf000303_0004
Pyrazolo[3.4-c1pyridin-6-yl)('quinolin-6-yl)methanone.
Figure imgf000303_0005
The title compound was prepared in a manner analogous to Example 1, using 3 -(3, 5- difluorophenyl)-7-methyl-2-(trifluoromethyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 35) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine, and quinoline-6-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C24H17F5N4O, 472.1; m/z found, 473.1 [M+H]+. 1H NMR (500 MHz, DMSO-r/e) d 8.98 (dd, J = 4.2, 1.7 Hz, 1H), 8.48 (dd, = 8.4, 1.7 Hz, 1H), 8.18 - 8.02 (m, 2H), 7.81 (dd, = 8.6, 2.0 Hz, 1H), 7.62 (dd, J= 8.3, 4.2 Hz, 1H), 7.57 - 7.42 (m, 1H), 7.41 - 7.29 (m, 2H), 5.76 (s, 1H), 3.65 (d, = 72.5 Hz, 1H), 3.98 - 3.48 (m, 1H), 2.83 (s, 1H), 2.48 - 2.28 (m, 1H), 1.57 (d, = 6.9 Hz, 3H).
Example 157: (3-(3.5-Difluorophenyl)-7-methyl-2-(methyl-d3)- tetrahvdro-6H-
Figure imgf000304_0001
Pyrazolo[3.4-clpyridin-6-yl)('quinolin-6-yl)methanone.
Figure imgf000304_0002
The title compound was prepared in a manner analogous to Example 1, using racemic 3 -(3, 5- difluorophenyl)-7-methyl-2-(methyl-d3)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine
(Intermediate 31) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine, and quinoline-6-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for
C24H17D3F2N4O, 421.1 ; m/z found, 422.1 [M+H]+. Ή NMR (500 MHz, DMSO- e) d 8.98 (dd, J = 4.2, 1.7 Hz, 1H), 8.57 - 8.40 (m, 1H), 8.17 - 8.07 (m, 2H), 7.80 (d, J= 8.9 Hz, 1H), 7.62 (dd, J
= 8.3, 4.2 Hz, 1H), 7.43 - 7.24 (m, 3H), 5.63 (s, 1H), 4.70 (s, 1H), 3.77 (d, J= 75.2 Hz, 1H),
2.91 (s, 1H), 2.47 - 2.29 (m, 1H), 1.51 (s, 3H).
Example 158: ('R)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000304_0003
clpyridin-6-yl)(quinolin-6-yl)methanone.
Figure imgf000304_0004
The title compound was obtained as a single enantiomer by Chiral SFC purification (Whelk 01 SS 5pm 250 x 20 mm, Mobile phase: 45% methanol, 55% CO2) of (3-(3,5-difluorophenyl)-2,7- dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin-6-yl)methanone (Example 106) to provide the title compound (retention time = 11.3 min). MS (ESI): mass calcd. for C24H20F2N4O, 418.1; m/z found, 419.1 [M+H] +. Ή NMR (500 MHz, DMSO- e) d 8.98 (dd, J =
4.2, 1.8 Hz, 1H), 8.49 (dd, = 8.3, 1.7 Hz, 1H), 8.16 - 8.06 (m, 2H), 7.80 (d, = 8.3 Hz, 1H), 7.62 (dd, J= 8.3, 4.2 Hz, 1H), 7.46 - 7.23 (m, 3H), 5.69 (d, J= 63.7 Hz, 1H), 4.75 (s, 1H), 3.85 (s, 3H), 3.71 (s, 1H), 2.91 (s, 1H), 2.35 (s, 1H), 1.51 (s, 3H). Example 159: ('S)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000305_0001
clpyridin-6-yl)(quinolin-6-yl)methanone.
Figure imgf000305_0002
The title compound was obtained as a single enantiomer by Chiral SFC purification (Whelk 01 SS 5pm 250 x 20 mm, Mobile phase: 45% methanol, 55% CO2) of (3-(3,5-difluorophenyl)-2,7- dimethyl-2, 4, 5, 7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin-6-yl)methanone (Example
106) to provide the title compound (retention time = 14.5 min). MS (ESI): mass calcd. for C24H20F2N4O, 418.1; m/z found, 419.1 [M+H] +. Ή NMR (500 MHz, DMSO- e) d 8.98 (dd, J =
4.2, 1.8 Hz, 1H), 8.54 - 8.41 (m, 1H), 8.16 - 8.04 (m, 2H), 7.80 (d, = 8.7 Hz, 1H), 7.62 (dd, J =
8.3, 4.2 Hz, 1H), 7.43 - 7.26 (m, 3H), 5.63 (s, 1H), 4.73 (s, 1H), 3.85 (s, 3H), 3.71 (s, 1H), 2.91 (s, 1H), 2.36 (S, 1H), 1.51 (s, 3H).
Example 160: ('3-('3.5-Difluorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000306_0001
c1pyridin-6-vn(isoauinolin-3-vnmethanone.
Figure imgf000306_0002
The title compound was prepared in a manner analogous to Example 106, using isoquinoline-3- carboxylic acid instead of quinoline-6-carboxylic acid in Step C. MS (ESI): mass calcd. for
C24H20F2N4O, 418.1; m/z found, 419.1 [M+H] +. Ή NMR (500 MHz, DMSO- e) d 9.37 (d, J = 5.9 Hz, 1H), 8.22 (d, J= 8.2 Hz, 1H), 8.17 - 8.06 (m, 2H), 7.92 - 7.74 (m, 2H), 7.32 (dd, J = 29.8, 7.5 Hz, 3H), 4.87 (dd, J= 157.2, 8.6 Hz, 1H), 3.84 (s, 3H), 3.75 (s, 1H), 3.21 - 2.74 (m, 2H), 2.33 (s, 1H), 1.51 (t, J= 8.7 Hz, 3H).
Example 161 : ('3-('3.5-Difluorophenyl)-2.7-dimethyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- c1pyridin-6-yl)('isoquinolin-7-yl)methanone.
Figure imgf000306_0003
The title compound was prepared in a manner analogous to Example 106, using isoquinoline-7- carboxylic acid instead of quinoline-6-carboxybc acid in Step C. MS (ESI): mass calcd. for
C24H20F2N4O, 418.1; m/z found, 419.1 [M+H] +. Ή NMR (500 MHz, DMSO- e) d 9.43 (d, J = 1.0 Hz, 1H), 8.58 (d, J= 5.7 Hz, 1H), 8.24 (s, 1H), 8.08 (d, J= 8.5 Hz, 1H), 7.94 - 7.75 (m, 2H), 7.42 - 7.22 (m, 3H), 5.69 - 5.53 (m, 1H), 4.72 (s, 1H), 3.85 (s, 3H), 3.68 (s, 1H), 3.04 (d, J = 127.6 Hz, 2H), 1.51 (s, 3H). Example 162: (4-Bromociuinolin-6-yl)(3-(3.5-difluorophenyl)-2.7-dimethyl- tetrahvdro-
Figure imgf000307_0001
6H-pyrazoloi3.4-c|pyridin-6-yl)methanone.
Figure imgf000307_0002
The title compound was prepared in a manner analogous to Example 106, using 4- bromoquinoline-6-carboxylic acid instead of quinobne-6-carboxybc acid in Step C. MS (ESI): mass calcd. for C24Hi9BrF2N40, 496.1; m/z found, 497.1 [M+H] +. ¾ NMR (500 MHz, DMSO- de) d 8.81 (d, J= 4.7 Hz, 1H), 8.24 - 8.14 (m, 2H), 8.04 (d, J= 4.7 Hz, 1H), 7.92 (d, J= 8.6 Hz, 1H), 7.44 - 7.23 (m, 3H), 5.60 (d, J= 30.1 Hz, 1H), 4.73 (s, 1H), 3.80 (d, J= 43.7 Hz, 3H), 3.65 (s, 1H), 2.96 - 2.79 (m, 1H), 2.39 (s, 1H), 1.53 (d, J= 6.7 Hz, 3H).
Example 163: (5-Chlorociuinolin-6-yl)(3-(3.5-difluorophenyl)-2.7-dimethyl- tetrahvdro-
Figure imgf000307_0003
6H-pyrazolo[3.4-c1pyridin-6-yl)methanone.
Figure imgf000307_0004
The title compound was prepared in a manner analogous to Example 106, using 5- chloroquinobne-6-carboxybc acid instead of quinobne-6-carboxylic acid in Step C. MS (ESI): mass calcd. for C24Hi9ClF2N40, 452.1 ; m/z found, 453.1 [M+H] +. ¾ NMR (500 MHz, DMSO- ek) 5 9.15 - 9.02 (m, 1H), 8.79 - 8.55 (m, 1H), 8.23 - 8.08 (m, 1H), 7.91 - 7.71 (m, 2H), 7.46 - 7.16 (m, 3H), 5.75 - 5.65 (m, 1H), 4.88 - 4.47 (m, 1H), 3.88 - 3.73 (m, 3H), 3.21 - 2.64 (m,
2H), 2.45 - 2.18 (m, 1H), 1.58 - 1.30 (m, 3H). Example 164: ('S)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000308_0001
c1pyridin-6-vn(8-(trifluoromethvnauinolin-6-vnmethanone.
Figure imgf000308_0002
The title compound was prepared in a manner analogous to Example 1, using (S)-3-(3,5- difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine, and 3- (trifluoromethyl)quinoline-6-carboxylic acid (Intermediate 23) instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C25H19F5N4O, 486.1; m/z found, 487.1 [M+H]+. Ή NMR (500 MHz, CDCh) d 9.14 (dd, J= 4.2, 1.8 Hz, 1H), 8.27 (d, J= 8.0 Hz, 1H), 8.18 - 8.09 (m, 2H), 7.58 (dd, J= 8.3, 4.2 Hz, 1H), 6.94 - 6.85 (m, 3H), 5.90 (s, 0.51H), 4.93 (s, 0.81H), 3.83 (s, 3.68H), 3.52 - 3.07 (m, 1H), 3.03 - 2.65 (m, 1H), 2.49 (s, 1H), 1.64 (s, 3H).
Example 165: ('S)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000308_0003
clpyridin-6-yl)(3-(trifluoromethyl)quinolin-6-yl)methanone.
Figure imgf000308_0004
The title compound was prepared in a manner analogous to Example 1, using (S)-3-(3,5- difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine and 3- (trifluoromethyl)quinoline-6-carboxylic acid (Intermediate 24) instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C25H19F5N4O, 486.1 ; m/z found, 487.1 [M+H]+. Ή NMR (500 MHz, CDCh) d 9.16 (d, J= 2.2 Hz, 1H), 8.48 (s, 1H), 8.26 (d, J= 8.6 Hz, 1H), 8.02 (d, J= 1.8 Hz, 1H), 7.90 (dd, J= 8.7, 1.8 Hz, 1H), 6.93 - 6.83 (m, 3H), 5.91 (s, 0.5H), 4.94 (s, 0.81H), 3.96
3.74 (m, 3.69H), 3.49 - 2.35 (m, 3H), 1.74 - 1.47 (m, 3H).
Example 166: ('S)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000309_0001
clpyridin-6-yl)(3-(2-fluoroethoxy)quinolin-6-yl)methanone.
Figure imgf000309_0002
The title compound was prepared in a manner analogous to Example 1, using (S)-3-(3,5- difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine, and 3-(2- fluoroethoxy)quinobne-6-carboxylic acid (Intermediate 18) instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C26H23F3N4O2, 480.2; m/z found, 481.3 [M+H]+. Ή NMR (400 MHz, CDCh) d 8.80 (d, J= 2.9 Hz, 1H), 8.21 (d, J= 8.6 Hz, 1H), 7.87 (d, J= 1.9 Hz, 1H), 7.65 (dd, J = 8.6, 1.8 Hz, 1H), 7.52 (d, = 2.8 Hz, 1H), 6.93-6.88 (m, 3H), 5.91 (s, 0.5H), 4.98 (s, 0.5H), 4.98-4.89 (m, 1H), 4.86-4.77 (m, 1H), 4.44 (dd, J= 5.4, 2.9 Hz, 1H), 4.37 (dd, J= 5.2, 3.0 Hz, 1H), 3.85 (m, 3H), 3.42-2.66 (m, 3H), 2.56 (m, 1H), 1.63 (s, 3H).
Example 167: ('3-('3.5-Difluorophenyl)-2.7-dimethyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl )(quinoxalin-6-yl jmethanone.
Figure imgf000309_0003
The title compound was prepared in a manner analogous to Example 106, using quinoxaline-6- carboxylic acid instead of quinoline-6-carboxylic acid in Step C. MS (ESI): mass calcd. for C23H19F2N5O, 419.1; m/z found, 420.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 7.97 - 7.85 (m, 2H), 7.68 - 7.59 (m, 2H), 7.55 - 7.42 (m, 1H), 7.39 - 7.25 (m, 3H), 5.60 (q, J= 6.7 Hz, 0.6H), 5.20 (q, J= 6.7 Hz, 0.4H), 4.75 - 4.61 (m, 0.4H), 4.13 (dd, J= 13.7, 4.9 Hz, 0.6H), 3.80 (d, = 30.8 Hz, 3H), 3.11 (td, = 12.7, 4.0 Hz, 1H), 2.92 - 2.71 (m, 1H), 2.50 - 2.31 (m, 1H),
1.53 (dd, J= 32.7, 6.7 Hz, 3H).
Example 168: ('S)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000310_0001
clpyridin-6-vn(quinoxalin-6-vnmethanone.
Figure imgf000310_0002
The title compound was obtained as a single enantiomer by Chiral SFC purification of racemic (3-(3,5-difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxabn-6-yl)methanone, Example 167: (Chiralcel OX 5um 250 x 20 mm, Mobile phase: 30% isopropanol, 70% CO2; 11.1 min retention time). MS (ESI): mass calcd. for C23H19F2N5O, 419.1; m/z found, 420.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 9.04 (s, 2H), 8.27 - 8.08 (m, 2H), 7.91 (d, J= 8.8 Hz, 1H), 7.42 - 7.22 (m, 3H), 5.65 (s, 1H), 5.04 - 4.34 (m, 1H), 3.80 (d, J= 49.4 Hz, 3H), 3.67 (d, = 13.5 Hz, 1H), 2.91 (s, 1H), 2.33 (d, J= 15.6 Hz, 1H), 1.53 (d, J = 6.8 Hz, 3H).
Example 169: ('R)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2 5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl )(quinoxalin-6-yl jmethanone.
Figure imgf000310_0003
The title compound was obtained as a single enantiomer by Chiral SFC purification of racemic (3-(3,5-difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxalin-6-yl)methanone, Example 167: (Chiralcel OX 5um 250 x 20 mm, Mobile phase: 30% isopropanol, 70% CO2; 9.6 min retention time). MS (ESI): mass calcd. for C23H19F2N5O, 419.1; m/z found, 420.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 7.97 - 7.85 (m, 2H), 7.68 - 7.59 (m, 2H), 7.55 - 7.42 (m, 1H), 7.39 - 7.25 (m, 3H), 5.60 (q, J= 6.7 Hz, 0.6H), 5.20 (q, J = 6.7 Hz, 0.4H), 4.75 - 4.61 (m, 0.4H), 4.13 (dd, J= 13.7, 4.9 Hz, 0.6H), 3.80 (d, J= 30.8 Hz,
3H), 3.11 (td, = 12.7, 4.0 Hz, 1H), 2.92 - 2.71 (m, 1H), 2.50 - 2.31 (m, 1H), 1.53 (dd, = 32.7, 6.7 Hz, 3H).
Example 170: ('S)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000311_0001
clpyridin-6-yl)( 1.5-naphthyridin-2-yl jmethanone.
Figure imgf000311_0002
The title compound was prepared in a manner analogous to Example 1, using (S)-3-(3,5- difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine and 1,5- naphthyridine-2-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for
C23H19F2N5O, 419.2; m/z found, 420.2 [M+H]+.
Figure imgf000311_0003
NMR (500 MHz, CDCb) d 9.07 - 9.02 (m, 1H), 8.55 - 8.41 (m, 2H), 7.99 (dd, J= 8.7, 2.7 Hz, 1H), 7.73 - 7.67 (m, 1H), 6.93 - 6.85 (m, 3H), 6.02 - 5.28 (m, 1H), 5.00 - 4.06 (m, 1H), 3.91 - 3.74 (m, 3H), 3.40 - 3.13 (m, 1H), 3.11 - 2.87 (m, 1H), 2.62 - 2.36 (m, 1H), 1.77 - 1.65 (m, 3H).
Example 171 : ('S)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000312_0001
c1pyridin-6-yl)t7-fluoroauinoxalin-6-yl)methanone.
Figure imgf000312_0002
The title compound was prepared in a manner analogous to Example 1, using (S)-3-(3,5- difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 39) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine and 7- fluoroquinoxaline-6-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C23H18F3N5O, 437.1; m/z found, 438.2 [M+H]+.
Figure imgf000312_0003
NMR (500 MHz, CDCh) d 8.91 - 8.85 (m,
2H), 8.16 (s, 1H), 7.84 (d, J= 9.4 Hz, 1H), 6.93 - 6.83 (m, 3H), 6.02 - 5.93 (m, 0.6H), 5.00 (dd, J= 13.1, 5.3 Hz, 0.42H), 4.88 - 4.77 (m, 0.38H), 3.92 - 3.75 (m, 3H), 3.64 (dd, J= 13.9, 5.2 Hz,
0.61H), 3.47 - 3.09 (m, 1H), 2.96 - 2.29 (m, 2H), 1.69 - 1.47 (m, 3H).
Example 172: ('S)-('3-('3.5-Dichlorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000312_0004
c1pyridin-6-yl)('2-methylbenzo[d1oxazol-6-yl)methanone.
Figure imgf000312_0005
The title compound was prepared in a manner analogous to Example 106, using 3,5- dichlorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 2-methylbenzo[d]oxazole-6-carboxylic acid instead of quinoline 6-carboxybc acid in Step C. MS (ESI): mass calcd. for C23H20CI2N4O2, 454.1; m/z found, 455.0 [M+H]+. (600 MHz, Methanol-d4) d 7.75 - 7.69 (m, 2H), 7.57 - 7.55 (m, 1H), 7.48 - 7.43 (m, 3H), 5.74 (s, 0.63H), 3.82 (s, 3.86H), 3.44 - 3.35 (m, 1.19H), 2.87 - 2.76 (m, 1H), 2.68 (s, 3.15H), 2.43 (s, 1H), 1.59 (s, 3.18H). Example 173: ('S)-('3-('3.5-Dichlorophenyl)-2.7-dimethyl-2 5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl1(T -methyl- lH-pyrazolor3.4-blpyridin-3-yl1methanone.
Figure imgf000313_0001
The title compound was prepared in a manner analogous to Example 106, using 3,5- dichlorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and l-methyl-lH-pyrazolo[3,4-b]pyridine-3-carboxybc acid instead of quinoline 6-carboxybc acid in Step C. MS (ESI): mass calcd. for C22H20CI2N6O, 454.1; m/z found, 455.0 [M+H]+. ¾ NMR (500 MHz, CDCb) d 8.61 - 8.53 (m, 2H), 7.42 (t, J= 1.9 Hz, 1H), 7.26 (s, 3H), 6.44 - 5.87 (m, 1H), 5.30 - 4.90 (m, 1H), 4.21 (s, 3H), 3.90 - 3.76 (m, 3H), 3.46 - 3.11 (m, 1H), 3.04 - 2.82 (m, 1H), 2.57 - 2.47 (m, 1H), 1.83 - 1.62 (m, 3H).
Example 174: ('S)-('3-('3.5-Dichlorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000313_0002
c1pyridin-6-yl)('quinolin-6-yl)methanone.
Figure imgf000313_0003
The title compound was prepared in a manner analogous to Example 106, using 3,5- dichlorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A. MS (ESI): mass calcd. for C24H20CI2N4O, 450.1; m/z found, 451.1 [M+H]+. (600 MHz, CDCb) d 8.98 (dd, J= 4.2, 1.7 Hz, 1H), 8.23 - 8.14 (m, 2H), 7.93 (d, J= 1.8 Hz, 1H), 7.76 (dd, J= 8.6, 1.9 Hz, 1H), 7.50 - 7.41 (m, 2H), 7.23 (d, J= 1.9 Hz, 2H), 5.91 (s, 0.54H), 5.15 - 4.78 (m, 0.82H), 3.82 (s, 3.61H), 3.45 - 2.30 (m, 3.06H), 1.73 - 1.49 (m, 3H).
Example 175: (S)-(3-(3,5-Dichlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)(quinoxalin-6-yl)methanone.
Figure imgf000314_0001
The title compound was prepared in a manner analogous to Example 106, using 3,5- dichlorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and quinoxaline-6-carboxylic acid instead of quinoline 6-carboxybc acid in Step C. MS (ESI): mass calcd. for C23H19CI2N5O, 451.1; m/z found, 452.0 [M+H]+. XH NMR (500 MHz, DMSO-r/e) d 9.04 (s, 2H), 8.23 - 8.10 (m, 2H), 7.97 - 7.83 (m, 1H), 7.71 (s, 1H), 7.62 (d, J= 1.9 Hz, 2H), 5.65 (s, 0.74H), 4.72 (s, 0.46H), 3.89 - 3.62 (m, 3.77H), 3.33 - 3.05 (m, 1.23H), 2.98 - 2.76 (m, 1H), 2.38 - 2.23 (m, 0.8H), 1.60 - 1.39 (m, 3H). Example 176: ('S)-('3-('3.5-Dichlorophenyl)-2.7-dimethyl-2 5.7-tetrahvdro-6H-pyrazolo[3.4- c1pyridin-6-yl)('2-methylguinoxalin-6-yl)methanone.
Figure imgf000315_0001
The title compound was prepared in a manner analogous to Example 106, using 3,5- dichlorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 2-methylquinoxabne-6-carboxybc acid (Intermediate 25) instead of 1 -naphthoic acid in Step C. MS (ESI): mass calcd. for C24H21CI2N5O, 465.1; m/z found, 466.1
Figure imgf000315_0002
8.93 (d, = 2.8 Hz, 1H), 8.12 (dd, J= 28.4, 8.5 Hz, 2H), 7.92 - 7.76 (m, 1H), 7.70 (t, J= 1.9 Hz, 1H), 7.61 (t, J= 1.9 Hz, 2H), 5.64 (s, 1H), 4.40 (d, J= 309.7 Hz, 1H), 3.83 (s, 3H), 3.66 (s, 1H), 2.89 (d, J= 15.2 Hz, 1H), 2.74 (d, J= 1.3 Hz, 3H), 2.32 (d, J= 15.1 Hz, 1H), 1.51 (s, 3H).
Example 177: ('3-('3-Chloro-5-fluorophenyl)-2.7-dimethyl-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000315_0003
clpyridin-6-yl)(quinolin-6-yl)methanone.
Figure imgf000315_0004
The title compound was prepared in a manner analogous to Example 106, using 3-chloro-5- fluoroboronic acid instead of 3,5-difluorophenylboronic acid in Step A. MS (ESI): mass calcd. for C24H20CIFN4O, 434.1; m/z found, 435.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 8.97 (dd, = 4.2, 1.8 Hz, 1H), 8.51 - 8.46 (m, 1H), 8.11 (d, = 8.3 Hz, 2H), 7.80 (s, 1H), 7.61 (dd, = 8.3, 4.2 Hz, 1H), 7.55 - 7.51 (m, 1H), 7.48 - 7.39 (m, 2H), 5.62 (s, 1H), 3.83 (s, 3H), 3.70 (s, 1H), 3.25 (s, 1H) 2.89 (s, 1H), 2.34 (s, 1H), 1.50 (s, 3H).
Example 178: (S)-(3-(3-Chloro-5-fluorophenyl)-2.7-dimethyl- tetrahvdro-6H-
Figure imgf000316_0001
pyrazolor3.4-c1pyridin-6-yl)(quinolin-6-yl)methanone.
Figure imgf000316_0002
The title compound was obtained as a single enantiomer by chiral SFC purification of racemic [(3-(3-chloro-5-fluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinobn-6-yl)methanone], Example 177 (Chiralcel OD 5pm 250 x 20 mm, Mobile phase: 16% methanol, 84% CO2. The enantiomeric purity was confirmed by analytical SFC using a
Chiralcel OD, 5 pm, 250 x 4.6 mm, Mobile phase: 20% methanol, 80% CO2 (100% single (S) enantiomer; 9.2 min retention time). MS (ESI): mass calcd. for C24H20CIFN4O, 434.1 ; m/z found, 435.0 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.97 (dd, J= 4.2, 1.8 Hz, 1H), 8.51 - 8.46 (m, 1H), 8.11 (d, J= 8.3 Hz, 2H), 7.80 (s, 1H), 7.61 (dd, J= 8.3, 4.2 Hz, 1H), 7.55 - 7.51 (m, 1H), 7.48 - 7.39 (m, 2H), 5.62 (s, 1H), 3.83 (s, 3H), 3.70 (s, 1H), 3.25 (s, 1H) 2.89 (s, 1H),
2.34 (s, 1H), 1.50 (s, 3H).
Example 179: (R)-(3-(3-Chloro-5-fluorophenyl)-2.7-dimethyl- tetrahvdro-6H-
Figure imgf000316_0003
Pyrazolo[3.4-c1pyridin-6-yl)('quinolin-6-yl)methanone.
Figure imgf000316_0004
The title compound was obtained as a single enantiomer by chiral SFC purification of racemic [(3-(3-chloro-5-fluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinolin-6-yl)methanone], Example 177 Chiralcel OD 5pm 250 x 20 mm, Mobile phase: 16% methanol, 84% CO2. The enantiomeric purity was confirmed by analytical SFC using a Chiralcel OD, 5 pm, 250 x 4.6 mm, Mobile phase: 20% methanol, 80% CO2 (100% single (R) enantiomer). MS (ESI): mass calcd. for C24H20CIFN4O, 434.1; m/z found, 435.0 [M+H]+.
Example 180: ('3-('3-Chloro-5-fluorophenyl)-2.7-dimethyl-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl )(quinoxalin-6-yl jmethanone.
Figure imgf000317_0001
The title compound was prepared in a manner analogous to Example 106, using 3-chloro-5- fluoroboronic acid instead of 3,5-difluorophenylboronic acid in Step A and quinoxaline-6- carboxylic acid instead of quinolone-6-carboxylic acid in Step C. MS (ESI): mass calcd. for C23H19CIFN5O, 435.1; m/z found, 436.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 9.03 (d, J = 1.9 Hz, 2H), 8.26 - 8.08 (m, 2H), 7.91 (d, J= 8.8 Hz, 1H), 7.64 - 7.35 (m, 3H), 5.65 (s, 0.56H), 4.71 (s, 0.44H), 3.84 (s, 3H), 3.66 (d, J= 13.7 Hz, 1H), 3.34 - 2.82 (m, 2H), 2.47 - 2.24 (m, 1H), 1.52 (d, = 6.7 Hz, 3H).
Example 181 : (SV(3-(3-Chloro-5-fluorophenylV2.7-dimethyl-2.4.5.7-tetrahvdro-6H- Pyrazolo[3.4-c1pyridin-6-yl)('quinoxalin-6-yl)methanone.
Figure imgf000317_0002
The title compound was obtained as a single enantiomer by chiral SFC purification of racemic (3-(3-chloro-5-fluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxalin-6-yl)methanone, Example 180 (Stationary Phase: Chiralcel OD 5 pm 250 x 20 mm, Mobile phase: 16% methanol, 84% CO2. The enantiomeric purity was confirmed by analytical SFC using a Chiralcel OD, 5pm, 250 x 4.6 mm, Mobile phase: 20% methanol, 80% CO2 (100% single (S) enantiomer; 7.2 min retention time). MS (ESI): mass calcd. for
C23H19CIFN5O, 435.1; m/z found, 436.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 9.03 (d, J = 1.9 Hz, 2H), 8.26 - 8.08 (m, 2H), 7.91 (d, J= 8.8 Hz, 1H), 7.64 - 7.35 (m, 3H), 5.65 (s,
0.56H), 4.71 (s, 0.44H), 3.84 (s, 3H), 3.66 (d, J= 13.7 Hz, 1H), 3.34 - 2.82 (m, 2H), 2.47 - 2.24
(m, 1H), 1.52 (d, J= 6.7 Hz, 3H).
Example 182: (R)-(3-(3-Chloro-5-fluorophenyl)-2.7-dimethyl- tetrahvdro-6H-
Figure imgf000318_0001
pyrazolo[3.4-c1pyridin-6-yl)('quinoxalin-6-yl)methanone.
Figure imgf000318_0002
The title compound was obtained as a single enantiomer by chiral SFC purification of racemic (3-(3-chloro-5-fluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxalin-6-yl)methanone, Example 180 (Stationary Phase: Chiralcel OD 5 pm 250 x 20 mm, Mobile phase: 16% methanol, 84% CO2. The enantiomeric purity was confirmed by analytical SFC using a Chiralcel OD, 5pm, 250 x 4.6 mm, Mobile phase: 20% methanol, 80% CO2 (100% single (R) enantiomer. MS (ESI): mass calcd. for C23H19CIFN5O, 435.1 ; m/z found, 436.1 [M+H]+. Example 183: (SV(3-(3-Chloro-4-methylphenylV2.7-dimethyl-2A5.7-tetrahvdro-6H-
Pyrazolo[3.4-c1pyridin-6-yl)('quinoxalin-6-yl)methanone.
Figure imgf000318_0003
The title compound was prepared in a manner analogous to Example 106, using 3-chloro-4- methylphenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and quinoxaline-6-carboxylic acid instead of quinoline 6-carboxybc acid in Step C. MS (ESI): mass calcd. for C24H22CIN5O, 431.1 ; m/z found, 432.1 [M+H] +. XH NMR (400 MHz, DMSO-r/e) d 9.04 (s, 2H), 8.29 - 8.11 (m, 2H), 7.91 (d, J= 8.7 Hz, 1H), 7.64 - 7.33 (m, 3H), 5.65 (s, 1H), 4.72 (s, 1H), 3.76 (d, J= 37.7 Hz, 3H), 2.85 (s, 1H), 2.39 (s, 3H),
2.31 (d, J= 17.1 Hz, 2H), 1.53 (s, 3H).
Example 184: (S)-(3-(3-Fluoro-5-(trifluoromethyl)phenyl)-2.7-dimethyl- tetrahvdro-6H-
Figure imgf000319_0001
Pyrazolo[3.4-c1pyridin-6-yl )('quinoxalin-6-yl )methanone.
Figure imgf000319_0002
The title compound was prepared in a manner analogous to Example 106, using (3-fluoro-5- (trifluoromethyl)phenyl)boronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert- butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridine-6-carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and quinoxaline-6-carboxylic acid instead of quinoline 6-carboxybc acid in Step C. MS (ESI): mass calcd. for C24H19F4N5O, 469.1; m/z found, 470.1 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 9.04 (d, J= 2.4 Hz, 2H), 8.28 - 8.10 (m, 2H), 7.99 - 7.65 (m, 4H), 5.67 (s, 1H), 4.74 (s, 1H), 3.82 (d, J= 33.4 Hz, 3H), 3.69 (d, J= 12.9 Hz, 1H), 2.92 (s, 1H), 2.34 (d, J= 13.1 Hz, 1H), 1.54 (d, = 6.7 Hz, 3H). Example 185: (SV(3-(3-Fluoro-4-methoxyphenylV2.7-dimethyl-2A5.7-tetrahvdro-6H- Pyrazoloi3.4-c1pyridin-6-yl)tauinoxalin-6-yl)methanone.
Figure imgf000320_0001
The title compound was prepared in a manner analogous to Example 106, using 3-fluoro-4- methoxyphenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and quinoxaline-6-carboxylic acid instead of quinoline 6-carboxybc acid in Step C. MS (ESI): mass calcd. for C24H22FN5O2, 431.1; m/z found, 432.1 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 9.04 (s, 2H), 8.26 - 8.09 (m, 2H), 7.97 - 7.82 (m, 1H), 7.42 (d, J
12.3 Hz, 1H), 7.29 (d, J= 8.2 Hz, 2H), 5.64 (s, 1H), 4.72 (s, 1H), 3.90 (s, 3H), 3.75 (d, J
37.5 Hz, 3H), 3.24 - 2.74 (m, 2H), 2.30 (d, J= 16.3 Hz, 1H), 1.53 (s, 3H). Example 186: (SV(3-(3-Fluoro-5-methoxyphenylV2.7-dimethyl-2.4.5.7-tetrahvdro-6H- Pyrazolo[3.4-c1pyridin-6-yl)('quinoxalin-6-yl)methanone.
Figure imgf000320_0002
The title compound was prepared in a manner analogous to Example 106, using 3-fluoro-5- methoxyphenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and quinoxaline-6-carboxylic acid instead of quinoline 6-carboxybc acid in Step C. MS (ESI): mass calcd. for C24H22FN5O2, 431.1; m/z found, 432.1 [M+H] +. 'H NMR (500 MHz, DMSO-r/e) d 9.02 (s, 2H), 8.26 - 8.02 (m, 2H), 7.98 - 7.80 (m, 1H), 7.00 - 6.84 (m, 3H), 5.63 (d, J= 7.6 Hz, 1H), 4.71 (s, 1H), 3.81 (d, J= 8.3 Hz, 6H), 3.37 - 2.82 (m,
2H), 2.31 (d, J= 15.0 Hz, 1H), 1.59 - 1.37 (m, 3H).
Example 187: (SV(3-(3-Fluoro-5-methoxyphenylV2.7-dimethyl-2.4.5.7-tetrahvdro-6H- Pyrazolo[3.4-c1pyridin-6-yl)('7-fluoroquinoxalin-6-yl)methanone.
Figure imgf000321_0001
The title compound was prepared in a manner analogous to Example 106, using 3-fluoro-5- methoxyphenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 7-fluoroquinoxaline-6-carboxylic acid instead of quinoline 6- carboxylic acid in Step C. MS (ESI): mass calcd. for C24H21F2N5O2, 449.1 ; m/z found, 450.1
Figure imgf000321_0002
9.09 - 8.95 (m, 2H), 8.25 (d, J= 6.9 Hz, 1H), 8.07 (d, J= 9.9 Hz, 1H), 7.02 - 6.83 (m, 3H), 5.69 (d, J= 6.9 Hz, 1H), 4.84 - 4.53 (m, 1H), 3.89 - 3.50 (m, 6H), 3.27 - 2.71 (m, 2H), 2.16 (s, 1H), 1.47 (dd, J= 53.8, 6.7 Hz, 3H).
Example 188: (SV(3-(3-Chloro-4-methoxyphenylV2.7-dimethyl-2A5.7-tetrahvdro-6H- pyrazolor3.4-c1pyridin-6-yl auinoxalin-6-yl1methanone.
Figure imgf000322_0001
The title compound was prepared in a manner analogous to Example 106, using 3-chloro-4- methoxyphenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and quinoxaline-6-carboxylic acid instead of quinoline 6-carboxybc acid in Step C. MS (ESI): mass calcd. for C24H22CIN5O2, 447.1; m/z found, 448.1 [M+H] +. 'H NMR (400 MHz, DMSO-r/e) d 9.04 (s, 2H), 8.23 - 8.09 (m, 2H), 7.91 (d, J= 8.7 Hz, 1H), 7.58 (d, J= 2.1 Hz, 1H), 7.45 (dd, J= 8.5, 2.2 Hz, 1H), 7.28 (d, J= 8.6 Hz, 1H), 5.64 (s, 1H), 4.72 (s, 1H), 3.92 (s, 3H), 3.74 (d, J= 41.4 Hz, 3H), 3.22 - 2.75 (m, 2H), 2.29 (d, J= 14.9 Hz, 1H), 1.53 (s, 3H).
Example 189: (SV(3-(4-(DifluoromethoxyV3-fluorophenv0-2.7-dimethyl-2.4.5.7-tetrahvdro- 6H-pyrazolo[3.4-c1pyridin-6-yl)('quinoxalin-6-yl)methanone.
Figure imgf000322_0002
The title compound was prepared in a manner analogous to Example 106, using (4- (difluoromethoxy)-3-fluorophenyl)boronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 7) in Step A, and quinoxaline-6-carboxylic acid instead of quinoline 6-carboxylic acid in Step C. MS (ESI): mass calcd. for C24H20F3N5O2, 467.1; m/z found, 468.1
Figure imgf000323_0001
9.04 (d, J= 2.2 Hz, 2H), 8.26 - 8.09 (m, 2H), 7.91 (d, J= 8.0 Hz, 1H), 7.64 (d, J= 11.5 Hz, 1H), 7.58 - 7.47 (m, 1H), 7.44 - 7.13 (m, 2H), 5.66 (s, 1H), 4.73 (s, 1H), 3.83 (s, 3H), 3.02 (d, J= 121.3 Hz, 2H), 2.32 (d, J= 13.5 Hz, 1H), 1.53 (s, 3H).
Example 190: (S)-(3-(3.5-Difluoro-4-methylphenyl)-2.7-dimethyl- tetrahvdro-6H-
Figure imgf000323_0002
Pyrazolo[3.4-c1pyridin-6-yl)('quinoxalin-6-yl)methanone.
Figure imgf000323_0003
The title compound was prepared in a manner analogous to Example 106, using (3,5-difluoro-4- methylphenyl)boronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and quinoxaline-6-carboxylic acid instead of quinoline 6-carboxylic acid in Step C. MS (ESI): mass calcd. for C24H21F2N5O, 433.1; m/z found, 434.1 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 9.04 (d, J= 2.3 Hz, 2H), 8.30 - 8.05 (m, 2H), 7.91 (d, J= 8.6 Hz, 1H), 7.28 (d, J= 7.0 Hz, 2H), 5.65 (s, 1H), 4.72 (s, 1H), 3.80 (d, J= 34.7 Hz, 3H), 2.90 (s, 2H), 2.32 (d, J= 15.0 Hz, 1H), 2.21 (s, 3H), 1.53 (s, 3H). Example 191 : (SV(2-Chloro-3-methoxyphenyl¥2.7-dimethyl-3-(3 A5-trifluorophenylV2A5.7- tetrahvdro-6H-pyrazolo[3.4-c1pyridin-6-yl)methanone.
Figure imgf000324_0001
The title compound was prepared in a manner analogous to Example 288, using 2-chloro-3- methoxybenzoic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H19CIF3N3O2, 449.1; m/z found, 450.0 [M+H]+. ¾ NMR (500 MHz, CDCh) d 7.34 - 7.20 (m, 1H), 7.01 - 6.74 (m, 4H), 5.98 - 5.87 (m, 0.63H), 5.04 - 4.93 (m, 0.4H), 4.86 - 4.63 (m, 0.4H), 3.96 - 3.87 (m, 3H), 3.85 - 3.76 (m, 3H), 3.61 - 3.29 (m, 1H), 3.26 - 2.94 (m, 0.59H), 2.89 - 2.75 (m, 0.61H), 2.57 - 2.43 (m, 0.76H), 2.32 - 2.22 (m, 0.61H), 1.67 - 1.36 (m, 3H).
Example 192: (SV(3-Chloro-5-methoxyphenyl¥2.7-dimethyl-3-(3 A5-trifluorophenylV2A5.7- tetrahvdro-6H-pyrazolo[3.4-c1pyridin-6-yl)methanone.
Figure imgf000324_0002
The title compound was prepared in a manner analogous to Example 288, using 3-chloro-5- methoxybenzoic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H19CIF3N3O2, 449.1; m/z found, 450.0 [M+H]+. Ή NMR (600 MHz, Methanol -ah) d 7.36 - 7.29 (m, 2H), 7.14 - 6.87 (m, 3H), 5.70 (d, J= 7.3 Hz, 0.67H), 4.86 - 4.71 (m, 0.54H), 3.91 - 3.71 (m, 6.84H), 3.46 - 3.18 (m, 0.95H), 2.88 - 2.70 (m, 1H), 2.58 - 2.39 (m, 1H), 1.61 - 1.47 (m, 3H). Example 193: ('S)-('2.7-Dimethyl-3-('3A5-trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000325_0001
c1pyridin-6-yl)('5-fluoro-2-(' l H-pyrazol- 1 -vDphenylimethanone.
Figure imgf000325_0002
The title compound was prepared in a manner analogous to Example 288, using 5-fluoro-2-(lH- pyrazol-l-yl)benzoic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H19F4N5O, 469.1 ; m/z found, 470.1 [M+H] +.
Figure imgf000325_0003
NMR (500 MHz, DMSO- ek) d 8.16 - 7.93 (m, 1H), 7.80 - 7.60 (m, 2H), 7.59 - 7.42 (m, 3H), 7.40 - 7.29 (m, 1H), 6.57 - 6.24 (m, 1H), 5.45 (q, J= 6.7 Hz, 1H), 3.85 - 3.67 (m, 3H), 3.50 - 3.35 (m, 1H), 3.24 - 2.69 (m, 2H), 2.38 - 2.08 (m, 1H), 1.38 (dd, = 60. l, 6.8 Hz, 3H).
Example 194: (S)-(3-( l H- l .2.4-Triazol- l -yl)phenyl)(2.7-dimethyl-3-(3A5-trifluorophenyl)- 2A5.7-tetrahydro-6H-pyrazolo[3 Aclpyridin-6-yl)methanone.
Figure imgf000325_0004
The title compound was prepared in a manner analogous to Example 288, using 3-(lH-l,2,4- triazol-l-yl)benzoic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H19F3N6O, 452.2; m/z found, 453.1 [M+H]+. ¾ NMR (600 MHz, CDCb) d 8.59 (s, 1H), 8.12 (s, 1H), 7.81 - 7.75 (m, 2H), 7.58 (t, J= 7.8 Hz, 1H), 7.45 (d, = 7.7 Hz, 1H), 7.02 - 6.94 (m, 2H), 5.86 (s, 0.48H), 5.08 - 4.77 (m, 0.89H), 3.82 (s, 3.66H), 3.45 - 3.01 (m, 1H), 2.92 - 2.64 (m, 1H), 2.43 (s, 1H), 1.66 - 1.56 (m, 3H). Example 195: ('S)-('2.7-Dimethyl-3-('3A5-trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000326_0001
c1pyridin-6-yl)('3-fluoro-2-('2H- l .2.3-triazol-2-yl)phenyl)methanone.
Figure imgf000326_0002
The title compound was prepared in a manner analogous to Example 288, using 3-fluoro-2-(2H- l,2,3-triazol-2-yl)benzoic acid (prepared according to methods described in Pat. Pub. No.
WO2011050202, April 28, 2011) instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F4N6O, 470.1; m/z found, 471.1 [M+H]+. Ή NMR (500 MHz, CDCh) 5 7.89 - 7.78 (m, 1.52H), 7.61 - 7.48 (m, 1.36H), 7.39 - 7.32 (m, 1.09H), 7.23 (d, J = 7.6, 1.2 Hz, 0.73H), 6.99 - 6.88 (m, 2H), 5.68 (q, J= 6.7 Hz, 0.7H), 4.93 - 4.66 (m, 0.51H), 3.84 - 3.76 (m, 3.09H), 3.67 (dd, J= 13.9, 5.3 Hz, 0.75H), 3.27 - 2.89 (m, 1H), 2.67 - 2.27 (m, 2H),
1.57 - 1.31 (m, 3.25H).
Example 196: ('S)-('2.7-Dimethyl-3-('3A5-trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazolo[3A clpyridin-6-yl )(4-fluoro-2-(2H- 1 2.3-triazol-2-yl jphenyl jmethanone.
Figure imgf000326_0003
The title compound was prepared in a manner analogous to Example 288, using 4-fluoro-2-(2H- l,2,3-triazol-2-yl)benzoic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F4N6O, 470.1; m/z found, 471.2 [M+H]+. Ή NMR (500 MHz, CDCh) 5 7.89 - 7.73 (m, 2.63H), 7.53 - 7.34 (m, 1.46H), 7.20 - 7.11 (m, 0.92H), 7.01 - 6.81 (m, 2H), 5.96 - 5.78 (m, 0.67H), 5.02 - 4.69 (m, 0.66H), 3.90 - 3.71 (m, 3.11H), 3.65 - 3.49 (m, 0.67H), 3.30 - 2.76 (m, 1.34H), 2.65 - 2.39 (m, 0.86H), 2.32 - 2.23 (m, 0.51H), 2.14 - 1.84 (m, 0.35H), 1.68 - 1.53 (m, 1.75H), 1.44 (d, = 6.8 Hz, 0.73H), 1.06 (d, = 6.7 Hz, 0.34H).
Example 197: ('S)-('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl)(5-methyl-2-(2H- 1.2.3-triazol-2-yl)phenyl)methanone.
Figure imgf000327_0001
The title compound was prepared in a manner analogous to Example 288, using 5-methyl-2-(2H- l,2,3-triazol-2-yl)benzoic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H21F3N6O, 466.2; m/z found, 467.1 [M+H]+. Ή NMR (600 MHz, Methanol-i/4) d 8.01 - 7.86 (m, 2H), 7.82 - 7.62 (m, 1H), 7.50 - 7.44 (m, 1H), 7.38 - 7.09 (m, 3H), 5.74 - 5.62 (m, 0.66H), 4.82 - 4.60 (m, 0.78H), 3.86 - 3.80 (m, 2H), 3.79 - 3.72 (m, 1H), 3.67 - 3.58 (m, 0.64H), 3.39 - 3.11 (m, 1.12H), 2.91 - 2.66 (m, 0.8H), 2.52 - 2.44 (m, 3H), 2.41 - 1.90 (m, 1H), 1.61 - 1.38 (m, 3H). Example 198: -('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazoloi3.4- c1pyridin-6-yl)n -methyl-5-(trifluoromethyl)- 1 H-pyrazol-4-yl)methanone.
Figure imgf000327_0002
The title compound was prepared in a manner analogous to Example 288, using l-methyl-5- (trifluoromethyl)-lH-pyrazole-4-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C20H17F6N5O, 457.1; m/z found, 458.0 [M+H]+. ¾ NMR (600 MHz, Methanol-i/4) d 7.68 - 7.63 (m, 1H), 7.27 (t, J= 7.3 Hz, 2H), 5.72 (q, J= 6.8 Hz, 0.68H), 4.05 (s, 3H), 3.85 - 3.74 (m, 3.8H), 3.45 - 3.32 (m, 0.91H), 3.16 (s, 0.43H), 2.73 - 2.60 (m, 1H), 2.58 - 2.40 (m, 1H), 1.55 - 1.43 (m, 3.16H).
Example 199: ('S)-(' l -('tert-Butyl)-5-('trifluoromethyl)- l H-pyrazol-4-yl)(2.7-dimethyl-3-(3.4.5- trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazolo c|pyridin-6-yl)methanone.
Figure imgf000328_0001
Figure imgf000328_0002
The title compound was prepared in a manner analogous to Example 288, using l-(tert-butyl)-5- (trifluoromethyl)-lH-pyrazole-4-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C23H23F6N5O, 499.2; m/z found, 500.1 [M+H]+. ¾ NMR (600 MHz, Methanol-i 4) d 7.64 - 7.60 (m, 1H), 7.31 - 7.24 (m, 2H), 5.71 (q, J= 6.8 Hz, 0.7H), 4.80 - 4.73 (m, 0.62H), 3.85 - 3.76 (m, 3H), 3.72 - 3.64 (m, 0.71H), 3.45 - 3.34 (m, 0.93H), 3.22 - 3.12 (m, 0.24H), 2.75 - 2.59 (m, 0.91H), 2.57 - 2.50 (m, 0.26H), 2.47 - 2.39 (m, 0.65H), 1.70 (s, 9H), 1.54 - 1.44 (m, 3H). Example 200: -('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazoloi3.4- clpyridin-6-yl)(5-methoxy- 1 -methyl- 1 H-pyrazol-3-yl)methanone.
Figure imgf000328_0003
The title compound was prepared in a manner analogous to Example 288, using 5-methoxy-l- methyl-lH-pyrazole-3 -carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C20H20F3N5O2, 419.1; m/z found, 420.1 [M+H] +. Ή NMR (500
MHz, DMSO-r/e) d 7.54 (dd, J= 8.6, 6.6 Hz, 2H), 6.02 (s, 2H), 5.00 - 4.52 (m, 1H), 3.90 (s, 3H), 3.78 (d, J= 17.2 Hz, 3H), 3.61 (s, 3H), 3.26 - 2.68 (m, 2H), 2.41 (d, J= 15.5 Hz, 1H), 1.54 - 1.32 (m, 3H).
Example 201 : (SV(5-Cvclopropyl-l-methyl-lH-pyrazol-4-yr)(2.7-dimethyl-3-(3A5- trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazolo c|pyridin-6-yl)methanone.
Figure imgf000329_0001
Figure imgf000329_0002
The title compound was prepared in a manner analogous to Example 288, using 5-cyclopropyl- 1- methyl-lH-pyrazole-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H22F3N5O, 429.2; m/z found, 430.1 [M+H]+.
Figure imgf000329_0003
(500 MHz, DMSO-r/e) 5 7.58 - 7.50 (m, 2H), 7.41 (s, 1H), 5.55 (s, 0.68H), 4.99 - 4.46 (m, 0.36H), 3.88 - 3.74 (m, 7.14H), 3.27 - 3.13 (m, 0.95H), 2.73 (s, 1H), 2.38 - 2.26 (m, 0.87H), 1.85 (s, 1H), 1.47 - 1.36 (m, 3H), 0.90 (s, 2H), 0.59 (s, 2H).
Example 202: -('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazoloi3.4- clpyridin-6-yl)(5-ethyl- 1 -phenyl- 1 H- l .2.4-triazol-3-yl)methanone.
Figure imgf000329_0004
The title compound was prepared in a manner analogous to Example 288, using 5-ethyl-l- phenyl-lH-l,2,4-triazole-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C25H23F3N6O, 480.2; m/z found, 481.2 [M+H]+. ¾ NMR (500 MHz, CDCb) d 7.56 - 7.43 (m, 5H), 7.00 - 6.91 (m, 2H), 5.93 - 5.55 (m, 1H), 4.95 - 4.48 (m, 1H), 3.85 - 3.74 (m, 3H), 3.39 - 3.06 (m, 1H), 2.99 - 2.78 (m, 3H), 2.49 - 2.36 (m, 1H), 1.73 - 1.57 (m, 3H), 1.39 - 1.32 (m, 3H).
Example 203: ('S)-('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl)(5-methoxypyridin-3-yl)methanone.
Figure imgf000330_0001
The title compound was prepared in a manner analogous to Example 288, using 5- methoxynicotinic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H19F3N4O2, 416.1; m/z found, 417.1 [M+H]+. ' H NMR (600 MHz, MethanoW/4) d 8.36 (s, 1H), 8.26 - 8.17 (m, 1H), 7.53 - 7.44 (m, 1H), 7.31 (t, J= 7.3 Hz, 2H), 5.73 (d, J= 7.4
Hz, 0.7H), 4.85 - 4.68 (m, 0.55H), 3.93 (s, 3H), 3.81 (d, J= 38.5 Hz, 3.78H), 3.47 - 3.37 (m, 0.68H), 3.29 - 3.21 (m, 0.31H), 2.89 - 2.76 (m, 1H), 2.60 - 2.42 (m, 1H), 1.63 - 1.50 (m, 3H).
Example 204: ('S)-6-('2.7-Dimethyl-3-('3A5-trifluorophenyl)-4.5.6.7-tetrahvdro-2H-pyrazolo[3.4- c1pyridine-6-carbonyl)-4-methyl-2H-benzoibiri 41oxazin-3t4H)-one.
Figure imgf000330_0002
The title compound was prepared in a manner analogous to Example 288, using 4-methyl-3-oxo- 3,4-dihydro-2H-benzo[b][l,4]oxazine-6-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol- 2-yl)benzoic acid. MS (ESI): mass calcd. for C24H21F3N4O3, 470.2; m/z found, 471.1
[M+H]+. (600 MHz, Methanol-i/4) d 7.32 (t, J= 7.3 Hz, 2H), 7.25 (s, 1H), 7.16 (d, J =
8.2 Hz, 1H), 7.10 (d, J= 8.2 Hz, 1H), 5.70 (s, 0.72H), 4.70 (s, 2.25H), 3.98 - 3.71 (m, 3.81H), 3.40 (s, 4.03H), 2.91 - 2.79 (m, 1H), 2.55 - 2.42 (m, 1H), 1.62 - 1.56 (m, 3.18H). Example 205: (SV(2.7-Dimethyl-3-(3.4.5-trifluorophenylV2.4.5.7-tetrahvdro-6H-pyrazolor3.4- clpyridin-6-yl)n H-indol-7-yl)methanone.
Figure imgf000331_0001
The title compound was prepared in a manner analogous to Example 288, using indole-7- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H19F3N4O, 424.2; m/z found, 425.1 [M+H]+. ¾ NMR (500 MHz, CDCh) d 9.17 (s, 1H), 7.73 (d, J= 7.9 Hz, 1H), 7.33 - 7.23 (m, 2H), 7.15 - 7.09 (m, 1H), 7.03 - 6.94 (m, 2H), 6.59 - 6.55 (m, 1H), 5.69 (s, 0.79H), 4.50 (s, 0.81H), 3.81 (s, 3H), 3.28 (t, J= 12.6 Hz, 1H), 2.94 - 2.82 (m, 1H), 2.51 - 2.43 (m, 1H), 1.69 - 1.61 (m, 3.42H).
Example 206: ('S)-('2.7-Dimethyl-3-('3A5-trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000331_0002
clpyridin-6-yl¥l -methyl- lH-indol-7-yllmethanone.
Figure imgf000331_0003
To a solution of [(S)-(2,7-dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridin-6-yl)(lH-indol-7-yl)methanone] (Example 205) (19.3 mg, 45.5 pmol) in THF (0.78 mL) at 0 °C was added NaH (60% dispersion, 1.83 mg, 45.9 pmol). After stirring for 15 minutes, Mel (3.1 pL, 50.1 pmol) was added and the cold bath removed. The reaction was stirred at room temperature for 3 h, and then quenched with saturated aqueous NH4Cl. EtOAc was added, the layers separated, and the aqueous layer extracted with EtOAc (x2). The combined organics were washed with brine, dried over Na2S04, filtered, and concentrated. The residue was purified by preparative HPLC to yield the title compound (17.1 mg, 86% yield). MS (ESI): mass calcd. for C24H21F3N4O, 438.2; m/z found, 439.1
Figure imgf000332_0001
NMR (500 MHz, CDCb) d 7.69 - 7.60 (m, 1H), 7.18 - 6.88 (m, 5H), 6.55 - 6.45 (m, 1H), 6.10 - 5.94 (m, 0.65H), 5.24 - 4.98 (m, 0.48H), 4.87 - 4.79 (m, 0.25H), 3.91 - 3.67 (m, 5.78H), 3.59 (s, 0.73H), 3.36 - 3.04 (m, 1.03H), 2.93 - 2.65 (m, 0.88H), 2.58 - 2.48 (m, 0.36H), 2.46 - 2.36 (m, 0.18H), 2.33 - 2.17 (m, 0.66H),
1.71 - 1.46 (m, 3H).
Example 207: (SV(2.7-dimethyl-3-(3.4.5-trifluorophenylV2.4.5.7-tetrahvdro-6H-pyrazolor3.4- clpyridin-6-vb( 1 -methyl- 1 H-indol-4-yl jmethanone.
Figure imgf000332_0002
The title compound was prepared in a manner analogous to Example 288, using 1 -methyl- 1H- indole-4-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H21F3N4O, 438.2; m/z found, 439.1 [M+H]+. ¾ NMR (500 MHz, CDCb) d 7.37 (d, J= 8.2 Hz, 1H), 7.26 - 7.21 (m, 1H), 7.14 - 6.90 (m, 3.77H), 6.55 - 5.90 (m, 1.25H), 5.01 (s, 0.48H), 3.91 - 3.68 (m, 6.28H), 3.33 - 2.08 (m, 2.54H), 1.75 - 1.34 (m, 4.68H).
Example 208: ('S)-('2.7-Dimethyl-3-('3A5-trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000332_0003
c1pyridin-6-yl)n H-indazol-7-yl)methanone.
Figure imgf000332_0004
The title compound was prepared in a manner analogous to Example 288, using lH-indazole-7- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H18F3N5O, 425.1; m/z found, 426.0 [M+H]+. ¾ NMR (600 MHz, Methanol-i/4) d 8.15 (s, 1H), 7.93 (d, J= 8.1 Hz, 1H), 7.46 (d, J= 7.0 Hz, 1H), 7.34 - 7.24 (m, 3H), 5.98 - 5.63 (m, 0.56H), 3.94 - 3.76 (m, 3.4H), 3.47 - 3.35 (m, 0.76H), 2.66 (d, J= 215.4 Hz, 2.15H), 1.73 - 1.48 (m, 3.35H), 1.38 - 1.32 (m, 0.78H). Example 209: ('S)-('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- indazol-7-yl )methanone.
Figure imgf000333_0001
The title compound was prepared in a manner analogous to Example 288, using 1 -methyl- 1H- indazole-7-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. Ή NMR (600 MHz, Methanol- ck) 5 8.15 - 8.05 (m, 1H), 7.93 - 7.87 (m, 1H), 7.49 - 7.16 (m, 4H), 6.02 - 5.78 (m, 0.66H), 5.12 - 4.90 (m, 0.52H), 4.71 - 4.58 (m, 0.25H), 4.07 (s, 1.66H), 3.94 (s, 0.62H), 3.89 - 3.71 (m, 4.1H), 3.65 (m, 0.42H), 3.52 - 3.40 (m, 0.62H), 2.94 - 2.74 (m, 0.9H), 2.68 - 2.58 (m, 0.35H), 2.52 - 2.31 (m, 0.91H), 1.70 - 1.47 (m, 3H).
Example 210: ('S)-('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl )(7-methyl- 1 H-indazol-5-yl jmethanone.
Figure imgf000333_0002
The title compound was prepared in a manner analogous to Example 288, using 7-methyl-lH- indazole-5-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. ¾ NMR (500 MHz, CDCb) d 10.9 (s, 1H), 8.12 (s, 1H), 7.67 (s, 1H), 7.22 (s, 1H), 7.06 - 6.93 (m, 2H), 5.85 (s, 0.35H), 5.23 - 4.62 (m, 0.65H), 3.80 (s, 3.49H), 3.21 (s, 1H), 2.79 (s, 1H), 2.60 - 2.35 (m, 4.29H), 1.93 - 1.47 (m, 3.23H). Example 211 : ('S)-('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- azol-S-yllmethanone.
Figure imgf000334_0001
The title compound was prepared in a manner analogous to Example 288, using 1 -methyl- 1H- indazole-5-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. ¾ NMR (500 MHz, CDCb) d 8.03 (d, = 0.9 Hz, 1H), 7.84 (s, 1H), 7.51 - 7.42 (m, 2H), 7.02 - 6.95 (m, 2H), 6.11 - 4.47 (m, 1.1H), 4.11 (s, 3.15H), 3.80 (s, 3.13H), 3.22 (s, 1H), 2.79 (s, 1H), 2.46 - 2.34 (m, 1H), 1.60 (d, J = 9.8 Hz, 3.61H). Example 212: -('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazoloi3.4- c1pyridin-6-yl)('imidazo[ 1.5-a1pyridin-8-yl)methanone.
Figure imgf000334_0002
The title compound was prepared in a manner analogous to Example 288, using imidazo[l,5- a]pyridine-8-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H18F3N5O, 425.1 ; m/z found, 426.1 [M+H] +.
Figure imgf000334_0003
NMR (500 MHz, DMSO- de) d 8.51 - 8.38 (m, 2H), 7.55 (s, 2H), 7.24 (s, 1H), 6.84 (dd, J= 6.5, 0.9 Hz, 1H), 6.74 (t, J = 6.8 Hz, 1H), 5.64 (s, 1H), 4.40 (d, J= 307.0 Hz, 1H), 3.80 (s, 4H), 2.64 (t, J= 1.9 Hz, 1H), 2.45 - 2.24 (m, 1H), 1.50 (s, 3H).
Example 213: ('S)-('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl)('imidazo[ 1.2-alpyridin-3-yl)methanone.
Figure imgf000335_0001
The title compound was prepared in a manner analogous to Example 288, using imidazo[l,2- a]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H18F3N5O, 425.1 ; m/z found, 426.1 [M+H] +.
Figure imgf000335_0002
NMR (500 MHz, DMSO- ek) d 8.92 (dt, = 7.0, 1.2 Hz, 1H), 8.09 (s, 1H), 7.80 - 7.67 (m, 1H), 7.58 (dd, J= 8.7, 6.6 Hz, 2H), 7.54 - 7.41 (m, 1H), 7.22 - 7.01 (m, 1H), 5.52 (q, J= 6.7 Hz, 1H), 4.45 (dd, J= 14.0, 5.0 Hz, 1H), 3.81 (s, 3H), 3.12 (d, = 50.9 Hz, 2H), 2.49 - 2.44 (m, 1H), 1.56 (d, = 6.7 Hz, 3H).
Example 214: ('S)-('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- c1pyridin-6-yl)tfuroi3.2-c1pyridin-4-yl)methanone.
Figure imgf000335_0003
The title compound was prepared in a manner analogous to Example 288, using furo[3,2- c]pyridine-4-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H17F3N4O2, 426.1 ; m/z found, 427.1 [M+H]+. Ή NMR (600 MHz, Methanol- ck) d 8.54 - 8.48 (m, 1H), 7.99 (dd, J= 13.6, 2.3 Hz, 1H), 7.74 - 7.71 (m, 1H), 7.35 - 7.27 (m, 2H), 7.06 - 6.97 (m, 1H), 5.83 (q, J= 6.8 Hz, 0.65H), 5.02 (q, J= 6.8 Hz, 0.36H), 3.90 - 3.82 (m, 2.73H), 3.76 (s, 1H), 3.46 - 3.36 (m, 0.7H), 3.30 - 3.24 (m, 0.58H), 2.94 - 2.79 (m, 1H), 2.66 - 2.33 (m, 1H), 1.70 - 1.50 (m, 3H).
Example 215: (SVBenzordlisoxazol-3-yl(2.7-dimethyl-3-(3A5-trifluorophenylV2A5.7- tetrahydro-6H-pyrazolo[3 Ac1pyridin-6-yl)methanone.
Figure imgf000336_0001
The title compound was prepared in a manner analogous to Example 288, using
benzo[d]isoxazole-3 -carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H17F3N4O2, 426.1; m/z found, 427.1 [M+H]+. Ή NMR (500 MHz, CDCh) d 8.04 - 7.93 (m, 1H), 7.67 - 7.57 (m, 2H), 7.44 - 7.36 (m, 1H), 7.03 - 6.94 (m, 2H), 6.00 - 5.60 (m, 1H), 5.06 - 4.56 (m, 1H), 3.89 - 3.73 (m, 3H), 3.45 - 3.15 (m, 1H), 2.99 - 2.81 (m, 1H), 2.60 - 2.44 (m, 1H), 1.75 - 1.64 (m, 3H).
Example 216: ('S)-('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- c1pyridin-6-yl)n H-pyrroloi3.2-c1pyridin-4-yl)methanone.
Figure imgf000336_0002
The title compound was prepared in a manner analogous to Example 288, using lH-pyrrolo[3,2- c]pyridine-4-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H18F3N5O, 425.1; m/z found, 426.2 [M+H]+. Ή NMR (500 MHz, Methanol- d ) d 8.22 (dd, J= 5.8, 2.0 Hz, 1H), 7.59 - 7.45 (m, 2H), 7.38 - 7.24 (m, 2H), 6.64 - 6.51 (m,
1H), 5.89 (q, J= 6.8 Hz, 0.66H), 4.98 - 4.91 (m, 0.57H), 4.84 - 4.73 (m, 0.25H), 3.89 - 3.74 (m, 3H), 3.67 - 3.56 (m, 0.64H), 3.41 - 3.23 (m, 0.88H), 2.96 - 2.69 (m, 1H), 2.66 - 2.30 (m, 1H), 1.71 - 1.41 (m, 3H).
Example 217: ('S)-('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl¥l -methyl- lH-pyrrolor3.2-clpyridin-4-yl1methanone.
Figure imgf000337_0001
The title compound was prepared in a manner analogous to Example 206, using Example 216 [(S)-(2,7-dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(lH-pyrrolo[3,2-c]pyridin-4-yl)methanone] instead of [(S)-(2,7-dimethyl-3-(3,4,5- trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(lH-indol-7-yl)methanone]. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+.
Figure imgf000337_0002
(600 MHz, Methanol-d4) d 8.29 - 8.22 (m, 1H), 7.62 - 7.55 (m, 1H), 7.47 - 7.38 (m, 1H), 7.35 - 7.24 (m, 2H), 6.61 - 6.51 (m, 1H), 5.90 - 5.82 (m, 0.66H), 4.98 - 4.92 (m, 0.27H), 4.79 - 4.73 (m, 0.33H), 3.94 - 3.73 (m, 6.41H), 3.61 - 3.55 (m, 0.65H), 3.38 - 3.22 (m, 0.7H), 2.96 - 2.67 (m, 1H), 2.63 - 2.29 (m, 1H), 1.70 - 1.39 (m, 3H).
Example 218: ('S)-('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- c1pyridin-6-yl)ri H-pyrrolo[3.2-c1pyridin-3-yl)methanone.
Figure imgf000337_0003
The title compound was prepared in a manner analogous to Example 288, using lH-pyrrolo[3,2- c]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H18F3N5O, 425.1 ; m/z found, 426.1 [M+H]+. Ή NMR (500 MHz, Methanol- d4) 5 8.98 (s, 1H), 8.24 (d, = 5.9 Hz, 1H), 7.82 (s, 1H), 7.52 (dd, = 5.8, 1.1 Hz, 1H), 7.35 - 7.27 (m, 2H), 5.66 (s, 1H), 4.52 (s, 1H), 3.82 (s, 3H), 3.50 - 3.36 (m, 1H), 2.94 - 2.84 (m, 1H), 2.60 - 2.50 (m, 1H), 1.65 - 1.60 (m, 3H). Example 219: (Si-dd-Dimethyld-d AS- tetrahvdro-OH-pyrazololdN-
Figure imgf000338_0001
yrrolor3.2-clpyridin-3-yl1methanone.
Figure imgf000338_0002
The title compound was prepared in a manner analogous to Example 206, using Example 218 [(S)-(2,7-dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(lH-pyrrolo[3,2-c]pyridin-3-yl)methanone] instead of [(S)-(2,7-dimethyl-3-(3,4,5- trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(lH-indol-7-yl)methanone]. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+.
Figure imgf000338_0003
(500 MHz, Methanol-i/4) d 8.98 (s, 1H), 8.29 (d, J= 6.0 Hz, 1H), 7.79 (s, 1H), 7.56 (dd, J= 6.0, 1.1 Hz, 1H), 7.36 - 7.28 (m, 2H), 5.66 (s, 0.89H), 4.51 (s, 0.81H), 3.93 (s, 3.19H), 3.82 (s, 3.13H), 3.44 (d, J = 9.0 Hz, 1H), 2.99 - 2.85 (m, 1H), 2.59 - 2.50 (m, 1H), 1.68 - 1.59 (m, 3H).
Example 220: (S)-(2.7-Dimethyl-3-(3 A5-trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazolor3 A c1pyridin-6-yl l -methyl- lH-pyrrolor3.2-b1pyridin-3-yl1methanone.
Figure imgf000338_0004
The title compound was prepared in a manner analogous to Example 288, using l-methyl-lH- pyrrolo[3,2-b]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. ¾ NMR (600 MHz, CDCh) d 8.57 - 8.52 (m, 1H), 7.79 - 7.61 (m, 2H), 7.20 - 7.16 (m, 1H), 7.02 - 6.96 (m, 2H), 5.81 (s, 0.82H), 4.99 - 4.22 (m, 0.81H), 3.93 - 3.70 (m, 6H), 3.29 (s, 1.9H), 2.38 (d, J = 15.2 Hz, 1H), 1.71 - 1.60 (m, 3.45H). Example 221 : ('S)-('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl¥l -methyl- lH-pyrrolor2.3-clpyridin-3-vEmethanone.
Figure imgf000339_0001
Step A: ('S)-('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl)n H-pyrrolo[2.3-clpyridin-3-yl)methanone. The title compound was prepared in a manner analogous to Example 288, using lH-pyrrolo[2,3-c]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H18F3N5O, 425.1; m/z found, 426.0 [M+H]+.
Step B: ('S)-('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- -methyl- lH-pyrrolor2.3-clpyridin-3-vEmethanone. The title compound was
Figure imgf000339_0002
prepared in a manner analogous to Example 206, using (S)-(2,7-dimethyl-3-(3,4,5- trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(lH-pyrrolo[2,3-c]pyridin-3- yl)methanone instead of [(S)-(2,7-dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridin-6-yl)(lH-indol-7-yl)methanone] MS (ESI): mass calcd. for
C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. Ή NMR (500 MHz, Methanol -L) d 9.34 (s, 1H), 8.50 (s, 1H), 8.35 (d, J= 6.5 Hz, 1H), 8.28 (d, J= 6.5 Hz, 1H), 7.36 - 7.27 (m, 2H), 5.65 (s,
0.9H), 4.41 (s, 0.91H), 4.18 (s, 3.14H), 3.83 (s, 3.16H), 3.49 (s, 0.88H), 2.99 - 2.88 (m, 1H), 2.65 - 2.51 (m, 1H), 1.69 - 1.61 (m, 3H). Example 222: ('S)-('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- c1pyridin-6-yl l -methyl- lH-pyrrolor2.3-b1pyridin-2- methanone.
Figure imgf000340_0001
Figure imgf000340_0002
The title compound was prepared in a manner analogous to Example 288, using 1 -methyl- 1H- pyrrolo[2,3-b]pyridine-2-carboxylic acid instead of 2-fluoro-6-(2H-l ,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. ¾ NMR (500 MHz, CDCb) 5 8.41 (dd, = 4.7, 1.6 Hz, 1H), 7.93 (dd, = 7.8, 1.6 Hz, 1H), 7.11 (dd, = 7.8, 4.7 Hz, 1H), 7.02 - 6.94 (m, 2H), 6.61 (s, 1H), 6.05 - 4.12 (m, 1.32H), 3.99 - 3.72 (m, 6.18H), 3.29 (s, 1H), 2.90 - 2.73 (m, 1H), 2.48 (d, J= 15.3 Hz, 1H), 1.71 - 1.55 (m, 3.5H).
Example 223: ('S)-('2.7-Dimethyl-3-('3A5-trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000340_0003
blpyridind-yllmethanone.
Figure imgf000340_0004
The title compound was prepared in a manner analogous to Example 288, using 1 -methyl- 1H- pyrrolo[2,3-b]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H-l ,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. ¾ NMR (600 MHz, Methanol-i/4) 5 8.35 (dd, J= 4.7, 1.6 Hz, 1H), 8.19 (d, J= 7.9 Hz, 1H), 7.85 (s, 1H), 7.33 (dd, = 8.1, 6.4 Hz, 2H), 7.25 (dd, = 7.9, 4.7 Hz, 1H), 5.65 (s, 1H), 4.51 (s, 1H), 3.95 (s, 3H), 3.83 (s, 3H), 3.42 (p, J= 1.6 Hz, 1H), 2.96 - 2.88 (m, 1H), 2.54 (dd, J= 15.4, 3.8 Hz, 1H), 1.62 (d, = 6.8 Hz, 3H). Example 224: (S)-(2.7-Dimethyl-3-(3 A5-trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazolor3 A vnmethanone.
Figure imgf000341_0001
Step A: ('S)-('2.7-Dimethyl-3-('3A5-trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000341_0002
clpyridin-6-yl)n H-pyrrolo c|pyridin-4-yl)methanone. The title compound was prepared in a
Figure imgf000341_0003
manner analogous to Example 288, using lH-pyrrolo[2,3-c]pyridine-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H18F3N5O, 425.1; m/z found, 426.0 [M+H]+.
Step B: ('S)-('2.7-Dimethyl-3-('3A5-trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazolo[3 A clpyridinA-vnd -methyl- lH- vnmethanone. The title compound was
Figure imgf000341_0004
prepared in a manner analogous to Example 206, using (S)-(2,7-dimethyl-3-(3,4,5- trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(lH-pyrrolo[2,3-c]pyridin-4- yl)methanone instead of [(S)-(2,7-dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridin-6-yl)(lH-indol-7-yl)methanone]. MS (ESI): mass calcd. for
C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. ¾ NMR (500 MHz, Methanol -L) d 8.86 (s,
1H), 8.16 (s, 1H), 7.59 (s, 1H), 7.30 (s, 2H), 6.59 - 6.35 (m, 1H), 5.88 (s, 0.61H), 4.99 - 4.87 (m, 1.21H), 4.00 (s, 3H), 3.92 - 3.66 (m, 3.75H), 3.45 - 3.37 (m, 0.54H), 2.98 - 2.29 (m, 1.88H),
1.75 - 1.38 (m, 3H). Example 225: ('S)-('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl)(T -methyl- lH-pyrrolor2.3-blpyridin-4-yl)methanone.
Figure imgf000341_0005
The title compound was prepared in a manner analogous to Example 288, using l-methyl-7- azaindole-4-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. Ή NMR (600 MHz, Methanol- ck) d 8.37 (d, J= 4.8 Hz, 1H), 7.54 - 7.44 (m, 1H), 7.39 - 7.24 (m, 2H), 7.17 - 7.10 (m, 1H), 6.50 - 6.31 (m, 1H), 5.87 (q, J= 6.8 Hz, 0.66H), 4.98 - 4.90 (m, 0.36H), 4.80 - 4.73 (m, 0.34H),
3.92 (s, 3H), 3.88 - 3.74 (m, 3H), 3.66 - 3.58 (m, 0.64H), 3.45 - 3.35 (m, 0.59H), 3.30 - 3.22 (m, 0.4H), 2.96 - 2.30 (m, 2H), 1.73 - 1.38 (m, 3H).
Example 226: ('S)-('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- c1pyridin-6-yl¥l -methyl- lH-pyrrolor2.3-b1pyridin-5-yl1methanone.
Figure imgf000342_0001
The title compound was prepared in a manner analogous to Example 288, using 1 -methyl- 1H- pyrrolo[2,3-b]pyridine-5-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. ¾ NMR (500 MHz, CDCb) d 8.46 (d, J= 2.0 Hz, 1H), 8.03 (d, J= 2.0 Hz, 1H), 7.25 (s, 1H), 7.01 - 6.94 (m, 2H), 6.50 (d, J= 3.5 Hz, 1H), 6.11 - 4.31 (m, 0.9H), 3.92 (s, 6.97H), 3.25 (s, 1H), 2.83 (s, 1H), 2.41 (d, J= 15.3 Hz, 1H), 1.68 - 1.53 (m, 3.13H).
Example 227: ('S)-('2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- c1pyridin-6-yl)('pyrazolon .5-a1pyridin-4-yl)niethanone.
Figure imgf000342_0002
The title compound was prepared in a manner analogous to Example 288, using pyrazolo[l,5- a]pyridine-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H18F3N5O, 425.1 ; m/z found, 426.1 [M+H] +.
Figure imgf000343_0001
NMR (500 MHz, DMSO- ck) d 8.84 - 8.73 (m, 1H), 8.07 (s, 1H), 7.54 (s, 2H), 7.28 (dd, J= 6.9, 1.0 Hz, 1H), 6.97 (t, J = 7.0 Hz, 1H), 6.50 (s, 1H), 5.66 (s, 1H), 3.81 (s, 3H), 3.55 (s, 1H), 2.71 (d, J= 20.5 Hz, 2H), 2.33
(s, 1H), 1.52 (s, 3H).
Example 228: (SV(2.7-Dimethyl-3-(3.4.5-trifluorophenylV2.4.5.7-tetrahvdro-6H-pyrazolor3.4- c1pyridin-6-yl)('pyrazolon .5-a1pyridin-5-yl)methanone.
Figure imgf000343_0002
The title compound was prepared in a manner analogous to Example 288, using pyrazolo[l,5- a]pyridine-5-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H18F3N5O, 425.1; m/z found, 426.0 [M+H]+. Ή NMR (600 MHz, Methanol- ck) d 8.63 (d, J= 7.2 Hz, 1H), 8.04 (d, J= 2.3 Hz, 1H), 7.80 (s, 1H), 7.33 - 7.27 (m, 2H), 6.93 (s, 1H), 6.76 (d, J= 2.3 Hz, 1H), 5.72 (s, 0.65H), 4.94 (s, 0.46H), 3.83 (s, 3.77H), 3.51 - 3.36 (m,
0.96H), 2.90 - 2.78 (m, 1H), 2.48 (s, 0.94H), 1.59 (d, J= 6.7 Hz, 3.21H).
Example 229: ('S)-('2.7-Dimethyl-3-('3A5-trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000343_0003
c1pyridin-6-yl)('pyrazolon .5-a1pyrazin-3-yl)methanone.
Figure imgf000343_0004
The title compound was prepared in a manner analogous to Example 288, using pyrazolo[l,5- a]pyrazine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H17F3N6O2, 426.1 ; m/z found, 427.1 [M+H] +. Ή NMR (500 MHz, DMSO-r/e) d 9.33 (d, J= 1.4 Hz, 1H), 8.91 (dd, J= 4.7, 1.5 Hz, 1H), 8.50 (s, 1H), 8.08 (d, J = 4.7 Hz, 1H), 7.57 (dd, J= 8.7, 6.6 Hz, 2H), 5.53 (s, 1H), 4.33 (s, 1H), 3.81 (s, 3H), 3.01 (s, 1H),
2.49 - 2.29 (m, 2H), 1.54 (d, J= 6.7 Hz, 3H).
Example 230: (SV(2.7-Dimethyl-3-(3.4.5-trifluorophenylV2.4.5.7-tetrahvdro-6H-pyrazolor3.4- yrazolodd-blpyridind-yllmethanone.
Figure imgf000344_0001
The title compound was prepared in a manner analogous to Example 288, using 1 -methyl- 1H- pyrazolo[3,4-b]pyridine-3-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H19F3N6O, 440.2; m/z found, 441.1 [M+H]+. ¾ NMR (500 MHz, CDCb) d 8.61 - 8.53 (m, 2H), 7.26 - 7.20 (m, 1H), 6.98 (s, 2H), 6.46 - 5.88 (m, 1H), 5.33 - 4.89 (m, 1H), 4.21 (s, 3H), 3.88 - 3.78 (m, 3H), 3.43 - 3.10 (m, 1H), 3.02 - 2.79 (m, 1H), 2.50
(d, J= 15.5 Hz, 1H), 1.80 - 1.62 (m, 3H).
Example 231 : (S)-(2.7-Dimethyl-3-(3 A pyrazololdd-
Figure imgf000344_0002
razolod Ablpyridin-S-yllmethanone.
Figure imgf000344_0003
The title compound was prepared in a manner analogous to Example 288, using 1 -methyl- 1H- pyrazolo[3,4-b]pyridine-5-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H19F3N6O, 440.2; m/z found, 441.1 [M+H]+. ¾ NMR (500 MHz, CDCI3) d 8.66 (d, J= 2.0 Hz, 1H), 8.19 (d, J= 2.0 Hz, 1H), 8.07 (s, 1H), 7.03 - 6.94 (m, 2H), 6.23 - 4.48 (m, 1.22H), 4.19 (s, 3.12H), 3.80 (s, 3.23H), 3.28 (s, 1H), 2.82 (s, 1H), 2.45 (d, J= 15.3 Hz, 1H), 1.70 - 1.57 (m, 3.43H).
Example 232: (S)-(2-(Difluoromethyl)-7-methyl-3-(3 A5-trifluorophenyl)- tetrahvdro-
Figure imgf000345_0001
6H-pyrazolo[3.4-clpyridin-6-yl)('quinolin-6-yl)methanone.
Figure imgf000345_0002
The title compound was prepared in a manner analogous to Example 1, using (S)-2- (difluoromethyl)-7-methyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c]pyridine (Intermediate 33) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c]pyridine and using quinoline-6-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C24H18F4N4O, 454.1; m/z found, 455.1 [M+H] +. Ή NMR (500 MHz, DMSO- e) d 8.99 (dd, J= 4.2, 1.7 Hz, 1H), 8.52 - 8.43 (m, 1H), 8.15 - 8.07 (m, 2H), 7.89 - 7.68 (m, 2H), 7.67 - 7.42 (m, 4H), 5.74 (s, 1H), 4.79 (d, J= 94.0 Hz, 1H), 3.74 (s, 1H), 2.88 (s, 1H), 2.42 (s,
1H), 1.56 (d, = 6.8 Hz, 3H).
Example 233: (R)-(2-(Difluoromethyl)-7-methyl-3-(3.4.5-trifluorophenyl)- tetrahvdro-
Figure imgf000345_0003
('quinolin-6-yl)methanone.
Figure imgf000345_0004
The title compound was prepared in a manner analogous to Example 1, using (R)-2- (difluoromethyl)-7-methyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c] pyridine (Intermediate 34) instead of 2-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c]pyridine and using quinoline-6-carboxylic acid instead of 1 -naphthoic acid. MS (ESI): mass calcd. for C24H18F4N4O, 454.1; m/z found, 455.1 [M+H] +. Ή NMR (500 MHz, DMSO-A) d 8.99 (dd, J= 4.2, 1.7 Hz, 1H), 8.56 - 8.40 (m, 1H), 8.18 - 8.03 (m, 2H), 7.90 - 7.67 (m, 2H), 7.68 - 7.36 (m, 4H), 5.74 (s, 1H), 4.85 (s, 1H), 3.73 (s, 1H), 2.89 (s, 1H), 2.41 (s, 1H), 1.56 (d, J = 6.8 Hz, 3H).
Example 234: -('2.7-Dimethyl-3-('3A5-trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazoloi3A c1pyridin-6-yl)('quinolin-6-yl)methanone.
Figure imgf000346_0001
The title compound was prepared in a manner analogous to Example 288, using quinoline-6- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H19F3N4O, 436.2; m/z found, 437.1 [M+H]+. ¾ NMR (500 MHz, CDCb) d 8.98 (dd, J = 4.2, 1.7 Hz, 1H), 8.23 - 8.14 (m, 2H), 7.93 (d, J= 1.8 Hz, 1H), 7.75 (dd, = 8.6, 1.9 Hz, 1H), 7.47 (dd, J= 8.3, 4.2 Hz, 1H), 7.02 - 6.94 (m, 2H), 5.90 (s, 0.46H), 5.17 - 4.71 (m, 0.75H), 3.81 (s, 3.57H), 3.40 - 3.04 (m, 1H), 2.93 - 2.66 (m, 1H), 2.44 (s, 1H), 1.61 (s, 3.22H).
Example 235: ('R)-('2.7-Dimethyl-3-('3A5-trifluorophenyl)-2 5.7-tetrahvdro-6H-pyrazolo[3.4- c1pyridin-6-vn(quinolin-6-vnmethanone.
Figure imgf000346_0002
The title compound was prepared in a manner analogous to Example 106, using 3,4,5- trifluorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (R)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 9) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A. MS (ESI): mass calcd. for C24H19F3N4O, 436.1; m/z found, 437.1 [M+H] +. NMR (500 MHz, CDCb) d 8.98 (dd, J= 4.2, 1.7 Hz, 1H), 8.23 - 8.14 (m, 2H), 7.93
(d, J= 1.8 Hz, 1H), 7.75 (dd, J= 8.6, 1.9 Hz, 1H), 7.47 (dd, J= 8.3, 4.2 Hz, 1H), 7.02 - 6.94 (m, 2H), 5.90 (s, 0.46H), 5.17 - 4.71 (m, 0.75H), 3.81 (s, 3.57H), 3.40 - 3.04 (m, 1H), 2.93 - 2.66 (m, 1H), 2.44 (s, 1H), 1.61 (s, 3.22H). Example 236: ('S)-('2.7-Dimethyl-3-('3A5-trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000347_0001
clpyridin-6-yl)(quinolin-8-yl)methanone.
Figure imgf000347_0002
The title compound was prepared in a manner analogous to Example 288, using quinoline-8- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H19F3N4O, 436.1 ; m/z found, 437.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 9.04 -
8.73 (m, 1H), 8.54 - 8.39 (m, 1H), 8.13 - 7.96 (m, 1H), 7.84 - 7.42 (m, 5H), 5.84 - 5.65 (m, 1H), 3.88 - 3.64 (m, 3H), 3.26 - 3.06 (m, 2H), 2.93 - 2.57 (m, 1H), 2.26 - 2.07 (m, 1H), 1.63 1.09 (m, 3H).
Example 237: ('S)-('2.7-Dimethyl-3-('3A5-trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000348_0001
clpyridinA-ylitisoauinolin- l -ylimethanone.
Figure imgf000348_0002
The title compound was prepared in a manner analogous to Example 288, using isoquinoline- 1- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H19F3N4O, 436.1; m/z found, 437.1 [M+H] +. Ή NMR (500 MHz, DMSO-A) d 8.54 (t, J = 5.4 Hz, 1H), 8.08 (dt, J= 8.3, 1.0 Hz, 1H), 7.99 - 7.78 (m, 3H), 7.80 - 7.66 (m, 1H), 7.63 - 7.49 (m, 2H), 5.78 (q, J= 6.7 Hz, 1H), 3.77 (d, J= 61.0 Hz, 3H), 3.29 - 3.11 (m, 2H), 2.66 - 2.54 (m, 1H), 2.32 - 2.20 (m, 1H), 1.46 (dd, = 134.2, 6.8 Hz, 3H).
Example 238: ('S)-('2.7-Dimethyl-3-('3A5-trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazolo[3A clpyridin-6-yl)(8-fluoroquinolin-4-yl)methanone.
Figure imgf000348_0003
The title compound was prepared in a manner analogous to Example 288, using 8- fluoroquinoline-4-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H18F4N4O, 454.1 ; m/z found, 455.1 [M+H] +. Ή NMR (500 MHz, DMSO-r/e) d 9.05 (d, J= 4.3 Hz, 1H), 7.81 - 7.39 (m, 6H), 5.76 (d, J= 6.3 Hz, 1H), 4.85 (s, 1H), 3.83 (s, 3H), 3.25 (d, = 8.4 Hz, 1H), 3.18 - 2.74 (m, 1H), 2.25 (d, J= 14.7 Hz, 1H), 1.69 - 1.24 (m, 3H). Example 239: ('S)-('2.7-Dimethyl-3-('3A5-trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000349_0001
c1pyridin-6-yl)('2-methylguinolin-4-yl)methanone.
Figure imgf000349_0002
The title compound was prepared in a manner analogous to Example 288, using 2- methylquinoline-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C25H21F3N4O, 450.1; m/z found, 451.0 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.01 (d, J= 8.7 Hz, 1H), 7.85 - 7.66 (m, 2H), 7.66 - 7.38 (m, 4H), 5.77 (dd, J = 13.9, 7.0 Hz, 1H), 3.76 (d, J= 70.7 Hz, 3H), 3.28 - 3.20 (m, 1H), 2.99 (s, 1H), 2.70 (s, 3H), 2.62 (d, = 47.3 Hz, 1H), 2.27 (d, = l6.7 Hz, 1H), 1.64 - 1.36 (m, 3H).
Example 240: ('S)-('2.7-Dimethyl-3-('3A5-trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazolo[3A clpyridin-6-yl)(2-methoxyquinolin-4-yl)methanone.
Figure imgf000349_0003
The title compound was prepared in a manner analogous to Example 288, using 2- methoxyquinoline-4-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid.
MS (ESI): mass calcd. for C25H21F3N4O2, 466.1; m/z found, 467.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 7.86 (t, J= 9.8 Hz, 1H), 7.74 (t, J= 7.4 Hz, 1H), 7.70 - 7.58 (m, 1H), 7.58 - 7.31 (m, 3H), 7.21 - 6.94 (m, 1H), 5.74 (q, J= 6.9 Hz, 1H), 4.08 (q, J= 5.2 Hz, 1H), 4.03 (s, 3H), 3.87 - 3.66 (m, 3H), 3.30 - 3.22 (m, 1H), 3.05 - 2.66 (m, 1H), 2.24 (dd, J= 15.1, 3.1 Hz, 1H), 1.65 - 1.36 (m, 3H). Example 241 : ('S)-('2.7-Dimethyl-3-('3A5-trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000350_0001
c1pyridin-6-yl)('8-fluoro-2-methylguinolin-4-yl)methanone.
Figure imgf000350_0002
The title compound was prepared in a manner analogous to Example 288, using 8-fluoro-2- methylquinoline-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C25H20F4N4O, 468.1 ; m/z found, 469.1 [M+H] +. Ή NMR (500 MHz, DMSO-r/e) d 7.61 (t, J= 7.9 Hz, 2H), 7.58 - 7.28 (m, 4H), 5.85 - 5.65 (m, 1H), 3.77 (d, J= 68.7 Hz, 3H), 3.27 - 3.06 (m, 2H), 2.73 (s, 3H), 2.25 (t, J= 18.4 Hz, 2H), 1.68 - 1.37 (m, 3H). Example 242: -('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazoloi3.4- clpyridin-6-yl )(quinoxalin-6-yl jmethanone.
Figure imgf000350_0003
The title compound was prepared in a manner analogous to Example 288, using quinoxabne-6- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F3N5O, 437.1 ; m/z found, 438.1 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 9.04 (d, J = 2.4 Hz, 2H), 8.33 - 8.07 (m, 2H), 8.00 - 7.77 (m, 1H), 7.57 (t, J= 7.6 Hz, 2H), 5.65 (s, 1H), 4.73 (s, 1H), 3.84 (s, 3H), 3.68 (d, J= 14.7 Hz, 1H), 3.23 - 2.76 (m, 1H), 2.33 (d, J= 14.7 Hz, 1H), 1.53 (d, J = 6.6 Hz, 3H). Example 243: ('S)-('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- c1pyridin-6-yl)('2-methylguinoxalin-6-yl)methanone.
Figure imgf000351_0001
The title compound was prepared in a manner analogous to Example 288, using 2- methylquinoxaline-6-carboxylic acid (Intermediate 25) instead of 2-fluoro-6-(2H-l,2,3-triazol- 2-yl)benzoic acid. MS (ESI): mass calcd. for C24H20F3N5O, 451.1; m/z found, 452.1 [M+H] +.
¾ NMR (500 MHz, DMSO-r/e) d 8.93 (d, J= 2.6 Hz, 1H), 8.17 - 7.96 (m, 2H), 7.84 (d, J= 8.8 Hz, 1H), 7.68 - 7.49 (m, 2H), 5.64 (s, 1H), 4.40 (d, J= 310.5 Hz, 1H), 3.79 (d, J= 43.5 Hz, 3H), 3.68 (s, 1H), 3.00 - 2.82 (m, 1H), 2.74 (d, J= 1.7 Hz, 3H), 2.41 - 2.27 (m, 1H), 1.51 (s, 3H).
Example 244: ('S)-('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- c1pyridin-6-yl)ri .5-naphthyridin-2-yl)methanone.
Figure imgf000351_0002
The title compound was prepared in a manner analogous to Example 288, using 1,5- naphthyridine-2-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F3N5O, 437.1; m/z found, 438.1 [M+H]+. ¾ NMR (600 MHz, Methanol-i/4) d 9.08 - 9.02 (m, 1H), 8.62 - 8.50 (m, 2H), 8.03 - 7.97 (m, 1H), 7.90 - 7.83 (m, 1H), 7.35 - 7.27 (m, 2H), 5.81 (q, J= 6.8 Hz, 0.66H), 5.13 (q, J= 6.8 Hz, 0.37H), 4.93 - 4.85 (m, 0.44H), 3.96 (dd, J= 13.9, 5.2 Hz, 0.69H), 3.90 - 3.72 (m, 3.1 H), 3.48 - 3.36 (m, 0.76H), 3.05 - 2.81 (m, 1H), 2.66 - 2.39 (m, 1H), 1.70 - 1.59 (m, 3H). Example 245: ('S)-('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- clpyridin-6-yl)ri .5-naphthyri din-3 -ylimethanone.
Figure imgf000352_0001
The title compound was prepared in a manner analogous to Example 288, using 1,5- naphthyridine-3 -carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS
(ESI): mass calcd. for C23H18F3N5O, 437.1; m/z found, 438.0 [M+H]+. ¾ NMR (600 MHz, Methanol-i/4) d 9.11 - 9.02 (m, 2H), 8.57 - 8.50 (m, 2H), 7.92 - 7.87 (m, 1H), 7.36 - 7.29 (m, 2H), 5.81 (s, 0.69H), 4.84 (s, 0.66H), 3.85 (s, 3.9H), 3.51 (s, 0.75H), 2.90 (m, 1H), 2.47 (m, 1H), 1.67 (s, 3H).
Example 246: ('S)-('2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- c1pyridin-6-yl)ri .6-naphthyridin-8-yl)methanone.
Figure imgf000352_0002
The title compound was prepared in a manner analogous to Example 288, using 1,6- naphthyridine-8-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F3N5O, 437.14; m/z found, 438.0 [M+H] +.
Figure imgf000352_0003
(500 MHz, DMSO-r/e) d 9.49 (d, J= 7.6 Hz, 1H), 9.23 - 9.01 (m, 1H), 8.79 - 8.58 (m, 2H), 7.86 - 7.40 (m, 3H), 5.83 - 5.64 (m, 1H), 5.03 - 4.40 (m, 1H), 3.92 - 3.68 (m, 3H), 3.09 - 2.57 (m, 2H), 2.32 - 2.02 (m, 1H), 1.62 - 1.19 (m, 3H). Example 247: (SV(2.7-Dimethyl-3-(5-(trifluoromethv0furan-2-v0-2.4.5.7-tetrahydro-6H- Pyrazolol3.4-c1pyridin-6-yl)tauinoxalin-6-yl)methanone.
Figure imgf000353_0001
The title compound was prepared in a manner analogous to Example 106, using (5- (trifluoromethyl)furan-2-yl)boronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert- butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridine-6-carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and quinoxaline-6-carboxylic acid instead of quinoline 6-carboxybc acid in Step C. MS (ESI): mass calcd. for C22H18F3N5O2, 441.1; m/z found, 442.1 [M+H]+. 'H
NMR (500 MHz, CDCb) d 8.91 (s, 2H), 8.23 - 8.14 (m, 2H), 7.84 (s, 1H), 6.93 (s, 1H), 6.53 (s, 1H), 5.91 (s, 0.46H), 4.96 (s, 0.77H), 4.20 - 3.77 (m, 3.77H), 3.53 - 2.60 (m, 3H), 1.61 (s, 3H).
Example 248: (SV(2.7-Dimethyl-3-(5-(trifluoromethv0pyridin-3-ylV2.4.5.7-tetrahvdro-6H- pyrazolor3.4-c1pyridin-6-yl auinoxalin-6-yl1methanone.
Figure imgf000353_0002
The title compound was prepared in a manner analogous to Example 106, using 5- (trifluoromethyl)pyridin-3-yl)boronic acid instead of 3,5-difluorophenylboronic acid and (S)- tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridine-6-carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3-
(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and quinoxaline-6-carboxylic acid instead of quinoline 6-carboxybc acid in Step C. MS (ESI): mass calcd. for C23H19F3N6O, 452.1; m/z found, 453.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 9.11— 8.97 (m, 4H), 8.49 - 8.32 (m, 1H), 8.26 - 8.09 (m, 2H), 7.91 (d, J= 8.9 Hz, 1H), 5.68 (s, 1H), 4.74 (s, 1H), 3.82 (d, J= 47.3 Hz, 3H), 3.68 (s, 1H), 2.93 (s, 1H), 2.35 (s, 1H), 1.54 (s, 3H).
Example 249: (2.7-Dimethyl-3-(T -methyl- lH-indol-4-ylV2A5.7-tetrahydro-6H-pyrazolor3.4- c1pyridin-6-yl)('quinolin-6-yl)methanone.
Figure imgf000354_0001
The title compound was prepared in a manner analogous to Example 98, using 2,7-dimethyl-6- (quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 11) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and l-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indole instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C27H25N5O, 435.2; m/z found, 436.1 [M+H]+. ¾ NMR (500 MHz, CDCh) d 8.95 (s, 1H), 8.22 - 8.10 (m, 2H), 7.93 (s, 1H),
7.82 - 7.73 (m, 1H), 7.49 - 7.38 (m, 2H), 7.34 - 7.27 (m, 1H), 7.18 - 7.02 (m, 2H), 6.28 (d, J = 17.6 Hz, 1H), 5.95 (s, 0.51H), 5.13 - 4.78 (m, 0.71H), 3.88 - 3.60 (m, 6.76H), 3.45 - 3.06 (m, 1H), 2.92 - 2.23 (m, 2H), 1.79 - 1.49 (m, 3H).
Example 250: (2.7-Dimethyl-3-(T -methyl- lH-indol-2-ylV2A5.7-tetrahydro-6H-pyrazolor3.4- c1pyridin-6-yr)(auinolin-6-yr)methanone.
Figure imgf000355_0001
The title compound was prepared in a manner analogous to Example 106, using 1 -methyl-2- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indole instead of 3,5-difluorophenylboronic acid in Step A. MS (ESI): mass calcd. for C27H25N5O, 435.2; m/z found, 436.2 [M+H]+. 'H NMR (500 MHz, CDCb) d 8.98 (d, J= 4.4 Hz, 1H), 8.23 - 8.14 (m, 2H), 7.94 (s, 1H), 7.77 (d, J = 8.7 Hz, 1H), 7.68 (d, J= 7.9 Hz, 1H), 7.47 (dd, J= 8.3, 4.2 Hz, 1H), 7.40 (d, J= 8.3 Hz, 1H), 7.35 - 7.29 (m, 1H), 7.23 - 7.17 (m, 1H), 6.59 (s, 1H), 5.95 (s, 0.47H), 5.14 - 4.80 (m, 0.73H), 3.94 - 3.55 (m, 6.79H), 3.44 - 3.01 (m, 1H), 2.95 - 2.28 (m, 2H), 1.75 - 1.53 (m, 3H).
Example 251 : ('2.7-Dimethyl-3-(' l -methyl- 1 H-indol-3-yl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- c1pyridin-6-yl)('quinolin-6-yl)methanone.
Figure imgf000355_0002
The title compound was prepared in a manner analogous to Example 98, using 2,7-dimethyl-6- (quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 11) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and l-methyl-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indole instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C27H25N5O, 435.2; m/z found, 436.2 [M+H]+. ¾ NMR (500 MHz, Methanol-r/4) d 8.93 (s, 1H), 8.46 (d, J= 8.4 Hz, 1H), 8.14 (d, J= 8.7 Hz, 1H), 8.08 (d, J= 1.8 Hz, 1H), 7.84 (d, J= 8.6 Hz, 1H), 7.62 (s, 1H), 7.47 (d, J = 8.2 Hz, 1H), 7.41 - 7.37 (m, 2H), 7.26 (t, J= 7.6 Hz, 1H), 7.15 (t, = 7.5 Hz, 1H), 5.91 - 5.78 (m, 0.62H), 4.97 - 4.76 (m, 0.73H), 4.59 (s, 0.21H), 3.64 - 3.94 (m, 6.74H), 3.50 - 3.38 (m, 0.72H), 2.89 - 2.69 (m, 1H), 2.57 - 2.28 (m, 1H), 1.74 - 1.55 (m, 3H). Example 252: (2.7-Dimethyl-3-(T -methyl- lH-indol-5-ylV2A5.7-tetrahydro-6H-pyrazolor3.4- clpyridin-6-yr)(quinolin-6-yr)methanone.
Figure imgf000356_0001
The title compound was prepared in a manner analogous to Example 98, using 2,7-dimethyl-6- (quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 11) instead of [2-methyl-6-(quinoline-6-carbonyl)-
4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and /V-methylindole-5-boronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C27H25N5O, 435.2; m/z found, 436.2 [M+H]+. Ή NMR (500 MHz, CDCh) d 8.97 (dd, J= 4.2, 1.8 Hz, 1H), 8.22 - 8.13 (m, 2H), 7.94 (d, J= 1.8 Hz, 1H), 7.78 (dd, J= 8.6, 1.9 Hz, 1H), 7.59 (dd, J= 1.6, 0.7 Hz, 1H), 7.48 - 7.40 (m, 2H), 7.21 - 7.12 (m, 2H), 6.55 (d, = 3.1 Hz, 1H), 5.94 (s, 0.42H), 5.16 - 4.82 (m, 0.7H), 3.94 - 3.68 (m, 6.65H), 3.44 - 3.11 (m, 1H), 2.98 - 2.70 (m, 1H), 2.59 - 2.36 (m, 1H), 1.74 - 1.51 (m, 3.23H).
Example 253: (2.7-Dimethyl-3-(T -methyl- lH-indol-7-ylV2.4.5.7-tetrahvdro-6H-pyrazolor3.4- c1pyridin-6-yl)('quinolin-6-yl)methanone.
Figure imgf000356_0002
The title compound was prepared in a manner analogous to Example 106, using l-methyl-7- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indole instead of 3,5-difluorophenylboronic acid in Step A. MS (ESI): mass calcd. for C27H25N5O, 435.2; m/z found, 436.2 [M+H]+. 'H NMR (500 MHz, CDCb) 5 8.97 (s, 1H), 8.23 - 8.11 (m, 2H), 7.91 (d, = l .8 Hz, 1H), 7.72 (td, = 8.5, l .5 Hz, 2H), 7.51 - 7.41 (m, 1H), 7.14 (t, J= 7.5 Hz, 1H), 7.07 - 6.97 (m, 2H), 6.57 (d, J
= 3.2 Hz, 1H), 5.95 (s, 0.53H), 5.15 - 4.75 (m, 0.47H), 3.89 - 3.15 (m, 8H), 2.71 - 2.29 (m, 2H), 1.78 - 1.52 (m, 3H).
Example 254: ('S)-('3-('3.5-Difluorophenyl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-[3-('2-fluoranylethoxy)-2-fluoro-phenyl1methanone.
Figure imgf000357_0001
The title compound was prepared in a manner analogous to Example 140, using 2-fluoro-3-(2- (tosyloxy)ethoxy)benzoic acid (Intermediate 128) instead of 3-(2-(tosyloxy)ethoxy)benzoic acid in Step A.
Example 255: [2-Chloro-3-('2-fluoranylethoxy)phenyl1-i('7S)-3-('3.5-difluorophenyl)-2.7- c|pyridin-6-yl1methanone.
Figure imgf000357_0002
The title compound was prepared analogous to Example 151, using 2-chloro-3-(2-((tetrahydro- 2H-pyran-2-yl)oxy)ethoxy)benzoic (Intermediate 129) instead of l-(2-((tetrahydro-2H-pyran-2- yl)oxy)ethyl)-lH-indole-5-carboxybc acid in Step A. Example 256: ('S)-i3-('3.5-Difluorophenyl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolo
Figure imgf000358_0001
c1pyridin-6-yl1-i3-('2-fluoranylethoxy)-5-fluoro-phenyl1methanone.
Figure imgf000358_0002
The title compound was prepared analogous to Example 140, using 3-fluoro-5-(2- (tosyloxy)ethoxy)benzoic acid (Intermediate 130) instead of 3-(2-(tosyloxy)ethoxy)benzoic acid in Step A.
Example 257: t3-Methoxyphenyl)-it7S)-7-methyl-2.3-diphenyl-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1methanone.
Figure imgf000358_0003
The title compound was prepared in a manner analogous to Example 288, using (S)-7-methyl- 2,3-diphenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c] pyridine (Intermediate 55) instead of (S)- 2,7-dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine and 3- methoxybenzoic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C27H25N3O2, 423.2; m/z found, 424 [M+H]+. Ή NMR (400 MHz, DMSO-r/e) d 7.43 - 7.27 (m, 7H), 7.27 - 7.11 (m, 4H), 7.10 - 6.93 (m, 3H), 5.66 (s, 1H), 3.80 (s, 3H), 2.84 (s, 2H), 2.54 - 2.51 (m, 2H), 1.55 (d, J= 6.7 Hz, 3H).
Example 258: (3-Fluoro-5-methyl-phenylV2.7-dimethyl-5.7-dihvdro-4H-pyrazolor3.4-
Figure imgf000358_0004
clpyridin-6-yll-(4-methoxyphenyl)methanone.
Figure imgf000359_0001
The title compound was prepared in a manner analogous to Example 288, using 4- methoxybenzoic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C23H24FN3O2, 393.19; m/z found, 394.2 [M+H] +. Ή NMR (400 MHz, DMSO-r/e) d 7.45 - 7.35 (m, 2H), 7.20 - 7.06 (m, 3H), 7.04 - 6.95 (m, 2H), 5.45 (s, 1H), 4.18 - 3.91 (m, 1H), 3.84 - 3.74 (m, 6H), 3.17 (s, 1H), 2.80 (t, J= 12.1 Hz, 1H), 2.43 - 2.26 (m, 4H), 1.45 (d, J= 6.7 Hz, 3H).
Example 259: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000359_0002
clpyridin-6-yll-(2-methoxyphenyl)methanone.
Figure imgf000359_0003
The title compound was prepared in a manner analogous to Example 288, using 2- methoxybenzoic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H20F3N3O2, 415.2; m/z found, 416.1 [M+H]+. Ή NMR (600 MHz, DMSO- e) d 7.57 - 7.48 (m, 2H), 7.44 - 7.38 (m, 1H), 7.28 - 7.13 (m, 1H), 7.12 - 6.95 (m, 2H), 5.61 (q, J =
6.7 Hz, 0.38H), 5.56 (q, J= 6.7 Hz, 0.32H), 4.73 - 4.65 (m, 0.28H), 4.58 - 4.52 (m, 0.16H), 4.51 - 4.45 (m, 0.13H), 3.85 - 3.71 (m, 5.65H), 3.58 (s, 0.36H), 3.45 - 3.36 (m, 0.80H), 3.25 - 3.11 (m, 0.72H), 3.05 - 2.93 (m, 0.27H), 2.75 - 2.54 (m, 1H), 2.37 - 2.31 (m, 0.31H), 2.27 - 2.21 (m, 0.37H), 1.47 - 1.24 (m, 3H). (Fractions of H’s that overlap with DMSO and water may not be reported) Example 260: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000360_0001
clpyridin-e-yll-n-methoxyphenvDmethanone.
Figure imgf000360_0002
The title compound was prepared in a manner analogous to Example 288, using 3- methoxybenzoic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid.
MS (ESI): mass calcd. for C22H20F3N3O2, 415.2; m/z found, 416.1 [M+H]+. 1H NMR (600 MHz, Methanol-A) d 7.48 - 7.34 (m, 1H), 7.35 - 7.23 (m, 2H), 7.05 (dd, J= 8.3, 2.5 Hz, 1H), 7.02 - 6.87 (m, 2H), 5.77 - 5.65 (m, 0.60H), 4.81 - 4.65 (m, 0.40H), 3.92 - 3.71 (m, 7H), 3.39 - 3.32 (m, 0.60H), 3.28 - 3.13 (m, 0.40H), 2.91 - 2.66 (m, 1H), 2.61 - 2.37 (m, 1H), 1.66 - 1.44 (m, 3H).
Example 261 : i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-(4-methoxyphenyl)methanone.
Figure imgf000360_0003
The title compound was prepared in a manner analogous to Example 288, using 4- methoxybenzoic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid.
MS (ESI): mass calcd. for C22H20F3N3O2, 415.2; m/z found, 416.1 [M+H]+. Ή NMR (600 MHz, Methanol-A) d 7.41 (d, J= 8.2 Hz, 2H), 7.34 - 7.26 (m, 2H), 7.04 - 7.00 (m, 2H), 5.82 - 5.44 (m, 1H), 4.06 - 3.85 (m, 1H), 3.85 (s, 3H), 3.81 (s, 3H), 3.41 - 3.32 (m, 1H), 2.89 - 2.71 (m, 1H), 2.56 - 2.35 (m, 1H), 1.55 (d, = 6.8 Hz, 3H). Example 262: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000361_0001
clpyridin-O-yll-iO-ttrifluoromethoxyiphenyllmethanone.
Figure imgf000361_0002
The title compound was prepared in a manner analogous to Example 288, using 3- (trifluoromethoxy)benzoic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H17F6N3O2, 469.1 ; m/z found, 470.1 [M+H]+. Ή NMR (500 MHz, Chlorofomw/) d 7.50 - 7.43 (m, 1H), 7.38 - 7.34 (m, 1H), 7.31 - 7.27 (m, 2H), 7.01 - 6.94 (m, 2H), 5.95 - 5.71 (m, 0.44H), 5.02 - 4.63 (m, 1H), 3.96 - 3.62 (m, 3.64H), 3.40 - 3.00 (m, 1H), 2.93 - 2.55 (m, 1H), 2.53 - 2.31 (m, 1H), 1.65 - 1.52 (m, 3H).
Example 263: it7S)-2.7-Dimethyl-3-t3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- salt.
Figure imgf000361_0003
The title compound was prepared in a manner analogous to Example 288, using 2- (trifluoromethoxy)benzoic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid.
MS (ESI): mass calcd. for C22H17F6N3O2, 469.1; m/z found, 470.1 [M+H]+. ¾ NMR (500 MHz, Chlorofomw/) d 7.50 - 7.25 (m, 4H), 7.01 - 6.91 (m, 2H), 5.96 - 5.85 (m, 0.64H), 4.99 - 4.89 (m, 0.39H), 4.80 - 4.67 (m, 0.40H), 3.87 - 3.74 (m, 3H), 3.61 - 3.51 (m, 0.65H), 3.37 - 3.21 (m, 0.65H), 3.17 - 3.00 (m, 0.35H), 2.88 - 2.70 (m, 0.55H), 2.59 - 2.42 (m, 0.86H), 2.37 - 2.28 (m, 0.68H), 1.63 - 1.38 (m, 3H). Example 264: [4-('Difluoromethoxy)phenyll-i('7S)-2.7-dimethyl-3-('3.4.5-trifluorophenyl)-5.7- dihvdro-4H-pyrazolor3.4-c1pyridin-6-yl1methanone.
Figure imgf000362_0001
The title compound was prepared in a manner analogous to Example 288, using 4- (difluoromethoxy)benzoic acid of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22HISF5N3C>2, 451.1; m/z found, 452.0 [M+H]+. Ή NMR (400 MHz, Methanol- cL) d 7.52 (s, 1H), 7.50 (s, 1H), 7.34 - 7.23 (m, 4H), 6.92 (t, J= 73.6 Hz, 1H), 5.92 - 5.39 (m, 1H), 3.82 (s, 4H), 3.44 - 3.31 (m, 1H), 2.91 - 2.69 (m, 1H), 2.65 - 2.35 (m, 1H), 1.56 (d, = 6.8 Hz, 3H).
Example 265: it7S)-2.7-Dimethyl-3-t3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('2-fluoro-4-methoxy-phenyl)methanone.
Figure imgf000362_0002
The title compound was prepared in a manner analogous to Example 288, using 2-fluoro-4- methoxybenzoic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C22H19F4N3O2, 433.14; m/z found, 434.1 [M+H] +. ' H NMR (400 MHz, Methanol-ώ) d 7.39 - 7.23 (m, 3H), 6.94 - 6.74 (m, 2H), 5.76 (q, J= 6.8 Hz, 1H), 3.90 - 3.77 (m, 6H), 3.49 - 3.38 (m, 1H), 3.30 - 3.07 (m, 1H), 2.84 - 2.36 (m, 2H), 1.62 - 1.43 (m, 3H). Example 266: 3-IY7S)-2.7-Dimethyl-3-('3A5-trifluorophenyl)-5.7-dihydro-4H-pyrazolo cl
Figure imgf000362_0003
pyridine-6-carbonyll-N-methyl-benzamide.
Figure imgf000363_0001
The title compound was prepared in a manner analogous to Example 288, using 3- (methylcarbamoyl)benzoic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid.
MS (ESI): mass calcd. for C23H21F3N4O2, 442.2; m/z found, 443.1 [M+H]+. Ή NMR (500 MHz, Chloroform-i/) d 7.85 - 7.79 (m, 2H), 7.57 - 7.53 (m, 1H), 7.52 - 7.47 (m, 1H), 7.01 - 6.94 (m, 2H), 6.16 (s, 1H), 5.84 (br s, 0.47H), 5.02 - 4.70 (m, 0.81H), 3.95 - 3.64 (m, 3.64H), 3.37 - 2.96 (m, 4H), 2.90 - 2.62 (m, 1H), 2.53 - 2.31 (m, 1H), 1.66 - 1.47 (m, 3H).
Example 267: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('4-imidazol- l -ylphenvQmethanone.
Figure imgf000363_0002
The title compound was prepared in a manner analogous to Example 288, using 4-(lH-imidazol- l-yl)benzoic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI):
mass calcd. for C24H2oF3N50, 451.2; m/z found, 452.1 [M+H]+. Ή NMR (400 MHz, Methanol- cL) 5 8.29 - 8.14 (m, 1H), 7.75 - 7.72 (m, 1H), 7.72 - 7.69 (m, 1H), 7.68 - 7.65 (m, 1H), 7.65 - 7.63 (m, 1H), 7.63 - 7.58 (m, 1H), 7.37 - 7.26 (m, 2H), 7.24 - 7.14 (m, 1H), 5.86 - 5.60 (m,
1H), 4.67 - 4.38 (m, 1H), 3.83 (s, 3H), 3.47 - 3.34 (m, 1H), 2.92 - 2.71 (m, 1H), 2.66 - 2.38 (m, 1H), 1.58 (d, = 6.8 Hz, 3H). Example 268: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-[4-n H-pyrazol-4-yl)phenyl1methanone.
Figure imgf000364_0001
The title compound was prepared in a manner analogous to Example 288, using 4-(lH-pyrazol- 4-yl)benzoic acid of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H2OF3N50, 451.2; m/z found, 452.0 [M+H]+. ' H NMR (400 MHz, Methanol-rA) d 8.12 - 7.91 (m, 2H), 7.77 - 7.66 (m, 2H), 7.52 - 7.42 (m, 2H), 7.36 - 7.25 (m, 2H), 5.85 - 5.56 (m, 1H),
4.04 - 3.73 (m, 4H), 3.44 - 3.34 (m, 1H), 2.91 - 2.74 (m, 1H), 2.69 - 2.32 (m, 1H), 1.57 (d, J = 6.8 Hz, 3H).
Example 269: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- cl pyridin-6- yll - G4- ( 1 H-pyrazol- 5 -vDphenyll methanone.
Figure imgf000364_0002
The title compound was prepared in a manner analogous to Example 288, using 4-(lH-pyrazol- 5-yl)benzoic acid of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H2OF3N50, 451.2; m/z found, 452.0 [M+H]+. Ή NMR (400 MHz, MethanoWA) d 8.01 - 7.84 (m, 2H), 7.70 (s, 1H), 7.59 - 7.44 (m, 2H), 7.36 - 7.26 (m, 2H), 6.75 (d, J= 2.3 Hz, 1H), 5.85 -
5.53 (m, 1H), 3.98 - 3.68 (m, 4H), 3.47 - 3.33 (m, 1H), 2.92 - 2.70 (m, 1H), 2.64 - 2.35 (m, 1H), 1.58 (d, = 6.8 Hz, 3H).
Example 270: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll - G3 -(T H-pyrazol-3 -yl jphenyllmethanone.
Figure imgf000365_0001
The title compound was prepared in a manner analogous to Example 288, using 3-(lH-pyrazol- 3-yl)benzoic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI):
mass calcd. for C24H2oF3N50, 451.2; m/z found, 452.0 [M+H]+. Ή NMR (400 MHz, Methanol- cL) d 7.98 - 7.89 (m, 1H), 7.89 - 7.80 (m, 1H), 7.79 - 7.63 (m, 1H), 7.62 - 7.48 (m, 1H), 7.46 - 7.35 (m, 1H), 7.35 - 7.19 (m, 1H), 6.74 (s, 1H), 5.85 - 5.63 (m, 1H), 4.01 - 3.70 (m, 4H), 3.46 - 3.32 (m, 1H), 2.95 - 2.69 (m, 1H), 2.61 - 2.32 (m, 1H), 1.68 - 1.45 (m, 3H). (The fraction of Hs that overlap with methanol or water are not reported). Example 271 : i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-[4-methoxy-3-n -niethylpyrazol-3-yl)phenyl1methanone.
Figure imgf000365_0002
The title compound was prepared in a manner analogous to Example 288, using 4-methoxy-3-(l- methyl-lH-pyrazol-3-yl)benzoic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C H^RN^CT, 495.2; m/z found, 496.0 [M+H]+. Ή NMR (400 MHz, Methanol-A) d 7.94 (d, J= 2.2 Hz, 1H), 7.58 (d, J= 2.3 Hz, 1H), 7.42 (dd, J= 8.6, 2.2 Hz, 1H), 7.37 - 7.25 (m, 2H), 7.18 (d, J= 8.6 Hz, 1H), 6.78 (d, J= 2.3 Hz, 1H), 5.94 - 5.54 (m, 1H), 3.96 (s, 3H), 3.93 (s, 3H), 3.86 - 3.75 (m, 4H), 3.45 - 3.29 (m, 1H), 2.88 - 2.74 (m, 1H), 2.57 - 2.38 (m, 1H), 1.57 (d, J= 6.8 Hz, 3H).
Example 272: it7S)-2.7-Diniethyl-3-t3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-[3-n H-pyrazol-4-yl)phenyl1methanone.
Figure imgf000366_0001
The title compound was prepared in a manner analogous to Example 288, using 3-(lH-pyrazol- 4-yl)benzoic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI):
mass calcd. for C H F N 451.2; m/z found, 452.1 [M+H]+. Ή NMR (400 MHz, Methanol- cL) d 8.13 - 7.92 (m, 2H), 7.77 - 7.69 (m, 1H), 7.68 - 7.60 (m, 1H), 7.49 (t, J= 7.7 Hz, 1H), 7.38 - 7.18 (m, 3H), 5.83 - 5.64 (m, 1H), 3.84 (s, 3H), 3.79 - 3.73 (m, 1H), 3.45 - 3.34 (m, 1H), 2.89 - 2.71 (m, 1H), 2.61 - 2.37 (m, 1H), 1.65 - 1.50 (m, 3H).
Example 273: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-[3-n -methylpyrazol-4-yl)phenyl1methanone.
Figure imgf000366_0002
The title compound was prepared in a manner analogous to Example 288, using 3 -(1 -methyl- 1H- pyrazol-4-yl)benzoic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C25H22F3N5O, 465.2; m/z found, 446.1 [M+H]+. ¾ NMR (400 MHz,
Chlorofornw/) d 7.76 (s, 1H), 7.62 (s, 1H), 7.54 - 7.49 (m, 2H), 7.40 (t, J= 7.9 Hz, 1H), 7.27 - 7.21 (m, 1H), 7.02 - 6.92 (m, 2H), 5.86 (brs, 0.55), 5.14 - 4.74 (m, 1H), 3.95 (s, 3.20H), 3.81 (brs, 3.23H), 3.38 - 3.00 (m, 1.17H), 2.91 - 2.58 (m, 1.16H), 2.41 (brs, 1.17H), 1.58 (brs, 3H).
Example 274: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1 - G 2-fluoro-5 -( 1 -methylpyrazol-4-yl jphenyll methanone.
Figure imgf000367_0001
The title compound was prepared in a manner analogous to Example 288, using 2-fluoro-5-(l- methyl-lH-pyrazol-4-yl)benzoic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C25H2IF4N50, 483.2; m/z found, 484.4 [M+H]+. Ή NMR (400 MHz, Methanol-A) d 7.99 (s, 1H), 7.88 - 7.74 (m, 1H), 7.72 - 7.64 (m, 1H), 7.58 (dd, J= 6.3, 2.3 Hz, 1H), 7.35 - 7.18 (m, 3H), 5.88 - 5.66 (m, 1H), 3.92 (s, 3H), 3.83 (s, 2.1H), 3.77 (s, 0.90H), 3.76 - 3.68 (m, 1H), 3.57 - 3.35 (m, 0.70H), 3.25 - 3.18 (m, 0.30H), 2.92 - 2.61 (m, 1H), 2.61 - 2.51 (m, 0.3 OH), 2.49 - 2.36 (m, 0.70H), 1.59 (d, J= 6.8 Hz, 2.1H), 1.48 (d, J= 6.8 Hz, 0.90H).
Example 275: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-[3-('4-fluoropyrazol- l -vQphenyllmethanone.
Figure imgf000367_0002
The title compound was prepared in a manner analogous to Example 296, using 3-(4-fluoro-lH- pyrazol-l-yl)benzoic acid (Intermediate 68) instead of 3-(l,2,4-triazol-4-yl)-5- (trifluoromethyl)benzoic acid. MS (ESI): mass calcd. for C24H19F4N5O, 469.2; m/z found, 470.2 [M+H]+. (300 MHz, DMSO-r/e) d 8.84 - 8.76 (m, 1H), 7.98 - 7.74 (m, 3H), 7.67 - 7.47 (m, 3H), 7.43 - 7.29 (m, 1H), 5.69 - 5.47 (m, 1H), 3.81 (s, 3H), 3.73 - 3.50 (m, 1H), 3.42 - 3.00 (m, 1H), 2.90 - 2.71 (m, 1H), 2.65 - 2.22 (m, 1H), 1.59 - 1.33 (m, 3H). Example 276: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-[3-('3-methyl- l .2.4-triazol- l -vQphenyllmethanone.
Figure imgf000368_0001
The title compound was prepared in a manner analogous to Example 296, using 3-(3-methyl-lH- l,2,4-triazol-l-yl)benzoic acid (Intermediate 112) instead of 3-(l,2,4-triazol-4-yl)-5- (trifluoromethyl)benzoic acid. MS (ESI): mass calcd. for C24H21F3N6O, 466.2; m/z found, 467.2 [M+H]+. (500 MHz, DMSO-r/e) d 9.24 (s, 1H), 7.98 - 7.90 (m, 1H), 7.89 - 7.79 (m,
1H), 7.64 (t, J= 7.9 Hz, 1H), 7.59 - 7.50 (m, 2H), 7.47 - 7.37 (m, 1H), 5.64 - 5.51 (m, 1H), 3.82 (s, 3H), 3.68 - 3.57 (m, 1H), 3.36 - 3.23 (m, 1H), 2.87 - 2.76 (m, 1H), 2.36 (s, 3H), 2.38 - 2.25 (m, 1H), 1.53 - 1.42 (m, 3H).
Example 277: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000368_0002
riazol- l -vDphenyllmethanone.
Figure imgf000368_0003
The title compound was prepared in a manner analogous to Example 296, using 3-fluoro-5-(lH- l,2,4-triazol-l-yl)benzoic acid (Intermediate 113) instead of 3-(l,2,4-triazol-4-yl)-5- (trifluoromethyl)benzoic acid. MS (ESI): mass calcd. for C23H18F4N6O, 470.2; m/z found, 471.2 [M+H]+. (500 MHz, DMSO-r/e) d 9.44 (s, 1H), 8.29 (s, 1H), 7.98 - 7.87 (m, 1H), 7.83 - 7.73 (m, 1H), 7.58 - 7.50 (m, 2H), 7.41 - 7.34 (m, 1H), 5.65 - 5.48 (m, 1H), 3.82 (s, 3H), 3.69 - 3.52 (m, 1H), 3.39 - 3.22 (m, 1H), 2.89 - 2.73 (m, 1H), 2.39 - 2.29 (m, 1H), 1.49 (d, J= 6.9 Hz, 3H). Example 278: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000369_0001
clpyridin-6-vn-i3-methoxy-5-ri .2.4-triazol- 1 -yliphenyllmethanone.
Figure imgf000369_0002
The title compound was prepared in a manner analogous to Example 296, using 3-methoxy-5- (lH-l,2,4-triazol-l-yl)benzoic acid (Intermediate 114) instead of 3-(l,2,4-triazol-4-yl)-5-
(trifluoromethyl)benzoic acid. MS (ESI): mass calcd. for C24H21F3N6O2, 482.2; m/z found, 483.2 [M+H]+. (500 MHz, DMSO-r/e) d 9.40 (s, 1H), 8.25 (s, 1H), 7.60 - 7.51 (m, 3H), 7.49 - 7.44 (m, 1H), 7.04 - 6.93 (m, 1H), 5.67 - 5.48 (m, 1H), 3.89 (s, 3H), 3.82 (br s, 3H), 3.70 - 3.61 (m, 1H), 3.30 - 3.21 (m, 1H), 2.87 - 2.70 (m, 1H), 2.40 - 2.27 (m, 1H), 1.48 (d, J= 6.9 Hz, 3H).
Example 279: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1 - G2-( 1.2.4-triazol- 1 -ypphenyll methanone.
Figure imgf000369_0003
The title compound was prepared in a manner analogous to Example 296, using 2-(lH-l,2,4- triazol-l-yl)benzoic acid instead of 3-(l,2,4-triazol-4-yl)-5-(trifluoromethyl)benzoic acid.MS (ESI): mass calcd. for C23H19F3N6O, 452.2; m/z found, 453.2 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) d 8.92 (s, 1H), 8.17 (s, 1H), 7.77 - 7.72 (m, 1H), 7.68 - 7.63 (m, 1H), 7.62 - 7.58 (m, 1H), 7.57 - 7.47 (m, 3H), 5.46 (q, J= 6.7 Hz, 1H), 3.81 (s, 3H), 3.50 - 3.44 (m, 1H), 3.18 - 3.09 (m, 1H), 2.81 - 2.71 (m, 1H), 2.33 - 2.26 (m, 1H), 1.31 (d, = 6.8 Hz, 3H). Example 280: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-r2-fluoro-6-(l.2.4-triazol-l -yllphenyllmethanone.
Figure imgf000370_0001
The title compound was prepared in a manner analogous to Example 296, using 2-fluoro-6-(lH- l,2,4-triazol-l-yl)benzoic acid (Intermediate 115) instead of 3-(l,2,4-triazol-4-yl)-5- (trifluoromethyl)benzoic acid. MS (ESI): mass calcd. for C23H18F4N6O, 470.2; m/z found, 471.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 9.01 (s, 1H), 8.17 (s, 1H), 7.73 - 7.46 (m, 5H), 5.44 (q, J= 6.5 Hz, 1H), 3.78 (s, 3H), 3.56 - 3.49 (m, 1H), 3.23 - 3.16 (m, 1H), 2.68 - 2.59 (m, 1H), 2.41 - 2.35 (m, 1H), 1.31 (d, J= 6.7 Hz, 3H).
Example 281 : i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000370_0002
clpyridin-6-yll-[5-fluoro-2-n .2.4-triazol- 1 -vDphenyllmethanone.
Figure imgf000370_0003
The title compound was prepared in a manner analogous to Example 296, using 5-fluoro-2-(lH- l,2,4-triazol-l-yl)benzoic acid (Intermediate 67) instead of 3-(l,2,4-triazol-4-yl)-5- (trifluoromethyl)benzoic acid. MS (ESI): mass calcd. for C23H18F4N6O, 470.2; m/z found, 471.1 [M+H]+. (500 MHz, DMSO-r/e) d 8.88 (s, 1H), 8.14 (s, 1H), 7.81 - 7.75 (m, 1H), 7.55 - 7.42 (m, 4H), 5.40 (q, J= 6.7 Hz, 1H), 3.78 (s, 3H), 3.46 (dd, J= 14.1, 5.2 Hz, 1H), 3.15 - 3.07
(m, 1H), 2.84 - 2.75 (m, 1H), 2.30 - 2.24 (m, 1H), 1.26 (d, J= 6.7 Hz, 3H).
Example 282: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll - G2- G3 -('trifluoromethyl )- 1 2.4-triazol- 1 -yllphenyll methanone.
Figure imgf000371_0001
The title compound was prepared in a manner analogous to Example 296, using 2-(3- (trifluoromethyl)-lH-l,2,4-triazol-l-yl)benzoic acid (Intermediate 66) instead of 3-(l,2,4-triazol- 4-yl)-5-(trifluoromethyl)benzoic acid. MS (ESI): mass calcd. for C24H18F6N6O, 520.2; m/z found, 521.2 [M+H]+. ¾ NMR (300 MHz, DMSO-r/e) d 9.33 (s, 1H), 7.94 - 7.22 (m, 6H), 5.53 - 5.31 (m, 1H), 3.81 (s, 3H), 3.61 - 3.49 (m, 1H), 2.95 - 2.76 (m, 1H), 2.63 - 2.19 (m, 2H), 1.29 (d, = 6.8 Hz, 3H).
Example 283: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-[3-('triazol-2-yl)phenyl1methanone.
Figure imgf000371_0002
The title compound was prepared in a manner analogous to Example 296, using 3-(2H-l,2,3- triazol-2-yl)benzoic acid (Intermediate 65) instead of 3-(l,2,4-triazol-4-yl)-5- (trifluoromethyl)benzoic acid. MS (ESI): mass calcd. for C23H19F3N6O, 452.2; m/z found, 453.2
Figure imgf000372_0001
, , , , , , 1H), 7.60 - 7.45 (m, 3H), 5.69 - 5.49 (m, 1H), 3.79 (s, 3H), 3.57 (dd, J= 14.1, 5.0 Hz, 1H), 3.37 - 3.26 (m, 1H), 2.70 - 2.59 (m, 1H), 2.38 - 2.26 (m, 1H), 1.47 (d, J= 6.7 Hz, 3H).
Example 286: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000373_0001
clpyridin-6-yll-[3-methyl-5-('triazol-2-yl)phenyllmethanone.
Figure imgf000373_0002
The title compound was prepared in a manner analogous to Example 296, using 3-methyl-5-(2H- l,2,3-triazol-2-yl)benzoic acid (Intermediate 117) instead of 3-(l,2,4-triazol-4-yl)-5- (trifluoromethyl)benzoic acid.MS (ESI): mass calcd. for C24H21F3N6O, 466.2; m/z found, 467.2 [M+H]+. ¾ NMR (500 MHz, DMSO-ifc) d 8.13 (s, 2H), 7.97 - 7.91 (m, 1H), 7.80 - 7.72 (m,
1H), 7.57 - 7.48 (m, 2H), 7.30 - 7.23 (m, 1H), 5.66 - 5.48 (m, 1H), 3.79 (s, 3H), 3.82 - 3.59 (m, 1H), 3.35 - 3.18 (m, 1H), 2.81 - 2.68 (m, 1H), 2.45 (s, 3H), 2.43 - 2.25 (m, 1H), 1.52 - 1.37 (m,
3H).
Example 287: it7S)-2.7-Dimethyl-3-t3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-i3-ttriazol-2-yl)-5-ttrifluoromethyl)phenyl1methanone.
Figure imgf000373_0003
The title compound was prepared in a manner analogous to Example 296, using 3-(2H-l,2,3- triazol-2-yl)-5-(trifluoromethyl)benzoic acid (Intermediate 118) instead of 3-(l,2,4-triazol-4-yl)- 5-(trifluoromethyl)benzoic acid. MS (ESI): mass calcd. for C24H18F6N6O, 520.2; m/z found,
521.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.35 - 8.31 (m, 1H), 8.28 - 8.25 (m, 1H), 8.23 (s, 2H), 7.86 - 7.81 (m, 1H), 7.56 - 7.48 (m, 2H), 5.65 - 5.47 (m, 1H), 3.79 (s, 3H), 3.67 - 3.56 (m, 1H), 3.39 - 3.22 (m, 1H), 2.79 - 2.66 (m, 1H), 2.46 - 2.29 (m, 1H), 1.55 - 1.39 (m, 3H).
Example 288: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll - G 2-fluoro-6-(triazol-2-yl)phenyll methanone.
Figure imgf000374_0001
To a solution of (S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c] pyridine (15 mg, 53.3 pmol) (Intermediate 40) in CH2CI2 (0.48 mL) was added 2-fluoro-6- (2H-l,2,3-triazol-2-yl)benzoic acid (prepared according to methods described in Pat. Pub. No. WO2012145581, October 26, 2012) (12.2 mg, 58.7 pmol), HATU (26.4 mg, 69.3 pmol), and
/V,/V-diisopropylethylamine (27.6 pL, 0.16 mmol). After stirring at room temperature for 30 min, the mixture was concentrated in vacuo and purified by preparative HPLC (XBridge Cl 8 column (5pm, 100 x 4.6mm), mobile phase of 5-95% ACN in 20 mM aqueous NH4OH) to afford the title compound as a white powder (21 mg, 84% yield). MS (ESI): mass calcd. for C23H18F4N6O, 470.1; m/z found, 471.2 [M+H]+. ¾ NMR (600 MHz, DMSO-r/e) d 8.19 - 8.05 (m, 1.62H), 7.93
- 7.90 (m, 0.40H), 7.87 - 7.83 (m, 0.91H), 7.74 - 7.66 (m, 1H), 7.59 - 7.38 (m, 3H), 5.59 - 5.49 (m, 0.74H), 4.73 - 4.62 (m, 0.28H), 4.57 - 4.51 (m, 0.17H), 3.81 (s, 2.26H), 3.76 (s, 0.22H),
3.70 (s, 0.52H), 3.64 - 3.52 (m, 0.72H), 3.38 - 3.17 (m, 0.73H), 3.07 - 3.00 (m, 0.22H), 2.84 - 2.76 (m, 0.15H), 2.71 - 2.60 (m, 0.63H), 2.45 - 2.22 (m, 1.47H), 1.47 (d, J= 6.7 Hz, 2.28H), 1.35 (d, = 6.8 Hz, 0.6H).
Example 289: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-[5-methoxy-2-ttriazol-2-yl)phenyl1methanone.
Figure imgf000375_0001
The title compound was prepared in a manner analogous to Example 296, using 5-methoxy-2- (2H-l,2,3-triazol-2-yl)benzoic acid instead (Intermediate 63) of 3-(l,2,4-triazol-4-yl)-5- (trifluoromethyl)benzoic acid. MS (ESI): mass calcd. for C24H21F3N6O2, 482.2; m/z found, 483.2
Figure imgf000375_0002
8.01 (s, 2H), 7.82 (d, J= 8.9 Hz, 1H), 7.58 - 7.49 (m,
2H), 7.19 (dd, J= 8.9, 2.9 Hz, 1H), 6.99 (d, J= 2.8 Hz, 1H), 5.47 (q, J= 6.7 Hz, 1H), 3.86 (s, 3H), 3.81 (s, 3H), 3.52 - 3.46 (m, 1H), 3.12 - 3.04 (m, 1H), 2.81 - 2.73 (m, 1H), 2.32 - 2.26 (m, 1H), 1.38 (d, J = 6.1 Hz, 3H).
Example 290: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll - G3 -(T 2.4-triazol-4-yl jphenyll methanone.
Figure imgf000375_0003
The title compound was prepared in a manner analogous to Example 296, using 3-(4H-l,2,4- triazol-4-yl)benzoic acid instead of 3-(l,2,4-triazol-4-yl)-5-(trifluoromethyl)benzoic acid. MS (ESI): mass calcd. for C23H19F3N6O, 452.2; m/z found, 453.2 [M+H]+. Ή NMR (300 MHz, DMSO-r/e) d 9.21 (s, 2H), 7.91 - 7.38 (m, 6H), 5.68 - 5.49 (m, 1H), 3.82 (s, 3H), 3.69 - 3.55 (m, 1H), 2.93 - 2.75 (m, 1H), 2.62 - 2.29 (m, 2H), 1.49 (d, J= 6.8 Hz, 3H).
Example 291 : i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-[4-fluoro-3-n .2.4-triazol-4-yl)phenyl1methanone.
Figure imgf000376_0001
The title compound was prepared in a manner analogous to Example 288, using 3-fluoro-5-(4H- l,2,4-triazol-4-yl)benzoic acid (Intermediate 120) instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C23H18F4N6O, 470.1; m/z found, 471.1 [M+H]+. ¾ NMR (600 MHz, Chlorofornw/) d 8.50 (s, 2H), 7.33 - 7.19 (m, 3H), 7.00 - 6.94 (m, 2H), 5.81
(brs, 0.46), 4.86 (d, J= 46.3 Hz, 1H), 3.90 - 3.67 (m, 3.61H), 3.49 - 3.04 (m, 1.27H), 2.90
2.59 (m, 1.17H), 2.47 (brs, 1.11H), 1.59 (s, 3H).
Example 293: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-[3-methyl-5-n .2.4-triazol-4-yl)phenyl1methanone.
Figure imgf000377_0001
The title compound was prepared in a manner analogous to Example 296, using 3-methyl-5-(4H- l,2,4-triazol-4-yl)benzoic acid (Intermediate 122) instead of 3-(l,2,4-triazol-4-yl)-5- (trifluoromethyl)benzoic acid.MS (ESI): mass calcd. for C24H21F3N6O, 466.2; m/z found, 467.2 [M+H]+. (500 MHz, DMSO-r/e) d 9.18 (s, 2H), 7.73 - 7.66 (m, 1H), 7.61 - 7.57 (m,
1H), 7.56 - 7.50 (m, 2H), 7.36 - 7.19 (m, 1H), 5.61 - 5.53 (m, 1H), 3.82 (s, 3H), 3.68 - 3.58 (m, 1H), 3.34 - 3.22 (m, 1H), 2.87 - 2.74 (m, 1H), 2.44 (s, 3H), 2.38 - 2.30 (m, 1H), 1.48 (d, J= 6.9 Hz, 3H). Example 294: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-[4-methyl-3-n .2.4-triazol-4-yl)phenyl1methanone.
Figure imgf000377_0002
The title compound was prepared in a manner analogous to Example 296, using 4-methyl-3-(4H- l,2,4-triazol-4-yl)benzoic acid (Intermediate 123) instead of 3-(l,2,4-triazol-4-yl)-5- (trifluoromethyl)benzoic acid. MS (ESI): mass calcd. for C24H21F3N6O, 466.2; m/z found, 467.2 [M+H]+. (300 MHz, DMSO-r/e) d 8.86 (s, 2H), 7.64 - 7.38 (m, 5H), 5.66 - 5.41 (m,
1H), 3.80 (s, 3H), 3.89 - 3.58 (m, 1H), 2.92 - 2.67 (m, 1H), 2.60 - 2.30 (m, 2H), 2.19 (s, 3H),
1.46 (d, = 6.8 Hz, 3H). Example 295: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1 - G3 -( 1 2.4-triazol-4-yl V 4-(trifluoromethyl1phenvH methanone.
Figure imgf000378_0001
The title compound was prepared in a manner analogous to Example 296, using 3-(4H-l,2,4- triazol-4-yl)-4-(trifluoromethyl)benzoic acid (Intermediate 126) instead of 3-(l,2,4-triazol-4-yl)- 5-(trifluoromethyl)benzoic acid. MS (ESI): mass calcd. for C24H18F6N6O, 520.2; m/z found, 521.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.85 (s, 2H), 8.09 (d, J= 8.1 Hz, 1H), 7.89 -
7.83 (m, 1H), 7.82 - 7.77 (m, 1H), 7.58 - 7.49 (m, 2H), 5.58 (q, J= 6.7 Hz, 1H), 3.82 (s, 3H), 3.61 (dd, J= 14.0, 5.0 Hz, 1H), 3.36 - 3.26 (m, 1H), 2.87 - 2.77 (m, 1H), 2.39 - 2.28 (m, 1H), 1.48 (d, J = 1.0 Hz, 3H).
Example 296: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-r3-(E2.4-triazol-4-ylV5-(trifluoromethyl)phenyl1methanone.
Figure imgf000378_0002
To a solution of (S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c]pyridine (Intermediate 40, 25 mg, 0.0889 mmol) in dichloromethane (800 pL) was added 3- (4H-l,2,4-triazol-4-yl)-5-(trifluoromethyl)benzoic acid (Intermediate 127) (23 mg, 0.0894 mmol), <9-(7-azabenzotriazol- l -yl)-/V,/V,/V',/V'-tetramethyluronium hexafluorophosphate (HATH, 37 mg, 0.0973 mmol, 0.19) and triethylamine (50 pL, 0.358 mmol, 0.725 g/mL). The reaction mixture was stirred at room temperature for 1 h. The mixture was diluted with dichloromethane (1 mL) and water (1 mL) and the layers were separated. The aqueous layer was extracted with dichloromethane (2 x 2 mL). The combined organic layers were washed with water (1 x 2 mL), dried over magnesium sulfate, filtered and evaporated. The crude product was purified by preparative HPLC to afford the title compound (30 mg, 0.058 mmol, 65%) as a white powder. Optical rotation: [ a]D 25 -27.3° (c 0.19, MeOH). MS (ESI): mass calcd. for C24HI8F6N60, 520.2; m/z found, 521.2 [M+H]+. ¾ NMR (500 MHz, DMSO-</6) d 9.32 (s, 2H), 8.33 - 8.28 (m, 1H), 8.15 - 8.11 (m, 1H), 7.87 - 7.81 (m, 1H), 7.57 - 7.48 (m, 2H), 5.65 - 5.55 (m, 1H), 3.83 (s, 3H), 3.63 - 3.56 (m, 1H), 3.37 - 3.26 (m, 1H), 2.85 - 2.76 (m, 1H), 2.39 - 2.30 (m, 1H), 1.51 (d, 7 =
6.7 Hz, 3H). vdro-dH-pyrazoloP.d-
Figure imgf000379_0004
The title compound was prepared in a manner analogous to Example 296, using 4-methoxy-3- (4H-l,2,4-triazol-4-yl)benzoic acid (Intermediate 124) instead of 3-(l,2,4-triazol-4-yl)-5- (trifluoromethyl)benzoic acid.MS (ESI): mass calcd. for C24H21F3N6O2, 482.2; m/z found, 483.2
Figure imgf000379_0001
8.84 (s, 2H), 7.72 - 7.45 (m, 4H), 7.36 (d, J= 8.4 Hz, 1H), 5.77 - 5.26 (m, 1H), 3.90 (s, 3H), 3.86 - 3.77 (m, 1H), 3.80 (s, 3H), 2.94 - 2.74 (m, 1H),
2.62 - 2.29 (m, 2H), 1.47 (d, J= 6.8 Hz, 3H).
Example 298: it7S)-2.7-Diniethyl-3-t3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazoloi3.4- c1pyridin-6-yl1-r3-methoxy-5-(E2.4-triazol-4- phenyl1methanone.
Figure imgf000379_0002
Figure imgf000379_0003
The title compound was prepared in a manner analogous to Example 296, using 3-methoxy-5- (4H-l,2,4-triazol-4-yl)benzoic acid (Intermediate 125) instead of 3-(l,2,4-triazol-4-yl)-5- (trifluoromethyl)benzoic acid. MS (ESI): mass calcd. for C24H21F3N6O2, 482.2; m/z found, 483.2 [M+H]+. (500 MHz, DMSO-r/e) d 9.20 (s, 2H), 7.55 - 7.47 (m, 2H), 7.45 - 7.39 (m, 1H), 7.35 - 7.31 (m, 1H), 7.05 - 6.90 (m, 1H), 5.59 - 5.50 (m, 1H), 3.86 (s, 3H), 3.80 (s, 3H),
3.66 - 3.55 (m, 1H), 3.28 - 3.18 (m, 1H), 2.84 - 2.74 (m, 1H), 2.35 - 2.26 (m, 1H), 1.45 (d, =
6.8 Hz, 3H).
Example 299: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-r2-(E2.4-triazol-4- phenyl1methanone.
Figure imgf000380_0001
Figure imgf000380_0002
The title compound was prepared in a manner analogous to Example 288, using 2-(4H-l,2,4- triazol-4-yl)benzoic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H19F3N6O, 452.2; m/z found, 453.1 [M+H]+. ¾ NMR (500 MHz,
Chlorofornw/) d 8.62 - 8.37 (m, 0.65H), 8.11 (s, 1.36H), 7.65 - 7.52 (m, 2.78H), 7.51 - 7.38 (m, 0.60H), 7.31 (d, = 7.6 Hz, 0.67H), 7.13 - 7.06 (m, 1.40H), 6.97 - 6.83 (m, 0.60H), 5.82 - 5.70 (m, 0.27H), 4.73 (dd, J= 13.2, 5.6 Hz, 0.83H), 4.48 (q, J= 6.8 Hz, 0.73H), 3.82 - 3.71 (m, 3.34H), 3.44 - 3.33 (m, 0.28H), 3.27 - 3.16 (m, 0.08H), 2.98 (td, J= 12.7, 4.3 Hz, 1H), 2.58 - 2.10 (m, 2H), 1.44 - 1.27 (m, 2.60H).
Example 300: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('6-methoxy-3-pyridyl)methanone.
Figure imgf000381_0001
The title compound was prepared in a manner analogous to Example 288, using 6- methoxynicotinic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for
Figure imgf000381_0002
416.1; m/z found, 417.0 [M+H]+. ' H NMR (400 MHz, Methanol- cL) d 8.29 (d, J= 2.4 Hz, 1H), 7.78 (dd, J= 8.6, 2.4 Hz, 1H), 7.46 - 7.21 (m, 2H), 6.89 (dd, J = 8.6, 0.8 Hz, 1H), 5.91 - 5.43 (m, 1H), 4.75 - 4.41 (m, 1H), 3.97 (s, 3H), 3.82 (s, 3H), 3.46 - 3.34 (m, 1H), 2.89 - 2.74 (m, 1H), 2.59 - 2.38 (m, 1H), 1.57 (d, J= 6.8 Hz, 3H).
Example 301 : i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-(5-methoxy-2-pyridyl)methanone.
Figure imgf000381_0003
The title compound was prepared in a manner analogous to Example 288, using 5- methoxypicolinic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for
Figure imgf000381_0004
416.1; m/z found, 417.0 [M+H]+. Ή NMR (400 MHz, Methanol- eh) d 8.39 - 8.23 (m, 1H), 7.64 (d, J= 8.6 Hz, 1H), 7.50 (dd, J= 8.7, 2.9 Hz, 1H), 7.36 - 7.21 (m, 2H), 5.70 (q, J= 6.8, 6.4 Hz, 0.70H), 5.28 - 5.11 (m, 0.30H), 4.83 - 4.58 (m, 0.30H), 4.01 (dd, J = 13.5, 4.9 Hz, 0.70H), 3.93 (s, 3H), 3.83 (s, 2.1H), 3.77 (s, 0.90H), 3.42 - 3.32 (m, 0.70H), 3.26 - 3.14 (m, 0.30H), 3.04 - 2.85 (m, 0.70H), 2.86 - 2.70 (m, 0.30H), 2.61 - 2.49 (m, 0.30H), 2.48 - 2.32 (m, 0.70H), 1.68 - 1.50 (m, 3H).
Example 302: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-(6-methoxy-3-methyl-2-pyridyl)methanone.
Figure imgf000382_0001
The title compound was prepared in a manner analogous to Example 288, using 6-methoxy-3- methylpicolinic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H21F3N4O2, 430.2; m/z found, 431.2
Figure imgf000382_0002
NMR (500 MHz, DMSO-r/e) d 7.67 - 7.62 (m, 1H), 7.60 - 7.49 (m, 2H), 6.86 - 6.79 (m, 1H), 5.60 (q, J= 6.7 Hz, 0.70H), 4.71
(dd, J= 13.0, 5.2 Hz, 0.33H), 4.48 (q, J= 6.7 Hz, 0.35H), 3.88 - 3.71 (m, 6H), 3.26 - 3.18 (m, 0.68H), 3.03 (td, J= 12.7, 3.9 Hz, 0.31H), 2.79 - 2.63 (m, 1H), 2.35 - 2.29 (m, 0.67H), 2.15 (s, 2H), 2.05 (s, 1H), 1.48 (d, J= 6.7 Hz, 2H), 1.42 (d, J= 6.7 Hz, 1H). (Fractions of H’s that overlap with DMSO and water are not reported)
Example 303: it7S)-2.7-Diniethyl-3-t3.4.5-trifluoroDhenyl)-5.7-dihvdro-4H-Dyrazoloi3.4- clpyridin-6-yll-(3-methoxy-2-pyridyl)methanone.
Figure imgf000382_0003
The title compound was prepared in a manner analogous to Example 288, using 3- methoxypicolinic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H19F3N4O2, 416.1; m/z found, 417.2
Figure imgf000382_0004
NMR (500 MHz, DMSO-r/e) d 8.18 - 8.13 (m, 1H), 7.62 - 7.42 (m, 4H), 5.58 (q, J= 6.7 Hz, 0.66H), 4.70 (dd, J= 13.0, 5.3 Hz, 0.36H), 4.44 (q, J= 6.7 Hz, 0.36H), 3.86 - 3.71 (m, 6H), 3.24 - 3.16 (m, 0.72H), 3.02 (td, J = 12.7, 4.0 Hz, 0.36H), 2.73 - 2.55 (m, 1H), 2.33 - 2.25 (m, 0.67H), 1.45 (d, J= 6.8 Hz, 2H), 1.32 (d, J= 6.8 Hz, 1H). (Fractions of H’s that overlap with DMSO and water may not be reported) Example 304: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000383_0001
Figure imgf000383_0002
The title compound was prepared in a manner analogous to Example 288, using 5- (methoxymethyl)nicotinic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H21F3N4O2, 430.2; m/z found, 431.2 [M+H]+. ¾ NMR (600 MHz, DMSO-r/e) d 8.65 - 8.63 (m, 1H), 8.58 (s, 1H), 7.74 - 7.72 (m, 1H), 7.60 - 7.50 (m, 2H), 5.63 - 5.52 (m, 0.74H), 4.74 - 4.46 (m, 2.78H); 3.91 - 3.52 (m, 4H), 3.33 (s, 3H), 3.16 - 3.02 (m, 0.26H), 2.91 - 2.72 (m, 1H), 2.41 - 2.29 (0.78H), 1.54 - 1.41 (m, 3H). (Fractions of H’s that overlap with DMSO and water may not be reported)
Example 305: it7S)-2.7-Diniethyl-3-t3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazoloi3.4- c1pyridin-6-yl1-t5-isopropoxy-3-pyridyl)methanone.
Figure imgf000383_0003
The title compound was prepared in a manner analogous to Example 288, using 5- isopropoxynicotinic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H23F3N4O2, 444.2; m/z found, 445.2 [M+H]+. ¾ NMR (500 MHz, DMSO- de) d 8.34 (d, J= 2.8 Hz, 1H), 8.22 - 8.12 (m, 1H), 7.59 - 7.50 (m, 2H), 7.43 - 7.39 (m, 1H), 5.63 - 5.49 (m, 0.71H), 4.83 - 4.52 (m, 1.53H), 3.87 - 3.53 (m, 3.84H), 2.92 - 2.70 (m, 1H), 2.9 - 2.28 (m, 0.82H), 1.50 - 1.43 (m, 3H), 1.32 - 1.27 (m, 6H). (Fractions of H’s that overlap with
DMSO and water may not be reported) Example 306: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluoroDhenyl)-5.7-dihvdro-4H-Dyrazolo[3.4- clpyridin-6-yll-(6-methoxy-2-methyl-3-pyridyl)methanone.
Figure imgf000384_0001
The title compound was prepared in a manner analogous to Example 288, using 6-methoxy-2- methylnicotinic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H21F3N4O2, 430.2; m/z found, 431.2
Figure imgf000384_0002
NMR (500 MHz, DMSO-r/e) d 7.74 - 7.30 (m, 3H), 6.76 - 6.67 (m, 1H), 5.68 - 5.58 (m, 0.71H), 4.76 - 4.66 (m, 0.26H), 4.61 - 4.44 (s, 0.25H), 3.91 - 3.73 (m, 6H), 3.07 - 2.97 (m, 0.24H), 2.81 - 2.59 (m, 1H), 2.38 - 2.12 (m, 3.68H), 1.53 - 1.26 (m, 3H). (Fractions of H’s that overlap with DMSO and water may not be reported)
Example 307: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('4-methoxy-3-methyl-2-pyridyl)methanone *TFA salt.
Figure imgf000384_0003
The title compound was prepared in a manner analogous to Example 288, using 4-methoxy-3- methylpicolinic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H21F3N4O2, 430.2; m/z found, 431.2
Figure imgf000384_0004
NMR (500 MHz, DMSO-r/e) d 8.41 - 8.35 (m, 1H), 7.60 - 7.48 (m, 2H), 7.17 - 7.10 (m, 1H), 5.61 (q, J= 6.7 Hz, 0.70H), 4.75 - 4.69 (m, 0.34H), 4.50 (q, J= 6.7 Hz, 0.35H), 3.95 - 3.91 (m, 3H), 3.82 (s, 2H), 3.75 (s, 1H),
3.33 - 3.28 (m, 0.65H), 3.25 - 3.17 (m, 0.79H), 3.08 - 3.00 (m, 0.35H), 2.78 - 2.70 (m, 0.38H), 2.67 - 2.58 (m, 0.74H), 2.31 - 2.25 (m, 0.70H), 2.06 (s, 2H), 1.99 (s, 1H), 1.48 (d, J= 6.8 Hz, 2H), 1.32 (d, = 6.8 Hz, 1H).
Example 308: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-('5-methoxy-2-methyl-3-pyridyl)methanone.
Figure imgf000385_0001
The title compound was prepared in a manner analogous to Example 288, using 5-methoxy-2- methylnicotinic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H21F3N4O2, 430.2; m/z found, 431.2 [M+H]+. Ή NMR (500 MHz, Chloroform- ) d 8.25 (d, J= 2.9 Hz, 1H), 7.06 - 6.87 (m, 3H), 5.92 (q, J= 6.7 Hz, 0.58H), 4.96 (dd, J= 13.2, 5.3 Hz, 0.43H), 4.88 - 4.59 (m, 0.45H), 3.90 - 3.75 (m, 6H), 3.63 - 3.47 (m, 0.58H), 3.36 - 3.22 (m, 0.59H), 3.10 - 2.99 (m, 0.39H), 2.84 - 2.73 (m, 0.40H), 2.63 - 2.24 (m, 4.64H), 1.66 - 1.38 (m, 3H). Example 309: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('4-methoxy-2-pyridyl)methanone.
Figure imgf000385_0002
The title compound was prepared in a manner analogous to Example 288, using 4- methoxypicolinic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H19F3N4O2, 416.1; m/z found, 417.2 [M+H]+. Ή NMR (500 MHz, Chloroform-^/) d 8.43 - 8.38 (m, 1H), 7.18 (dd, J= 20.1, 2.5 Hz, 1H), 7.02 - 6.92 (m, 2H), 6.89 - 6.83 (m, 1H), 5.85 (q, J= 6.8 Hz, 0.55H), 5.28 (q, J= 6.7 Hz, 0.45H), 4.87 (dd, J= 13.1, 5.3 Hz, 0.46H), 4.08 (dd, J= 13.6, 5.0 Hz, 0.57H), 3.94 - 3.72 (m, 6H), 3.31 - 3.22 (m, 0.56H), 3.10 (td, J= 12.7, 4.0 Hz, 0.45H), 2.97 - 2.79 (m, 1H), 2.51 - 2.29 (m, 1H), 1.64 - 1.57 (m, 3H).
Example 310: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-(5-methoxy-6-methyl-3-pyridyl)methanone.
Figure imgf000386_0001
The title compound was prepared in a manner analogous to Example 288, using 5-methoxy-6- methylnicotinic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H21F3N4O2, 430.2; m/z found, 431.2
Figure imgf000386_0002
NMR (500 MHz, DMSO-r/e) d 8.07 (s, 1H), 7.59 - 7.50 (m, 2H), 7.35 (d, J= 1.7 Hz, 1H), 5.55 (s, 0.69H), 4.83 - 4.50 (m,
0.53H), 3.91 - 3.60 (m, 7.24H), 2.92 - 2.74 (m, 1H), 2.43 - 2.30 (m, 4H), 1.48 (d, J= 6.8 Hz, 3H). (Fractions of H’s that overlap with DMSO and water may not be reported)
Example 311 : i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-(3-methoxy-4-pyridyl)methanone.
Figure imgf000386_0003
The title compound was prepared in a manner analogous to Example 288, using 3- methoxyisonicotinic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H19F3N4O2, 416.1 ; m/z found, 417.2 [M+H]+. ¾ NMR (500 MHz, DMSO- de) d 8.57 - 8.44 (m, 1H), 8.34 - 8.23 (m, 1H), 7.60 - 7.46 (m, 2H), 7.39 - 7.06 (m, 1H), 5.64 - 5.51 (m, 0.73H), 4.72 - 4.63 (m, 0.29H), 4.53 - 4.37 (m, 0.34H), 3.99 - 3.89 (m, 2.60H), 3.84 - 3.70 (m, 3.3 OH), 3.10 - 2.95 (m, 0.26H), 2.79 - 2.56 (m, 1.18H), 2.41 - 2.21 (m, 0.72H), 1.50 - 1.26 (m, 3H). (Fractions of H’s that overlap with DMSO and water may not be reported)
Example 312: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('2-methoxy-4-pyridyl)methanone.
Figure imgf000387_0001
The title compound was prepared in a manner analogous to Example 288, using 2- methoxyisonicotinic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H19F3N4O2, 416.1 ; m/z found, 417.2 [M+H]+. ¾ NMR (500 MHz, DMSO- de) d 8.29 - 8.25 (m, 1H), 7.59 - 7.49 (m, 2H), 7.03 - 6.92 (m, 1H), 6.86 - 6.77 (m, 1H), 5.55 (q, J= 6.7 Hz, 0.72H), 4.66 - 4.55 (m, 0.51H), 3.89 (s, 3H), 3.85 - 3.71 (m, 3H), 3.55 - 3.47 (m, 0.75H), 3.10 - 3.01 (m, 0.25H), 2.86 - 2.69 (m, 1H), 2.35 - 2.25 (m, 0.69H), 1.51 - 1.36 (m,
3H). (Fractions of H’s that overlap with DMSO and water are not reported) Example 313: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-(5-methoxy-4-methyl-3-pyridvf)methanone.
Figure imgf000387_0002
The title compound was prepared in a manner analogous to Example 288, using 5-methoxy-4- methylnicotinic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H21F3N4O2, 430.2; m/z found, 431.2 [M+H]+. Ή NMR (500 MHz, Chloroform-^/) d 8.26 - 7.93 (m, 2H), 7.02 - 6.89 (m, 2H), 6.00 - 5.88 (m, 0.58H), 5.03 - 4.92 (m, 0.46H), 4.87 (br s, 0.13H), 4.68 - 4.56 (m, 0.32H), 4.01 - 3.89 (m, 3H), 3.86 - 3.74 (m, 3H), 3.65 - 3.48 (m, 0.59H), 3.32 - 3.21 (m, 0.59H), 3.06 (td, J= 12.7, 3.9 Hz, 0.43H), 2.86 - 2.73 (m, 0.42H), 2.66 - 2.44 (m, 1H), 2.36 - 1.98 (m, 3.66H), 1.67 - 1.33 (m, 3H).
Example 314: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-(2-methoxy-3-methyl-4-pyridyl)methanone.
Figure imgf000388_0001
The title compound was prepared in a manner analogous to Example 288, using 2-methoxy-3- methylisonicotinic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H21F3N4O2, 430.2; m/z found, 431.2 [M+H]+. ¾ NMR (500 MHz, DMSO- de) d 8.15 - 8.02 (m, 1H), 7.60 - 7.46 (m, 2H), 7.00 - 6.60 (m, 1H), 5.62 (q, J= 6.7 Hz, 0.76H), 4.76 - 4.55 (m, 0.37H), 4.45 - 4.36 (m, 0.17H), 3.94 - 3.88 (m, 3H), 3.81 (s, 2.25H), 3.76 (s, 0.76H), 3.10 - 2.98 (m, 0.25H), 2.81 - 2.61 (m, 0.80H), 2.34 - 2.23 (m, 0.76H), 2.14 - 1.82 (m, 3H), 1.52 - 1.26 (m, 3H). (Fractions of H’s that overlap with DMSO and water may not be reported)
Example 315: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-(3-fluoro-2-methoxy-4-pyridyl)methanone.
Figure imgf000388_0002
The title compound was prepared in a manner analogous to Example 288, using 3-fluoro-2- methoxyisonicotinic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H18F4N4O2, 434.1 ; m/z found, 435.2 [M+H]+. ¾ NMR (500 MHz, DMSO- ek) d 8.07 (d, J= 5.0 Hz, 1H), 7.59 - 7.49 (m, 2H), 7.08 - 6.98 (m, 1H), 5.59 (q, J= 6.7 Hz, 0.76H), 4.67 (dd, J= 13.2, 5.3 Hz, 0.29H), 4.59 (q, J= 6.6 Hz, 0.28H), 4.01 - 3.95 (m, 3H), 3.81 (s, 2.24H), 3.76 (s, 0.83H), 3.54 - 3.47 (m, 0.79H), 3.13 - 3.05 (m, 0.27H), 2.77 - 2.62 (m, 1H), 2.33 - 2.28 (m, 0.68H), 1.47 - 1.37 (d, J= 6.8 Hz, 2.27H), 1.37 (d, J= 6.7 Hz, 0.80H).
(Fractions of H’s that overlap with DMSO and water are not reported)
Example 316: (3-Chloro-2-methoxy-4-pyridylVr(7SV2.7-dimethyl-3-(3 A5-trifluorophenylV5.7- dihvdro-4H-pyrazolo c|pyridin-6-yl1methanone.
Figure imgf000389_0001
Figure imgf000389_0002
The title compound was prepared in a manner analogous to Example 288, using 3-chloro-2- methoxyisonicotinic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H18CIF3N4O2, 450.1 ; m/z found, 451.2 [M+H]+. ¾ NMR (500 MHz, Chlorofomw/) d 8.16 - 8.10 (m, 0.87H), 8.06 (d, J= 5.0 Hz, 0.12H), 7.02 - 6.91 (m, 2H), 6.89 (d, J= 5.0 Hz, 0.25H), 6.83 (d, J= 5.0 Hz, 0.62H), 6.71 (d, J= 5.0 Hz, 0.12H), 5.92 - 5.85 (m, 0.62H), 4.94 (dd, J= 13.1, 5.2 Hz, 0.41H), 4.75 (q, J= 6.8 Hz, 0.14H), 4.63 (q, J= 6.7 Hz, 0.26H), 4.08 - 4.02 (m, 3H), 3.85 - 3.76 (m, 3H), 3.54 - 3.44 (m, 0.63H), 3.43 - 3.33 (m,
0.39H), 3.31 - 3.22 (m, 0.23H), 3.11 (td, J= 12.7, 4.1 Hz, 0.12H), 3.03 (td, J= 12.7, 3.8 Hz, 0.24H), 2.87 - 2.74 (m, 0.61H), 2.57 - 2.45 (m, 0.77H), 2.37 - 2.28 (m, 0.62H), 1.65 - 1.39 (m, 3H). Example 317: ('3-Chloro-4-methoxy-2-pyridyl)-i('7S)-2.7-dimethyl-3-('3.4.5-trifluorophenyl)-5.7- ridin-6-yl1methanone.
Figure imgf000389_0003
The title compound was prepared in a manner analogous to Example 288, using 3-chloro-4- methoxypicolinic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C21H18CIF3N4O2, 450.1 ; m/z found, 451.1
[M+H]+. (500 MHz, Chloroform-r/) d 8.43 - 8.39 (m, 1H), 7.01 - 6.91 (m, 2H), 6.90 - 6.86 (m, 1H), 5.91 (q, J= 6.8 Hz, 0.58H), 5.00 - 4.94 (m, 0.44H), 4.67 (q, J= 6.7 Hz, 0.43H),
4.01 - 3.97 (m, 3H), 3.83 (s, 1.79H), 3.76 (s, 1.27H), 3.45 - 3.39 (m, 0.59H), 3.35 - 3.27 (m, 0.59H), 3.08 (td, J= 12.7, 3.9 Hz, 0.42H), 2.88 - 2.72 (m, 1H), 2.52 - 2.46 (m, 0.42H), 2.31 - 2.23 (m, 0.59H), 1.64 (d, = 6.8 Hz, 1.79H), 1.49 (d, = 6.8 Hz, 1.32H).
Example 318: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-(5-pyrazol- 1 -yl-3-pyridyl)methanone.
Figure imgf000390_0001
The title compound was prepared in a manner analogous to Example 296, using 5-(lH-pyrazol- l-yl)nicotinic acid (Intermediate 119) instead of 3-(l,2,4-triazol-4-yl)-5-(trifluoromethyl)benzoic acid.MS (ESI): mass calcd. for C23H19F3N6O, 452.2; m/z found, 453.2
Figure imgf000390_0002
NMR (500 MHz, DMSO-r/e) d 9.25 (d, J= 2.5 Hz, 1H), 8.72 (d, J= 2.6 Hz, 1H), 8.61 - 8.54 (m, 1H), 8.36 - 8.25 (m, 1H), 7.87 (d, J= 1.8 Hz, 1H), 7.62 - 7.51 (m, 2H), 6.68 - 6.62 (m, 1H), 5.68 - 5.55 (m, 1H), 3.84 (s, 3H), 3.71 - 3.62 (m, 1H), 3.41 - 3.26 (m, 1H), 2.95 - 2.83 (m, 1H), 2.42 - 2.30 (m, 1H), 1.52 (d, J= 6.9 Hz, 3H).
Example 319: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000390_0003
clpyridin-6-yll-[6-methyl-3-('triazol-2-yl)-2-pyridyllmethanone.
Figure imgf000391_0001
The title compound was prepared in a manner analogous to Example 296, using 6-methyl-3-(2H- l,2,3-triazol-2-yl)picolinic acid [prepared according to methods described in Pat. Pub. No.
WO2016040789] instead of 3-(l,2,4-triazol-4-yl)-5-(trifluoromethyl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N7O, 467.2; m/z found, 468.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.26 (d, J= 8.4 Hz, 1H), 8.11 (s, 2H), 7.60 - 7.48 (m, 3H), 5.47 (q, J= 6.7 Hz, 1H), 3.82 (s, 3H), 3.52 - 3.46 (m, 1H), 3.26 - 3.18 (m, 1H), 2.70 - 2.61 (m, 1H), 2.58 (s, 3H), 2.33 - 2.27 (m, 1H), 1.47 (d, J = 6.1 Hz, 3H). Example 320: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-t6-pyrazol- l -yl-2-pyridyl)methanone.
Figure imgf000391_0002
The title compound was prepared in a manner analogous to Example 296, using 6-(lH-pyrazol- l-yl)picobnic acid instead of 3-(l,2,4-triazol-4-yl)-5-(trifluoromethyl)benzoic acid. MS (ESI): mass calcd. for C23H19F3N6O, 452.2; m/z found, 453.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) 5 8.65 (d, = 2.6 Hz, 1H), 8.17 - 8.09 (m, 1H), 8.07 - 8.01 (m, 1H), 7.86 (d, = l .5 Hz, 1H),
7.62 - 7.48 (m, 3H), 6.62 - 6.58 (m, 1H), 5.58 (q, J= 6.7 Hz, 1H), 3.82 (s, 3H), 3.81 - 3.78 (m, 1H), 3.30 - 3.22 (m, 1H), 2.97 - 2.88 (m, 1H), 2.39 - 2.32 (m, 1H), 1.50 (d, J= 6.8 Hz, 3H). Example 321 : i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll -(5 -methyl- 1 -phenyl- 1.2.4-triazol-3 -ylimethanone.
Figure imgf000392_0001
The title compound was prepared in a manner analogous to Example 288, using 5-methyl-l- phenyl-lH-l,2,4-triazole-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H21F3N6O, 466.2; m/z found, 467.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 7.68 - 7.50 (m, 7H), 5.58 (q, J= 6.7 Hz, 0.58H), 5.28 (q, J= 6.7 Hz, 0.38H), 4.66 (dd, J= 13.0, 5.2 Hz, 0.38H), 4.23 (dd, J= 13.6, 5.0 Hz, 0.57H), 3.83 - 3.73 (m, 3H), 3.12 - 3.03 (m, 0.39H), 2.85 - 2.69 (m, 1H), 2.53 - 2.51 (m, 3H), 1.55 - 1.44 (m, 3H). (Fractions of H’s that may overlap with DMSO and water are not reported) Example 322: i('7S)-2.7-Diiiiethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-gII-P -(^-fluorophenyl )-5-inethyl- l .2.4-triazol-3-yl1niethanone.
Figure imgf000392_0002
The title compound was prepared in a manner analogous to Example 288, using l-(4- fluorophenyl)-5-methyl-lH-l,2,4-triazole-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3- triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H20F4N6O, 484.2; m/z found, 485.1
[M+H]+. (500 MHz, DMSO-r/e) d 7.74 - 7.68 (m, 2H), 7.59 - 7.51 (m, 2H), 7.48 - 7.41 (m, 2H), 5.58 (q, J= 6.7 Hz, 0.59H), 5.27 (q, J= 6.7 Hz, 0.39H), 4.65 (dd, J= 13.0, 5.2 Hz, 0.38H), 4.22 (dd, J= 13.7, 5.0 Hz, 0.57H), 3.84 - 3.73 (m, 3H), 3.11 - 3.03 (m, 0.40H), 2.84 - 2.69 (m, 1H), 1.55 - 1.43 (m, 3H). (Fractions of H’s that may overlap with DMSO and water are not reported) Example 323: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000393_0001
c1pyridin-6-yl1-rl-(2-pyridylVl.2.4-triazol-3-yl1methanone.
Figure imgf000393_0002
The title compound was prepared in a manner analogous to Example 288, using l-(pyridin-2-yl)- lH-l,2,4-triazole-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid.
MS (ESI): mass calcd. for C22H18F3N7O, 453.2; m/z found, 454.1 [M+H]+.
Figure imgf000393_0003
(500 MHz, DMSO-r/e) 5 9.52 - 9.49 (m, 1H), 8.61 - 8.57 (m, 1H), 8.14 - 8.09 (m, 1H), 7.94 - 7.88 (m, 1H), 7.60 - 7.51 (m, 3H), 5.60 (q, = 6.8 Hz, 0.63H), 5.19 (q, J= 6.6 Hz, 0.38H), 4.68 (dd, J= 13.0, 5.2 Hz, 0.41H), 4.12 (dd, J= 13.8, 4.9 Hz, 0.58H), 3.85 - 3.73 (m, 3H), 3.12 (td, J= 12.7, 4.0 Hz, 0.42H), 2.91 - 2.74 (m, 1H), 1.59 - 1.47 (m, 3H). (Fractions of H’s that may overlap with DMSO and water are not reported)
Example 324: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1 - G 1 -(3 -fluoro-2-pyridylV 1 2.4-triazol-3 -yllmethanone.
Figure imgf000393_0004
The title compound was prepared in a manner analogous to Example 288, using l-(3- fluoropyridin-2-yl)-lH-l,2,4-triazole-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C22H17F4N7O, 471.1; m/z found, 472.2 [M+H]+. ¾ NMR (500 MHz, Chloroform-^ d 9.01 - 8.97 (m, 1H), 8.41 - 8.36 (m, 1H), 7.75 - 7.69 (m, 1H), 7.47 - 7.42 (m, 1H), 7.02 - 6.92 (m, 2H), 5.89 (q, J= 6.8 Hz, 0.52H), 5.52 (q, J= 6.7 Hz,
0.46H), 4.93 (dd, J= 13.1, 5.2 Hz, 0.48H), 4.39 (dd, J= 13.8, 4.9 Hz, 0.54H), 3.84 (s, 1.58H), 3.77 (s, 1.36H), 3.40 - 3.32 (m, 0.52H), 3.18 - 3.10 (m, 0.46H), 3.02 - 2.93 (m, 0.53H), 2.89 - 2.80 (m, 0.45H), 2.50 - 2.39 (m, 1H), 1.72 (d, = 6.7 Hz, 1.40H), 1.63 (d, = 6.8 Hz, 1.62H).
Example 325: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-[5-('2-pyridyl)-2-thienyllmethanone.
Figure imgf000394_0001
The title compound was prepared in a manner analogous to Example 288, using 5-(pyridin-2- yl)thiophene-2-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C24H19F3N4OS, 468.1; m/z found, 469.1
[M+H]+. (500 MHz, DMSO-r/e) d 8.59 - 8.54 (m, 1H), 8.03 - 7.99 (m, 1H), 7.88 (td, J
= 7.7, 1.8 Hz, 1H), 7.81 (d, = 3.9 Hz, 1H), 7.62 - 7.53 (m, 2H), 7.50 (d, = 3.9 Hz, 1H), 7.34 (ddd, = 7.5, 4.8, 1.1 Hz, 1H), 5.42 (br s, 1H), 4.30 (br s, 1H), 3.80 (s, 3H), 3.03 - 2.84 (m, 1H), 1.62 - 1.40 (m, 3H). (Fractions of Hs that may overlap with DMSO and water are not reported).
Example 326: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('5-methoxypyrazin-2-yl)methanone.
Figure imgf000394_0002
The title compound was prepared in a manner analogous to Example 288, using 5- methoxypyrazine-2-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C2OHISF3N5C>2, 417.1; m/z found, 418.0 [M+H]+. Ή NMR (400 MHz, Methanol-^) d 8.50 (d, J= 1.4 Hz, 1H), 8.27 - 8.20 (m, 1H), 7.36 - 7.21 (m, 2H), 5.69 (q, J = 6.7 Hz, 0.65H), 5.40 - 5.15 (m, 0.35H), 4.80 - 4.67 (m, 0.35H), 4.19 - 4.07 (m, 0.65H), 4.04 (s, 3H), 3.83 (s, 2H), 3.77 (s, 1H), 3.43 - 3.32 (m, 0.65H), 3.28 - 3.15 (m, 0.35H), 3.04 - 2.86 (m, 0.65H), 2.89 - 2.74 (m, 0.35H), 2.62 - 2.50 (m, 0.35H), 2.50 - 2.38 (m, 0.65H), 1.70 - 1.61 (m, 1H), 1.58 (d, J= 6.7 Hz, 2H). Example 327: (E5-Dimethylpyrazol-4-ylVr(7SV3-(3-fluoro-5-methyl-phenylV2.7-dimethyl-5.7- dihvdro-4H-pyrazolo[3.4-clpyridin-6-yllmethanone.
Figure imgf000395_0001
The title compound was prepared in a manner analogous to Example 288, using (S)-3-(3-fluoro- 5-methylphenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 42) instead of (S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c]pyridine (Intermediate 40) and 1,5 -dimethyl- lH-pyrazole-4-carboxylic acid instead of 2- fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H24FN5O, 381.2; m/z found, 382.2 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 7.54 (s, 1H), 7.22 - 7.06 (m, 3H), 5.38 (s, 1H), 4.33 - 3.92 (m, 1H), 3.76 (d, J= 10.1 Hz, 6H), 3.26 - 3.13 (m, 1H), 2.80 (t, J= 12.8 Hz, 1H), 2.43 - 2.33 (m, 4H), 2.30 (s, 3H), 1.44 (d, J= 6.7 Hz, 3H).
Example 328: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll -(5-isopropyl- l-methyl-pyrazolM-vDmethanone.
Figure imgf000395_0002
The title compound was prepared in a manner analogous to Example 288, using 5-isopropyl- 1- methyl-lH-pyrazole-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H24F3N5O, 431.2; m/z found, 432.1 [M+H] +. ¾ NMR (500 MHz, DMSO-i/e) d 7.63 - 7.49 (m, 2H), 7.42 (s, 1H), 5.51 (s, 1H), 5.07 - 4.32 (m, 1H), 3.84 - 3.74 (m, 6H), 3.27 - 2.98 (m, 2H), 2.79 (s, 1H), 2.36 (d, J= 15.7 Hz, 1H), 1.41 (d, = 6.7 Hz, 3H), 1.22 (dd, J= 26.6, 5.8 Hz, 6H). Example 329: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-nP-P -('trifluoromethyl)pyrazol-4-yllmethanone.
Figure imgf000396_0001
The title compound was prepared in a manner analogous to Example 288, using 1- (trifluoromethyl)-lH-pyrazole-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C19H15F6N5O, 443.1; m/z found, 444.2 [M+H]+. ¾
NMR (500 MHz, Chloroform-r/) d 8.15 - 8.12 (m, 1H), 7.94 (s, 1H), 7.00 - 6.92 (m, 2H), 5.93 - 5.05 (m, 1H), 4.95 - 4.00 (m, 1H), 3.81 (s, 3H), 3.53 - 2.99 (m, 1H), 2.86 - 2.68 (m, 1H), 2.58 - 2.38 (m, 1H), 1.62 (s, 3H). Example 330: r5-(DifluoromethylVl-methyl-pyrazol-4-ylTr(7SV2.7-dimethyl-3-(3.4.5- trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000396_0002
The title compound was prepared in a manner analogous to Example 288, using 5- (difluoromethyl)-l -methyl- lH-pyrazole-4-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3- triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C20H18F5N5O, 439.1; m/z found, 440.1
[M+H]+. (400 MHz, Chloroform-r/) d 7.56 (brs, 1H), 7.29 - 6.93 (m, 3H), 5.87 - 5.25 (m, 1H), 5.01 - 4.00 (m, 4H), 3.80 (s, 3H), 3.55 - 3.00 (m, 1H), 2.84 - 2.67 (m, 1H), 2.54 - 2.40 (m, 1H), 1.59 (s, 3H).
Example 331 : P -Cvclopropylpyrazol-4-yl)-[('7S)-2.7-dimethyl-3-('3.4.5-trifluorophenyl)-5.7- dihvdro-4H-pyrazolo[3.4-c|pyridin-6-yl1methanone.
Figure imgf000397_0001
The title compound was prepared in a manner analogous to Example 288, using l-cyclopropyl- lH-pyrazole-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H20F3N5O, 415.2; m/z found, 416.1 [M+H]+. Ή NMR (500 MHz, Chloroform-r/) 5 7.81 (s, 1H), 7.66 (s, 1H), 7.01 - 6.91 (m, 2H), 5.54 (brs, 1H), 4.89 - 4.14 (m, 1H), 3.80 (s, 3H), 3.67 - 3.57 (m, 1H), 3.18 (brs, 1H), 2.83 - 2.68 (m, 1H), 2.54 - 2.38 (m, 1H), 1.61 (s, 3H), 1.19 - 1.00 (m, 4H).
Example 332: P -Cvclopropyl-3-('trifluoromethyl)pyrazol-4-yl1-[('7S)-2.7-dimethyl-3-('3.4.5- trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000397_0002
The title compound was prepared in a manner analogous to Example 288, using potassium 1- cyclopropyl-3-(trifluoromethyl)-lH-pyrazole-4-carboxylate (Intermediate 82) instead of 2- fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C22H19F6N5O, 483.1; m/z found, 484.1 [M+H]+. Ή NMR (500 MHz, Chloroform- ) d 7.59 (s, 1H), 6.96 (t , J= 6.9 Hz, 2H), 5.85 (brs, 0.51H), 4.92 (brs, 0.70H), 3.81 (s, 3H), 3.72 - 3.61 (m, 1H), 3.38 - 2.96 (m, 1H), 2.82 - 2.50 (m, 2.21H), 2.39 (brs, 1H), 1.78 (brs, 1H), 1.34 - 1.17 (m, 1.93H), 1.14 - 1.01 (m, 3.84H). Example 333: (5-Cvclobutyl-l-methyl-pyrazol-4-ylVr(7SV2.7-dimethyl-3-(3A5- trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-clpyridin-6-yllmethanone.
Figure imgf000398_0001
The title compound was prepared in a manner analogous to Example 288, using potassium 5- cy cl obuty 1-1 -methyl- lH-pyrazole-4-carboxylate (Intermediate 80) instead of 2-fluoro-6-(2H- l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for
C23H24F3N5O, 443.2; m/z found, 444.1 [M+H]+. Ή NMR (500 MHz, Chloroform- ) d 7.36 (s, 1H), 7.00 - 6.92 (m, 2H), 5.81 (brs, 0.53H), 5.26 - 4.74 (m, 0.74H), 4.04 (brs, 0.56H), 3.86 - 3.73 (m, 6.27H), 3.72 - 3.56 (m, 1H), 3.40 - 2.88 (m, 1H), 2.68 (brs, 1H), 2.52 - 2.13 (m, 5H), 2.13 - 1.71 (m, 2H), 1.53 (s, 3H).
Example 334: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-nII-P -methyl-5-P -methylcvclopropyl)pyrazol-4-yl1methanone.
Figure imgf000398_0002
The title compound was prepared in a manner analogous to Example 288, using l-methyl-5-(l- methylcyclopropyl)-lH-pyrazole-4-carboxylic acid (Intermediate 71) instead of 2-fluoro-6-(2H- l,2,3-triazol-2-yl)benzoic acid, stirring at 40 °C overnight. MS (ESI): mass calcd. for
C23H24F3N5O, 443.2; m/z found, 444.3 [M+H]+. 'H NMR (500 MHz, Chloroform- ) d 7.39 (s, 1H), 7.00 - 6.92 (m, 2H), 6.09 - 4.55 (m, 1.48H), 4.23 - 3.72 (m, 7.90H), 3.17 (brs, 1.10H), 2.69 (brs, 1.09H), 2.41 (d, = l4.7 Hz, 1.14H), 1.57 (d, = 9.7 Hz, 4.93H), 1.40 (s, 3.28H).
Example 335: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c|pyridin-6-yl1-r5-(4 -fluorocvclopropylV 1 -methyl-pyrazol-4-yllmethanone.
Figure imgf000399_0001
The title compound was prepared in a manner analogous to Example 288, using potassium 5-(l- fluorocyclopropyl)-l-methyl-lH-pyrazole-4-carboxylate (Intermediate 73) instead of 2-fluoro-6- (2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C22H21F4N5O, 447.2; m/z found, 448.2 [M+H]+. ' H NMR (500 MHz, Chloroform- ) d 7.49 (s, 1H), 6.96 (t, J= 6.9 Hz, 2H), 5.88 (s, 0.62H), 5.21 - 4.79 (m, 0.68H), 4.10 - 3.98 (m, 3.64H), 3.82 (s, 3H), 3.38 - 2.97 (m, 1H), 2.84 - 2.56 (m, 1H), 2.53 - 2.29 (m, 1H), 1.61 - 1.32 (m, 5H),
1.23 - 0.99 (m, 2H).
Example 336: (5 -(2.2-Difluorocvclopropyl V 1 -methyl- 1 H-pyrazol-4-yl) -2.7-dimethyl-3-
Figure imgf000399_0002
('3.4.5-trifluorophenyl)-4.5-dihvdro-2H-pyrazolo[3.4-c1pyridin-6-yl)methanone.
Figure imgf000399_0003
The title compound was prepared in a manner analogous to Example 288, using 5-(2,2- difluorocyclopropyl)-l -methyl- lH-pyrazole-4-carboxy lie acid (Intermediate 75) instead of 2- fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H20F5N5O, 465.2; m/z found, 466.2 [M+H]+. ¾ NMR (500 MHz, Chloroform-r/) d 7.49 (s, 1H), 7.00 - 6.93 (m, 2H), 5.76 (brs, 0.56H), 5.25 - 4.56 (m, 0.82H), 3.86 (d, J= 52.3 Hz, 6.89H), 3.42 - 2.97 (m,
1H), 2.81 - 2.56 (m, 2.19H), 2.43 (m, 1H), 2.01 (brs, 1H), 1.58 - 1.54 (m, 3H), 1.14 - 1.06 (m, 0.69H).
Example 337: ( 5 -((R* difluorocvclopropyl V 1 -methyl- 1 H-pyrazol-4-vf)(( S dimethyl-3 -
Figure imgf000400_0001
Figure imgf000400_0002
('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4-c1pyridin-6-yl)methanone.
Figure imgf000400_0003
The title compound was obtained as a single enantiomer by chiral SFC purification of racemic (5-(2,2-Difluorocyclopropyl)-l-methyl-lH-pyrazol-4-yl)((S)-2,7-dimethyl-3-(3,4,5- trifluorophenyl)-4,5-dihydro-2H-pyrazolo[3,4-c]pyridin-6-yl)methanone (Example 336)
(stationary phase: Chiral cel OZ, 5 pm 250 x 21 mm; mobile phase: 40% MeOH with 0.2% TEA, 60% CO2; flow rate: 42mL/min). MS (ESI): mass calcd. for C22H20F5N5O, 465.2; m/z found, 466.2 [M+H]+. ¾ NMR (500 MHz, Chloroform-r/) d 7.49 (s, 1H), 7.00 - 6.93 (m, 2H), 5.76 (brs, 0.56H), 5.25 - 4.56 (m, 0.82H), 3.86 (d, J= 52.3 Hz, 6.89H), 3.42 - 2.97 (m, 1H), 2.81 - 2.56 (m, 2.19H), 2.43 (m, 1H), 2.01 (brs, 1H), 1.58 - 1.54 (m, 3H), 1.14 - 1.06 (m, 0.69H). (R*; absolute stereochemistry on cyclopropane was not determined). Example 338: (5-( DifluorocvclopropylVl-methyl-lH-pyrazol-4- ((SV2.7-dimethyl-
Figure imgf000401_0001
Figure imgf000401_0002
vflmethanone.
Figure imgf000401_0003
The title compound was obtained as a single enantiomer by chiral SFC purification of racemic (5-(2,2-Difluorocyclopropyl)-l-methyl-lH-pyrazol-4-yl)((S)-2,7-dimethyl-3-(3,4,5- trifluorophenyl)-4,5-dihydro-2H-pyrazolo[3,4-c]pyridin-6-yl)methanone (Example 336) (stationary phase: Chiral cel OZ, 5 pm 250 x 21 mm; mobile phase: 40% MeOH with 0.2% TEA, 60% CCh; flow rate: 42mL/min). MS (ESI): mass calcd. for C22H20F5N5O, 465.2; m/z found, 466.2 [M+H]+. ¾ NMR (500 MHz, Chloroform-r/) d 7.48 (s, 1H), 7.01 - 6.93 (m, 2H), 5.80 (brs, 0.56H), 5.36 - 4.64 (m, 0.91H), 4.09 (brs, 0.63H), 3.90 (s, 3H), 3.81 (s, 3H), 3.39 - 2.97 (m, 1H), 2.81 - 2.54 (m, 2.78H), 2.47 - 2.33 (m, 1H), 1.93 (brs, 1H), 1.73 - 1.46 (m, 2.20H), 1.08 (t, J = 7.2 Hz, 1H). (S*; absolute stereochemistry on cyclopropane was not determined).
Example 339: ('('S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- c1pyridin-6-yl)t67.s-5-t2-fluorocvclopropyl)- l -methyl- 1 H-pyrazol-4-yl)methanone.
Figure imgf000401_0004
The title compound was prepared in a manner analogous to Example 288, using potassium cis- 5- (2-fluorocyclopropyl)-l -methyl- lH-pyrazole-4-carboxy late (Intermediate 77) instead of 2- fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C22H21F4N5O, 447.2; m/z found, 448.2 [M+H]+. 'H NMR (600 MHz, Chloroform- ) d 7.46 (s, 1H), 7.02 - 6.90 (m, 2H), 5.81 (brs, 0.68H), 5.18 (brs, 0.33H), 5.00 - 4.72 (m, 1.48H), 4.04 (brs, 0.49H), 3.92 (s, 3H), 3.81 (s, 3H), 3.33 - 2.96 (m, 1H), 2.69 (brs, 1H), 2.40 (d, J= 15.1 Hz, 1H), 1.98 (brs, 1H), 1.55 (s, 1.47H), 1.44 - 1.04 (m, 3.62H). (Mixture of isomers with relative cv.s-configuration at starred stereocenters).
Example 340: ((SV2.7-Dimethyl-3-(3.4.5-trifluorophenylV2.4.5.7-tetrahvdro-6H-pyrazolor3.4- clpyridin-6-yl)(7r< v-5-(2-fluorocvclopropyl)- 1 -methyl- 1 H-pyrazol-4-yl)methanone.
Figure imgf000402_0001
Method A: The title compound was prepared in a manner analogous to Example 288, using potassium ra«.s-5-(2-fluorocyclopropyl)- l -methyl- 1 H-pyrazole-4-carboxylate (Intermediate 78) instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C22H21F4N5O, 447.2; m/z found, 448.2 [M+H]+. Ή NMR (500 MHz,
Chlorofomw/) d 7.42 (d, J= 3.3 Hz, 1H), 7.00 - 6.93 (m, 2H), 5.81 (brs, 0.53H), 5.20 - 4.64 (m, 1.84H), 4.17 - 3.86 (m, 3.45H), 3.81 (s, 3H), 3.42 - 2.96 (m, 1H), 2.69 (brs, 1H), 2.42 (d, J = 15.1 Hz, 1H), 2.32 - 2.16 (m, 1H), 1.54 (s, 3.62H), 1.13 (m, 1.38H). (Mixture of isomers with relative /ra«.s-configuration at starred stereocenters).
Method B: The title compound was prepared in a manner analogous to Example 288, using /ra«.s-5-(2-fluorocyclopropyl)- l -methyl- 1 H-pyrazole-4-carboxylic acid (Intermediate 79) instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid, stirring at 36 °C overnight. Example 341 : ('('S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolo[3.4- c1pyridin-6-yl)n -methyl-67.s-5-('2-methylcvclopropyl)- l H-pyrazol-4-yl)methanone.
Figure imgf000403_0001
Method A: The title compound was prepared in a manner analogous to Example 288, using potassium /ra«.s-5-(2-fluorocyclopropyl)- l -methyl- 1 H-pyrazole-4-carboxylate (Intermediate 78) instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C22H21F4N5O, 447.2; m/z found, 448.2 [M+H]+. Ή NMR (500 MHz,
Chloroform-i/) d 7.42 (d, J= 3.3 Hz, 1H), 7.00 - 6.93 (m, 2H), 5.81 (brs, 0.53H), 5.20 - 4.64 (m, 1.84H), 4.17 - 3.86 (m, 3.45H), 3.81 (s, 3H), 3.42 - 2.96 (m, 1H), 2.69 (brs, 1H), 2.42 (d, J = 15.1 Hz, 1H), 2.32 - 2.16 (m, 1H), 1.54 (s, 3.62H), 1.13 (m, 1.38H). (Mixture of isomers with relative /ra«.s-configuration at starred stereocenters).
Method B: The title compound was prepared in a manner analogous to Example 288, using /ra«.s-5-(2-fluorocyclopropyl)- l -methyl- 1 H-pyrazole-4-carboxylic acid (Intermediate 79) instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid, stirring at 36 °C overnight.
Example 342: (S* V(2-(Bicvclor 1.1.1 lpentan- 1 -yl)-7-methyl-3-phenyl-2A5.7-tetrahvdro-6H- Pyrazolo[3.4-c1pyridin-6-yl)('5-cvclopropyl- 1 -methyl- 1 H-pyrazol-4-yl)methanone.
Figure imgf000403_0002
The title compound was isolated by SFC purification of race««c-(2-(Bicyclo[l. l . l]pentan-l-yl)- 7-methyl-3-phenyl-2, 4,5, 7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(5-cyclopropyl-l -methyl- lH-pyrazol-4-yl)methanone (Example 615) (stationary phase: Chiralpak AD, 5pm 250 x 30 mm; mobile phase: 20% MeOH with 0.2% TEA, 80% CO2; flow rate: 85mL/min). MS (ESI): mass calcd. for C26H29N5O, 427.2; m/z found, 428.1
Figure imgf000404_0001
NMR (500 MHz, Chloroform-r/) d 7.45 - 7.36 (m, 4H), 7.33 - 7.29 (m, 2H), 5.91 (brs, 0.41H), 5.16 (brs, 0.39H), 4.82 (brs, 0.42H), 3.98 - 3.82 (m, 3.37H), 3.39 - 2.94 (m, 1H), 2.56 (brs, 1H), 2.43 - 2.20 (m, 2H), 2.06 (s, 6H),
1.73 (s, 1H), 1.55 (brs, 3.16H), 1.07 - 0.54 (m, 4.34H). (S*: single enantiomer, but absolute configuration was not determined).
Example 343: (Ί .3-Dimethylpyrazol-4-yl)-[('7S)-2.7-dimethyl-3-('3.4.5-trifluorophenyl)-5.7- |pyridin-6-yl1methanone.
Figure imgf000404_0002
The title compound was prepared in a manner analogous to Example 288, using l,3-dimethyl- lH-pyrazole-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid, stirring at 36 °C overnight. MS (ESI): mass calcd. for C20H20F3N5O, 403.2; m/z found, 404.1
[M+H]+. (500 MHz, Chloroform-r/) d 7.42 (s, 1H), 7.01 - 6.93 (m, 2H), 5.55 (brs, 1H),
4.43 (brs, 1H), 3.85 (s, 3H), 3.81 (s, 3H), 3.18 (s, 1H), 2.76 - 2.63 (m, 1H), 2.47 - 2.37 (m, 1H), 2.31 (s, 3H), 1.55 (d, J= 6.8 Hz, 3H).
Example 344: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll -( 1.3.5-trimethylpyrazol-4-yl)methanone.
Figure imgf000404_0003
The title compound was prepared in a manner analogous to Example 288, using l,3,5-trimethyl- lH-pyrazole-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid, stirring overnight. MS (ESI): mass calcd. for C21H22F3N5O, 417.2; m/z found, 418.1 [M+H]+. 1H NMR (500 MHz, Chlorofornw/) d 7.00 - 6.92 (m, 2H), 6.18 - 3.87 (m, 2H), 3.81 (s, 3H), 3.72 (s, 3H), 3.18 (brs, 1H), 2.62 (brs, 1H), 2.42 (d, J= 14.3 Hz, 1H), 2.29 - 2.15 (m, 6H), 1.49 (s, 3H).
Example 345: (Ί .5-Dimethylpyrazol-4-yl)-[('7S)-2.7-dimethyl-3-('3.4.5-trifluorophenyl)-5.7- dihvdro-4H-pyrazolor3.4-c1pyridin-6-yl1methanone.
Figure imgf000405_0001
The title compound was prepared in a manner analogous to Example 288, using l,5-dimethyl- lH-pyrazole-4-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C20H20F3N5O, 403.2; m/z found, 404.3 [M+H]+. Ή NMR (500 MHz, Chlorofornw/) d 7.50 (s, 1H), 7.01 - 6.94 (m, 2H), 5.59 (brs, 1H), 4.46 (brs, 1H), 3.80 (d, J= 5.3 Hz, 6H), 3.20 (brs, 1H), 2.85 - 2.69 (m, 1H), 2.46 - 2.36 (m, 4H), 1.58 (s, 3H).
Example 346: rl-Cvclopropyl-5-(trifluoromethyl)pyrazol-4-yl1-r(7SV2.7-dimethyl-3-(3.4.5- trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000405_0002
The title compound was prepared in a manner analogous to Example 288, using potassium 1- cyclopropyl-5-(trifluoromethyl)-lH-pyrazole-4-carboxylate (Intermediate 81) instead of 2- fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C22H19F6N5O, 483.1; m/z found, 484.0 [M+H]+. 'H NMR (500 MHz, Chloroform- ) d 7.46 - 7.43 (m, 1H), 7.02 - 6.91 (m, 2H), 5.84 (q, J= 6.7 Hz, 0.59H), 4.92 - 4.84 (m, 0.85H), 3.85 - 3.77 (m, 3H), 3.76 - 3.70 (m, 0.67H), 3.69 - 3.60 (m, 1H), 3.35 - 2.97 (m, 1H), 2.79 - 2.51 (m, 1H), 2.48 - 2.32 (m, 1H), 1.58 - 1.53 (m, 1.77H), 1.46 (d, = 6.7 Hz, 1.27H), 1.41 - 1.29 (m, 2H), 1.17 - 1.07 (m, 2H).
Example 347: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-nII-GI -methyl-3-P -methylcvclopropyl)pyrazol-4-yl1methanone.
Figure imgf000406_0001
The title compound was prepared in a manner analogous to Example 288, using 1 -methyl-3 -(1- methylcyclopropyl)-lH-pyrazole-4-carboxylic acid (Intermediate 72) instead of 2-fluoro-6-(2H- l,2,3-triazol-2-yl)benzoic acid at 40 °C overnight. MS (ESI): mass calcd. for C23H24F3N5O,
.92
Figure imgf000406_0002
The title compound was prepared in a manner analogous to Example 288, using potassium 3-(l- fluorocyclopropyl)-l-methyl-lH-pyrazole-4-carboxylate (Intermediate 74) instead of 2-fluoro-6- (2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C22H21F4N5O, 447.2; m/z found, 448.0 [M+H]+. ' H NMR (500 MHz, Chloroform- ) d 7.44 (s, 1H), 7.00 - 6.92 (m, 2H), 5.89 (brs, 0.76H), 5.27 - 4.72 (m, 1.05H), 4.14 - 3.98 (m, 0.53H), 3.93 - 3.76 (m, 6.13H), 3.44 - 2.95 (m, 1.41H), 2.64 (brs, 1.23H), 2.39 (brs, 1.22H), 1.58 (s, 1.55H), 1.44 - 1.22 (m, 2.19H), 1.21 - 1.09 (m, 2.13H).
Example 349: (RV(5-cvclopropyl-l -methyl- lH-pyrazol-4-yl) (7-methyl-2.3-diphenyl-2A5.7- tetrahvdro-6H-pyrazolor3.4-c1 pyridin-6-yl) methanone.
Figure imgf000407_0001
The title compound was prepared in a manner analogous to Example 288, using (R)-7-methyl- 2,3-diphenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 56) instead of (S)-2,7- dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 40) and 5-cyclopropyl-l-methyl-lH-pyrazole-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3- triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C27H27N5O, 437.2; m/z found, 438.1
Figure imgf000407_0002
The title compound was prepared in a manner analogous to Example 288, using (S)-7-methyl- 2,3-diphenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 55) instead of (S)-2,7- dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 40) and 5-cyclopropyl-l-methyl-lH-pyrazole-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3- triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C27H27N5O, 437.2; m/z found, 438.1
[M+H]+. NMR (400 MHz, DMSO-r/e) d 7.45 (s, 1H), 7.40 - 7.28 (m, 6H), 7.24 - 7.15 (m, 4H), 5.81 - 5.54 (m, 1H), 5.03 - 4.47 (m, 1H), 3.85 (s, 4H), 2.87 - 2.68 (m, 1H), 2.49 - 2.31 (m, 1H), 1.87 (s, 1H), 1.51 (d, J= 6.8 Hz, 3H), 0.92 (s, 2H), 0.62 (s, 2H). Example 351 : (Ί .2-Dimethylpyrrol-3-yl)-[('7S)-2.7-dimethyl-3-('3.4.5-trifluorophenyl)-5.7- dihvdro-4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000408_0001
The title compound was prepared in a manner analogous to Example 288, using l,2-dimethyl- lH-pyrrole-3 -carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H21F3N4O, 402.2; m/z found, 403.2 [M+H]+. ¾ NMR (500 MHz, Chlorofornw/) d 7.01 - 6.93 (m, 2H), 6.47 (d, J= 2.9 Hz, 1H), 6.13 (d, J= 2.9 Hz, 1H), 5.61 (brs, 1H), 4.52 (brs, 1H), 3.80 (s, 3H), 3.51 (s, 3H), 3.15 (brs, 1H), 2.82 - 2.71 (m, 1H), 2.40 (dd, J= 15.2, 3.9 Hz, 1H), 2.31 (s, 3H), 1.57 - 1.54 (m, 3H). Example 352: (4.5-Dimethylisoxazol-3-ylVr(7SV2.7-dimethyl-3-(3A5-trifluorophenylV5.7- dihvdro-4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000409_0001
The title compound was prepared in a manner analogous to Example 288, using 4,5- dimethylisoxazole-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C20H19F3N4O2, 404.1; m/z found, 405.1 [M+H]+. Ή NMR (500 MHz, Chloroform-i/) d 7.02 - 6.94 (m, 2H), 5.87 (q, J= 6.8 Hz, 0.61H), 5.25 (q, J= 6.7 Hz, 0.39H), 4.93 - 4.86 (m, 0.40H), 4.24 - 4.16 (m, 0.62H), 3.83 (s, 1.83H), 3.78 (s, 1.15H), 3.38 - 3.25 (m, 0.62H), 3.13 - 3.04 (m, 0.39H), 2.90 - 2.70 (m, 1H), 2.53 - 2.44 (m, 0.43H), 2.43 - 2.33 (m, 3.63H), 2.02 (s, 1.89H), 1.96 (s, 1.19H), 1.63 - 1.58 (m, 3H). Example 353: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-(5-fluoro- 1 H-indol-6-yl)methanone.
Figure imgf000409_0002
The title compound was prepared in a manner analogous to Example 288, using 5-fluoro-lH- indole-6-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F4N4O, 426.1 ; m/z found, 427.1 [M+H]+. Ή NMR (500 MHz, DMSO- e) d 11.32 (s, 1H), 7.61 - 7.27 (m, 5H), 6.51 - 6.45 (m, 1H), 5.65 (br s, 0.66H), 4.77 - 4.62 (m, 0.59H), 3.86 - 3.70 (m, 3H), 3.63 - 3.55 (m, 0.68H), 3.12 - 3.01 (m, 0.31H), 2.82 - 2.58 (m, 1H), 2.38 - 2.26 (m, 0.71H), 1.54 - 1.30 (m, 3H). (Fractions of Hs that may overlap with DMSO and water are not reported). Example 354: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000410_0001
clpyridin-6-vn-f7-fluoro- 1 H-indol-4-yl)methanone.
Figure imgf000410_0002
The title compound was prepared in a manner analogous to Example 288, using 7-fluoro-lH- indole-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F4N4O, 442.1; m/z found, 443.2 [M+H]+. Ή NMR (500 MHz,
Chloroform-i/) d 8.49 (s, 1H), 7.30 - 7.24 (m, 1H), 7.07 (dd, J= 8.0, 4.4 Hz, 1H), 7.01 - 6.89 (m, 3H), 6.56 (s, 1H), 6.15 - 5.76 (m, 0.37H), 5.29 - 4.68 (m, 0.62H), 3.97 - 3.63 (m, 3.64H), 3.20 (br s, 1H), 2.97 - 2.16 (m, 1.85H), 1.79 - 1.33 (m, 3H).
Example 355: it7S)-2.7-Dimethyl-3-t3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-(5-fluoro- 1 H-indol-3 -vQmethanone.
Figure imgf000410_0003
The title compound was prepared in a manner analogous to Example 288, using 5-fluoro-lH- indole-3 -carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F4N4O, 442.1; m/z found, 443.2 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) 5 11.71 (s, 1H), 7.82 (s, 1H), 7.60 - 7.52 (m, 2H), 7.46 (dd, = 8.8, 4.6 Hz, 1H), 7.42 (dd, = 10.1, 2.6 Hz, 1H), 7.02 (td, J= 9.1, 2.6 Hz, 1H), 5.58 - 5.44 (m, 1H), 4.45 - 4.28 (m, 1H), 3.80 (s, 3H), 3.34 - 3.20 (m, 1H), 2.96 - 2.86 (m, 1H), 2.46 - 2.39 (m, 1H), 1.51 (d, = 6.7 Hz, 3H). Example 356: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000411_0001
clpyridin-6-yll -(5-fluoro- 1 -methyl-indol-3 -vDmethanone.
Figure imgf000411_0002
The title compound was prepared in a manner analogous to Example 288, using 5-fluoro- 1- methyl- 1 H-indole-3 -carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C24H20F4N4O, 456.2; m/z found, 457.2 [M+H]+. (500 MHz, DMSO-r/e) d 7.85 (s, 1H), 7.59 - 7.50 (m, 3H), 7.47 (dd, J= 10.0, 2.6 Hz, 1H), 7.09 (td, = 9.2, 2.6 Hz, 1H), 5.55 - 5.46 (m, 1H), 4.45 - 4.31 (m, 1H), 3.87 (s, 3H), 3.80 (s, 3H), 2.96 - 2.83 (m, 1H), 2.47 - 2.41 (m, 1H), 1.51 (d, J= 6.8 Hz, 3H). (Fractions of Hs that may overlap with DMSO and water are not reported).
Example 357: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-(4-fluoro- 1 H-indol-3 -vDmethanone.
Figure imgf000411_0003
The title compound was prepared in a manner analogous to Example 288, using 4-fluoro-lH- indole-3 -carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C23H18F4N4O, 442.1 ; m/z found, 443.2 [M+H]+. Ή NMR (400 MHz, DMSO-r/e) d 11.74 (s, 1H), 7.60 (s, 1H), 7.57 - 7.46 (m, 2H), 7.31 - 7.27 (m, 1H), 7.13 (td, J= 8.0, 5.1 Hz, 1H), 6.83 (dd, J= 11.0, 7.8 Hz, 1H), 5.77 - 5.32 (m, 1H), 4.25 - 3.71 (m, 4H), 3.29 - 3.13 (m, 1H), 2.75 - 2.62 (m, 1H), 2.41 - 2.28 (m, 1H), 1.43 (d, = 6.8 Hz,
3H). Example 358: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluoroDhenyl)-5.7-dihvdro-4H-Dyrazolo[3.4- clpyridin-6-vn-(6-fluoro- 1 H-indol-3-yl)methanone.
Figure imgf000412_0001
The title compound was prepared in a manner analogous to Example 288, using 6-fluoro-lH- indole-3 -carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F4N4O, 442.1 ; m/z found, 443.1 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) d 11.63 (s, 1H), 7.76 - 7.67 (m, 2H), 7.60 - 7.52 (m, 2H), 7.23 (dd, J= 9.8, 2.4 Hz, 1H), 6.99 - 6.93 (m, 1H), 5.57 - 5.43 (m, 1H), 4.43 - 4.27 (m, 1H), 3.80 (s, 3H), 3.31 - 3.19 (m, 1H), 2.94 - 2.84 (m, 1H), 2.46 - 2.38 (m, 1H), 1.50 (d, J= 6.8 Hz, 3H).
Example 359: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('7-fluoro- l H-indol-3-yl)methanone.
Figure imgf000412_0002
The title compound was prepared in a manner analogous to Example 288, using 7-fluoro-lH- indole-3 -carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F4N4O, 442.1 ; m/z found, 443.1 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) d 12.12 (s, 1H), 7.76 (s, 1H), 7.60 - 7.52 (m, 2H), 7.50 (d, J= 7.9 Hz, 1H), 7.09 - 6.97 (m, 2H), 5.51 (br s, 1H), 4.31 (br s, 1H), 3.80 (s, 3H), 3.30 - 3.20 (m, 1H), 2.95 - 2.84 (m, 1H), 2.45 - 2.38 (m, 1H), 1.50 (d, J= 6.8 Hz, 3H). Example 360: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000413_0001
clpyridin-6-yl1-f6-methyl- 1 H-indol-3-yl)methanone *TFA salt.
Figure imgf000413_0002
The title compound was prepared in a manner analogous to Example 288, using 6-methyl- 1H- indole-3 -carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H21F3N4O, 438.2; m/z found, 439.1 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) d 11.44- 11.39 (m, 1H), 7.62 (d, =2.7Hz, 1H), 7.59-7.52 (m, 3H), 7.25-7.21 (m, 1H), 6.95 -6.89 (m, 1H), 5.56-5.47 (m, 1H), 4.40-4.29 (m, 1H), 3.79 (s, 3H), 3.29 - 3.18 (m, 1H), 2.92 -2.82 (m, 1H), 2.45- 2.37 (m, 4H), 1.49 (d, =6.8Hz, 3H).
Example 361 : it7S)-2.7-Dimethyl-3-t3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1 -( 1 H-indazol-3 -vQmethanone.
Figure imgf000413_0003
The title compound was prepared in a manner analogous to Example 288, using lH-indazole-3- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H18F3N5O, 425.1 ; m/z found, 426.1 [M+H]+. ¾ NMR (500 MHz, Chloroform- ) d 10.44 -10.11 (m, 1H), 8.18 (d, =8.2Hz, 1H), 7.54-7.48 (m, 1H), 7.47- 7.39 (m, 1H), 7.31-7.22 (m, 1H), 7.03 -6.93 (m, 2H), 6.17-5.91 (m, 1H), 5.05-4.87 (m, 1H), 3.92-3.72 (m, 3H), 3.40- 3.10 (m, 1H), 3.04 - 2.82 (m, 1H), 2.57- 2.39 (m, 1H), 1.78-1.61 (m, 3H).
Example 362: it7S)-2.7-Dimethyl-3-t3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('4-fluoro- l H-indazol-3-yl)methanone *TFA salt.
Figure imgf000414_0001
The title compound was prepared in a manner analogous to Example 288, using and 4-fluoro- lH-indazole-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H17F4N5O, 443.1; m/z found, 444.1 [M+H]+. 1H NMR (500 MHz, DMSO-r/e) d 13.76 - 13.66 (m, 1H), 7.60 - 7.50 (m, 2H), 7.47 - 7.38 (m, 2H), 6.98 - 6.91 (m, 1H), 5.68 (q, J= 6.7 Hz, 0.64H), 5.08 - 5.01 (m, 0.36H), 4.79 - 4.72 (m, 0.39H), 3.84 - 3.72 (m, 3H), 3.15 - 3.07 (m, 0.42H), 2.81 - 2.67 (m, 1H), 2.39 - 2.32 (dd, = 3.7, 2.0 Hz, 0.57H), 1.51 (d, J= 6.8 Hz, 2H), 1.45 (d, J= 6.7 Hz, 1H). (Hs that may overlap with water and DMSO are not reported).
Example 363: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-(6-fluoro- 1 H-indazol-3 -vQmethanone.
Figure imgf000414_0002
The title compound was prepared in a manner analogous to Example 288, using and 6-fluoro- lH-indazole-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H17F4N5O, 443.1; m/z found, 444.1 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) d 13.63 (s, 1H), 8.04 - 7.98 (m, 1H), 7.59 - 7.51 (m, 2H), 7.42 (dd, J= 9.4, 2.2 Hz, 1H), 7.11 (td, = 9.2, 2.2 Hz, 1H), 6.09 - 5.96 (m, 0.38H), 5.75 - 5.63 (m, 0.56H), 5.00 - 4.69 (m, 1H), 3.86 - 3.71 (m, 3H), 3.16 - 3.04 (m, 0.43H), 2.94 - 2.74 (m, 1H), 1.63 - 1.46 (m, 3H). (Fractions of Hs that may overlap with DMSO and water are not reported). Example 364: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000415_0001
ndazol-3-yl)methanone.
Figure imgf000415_0002
The title compound was prepared in a manner analogous to Example 288, using and 5-fluoro- lH-indazole-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C22H17F4N5O, 443.1; m/z found, 444.2
[M+H]+. (500 MHz, DMSO-r/e) d 13.72 (s, 1H), 7.73 - 7.65 (m, 2H), 7.59 - 7.51 (m, 2H), 7.33 (td, = 9.1, 2.5 Hz, 1H), 6.19 - 6.07 (m, 0.36H), 5.74 - 7.63 (m, 0.53H), 5.10 - 5.00 (m, 0.53H), 4.80 - 4.69 (m, 0.40H), 3.86 - 3.72 (m, 3H), 3.16 - 3.03 (m, 0.42H), 2.95 - 2.74 (m, 1H), 1.67 - 1.45 (m, 3H). (Fractions of Hs that may overlap with DMSO and water are not reported).
Example 365: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('2-methylindazol-3-yl)methanone.
Figure imgf000415_0003
The title compound was prepared in a manner analogous to Example 288, using 2-methyl-2H- indazole-3-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. Ή NMR (500 MHz, DMSO- e) d 7.72 - 7.68 (m, 1H), 7.65 - 7.46 (m, 3H), 7.35 - 7.29 (m, 1H), 7.21 - 7.13 (m, 1H), 5.90 - 5.50 (m, 0.58H), 4.15 (s, 3H), 3.88 - 3.63 (m, 3.5H), 3.52 - 3.32 (m, 0.76H), 2.88 - 2.65 (m, 0.73H),
1.69 - 1.34 (m, 3H). (Fractions of Hs that may overlap with DMSO and water are not reported). Example 366: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluoroDhenyl)-5.7-dihvdro-4H-Dyrazolo[3.4- clpyridin-6-yll-( 1 -methylbenzimidazol-4-yl)methanone.
Figure imgf000416_0001
The title compound was prepared in a manner analogous to Example 288, using 1 -methyl- 1H- benzo[d]imidazole-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+.
Figure imgf000416_0002
NMR (400 MHz, Methanol-A) d 9.30 - 9.04 (m, 1H), 8.05 - 7.90 (m, 1H), 7.76 - 7.68 (m, 1H), 7.68 - 7.61 (m, 1H), 7.34 - 7.24 (m, 2H), 6.00 - 5.71 (m, 1H), 4.13 (s, 3H), 3.98 - 3.59 (m, 4H), 3.49 - 3.34 (m, 1H), 3.07 - 2.73 (m, 1H), 2.64 - 2.29 (m, 1H), 1.65 (s, 3H).
Example 367: 1 H-Benzotriazol-4-yl-[('7S)-2.7-dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro- 4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000416_0003
The title compound was prepared in a manner analogous to Example 288, using 1H- benzo[d][l,2,3]triazole-7-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H17F3N6O, 426.1; m/z found, 427.0 [M+H]+. ¾ NMR (600 MHz, Methanol-i/ ) d 8.01 - 7.90 (m, 1H), 7.52 (dd, J= 8.3, 7.0 Hz, 1H), 7.47 - 7.39 (m, 1H), 7.35 - 7.22 (m, 2H), 5.96 - 5.77 (m, 1H), 3.99 - 3.61 (m, 4H), 3.42 - 3.34 (m, 1H), 2.89 - 2.73 (m, 1H), 2.67 - 2.24 (m, 1H), 1.67 (s, 3H). Example 368: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000417_0001
clpyridin-6-nII-P H-pyrroloi2.3-b1pyridin-5-yl)methanone.
Figure imgf000417_0002
The title compound was prepared in a manner analogous to Example 288, using lH-pyrrolo[2,3- b]pyridine-5-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H18F3N5O, 425.1; m/z found, 426.2 [M+H]+. Ή NMR (500 MHz, DMSO-i/e) 5 11.89 (s, 1H), 8.32 - 8.26 (m, 1H), 8.06 (d, = 2.0 Hz, 1H), 7.61 - 7.51 (m, 3H), 6.56 - 6.51 (m, 1H), 5.55 (br s, 1H), 3.92 - 3.67 (m, 3.64H), 2.97 - 2.82 (m, 1H), 2.44 - 2.32 (m, 0.87H), 1.49 (d, J= 6.8 Hz, 3H). (Fractions of Hs that may overlap with DMSO and water are not reported).
Example 369: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1 -(5-fluoro- 1 H-pyrrolo[2.3-b1pyridin-4-yl)methanone.
Figure imgf000417_0003
The title compound was prepared in a manner analogous to Example 288, using 5-fluoro-lH- pyrrolo[2,3-b]pyridine-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C22H17F4N5O, 443.1; m/z found, 444.2 [M+H]+. ¾ NMR (500 MHz, Chlorofomw/) d 9.00 - 8.86 (m, 1H), 8.32 - 8.16 (m, 1H), 7.47 - 7.29 (m, 1H), 7.04 - 6.87 (m, 2H), 6.59 - 6.23 (m, 1H), 6.06 - 5.95 (m, 0.65H), 5.11 - 5.01 (m, 0.39H), 4.90 - 4.75 (s, 0.39H), 3.85 (s, 2H), 3.81 - 3.71 (m, 1H), 3.65 (dd, J= 13.8, 5.1
Hz, 0.67H), 3.46 - 3.25 (m, 0.65H), 3.19 - 3.08 (m, 0.37H), 2.91 - 2.74 (m, 0.71H), 2.60 - 2.43 (m, 0.66H), 2.40 - 2.24 (m, 0.66H), 1.73 - 1.30 (m, 3H). Example 370: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluoroDhenyl)-5.7-dihvdro-4H-Dyrazolo[3.4- clpyridin-6-yll-(5-fluoro-l-methyl-pyrrolor2.3-blpyridin-4- methanone.
Figure imgf000418_0001
Figure imgf000418_0002
The title compound was prepared in a manner analogous to Example 288, using 5-fluoro-l- methyl-lH-pyrrolo[2,3-b]pyridine-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C23H19F4N5O, 457.1 ; m/z found, 458.2 [M+H]+.
Figure imgf000418_0003
NMR (500 MHz, DMSO-r/e) d 8.43 - 8.30 (m, 1H), 7.75 - 7.47 (m, 3H), 6.46 - 6.13 (m, 1H), 5.71 (q, = 6.7 Hz, 0.63H), 4.85 - 4.75 (m, 0.33H), 4.64 - 4.51 (m, 0.34H), 3.90 - 3.68 (m, 6H), 3.51 - 3.41 (m, 0.74H), 3.18 - 3.05 (m, 0.33H), 2.98 - 2.87 (m,
0.33H), 2.79 - 2.69 (m, 0.15H), 2.37 - 2.24 (m, 0.64H), 1.60 - 1.21 (m, 3H). (Fractions of Hs that may overlap with DMSO and water are not reported).
Example 371 : i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-[5-('trifluoroniethyl)- l H-pyrrolo[2.3-b1pyridin-4-yl1 methanone*TFA salt.
Figure imgf000418_0004
Step A: ('S)-('2.7-Dimethyl-3-('3A5-trifluorophenyl)-2A5.7-tetrahvdro-6H-pyrazolo
Figure imgf000418_0005
c1pyridin-6-yl)('5-('trifluoromethyl)- l - ('trimethylsilyl)ethoxy)methyl)- l H-pyrrolo[2.3-
Figure imgf000418_0006
b1pyridin-4-yl)methanone. The title compound was prepared in a manner analogous to Example 288, using 5-trifluoromethyl)-l-((2-(trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[2,3-b]pyridine-4- carboxylic acid (Intermediate 60) instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C29H3iF6N502Si, 623.2; m/z found, 624.3 [M+H] +.
Step B : (Si-IY 7S)-2.7-Dimethyl-3-(3.4.5 -trifluorophenvO- 5.7-dihvdro-4H-pyrazolo [3.4- c1pyridin-6-yl1-[5-('trifluoromethyl)- l H-pyrrolo[2.3-b1pyridin-4-yl1methanone. TFA (0.09 mF, 1.3 mmol) was added to a mixture of (S)-(2,7-dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7- tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(5-(trifluoromethyl)-l-((2-
(trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[2,3-b]pyridin-4-yl)methanone (78.5 mg, 0.13 mmol) in DCM (1.7 mF). After 6 days, the reaction mixture was concentrated under reduced pressure and ammonia (7N in MeOH, 1.8 mF, 126 mmol) was added to the crude material. After completion, the reaction mixture was concentrated under reduce pressure. MeOH was added, the solids were filtered off. Purification of the filtrate (preparative HPFC, METHOD A followed by METHOD E) afforded the title compound. MS (ESI): mass calcd. for C23H17F6N5O, 493.1 ; m/z found, 494.2 [M+H] +.
Example 372: it7S)-3-t3.5-Difluorophenyl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-nII-P -('2-fluoranylethyl)pyrrolo[2.3-b1pyridin-4-yl1methanone.
Figure imgf000419_0001
The title compound was prepared in a manner analogous to Example 140, using (S)-2-(4-(3-(3,5- difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-6-carbonyl)-lH- pyrrolo[2,3-b]pyridin-l-yl)ethyl 4-methylbenzenesulfonate (Intermediate 131) instead of (S)-2- (3-(3-(3,5-difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-6- carbonyl)phenoxy) ethyl 4-methylbenzenesulfonate in Step B.
Example 373: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1 -(1 H-pyrrolo G 2.3 -blpyri din-3 -vQmethanone.
Figure imgf000420_0001
The title compound was prepared in a manner analogous to Example 288, using lH-pyrrolo[2,3- b]pyridine-3 -carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C22H18F3N5O, 425.1 ; m/z found, 426.2 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) d 12.18 (s, 1H), 8.29 (dd, J= 4.7, 1.6 Hz, 1H), 8.10 (dd, J= 7.9, 1.6 Hz, 1H), 7.87 (s, 1H), 7.60 - 7.52 (m, 2H), 7.16 (dd, J= 7.9, 4.7 Hz, 1H), 5.58 - 5.44 (m, 1H), 4.43 - 4.27 (m, 1H), 3.80 (s, 3H), 2.98 - 2.86 (m, 1H), 1.51 (d, J= 6.8 Hz, 3H). (Fractions of Hs that may overlap with DMSO and water are not reported). Example 374: i('7S)-2.7-Diiiiethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll -(5-fluoro- 1 H-pyrrolor2.3-b1pyridin-3 -yliniethanone.
Figure imgf000420_0002
The title compound was prepared in a manner analogous to Example 288, using 5-fluoro-lH- pyrrolo[2,3-b]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C22H17F4N5O, 443.1; m/z found, 444.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 12.38 (s, 1H), 8.31 - 8.27 (m, 1H), 7.99 (s, 1H), 7.90 (dd, J= 9.4, 2.8 Hz, 1H), 7.60 - 7.51 (m, 2H), 5.58 - 5.45 (m, 1H), 4.45 - 4.29 (m, 1H), 3.80 (s, 3H), 3.01 - 2.87 (m, 1H), 2.47 - 2.40 (m, 1H), 1.51 (d, = 6.8 Hz, 3H). Example 375: it7S)-2.7-Diiiiethyl-3-t3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazoloi3.4- c1pyridin-6-yl1-('2-iiiethyl- l H-pyrrolo[2.3-b1pyridin-3-yl)niethanone.
Figure imgf000421_0001
The title compound was prepared in a manner analogous to Example 288, using 2-methyl- 1H- pyrrolo[2,3-b]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 11.93 (s, 1H), 8.18 (dd, = 4.7, l.6 Hz, 1H),
7.74 - 7.64 (m, 1H), 7.59 - 7.49 (m, 2H), 7.08 (dd, J= 7.9, 4.7 Hz, 1H), 5.53 (s, 1H), 4.07 (s, 1H), 3.80 (s, 3H), 2.72 - 2.62 (m, 1H), 2.44 - 2.32 (m, 4), 1.44 (d, J= 6.8 Hz, 3H). (Fractions of Hs that may overlap with DMSO and water are not reported). Example 376: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll -(T H-pyrrolo G2.3 -cl pyridin-7-yl imethanone.
Figure imgf000421_0002
The title compound was prepared in a manner analogous to Example 288, using lH-pyrrolo[2,3- c]pyridine-7-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid, and 2,4,6- tripropyl-l,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide (T3P®) and DMF instead of HATU and DCM, respectively. MS (ESI): mass calcd. for C22H18F3N5O, 425.1 ; m/z found, 426.1
[M+H]+.
Example 377: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('3-fluoropyrazolon .5-a1pyridin-4-yl imethanone.
Figure imgf000422_0001
The title compound was prepared in a manner analogous to Example 288, using 3- fluoropyrazolo[l,5-a]pyridine-4-carboxylic acid (Intermediate 69) instead of 2-fluoro-6-(2H- l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H17F4N5O, 443.1 ; m/z found, 444.1 [M+H]+. (500 MHz, Chloroform-^ d 8.32 (d, J= 7.0 Hz, 1H), 7.90 - 7.77 (m, 1H),
7.11 - 7.03 (m, 1H), 7.02 - 6.92 (m, 2H), 6.82 - 6.73 (m, 1H), 5.94 (q, J= 6.7 Hz, 0.58H), 5.03 - 4.82 (m, 0.76H), 3.89 - 3.74 (m, 3H), 3.74 - 3.65 (m, 0.64H), 3.35 (t, J= 14.3 Hz, 0.58H), 3.18 - 3.03 (m, 0.37H), 2.91 - 2.78 (m, 0.38H), 2.67 - 2.45 (m, 1H), 2.32 (d, J= 14.7 Hz, 0.58H), 1.64 (d, = 6.7 Hz, 1.84H), 1.46 (d, = 6. l Hz, 1.15H).
Example 378: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('3-fluoropyrazolon .5-a1pyridin-5-yl)methanone.
Figure imgf000422_0002
The title compound was prepared in a manner analogous to Example 288, using 3- fluoropyrazolo[l,5-a]pyridine-5-carboxylic acid (Intermediate 70) instead of 2-fluoro-6-(2H- l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H17F4N5O, 443.1 ; m/z found, 444.1
Figure imgf000422_0003
8.70 - 8.61 (m, 1H), 8.20 (d, J= 3.5 Hz, 1H), 7.77 (dd, = 1.8, 1.1 Hz, 1H), 7.60 - 7.48 (m, 2H), 6.90 (d, = 7.2 Hz, 1H), 5.56 (s, 1H), 4.72 (d, = 112.4 Hz, 1H), 3.90 - 3.62 (m, 4H), 2.86 (s, 1H), 2.42-2.32 (m, 1H), 1.48 (d, = 6.8 Hz, 3H). Example 379: (3-Bromopyrazolorl.5-alpyridin-4-ylVr(7SV2.7-dimethyl-3-(3.4.5- trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-c1pyridin-6-yl1methanone.
Figure imgf000423_0001
The title compound was prepared in a manner analogous to Example 288, using 3- bromopyrazolo[l,5-a]pyridine-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C22Hi7BrF3N50, 503.1; m/z found, 504.0
[M+H]+. (500 MHz, Chloroform-r/) d 8.48 (d, J= 7.0 Hz, 1H), 8.02 - 7.86 (m, 1H), 7.20 - 7.09 (m, 1H), 7.03 - 6.90 (m, 2H), 6.89 - 6.76 (m, 1H), 6.01 - 5.90 (m, 0.63H), 5.08 - 4.93 (m, 0.49H), 4.66 (q, J= 6.7 Hz, 0.25H), 3.87 - 3.72 (m, 3H), 3.63 (dd, J= 14.0, 4.6 Hz, 0.24H), 3.52 (dd, J= 13.9, 4.8 Hz, 0.38H), 3.40 - 3.28 (m, 0.62H), 3.20 - 3.05 (m, 0.37H), 3.01
- 2.71 (m, 0.61H), 2.63 - 2.47 (m, 0.77H), 2.36 - 2.28 (m, 0.38H), 2.22 - 2.15 (m, 0.23H), 1.71 (d, = 6.8 Hz, 1.19H), 1.65 (d, = 6.8 Hz, 0.79H), 1.49 - 1.40 (m, 1.16H).
Example 380: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll -(3 -methylpyrazolor 1.5 -al pyridin-4-yl)methanone.
Figure imgf000423_0002
To a suspension of (S)-(3-bromopyrazolo[l,5-a]pyridin-4-yl)(2,7-dimethyl-3-(3,4,5- trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)methanone (Example 379) (81 mg, 0.16 mmol), potassium carbonate (67 mg, 0.48 mmol), and Pd(PPh3)4 (19 mg, 16.1 pmol), in DMF (0.36 mL) was added trimethylboroxine (51 pL, 0.36 mmol). The headspace was purged of air under vacuum and then backfilled with nitrogen three times, then the reaction heated to 100 °C for 16 h. After cooling to room temperature, EtOAc and H2O were added, then the aqueous layer separated and extracted with EtOAc (x3). The combined organics were washed with brine (x5), dried over Na2S04, filtered, and concentrated in vacuo. The material was purified by SFC (stationary phase: Chiralcel OZ, 5pm 250 x 21 mm, mobile phase: 38% MeOH with 0.2% TEA, 62% CO2) to afford the title compound in 20% yield. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. Ή NMR (600 MHz, Chloroform- ) d 8.48 - 8.41 (m, 1H), 7.86 - 7.68 (m, 1H), 7.10 - 6.83 (m, 3H), 6.80 - 6.64 (m, 1H), 5.95 (m, 0.59H), 5.30 (s, 0.21H), 5.12 - 4.97 (m, 0.51H), 4.73 (m, 0.29H), 3.91 - 3.70 (m, 3.20H), 3.62 (dd, J = 14.0, 5.0 Hz, 0.43H), 3.36 - 3.21 (m, 0.59H), 3.09 (m, 0.39H), 2.81 (m, 0.38H), 2.70 - 2.39 (m, 0.93H), 2.38 - 2.21 (m, 2.17H), 2.14 (s, 0.47H), 2.04 (s, 0.96H), 1.69 - 1.61 (m, 1.78H), 1.48 (d, J= 6.5 Hz, 0.93H), 1.32 (d, J= 6.7 Hz, 0.31H).
Example 381 : i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-pyrazolorl.5-a1pyridin-3-yl-methanone *TFA salt.
Figure imgf000424_0001
The title compound was prepared in a manner analogous to Example 288, using pyrazolo[l,5- a]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H18F3N5O, 425.1 ; m/z found, 426.1 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) d 8.82 - 8.78 (m, 1H), 8.33 (s, 1H), 7.94 - 7.90 (m, 1H), 7.61 - 7.53 (m, 2H), 7.47 - 7.41 (m, 1H), 7.07 (td, = 6.9, 1.4 Hz, 1H), 5.54 - 5.43 (m, 1H), 4.40 - 4.28 (m, 1H), 3.80 (s, 3H), 3.37 - 3.24 (m, 1H), 3.06 - 2.92 (m, 1H), 2.48 - 2.43 (m, 1H), 1.58 - 1.46 (m, 3H).
Example 382: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll -(2-methylpyrazolor 1.5 -al pyri din-3 -vOmethanone.
Figure imgf000425_0001
The title compound was prepared in a manner analogous to Example 288, using 2- methylpyrazolo[l,5-a]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.70 - 8.60 (m, 1H), 7.60 - 7.51 (m, 2H), 7.45 (d, J= 8.9 Hz,
1H), 7.37 - 7.30 (m, 1H), 7.00 - 6.90 (m, 1H), 4.08 (q, = 5.2 Hz, 1H), 3.81 (s, 3H), 3.17 (d, J = 4.8 Hz, 2H), 2.76 - 2.63 (m, 1H), 2.40 - 2.35 (m, 4H), 1.45 (d, J= 6.8 Hz, 3H).
Example 383: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1 -(5 -methylpyrazolor E 5 -al pyri din-3 -vOmethanone.
Figure imgf000425_0002
The title compound was prepared in a manner analogous to Example 288, using 5- methylpyrazolo[l,5-a]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.69 - 8.66 (m, 1H), 8.25 (s, 1H), 7.72 - 7.70 (m, 1H), 7.60 - 7.53 (m, 2H), 6.91 (dd, J= 7.0, 2.0 Hz, 1H), 5.54 - 5.42 (m, 1H), 4.41 - 4.26 (m, 1H), 3.80 (s, 3H), 3.04 - 2.92 (m, 1H), 2.41 - 2.39 (m, 3H), 1.52 (d, J= 6.7 Hz, 3H). (Fractions of Hs that may overlap with DMSO and water are not reported). Example 384: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('6-fluoropyrazolon .5-a1pyridin-3-yl)niethanone.
Figure imgf000426_0001
The title compound was prepared in a manner analogous to Example 288, using 6- fluoropyrazolo[ 1,5 -a] pyridine-3 -carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C22H17F4N5O, 443.1 ; m/z found, 444.1 [M+H] +. ' H NMR (500 MHz, DMSO-r/e) 5 9.18 - 9.09 (m, 1H), 8.36 (s, 1H), 8.03 - 7.85 (m, 1H), 7.63 - 7.48 (m, 3H), 5.49 (s, 1H), 4.34 (s, 1H), 3.80 (s, 3H), 2.99 (s, 1H), 2.49 - 2.29 (m, 2H), 1.53 (d, J = 6.7 Hz, 3H).
Example 385: (2-Cvclopropyl-7-methyl-pyrazolorE5-alpyridin-3-ylVr(7SV2.7-dimethyl-3- ('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000426_0002
The title compound was prepared in a manner analogous to Example 288, using 2-cyclopropyl-7- methylpyrazolo[ 1,5 -a] pyridine-3 -carboxylic acid (Intermediate 83) instead of 2-fluoro-6-(2H- l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C26H24F3N5O, 479.2; m/z found, 480.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) 5 7.54 (dd, J= 8.7, 6.6 Hz, 2H), 7.37 - 7.20 (m,
2H), 6.89 - 6.78 (m, 1H), 5.55 (s, 1H), 4.16 - 4.01 (m, 1H), 3.80 (s, 3H), 3.24 - 3.18 (m, 1H),
2.62 (s, 4H), 2.44 - 2.28 (m, 1H), 2.15 - 1.94 (m, 1H), 1.45 (d, = 6.6 Hz, 3H), 1.04 - 0.93 (m, 4H). Example 386: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1 pyridin-6-yll -t7-methylpyrazolon 5-al pyridin-3-yl imethanone.
Figure imgf000427_0001
The title compound was prepared in a manner analogous to Example 288, using 7- methylpyrazolo[l,5-a]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H] +. XH NMR (500 MHz, DMSO-r/e) d 8.35 (s, 1H), 7.88 - 7.75 (m, 1H), 7.63 - 7.51 (m, 2H), 7.39 (dd, J = 8.9, 6.9 Hz, 1H), 7.03 - 6.94 (m, 1H), 5.60 - 5.42 (m, 1H), 4.45 - 4.25 (m, 1H), 3.80 (s, 3H), 3.29 - 3.16 (m, 1H), 3.05 - 2.89 (m, 1H), 2.73 (s, 3H), 2.49 - 2.41 (m, 1H), 1.53 (d, = 6.7 Hz, 3H). Example 387: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-t7-methoxypyrazolon 5-a1pyridin-3-yl)methanone.
Figure imgf000427_0002
The title compound was prepared in a manner analogous to Example 288, using 7- methoxypyrazolo[l,5-a]pyridine-3-carboxybc acid instead instead of 2-fluoro-6-(2H-l,2,3- triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O2, 455.2; m/z found, 456.2
[M+H]+. (500 MHz, Chloroform-^ d 8.15 (s, 1H), 7.68 (dd, J= 8.8, 1.1 Hz, 1H), 7.32 (dd, J= 8.9, 7.5 Hz, 1H), 7.02 - 6.95 (m, 2H), 6.26 - 6.22 (m, 1H), 5.76 - 5.61 (m, 1H), 4.66 - 4.50 (m, 1H), 4.18 (s, 3H), 3.81 (s, 3H), 3.38 - 3.19 (m, 1H), 2.91 - 2.81 (m, 1H), 2.54 - 2.45 (m, 1H), 1.67 (d, J= 6.8 Hz, 3H).
Example 388: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-t6-methoxypyrazolon 5-a1pyridin-3-yl)methanone *TFA salt.
Figure imgf000428_0001
The title compound was prepared in a manner analogous to Example 288, using 6- methoxypyrazolo[l,5-a]pyridine-3-carboxylic acid instead instead of 2-fluoro-6-(2H-l,2,3- triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O2, 455.2; m/z found, 456.1 [M+H]+. (500 MHz, DMSO-r/e) d 8.53 - 8.51 (m, 1H), 8.23 (s, 1H), 7.86 - 7.82 (m,
1H), 7.60 - 7.53 (m, 2H), 7.25 (dd, J= 9.6, 2.2 Hz, 1H), 5.53 - 5.43 (m, 1H), 4.42 - 4.31 (m, 1H), 3.85 (s, 3H), 3.80 (s, 3H), 3.37 - 3.22 (m, 1H), 3.05 - 2.92 (m, 1H), 2.48 - 2.42 (m, 1H), 1.59 - 1..46 (m, 3H). Example 389: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('5-methoxypyrazolon .5-a1pyridin-3-yl)methanone.
Figure imgf000428_0002
The title compound was prepared in a manner analogous to Example 288, using 5- methoxypyrazolo[l,5-a]pyridine-3-carboxybc acid instead instead of 2-fluoro-6-(2H-l,2,3- triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O2, 455.2; m/z found, 456.2
Figure imgf000428_0003
8.65 (d, J= 7.5 Hz, 1H), 8.23 (s, 1H), 7.61 - 7.52 (m, 2H), 7.25 - 7.21 (m, 1H), 6.74 (dd, = 7.5, 2.8 Hz, 1H), 5.51 - 5.42 (m, 1H), 4.42 - 4.31 (m,
1H), 3.86 (s, 3H), 3.80 (s, 3H), 3.06 - 2.94 (m, 1H), 1.58 - 1.46 (m, 3H). (Fractions of H’s that overlap with DMSO and water may not be reported) Example 390: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo cl
Figure imgf000429_0001
pyridin-6-yll -(4-methoxypyrazolor 1.5 -a1pyridin-3-yl)methanone.
Figure imgf000429_0002
The title compound was prepared in a manner analogous to Example 288, using 4- methoxypyrazolo[ 1,5 -a] pyridine-3 -carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 455.2; m/z found, 456.1 [M+H] +. XH NMR (500 MHz, DMSO-r/e) d 8.36 (d, J= 6.8 Hz, 1H), 8.02 (s, 1H), 7.61 - 7.42 (m, 2H), 7.00 - 6.58 (m, 2H), 5.81 - 5.50 (m, 1H), 4.16 - 3.95 (m, 1H), 3.92 - 3.58 (m, 6H), 3.57 - 3.41 (m,
1H), 3.21 - 3.09 (m, 2H), 1.54 - 1.21 (m, 3H).
Example 391 : it7S)-2.7-Dimethyl-3-t3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-imidazor 1.2-a1pyridin-6-yl-methanone.
Figure imgf000429_0003
The title compound was prepared in a manner analogous to Example 288, using imidazo[l,2- a]pyridine-6-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H18F3N5O, 425.1; m/z found, 426.2 [M+H]+. ¾ NMR (500 MHz,
Chlorofornw/) d 8.38 (s, 1H), 7.71 (d, J= 1.0 Hz, 1H), 7.69 - 7.60 (m, 2H), 7.24 - 7.20 (m, 1H), 7.01 - 6.93 (m, 2H), 3.81 (s, 3H), 3.28 (brs, 1H), 2.79 (brs, 1H), 2.50 - 2.42 (m, 1H), 1.65 - 1.57 (m, 5H). Example 392: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000430_0001
clpyridin-6-yll-imidazor 1.2-a1pyridin-8-yl-methanone.
Figure imgf000430_0002
The title compound was prepared in a manner analogous to Example 288, using imidazo[l,2- a]pyridine-8-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H18F3N5O, 425.2; m/z found, 426.1 [M+H] +. Ή NMR (400 MHz, DMSO-r/e) d 8.69 - 8.56 (m, 1H), 8.08 - 7.98 (m, 1H), 7.63 - 7.46 (m, 3H), 7.28 - 7.18 (m, 1H), 6.96 (t, J= 6.8 Hz, 1H), 5.66 (q, J= 6.7 Hz, 1H), 4.85 - 4.55 (m, 1H), 3.86 - 3.69 (m, 3H), 3.25 - 3.00 (m, 1H), 2.83 - 2.63 (m, 1H), 2.33 - 2.14 (m, 1H), 1.42 (dd, = 68.2, 6.8 Hz, 3H).
Example 393: it7S)-2.7-Dimethyl-3-t3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('7-fluoroimidazon .2-a1pyridin-3-yl)methanone.
Figure imgf000430_0003
The title compound was prepared in a manner analogous to Example 288, using 7- fluoroimidazo[l,2-a]pyridine-3 -carboxylic acid (Intermediate 84) instead of 2-fluoro-6-(2H- l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H17F4N5O, 443.2; m/z found,
444.1 [M+H] +. ¾ NMR (400 MHz, DMSO-r/e) d 9.01 - 8.90 (m, 1H), 8.09 (s, 1H), 7.66 - 7.47 (m, 3H), 7.25 - 7.02 (m, 1H), 5.60 - 4.39 (m, 3H), 3.85 - 3.73 (m, 3H), 3.48 - 3.34 (m, 1H), 3.15 - 2.95 (m, 1H), 1.56 (d, J= 6.7 Hz, 3H).
Example 394: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1 pyridin-6-yll -(2-methylimidazor 1.2-a1pyridin-5-yl)methanone.
Figure imgf000431_0001
The title compound was prepared in a manner analogous to Example 288, using 2- methylimidazo[l,2-a]pyridine-5-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H] +. XH NMR (400 MHz, DMSO-r/e) d 7.61 - 7.45 (m, 4H), 7.32 - 7.21 (m, 1H), 7.00 (dd, = 6.9, 1.1 Hz, 1H), 5.70 - 5.50 (m, 1H), 4.96 - 4.16 (m, 1H), 3.91 - 3.55 (m, 4H), 2.96 - 2.73 (m, 1H), 2.44 - 2.23 (m, 4H), 1.55 (s, 3H).
Example 395: i('7S)-3-('3-Chloro-5-methoxy-phenyl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolo[3.4- cl pyridin-6-ylT(2-methylimidazorE2-a1 pyridin-3-yl) methanone.
Figure imgf000431_0002
The title compound was prepared in a manner analogous to Example 288, using (S)-3-(3-chloro- 5-methoxyphenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 41) instead of (S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c]pyridine (Intermediate 40) and 2-methylimidazo[l,2-a]pyridine-3 -carboxylic acid instead of 2- fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H24CIN5O2, 449.2; m/z found, 450.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.34 (d, J= 6.9 Hz, 1H), 7.56 (dt, J = 9.0, 1.2 Hz, 1H), 7.41 - 7.30 (m, 1H), 7.15 - 7.08 (m, 2H), 7.03 - 6.91 (m, 2H), 5.68 - 5.47 (m, 1H), 4.17 - 3.94 (m, 1H), 3.89 - 3.71 (m, 6H), 3.47 - 3.36 (m, 1H), 2.71 (d, = l2.0 Hz, 1H), 2.46 - 2.32 (m, 4H), 1.49 (d, J= 6.8 Hz, 3H). Example 396: r(7SV3-(3-Fluoro-5-methyl-phenylV2.7-dimethyl-5.7-dihvdro-4H-pyrazolor3.4-cl pyridin-6-yl1-('2-methylimidazoi l 2-al pyri din-3 -vOmethanone.
Figure imgf000432_0001
The title compound was prepared in a manner analogous to Example 288, using (S)-3-(3-fluoro- 5-methylphenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 42) instead of (S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c]pyridine (Intermediate 40) and 2-methylimidazo[l,2-a]pyridine-3 -carboxylic acid instead of 2- fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H24FN5O, 417.5; m/z found, 418.2 [M+H]+. ¾ NMR (500 MHz, DMSO- e) d ' H NMR (400 MHz, DMSO-r/e) d 8.39 - 8.28 (m, 1H), 7.61 - 7.50 (m, 1H), 7.37 - 7.29 (m, 1H), 7.21 - 7.06 (m, 3H), 7.03 - 6.90 (m,
1H), 5.68 - 5.50 (m, 1H), 4.14 - 3.95 (m, 1H), 3.80 (s, 3H), 3.46 - 3.34 (m, 1H), 2.69 (t, J= 12.4 Hz, 1H), 2.47 - 2.41 (m, 1H), 2.39 - 2.33 (m, 6H), 1.49 (d, J= 6.8 Hz, 3H).
Example 397: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('2-methylimidazon .2-a1pyridin-3-yl)methanone.
Figure imgf000432_0002
The title compound was prepared in a manner analogous to Example 288, using 2- methybmidazo[l,2-a]pyridine-3 -carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. ¾ NMR (600 MHz, Chloroform-^ d 8.38 (s, 1H), 7.56 (d, J= 9.0 Hz, 1H), 7.26 (m, 1H), 6.97 (brs, 2H), 6.86 (t, J= 6.1 Hz, 1H), 5.90 (brs, 1H), 4.89 (brs, 0.3H), 4.25 (brs, 0.78H), 3.84 (s, 3H), 3.42 (brs, 1H), 2.62 (m, 4.90H), 1.62 (s, 3H). Example 398: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluoroDhenyl)-5.7-dihvdro-4H-Dyrazolo[3.4- clpyri din-6-yl1-(3 -methyl imidazon .2-a1pyridin-2-yl)methanone.
Figure imgf000433_0001
The title compound was prepared in a manner analogous to Example 288, using 3- methylimidazo[l,2-a]pyridine-2-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.33 (d, J= 6.9 Hz, 1H), 7.66 - 7.49 (m, 3H), 7.41 - 7.27 (m, 1H), 7.10 - 6.98 (m, 1H), 5.98 - 5.58 (m, 1H), 4.82 - 4.65 (m, 1H), 3.88 - 3.69 (m, 3H), 3.10 - 2.67 (m, 2H), 2.58 (s, 3H), 2.45 - 2.34 (m, 1H), 1.58 - 1.42 (m, 3H).
Example 399: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('7-methylimidazon .2-a1pyridin-3-yl)methanone.
Figure imgf000433_0002
The title compound was prepared in a manner analogous to Example 288, using 7- methybmidazo[l,2-a]pyridine-3 -carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 8.84 - 8.80 (m, 1H), 8.02 (s, 1H), 7.62 - 7.53 (m, 2H), 7.52 - 7.49 (m, 1H), 6.95 (dd, J= 7.2, 1.8 Hz, 1H), 5.51 (q, J= 6.7 Hz, 1H), 4.49 - 4.40 (m, 1H), 3.81 (s, 3H), 3.12 - 2.97 (m, 1H), 2.42 - 2.39 (m, 3H), 1.55 (d, J= 6.7 Hz, 3H). (Fractions of Hs that may overlap with DMSO and water are not reported). Example 400: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000434_0001
zoi l .2-a1pyridin-3-yl)methanone.
Figure imgf000434_0002
The title compound was prepared in a manner analogous to Example 288, using 6- methylimidazo[l ,2-a]pyridine-3 -carboxylic acid instead of 2-fluoro-6-(2H-l ,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.76 - 8.68 (m, 1H), 8.03 (s, 1H), 7.67 - 7.53 (m, 3H), 7.32 (dd, J = 9.2, 1.8 Hz, 1H), 5.57 - 5.45 (m, 1H), 4.51 - 4.38 (m, 1H), 3.81 (s, 3H), 3.20 - 2.99 (m, 2H), 2.49 - 2.45 (m, 1H), 2.37 - 2.30 (m, 3H), 1.56 (d, J= 6.7 Hz, 3H).
Example 401 : i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('5-methylimidazon .2-a1pyridin-3-yl)methanone.
Figure imgf000434_0003
The title compound was prepared in a manner analogous to Example 288, using lithium (I) 5- methylimidazo[l,2-a]pyridine-3-carboxylate instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 7.91 (s, 1H), 7.63 - 7.53 (m, 3H), 7.36 (t, J= 7.9 Hz, 1H), 6.90 (d, J= 6.9 Hz, 1H), 5.58 (s, 1H), 4.09 (s, 1H), 3.80 (d, J= 39.8 Hz, 3H), 3.21 - 2.72 (m, 3H), 2.54 (s, 2H), 2.40 (d, = 15.6 Hz, 1H), 1.51 (d, = 6.7 Hz, 3H). Example 402: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000435_0001
c1pyridin-6-yl1-('7-fluoro-2-methyl-imidazoi l .2-a1pyridin-3-yl)methanone.
Figure imgf000435_0002
The title compound was prepared in a manner analogous to Example 288, using potassium 7- fluoro-2-methylimidazo[l,2-a]pyridine-3-carboxylate (Intermediate 85) instead of 2-fluoro-6- (2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H19F4N5O, 457.2; m/z found, 458.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.40 (dd, J= 7.6, 5.8 Hz, 1H), 7.60 - 7.38 (m, 3H), 7.13 - 6.86 (m, 1H), 5.70 - 5.37 (m, 1H), 4.16 - 3.96 (m, 1H), 3.82 (s, 3H), 3.50 - 3.34 (m, 1H), 2.80 - 2.67 (m, 1H), 2.46 - 2.40 (m, 1H), 2.35 (s, 3H), 1.49 (d, J= 6.8 Hz, 3H).
Example 403: (2.8-Dimethylimidazorl.2-a1 pyridin-3-ylVr(7SV2.7-dimethyl-3-(3.4.5- trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-c1 pyridin-6-yllmethanone.
Figure imgf000435_0003
The title compound was prepared in a manner analogous to Example 288, using 2,8- dimethylimidazo[l,2-a]pyridine-3 -carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C24H22F3N5O, 453.2; m/z found, 454.2 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 8.17 (d, J= 6.8 Hz, 1H), 7.55 (dd, J= 8.7, 6.7 Hz, 2H), 7.16 (dt, J = 6.9, 1.2 Hz, 1H), 6.88 (t, = 6.9 Hz, 1H), 5.57 (s, 1H), 4.17 - 3.94 (m, 1H), 3.81 (s, 3H), 3.46 - 3.35 (m, 1H), 2.81 - 2.63 (m, 1H), 2.49 (s, 3H), 2.37 (s, 4H), 1.48 (d, J= 6.7 Hz, 3H).
Example 404 : ( 2.7-Dimethylimidazo G 1.2-al pyridin-3 -yl V G ( 7S V2.7-dimethyl-3 -( 3.4.5- trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-c1pyridin-6-yl1methanone.
Figure imgf000436_0001
The title compound was prepared in a manner analogous to Example 288, using 2,7- dimethybmidazo[l,2-a]pyridine-3 -carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C24H22F3N5O, 453.2; m/z found, 454.2 [M+H]+. ¾ NMR (600 MHz, Chlorofornw/) d 8.28 (s, 1H), 7.29 (s, 1H), 6.97 (s, 2H), 6.69 (d, J= 7.0 Hz, 1H), 6.22 - 4.02 (m, 1H), 3.84 (s, 3H), 3.41 (brs, 1H), 2.93 - 2.26 (m, 9H), 1.60 (brs, 3H).
Example 405: (2.6-Dimethylimidazorl.2-alpyridin-3-ylVr(7SV2.7-dimethyl-3-(3.4.5- trifluorophenyl)-5.7-dihvdro-4H-pyrazolo clpyridin-6-yllmethanone.
Figure imgf000436_0002
Figure imgf000436_0003
The title compound was prepared in a manner analogous to Example 288, using 2,6- dimethylimidazo[l,2-a]pyridine-3 -carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C24H22F3N5O, 453.2; m/z found, 454.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.14 (s, 1H), 7.55 (dd, J= 8.6, 6.5 Hz, 2H), 7.47 (dd, = 9. l, 0.9 Hz, 1H), 7.21 (dd, = 9.2, 1.7 Hz, 1H), 5.60 (s, 1H), 4.20 - 3.93 (m, 1H), 3.82 (s, 3H), 3.21 - 3.13 (m, 1H), 2.72 (s, 1H), 2.48 - 2.40 (m, 1H), 2.36 - 2.24 (m, 6H), 1.49 (d, = 6.8 Hz, 3H).
Example 406: r(7SV3-(3-Chloro-5-methoxy-phenylV2.7-dimethyl-5.7-dihvdro-4H- Pyrazolo[3.4-c1pyridin-6-yl1-('6-fluoro-2-methyl-imidazon .2-a1pyridin-3-yl)methanone.
Figure imgf000437_0001
The title compound was prepared in a manner analogous to Example 288, using (S)-3-(3-chloro- 5-methoxyphenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c] pyridine (Intermediate 41) instead of (S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c]pyridine and 6-fluoro-2-methylimidazo[l,2-a]pyridine-3-carboxylic acid instead of 2-fluoro-6- (2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C24H23CIFN5O2, 467.2; m/z found, 468.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 8.45 (dd, J= 4.7, 2.4 Hz, 1H), 7.69 - 7.60 (m, 1H), 7.53 - 7.38 (m, 1H), 7.18 - 7.05 (m, 2H), 6.99 (dd, = 2.3, 1.4 Hz, 1H), 5.70 - 5.48 (m, 1H), 4.17 - 3.98 (m, 1H), 3.86 - 3.75 (m, 6H), 3.47 - 3.37 (m, 1H), 2.72 (t, J= 13.0 Hz, 1H), 2.46 - 2.34 (m, 4H), 1.50 (d, J= 6.6 Hz, 3H).
Example 407: r(7S)-2.7-Dimethyl-3-(3 AS-trifluorophenvD-
Figure imgf000437_0002
thyl-imidazon .2-a1pyridin-3-yl)methanone.
Figure imgf000437_0003
The title compound was prepared in a manner analogous to Example 288, using 6-fluoro-2- methybmidazo[l,2-a]pyridine-3 -carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C23H19F4N5O, 457.2; m/z found, 458.1 [M+H]+. ¾ NMR (600 MHz, Chlorofornw/) d 8.38 (s, 1H), 7.53 (dd, J= 9.8, 5.0 Hz, 1H), 7.23 - 7.17 (m, 1H), 6.98 (s, 2H), 6.22 - 3.94 (m, 2H), 3.84 (s, 3H), 3.43 (brs, 1H), 2.98 - 2.29 (m, 5H), 1.62 (brs, 3H). Example 408: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000438_0001
c1pyridin-6-yl1-('6-fluoro-2.8-dimethyl-imidazoi l .2-a1pyridin-3-yl)methanone.
Figure imgf000438_0002
The title compound was prepared in a manner analogous to Example 288, using potassium 6- fluoro-2,8-dimethylimidazo[l,2-a]pyridine-3-carboxylate (Intermediate 86) instead of 2-fluoro- 6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H21F4N5O, 471.2; m/z found, 472.2 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 8.28 (dd, J= 5.0, 2.4 Hz, 1H), 7.54 (dd, J= 8.7, 6.6 Hz, 2H), 7.37 - 7.20 (m, 1H), 5.56 (s, 1H), 4.02 (d, J= 22.7 Hz, 1H), 3.81 (s, 3H), 3.39 (t, J= 12.7 Hz, 1H), 2.84 - 2.64 (m, 1H), 2.52 (s, 3H), 2.46 - 2.39 (m, 1H), 2.37 (s, 3H), 1.49 (d, J= 6.7 Hz, 3H).
Example 409: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('6-fluoro-2.7-dimethyl-imidazon .2-a1pyridin-3-yl)methanone.
Figure imgf000438_0003
The title compound was prepared in a manner analogous to Example 288, using potassium 6- fluoro-2,7-dimethylimidazo[l,2-a]pyridine-3-carboxylate (Intermediate 87) instead of 2-fluoro- 6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H21F4N5O, 471.2; m/z found, 472.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.39 (d, J= 5.2 Hz, 1H), 7.62 - 7.42 (m, 3H), 5.70 - 5.42 (m, 1H), 4.14 - 3.97 (m, 1H), 3.81 (s, 3H), 3.46 - 3.34 (m, 1H), 2.81 - 2.65 (m, 1H), 2.47 - 2.39 (m, 1H), 2.35 (d, J= 2.1 Hz, 6H), 1.49 (d, J= 6.8 Hz, 3H). Example 410: (6.8-Difluoro-2-methyl-imidazorl.2-a1pyridin-3-ylVr(7SV2.7-dimethyl-3-(3.4.5- trifluorophenyl)-5.7-dihvdro-4H-pyrazolo clpyridin-6-yllmethanone.
Figure imgf000439_0001
Figure imgf000439_0002
The title compound was prepared in a manner analogous to Example 288, using potassium 6,8- difluoro-2-methylimidazo[l,2-a] pyridine-3 -carboxylate (Intermediate 88) instead of 2-fluoro-6- (2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F5N5O, 475.2; m/z found, 476.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.36 (d, J= 2.9 Hz, 1H), 7.69 - 7.60 (m, 1H), 7.54 (dd, J= 8.6, 6.6 Hz, 2H), 5.69 - 5.43 (m, 1H), 4.13 - 3.91 (m, 1H), 3.82 (s, 3H), 3.45 - 3.34 (m, 1H), 2.82 - 2.67 (m, 1H), 2.46 - 2.33 (m, 4H), 1.60 - 1.44 (m, 3H).
Example 411 : r(7S)-2.7-Dimethyl-3-(3 AS-trifluorophenvD-
Figure imgf000439_0003
yl-imidazon .2-a1pyridin-3-yl)methanone.
Figure imgf000439_0004
The title compound was prepared in a manner analogous to Example 288, using potassium 7- methoxy-2-methybmidazo[l,2-a]pyridine-3-carboxylate (Intermediate 89) instead of 2-fluoro-6- (2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H22F3N5O2, 469.2; m/z found, 470.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 7.88 - 7.78 (m, 1H), 7.56 - 7.45 (m, 3H), 7.14 (dd, J= 9.7, 2.4 Hz, 1H), 5.53 (s, 1H), 4.09 (s, 1H), 3.82 (s, 3H), 3.72 (s, 3H), 3.48 - 3.34 (m, 1H), 2.75 (d, J= 12.9 Hz, 1H), 2.48 - 2.39 (m, 1H), 2.34 (s, 3H), 1.48 (d, J= 6.8 Hz, 3H). Example 412: r2-(Difluoromethyl)imidazorl.2-alpyridin-3-yl1-r(7SV2.7-dimethyl-3-(3.4.5- trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-c1pyridin-6-yl1methanone.
Figure imgf000440_0001
The title compound was prepared in a manner analogous to Example 288, using 2- (difluoromethyl)imidazo[l,2-a]pyridine-3 -carboxylic acid instead of 2-fluoro-6-(2H-l,2,3- triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F5N5O, 475.1; m/z found, 476.1 [M+H]+. (500 MHz, Chloroform-r/) d 8.18 (d, J= 6.9 Hz, 1H), 7.71 - 7.66 (m, 1H), 7.39 - 7.32 (m, 1H), 7.03 - 6.87 (m, 4H), 5.78 (brs, 1H), 4.24 (brs, 1H), 3.83 (s, 3H), 3.39 (brs, 1H), 3.02 - 2.35 (m, 2H), 1.61 (d, = 6.6 Hz, 3H).
Example 413: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1 pyridin-6-yll - [2-('trifluoromethyl) imidazoj E2-a1 pyri din-3 -yll methanone.
Figure imgf000440_0002
The title compound was prepared in a manner analogous to Example 288, using 2- (trifluoromethyl)imidazo[l,2-a]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 - triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H17F6N5O, 493.1; m/z found, 494.1 [M+H]+. (400 MHz, DMSO-r/e) d 8.28 (d, J= 67.0 Hz, 1H), 7.85 - 7.76 (m, 1H), 7.60 - 7.44 (m, 3H), 7.29 - 7.07 (m, 1H), 5.87 - 5.58 (m, 1H), 3.91 - 3.64 (m, 4H), 3.46 - 3.36 (m, 1H), 2.65 - 2.53 (m, 1H), 2.46 - 2.28 (m, 1H), 1.68 - 1.41 (m, 3H). Example 414: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000441_0001
c1pyridin-6-yl1-[5-methyl-2-('trifluoromethyl)imidazoi l .2-a1pyridin-3-yl1methanone.
Figure imgf000441_0002
The title compound was prepared in a manner analogous to Example 288, using 5-methyl-2- (trifluoromethyl)imidazo[l,2-a]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 - triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H19F6N5O, 507.1; m/z found, 508.0
[M+H]+. (400 MHz, DMSO-r/e) d 8.28 (d, J= 67.0 Hz, 1H), 7.85 - 7.76 (m, 1H), 7.60 - 7.44 (m, 3H), 7.29 - 7.07 (m, 1H), 5.87 - 5.58 (m, 1H), 3.91 - 3.64 (m, 4H), 3.46 - 3.36 (m, 1H), 2.65 - 2.53 (m, 1H), 2.46 - 2.28 (m, 1H), 1.68 - 1.41 (m, 3H).
Example 415: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1 pyridin-6-vH-Pyrrolor 1 2-al pyrazin-l -yl-methanone.
Figure imgf000441_0003
The title compound was prepared in a manner analogous to Example 288, using potassium pyrrolo[l,2-a]pyrazine-l-carboxylate (Intermediate 91) instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C22H18F3N5O, 425.2; m/z found, 426.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 8.38 - 8.28 (m, 1H), 7.93 - 7.78 (m, 1H), 7.61 - 7.39 (m, 3H), 7.02 - 6.84 (m, 1H), 6.77 - 6.56 (m, 1H), 5.74 - 5.51 (m, 1H), 4.84 - 4.63 (m, 1H), 3.86 - 3.68 (m, 3H), 3.25 - 2.98 (m, 1H), 2.89 - 2.58 (m, 1H), 2.40 - 2.24 (m, 1H), 1.62 - 1.32 (m, 3H). Example 416: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo cl
Figure imgf000442_0001
pyridin-6-yll-pyrrolor 1.2-a1pyrazin-8-yl-methanone.
Figure imgf000442_0002
The title compound was prepared in a manner analogous to Example 288, using pyrrolo[l,2- a]pyrazine-8-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H18F3N5O, 425.2; m/z found, 426.1 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) 5 9.10 - 8.97 (m, 1H), 8.38 (dd, J= 4.8, 1.6 Hz, 1H), 7.91 - 7.71 (m, 1H), 7.69 - 7.47 (m, 3H), 7.16 (d, J= 2.7 Hz, 1H), 5.57 - 5.37 (m, 1H), 4.42 - 4.26 (m, 1H), 3.80 (s, 3H), 3.24 - 3.28 (m, 1H), 3.07 - 2.89 (m, 1H), 2.47 - 2.31 (m, 1H), 1.59 - 1.42 (m, 3H).
Example 417: (2.4-Dimethylpyrrolo|T.2-al pyrimidin-8-ylVr(7SV2.7-dimethyl-3-(3.4.5- trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-c1 pyridin-6-yll methanone.
Figure imgf000442_0003
The title compound was prepared in a manner analogous to Example 288, using 2,4- dimethylpyrrolo[l,2-a]pyrimidine-8-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C24H22F3N5O, 453.2; m/z found, 454.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) 5 7.58 - 7.46 (m, 2H), 7.37 (d, J= 3.2 Hz, 1H), 7.13 - 7.01 (m, 1H), 6.72 - 6.62 (m, 1H), 5.66 - 5.27 (m, 1H), 4.22 - 3.89 (m, 1H), 3.78 (s, 3H), 3.26 - 3.03 (m, 2H), 2.60 - 2.56 (m, 3H), 2.46 - 2.32 (m, 4H), 1.50 (s, 3H). Example 418: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000443_0001
clpyridin-O-yll-n-methylimidazoi l .5-alpyridin-6-yl)methanone.
Figure imgf000443_0002
The title compound was prepared in a manner analogous to Example 288, using 3- methylimidazo[l ,5-a]pyridine-6-carboxylic acid instead of 2-fluoro-6-(2H-l ,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 8.28 - 8.07 (m, 1H), 7.61 - 7.48 (m, 3H), 7.40 - 7.26 (m, 1H), 6.72 (d, J= 9.3 Hz, 1H), 5.67 - 5.33 (m, 1H), 4.25 - 3.84 (m, 1H), 3.80 (s, 3H), 3.27 - 3.05 (m, 1H), 2.93 - 2.73 (m, 1H), 2.62 (s, 3H), 2.45 - 2.32 (m, 1H), 1.58 - 1.29 (m, 3H).
Example 419: it7S)-2.7-Dimethyl-3-t3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1 pyridin-6-yll -(7 -methylimidazo G E 5 -alpyridin- 1 -vQmethanone.
Figure imgf000443_0003
The title compound was prepared in a manner analogous to Example 288, using 7- methybmidazo[l ,5 -a] pyridine- 1 -carboxylic acid instead of 2-fluoro-6-(2H-l ,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C23H20F3N5O, 439.2; m/z found, 440.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.42 - 8.35 (m, 2H), 7.90 - 7.86 (m, 1H), 7.58 - 7.49 (m, 2H), 6.74 (dd, J= 7.1, 1.7 Hz, 1H), 6.68 - 6.50 (m, 0.32H), 5.73 - 5.46 (m, 1H), 4.79 - 4.57 (m, 0.32H), 3.79 (s, 3H), 3.10 - 2.67 (m, 1.45H), 2.46 - 2.40 (m, 1H), 2.34 - 2.31 (m, 3H), 1.67 - 1.40 (m, 3H). (Fractions of Hs that may overlap with DMSO and water are not reported). Example 420: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluoroDhenyl)-5.7-dihvdro-4H-Dyrazolo[3.4- clpyridin-6-yll-imidazorE5-alpyridin-l-yl-methanone.
Figure imgf000444_0001
The title compound was prepared in a manner analogous to Example 288, using imidazo[l,5- a]pyridine-l -carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H18F3N5O, 425.1; m/z found, 426.1 [M+H]+. 1H NMR (500 MHz,
Chlorofornw/) d 8.27 (d, J= 9.3 Hz, 1H), 8.05 - 8.02 (m, 1H), 7.99 (dt, J= 7.0, 1.1 Hz, 1H),
7.03 - 6.94 (m, 3H), 6.77 - 6.51 (m, 1.35H), 6.09 - 5.36 (m, 1H), 5.11 - 4.74 (m, 0.41H), 3.82 (s, 3H), 3.46 - 2.77 (m, 2H), 2.52 - 2.43 (m, 1H), 1.68 (br s, 3H).
Example 421 : ( 3 -Cvclopropylimidazo G E 5 -al pyridin- 1 -yl V G ( 7S dimethyl-3 -(3.4.5-
Figure imgf000444_0002
trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-clpyridin-6-yllmethanone.
Figure imgf000444_0003
The title compound was prepared in a manner analogous to Example 288, using 3- cyclopropylimidazo[l,5-a]pyridine-l-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C25H22F3N5O, 465.2; m/z found, 466.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 8.58 - 8.42 (m, 1H), 8.15 - 7.95 (m, 1H), 7.63 - 7.46 (m, 2H), 7.13 - 7.01 (m, 1H), 6.97 - 6.88 (m, 1H), 6.80 - 6.20 (m, 1H), 5.86 - 4.33 (m, 1H), 3.78 (s, 3H),
3.23 - 2.67 (m, 2H), 2.49 - 2.34 (m, 2H), 1.52 (s, 3H), 1.18 - 0.90 (m, 4H). Example 422: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000445_0001
clpyridin-6-yll -(I H-pyrazolo G 3.4-b1pyridin-4-yl)methanone.
Figure imgf000445_0002
The title compound was prepared in a manner analogous to Example 288, using 1H- pyrazolo[3,4-b]pyridine-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C21H17F3N6O, 426.1; m/z found, 427.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 13.93 (s, 1H), 8.62 (d, J= 4.6 Hz, 1H), 8.14 - 7.97 (m, 1H), 7.63 - 7.49 (m, 2H), 7.21 (d, = 4.6 Hz, 1H), 5.73 - 5.65 (m, 0.68H), 4.80 - 4.52 (m, 0.50H), 3.87 - 3.69 (m, 3H), 3.52 - 3.44 (m, 0.66H), 3.17 - 3.08 (m, 0.23H), 2.96 - 2.85 (s, 0.22H), 2.79 - 2.68 (m, 0.66H), 2.33 - 2.25 (m, 0.69H), 1.59 - 1.31 (m, 3H). (Fractions of Hs that may overlap with DMSO and water are not reported).
Example 423: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-nII-P H-pyrazolo[3.4-b1pyridin-5-yl)niethanone *TFA salt.
Figure imgf000445_0003
Step A: (S V(2.7-Dimethyl-3 -(3.4.5 -trifluorophenyl)-4.5 -dihydro-2H-pyrazolo cl pyridin-
Figure imgf000445_0004
6(7H)-yl)( l -(Y2-('trimethylsilyl)ethoxy)methyl)- l H-pyrazolo[3.4-b1pyridin-5-yl)niethanone. The title compound was prepared in a manner analogous to Example 288, using l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrazolo[3,4-b]pyridine-5-carboxylic acid (Intermediate 61) instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. Step B: r(7SV2.7-Dimethyl-3-(3A5-trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-clpyridin-6- yll-P H-pyrazoloi3.4-b1pyridin-5-yl)methanone. The title compound was prepared in a manner analogous to Example 371, Step B. MS (ESI): mass calcd. for C21H17F3N6O, 426.1 ; m/z found, 427.2 [M+H]+.
Example 424: (E6-Dimethylpyrazolor3.4-blpyridin-4-ylVr(7SV2.7-dimethyl-3-(3A5- trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000446_0001
The title compound was prepared in a manner analogous to Example 288, using l,6-dimethyl- lH-pyrazolo[3,4-b]pyridine-4-carboxylic acid instead of 2-fluoro-6-(2H-l ,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C23H21F3N6O, 454.2; m/z found, 455.1 [M+H]+. ¾ NMR (400 MHz, DMSOAe) d 8.08 - 7.78 (m, 1H), 7.65 - 7.43 (m, 2H), 7.12 (s, 1H), 5.75 - 5.51 (m, 1H), 4.87 - 4.43 (m, 1H), 4.05 (s, 3H), 3.87 - 3.67 (m, 3H), 3.55 - 3.34 (m, 1H), 3.30 - 3.07 (m, 1H), 2.66 (s, 3H), 2.39 - 2.21 (m, 1H), 1.61 - 1.27 (m, 3H).
Example 425: (E3-Dimethylpyrazolor3.4-b1pyridin-4-ylVr(7SV2.7-dimethyl-3-(3.4.5- trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000446_0002
The title compound was prepared in a manner analogous to Example 288, using l,3-dimethyl- lH-pyrazolo[3,4-b]pyridine-4-carboxybc acid instead of 2-fluoro-6-(2H-l ,2,3-triazol-2- yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C23H21F3N6O, 454.2; m/z found, 455.2 [M+H]+.
Figure imgf000447_0001
NMR (600 MHz, DMSO-r/e) d 8.64 - 8.69 (m, 1H), 7.58 - 7.49 (m, 2H), 7.25 - 7.10 (m, 1H), 5.71 (q, J= 6.8 Hz, 0.78H), 4.83 - 4.77 (m, 0.24H), 4.41 (br s, 0.09H), 4.05 - 3.97 (m, 3H), 3.83 (s, 2.29H), 3.73 (s, 0.72H), 3.14 (td, J= 12.7, 4.0 Hz, 0.31H), 2.84 - 2.69 (m, 0.73H), 2.59 - 2.55 (m, 0.32H), 2.46 - 2.10 (m, 4H), 1.54 - 1.28 (m, 3H). (Fractions of Hs that may overlap with DMSO and water are not reported).
Example 426: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c|pyridin-6-yl1 -(I H-pyrazolo G 3.4-b1pyridin-3-yl)methanone.
Figure imgf000447_0002
The title compound was prepared in a manner analogous to Example 288, using 1H- pyrazolo[3,4-b]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H17F3N6O, 426.1; m/z found, 427.1 [M+H]+. ¾ NMR (500 MHz, Chlorofornw/) d 12.11 (s, 0.48H), 11.17 (s, 0.43H), 8.67 - 8.54 (m, 2H), 7.33 - 7.25 (m, 1H), 7.04 - 6.94 (m, 2H), 6.44 - 6.35 (m, 0.48H), 6.00 - 5.89 (m, 0.42H), 5.24 - 5.13 (m, 0.46H), 5.04 - 4.92 (m, 0.53H), 3.92 - 3.82 (m, 3H), 3.43 - 3.32 (m, 0.45H), 3.25 - 3.14 (m,
0.52H), 3.07 - 3.82 (m, 1H), 2.57 - 2.46 (m, 1H), 1.90 - 1.60 (m, 3H).
Example 427: it7S)-2.7-Diiiiethyl-3-t3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazoloi3.4- clpyridin-6-nII-P -methylpyrazolo b1pyridin-3-yl)methanone.
Figure imgf000447_0003
Figure imgf000447_0004
The title compound was prepared in a manner analogous to Example 288, using 1 -methyl- 1H- pyrazolo[3,4-b]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H19F3N6O, 440.2; m/z found, 441.2 [M+H]+. ¾ NMR (500 MHz, Chloroform-i/) d 8.61 - 8.53 (m, 2H), 7.26 - 7.19 (m, 1H), 7.04 - 6.92 (m, 2H), 6.43 - 6.34 (m, 0.46H), 5.99 - 5.88 (m, 0.45H), 5.31 - 5.18 (m, 0.49H), 5.02 - 4.89 (m, 0.53H), 4.21 (s, 3H), 3.90 - 3.75 (m, 3H), 3.43 - 3.31 (m, 0.47H), 3.21 - 3.10 (m, 0.49H), 3.04 - 2.79 (m, 1H), 2.55 - 2.45 (m, 1H), 1.80 - 1.60 (m, 3H).
Example 428: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('5-fluoro- l H-pyrazoloi3.4-b1pyridin-3-yl)methanone »TFA salt.
Figure imgf000448_0001
The title compound was prepared in a manner analogous to Example 288, using 5-fluoro-lH- pyrazolo[3,4-b]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C21H16F4N6O, 444.1; m/z found, 445.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 14.45 - 14.31 (m, 1H), 8.68 - 8.65 (m, 1H), 8.23 - 8.16 (m, 1H), 7.59 - 7.50 (m, 2H), 6.22 - 6.11 (m, 0.40H), 5.73 - 5.61 (m, 0.58H), 5.15 - 5.02 (m, 0.59H), 4.79 - 4.69 (d, J= 12.5 Hz, 0.44H), 3.86 - 3.72 (m, 3H), 3.17 - 3.06 (m,
0.43H), 2.96 - 2.72 (m, 1H), 1.66 - 1.46 (m, 3H). (Fractions of Hs that may overlap with DMSO and water are not reported).
Example 429: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('2-niethylpyrazolo[3.4-c1pyridin-7-yl)niethanone.
Figure imgf000448_0002
The title compound was prepared in a manner analogous to Example 206, using [(7S)-2,7- dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(lH- pyrazolo[3,4-c]pyridin-7-yl)methanone (Example 432) instead of [(S)-(2,7-dimethyl-3-(3,4,5- trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(lH-indol-7- yl)methanone] (Example 205) and DMF instead of THF. MS (ESI): mass calcd. for
C22H19F3N6O, 440.2; m/z found, 441.0 [M+H]+. Ή NMR (500 MHz, Methanol -ίL) d 8.49 - 8.41 (m, 1H), 8.15 - 8.08 (m, 1H), 7.85 - 7.75 (m, 1H), 7.35 - 7.24 (m, 2H), 5.93 - 5.81 (m, 0.70H), 4.99 - 4.91 (m, 0.30H), 4.70 - 4.66 (m, 0.30H), 4.31 (s, 2.1H), 4.29 (s, 0.90H), 3.84 (s, 2.1H), 3.74 (s, 0.90H), 3.57 - 3.50 (m, 0.70H), 3.46 - 3.41 (m, 0.30H), 3.42 - 3.35 (m, 0.70H), 2.81 - 2.70 (m, 1H), 2.64 - 2.55 (m, 0.30H), 2.37 - 2.28 (m, 0.70H), 1.68 (d, = 6.8 Hz, 2.1H), 1.47 (d, = 6.8 Hz, 0.90H).
Example 430: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- cl pyri din-3 -vDmethanone.
Figure imgf000449_0001
The title compound was prepared in a manner analogous to Example 288, using 1H- pyrazolo[3,4-c]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H17F3N6O, 426.1; m/z found, 427.1 [M+H]+. ¾ NMR (400 MHz, DMSO-i e) 5 14.15 (s, 1H), 9.17 - 9.11 (m, 1H), 8.33 (d, = 5.6 Hz, 1H), 7.94 (dd, =
5.6, 1.3 Hz, 1H), 7.60 - 7.50 (m, 2H), 6.12 - 5.98 (m, 0.36H), 5.75 - 5.64 (m, 0.54H), 5.01 - 4.87 (m, 0.56H), 4.83 - 4.69 (m, 0.42H), 386 - 3.70 (m, 3H), 3.18 - 3.06 (m, 0.47H), 2.97 - 2.74 (m, 1H), 1.66 - 1.46 (m, 3H). (Fractions of Hs that may overlap with DMSO and water are not reported).
Example 431 : -2.7-Diniethyl-3-t3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazoloi3.4- c1pyridin-6-yl1-( 1 -niethylpyrazolo[3.4-c1pyridin-3-yl)niethanone*TFA salt.
Figure imgf000450_0001
The title compound was prepared in a manner analogous to Example 288, using 1 -methyl- 1H- pyrazolo[3,4-c]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C22H19F3N6O, 440.2; m/z found, 441.2 [M+H]+. ¾ NMR (500 MHz, Chlorofornw/) d 9.46 (s, 1H), 8.54 - 8.36 (m, 2H), 7.04 -
6.93 (m, 2H), 6.29 - 6.21 (m, 0.51H), 5.96 - 5.89 (m, 0.42H), 5.15 - 5.07 (m, 0.46H), 4.99 - 4.91 (m, 0.56H), 4.35 (s, 3H), 3.88 - 3.77 (m, 3H), 3.47 - 3.38 (m, 0.44H), 3.25 - 3.15 (m, 0.56H), 3.03 - 2.79 (m, 1H), 2.57 - 2.51 (m, 1H), 1.82 - 1.62 (m, 3H). Example 432: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll -(T H-pyrazolo G3 4-cl pyridin-7-yl imethanone.
Figure imgf000450_0002
The title compound was prepared in a manner analogous to Example 288, using 1H- pyrazolo[3,4-c]pyridine-7-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H17F3N6O, 426.1 ; m/z found, 427.0 [M+H]+. ¾ NMR (500 MHz, Methanol-i/4) d 8.35 - 8.27 (m, 1H), 8.26 (s, 1H), 7.96 - 7.86 (m, 1H), 7.37 - 7.25 (m,
2H), 5.86 (q, J= 6.8 Hz, 0.65H), 5.62 - 5.47 (m, 0.35H), 4.99 - 4.88 (m, 0.35H), 4.41 - 4.29 (m, 0.65H), 3.85 (s, 2H), 3.76 (s, 1H), 3.47 - 3.36 (m, 0.65H), 3.31 - 3.23 (m, 0.35H), 2.98 - 2.86 (m, 1H), 2.65 - 2.55 (m, 0.35H), 2.49 - 2.39 (m, 0.65H), 1.67 (d, J = 6.8 Hz, 2H), 1.61 (d, J = 6.7 Hz, 1H). Example 433: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000451_0001
clpyridin-6-nII-P -methylpyrazoloi3.4-c1pyridin-7-yl)methanone.
Figure imgf000451_0002
The title compound was prepared in a manner analogous to Example 206, using [(7S)-2,7- dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(lH- pyrazolo[3,4-c]pyridin-7-yl)methanone Example 432 instead of [(S)-(2,7-dimethyl-3-(3,4,5- trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(lH-indol-7- yl)methanone] (Example 205) and DMF instead of THF. MS (ESI): mass calcd. for
C22H19F3N6O, 440.2; m/z found, 441.0 [M+H]+. Ή NMR (500 MHz, Methanol - 4) d 8.28 (d, J = 5.6 Hz, 0.3 OH), 8.27 (d, J= 5.6 Hz, 0.70H), 8.22 (s, 0.70H), 8.22 (s, 0.30H), 7.93 - 7.83 (m,
1H), 7.35 - 7.25 (m, 2H), 5.89 (q, J= 6.8 Hz, 0.70H), 5.02 - 4.95 (m, 0.30H), 4.79 - 4.68 (m,
0.3 OH), 4.13 (s, 2.1H), 4.02 (s, 0.90H), 3.85 (s, 2.1H), 3.76 (s, 0.90H), 3.69 - 3.58 (m, 0.70H), 3.52 - 3.38 (m, 0.70H), 3.37 - 3.32 (m, 0.30H), 3.02 - 2.74 (m, 1H), 2.72 - 2.57 (m, 0.30H), 2.49 - 2.31 (m, 0.70H), 1.68 (d, = 6.8 Hz, 2.1H), 1.51 (d, = 6.8 Hz, 0.90H).
Example 434: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- cl pyridin-7-yl jmethanone.
Figure imgf000451_0003
The title compound was prepared in a manner analogous to Example 288, using 1H- pyrazolo[4,3-c]pyridine-7-carboxylic acid instead of 2-fluoro-6-(2H-l ,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H17F3N6O, 426.1; m/z found, 427.0 [M+H]+. ¾ NMR (400 MHz, Methanol-^) d 9.56 (s, 1H), 8.80 (s, 1H), 8.65 (s, 1H), 7.44 - 7.17 (m, 2H), 6.05 - 5.58 (m, 1H), 4.04 - 3.67 (m, 4H), 3.58 - 3.40 (m, 1H), 2.99 - 2.72 (m, 1H), 2.66 - 2.34 (m, 1H), 1.66 (s, 3H). Example 435: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- cl pyri din-3 -vQmethanone.
Figure imgf000452_0001
The title compound was prepared in a manner analogous to Example 288, using 1H- pyrazolo[4,3-c]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H17F3N6O, 426.1 ; m/z found, 427.1 [M+H]+. ¾ NMR (500 MHz, Chlorofornw/) d 11.75 - 10.72 (m, 1H), 9.12 - 9.07 (m, 1H), 8.49 - 8.40 (m, 1H), 8.14 - 8.09 (m, 1H), 7.03 - 6.94 (m, 2H), 6.26 - 6.17 (m, 0.48H), 6.00 - 5.91 (m, 0.41H), 5.05 - 4.95 (m, 1H), 3.89 - 3.79 (m, 3H), 3.44 - 3.34 (m, 0.43H), 3.25 - 3.14 (m, 0.50H), 3.04 - 2.82 (m, 1H), 2.58 - 2.44 (m, 1H), 1.80 - 1.62 (m, 3H).
Example 436: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1 pyridin-6-yll -( 1 H-pyrazolo G 4.3 -blpyri din-3 -yllmethanone.
Figure imgf000452_0002
The title compound was prepared in a manner analogous to Example 288, using 1H- pyrazolo[4,3-b]pyridine-3-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H17F3N6O, 426.1; m/z found, 427.1 [M+H]+.
Figure imgf000453_0001
The title compound was prepared in a manner analogous to Example 288, using
[l,2,4]triazolo[4,3-a]pyridine-5-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C21H17F3N6O, 426.1; m/z found, 427.0 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 9.15 (s, 1H), 8.00 - 7.84 (m, 1H), 7.62 - 7.41 (m, 3H), 7.25 - 7.15 (m, 1H), 5.70 - 5.36 (m, 1H), 5.11 - 4.33 (m, 1H), 4.03 - 3.72 (m, 4H), 3.06 - 2.83 (m, 1H), 2.46 - 2.31 (m, 1H), 1.61 - 1.49 (m, 3H). Example 439: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000454_0001
.3-a1pyridin-6-vnmethanone.
Figure imgf000454_0002
The title compound was prepared in a manner analogous to Example 288, using
[l,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C21H17F3N6O, 426.1; m/z found, 427.0 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 9.26 (d, J= 0.8 Hz, 1H), 8.78 (t, J= 1.4 Hz, 1H), 7.91 - 7.65 (m, 1H), 7.64 - 7.52 (m, 2H), 7.47 - 7.29 (m, 1H), 5.61 - 5.31 (m, 1H), 4.77 - 4.20 (m, 1H), 4.00 - 3.74 (m, 4H), 2.95 - 2.78 (m, 1H), 2.47 - 2.32 (m, 1H), 1.49 (d, = 6.8 Hz, 3H).
Example 440: r3-(DifluoromethylVrl.2.41triazolor4.3-a1pyridin-6-ylTr(7SV2.7-dimethyl-3- ('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000454_0003
The title compound was prepared in a manner analogous to Example 288, using 3- (difluoromethyl)-[l,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid instead of 2-fluoro-6-(2H- l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H17F5N6O, 476.1 ; m/z found, 477.1
Figure imgf000454_0004
8.78 (s, 1H), 8.02 (dd, J= 9.4, 1.1 Hz, 1H), 7.77 (t, J = 51.7 Hz, 1H), 7.60 - 7.44 (m, 3H), 5.65 - 5.44 (m, 1H), 5.02 - 4.44 (m, 1H), 3.94 - 3.61 (m, 4H), 2.94 - 2.75 (m, 1H), 2.46 - 2.21 (m, 1H), 1.50 (d, = 6.7 Hz, 3H). Example 441 : i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000455_0001
clpyridin-e-yll-ltriazoloi l .5-a1pyridin-3-yl)methanone.
Figure imgf000455_0002
The title compound was prepared in a manner analogous to Example 288, using
[l,2,3]triazolo[l,5-a]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C21H17F3N6O, 426.1; m/z found, 427.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 9.23 (dt, = 7.0, 1.0 Hz, 1H), 8.25 (dt, = 9.0, 1.2 Hz, 1H), 7.68
- 7.63 (m, 1H), 7.60 - 7.51 (m, 2H), 7.35 (td, J= 6.8, 1.3 Hz, 1H), 6.48 - 6.42 (m, 0.37H), 5.75
- 5.61 (m, 0.55H), 5.43 - 5.29 (m, 0.55H), 4.82 - 4.66 (m, 0.39H), 3.88 - 3.73 (m, 3H), 3.19 - 2.72 (m, 1.58H), 1.72 - 1.44 (m, 3H). (Fractions of Hs that may overlap with DMSO and water are not reported).
Example 442: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1 pyridin-6-yll -(2-methylpyrazolorE5-bl pyridazin-3-yl) methanone.
Figure imgf000455_0003
The title compound was prepared in a manner analogous to Example 288, using 2- methylpyrazolo[l,5-b]pyridazine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C22H19F3N6O, 440.2; m/z found, 441.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.47 (dd, = 4.4, 1.9 Hz, 1H), 8.05 (dd, = 9.0, 1.8 Hz, 1H), 7.60 - 7.49 (m, 2H), 7.30 (dd, J= 9.0, 4.5 Hz, 1H), 5.68 - 5.37 (m, 1H), 4.11 - 3.92 (m, 1H), 3.81 (s,
3H), 3.29 - 3.16 (m, 1H), 2.76 - 2.63 (m, 1H), 2.43 (s, 3H), 2.41 - 2.33 (m, 1H), 1.48 - 1.45 (m, 3H). Example 443: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluoroDhenyl)-5.7-dihvdro-4H-Dyrazolo[3.4-c1 pyridin-6-yll -(5-methylpyrazolorE5-bl pyridazin-3-yl) methanone.
Figure imgf000456_0001
The title compound was prepared in a manner analogous to Example 288, using potassium 5- methylpyrazolo[l,5-b]pyridazine-3-carboxylate (Intermediate 93) instead of 2-fluoro-6-(2H- l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H19F3N6O, 440.2; m/z found, 441.1
Figure imgf000456_0002
8.43 (d, J= 4.6 Hz, 1H), 8.25 (s, 1H), 7.55 (dd, J = 8.7, 6.7 Hz, 2H), 7.15 (d, J= 4.5 Hz, 1H), 5.64 (s, 1H), 4.18 - 3.69 (m, 4H), 3.01 - 2.68 (m, 2H), 2.47 - 2.36 (m, 3H), 2.40 - 2.30 (m, 1H), 1.55 - 1.37 (m, 3H).
Example 444: (2-Cvclopropyl-4-methyl-pyrazolori .5-b1pyridazin-3-yl)-IY7S)-2.7-dimethyl-3- ('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000456_0003
The title compound was prepared in a manner analogous to Example 288, using potassium 2- cyclopropyl-4-methylpyrazolo[l,5-b]pyridazine-3-carboxylate (Intermediate 108) instead of 2- fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C25H23F3N6O, 480.2; m/z found, 481.3 [M+H]+.
Figure imgf000456_0004
(400 MHz, DMSO-r/e) d 8.38 - 8.25 (m, 1H), 7.61 - 7.42 (m, 2H), 7.19 - 6.82 (m, 1H), 5.89 - 5.49 (m, 1H), 3.88 - 3.76 (m, 3H), 3.77 - 3.60 (m, 1H), 3.28 - 2.94 (m, 1H), 2.47 - 2.19 (m, 4H), 1.98 - 1.83 (m, 1H), 1.59 - 1.34 (m, 3H), 1.16 - 0.79
(m, 5H). Example 445: (2-Cvclopropyl-5-methyl-pyrazolorl.5-b1pyridazin-3-ylVr(7SV2.7-dimethyl-3- ('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000457_0001
The title compound was prepared in a manner analogous to Example 288, using potassium 2- cyclopropyl-5-methylpyrazolo[l,5-b]pyridazine-3-carboxylate (Intermediate 109) instead of 2- fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C25H23F3N6O, 480.2; m/z found, 481.3 [M+H]+.
Figure imgf000457_0002
(400 MHz, DMSO-r/e) d 8.31 (d, J= 2.4 Hz, 1H), 7.79 (t, J = 1.8 Hz, 1H), 7.63 - 7.46 (m, 2H), 5.71 - 5.37 (m, 1H), 4.19 - 3.99 (m, 1H), 3.81 (s, 3H), 3.55 - 3.34 (m, 1H), 2.79 - 2.58 (m, 1H), 2.44 - 2.26 (m, 4H), 2.05 - 1.85 (m, 1H), 1.53 - 1.41 (m,
3H), 1.11 - 0.85 (m, 4H).
Example 446: (2.4-Dimethylpyrazolo|T.5-al pyrazin-3-ylVr(7SV2.7-dimethyl-3-(3.4.5- trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-c1 pyridin-6-vH methanone.
Figure imgf000457_0003
The title compound was prepared in a manner analogous to Example 288, using potassium 2,4- dimethylpyrazolo[l,5-a]pyrazine-3-carboxylate (Intermediate 94) instead of 2-fluoro-6-(2H- l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H21F3N6O, 454.2; m/z found, 455.1 [M+H]+. NMR (400 MHz, DMSO-r/e) d 8.65 - 8.55 (m, 1H), 7.86 - 7.74 (m, 1H), 7.62 - 7.49 (m, 2H), 5.86 - 5.68 (m, 0.70H), 4.90 - 4.56 (m, 0.30H), 3.87 - 3.56 (m, 4H), 3.29 - 3.06 (m, 1H), 2.89 - 2.59 (m, 1H), 2.58 - 2.52 (m, 3H), 2.45 - 2.35 (m, 3H), 2.31 - 2.19 (m, 1H), 1.54 - 1.24 (m, 3H).
Example 447: (2-Cvclopropyl-4-methyl-pyrazolorl.5-alpyrazin-3-ylVr(7SV2.7-dimethyl-3- ('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-clpyridin-6-yllmethanone.
Figure imgf000458_0001
The title compound was prepared in a manner analogous to Example 288, using potassium 2- cyclopropyl-4-methylpyrazolo[l,5-a]pyrazine-3-carboxylate (Intermediate 95) instead of 2- fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C25H23F3N6O, 480.2; m/z found, 481.2 [M+H]+. ¾ NMR (400 MHz, Methanol-r/4) d 8.45 - 8.32 (m, 1H), 7.81 - 7.67 (m, 1H), 7.40 - 7.21 (m, 2H), 6.05 - 5.80 (m, 1H), 5.27 - 4.95 (m, 1H), 4.08 - 3.75 (m, 4H), 3.69 - 3.38 (m, 1H), 2.74 - 2.56 (m, 3H), 2.56 - 2.31 (m, 1H), 2.13 - 1.91 (m, 1H), 1.69 - 1.38 (m, 3H), 1.27 - 0.96 (m, 4H). Example 448: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1 pyridin-6-vH-Pyrazolor E5-a1pyrimidin-3-yl-methanone.
Figure imgf000458_0002
The title compound was prepared in a manner analogous to Example 288, using pyrazolo[l,5- a]pyrimidine-3-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C21H17F3N6O, 426.1 ; m/z found, 427.2
[M+H]+. ¾ NMR (600 MHz, DMSO-r/e) d 9.22 (dd, = 7.0, 1.7 Hz, 1H), 8.70 (dd, = 4. l, 1.8 Hz, 1H), 8.45 (s, 1H), 7.58 - 7.51 (m, 2H), 7.18 (dd, J= 7.0, 4.1 Hz, 1H), 5.71 - 5.03 (m, 1.25H), 4.81 - 4.46 (m, 0.38H), 4.15 - 3.61 (m, 4H), 2.47 - 2.34 (m, 1H), 1.48 (d, = 6.7 Hz, 3H). (Fractions of Hs that overlap with DMSO and water are not reported). Example 449: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1 -(2-methylpyrazolor E 5 -al pyrimidin-3 -vDmethanone.
Figure imgf000459_0001
The title compound was prepared in a manner analogous to Example 288, using 2- methylpyrazolo[l,5-a]pyrimidine-3-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C22H19F3N6O, 440.2; m/z found, 441.1 [M+H]+ ¾ NMR (400 MHz, DMSO-r/e) d 9.08 (dd, = 7.0, 1.8 Hz, 1H), 8.61 (dd, = 4.2, 1.7 Hz, 1H), 7.63 - 7.48 (m, 2H), 7.08 (dd, = 7.0, 4.1 Hz, 1H), 5.71 - 5.61 (m, 1H), 5.04 - 4.69 (m, 1H), 3.93 - 3.69 (m, 4H), 2.97 - 2.75 (m, 1H), 2.48 - 2.23 (m, 4H), 1.57 - 1.25 (m, 3H) Example 450: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1 pyridin-6-yll -(7-methylpyrazolorE5-a1 pyrimidin-3 -yf) methanone.
Figure imgf000459_0002
The title compound was prepared in a manner analogous to Example 288, using 7- methylpyrazolo[l,5-a]pyrimidine-3-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C22H19F3N6O, 440.2; m/z found, 441.1 [M+H]+ ¾ NMR (500 MHz, DMSO-r/e) d 8.60 (d, J= 4.3 Hz, 1H), 8.46 (s, 1H), 7.54 (dd, J= 8.6, 6.6 Hz, 2H), 7.14 (dd, = 4.3, 1.0 Hz, 1H), 5.59 (s, 1H), 4.13 - 3.91 (m, 1H), 3.79 (s, 3H), 3.24 - 2.93 (m, 2H), 2.83 - 2.74 (m, 3H), 2.46 - 2.32 (m, 1H), 1.48 (d, J= 6.7 Hz, 3H).
Example 451 : i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll -(6-methylpyrazolor E 5 -al pyrimidin-3 -vQmethanone.
Figure imgf000460_0001
The title compound was prepared in a manner analogous to Example 288, using 6- methylpyrazolo[l,5-a]pyrimidine-3-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C22H19F3N6O, 440.2; m/z found, 441.2 [M+H]+. ¾ NMR (600 MHz, DMSO-r/e) 5 9.08 - 9.06 (m, 1H), 8.64 - 8.60 (m, 1H), 8.35 (s, 1H), 7.58 - 7.51 (m, 2H), 5.71 - 5.01 (m, 1.27H), 4.80 - 4.46 (m, 0.39H), 4.15 - 3.65 (m, 4H), 2.46 - 2.32 (m, 4H), 1.48 (d, J= 6.7 Hz, 3H). (Fractions of H’s that overlap with DMSO and water may not be reported) Example 452: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-imidazor 1.2-b1pyridazin-6-yl-methanone.
Figure imgf000460_0002
The title compound was prepared in a manner analogous to Example 288, using imidazo[l,2- b]pyridazine-6-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H17F3N6O, 426.1 ; m/z found, 427.2 [M+H]+. Ή NMR (500 MHz,
Chlorofomw/) 5 8.08 - 8.01 (m, 1H), 8.01 - 7.97 (m, 1H), 7.87 (dd, j= 3.9, 1.3 Hz, 1H), 7.39 - 7.33 (m, 1H), 7.02 - 6.93 (m, 2H), 5.86 (q, j= 6.7 Hz, 0.51H), 5.34 - 5.27 (m, 0.64H), 4.88 (dd, J= 13.1, 5.3 Hz, 0.43H), 4.12 (dd, J= 13.8, 5.0 Hz, 0.51H), 3.84 (s, 1.53H), 3.77 (s, 1.33H), 3.44 - 3.32 (m, 0.51H), 3.24 - 3.13 (m, 0.44H), 3.01 - 2.79 (m, 1H), 2.58 - 2.40 (m, 1H), 1.71 (d, J= 6.7 Hz, 1.35H), 1.65 (d, J= 6.8 Hz, 1.65H). Example 453: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-cl pyridin-6-yll -(2-methylimidazor 1.2-blpyridazin-6-yl)methanone.
Figure imgf000461_0001
The title compound was prepared in a manner analogous to Example 288, using 2- methylimidazo[l,2-b]pyridazine-6-carboxylic acid (Intermediate 96) instead of 2-fluoro-6-(2H- l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H19F3N6O, 440.2; m/z found, 441.1
Figure imgf000461_0002
The title compound was prepared in a manner analogous to Example 288, using imidazo[l,2- b]pyridazine-3-carboxybc acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H17F3N6O, 426.1 ; m/z found, 427.1 [M+H]+. Ή NMR (500 MHz,
Chlorofomw/) d 8.46 (dd, J= 4.4, 1.6 Hz, 1H), 8.03 (dd, J= 9.2, 1.7 Hz, 1H), 7.98 (s, 1H), 7.15 (dd, J= 9.2, 4.4 Hz, 1H), 7.02 - 6.94 (m, 2H), 6.14 - 4.60 (m, 1H), 4.24 - 3.68 (m, 4H), 3.34 (brs, 1H), 2.88 (brs, 1H), 2.46 (d, J= 15.0 Hz, 1H), 1.66 (d, J= 6.8 Hz, 3H).
Example 455: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-('2-methylimidazo[ l .2-blpyridazin-3-yl)methanone.
Figure imgf000462_0001
The title compound was prepared in a manner analogous to Example 288, using 2- methylimidazo[l,2-b]pyridazine-3-carboxylic acid hydrochloride instead of 2-fluoro-6-(2H- l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H19F3N6O, 440.2; m/z found, 441.1 [M+H]+. 1H NMR (500 MHz, DMSO-i/e) 5 8.54 (s, 1H), 8.10 (dd, J= 9.2, 1.6 Hz, 1H), 7.55 (d,
J= 8.0 Hz, 2H), 7.28 (dd, J= 9.2, 4.5 Hz, 1H), 5.72 - 5.63 (m, 0.66H), 4.88 - 4.57 (m, 0.34H), 3.82 (s, 3H), 3.49 - 3.35 (m, 1H), 2.72 (d, J= 25.5 Hz, 1H), 2.44 - 2.27 (m, 4H), 1.62 - 1.25 (m, 3H). (one proton under water peak). Example 456: (2.8-DimethylimidazorE2-b1 pyridazin-3-ylVr(7SV2.7-dimethyl-3-(3.4.5- trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-c1 pyridin-6-yllmethanone.
Figure imgf000462_0002
The title compound was prepared in a manner analogous to Example 288, using potassium 2,8- dimethylimidazo[l,2-b]pyridazine-3-carboxylate (Intermediate 97) instead of 2-fluoro-6-(2H- l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H21F3N6O, 454.2; m/z found, 455.1
Figure imgf000462_0003
8.40 (d, J= 4.7 Hz, 1H), 7.54 (t, J= 7.5 Hz, 2H), 7.20 - 7.04 (m, 1H), 5.66 (s, 1H), 4.85 - 4.45 (m, 1H), 3.81 (s, 3H), 3.42 (s, 1H), 2.73 (s, 1H), 2.60 - 2.55 (m, 3H), 2.43 - 2.24 (m, 4H), 1.42 (d, J= 72.4 Hz, 3H).
Example 457: (2.7-Dimethylimidazon.2-bl pyridazin-3-ylVr(7SV2.7-dimethyl-3-(3.4.5- trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-cl pyridin-6-yll methanone.
Figure imgf000463_0001
The title compound was prepared in a manner analogous to Example 288, using potassium 2,7- dimethylimidazo[l,2-b]pyridazine-3-carboxylate (Intermediate 98) instead of 2-fluoro-6-(2H- l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H21F3N6O, 454.2; m/z found, 455.1
Figure imgf000463_0002
8.43 (s, 1H), 7.88 (dd, J= 2.1, 1.2 Hz, 1H), 7.54 (t,
= 7.6 Hz, 2H), 5.65 (s, 1H), 4.85 - 4.53 (m, 1H), 3.81 (s, 3H), 3.54 - 3.40 (m, 1H), 3.23 - 3.01 (m, 1H), 2.86 - 2.65 (m, 1H), 2.40 - 2.38 (m, 3H), 2.37 - 2.31 (m, 3H), 1.50 (s, 3H).
Example 458: r(7SV2.7-Dimethyl-3-(3.4.5-trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-cl pyridin-6-yll-('2-methylimidazon .2-alpyrimidin-3-yl)methanone.
Figure imgf000463_0003
The title compound was prepared in a manner analogous to Example 288, using 2- methylimidazo[l,2-a]pyrimidine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C22H19F3N6O, 440.2; m/z found, 441.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 8.76 (dd, J= 6.9, 2.0 Hz, 1H), 8.60 (dd, J= 4.2, 2.0 Hz, 1H), 7.54 (dd, = 8.7, 6.6 Hz, 2H), 7.13 (dd, = 6.8, 4.2 Hz, 1H), 5.58 (s, 1H), 4.18 - 3.98 (m, 1H), 3.82 (s, 3H), 3.41 (t, J= 12.7 Hz, 1H), 2.84 - 2.68 (m, 1H), 2.47 - 2.44 (m, 1H), 2.42 (s, 3H), 1.50 (d, J= 6.7 Hz, 3H).
Example 459: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluoroDhenyl)-5.7-dihvdro-4H-Dyrazolo[3.4- clpyridin-6-yll-('2.5.8-trimethylimidazo[ l .2-a1pyrazin-3-yl)methanone.
Figure imgf000464_0001
The title compound was prepared in a manner analogous to Example 288, using potassium 2,5,8- trimethylimidazo[l,2-a]pyrazine-3-carboxylate (Intermediate 99) instead of 2-fluoro-6-(2H- l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H23F3N6O, 468.1 ; m/z found, 469.2 [M+H]+. (400 MHz, DMSO-r/e) d 7.65 - 7.46 (m, 3H), 5.90 - 5.53 (m, 1H), 3.86 - 3.69 (m, 3H), 3.61 - 3.44 (m, 1H), 2.80 - 2.60 (m, 4H), 2.44 (m, 2H), 2.41 - 2.35 (m, 4H), 2.34 - 2.21 (m, 1H), 2.20 - 2.06 (m, 1H), 1.58 - 1.26 (m, 3H).
Example 460: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo cl
Figure imgf000464_0002
pyridin-6-yll -(6-methylimidazor 1.5-alpyrimidin-8-yl )methanone.
Figure imgf000464_0003
The title compound was prepared in a manner analogous to Example 288, using lithium 6- methylimidazo[l,5-a]pyrimidine-8-carboxylate instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C22H19F3N6O, 440.2; m/z found, 441.1 [M+H]+. XH NMR (500 MHz, DMSO-r/e) d 8.63 (dd, J= 7.2, 1.7 Hz, 1H), 8.37 - 8.28 (m, 1H), 7.60 - 7.48 (m, 2H), 6.88 (dd, J= 7.2, 3.7 Hz, 1H), 5.65 - 5.40 (m, 1H), 4.71 - 4.28 (m, 1H), 3.84 - 3.65 (m,
3H), 3.27 - 2.71 (m, 2H), 2.62 (s, 3H), 2.44 - 2.25 (m, 1H), 1.48 (s, 3H).
Example 461 : it7S)-2.7-Dimethyl-3-t3.4.5-trifluoroDhenyl)-5.7-dihvdro-4H-Dyrazolo[3.4-c1 pyridin-6-yll -(3-methylimidazor 1.5-a1pyrimidin-8-yl jmethanone.
Figure imgf000465_0001
The title compound was prepared in a manner analogous to Example 288, using lithium 3- methylimidazo[l,5-a]pyrimidine-8-carboxylate instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C22H19F3N6O, 440.2; m/z found, 441.1 [M+H]+. XH NMR (500 MHz, DMSO-r/e) d 8.65 - 8.55 (m, 1H), 8.37 - 8.20 (m, 2H), 7.61 - 7.41 (m, 2H), 5.68 - 5.39 (m, 1H), 4.74 - 4.29 (m, 1H), 3.87 - 3.63 (m, 3H), 3.25 - 2.74 (m, 2H), 2.44 - 2.32
(m, 1H), 2.30 - 2.22 (m, 3H), 1.49 (s, 3H).
Example 462: it7S)-2.7-Dimethyl-3-t3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1 pyridin-6-yll -(3-methylimidazorE5-a1 pyrazin- 1 -yl) methanone.
Figure imgf000465_0002
The title compound was prepared in a manner analogous to Example 288, using sodium 3- methylimidazo[l,5-a]pyrazine-l-carboxylate (Intermediate 100) instead of 2-fluoro-6-(2H- 1,2,3- triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H19F3N6O, 440.2; m/z found, 441.1
Figure imgf000466_0001
9.41 (d, J= 1.6 Hz, 1H), 8.29 (dd, J= 5.0, 1.6 Hz, 1H), 7.75 (d, J= 4.9 Hz, 1H), 7.64 - 7.47 (m, 2H), 6.74 - 6.48 (m, 0.60H), 5.78 - 5.45 (m, 0.40H), 4.87 - 4.46 (m, 1H), 3.80 (s, 3H), 3.21 - 2.76 (m, 2H), 2.69 (s, 3H), 2.48 - 2.37 (m, 1H), 1.61 - 1.42 (m, 3H).
Example 463: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1 pyridin-6-yl1-[3-('trifluoromethyl) imidazon.5-a1 pyrazin-l-yllmethanone.
Figure imgf000466_0002
The title compound was prepared in a manner analogous to Example 288, using 3-
(trifluoromethyl)imidazo[l,5-a]pyrazine-l-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3- triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H16F3N6O, 494.1; m/z found, 495.1
4
Figure imgf000466_0003
The title compound was prepared in a manner analogous to Example 288, using potassium 5- methyl-7H-pyrrolo[2,3-d]pyrimidine-4-carboxylate (Intermediate 101) instead of 2-fluoro-6- (2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H19F3N6O, 440.2; m/z found, 441.1 [M+H]+. ¾ NMR (400 MHz, Methanol-d4) d 8.77 (d, J= 4.8 Hz, 1H), 7.42 - 7.23 (m, 3H), 5.93 - 5.83 (m, 1H), 5.04 - 4.87 (m, 1H), 3.86 - 3.73 (m, 3H), 3.56 - 3.36 (m, 2H), 2.94 - 2.62 (m, 2H), 2.31 - 2.07 (m, 3H), 1.70 - 1.46 (m, 3H).
Example 465: r(7SV3-(3-Fluoro-5-methyl-phenylV2.7-dimethyl-5.7-dihvdro-4H-pyrazolor3.4-cl pyridin-6-yll -('7-methylpyrrolo[2.3-d1 pyrimidin-4-yl) methanone.
Figure imgf000467_0001
The title compound was prepared in a manner analogous to Example 288, using (S)-3-(3-fluoro- 5-methylphenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c] pyridine (Intermediate 42) instead of (S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c]pyridine and 7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-carboxylic acid instead of 2-fluoro-6- (2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C23H23FN6O, 418.2; m/z found, 419.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) 5 8.86 (d, = 5.4 Hz, 1H), 7.70 (dd, J= 4.8, 3.5 Hz, 1H), 7.21 - 7.06 (m, 3H), 6.54 (dd, J= 17.2, 3.5 Hz, 1H), 5.80 - 5.59 (m, 1H), 4.88 - 4.65 (m, 1H), 3.90 - 3.84 (m, 3H), 3.83 - 3.70 (m, 3H), 3.27 - 3.08 (m, 1H), 2.86 - 2.60 (m, 1H), 2.41 - 2.24 (m, 4H), 1.57 - 1.35 (m, 3H).
Example 466: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('7-methylpyrrolo[2.3-d1pyrimidin-4-yl)methanone.
Figure imgf000467_0002
The title compound was prepared in a manner analogous to Example 288, using 7-methyl-7H- pyrrolo[2,3-d]pyrimidine-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H19F3N6O, 440.2; m/z found, 441.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 8.93 - 8.78 (m, 1H), 7.74 - 7.65 (m, 1H), 7.64 - 7.42 (m, 2H), 6.54 (dd, J = 18.7, 3.5 Hz, 1H), 5.75 - 5.61 (m, 1H), 4.90 - 4.62 (m, 1H), 3.86 (s, 3H), 3.84 - 3.69 (m, 3H),
3.26 - 3.08 (m, 1H), 2.85 - 2.65 (m, 1H), 2.39 - 2.22 (m, 1H), 1.55 - 1.33 (m, 3H).
Example 467: (5.7-Dimethylpyrrolor2.3-d1 pyrimidin-4-ylVr(7SV2.7-dimethyl-3-(3.4.5- trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-cl pyridin-6-yll methanone.
Figure imgf000468_0001
The title compound was prepared in a manner analogous to Example 288, using potassium 5,7- dimethyl-7H-pyrrolo[2,3-d]pyrimidine-4-carboxylate (Intermediate 102) instead of 2-fluoro-6- (2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H21F3N6O, 454.2; m/z found, 455.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 8.80 (d, J= 5.2 Hz, 1H), 7.59 - 7.49 (m, 2H), 7.48 - 7.41 (m, 1H), 5.73 - 5.61 (m, 1H), 4.82 - 4.49 (m, 1H), 3.83 - 3.73 (m, 6H), 3.28 - 3.09
(m, 1H), 2.81 - 2.52 (m, 2H), 2.19 - 2.06 (m, 3H), 1.55 - 1.32 (m, 3H).
Example 468: i('7S)-2.7-Diniethyl-3-[3-('trifluoroniethyl) phenyll-5.7-dihvdro-4H-pyrazolor3.4- cl pyridin-6-yll -(6-quinolyllmethanone.
Figure imgf000468_0002
The title compound was prepared in a manner analogous to Example 288, using (S)-2,7- dimethyl-3-(3-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 50) instead of (S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H- pyrazolo[3,4-c]pyridine and quinoline-6-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol- 2-yl) benzoic acid. MS (ESI): mass calcd. for C25H21F3N4O, 450.2; m/z found, 451.2 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 8.98 (dd, = 4.2, 1.7 Hz, 1H), 8.48 (dd, = 8.2, 1.8 Hz, 1H), 8.10 (d, = 8.5 Hz, 2H), 7.90 - 7.73 (m, 5H), 7.67 - 7.53 (m, 1H), 5.78 - 5.50 (m, 1H), 4.90 -
4.38 (m, 1H), 3.98 - 3.58 (m, 4H), 3.01 - 2.75 (m, 1H), 2.46 - 2.21 (m, 1H), 1.58 - 1.43 (m, 3H).
Example 469: (6.7-Dimethylpyrrolor2.3-dl pyrimidin-4-ylVr(7SV2.7-dimethyl-3-(3.4.5- trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-c1 pyridin-6-vHmethanone.
Figure imgf000469_0001
The title compound was prepared in a manner analogous to Example 288, using 6,7-dimethyl- 7H-pyrrolo[2,3-d]pyrimidine-4-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C23H21F3N6O, 454.2; m/z found, 455.1 [M+H]+. XH NMR (500 MHz, DMSO-r/e) d 8.76 (d, J= 5.3 Hz, 1H), 7.61 - 7.45 (m, 2H), 6.38 - 6.23 (m, 1H), 5.73 - 5.56 (m, 1H), 5.03 - 4.40 (m, 1H), 3.86 - 3.73 (m, 6H), 3.70 - 3.60 (m, 1H), 3.28 - 3.06 (m, 1H), 2.84 - 2.63 (m, 1H), 2.49 - 2.46 (m, 3H), 1.63 - 1.32 (m, 3H).
Example 470: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('7H-purin-6-yl)methanone.
Figure imgf000469_0002
The title compound was prepared in a manner analogous to Example 288, using 7H-purine-6- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C20H16F3N7O, 427.2; m/z found, 428.1 [M+H]+.
Figure imgf000470_0001
NMR (500 MHz, DMSO-r/e) d 13.69 (s, 1H), 8.97 - 8.93 (m, 1H), 8.69 - 8.61 (m, 1H), 7.60 - 7.47 (m, 2H), 5.68 (q, J = 6.1 Hz, 0.67H), 4.91 - 4.73 (m, 0.67H), 3.86 - 3.57 (m, 3.80H), 3.15 (td, J= 12.7,
4.0 Hz, 0.44H), 2.84 - 2.69 (m, 1H), 2.59 - 2.53 (m, 0.38H), 2.35 - 2.25 (m, 0.64H), 1.54 (d, J = 6.8 Hz, 2H), 1.40 (d, J= 6.7 Hz, 1H). (Fractions of Hs that overlap with DMSO and water are not reported). Example 471 : i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1 pyridin-6-yll -( 1 -methylpyrazolo [3 4-dl pyrimidin-4-yl jmethanone.
Figure imgf000470_0002
The title compound was prepared in a manner analogous to Example 288, using 1 -methyl- 1H- pyrazolo[3,4-d]pyrimidine-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C21H18F3N7O, 441.2; m/z found, 442.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 9.11 (d, J= 6.5 Hz, 1H), 8.36 (d, J= 22.2 Hz, 1H), 7.62 - 7.45 (m, 2H), 5.73 - 5.57 (m, 1H), 5.09 - 4.60 (m, 1H), 4.17 - 4.01 (m, 3H), 3.87 - 3.69 (m, 4H), 2.94 - 2.66 (m, 1H), 2.39 - 2.24 (m, 1H), 1.58 - 1.42 (m, 3H). Example 472: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('5-methyl-n 2.41triazolon .5-a1pyriniidin-7-yl)niethanone.
Figure imgf000470_0003
The title compound was prepared in a manner analogous to Example 288, using 5-methyl- [l,2,4]triazolo[l,5-a]pyrimidine-7-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C21H18F3N7O, 441.2; m/z found, 442.2 [M+H]+.
Figure imgf000471_0001
NMR (500 MHz, DMSO-r/e) d 8.76 (s, 1H), 7.59 - 7.51 (m, 2H), 7.49 - 7.42 (m, 1H), 5.60 (q, J= 6.7 Hz, 0.65H), 5.02 (q, J= 6.7 Hz, 0.39H), 4.67 (dd, J= 13.0, 5.3
Hz, 0.39H), 3.90 - 3.71 (m, 3.78H), 3.13 (td, J= 12.6, 3.9 Hz, 0.43H), 2.87 - 2.72 (m, 4H), 2.38 - 2.30 (m, 0.71H), 1.53 - 1.48 (m, 3H). (Fractions of Hs that overlap with DMSO and water are not reported). Example 473: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1 pyridin-6-yll -(7-methylciuinoxalin-6-yl) methanone.
Figure imgf000471_0002
The title compound was prepared in a manner analogous to Example 288, using 7- methylquinoxaline-6-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H20F3N5O, 451.2; m/z found, 452.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 9.01 - 8.91 (m, 2H), 8.01 (d, J= 34.5 Hz, 2H), 7.64 - 7.50 (m, 2H), 5.78 - 5.66 (m, 1H), 4.94 - 4.29 (m, 1H), 3.87 - 3.72 (m, 3H), 3.60 - 3.34 (m, 1H), 3.22 - 2.73 (m, 1H), 2.70 - 2.54 (m, 1H), 2.49 - 2.17 (m, 3H), 1.60 - 1.25 (m, 3H). Example 474: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1 pyridin-6-yll -(2-methylciuinoxalin-5-yl)methanone.
Figure imgf000471_0003
The title compound was prepared in a manner analogous to Example 288, using 2- methylquinoxaline-5-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C24H20F3N5O, 451.2; m/z found, 452.1 [M+H]+. (500 MHz, Chloroform-r/) d 8.79 - 8.63 (m, 1H), 8.13 - 8.07 (m, 1H), 7.79 - 7.58 (m, 2H), 7.03 - 6.87 (m, 2H), 6.12 (q, J= 6.8 Hz, 0.24H), 6.05 (q, J= 6.7 Hz, 0.30H), 5.18 - 5.08 (m, 0.44H), 4.73 (q, J= 6.7 Hz, 0.20H), 4.54 (q, J= 6.8 Hz, 0.23H), 3.85 (d, J= 5.9 Hz, 1.73H), 3.74 (d, J= 5.0 Hz, 1.29H), 3.48 - 3.32 (m, 0.57H), 3.29 - 3.17 (m, 0.77H), 3.15 - 3.01 (m, 0.44H), 2.92 - 2.81 (m, 0.21H), 2.80 - 2.66 (m, 2.58H), 2.59 - 2.48 (m, 0.74H), 2.39 (s, 0.67H), 2.25 - 2.19 (m, 0.30H), 2.15 - 2.08 (m, 0.25H), 1.75 (d, J= 6.7 Hz, 0.93H), 1.67 (d, J = 6.8 Hz, 0.76H), 1.39 (d, J= 6.8 Hz, 0.66H), 1.34 (d, J= 6.8 Hz, 0.58H).
Example 475: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-(3-methylquinoxalin-5-yl)methanone.
Figure imgf000472_0001
The title compound was prepared in a manner analogous to Example 288, using 3- methylquinoxaline-5-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C24H20F3N5O, 451.2; m/z found, 452.2 [M+H]+. (500 MHz, DMSO-r/e) d 8.95 - 8.81 (m, 1H), 8.15 - 8.08 (m, 1H), 7.87 - 7.70 (m, 2H), 7.59 - 7.41 (m, 2H), 5.79 - 5.72 (m, 0.81H), 4.89 - 4.81 (m, 0.27H), 4.49 - 4.42 (m, 0.16H), 4.32 - 4.26 (m, 0.14H), 3.85 - 3.68 (m, 3H), 3.22 - 3.05 (m, 1.55H), 2.93 - 2.77 (m, 0.28H), 2.22 - 2.14 (m, 0.75H), 1.61 - 1.50 (m, 2H), 1.32 - 1.20 (m, 1H). (Fractions of Hs that overlap with DMSO and water are not reported).
Example 476: (2.3-Dimethylauinoxabn-6-ylVr(7SV2.7-dimethyl-3-(3.4.5-trifluorophenylV5.7- dihvdro-4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000473_0001
The title compound was prepared in a manner analogous to Example 288, using 2,3- dimethylquinoxaline-6-carboxylic acid (Intermediate 103) instead of 2-fluoro-6-(2H-l,2,3- triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C25H22F3N5O, 465.2; m/z found, 466.0
Figure imgf000473_0002
8.04 (d, J= 8.5 Hz, 1H), 7.97 (s, 1H), 7.74 (d, J = 8.4 Hz, 1H), 7.63 - 7.49 (m, 2H), 5.73 - 5.47 (m, 1H), 4.95 - 4.15 (m, 1H), 3.96 - 3.50 (m, 4H), 3.09 - 2.78 (m, 1H), 2.78 - 2.59 (m, 6H), 2.39 - 2.20 (m, 1H), 1.50 (s, 3H).
Example 477: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000473_0003
c1pyridin-6-yl1-guinoxalin-2-yl-methanone.
Figure imgf000473_0004
The title compound was prepared in a manner analogous to Example 288, using quinoxaline-2- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F3N5O, 437.1 ; m/z found, 438.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 9.15 - 9.13 (m, 1H), 8.20 - 8.13 (m, 2H), 8.00 - 7.93 (m, 2H), 7.60 - 7.52 (m, 2H), 5.66 (q, J= 6.8 Hz,
0.71H), 5.18 (q, J= 6.7 Hz, 0.35H), 4.77 - 4.71 (m, 0.35H), 4.02 - 3.96 (m, 0.76H), 3.83 (s, 2H), 3.75 (s, 1H), 3.01 - 2.92 (m, 0.72H), 2.87 - 2.78 (m, 0.36H), 2.41 - 2.35 (m, 0.75H), 1.60 (d, J = 6.7 Hz, 1H), 1.55 (d, J= 6.8 Hz, 2H). (Fractions of Hs that overlap with DMSO and water are not reported).
Example 478: Cinnolin-3-yl-it7S)-2.7-dimethyl-3-t3.4.5-trifluorophenyl)-5.7-dihvdro-4H- Pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000474_0001
The title compound was prepared in a manner analogous to Example 288, using cinnoline-3- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F3N5O, 437.1; m/z found, 438.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 8.59 - 8.51 (m, 2H), 8.21 - 8.16 (m, 1H), 8.10 - 8.03 (m, 1H), 8.00 - 7.94 (m, 1H), 7.60 - 7.51 (m,
2H), 5.72 (q, J= 6.8 Hz, 0.64H), 4.97 (q, J= 6.6 Hz, 0.32H), 4.82 - 4.75 (m, 0.32H), 3.87 - 3.70 (m, 3.68H), 2.97 - 2.79 (m, 1H), 2.40 - 2.30 (m, 0.71H), 1.60 - 1.51 (m, 3H). (Fractions of H’s that overlap with DMSO and water may not be reported) Example 479: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-quinazolin-6-yl-methanone.
Figure imgf000474_0002
The title compound was prepared in a manner analogous to Example 288, using quinazoline-6- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F3N5O, 437.1; m/z found, 438.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 9.71 (s, 1H), 9.37 (s, 1H), 8.31 - 8.24 (m, 1H), 8.14 - 8.01 (m, 2H), 7.60 - 7.50 (m, 2H), 5.70 - 5.54 (m, 0.65H), 4.82 - 4.59 (s, 0.39H), 3.91 - 3.59 (m, 3.80H), 2.96 - 2.77 (s, 1H), 1.59 - 1.41 (m, 3H). (Fractions of Hs that overlap with DMSO and water are not reported). Example 480: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-auinazolin-7-yl-methanone.
Figure imgf000475_0001
The title compound was prepared in a manner analogous to Example 288, using quinazoline-7- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F3N5O, 437.1; m/z found, 438.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 9.72 - 9.78 (m, 1H), 9.39 - 9.36 (m, 1H), 8.31 - 8.27 (m, 1H), 8.06 - 7.96 (m, 1H), 7.83 - 7.71 (m,
1H), 7.60 - 7.52 (m, 2H), 5.69 - 5.59 (m, 0.66H), 4.76 - 4.60 (m, 0.44H), 3.89 - 3.66 (m, 3H), 3.64 - 3.52 (m, 0.72H), 2.94 - 2.77 (m, 1H), 2.35 - 2.25 (m, 0.67H), 1.58 - 1.39 (m, 3H).
(Fractions of Hs that overlap with DMSO and water are not reported). Example 481 : i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-t8-fluoroauinazolin-4-yl)methanone.
Figure imgf000475_0002
The title compound was prepared in a manner analogous to Example 288, using 8- fluoroquinazoline-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H17F4N5O, 455.1 ; m/z found, 456.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 9.44 - 9.40 (m, 1H), 8.01 - 7.91 (m, 1H), 7.85 - 7.72 (m, 2H), 7.62 - 7.49 (m, 2H), 5.74 (q, J= 6.7 Hz, 0.76H), 4.83 (dd, J= 13.0, 5.2 Hz, 0.36H), 4.60 (q, J= 6.6 Hz, 0.37H), 3.83 (s, 2H), 3.72 (s, 1H), 3.47 - 3.40 (m, 0.80H), 2.97 - 2.88 (m, 0.36H), 2.67 - 2.54 (m, 1.19H), 2.30 - 2.23 (m, 0.72H), 1.60 (d, J= 6.8 Hz, 2H), 1.38 (d, J= 6.7 Hz, 1H). (Fractions of Hs that overlap with DMSO and water are not reported). Example 482: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000476_0001
c1pyridin-6-yl1-guinazolin-4-yl-methanone.
Figure imgf000476_0002
The title compound was prepared in a manner analogous to Example 288, using lithium quinazoline-4-carboxylate instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F3N5O, 437.2; m/z found, 438.1 [M+H]+.
Figure imgf000476_0003
NMR (500 MHz, DMSO- ek) d 9.36 (d, J= 5.3 Hz, 1H), 8.20 - 8.04 (m, 2H), 7.99 - 7.74 (m, 2H), 7.64 - 7.40 (m, 2H), 5.83 - 5.63 (m, 1H), 4.93 - 4.39 (m, 1H), 3.87 - 3.66 (m, 3H), 3.45 - 3.33 (m, 1H), 3.25 - 2.87 (m, 1H), 2.71 - 2.55 (m, 1H), 1.65 - 1.33 (m, 3H).
Example 483: (2-Deuteri oquinoxalin-6-yl)-r(7S)-2.7-dimethyl-3- trifluorophenyl)-5.7-
Figure imgf000476_0004
dihvdro-4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000476_0005
The title compound was prepared in a manner analogous to Example 288, using lithium(I) quinoxaline-6-carboxylate-2-d (Intermediate 104) instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C23H17F3N5O, 438.2; m/z found, 439.0 [M+H]+. XH NMR (500 MHz, DMSO-r/e) d 9.09 - 8.98 (m, 1H), 8.25 - 8.10 (m, 2H), 7.98 - 7.84 (m, 1H), 7.57 (dd, J= 8.7, 6.7 Hz, 2H), 5.73 - 5.53 (m, 1H), 4.83 - 4.58 (m, 1H), 3.91 - 3.58 (m, 4H), 3.02 - 2.78 (m, 1H), 2.45 - 2.21 (m, 1H), 1.52 (s, 3H).
Example 484: i(7S)-2.7-Dimethyl-3-(3A5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000476_0006
c1pyridin-6-yl1-pyridor4.3-d1pyrimidin-5-yl-methanone.
Figure imgf000477_0001
The title compound was prepared in a manner analogous to Example 288, using pyrido[4,3- d]pyrimidine-5-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H17F3N6O, 438.1; m/z found, 439.1 [M+H]+. 1H NMR (400 MHz, DMSO-r/e) d 9.64 - 9.54 (m, 2H), 9.01 - 8.96 (m, 1H), 8.07 - 8.03 (m, 1H), 7.62 - 7.49 (m, 2H), 5.75 (q, J= 6.7 Hz, 0.67H), 4.87 - 4.80 (m, 0.34H), 4.72 (q, J= 6.6 Hz, 0.36H), 3.83 (s, 2H),
3.73 (s, 1H), 3.60 - 3.52 (m, 0.66H), 3.24 - 3.15 (m, 0.47H), 3.06 - 2.93 (m, 0.49H), 2.81 - 2.69 (m, 0.81H), 2.58 - 2.51 (m, 0.36H), 2.33 - 2.26 (m, 0.72H), 1.61 (d, J= 6.8 Hz, 2H), 1.44 (d, = 6.7 Hz, 1H). (Fractions of Hs that overlap with DMSO and water are not reported).
Example 485: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1 -( E 5 -naphthyridin-4-yl jmethanone.
Figure imgf000477_0002
The title compound was prepared in a manner analogous to Example 288, using 1,5- naphthyridine-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F3N5O, 437.2; m/z found, 438.1 [M+H]+. Ή NMR (400 MHz, DMSO-r/e) d 9.11 - 9.02 (m, 2H), 8.57 - 8.46 (m, 1H), 7.94 - 7.73 (m, 2H), 7.61 - 7.45 (m, 3H), 5.81 - 5.54 (m, 1H), 3.86 - 3.78 (m, 3H), 3.78 - 3.67 (m, 1H), 2.73 - 2.57 (m, 1H), 2.26 - 2.09 (m, 1H), 1.56 (dd, J= 15.5, 6.8 Hz, 3H) Example 486: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000478_0001
clpyridin-6-nII-P .6-naphthyridin-5-yl)methanone.
Figure imgf000478_0002
The title compound was prepared in a manner analogous to Example 288, using 1,6- naphthyridine-5-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F3N5O, 437.1; m/z found, 438.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) 5 9.22 - 9.17 (m, 1H), 8.79 - 8.75 (m, 1H), 8.36 - 8.31 (m, 1H), 8.06 - 8.00 (m, 1H), 7.75 (dd, J= 8.5, 4.2 Hz, 0.68H), 7.71 (dd, J= 8.5, 4.2 Hz, 0.34H), 7.62 - 7.48 (m, 2H), 5.77 (q, J= 6.7 Hz, 0.69H), 4.86 (dd, J= 12.9, 5.2 Hz, 0.34H), 4.54 (q, J= 6.7 Hz, 0.35H), 3.83 (s, 2H), 3.72 (s, 1H), 3.17 (td, J= 12.7, 3.9 Hz, 0.36H), 2.96 - 2.88 (m, 0.34H), 2.69 - 2.60 (m, 0.73H),
2.30 - 2.23 (m, 0.68H), 1.60 (d, J= 6.8 Hz, 2H), 1.36 (d, J= 6.8 Hz, 1H). (Fractions of Hs that overlap with DMSO and water are not reported).
Example 487: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('2-niethyl- l .6-naphthyridin-5-yl)niethanone.
Figure imgf000478_0003
The title compound was prepared in a manner analogous to Example 288, using 2-methyl-l,6- naphthyridine-5-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C24H20F3N5O, 451.2; m/z found, 452.1
[M+H]+. (500 MHz, DMSO-r/e) 5 8.73 - 8.68 (m, 1H), 8.22 - 8.17 (m, 1H), 7.93 - 7.89
(m, 1H), 7.64 - 7.48 (m, 3H), 5.76 (q, J= 6.7 Hz, 0.70H), 4.84 (dd, J= 12.9, 5.2 Hz, 0.37H), 4.51 (q, J= 6.7 Hz, 0.38H), 3.83 (s, 2H), 3.72 (s, 1H), 3.20 - 3.12 (m, 0.38H), 2.95 - 2.87 (m, 0.36H), 2.76 - 2.70 (m, 3H), 2.29 - 2.22 (m, 0.66H), 1.58 (d, J= 6.7 Hz, 2H), 1.34 (d, J= 6.7 Hz, 1H). (Fractions of Hs that overlap with DMSO or water are not reported). Example 488: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-nII-P .6-naphthyridin-3-yl)methanone.
Figure imgf000479_0001
The title compound was prepared in a manner analogous to Example 288, using 1,6- naphthyridine-3 -carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F3N5O, 437.2; m/z found, 438.1 [M+H]+. Ή NMR (400 MHz, DMSO-i/6) d 9.51 (d, J= 1.0 Hz, 1H), 9.23 - 9.11 (m, 1H), 8.82 (d, = 5.9 Hz, 1H), 8.72 (dd, J = 2.2, 0.9 Hz, 1H), 7.99 (dt, J= 5.9, 1.0 Hz, 1H), 7.56 (dd, J= 8.7, 6.6 Hz, 2H), 5.74 - 4.56 (m, 2H), 3.91 - 3.62 (m, 4H), 2.94 (s, 1H), 2.38 (d, J= 15.7 Hz, 1H), 1.53 (d, J= 6.7 Hz, 3H). Example 489: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- cl pyridin-6- yll -(1.7 -naphthyridin- 5 -vDmethanone.
Figure imgf000479_0002
The title compound was prepared in a manner analogous to Example 288, using 1,7- naphthyridine-5-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F3N5O, 437.1 ; m/z found, 438.1 [M+H]+. ¾ NMR (500 MHz,
DMSO-r/e) 5 9.52 - 9.47 (m, 1H), 9.18 - 9.10 (m, 1H), 8.79 - 8.57 (m, 1H), 8.26 - 8.03 (m, 1H), 7.93 - 8.75 (d, J= 40.3 Hz, 1H), 7.63 - 7.44 (m, 2H), 5.82 - 5.73 (m, 0.72H), 4.89 - 4.79 (m, 0.23H), 4.54 - 4.36 (m, 0.12H), 3.84 (s, 2.32H), 3.71 (s, 0.71H), 3.06 - 2.81 (m, 0.74H), 2.31 - 2.21 (m, 0.78H), 1.67 - 1.32 (m, 3H). (Fractions of Hs that overlap with DMSO and water are not reported).
Example 490: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- cl pyridin-6- yll -( E 8 -naphthyridin- 3 -vDmethanone.
Figure imgf000480_0001
The title compound was prepared in a manner analogous to Example 288, using 1,8- naphthyridine-3 -carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F3N5O, 437.1; m/z found, 438.1 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) d 9.17 (dd, = 4.2, 2.0 Hz, 1H), 9.13 (s, 1H), 8.62 (d, = 2.4 Hz, 1H), 8.60 - 8.55 (m, 1H), 7.73 (dd, J= 8.1, 4.2 Hz, 1H), 7.60 - 7.52 (m, 2H), 5.70 - 5.58 (m, 0.70H), 4.88 - 4.61 (m, 0.37H), 3.92 - 3.62 (m, 3.88H), 3.02 - 2.76 (m, 1H), 1.58 - 1.44 (m, 3H). (Fractions of Hs that overlap with DMSO and water are not reported).
Example 491 : i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-nII-P .8-naphthyridin-4-yl)methanone.
Figure imgf000480_0002
The title compound was prepared in a manner analogous to Example 288, using 1,8- naphthyridine-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H18F3N5O, 437.1; m/z found, 438.1 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) d 9.22 - 9.08 (m, 2H), 8.41 - 8.02 (m, 1H), 7.81 - 7.40 (m, 4H), 5.83 - 5.70 (s, 0.72H), 4.90 - 4.77 (m, 0.24H), 4.70 - 4.59 (m, 0.04H), 4.41 - 4.26 (m, 0.14H), 3.87 - 3.64 (m, 3H), 1.68 - 1.34 (m, 3H). (Fractions of Hs that overlap with DMSO and water are not reported).
Example 492: r(7SV2.7-Dimethyl-3-(o-tolyr)-5.7-dihvdro-4H-pyrazolor3.4-clpyridin-6-ylT(6- quinolyl jmethanone.
Figure imgf000481_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and o-tolylboronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C25H24N4O, 396.2; m/z found, 397.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.90 (d, J= 3.4 Hz, 1H), 8.34 (d, J= 8.2 Hz, 1H), 8.06 (d, J= 8.2 Hz, 1H), 7.99 (s, 1H), 7.71 (d, J =
8.7 Hz, 1H), 7.51 (dd, = 8.2, 4.0 Hz, 1H), 7.37 - 7.29 (m, 2H), 7.28 - 7.14 (m, 2H), 5.72 - 5.51 (m, 1H), 3.86 - 3.64 (m, 1H), 3.62 - 3.44 (m, 3H), 3.37 - 3.16 (m, 1H), 2.70 - 2.55 (m, 1H),
2.35 - 2.12 (m, 4H), 1.56 (d, J= 5.8 Hz, 3H). Example 493: l('7S)-2.7-Dimethyl-3-12-('trifluoromethyl)phenyl1-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('6-quinolyl)methanone.
Figure imgf000481_0002
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and (2-(trifluoromethyl)phenyl)boronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C25H21F3N4O, 450.2; m/z found, 451.2 [M+H]+.
Figure imgf000482_0001
NMR (500 MHz, DMSO-r/e) d 8.92 - 8.88 (m, 1H), 8.37 - 8.31 (m, 1H), 8.09 - 8.02 (m, 2H), 7.97 (d, J= 9.2 Hz, 1H), 7.85 (t, J= 9.3 Hz, 1H), 7.79 - 7.73 (m, 1H), 7.71 - 7.67 (m, 1H), 7.53 - 7.49 (m, 1H), 7.48 - 7.41 (m, 1H), 5.68 - 3.71 (m, 1H), 3.61 - 3.46 (m, 3H), 3.45 - 3.27 (m, 1H), 3.27 - 3.12 (m, 1H), 2.98 - 2.93 (m, 1H), 2.30 - 2.10 (m, 1H), 1.56 (d, = 6.9 Hz, 3H).
Example 494: l('7S)-2.7-Dimethyl-3-14-('trifluoromethyl)phenyl1-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-(6-quinolyl)methanone.
Figure imgf000482_0002
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and (4-(trifluoromethyl)phenyl)boronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C25H21F3N4O, 450.2; m/z found, 451.0 [M+H]+.
Figure imgf000482_0003
NMR (500 MHz, DMSO-r/e) d 8.94 - 8.89 (m, 1H), 8.37 (d, J= 8.2 Hz, 1H), 8.08 (d, J= 8.6 Hz, 1H), 8.02 (s, 1H), 7.79 (d, J= 8.1 Hz, 1H), 7.74 (d, J= 8.6 Hz, 1H), 7.66 (d, J= 8.0 Hz, 2H), 7.56 - 7.50 (m, 1H), 5.80 - 4.49 (m, 1H), 4.15 - 3.62 (m, 4H), 3.47 - 3.11 (m, 1H), 2.97 - 2.85 (m, 1H), 2.48 - 2.32 (m, 1H), 1.59 - 1.53 (m, 3H). (Fractions of Hs that overlap with DMSO or water are not reported). Example 495: i('7S)-3-('3-Methoxyphenyl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolo clpyridin-
Figure imgf000483_0001
6-yl1-(6-guinolvnmethanone.
Figure imgf000483_0002
The title compound was prepared in a manner analogous to Example 288, using (S)-3-(3- methoxyphenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 48) instead of (S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c]pyridine and quinoline-6-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C25H24N4O2, 412.2; m/z found, 413.1 ¾ NMR (400 MHz, DMSO-r/e) d 8.98 (dd, J= 4.2, 1.7 Hz, 1H), 8.57 - 8.40 (m, 1H), 8.14 - 8.03 (m, 2H), 7.80 (d, J = 8.7 Hz, 1H), 7.61 (dd, J= 8.3, 4.2 Hz, 1H), 7.43 (dd, J= 8.9, 7.5 Hz, 1H), 7.11 - 6.89 (m, 3H),
5.63 (s, 1H), 4.93 - 4.36 (m, 1H), 3.87 - 3.75 (m, 6H), 3.62 (s, 1H), 2.98 - 2.73 (m, 1H), 2.47 - 2.22 (m, 1H), 1.57 - 1.43 (m, 3H).
Example 496: it7S)-3-t2-Methoxyphenyl)-2.7-diniethyl-5.7-dihvdro-4H-pyrazolo[3.4-c1pyridin- 6-yll-(6-quinolyl)methanone.
Figure imgf000483_0003
The title compound was prepared in a manner analogous to Example 288, using (S)-3-(2- methoxyphenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 47) instead of (S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c]pyridine and quinobne-6-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C25H24N4O2, 412.2; m/z found, 413.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 8.97 (dd, = 4.3, 1.7 Hz, 1H), 8.55 - 8.36 (m, 1H), 8.17 - 8.06 (m, 2H), 7.78 (dd, = 8.7, 1.9 Hz, 1H), 7.60 (dd, J= 8.3, 4.2 Hz, 1H), 7.53 - 7.43 (m, 1H), 7.29 (dd, = 7.5, 1.8 Hz, 1H), 7.24 - 7.12 (m, 1H), 7.11 - 7.01 (m, 1H), 5.73 - 5.42 (m, 1H), 4.83 - 4.59 (m, 1H), 3.81 (s, 3H), 3.63 (s, 3H), 3.27 - 3.03 (m, 1H), 2.76 - 2.58 (m, 1H), 2.42 - 2.13 (m, 1H), 1.62 - 1.42 (m, 3H). Example 497: i('7S)-3-('4-Ethoxyphenyl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolo[3.4-clpyridin- 6-yll-(6-quinolyl)methanone.
Figure imgf000484_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)-
4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and (4-ethoxyphenyl)boronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C26H26N4O2, 426.2; m/z found, 427.2 [M+H]+. Ή NMR (500 MHz, DMSO- e) d 8.90 (d, = 4.0 Hz, 1H), 8.36 (d, J= 8.1 Hz, 1H), 8.07 (d, = 8.6 Hz, 1H), 8.00 (s, 1H), 7.72 (d, = 8.5 Hz, 1H), 7.52 (dd, = 8.2, 4.1 Hz, 1H), 7.29 (d, J= 8.4 Hz, 1H), 6.96 (d, = 8.3 Hz, 1H), 5.69 - 5.53 (m, 1H), 4.07 (q, = 6.8 Hz, 2H), 3.77 (s, 4H), 3.35 - 3.22 (m, 1H), 2.87 - 2.78 (m, 1H), 2.41 - 2.29 (m, 1H), 1.53 (bs, 3H), 1.42 (t, J= 6.9 Hz, 3H). (Fractions of Hs that overlap with DMSO or water are not reported). Example 498: l('7S)-3-('3-Isopropoxyphenyl)-2.7-diniethyl-5.7-dihvdro-4H-pyrazolol3.4- c1pyridin-6-yl1-('6-quinolyl)methanone.
Figure imgf000484_0002
The title compound was prepared in a manner analogous to Example 288, using (S)-3-(3- isopropoxyphenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 46) instead of (S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c]pyridine and quinoline-6-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C27H28N4O2, 440.2; m/z found, 441.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 8.98 (dd, J= 4.2, 1.8 Hz, 1H), 8.54 - 8.41 (m, 1H), 8.17 - 8.04 (m, 2H), 7.80 (d, J= 8.6 Hz, 1H), 7.61 (dd, J= 8.3, 4.2 Hz, 1H), 7.45 - 7.34 (m, 1H), 7.06 - 6.92 (m, 3H), 5.76 - 5.54 (m, 1H), 4.75 - 4.59 (m, 1H), 3.92 - 3.58 (m, 4H), 3.26 - 3.08 (m, 1H), 2.91 - 2.77 (m, 1H), 2.43 - 2.24 (m, 1H), 1.51 (s, 3H), 1.28 (d, J= 6.0 Hz, 6H).
Example 499: i('7S)-3-[3-('Difluoroniethoxy)phenyl1-2.7-diniethyl-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-(6-quinolyl)methanone.
Figure imgf000485_0001
The title compound was prepared in a manner analogous to Example 288, using (S)-3-(3- (difluoromethoxy)phenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine
(Intermediate 45) instead of (S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H- pyrazolo[3,4-c]pyridine and quinobne-6-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol- 2-yl) benzoic acid. MS (ESI): mass calcd. for C25H22F2N4O2, 448.2; m/z found, 449.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 8.98 (dd, = 4.3, 1.7 Hz, 1H), 8.52 - 8.35 (m, 1H), 8.18—
8.03 (m, 2H), 7.87 - 7.68 (m, 1H), 7.64 - 7.46 (m, 2H), 7.43 - 7.07 (m, 4H), 5.83 - 5.40 (m,
1H), 4.88 - 4.53 (m, 1H), 3.91 - 3.59 (m, 4H), 3.00 - 2.70 (m, 1H), 2.43 - 2.25 (m, 1H), 1.61 - 1.36 (m, 3H).
Example 500: i('7S)-2.7-Diniethyl-3-[4-('trifluoroniethoxy)phenyl1-5.7-dihvdro-4H- pyrazolo cl pyridin-6-yll -(6-quinolyl)methanone.
Figure imgf000486_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4, 5, 6, 7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and (4-(trifluoromethoxy)phenyl)boronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C25H21F3N4O2, 466.2; m/z found, 467.2 [M+H]+. Ή NMR (400 MHz, DMSO-r/e) d 9.01 - 8.97 (m, 1H), 8.53 - 8.47 (m, 1H), 8.14 - 8.07 (m, 2H), 7.84 - 7.77 (m, 1H), 7.67 - 7.61 (m, 3H), 7.54 - 7.48 (m, 2H), 5.68 - 5.56 (m, 1H), 3.92 - 3.75 (m, 3H), 3.73 - 3.58 (m, 1H), 3.33 - 3.23 (m, 1H), 2.90 - 2.79 (m, 1H), 2.45 - 2.33 (m, 1H), 1.57 - 1.45 (m, 3H).
Example 501 : l('7S)-2.7-Dimethyl-3-13-('trifluoromethoxy)phenyl1-5.7-dihvdro-4H- pyrazolo G3 4-cl pyridin-6-yll -('6-quinolyl)methanone.
Figure imgf000486_0002
The title compound was prepared in a manner analogous to Example 288, using (S)-2,7- dimethyl-3-(3-(trifluoromethoxy)phenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine
(Intermediate 44) instead of (S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H- pyrazolo[3,4-c]pyridine and quinobne-6-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol- 2-yl) benzoic acid. MS (ESI): mass calcd. for C25H21F3N4O2, 466.2; m/z found, 467.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 8.98 (dd, = 4.3, 1.7 Hz, 1H), 8.48 (dd, J= 8.4, 1.7 Hz, 1H), 8.16 - 8.04 (m, 2H), 7.86 - 7.75 (m, 1H), 7.71 - 7.42 (m, 5H), 5.77 - 5.47 (m, 1H), 4.92 - 4.50 (m, 1H), 3.94 - 3.60 (m, 4H), 2.99 - 2.73 (m, 1H), 2.46 - 2.26 (m, 1H), 1.61 - 1.42 (m, 3H).
Example 502: i('7S)-3-('2.4-Difluorophenyl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-(6-quinolyl)methanone.
Figure imgf000487_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and (2,4-difluorophenyl)boronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C24H20F2N4O, 418.2; m/z found, 419.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.90 (d, J= 3.1 Hz, 1H), 8.35 (d, J= 8.1 Hz, 1H), 8.07 (d, J= 8.5 Hz, 1H), 7.99 (s, 1H), 7.72 (d, J= 8.5 Hz, 1H), 7.55 - 7.45 (m, 2H), 7.19- 7.09 (m, 2H), 5.75 - 5.56 (m, 1H), 3.71 (s, 4H), 3.36 - 3.18 (m, 1H), 2.78 - 2.67 (m, 1H), 2.36- 2.21 (m, 1H), 1.56 (d, J= 5.5 Hz, 3H).
Example 503: l('7S)-3-('2.3-Difluorophenyl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolol3.4- c1pyridin-6-yl1-t6-quinolyl)methanone.
Figure imgf000487_0002
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and (2,3-difluorophenyl)boronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C24H20F2N4O, 418.2; m/z found, 419.2 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) d 8.90 (d, J= 3.9 Hz, 1H), 8.35 (d, J= 8.2 Hz, 1H), 8.07 (d, J= 8.6 Hz, 1H), 7.51 (dd, = 8.2, 4.1 Hz, 1H), 7.47 - 7.36 (m, 1H), 7.35 - 7.27 (m, 1H), 7.26- 7.16 (m, 1H), 5.75 - 5.51 (m, 1H), 3.94 - 3.43 (m, 4H), 3.36 - 3.14 (m, 1H), 2.83 - 2.69 (m, 1H), 2.42 - 2.24 (m, 1H), 1.56 (d, J= 6.0 Hz, 3H). (Fraction of Hs that overlap with DMSO or water are not reported).
Example 504: i('7S)-3-('4-Chloro-3-fluoro-phenyl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-('6-quinolyl)methanone.
Figure imgf000488_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and (4-chloro-3-fluorophenyl)boronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C24H20CIFN4O, 434.1 ; m/z found, 435.0 [M+H]+. Ή NMR (500 MHz, CD3OD) d 8.98 - 8.93 (m, 1H), 8.49 (d, J= 8.4 Hz, 1H), 8.16 (d, J= 8.7 Hz, 1H), 8.10 (s, 1H), 7.89 - 7.80 (m, 1H), 7.68 - 7.61 (m, 2H), 7.43 (d, J= 9.8 Hz, 1H), 7.29 (d, J= 8.3 Hz, 1H), 5.87 - 5.71 (m, 1H), 3.92 - 3.81 (m, 3H), 3.81 - 3.71 (m, 1H), 3.57 - 3.37 (m, 1H), 2.92 - 2.83 (m, 1H), 2.62 - 2.40 (m, 1H), 1.69 - 1.56 (m, 3H).
Example 505: -3-t3-Chloro-4-fluoro-phenyl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolo[3.4-
Figure imgf000488_0002
c1pyridin-6-yl]-('6-quinolyl)methanone.
Figure imgf000489_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4, 5, 6, 7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and (3-chloro-4-fluorophenyl)boronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C24H20CIFN4O, 434.1 ; m/z found, 435.2 [M+H]+. Ή NMR (500 MHz, CD3OD) d 8.98 - 8.93 (m, 1H), 8.48 (d, J= 8.3 Hz, 1H), 8.16 (d, J= 8.6 Hz, 1H), 8.09 (s, 1H), 7.88 - 7.81 (m, 1H), 7.66 - 7.61 (m, 2H), 7.46 - 7.40 (m, 2H), 5.88 - 5.71 (m, 1H), 3.88 - 3.78 (m, 3H), 3.78 - 3.67 (m, 1H), 3.52 - 3.36 (m, 1H), 2.90 - 2.81 (m, 1H), 2.54 - 2.36 (m,
1H), 1.67 - 1.56 (m, 3H).
Example 506: l('7S)-3-('2-Chloro-4-fluoro-phenyl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolol3.4- clpyridin-6-yll-(6-quinolyl)methanone.
Figure imgf000489_0002
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and (2-chloro-4-fluorophenyl)boronic acid instead of 3-(difluoromethoxy)phenylboronic acid.
MS (ESI): mass calcd. for C24H20CIFN4O, 434.1 ; m/z found, 435.0 [M+H]+.
Figure imgf000489_0003
(500 MHz, CD3OD) d 8.96 (s, 1H), 8.51 (d, J= 8.4 Hz, 1H), 8.16 (d, J= 8.5 Hz, 1H), 8.10 (s, 1H), 7.85 (dd, J= 8.7, 1.9 Hz, 1H), 7.68 - 7.61 (m, 1H), 7.53 - 7.43 (m, 2H), 7.30 - 7.24 (m, 1H), 5.94 - 5.74 (m, 1H), 3.92 - 3.72 (m, 1H), 3.72 - 3.58 (m, 3H), 3.55 - 3.35 (m, 1H), 2.79 - 2.63 (m, 1H), 2.49 - 2.24 (m, 1H), 1.68 - 1.56 (m, 3H).
Example 507: r(7SV3-(3.4-DichlorophenylV2.7-dimethyl-5.7-dihvdro-4H-pyrazolor3.4- clpyridin^-yll-^-quinolyllmethanone.
Figure imgf000490_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and (3,4-dichlorophenyl)boronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C24H20CI2N4O, 450.1; m/z found, 451.0 [M+H]+. Ή NMR (500 MHz, CD3OD) 5 8.97 - 8.94 (m, 1H), 8.50 (d, J= 8.7 Hz, 1H), 8.17 (d, J= 8.7 Hz, 1H), 8.10 (s, 1H), 7.89 - 7.83 (m, 1H), 7.72 - 7.62 (m, 3H), 7.44 - 7.38 (m, 1H), 5.92 - 5.70 (m, 1H), 3.92 - 3.79 (m, 3H), 3.79 - 3.64 (m, 1H), 3.49 - 3.37 (m, 1H), 2.89 - 2.82 (m, 1H), 2.61 - 2.39 (m, 1H), 1.70 - 1.55 (m, 3H). Example 508: l('7S)-3-('5-Fluoro-2-methoxy-phenyl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolol3.4- c1pyridin-6-yl1-('6-quinolyl)methanone.
Figure imgf000490_0002
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and (5-fluoro-2-methoxyphenyl)boronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C25H23FN4O2, 430.2; m/z found, 431.2 [M+H]+. Ή NMR (400 MHz, CDCb) d 8.97 - 8.91 (m, 1H), 8.17 (d, J= 8.3 Hz, 1H), 8.13 (d, = 8.6 Hz, 1H), 7.93 - 7.88 (m, 1H), 7.74 (d, J= 8.8 Hz, 1H), 7.43 (dd, J= 8.3, 4.2 Hz, 1H), 7.14 - 7.04 (m, 1H), 6.96 - 6.88 (m, 2H), 5.91 - 4.82 (m, 1H), 3.80 (s, 3H), 3.71 - 3.59 (m, 3H), 3.40 - 3.12 (m, 1H), 2.95 - 2.60 (m, 1H), 2.47 - 2.22 (m, 1H), 1.90 - 1.65 (m, 1H), 1.65 - 1.39 (m, 3H).
Example 509: l('7S)-3-('4-Fluoro-3-methoxy-phenyl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolol3.4- clpyridin-6-yll-(6-quinolyl)methanone.
Figure imgf000491_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and (2-fluoro-3-methoxyphenyl)boronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C25H23FN4O2, 430.2; m/z found, 431.2 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) d 8.90 (d, J= 3.8 Hz, 1H), 8.36 (d, J= 8.1 Hz, 1H), 8.07 (d, J= 8.5 Hz, 1H), 8.00 (s, 1H), 7.72 (d, = 8.3 Hz, 1H), 7.51 (dd, = 8.2, 4.1 Hz, 1H), 7.23 - 7.11 (m, 2H), 6.91 (t, = 6.5 Hz, 1H), 5.73 - 5.55 (m, 1H), 3.92 (s, 3H), 3.81 - 3.65 (m, 3H), 3.37 - 3.12 (m, 2H), 2.78 - 2.71 (m, 1H), 2.37 - 2.28 (m, 1H), 1.55 (d, J= 5.2 Hz, 3H).
Example 510: l(7SV3-(2-Fluoro-3-methoxy-phenylV2.7-dimethyl-5.7-dihvdro-4H-pyrazolol3.4- c1pyridin-6-yl]-('6-quinolyl)methanone.
Figure imgf000492_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4, 5, 6, 7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and (4-fluoro-3-methoxyphenyl)boronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C25H23FN4O2, 430.2; m/z found, 431.0 [M+H]+. Ή NMR (400 MHz, CDCb) 5 8.95 (d, = 4.2 Hz, 1H), 8.18 (bs, 1H), 8.14 (d, J= 8.6 Hz, 1H), 7.91 (s, 1H), 7.73 (d, J = 8.6 Hz, 1H), 7.44 (dd, J= 8.3, 4.2 Hz, 1H), 7.16 (m, 1H), 6.89 (d, = 9.5 Hz, 1H), 6.87 - 6.78 (m, 1H), 6.03 - 5.70 (m, 1H), 5.08 - 4.70 (m, 1H), 3.89 (s, 3H), 3.83 - 3.69 (m, 3H), 3.37 - 3.05
(m, 1H), 2.92 - 2.60 (m, 1H), 2.54 - 2.27 (m, 1H), 1.80 (s, 3H).
Example 511 : r(7SV3-(3-Fluoro-5-methyl-phenylV2.7-dimethyl-5.7-dihvdro-4H-pyrazolor3.4- clpyridin-6-yll-(6-quinolyl)methanone.
Figure imgf000492_0002
The title compound was prepared in a manner analogous to Example 288, using (S)-3-(3-fluoro- 5-methylphenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c] pyridine (Intermediate 42) instead of (S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c]pyridine and quinobne-6-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C23H23FN4O, 414.2; m/z found, 415.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) 5 8.98 (dd, J= 4.2, 1.7 Hz, 1H), 8.54 - 8.44 (m, 1H), 8.17 - 8.03 (m, 2H), 7.80 (d, J= 8.7 Hz, 1H), 7.61 (dd, J= 8.3, 4.2 Hz, 1H), 7.20 - 7.07 (m, 3H), 5.71 - 5.55 (m, 1H), 4.79 - 4.60 (m, 1H), 3.89 - 3.64 (m, 4H), 2.96 - 2.78 (m, 1H), 2.43 - 2.29 (m, 4H), 1.51 (d, = 6.6 Hz, 3H).
Example 512: r(7SV3-(4-Methoxy-3-methyl-phenylV2.7-dimethyl-5.7-dihvdro-4H- quinolyQmethanone.
Figure imgf000493_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and (4-methoxy-3-methylphenyl)boronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C26H26N4O2, 426.2; m/z found, 427.2 [M+H]+. Ή NMR (500 MHz, CD3OD) d 8.95 (s, 1H), 8.49 (d, J= 8.3 Hz, 1H), 8.16 (d, J= 8.7 Hz, 1H), 8.09 (s, 1H), 7.85 (d, J = 8.8 Hz, 1H), 7.66 - 7.60 (m, 1H), 7.23 (d, = 8.4 Hz, 1H), 7.19 (s, 1H), 7.04 (d, = 7.7 Hz, 1H), 5.86 - 5.70 (m, 1H), 3.88 (s, 3H), 3.80 (s, 3H), 3.76 - 3.65 (m, 1H), 3.48 - 3.36 (m, 1H),
2.86 - 2.77 (m, 1H), 2.50 - 2.33 (m, 1H), 2.25 (s, 3H), 1.66 - 1.54 (m, 3H).
Example 513: (3-Chloro-5-methoxy-phenylV2.7-dimethyl-5.7-dihvdro-4H-
Figure imgf000493_0002
pyrazolo G3 ,4-cl pyridin-6-yll -(6-quinolyl)methanone.
Figure imgf000493_0003
The title compound was prepared in a manner analogous to Example 288, using (S)-3-(3-chloro- 5-methoxyphenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c] pyridine (Intermediate 41) instead of (S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- c]pyridine and quinoline-6-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C25H23CIN4O2, 446.2; m/z found, 447.1 [M+H] +. ¾ NMR (500 MHz, DMSO-r/e) d 8.98 (dd, J= 4.2, 1.8 Hz, 1H), 8.58 - 8.38 (m, 1H), 8.23 - 8.02 (m, 2H), 7.85 - 7.75 (m, 1H), 7.61 (dd, J= 8.3, 4.2 Hz, 1H), 7.16 - 7.09 (m, 2H), 7.02 (t, J= 1.8 Hz, 1H),
5.72 - 5.49 (m, 1H), 4.89 - 3.95 (m, 2H), 3.87 - 3.64 (m, 6H), 2.97 - 2.72 (m, 1H), 2.37-2.31 (m, 1H), 1.57 - 1.43 (m, 3H).
Example 514: i('7S)-3-('4-Chloro-2.3-difluoro-phenyl)-2.7-diniethyl-5.7-dihvdro-4H- pyrazolo [3.4-cl pyridin-6-yll -(6-quinolyl)methanone.
Figure imgf000494_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and (4-chloro-2,3-difluorophenyl)boronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C24H19CIF2N4O, 452.1; m/z found, 453.0 [M+H]+.
Figure imgf000494_0002
NMR (500 MHz, CD3OD) 5 8.95 (s, 1H), 8.49 (d, = 8.4 Hz, 1H), 8.16 (d, J= 8.7 Hz, 1H), 8.10 (s, 1H), 7.85 (d, J= 8.7 Hz, 1H), 7.52 - 7.46 (m, 1H), 7.32 - 7.25 (m, 1H), 5.93 - 5.73 (m, 1H), 3.90 - 3.67 (m, 4H), 2.99 - 2.70 (m, 2H), 2.54 - 2.36 (m, 1H), 1.68 - 1.57 (m, 3H). (Fraction of Hs that overlap with methanol or water are not reported).
Example 515: l('7S)-2.7-Diiiiethyl-3-('2.3.4-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('6-quinolyl)methanone.
Figure imgf000495_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4, 5, 6, 7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and (2,3,4-trifluorophenyl)boronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C24H19F3N4O, 436.2; m/z found, 437.2 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) d 8.91 (d, J= 3.8 Hz, 1H), 8.35 (d, J= 8.2 Hz, 1H), 8.07 (d, J= 8.6 Hz, 1H), 8.00 (s, 1H), 7.72 (d, = 8.6 Hz, 1H), 7.52 (dd, = 8.3, 4.1 Hz, 1H), 7.36 - 7.27 (m, 2H), 5.76 - 5.56 (m, 1H), 3.73 (s, 4H), 3.40 - 3.22 (m, 1H), 2.80 - 2.69 (m, 1H), 2.35 - 2.31 (m, 1H), 1.55 (d, = 6. l
Hz, 3H).
Example 516: l('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1 -( 1 -oxidoquinolin- 1 -ium-6-yl)methanone.
Figure imgf000495_0002
To an ice-cold solution of (S)-(2,7-dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridin-6-yl)(quinobn-6-yl)methanone (Example 234, 160 mg, 0.37 mmol) in DCM (5.0 mL) was added 3-chlorobenzoperoxoic acid (95 mg, 0.55 mmol) portion wise, at 0 °C over a period of 10 minutes and the mixture was slowly warmed to rt. After stirring for lh, the reaction mixture was quenched with a saturated aqueous solution of NaHCC and extracted with DCM (2x). The combined organics were washed with brine, dried over Na^SCE, filtered, and concentrated in vacuo. The crude product was purified by reverse-phase (Method A) to afford the title compound as a white solid (121 mg, 72% yield). MS (ESI): mass calcd. for
C24H19F3N4O2, 452.2; m/z found, 453.1 [M+H]+.
Figure imgf000496_0001
(400 MHz, DMSO-r/e) d 8.67 - 8.54 (m, 2H), 8.20 (s, 1H), 8.03 (d, J= 8.5 Hz, 1H), 7.83 (d, J= 9.1 Hz, 1H), 7.60 - 7.44 (m, 3H), 5.70 - 5.50 (m, 1H), 4.86 - 4.39 (m, 1H), 3.87 - 3.56 (m, 4H), 2.95 - 2.77 (m, 1H), 2.45 - 2.26 (m, 1H), 1.57 - 1.43 (m, 3H).
Example 517: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-t2-hvdroxy-6-quinolyl)methanone.
Figure imgf000496_0002
The title compound was prepared in a manner analogous to Example 288, using 2- hydroxyquinoline-6-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H19F3N4O2, 452.1; m/z found, 453.0 [M+H]+. ¾ NMR (600 MHz, DMSO-ifc) 5 11.91 (s, 1H), 7.98 (d, = 9.5 Hz, 1H), 7.83 - 7.69 (m, 1H), 7.62 - 7.48 (m, 3H), 7.37 (d, J= 8.4 Hz, 1H), 6.56 (d, J= 9.6 Hz, 1H), 5.53 (s, 1H), 4.95 - 4.30 (m, 1H), 3.89 - 3.64 (m, 4H), 3.28 (s, 1H), 2.38 (s, 1H), 1.54 - 1.39 (m, 3H).
Example 518: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('4-hvdroxy-6-quinolyl)methanone.
Figure imgf000496_0003
The title compound was prepared in a manner analogous to Example 288, using 4- hydroxyquinoline-7-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H19F3N4O2, 452.2; m/z found, 453.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 12.52 - 11.29 (m, 1H), 8.08 (s, 1H), 7.96 (d, J= 7.4 Hz, 1H), 7.70 (dd, J = 8.5, 2.0 Hz, 1H), 7.67 - 7.48 (m, 3H), 6.08 (d, = 7.4 Hz, 1H), 5.56 (s, 1H), 5.00 - 4.31 (m, 1H), 3.95 - 3.63 (m, 4H), 2.88 - 2.71 (m, 1H), 2.46 - 2.29 (m, 1H), 1.57 - 1.40 (m, 3H).
Example 519: r(7S)-2.7-Dimethyl-3-(6-methyl-3-pyridyl)-5.7-dihvdro-4H-pyrazolor3.4- clpyridin-6-yll-('6-quinolyl)methanone.
Figure imgf000497_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 2-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C24H23N5O, 397.2; m/z found, 398.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.91 (d, J= 4.0 Hz, 1H), 8.48 (s, 1H), 8.36 (d,
J= 8.2 Hz, 1H), 8.07 (d, = 8.6 Hz, 1H), 8.00 (s, 1H), 7.77 - 7.68 (m, 1H), 7.52 (dd, = 8.2, 4.1 Hz, 1H), 7.31 (d, J= 8.0 Hz, 1H), 5.73 - 5.55 (m, 1H), 3.80 (s, 4H), 3.36 - 3.20 (m, 1H), 2.94 - 2.82 (m, 1H), 2.56 (s, 3H), 2.44 - 2.31 (m, 1H), 1.55 (d, J= 5.8 Hz, 3H). Example 520: l('7S)-2.7-Dimethyl-3-('2-methyl-4-pyridyl)-5.7-dihvdro-4H-pyrazolol3.4- c1pyridin-6-yl1-('6-quinolyl)methanone.
Figure imgf000497_0002
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 2-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C24H23N5O, 397.2; m/z found, 398.2 [M+H]+. ¾ NMR (500 MHz, CDCh) d 9.00 (d, J= 4.1 Hz, 1H), 8.63 (d, = 4.7 Hz, 1H), 8.21 (d, = 8.2 Hz, 1H), 8.18 (d, J= 8.7 Hz, 1H), 7.95 (s, 1H), 7.77 (d, = 8.6 Hz, 1H), 7.48 (dd, = 8.2, 4.2 Hz, 1H), 7.14 (s, 1H), 7.09 (d, = 5.0 Hz, 1H), 6.04 - 5.80 (m, 1H), 5.11 - 4.80 (m, 1H), 3.93 - 3.76 (m, 3H), 3.37 - 3.11 (m, 1H), 3.03 - 2.77 (m, 1H), 2.62 (s, 3H), 2.56 - 2.34 (m, 1H), 1.61 (s, 3H).
Example 521 : l('7S)-3-16-('Difluoromethyl)-3-pyridyl1-2.7-dimethyl-5.7-dihvdro-4H- -ciuinolyl)methanone.
Figure imgf000498_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 2-difluoromethyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C24H21F2N5O, 433.2; m/z found, 434.2 [M+H]+.
Figure imgf000498_0002
NMR (500 MHz, DMSO-r/e) d 8.91 (d, J= 3.9 Hz, 1H), 8.75 (s, 1H), 8.37 (d, J= 8.3 Hz, 1H), 8.08 (t, J= 7.3 Hz, 1H), 8.02 (s, 1H), 7.80 (d, = 8. l Hz, 1H), 7.74 (d, J= 8.3 Hz, 1H), 7.52 (dd, = 8.3, 4.2 Hz, 1H), 6.80 (t, J= 55.1 Hz, 1H), 5.71 - 5.59 (m, 1H), 3.96 - 3.70 (m, 4H), 3.39 - 3.21 (m, 1H), 2.96 - 2.90 (m, 1H), 2.47 - 2.37 (m, 1H), 1.56 (d, J = 6.1 Hz, 3H). (Fraction of Hs that overlap with DMSO or water are not reported). Example 522: i('7S)-2.7-Dimethyl-3-i6-('trifluoromethyl)-3-Dyridyl1-5.7-dihvdro-4H- -ciuinolyl)methanone.
Figure imgf000499_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 2-trifluoromethyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C24H20F3N5O, 451.2; m/z found, 452.0 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 9.01 - 8.92 (m, 2H), 8.48 (d, J= 8.1 Hz, 1H), 8.27 (d, = 8.0 Hz, 1H), 8.15 - 8.02 (m, 3H), 7.80 (d, = 7.5 Hz, 1H), 7.61 (dd, = 8. l, 4.1 Hz, 1H), 5.86 - 5.51 (m, 1H), 3.97 - 3.62 (m, 4H), 3.28 - 3.05 (m, 1H), 3.02 - 2.84 (m, 1H), 2.45 - 2.31 (m, 1H), 1.53 (d, = 3.3 Hz, 3H).
Example 523: r(7SV2.7-Dimethyl-3-r2-(trifluoromethylV4-pyridyll-5.7-dihvdro-4H- pyrazolo 13 4-cl pyridin-6-yll -('6-quinolyl)methanone.
Figure imgf000499_0002
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 2-trifluoromethyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C24H20F3N5O, 451.2; m/z found, 452.2 [M+H]+. ¾ NMR (400 MHz, CDCb) d 8.99 - 8.93 (m, 1H), 8.86 - 8.81 (m, 1H), 8.21 - 8.16 (m, 1H), 8.15 (d, = 8.7 Hz, 1H), 7.94 - 7.89 (m, 1H), 7.77 - 7.69 (m, 1H), 7.63 (s,
1H), 7.49 - 7.41 (m, 2H), 6.08 - 4.90 (m, 1H), 3.93 - 3.81 (m, 3H), 3.42 - 3.09 (m, 2H), 3.03 - 2.74 (m, 1H), 2.56 - 2.36 (m, 1H), 1.91 - 1.44 (m, 3H).
Example 524: i('7S)-2.7-Dimethyl-3-[5-('trifluoromethyl)-3-thienyl1-5.7-dihvdro-4H- pyrazolo cl pyridin-6-yll -('6-quinolyl)methanone.
Figure imgf000500_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and (5-(trifluoromethyl)thiophen-3-yl)boronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C23H19F3N4OS, 456.1; m/z found, 457.2 [M+H]+.
Figure imgf000500_0002
NMR (500 MHz, DMSO-r/e) d 8.93 - 8.89 (m, 1H), 8.38 - 8.35 (m, 1H), 8.10 - 8.06 (m, 1H), 8.02 - 7.98 (m, 2H), 7.75 - 7.71 (m, 2H), 7.54 - 7.50 (m, 1H), 5.72 - 4.64 (m, 1H), 4.06 - 3.64 (m, 4H), 3.36 - 3.11 (m, 1H), 2.98 - 2.85 (m, 2H), 2.47 - 2.35 (m, 1H), 1.53 (d, J= 6.7 Hz, 3H).
Example 525: l('7S)-3-('6-Methoxy-3-pyridyl)-2.7-diniethyl-5.7-dihvdro-4H-pyrazolol3.4- clpyridin-6-yll-(6-quinolyl)methanone.
Figure imgf000501_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4, 5, 6, 7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 2-methoxy-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C24H23N5O2, 413.2; m/z found, 414.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.91 (d, J= 4.0 Hz, 1H), 8.36 (d, J= 8.2 Hz, 1H), 8.19 (s, 1H), 8.07 (d, J= 8.5 Hz, 1H), 8.00 (s, 1H), 7.76 - 7.69 (m, 2H), 7.52 (dd, J= 8.2, 4.1 Hz, 1H), 6.86 (d, = 8.5 Hz, 1H), 5.70 - 5.54 (m, 1H), 3.93 (s, 3H), 3.79 (s, 4H), 3.33 - 3.21
(m, 1H), 2.93 - 2.81 (m, 1H), 2.44 - 2.32 (m, 1H), 1.54 (d, J= 5.9 Hz, 3H).
Example 526: l('7S)-3-('2-Methoxy-4-pyridyl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-(6-quinolyl)methanone.
Figure imgf000501_0002
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 2-methoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine instead of 3-
(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C24H23N5O2, 413.2; m/z found, 414.2 [M+H]+. ¾ NMR (400 MHz, CDCb) d 8.98 (m, 1H), 8.25 (d, J= 5.1 Hz, 1H), 8.22 (d, J = 8.5 Hz, 1H), 8.18 (d, J= 8.7 Hz, 1H), 7.93 (s, 1H), 7.75 (dd, J= 8.6, 1.4 Hz, 1H), 7.48 (dd, J = 8.1, 4.2 Hz, 1H), 6.83 (d, = 5. l Hz, 1H), 6.69 (s, 1H), 6.11 - 5.71 (m, 1H), 5.05 - 4.75 (m, 1H), 3.97 (s, 3H), 3.91 - 3.79 (m, 3H), 3.32 - 3.02 (m, 1H), 2.97 - 2.72 (m, 1H), 2.50 (d, J= 25.1 Hz, 1H), 1.69 - 1.48 (m, 3H).
Example 527: i('7S)-3-[6-('Difluoromethoxy)-3-pyridyll-2.7-dimethyl-5.7-dihvdro-4H- 6-ciuinolyl)methanone.
Figure imgf000502_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 2-difluoromethoxy-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C24H21F2N5O2, 449.2; m/z found, 450.1 [M+H]+. ¾ NMR (400 MHz, CDCb) d 8.95 (dd, J= 4.1, 1.4 Hz, 1H), 8.23 - 8.15 (m, 2H), 8.14 (d, J= 8.8 Hz, 1H), 7.91 (s, 1H), 7.79 - 7.68 (m, 2H), 7.67 - 7.29 (m, 2H), 7.02 (d, J= 8.4 Hz, 1H), 6.10 - 5.68 (m, 1H), 5.13 - 4.74 (m, 1H), 3.78 (s, 3H), 3.35 - 3.09 (m, 1H), 2.95 - 2.65 (m, 1H), 2.51 - 2.27 (m, 1H), 1.60 (s, 3H). Example 528: l('7S)-3-15-('Difluoromethoxy)-3-pyridyl1-2.7-dimethyl-5.7-dihvdro-4H- pyrazolo G3 4-cl pyridin-6-yll -(6-quinolvOmethanone.
Figure imgf000503_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4, 5, 6, 7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 3-difluoromethoxy-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C24H21F2N5O2, 449.2; m/z found, 450.2 [M+H]+.
Figure imgf000503_0002
NMR (500 MHz, DMSO-r/e) d 8.91 (d, J= 2.8 Hz, 1H), 8.51 (s, 1H), 8.46 (s, 1H), 8.37 (d, J= 8.0 Hz, 1H), 8.08 (d, J= 8.6 Hz, 1H), 8.01 (s, 1H), 7.79 - 7.69 (m, 2H), 7.52 (d, J= 8.2, 4.1 Hz, 1H), 7.26 (t, J= 73.1 Hz, 1H), 5.72 - 5.56 (m, 1H), 3.95 - 3.71 (m, 4H),
3.38 - 3.21 (m, 1H), 2.96 - 2.85 (m, 1H), 2.45 - 2.29 (m, 1H), 1.55 (br s, 3H).
Example 529: l('7S)-3-('6-Methoxy-5-methyl-3-pyridyl)-2.7-dimethyl-5.7-dihvdro-4H- pyrazolo G3 4-cl pyridin-6-yll -(6-ciuinolyl)methanone.
Figure imgf000503_0003
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 2-methoxy-3-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C25H25N5O2, 427.2; m/z found, 428.2 [M+H]+. ¾ NMR (400 MHz, CDCb) d 8.98 - 8.92 (m, 1H), 8.20 - 8.10 (m, 2H), 8.00 - 7.95 (m, 1H), 7.93 - 7.88 (m, 1H), 7.77 - 7.70 (m, 1H), 7.48 - 7.40 (m, 1H), 7.36 - 7.31 (m,
1H), 5.91 - 4.83 (m, 1H), 3.99 (s, 3H), 3.84 - 3.71 (m, 4H), 3.41 - 3.08 (m, 1H), 2.94 - 2.63 (m, 1H), 2.52 - 2.28 (m, 1H), 2.22 (s, 3H), 1.84 - 1.39 (m, 3H). Example 530: i('7S)-3-[6-Methoxy-5-('trifluoromethyl)-3-pyridyll-2.7-dimethyl-5.7-dihvdro-4H- 6-ciuinolyl)methanone.
Figure imgf000504_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)-
4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 2-methoxy-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)pyridine instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C25H22F3N5O2, 481.2; m/z found, 482.1 [M+H]+.
Figure imgf000504_0002
NMR (500 MHz, DMSO-r/e) d 8.93 - 8.89 (m, 1H), 8.47 (s, 1H), 8.36 (d, = 8.1 Hz, 1H), 8.08 (d, J= 8.7 Hz, 1H), 8.04 (s, 1H), 8.01 (s, 1H), 7.73 (d, = 8.8
Hz, 1H), 7.52 (dd, = 8.3, 4.1 Hz, 1H), 5.64 (s, 1H), 4.09 (s, 3H), 3.81 (s, 4H), 3.39 - 3.11 (m, 1H), 2.95 - 2.83 (m, 1H), 2.43 - 2.27 (m, 1H), 1.55 (s, 3H).
Example 531 : r(7SV3-(lH-Indol-7-ylV2.7-dimethyl-5.7-dihvdro-4H-pyrazolor3.4-clpyridin-6-
Figure imgf000504_0003
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 7-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indole instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C26H23N5O, 421.2; m/z found, 422.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 10.87 (d, J= 13.1 Hz, 1H), 8.90 (s, 1H), 8.35 (d, J= 7.3 Hz, 1H), 8.13 - 7.95 (m, 2H), 7.75 (dd, J= 23.2, 10.5 Hz, 1H), 7.59 (d, J= 7.8 Hz, 1H), 7.51 (d, = 4.6 Hz, 1H), 7.23 (d, = 29.8 Hz, 1H), 7.13 - 6.96 (m, 2H), 6.47 (s, 1H), 5.71 (d, J= 37.9 Hz, 1H), 3.86 - 3.58 (m, 4H), 3.34 - 3.20 (m, 1H), 2.88 - 2.71 (m, 1H), 2.30 - 2.12 (m, 1H), 1.61 (br s, 3H).
Example 532: l('7S)-3-('Benzofuran-6-yl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolo[3.4-c1pyridin-
6-yl1-('6-quinolyl)methanone.
Figure imgf000505_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 2-(benzofuran-6-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C26H22N4O2, 422.2; m/z found, 423.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.93 - 8.88 (m, 1H), 8.37 (d, J= 8.3 Hz, 1H), 8.07 (d, J= 8.6 Hz, 1H), 8.01 (s, 1H), 7.90 - 7.86 (m, 1H), 7.76 - 7.69 (m, 2H), 7.59 (s, 1H), 7.54 - 7.49 (m, 1H), 7.27 (d, = 8. l Hz, 1H), 6.93 - 6.89 (m, 1H), 5.75 - 4.65 (m, 1H), 3.84 (s, 3H), 3.39 - 3.11 (m, 1H), 2.95 - 2.85 (m, 1H), 2.49 - 2.31 (m, 2H), 1.60 - 1.50 (m, 3H). Example 533: i('7S)-3-('Benzofuran-5-yl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolo clpyridin-
Figure imgf000506_0001
6-yl1-(6-guinolvnmethanone.
Figure imgf000506_0002
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 2-(benzofuran-5-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C26H22N4O2, 422.2; m/z found, 423.2 [M+H]+. ¾ NMK (500 MHz, DMSO-r/e) d 8.93 - 8.88 (m, 1H), 8.36 (d, J= 8.2 Hz, 1H),
8.07 (d, J= 8.6 Hz, 1H), 8.01 (s, 1H), 7.89 - 7.85 (m, 1H), 7.73 (d, J= 8.6 Hz, 1H), 7.68 - 7.64 (m, 1H), 7.62 (d, = 8.5 Hz, 1H), 7.54 - 7.49 (m, 1H), 7.35 - 7.31 (m, 1H), 6.93 - 6.89 (m, 1H), 5.70 - 4.66 (m, 1H), 3.96 - 3.59 (m, 4H), 3.41 - 3.16 (m, 1H), 2.91 - 2.82 (m, 1H), 2.45 - 2.31 (m, 1H), 1.56 (d, J= 6.7 Hz, 3H).
Example 534: l('7S)-3-('Benzofuran-7-yl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolo[3.4-c1pyridin- 6-yl1-('6-quinolyl)methanone.
Figure imgf000506_0003
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 2-(benzofuran-7-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C26H22N4O2, 422.2; m/z found, 423.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.90 (d, J= 3.5 Hz, 1H), 8.36 (d, J= 8.2 Hz, 1H), 8.07 (d, J= 8.1 Hz, 1H), 8.01 (s, 1H), 7.89 (s, 1H), 7.73 (d, J= 8.6 Hz, 1H), 7.70 (d, J= 7.5 Hz, 1H), 7.51 (dd, J= 8.2, 4.1 Hz, 1H), 7.34 (t, J= 7.5 Hz, 1H), 7.29 (d, J= 7.3 Hz, 1H), 6.94 (s, 1H), 5.76 - 5.58 (m, 1H), 3.77 (s, 4H), 3.43 - 3.23 (m, 1H), 2.86 - 2.76 (m, 1H), 2.41 - 2.29 (m, 1H), 1.58 (br s, 3H).
Example 535: i('7S)-3-('Benzofuran-4-yl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolo[3.4-c1pyridin- 6-yl1-('6-quinolyl)methanone.
Figure imgf000507_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 2-(benzofuran-4-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C26H22N4O2, 422.2; m/z found, 423.0 [M+H]+. ¾ NMR (500 MHz, CD3OD) d 8.95 (s, 1H), 8.51 (d, = 8.3 Hz, 1H), 8.16 (d, = 8.5 Hz, 1H), 8.12 (s, 1H), 7.92 - 7.85 (m, 2H), 7.69 - 7.61 (m, 2H), 7.49 - 7.42 (m, 1H), 7.31 - 7.24 (m, 1H), 6.85 - 6.68 (m, 1H), 5.93 - 5.75 (m, 1H), 3.85 - 3.70 (m, 3H), 3.70 - 3.57 (m,
1H), 3.54 - 3.35 (m, 1H), 2.86 - 2.69 (m, 1H), 2.48 - 2.29 (m, 1H), 1.73 - 1.59 (m, 3H).
Example 536: l('7S)-3-('5-Fluorobenzofuran-7-yl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('6-quinolyl)methanone.
Figure imgf000508_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4, 5, 6, 7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 2-(5-fluorobenzofuran-7-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C26H21FN4O2, 440.2; m/z found, 441.0 [M+H]+.
Figure imgf000508_0002
NMR (500 MHz, CD3OD) d 8.94 (s, 1H), 8.48 (d, J= 8.3 Hz, 1H),
8.15 (d, = 8.7 Hz, 1H), 8.11 - 8.07 (m, 1H), 7.94 - 7.90 (m, 1H), 7.88 - 7.82 (m, 1H), 7.68 - 7.61 (m, 1H), 7.51 - 7.46 (m, 1H), 7.19 (dd, J= 9.5, 2.2 Hz, 1H), 6.98 (s, 1H), 5.96 - 5.76 (m,
1H), 3.90 - 3.75 (m, 3H), 3.75 - 3.62 (m, 1H), 3.54 - 3.33 (m, 1H), 2.92 - 2.77 (m, 1H), 2.55 - 2.34 (m, 1H), 1.69 - 1.53 (m, 3H).
Example 537: l('7S)-3-(' l .3-Benzothiazol-4-yl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolol3.4- clpyridin-6-yll-(6-quinolyl)methanone.
Figure imgf000508_0003
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzo[d]thiazole instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C25H21N5OS, 439.1; m/z found, 440.2 [M+H]+. ¾ NMR (500 MHz, CDCb) d 9.09 (s, 1H), 8.98 (s, 1H), 8.22 (d, J= 8.5 Hz, 1H), 8.19 (d, = 9.6 Hz, 1H), 8.09 (d, = 8. l Hz, 1H), 7.96 (s, 1H), 7.80 (d, = 7.6 Hz, 1H), 7.58 (t, = 7.7 Hz, 1H), 7.50 - 7.46 (m, 2H), 6.09 - 5.89 (m, 1H), 5.10 - 4.89 (m, 1H), 3.81 (s, 3H), 3.40 - 3.19 (m, 1H), 2.95 - 2.74 (m, 1H), 2.50 - 2.32 (m, 1H), 1.71 (s, 3H). Example 538: -3-(2.1.3-Benzoxadiazol-4-yl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolo[3.4-
Figure imgf000509_0001
clpyridin^-yll-^-quinolyllmethanone.
Figure imgf000509_0002
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)-
4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and benzo[c][l,2,5]oxadiazol-4-ylboronic acid instead of 3-(difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C24H20N6O2, 424.2; m/z found, 425.0 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) d 8.91 (d, J= 4.1 Hz, 1H), 8.36 (d, J= 8.3 Hz, 1H), 8.07 (d, J= 8.6 Hz, 1H), 8.05 - 8.00 (m, 2H), 7.76 - 7.72 (m, 1H), 7.72 - 7.66 (m, 1H), 7.63 (d, J= 6.6 Hz, 1H), 7.55 -
7.49 (m, 1H), 5.75 - 4.76 (m, 1H), 4.01 - 3.61 (m, 4H), 3.40 - 3.20 (m, 1H), 2.91 - 2.82 (m,
1H), 2.47 - 2.34 (m, 1H), 1.59 (d, = 6.7 Hz, 3H).
Example 539: -3-t2.3-Dihvdrobenzofuran-7-yl)-2.7-diniethyl-5.7-dihvdro-4H-
Figure imgf000509_0003
pyrazolo G3 4-cl pyridin-6-yll -(6-quinolyl)methanone.
Figure imgf000509_0004
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 2-(2,3-dihydrobenzofuran-7-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C26H24N4O2, 424.2; m/z found, 425.0 [M+H]+. ¾ NMR (500 MHz, CD3OD) d 8.96 - 8.92 (m, 1H), 8.50 - 8.44 (m, 1H), 8.18 - 8.12 (m, 1H), 8.10 - 8.06 (m, 1H), 7.86 - 7.81 (m, 1H), 7.65 - 7.59 (m, 1H), 7.34 - 7.29 (m,
1H), 7.13 - 7.08 (m, 1H), 7.00 - 6.92 (m, 1H), 5.89 - 5.71 (m, 1H), 4.67 - 4.56 (m, 2H), 3.87 -
3.69 (m, 3H), 3.69 - 3.53 (m, 1H), 3.49 - 3.32 (m, 1H), 3.30 - 3.20 (m, 2H), 2.86 - 2.69 (m,
1H), 2.56 - 2.35 (m, 1H), 1.68 - 1.53 (m, 3H).
Example 540: r(7SV3-(E3-Benzodioxol-5-ylV2.7-dimethyl-5.7-dihvdro-4H-pyrazolor3.4- clpyridin-6-yll-('6-quinolyl)methanone.
Figure imgf000510_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 2-(benzo[d][l,3]dioxol-5-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C25H22N4O3, 426.2; m/z found, 427.0 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.90 (d, J= 4.0 Hz, 1H), 8.36 (d, J= 8.2 Hz, 1H), 8.07 (d, J= 8.6 Hz, 1H), 8.00 (s, 1H), 7.72 (d, J= 8.4 Hz, 1H), 7.52 (dd, J= 8.2, 4.2 Hz, 1H), 6.99 - 6.90 (m, 2H), 6.85 (d, J= 8.0 Hz, 1H), 6.05 (s, 2H), 5.69 - 5.54 (m, 1H), 3.90 - 3.63 (m, 4H), 3.33 - 3.22 (m, 1H), 2.88 - 2.79 (m, 1H), 2.41 - 2.29 (m, 1H), 1.53 (d, J= 5.2 Hz, 3H).
Example 541 : r(7S)-3-(l.3-Benzodioxol-4-yl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolor3.4- c1pyridin-6-yl]-('6-quinolyl)methanone.
Figure imgf000511_0001
The title compound was prepared in a manner analogous to Example 98, using (S)-2,7-dimethyl- 6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl
trifluoromethanesulfonate (Intermediate 49) instead of [2-methyl-6-(quinoline-6-carbonyl)- 4, 5, 6, 7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate] (Intermediate 10) and 2-(benzo[d][l,3]dioxol-4-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane instead of 3- (difluoromethoxy)phenylboronic acid. MS (ESI): mass calcd. for C25H22N4O3, 426.2; m/z found, 427.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.90 (d, J= 3.9 Hz, 1H), 8.36 (d, J= 8.2 Hz, 1H), 8.07 (d, J= 8.5Hz, 1H), 8.00 (s, 1H), 7.72 (d, = 8.6 Hz, 1H), 7.51 (dd, = 8.2, 4.1 Hz, 1H), 6.94 - 6.87 (m, 2H), 6.82 (d, = 7.4 Hz, 1H), 6.07 (s, 1H), 6.04 (s, 1H), 5.71- 5.54 (m,
1H), 3.77 (s, 4H), 3.33 - 3.23 (m, 1H), 2.82 - 2.73 (m, 1H), 2.41 - 2.32 (m, 1H), 1.54 (br s, 3H).
Example 542: -3-t2.2-Difluoro- l .3-benzodioxol-4-yl)-2.7-dimethyl-5.7-dihvdro-4H-
Figure imgf000511_0002
pyrazolo G3 4-cl pyridin-6-yll -('6-quinolyl)methanone.
Figure imgf000511_0003
The title compound was prepared in a manner analogous to Example 288, using (S)-3-(2,2- difluorobenzo[d][l,3]dioxol-4-yl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 43) instead of (S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H- pyrazolo[3,4-c]pyridine and quinobne-6-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol- 2-yl) benzoic acid. MS (ESI): mass calcd. for C25H20F2N4O3, 462.1; m/z found, 463.0 [M+H] +.
¾ NMR (500 MHz, DMSO-r/e) d 9.03 - 8.91 (m, 1H), 8.47 (d, J= 8.3 Hz, 1H), 8.16 - 8.05 (m, 2H), 7.79 (dd, J= 8.6, 1.9 Hz, 1H), 7.64 - 7.50 (m, 2H), 7.41 - 7.31 (m, 2H), 5.77 - 5.49 (m, 1H), 4.88 - 4.47 (m, 1H), 3.87 - 3.65 (m, 4H), 2.85 - 2.69 (m, 1H), 2.43 - 2.29 (m, 1H), 1.63 - 1.40 (m, 3H).
Example 543: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-('5-isoquinolyl)methanone.
Figure imgf000512_0001
The title compound was prepared in a manner analogous to Example 288, using isoquinoline-5- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H19F3N4O, 436.2; m/z found, 437.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 9.44 - 9.38 (m, 1H), 8.65 - 8.38 (m, 1H), 8.27 - 8.19 (m, 1H), 7.94 - 7.40 (m, 5H), 5.87 - 5.72 (m,
0.75H), 4.93 - 4.78 (m, 0.28H), 4.71 - 4.58 (m, 0.07H), 4.38 - 4.25 (m, 0.17H), 3.89 - 3.63 (m, 3H), 3.18 - 2.93 (m, 0.43H), 2.84 - 2.71 (s, 0.48H), 2.29 - 2.18 (m, 0.72H), 1.69 - 1.30 (m, 3H). (Fractions of Hs that overlap with DMSO and water are not reported). Example 544: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('6-isoquinolyl)methanone.
Figure imgf000512_0002
The title compound was prepared in a manner analogous to Example 288, using isoquinoline-6- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C24H19F3N4O, 436.1 ; m/z found, 437.3 [M+H]+. Ή NMR (400 MHz, DMSO- e) d 9.40 (d, J= 1.0 Hz, 1H), 8.58 (d, J= 5.7 Hz, 1H), 8.24 (d, J= 8.4 Hz, 1H), 8.12 - 7.88 (m, 2H), 7.77 - 7.65 (m, 1H), 7.60 - 7.41 (m, 2H), 5.74 - 5.47 (m, 1H), 3.88 - 3.56 (m, 4H), 2.93 - 2.66 (m, 2H), 2.39 - 2.22 (m, 1H), 1.60 - 1.26 (m, 3H).
Example 545: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-('5-fluoro-3-quinolyl)methanone.
Figure imgf000513_0001
The title compound was prepared in a manner analogous to Example 288, using 5- fluoroquinoline-3 -carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C24H18F4N4O, 454.1; m/z found, 455.0 [M+H]+. Ή NMR (400 MHz, DMSO-r/e) d 9.03 (s, 1H), 8.54 (s, 1H), 8.02 - 7.75 (m, 2H), 7.66 - 7.41 (m, 3H), 5.74 - 5.46 (m, 1H), 4.94 - 4.35 (m, 1H), 3.96 - 3.63 (m, 4H), 2.97 - 2.79 (m, 1H), 2.41 - 2.29 (m, 1H), 1.62 - 1.45 (m, 3H).
Example 546: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('8-fluoro-4-isoquinolyl)methanone.
Figure imgf000513_0002
The title compound was prepared in a manner analogous to Example 288, using 8- fluoroisoquinoline-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C24H18F4N4O, 454.1; m/z found, 455.1 [M+H]+.
Figure imgf000513_0003
NMR (600 MHz, DMSO-r/e) d 9.59 - 9.52 (m, 1H), 8.78 - 8.39 (m, 1H), 7.97 - 7.40 (m, 5H), 5.83 - 5.74 (d, J = 17.8 Hz, 0.78H), 4.92 - 4.63 (m, 0.53H), 4.42 - 4.32 (s, 0.23H), 3.88 - 3.65 (m, 3.32H), 3.05 - 2.80 (m, 0.88H), 2.44 - 2.33 (m, 0.21H), 2.30 - 2.20 (m, 0.82H), 1.67 - 1.37 (m, 3H). (Fraction of Hs that overlap with DMSO and water are not reported).
Example 547: ('4-Bronio-6-quinolyl)-[('7S)-2.7-diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro- methanone.
Figure imgf000514_0001
The title compound was prepared in a manner analogous to Example 288, using 4- bromoquinoline-6-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl) benzoic acid.
MS (ESI): mass calcd. for C24Hi8BrF3N40, 514.1 ; m/z found, 515.0 [M+H]+. Ή NMR (500 MHz, DMSO-r/e) d 8.81 (d, J= 4.6 Hz, 1H), 8.24 - 8.13 (m, 2H), 8.04 (d, J= 4.7 Hz, 1H), 7.95 - 7.83 (m, 1H), 7.64 - 7.49 (m, 2H), 5.75 - 5.45 (m, 1H), 4.88 - 4.49 (m, 1H), 3.91 - 3.57 (m,
4H), 2.91 - 2.79 (m, 1H), 2.46 - 2.28 (m, 1H), 1.53 (d, J= 6.8 Hz, 3H).
Example 548: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-(2-methyl-6-quinolyl)methanone.
Figure imgf000514_0002
The title compound was prepared in a manner analogous to Example 288, using 2- methylquinoline-6-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C25H21F3N4O, 450.2; m/z found, 451.2 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 8.35 (d, J= 8.4 Hz, 1H), 8.08 - 7.94 (m, 2H), 7.79 - 7.67 (m, 1H), 7.65 - 7.44 (m, 3H), 5.73 - 5.48 (m, 0.60H), 4.82 - 4.52 (m, 0.40H), 3.91 - 3.59 (m, 4H), 3.27 - 2.76 (m, 2H), 2.69 (s, 3H), 2.46 - 2.18 (m, 1H), 1.56 - 1.39 (m, 3H).
Example 549: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-(4-methyl-6-quinolyl)methanone.
Figure imgf000515_0001
The title compound was prepared in a manner analogous to Example 288, using 4- methylquinoline-6-carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C25H21F3N4O, 450.2; m/z found, 451.0 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 8.83 (d, J= 4.3 Hz, 1H), 8.18 - 8.02 (m, 2H), 7.83 - 7.69 (m, 1H), 7.63 - 7.41 (m, 3H), 5.72 - 5.51 (m, 1H), 4.86 - 4.54 (m, 1H), 3.89 - 3.55 (m, 4H), 3.18 - 2.77 (m, 1H), 2.76 - 2.64 (m, 3H), 2.43 - 2.26 (m, 1H), 1.52 (d, J= 6.7 Hz, 3H).
Example 550: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-(8-methoxy-4-quinolyl)methanone.
Figure imgf000515_0002
The title compound was prepared in a manner analogous to Example 288, using 8- methoxyquinoline-4-carboxybc acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C25H21F3N4O2, 466.2; m/z found, 467.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 8.92 (d, J= 4.2 Hz, 1H), 7.69 - 7.42 (m, 4H), 7.32 - 7.11 (m, 2H), 5.86 - 5.68 (m, 1H), 4.92 - 4.21 (m, 1H), 3.99 (d, J= 6.0 Hz, 3H), 3.76 (d, J= 54.2 Hz, 3H), 3.21 (d, J = 7.1 Hz, 2H), 2.84 - 2.60 (m, 1H), 2.41 - 2.17 (m, 1H), 1.64 - 1.52 (m, 2H).
Example 551 : 5.6-Dihvdro-4H-pyrrolorE2-blpyrazol-3-yl-r(7SV2.7-dimethyl-3-(3A5- trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-clpyridin-6-yllmethanone.
Figure imgf000516_0001
The title compound was prepared in a manner analogous to Example 288, using 5,6-dihydro-4H- pyrrolo[l,2-b]pyrazole-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C21H20F3N5O, 415.2; m/z found, 416.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 7.71 (s, 1H), 7.60 - 7.47 (m, 2H), 5.40 (s, 1H), 4.36 - 4.19 (m, 1H), 4.09 (t, J = 7.3 Hz, 2H), 3.79 (s, 3H), 3.29 - 3.13 (m, 1H), 3.01 - 2.79 (m, 3H), 2.62 - 2.53 (m, 2H), 2.48 - 2.35 (m, 1H), 1.53 - 1.35 (m, 3H).
Example 552: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('4.5.6.7-tetrahvdropyrazolon .5-a1pyridin-3-yl)niethanone.
Figure imgf000516_0002
The title compound was prepared in a manner analogous to Example 288, using 4, 5,6,7- tetrahydropyrazolo[l,5-a]pyridine-3-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C22H22F3N5O, 429.2; m/z found, 430.2 [M+H]+. ' H NMR (500 MHz, DMSO-r/e) 5 7.61 (s, 1H), 7.59 - 7.50 (m, 2H), 5.52 - 5.24 (m, 1H), 4.26 -
3.99 (m, 3H), 3.79 (s, 3H), 3.26 - 3.14 (m, 1H), 2.95 - 2.66 (m, 3H), 2.46 - 2.30 (m, 1H), 2.03 - 1.89 (m, 2H), 1.87 - 1.68 (m, 2H), 1.49 - 1.36 (m, 3H). Example 553: 6.7-Dihvdro-5H-pyrazolor5.l-birl.31oxazin-2-yl-r(7SV2.7-dimethyl-3-(3.4.5- trifluorophenyl)-5.7-dihvdro-4H-pyrazolo clpyridin-6-yllmethanone.
Figure imgf000517_0001
Figure imgf000517_0002
The title compound was prepared in a manner analogous to Example 288, using 6, 7-dihydro- 5H- pyrazolo[5,l-b][l,3]oxazine-2-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C21H20F3N5O, 431.2; m/z found, 432.1 [M+H]+. ' H NMR (400 MHz, DMSO-r/e) d 7.61 - 7.45 (m, 2H), 5.90 - 5.74 (m, 1H), 5.61 - 5.30 (m, 1H), 4.84 - 4.53 (m, 1H), 4.38 - 4.23 (m, 2H), 4.22 - 4.06 (m, 2H), 3.84 - 3.67 (m, 3H), 3.27 - 2.60 (m, 2H), 2.39 (d, = 15.6 Hz, 1H), 2.27 - 2.14 (m, 2H), 1.54 - 1.35 (m, 3H).
Example 554: 6.7-Dihvdro-5H-pyrazolor5.l-birE31oxazin-3-yl-r(7SV2.7-dimethyl-3-(3A5- trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000517_0003
The title compound was prepared in a manner analogous to Example 288, using 6, 7-dihydro- 5H- pyrazolo[5,l-b][l,3]oxazine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C21H20F3N5O, 431.2; m/z found, 432.1 [M+H]+. ' H NMR (400 MHz, DMSO-r/e) d 7.61 - 7.51 (m, 2H), 7.48 (s, 1H), 5.42 - 5.20 (m, 1H), 4.49 - 4.26 (m, 2H), 4.18 - 4.02 (m, 3H), 3.78 (s, 3H), 3.27 - 3.05 (m, 1H), 2.80 (t, J= 12.6 Hz, 1H), 2.45 - 2.31 (m, 1H), 2.28 - 2.06 (m, 2H), 1.52 - 1.27 (m, 3H). Example 555: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000518_0001
c1pyridin-6-yl1-(3-methyl-6.7-dihvdro-5H-pyrazolor5.l-birl.31oxazin-2- methanone.
Figure imgf000518_0002
Figure imgf000518_0003
The title compound was prepared in a manner analogous to Example 288, using 3-methyl-6,7- dihydro-5H-pyrazolo[5,l-b][l,3]oxazine-2-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3- triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C22H22F3N5O2, 445.2; m/z found, 446.1 [M+H]+.
Figure imgf000518_0004
7.54 (dd, J= 8.7, 6.7 Hz, 2H), 5.56 (q, J= 6.7 Hz, 1H), 4.68 - 4.37 (m, 1H), 4.30 (t, J= 5.2 Hz, 2H), 4.15 - 4.01 (m, 2H), 3.84 - 3.72 (m, 3H), 3.17 - 2.65 (m, 2H), 2.48 - 2.30 (m, 1H), 2.25 - 2.10 (m, 2H), 1.84 (s, 3H), 1.49 - 1.35 (m, 3H).
Example 556: it7S)-2.7-Dimethyl-3-t3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('2.6.6-trimethyl-4.7-dihvdropyrazolo[5. 1 oxazin-3-yl)methanone.
Figure imgf000518_0005
Figure imgf000518_0006
The title compound was prepared in a manner analogous to Example 288, using 2,6,6-trimethyl- 6,7-dihydro-4H-pyrazolo[5,l-c][l,4]oxazine-3-carboxylic acid (Intermediate 105) instead of 2- fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C24H26F3N5O2, 473.2; m/z found, 474.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 7.62 - 7.45 (m, 2H), 5.53 - 5.35 (m, 1H), 4.70 (q, J= 16.1 Hz, 2H), 3.92 - 3.84 (m, 2H), 3.80 (s, 3H), 3.28 - 3.09 (m, 2H), 2.71 - 2.56 (m, 1H), 2.43 - 2.30 (m, 1H), 2.13 (s, 3H), 1.38 (d, J= 6.8 Hz, 3H), 1.27 (d, = 3.4 Hz, 6H). Example 557: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000519_0001
c1pyridin-6-yl1-('3.6.6-trimethyl-4.7-dihvdropyrazoloi5. 1 -cli l .41oxazin-2-yl)methanone.
Figure imgf000519_0002
The title compound was prepared in a manner analogous to Example 288, using ethyl 3,6,6- trimethyl-6, 7-dihydro-4H-pyrazolo[5,l-c][l,4]oxazine-2-carboxylate (Intermediate 106) instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C24H26F3N5O2, 473.2; m/z found, 474.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 7.59 - 7.47 (m, 2H), 5.66 - 5.40 (m, 1H), 4.77 (s, 2H), 4.68 - 4.29 (m, 1H), 3.97 - 3.88 (m, 2H), 3.84 - 3.72 (m, 3H), 3.28 - 3.10 (m, 1H), 3.09 - 2.58 (m, 1H), 2.47 - 2.30 (m, 1H), 1.99 - 1.85 (m, 3H), 1.50 - 1.37 (m, 3H), 1.34 - 1.23 (m, 6H).
Example 558: (( S Dimethyl-3 -( 3 A5-trifluorophenyl)-4.5 -dihydro-2H-pyrazolo [3.4-
Figure imgf000519_0003
c1pyridin-6('7H)-yl)('7-('trifluoromethyl)-4.5.6.7-tetrahvdropyrazolon .5-a1pyrimidin-3- vDmethanone.
Figure imgf000519_0004
The title compound was prepared in a manner analogous to Example 288, using 7- (trifluoromethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrimidine-3-carboxylic acid instead of 2- fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C22H20F6N6O, 498.2; m/z found, 499.0 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 7.61 (d, J= 3.2 Hz, 1H), 7.59 - 7.48 (m, 2H), 7.16 - 7.04 (m, 1H), 5.44 - 5.28 (m, 1H), 5.23 - 5.05 (m, 1H), 4.40 - 4.06 (m,
1H), 3.83 - 3.71 (m, 3H), 3.52 - 3.35 (m, 1H), 3.21 - 3.10 (m, 2H), 2.94 - 2.73 (m, 1H), 2.48 - 2.37 (m, 1H), 2.37 - 2.07 (m, 2H), 1.53 - 1.38 (m, 3H). Example 559: 6.7-Dihvdro-5H-pyrrolorl.2-a1imidazol-3-yl-r(7SV2.7-dimethyl-3-(3.4.5- trifluorophenyl)-5.7-dihvdro-4H-pyrazolo clpyridin-6-yllmethanone.
Figure imgf000520_0001
Figure imgf000520_0002
The title compound was prepared in a manner analogous to Example 288, using 6, 7-dihydro- 5H- pyrrolo[l,2-a]imidazole-3-carboxylic acid hydrochloride instead of 2-fluoro-6-(2H- 1,2,3 -triazol- 2-yl)benzoic acid. MS (ESI): mass calcd. for C21H20F3N5O, 415.2; m/z found, 416.2 [M+H]+. ¾ NMR (500 MHz, Chloroform-r/) d 7.59 - 7.52 (m, 2H), 7.40 (s, 1H), 5.44 (q, J= 6.7 Hz, 1H), 4.46 - 4.36 (m, 1H), 4.21 - 4.13 (m, 1H), 4.02 - 3.94 (m, 1H), 3.79 (s, 3H), 2.96 - 2.70 (m, 3H), 1.56 - 1.38 (m, 3H). (Fractions of Hs that overlap with DMSO and water are not reported).
Example 560: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('5.6.7.8-tetrahvdroimidazon .2-a1pyridin-3-yl)methanone.
Figure imgf000520_0003
The title compound was prepared in a manner analogous to Example 288, using 5, 6, 7, 8- tetrahydroimidazo[l,2-a]pyridine-3 -carboxylic acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C22H22F3N5O, 429.2; m/z found, 430.1 [M+H]+. XH NMR (500 MHz, DMSO-r/e) d 7.56 (dd, = 8.7, 6.6 Hz, 2H), 7.24 (s, 1H), 5.51 - 5.32 (m, 1H), 4.42 - 4.20 (m, 1H), 4.20 - 4.06 (m, 1H), 3.96 - 3.82 (m, 1H), 3.80 (s, 3H), 3.17 (s, 1H), 2.97 - 2.84 (m, 1H), 2.84 - 2.71 (m, 2H), 2.46 - 2.34 (m, 1H), 1.95 - 1.77 (m, 4H), 1.52 - 1.38 (m,
3H). Example 561 : r2-(DifluoromethylV5.6.7.8-tetrahvdroimidazorE2-alpyridin-3-vHT(7SV2.7- dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazoloi3.4-c1pyridin-6-yl1methanone.
Figure imgf000521_0001
The title compound was prepared in a manner analogous to Example 288, using 2- (difluoromethyl)-5,6,7,8-tetrahydroimidazo[l,2-a]pyridine-3-carboxylic acid instead of 2-fluoro- 6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C23H22F5N5O, 479.2; m/z found, 480.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 7.56 (dd, J= 8.7, 6.6 Hz, 2H), 7.24 (s, 1H), 5.51 - 5.32 (m, 1H), 4.42 - 4.20 (m, 1H), 4.20 - 4.06 (m, 1H), 3.96 - 3.82 (m, 1H), 3.80 (s, 3H), 3.17 (s, 1H), 2.97 - 2.84 (m, 1H), 2.84 - 2.71 (m, 2H), 2.46 - 2.34 (m, 1H), 1.95 - 1.77 (m, 4H), 1.52 - 1.38 (m, 3H).
Example 562: 6.8-Dihydro- 5H-imidazo -cl G 1.41 oxazin-3 -yl- G ( 7S)-2.7-dimethyl-3 -( 3.4.5-
Figure imgf000521_0002
trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000521_0003
The title compound was prepared in a manner analogous to Example 288, using 5,6-dihydro-8H- imidazo[2,l-c][l,4]oxazine-3-carboxylic acid hydrochloride instead of 2-fluoro-6-(2H-l,2,3- triazol-2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C21H20F3N5O2, 431.2; m/z found, 432.2 [M+H]+.
Figure imgf000521_0004
NMR (500 MHz, DMSO-r/e) d 7.60 - 7.51 (m, 2H), 7.36 (s, 1H), 5.48 - 5.38 (m, 1H), 4.84 - 4.71 (m, 2H), 4.41 - 4.28 (m, 1H), 4.26 - 4.17 (m, 1H), 4.09 - 3.89 (m, 3H), 3.80 (s, 3H), 3.01 - 2.85 (m, 1H), 2.48 - 2.42 (m, 1H), 1.55 - 1.42 (m, 3H).
(Fractions of Hs that overlap with DMSO and water are not reported). Example 563: 3.4-Dihvdro-2H-pyranor2.3-blpyridin-6-yl-r(7SV2.7-dimethyl-3-(3A5- trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-c1pyridin-6-yl1methanone.
Figure imgf000522_0001
The title compound was prepared in a manner analogous to Example 288, using 3,4-dihydro-2H- pyrano[2,3-b]pyridine-6-carboxylic acid instead of 2-fluoro-6-(2H-l ,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H21F3N4O2, 442.2; m/z found, 443.1 [M+H]+. 1H NMR (500 MHz, DMSO-r/e) d 8.10 - 8.06 (m, 1H), 7.62 - 7.52 (m, 3H), 5.61 - 5.37 (m, 0.78H), 4.34 - 4.29 (m, 2H), 3.8 - 3.67 (m, 3.85H), 2.92 - 2.75 (m, 3H), 1.97 - 1.89 (m, 2H), 1.45 (d, J= 6.8 Hz, 3H). (Fractions of Hs that overlap with DMSO and water are not reported).
Example 564: 3.4-Dihvdro-2H-pyranor2.3-b1pyridin-5-yl-r(7SV2.7-dimethyl-3-(3.4.5- trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000522_0002
The title compound was prepared in a manner analogous to Example 288, using 3,4-dihydro-2H- pyrano[2,3-b]pyridine-5-carboxylic acid (Intermediate 58) instead of 2-fluoro-6-(2H-l,2,3- triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C23H21F3N4O2, 442.2; m/z found, 443.2 [M+H]+. (500 MHz, Chloroform-r/) d 8.20 - 8.05 (m, 1H), 7.02 - 6.90 (m, 2H), 6.86 - 6.60 (m, 1H), 5.93 - 5.84 (m, 0.57H), 4.97 - 4.87 (m, 0.49H), 4.69 - 4.59 (m, 0.28H), 4.46 - 4.25 (m, 2H), 3.86 - 3.76 (m, 3H), 3.67 - 3.47 (m, 0.63H), 3.32 - 3.22 (m, 0.56H), 3.08 - 2.91 (m, 1H), 2.89 - 2.22 (m, 3H), 2.12 - 1.86 (m, 2H), 1.64 - 1.34 (m, 3H). Example 565: 6.8-Dihvdro-5H-pyranor3.4-blpyridin-4-yl-r(7SV2.7-dimethyl-3-(3A5- trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-c1pyridin-6-yl1methanone.
Figure imgf000523_0001
The title compound was prepared in a manner analogous to Example 288, using 5,8-dihydro-6H- pyrano[3,4-b]pyridine-4-carboxylic acid (Intermediate 57) instead of 2-fluoro-6-(2H-l,2,3- triazol-2-yl) benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C23H21F3N4O2, 442.1; m/z found, 443.2 [M+H]+.
Example 566: 6.8-Dihvdro-5H-pyranor3.4-blpyridin-2-yl-r(7SV2.7-dimethyl-3-(3A5- trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000523_0002
The title compound was prepared in a manner analogous to Example 288, using 5,8-dihydro-6H- pyrano[3,4-b]pyridine-2-carboxylic acid (Intermediate 59) instead of 2-fluoro-6-(2H-l,2,3- triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C23H21F3N4O2, 442.2; m/z found, 443.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) 5 7.73 - 7.69 (m, 1H), 7.58 - 7.50 (m, 2H), 7.42 - 7.38
(m, 1H), 5.56 (q, J= 6.7 Hz, 0.63H), 4.89 (q, J= 6.6 Hz, 0.42H), 4.73 - 4.59 (m, 2.56H), 3.99 - 3.71 (m, 6H), 3.07 - 2.99 (m, 0.41H), 2.92 - 2.85 (m, 2H), 2.81 - 2.70 (m, 1H), 2.35 - 2.28 (m, 0.59H), 1.49 - 1.43 (m, 3H). (Fractions of Hs that overlap with DMSO and water are not reported). Example 567: 7.8-Dihvdro-5H-pyranor4.3-blpyridin-3-yl-r(7SV2.7-dimethyl-3-(3A5- trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-c1pyridin-6-yl1methanone.
Figure imgf000524_0001
The title compound was prepared in a manner analogous to Example 288, using 7,8-dihydro-5H- pyrano[4,3-b]pyridine-3-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C23H21F3N4O2, 442.2; m/z found, 443.2 [M+H]+. ¾ NMR (500 MHz, Chlorofornw/) d 8.52 (s, 1H), 7.41 (s, 1H), 7.01 - 6.92 (m, 2H), 5.82 (s, 0.46H), 5.03 - 4.66 (m, 3H), 4.10 (t, J= 5.8 Hz, 2H), 3.89 - 3.70 (m, 3.59H), 3.45 - 2.97 (m, 3H), 2.90 - 2.60 (m, 1H), 2.53 - 2.32 (m, 1H), 1.66 - 1.51 (m, 3H).
Example 568: 3.4-Dihvdro-2H-pyranor3.2-b1pyridin-8-yl-r(7SV2.7-dimethyl-3-(3.4.5- trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000524_0002
The title compound was prepared in a manner analogous to Example 288, using 3,4-dihydro-2H- pyrano[3,2-b]pyridine-8-carboxybc acid instead of 2-fluoro-6-(2H-l ,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C23H21F3N4O2, 442.2; m/z found, 443.1 [M+H]+.
Figure imgf000524_0003
(500 MHz, DMSO-r/6) 5 8.11 (d, = 4.7 Hz, 1H), 7.58 - 7.40 (m, 2H), 7.17 - 6.89 (m, 1H), 5.71 - 5.35 (m, 0.70H), 4.76 - 4.41 (m, 0.30H), 4.31 - 4.14 (m, 2H), 3.86 - 3.72 (m, 3H), 3.48 - 3.35 (m, 1H), 3.29 - 3.12 (m, 1H), 3.00 - 2.80 (m, 2H), 2.71 - 2.54 (m, 1H), 2.46 - 2.16 (m, 1H), 2.12 - 1.95 (m, 2H), 1.51 - 1.29 (m, 3H). Example 569: 2.3-Dihvdro-rE41dioxinor2.3-blpyridin-8-ylT(7SV2.7-dimethyl-3-(3A5- trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-c1pyridin-6-yl1methanone.
Figure imgf000525_0001
The title compound was prepared in a manner analogous to Example 288, using 2,3-dihydro- [l,4]dioxino[2,3-b]pyridine-8-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C22H19F3N4O3, 444.1 ; m/z found, 445.2 [M+H]+. XH NMR (500 MHz, DMSO-r/e) d 7.85 - 7.72 (m, 1H), 7.58 - 7.46 (m, 2H), 7.01 - 6.67 (m, 1H), 5.63 - 5.49 (m, 0.76H), 4.72 - 4.23 (m, 4.56H), 4.19 - 4.05 (m, 0.25H), 3.85 - 3.69 (m, 3H), 3.56 - 3.44 (m, 0.81H), 3.10 - 2.96 (m, 0.26H), 2.77 - 2.57 (m, 1H), 2.42 - 2.23 (m, 0.72H), 1.50 - 1.29 (m, 3H). (Fractions of Hs that overlap with DMSO and water are not reported).
Example 570: 2.3-Dihvdro-rl.41dioxinor2.3-b1pyridin-7-yl-r(7SV2.7-dimethyl-3-(3.4.5- trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-c1pyridin-6-yl1methanone.
Figure imgf000525_0002
The title compound was prepared in a manner analogous to Example 288, using 2,3-dihydro- [l,4]dioxino[2,3-b]pyridine-7-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C22H19F3N4O3, 444.1 ; m/z found, 445.2 [M+H]+. XH NMR (500 MHz, DMSO-r/e) d 7.84 (s, 1H), 7.59 - 7.51 (m, 2H), 7.36 (s, 1H), 5.50 (br s, 0.74H), 4.97 - 4.39 (m, 2.82H), 4.36 - 4.23 (m, 2.25H), 3.89 - 3.61 (m, 4H), 2.87 (br s, 1H), 2.42 - 2.28 (m, 0.88H), 1.45 (d, J = 6.7 Hz, 3H). (Fractions of Hs that overlap with DMSO and water are not reported). Example 571 : 3.4-Dihvdro-2H-pyridor3.2-birl.41oxazin-7-yl-r(7SV2.7-dimethyl-3-(3.4.5- trifluorophenyl)-5.7-dihvdro-4H-pyrazolo clpyridin-6-yllmethanone.
Figure imgf000526_0001
Figure imgf000526_0002
The title compound was prepared in a manner analogous to Example 288, using 3,4-dihydro-2H- pyrido[3,2-b][l,4]oxazine-7-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C22H20F3N5O2, 443.2; m/z found, 444.2 [M+H]+. Ή NMR (500 MHz, Chloroform-^ d 7.84 (d, J= 1.9 Hz, 1H), 7.11 - 7.07 (m, 1H), 7.00 - 6.93 (m, 2H), 5.47 (br s, 1H), 5.03 (s, 1H), 4.71 - 4.03 (m, 3H), 3.80 (s, 3H), 3.64 - 3.55 (m, 2H), 3.20 (s, 1H), 2.84 - 2.71 (m, 1H), 2.45 - 2.36 (m, 1H), 1.58 (d, J= 6.8 Hz, 3H).
Example 572: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1 -(4-methyl-2.3 -dihydropyrido bli l .41 oxazin-7-yl jmethanone.
Figure imgf000526_0003
Figure imgf000526_0004
The title compound was prepared in a manner analogous to Example 288, using 4-methyl-3,4- dihydro-2H-pyrido[3,2-b][l,4]oxazine-7-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol- 2-yl) benzoic acid. MS (ESI): mass calcd. for C23H22F3N5O2, 457.2; m/z found, 458.2
[M+H]+. (500 MHz, Chloroform-;/) d 7.91 (d, J= 1.9 Hz, 1H), 7.04 (d, J= 1.9 Hz, 1H), 7.00 - 6.93 (m, 2H), 5.48 (br s, 1H), 4.57 - 4.16 (m, 3H), 3.80 (s, 3H), 3.54 - 3.46 (m, 2H), 3.29 - 3.11 (m, 4H), 2.85 - 2.75 (m, 1H), 2.44 - 2.37 (m, 1H), 1.58 (d, J= 6.8 Hz, 3H). Example 573: 3.4-Dihvdro-2H-pyranor2.3-clpyridin-6-yl-r(7SV2.7-dimethyl-3-(3A5- trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-c1pyridin-6-yl1methanone.
Figure imgf000527_0001
The title compound was prepared in a manner analogous to Example 288, using 3,4-dihydro-2H- pyrano[2,3-c]pyridine-6-carboxylic acid instead of 2-fluoro-6-(2H-l ,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C23H21F3N4O2, 442.2; m/z found, 443.1 [M+H]+. ¾ NMR (400 MHz, Chloroform-i/) d 8.09 (s, 1H), 7.50 - 7.40 (m, 1H), 7.04 - 6.90 (m, 2H), 5.87 - 5.77 (m, 0.52H), 5.51 - 5.41 (m, 0.42H), 4.88 - 4.77 (m, 0.46H), 4.34 - 7.22 (m, 2.60H), 3.87 - 3.73 (m, 3H), 3.31 - 3.19 (m, 0.55H), 3.15 - 2.91 (m, 1H), 2.90 - 2.7l(m, 2.49H), 2.49 - 2.29 (m, 1H), 2.10 - 1.99 (m, 2H), 1.66 - 1.56 (m, 3H).
Example 574: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-nII-P .2.3.4-tetrahydroisoquinolin-5-yl)niethanone.
Figure imgf000527_0002
Step A: tert-Butyl ('S)-5-('2.7-diniethyl-3-('3.4.5-trifluorophenyl)-4.5.6.7-tetrahydro-2H- Pyrazolo[3.4-c1pyridine-6-carbonyl)-3.4-dihvdroisoquinoline-2n H)-carboxylate. The title compound was prepared in a manner analogous to Example 288, using 2-(tert-butoxycarbonyl)- l,2,3,4-tetrahydroisoquinoline-5-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C29H31F3N4O, 540.2; m/z found, 541.2 [M+H] +.
Step B: r(7SV2.7-Dimethyl-3-(3A5-trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-clpyridin-6- yll -( 1.2.3.4-tetrahydroisoquinolin-5-yl)niethanone. TFA (0.24 mL, 3.1 mmol) was added to a mixture of tert-butyl (S)-5-(2,7-dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H- pyrazolo[3,4-c]pyridine-6-carbonyl)-3,4-dihydroisoquinoline-2(lH)-carboxylate (85.1 mg, 0.16 mmol) in DCM (2.2 mL). Upon completion, volatiles were removed. Purification of the filtrate (preparative HPLC, METHOD A followed by METHOD E) afforded the title compound (46 mg, 66%). MS (ESI): mass calcd. for C24H23F3N4O, 440.2; m/z found, 441.1 [M+H] +. Ή NMR (500
MHz, Chloroform-^ d 7.24 - 6.89 (m, 5H), 5.98 - 5.88 (m, 0.58H), 5.03 - 4.92 (m, 0.52H), 4.67 (q, J= 6.7 Hz, 0.3 OH), 4.10 - 3.97 (m, 2H), 3.87 - 3.74 (m, 3H), 3.73 - 3.65 (m, 0.20H), 3.56 (dd, J= 13.5, 5.1 Hz, 0.43H), 3.27 - 2.90 (m, 3.65H), 2.86 - 2.43 (m, 2.48H), 2.35 - 2.21 (m, 0.88H), 1.61 - 1.33 (m, 3H).
Example 575: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-nII-P .2.3.4-tetrahydroisoquinolin-8-yl)methanone.
Figure imgf000528_0001
The title compound was prepared in a manner analogous to Example 574 using 2-(tert- butoxycarbonyl)-l,2,3,4-tetrahydroisoquinoline-8-carboxylic acid in Step A. MS (ESI): mass calcd. for C24H23F3N4O, 440.2; m/z found, 441.1 [M+H]+.
Example 576: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-isochroman-5-yl-methanone.
Figure imgf000528_0002
The title compound was prepared in a manner analogous to Example 288, using isochromane-5- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C24H22F3N3O2, 441.2; m/z found, 442.2 [M+H]+. Example 577: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-isochroman-7-yl-methanone.
Figure imgf000529_0001
The title compound was prepared in a manner analogous to Example 288, using isochromane-7- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C24H22F3N3O2, 441.2; m/z found, 442.1 [M+H]+. Ή NMR (500 MHz, Chloroform- ) d 7.23 - 7.19 (m, 1H), 7.18 - 7.14 (m, 1H), 7.06 (s, 1H), 7.01 - 6.93 (m, 2H), 5.82 (br s, 0.46H), 5.13 - 4.68 (m, 3H), 3.98 (t, J= 5.7 Hz, 2H), 3.89 - 3.72 (m, 3.5H), 3.35 - 2.97 (m, 1H), 2.92 - 2.56 (m, 3H), 2.50 - 2.29 (m, 1H), 1.62 - 1.49 (m, 3H). Example 578: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-isochroman-6-yl-methanone.
Figure imgf000529_0002
The title compound was prepared in a manner analogous to Example 288, using isochromane-6- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C24H22F3N3O2, 441.2; m/z found, 442.2 [M+H]+. Ή NMR (500 MHz, Chloroform- ) d 7.22 - 7.17 (m, 2H), 7.04 - 6.93 (m, 3H), 5.93 - 5.72 (m, 0.45H), 5.13 - 4.72 (m, 3H), 3.98 (t, J= 5.7 Hz, 2H), 3.92 - 3.69 (m, 3.52H), 3.35 - 2.97 (m, 1H), 2.94 - 2.57 (m, 3H), 2.40 (s, 1H), 1.65 - 1.46 (m, 3H).
Example 579: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yl1-isochroman-8-yl-methanone.
Figure imgf000530_0001
The title compound was prepared in a manner analogous to Example 288, using isochromane-8- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C24H22F3N3O2, 441.2; m/z found, 442.1 [M+H]+.
Example 580: Chroman-6-yl-[('7S)-2.7-dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H- Pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000530_0002
The title compound was prepared in a manner analogous to Example 288, using chromane-6- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C24H22F3N3O2, 441.2; m/z found, 442.2 [M+H]+. Ή NMR (500 MHz, Chloroform- ) d 7.18 - 7.13 (m, 2H), 7.01 - 6.93 (m, 2H), 6.79 (d, = 8.2 Hz, 1H), 5.93 - 3.61 (m, 7H), 3.17 (br s, 1H), 2.87 - 2.65 (m, 3H), 2.44 - 2.34 (m, 1H), 2.06 - 1.96 (m, 2H), 1.58 - 1.52 (s, 3H). Example 581 : Chroman-5-yl-[('7S)-2.7-dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H- Pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000531_0001
The title compound was prepared in a manner analogous to Example 288, using chromane-5- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C24H22F3N3O2, 441.2; m/z found, 442.1 [M+H]+. Ή NMR (500 MHz, Chloroform- ) d 7.18 - 6.60 (m, 5H), 5.98 - 5.87 (m, 0.57H), 5.07 - 4.91 (m, 0.54H), 4.77 - 4.68 (m, 0.29H), 4.30 -
4.07 (m, 2H), 3.86 - 3.69 (m, 3H), 3.61 (dd, J= 13.6, 5.1 Hz, 0.41H), 3.22 (td, J= 12.9, 3.6 Hz, 0.58H), 3.06 - 2.89 (m, 1H), 2.87 - 2.69 (m, 0.71H), 2.66 - 2.40 (m, 2H), 2.38 - 2.18 (m, 0.86H), 2.11 - 1.83 (m, 2H), 1.63 - 1.32 (m, 3H). Example 582: Chroman-7-yl-[('7S)-2.7-dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H- Pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000531_0002
The title compound was prepared in a manner analogous to Example 288, using chromane-7- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C24H22F3N3O2, 441.2; m/z found, 442.1 [M+H]+. Ή NMR (500 MHz, Chloroform- ) d 7.09 - 7.03 (m, 1H), 7.00 - 6.93 (m, 2H), 6.90 - 6.85 (m, 1H), 6.84 - 6.80 (m, 1H), 5.81 (br s,
0.46H), 5.13 - 4.67 (m, 1H), 4.24 - 4.15 (m, 2H), 3.99 - 3.68 (m, 3.62H), 3.33 - 2.95 (m, 1H), 2.88 - 2.58 (m, 3H), 2.38 (br s, 1H), 2.05 - 1.98 (m, 2H), 1.63 -1.45 (m, 3H). Example 583: Chroman-8-yl-[('7S)-2.7-dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H- Pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000532_0001
The title compound was prepared in a manner analogous to Example 288, using chromane-8- carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl) benzoic acid. MS (ESI): mass calcd. for C24H22F3N3O2, 441.2; m/z found, 442.1 [M+H]+. 1H NMR (500 MHz, Chloroform- ) d 7.10 - 6.77 (m, 5H), 5.94 - 5.87 (m, 0.55H), 5.01 - 4.92 (m, 0.48H), 4.91 - 4.85 (m, 0.28H), 4.82 -
4.76 (m, 0.22H), 4.30 - 4.10 (m, 1.69H), 4.06 - 3.98 (m, 0.21H), 3.94 - 3.87 (m, 0.22H), 3.85 - 3.72 (m, 3H), 3.70 - 3.60 (m, 0.61 H), 3.32 - 3.14 (m, 0.60H), 3.09 - 2.93 (m, 0.47H), 2.88 - 2.67 (m, 2.74H), 2.56 - 2.39 (m, 0.76H), 2.33 - 2.22 (m, 0.59H), 2.12 - 1.85 (m, 2.18H), 1.62 - 1.34 (m, 3H).
Example 584: 4-IY7S)-2.7-Dimethyl-3-('3 A5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000532_0002
l.3-benzoxazol-2-one.
Figure imgf000532_0003
The title compound was prepared in a manner analogous to Example 288, using 2-oxo-2,3- dihydrobenzo[d]oxazole-4-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H17F3N4O3, 442.1; m/z found, 443.0 [M+H]+. ¾ NMR (400 MHz, Methanol-^) d 7.32 - 7.26 (m, 3H), 7.20 - 7.14 (m, 2H), 5.97 - 5.59 (m, 1H), 3.82 (s, 4H), 3.47 - 3.34 (m, 1H), 2.89 - 2.69 (m, 1H), 2.58 - 2.37 (m, 1H), 1.38 - 1.32 (m, 3H). Example 585: 4-IY7S)-2.7-Diniethyl-3-('3A5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000532_0004
c1pyridine-6-carbonyl1-3-methyl-E3-benzoxazol-2-one.
Figure imgf000533_0001
The title compound was prepared in a manner analogous to Example 206, using 4-[(7S)-2,7- dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-6-carbonyl]-3H-l,3- benzoxazol-2-one (Example 584) instead of [(S)-(2,7-dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7- tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(lH-indol-7-yl)methanone] (Example 205).
MS (ESI): mass calcd. for C23H19F3N4O3, 456.1; m/z found, 457.0 [M+H]+. Ή NMR (400 MHz, Methanol-A) d 7.46 - 7.11 (m, 5H), 5.98 - 5.84 (m, 0.30H), 5.77 (q, J= 6.6 Hz, 0.70H), 3.84 (s, 2.1H), 3.77 (s, 0.90H), 3.73 (dd, J= 14.1, 5.3 Hz, 0.30H), 3.48 - 3.36 (m, 3.70H), 3.30 - 3.25 (m, 0.3 OH), 3.20 - 3.09 (m, 0.70H), 2.90 - 2.71 (m, 1H), 2.60 (dd, J= 15.6, 4.0 Hz, 0.30H), 2.47 - 2.36 (m, 0.70H), 1.61 (d, = 6.8 Hz, 2.1H), 1.53 (d, = 6.6 Hz, 0.90H).
Example 586: 5-[('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridine-6-carbonyl1-3H-E3-benzoxazol-2-one.
Figure imgf000533_0002
The title compound was prepared in a manner analogous to Example 288, using 2-oxo-2,3- dihydrobenzo[d]oxazole-5-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H17F3N4O3, 442.1 ; m/z found, 443.0 [M+H]+. Ή NMR (400 MHz, Methanol-i 4) d 7.43 - 7.21 (m, 3H), 7.22 - 7.06 (m, 2H), 5.98 - 5.51 (m, 1H), 4.16 - 3.68 (m, 4H), 3.39 - 3.19 (m, 1H), 2.90 - 2.71 (m, 1H), 2.56 - 2.42 (m, 1H), 1.56 (d, = 6.8 Hz, 3H). Example 587: 7-IY7S)-2.7-Dimethyl-3-('3A5-trifluorophenyl)-5.7-dihydro-4H-pyrazolo
Figure imgf000534_0001
c1pyridine-6-carbonyl1-3H-l.3-benzoxazol-2-one.
Figure imgf000534_0002
The title compound was prepared in a manner analogous to Example 288, using 2-oxo-2,3- dihydrobenzo[d]oxazole-7-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H17F3N4O3, 442.1; m/z found, 443.1 [M+H]+. 1H NMR (400 MHz, DMSO-r/e) d 11.84 (s, 1H), 7.61 - 7.47 (m, 2H), 7.26 - 7.14 (m, 2H), 7.12 - 7.01 (m, 1H), 5.61 (q, J = 6.1 Hz, 0.69H), 4.74 - 4.62 (m, 0.52H), 3.85 - 3.70 (m, 3H), 3.66 - 3.55 (m, 0.72H), 2.81 - 2.64 (m, 1H), 2.40 - 2.27 (m, 0.77H), 1.54 - 1.34 (m, 3H). (Fractions of Hs that overlap with DMSO and water are not reported).
Example 588: 6-IY7S)-2.7-Dimethyl-3-('3A5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000534_0003
c1pyridine-6-carbonyl1-3H-E3-benzoxazol-2-one.
Figure imgf000534_0004
The title compound was prepared in a manner analogous to Example 288, using 2-oxo-2,3- dihydrobenzo[d]oxazole-6-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H17F3N4O3, 442.1; m/z found, 443.1 [M+H]+. ¾ NMK (500 MHz, DMSO-i e) 5 11.83 (br s, 1H), 7.59 - 7.50 (m, 2H), 7.36 (s, 1H), 7.24 - 7.18 (m, 1H), 7.16 - 7.11 (m, 1H), 5.63 - 5.30 (m, 0.55H), 3.90 - 3.59 (m, 4H), 2.93 - 2.75 (m, 1H), 2.41 - 2.30 (m, 1H), 1.45 (d, J= 6.7 Hz, 3H). (Fractions of Hs that overlap with DMSO and water are not reported). Example 589: 7-i -2.7-dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazoloi3.4-
Figure imgf000535_0001
clpyridine-6-carbonyll-3-methyl-E3-benzoxazol-2-one.
Figure imgf000535_0002
The title compound was prepared in a manner analogous to Example 288, using 3-methyl-2-oxo- 2,3-dihydrobenzo[d]oxazole-7-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol-2- yl)benzoic acid. MS (ESI): mass calcd. for C23H19F3N4O3, 456.1 ; m/z found, 457.2 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 7.61 - 7.48 (m, 2H), 7.38 - 7.28 (m, 2H), 7.17 - 7.06 (m, 1H), 5.62 (q, J= 6.7 Hz, 0.71H), 4.74 - 4.64 (m, 0.58H), 3.85 - 3.71 (m, 3H), 3.63 - 3.56 (m, 0.73H), 3.36 (s, 3H), 3.14 - 3.04 (m, 0.27H), 2.82 - 2.65 (m, 1H), 2.38 - 2.29 (m, 0.68H), 1.55 - 1.33
(m, 3H). (Fractions of Hs that overlap with DMSO and water are not reported).
Example 590: 7-IY7S)-2.7-Dimethyl-3-('3A5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000535_0003
c1pyridine-6-carbonyl1-4-methyl-E4-benzoxazin-3-one*TFA salt.
Figure imgf000535_0004
The title compound was prepared in a manner analogous to Example 288, using 4-methyl-3-oxo- 3,4-dihydro-2H-benzo[b][l,4]oxazine-7-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol- 2-yl)benzoic acid. MS (ESI): mass calcd. for C24H21F3N4O3, 470.2; m/z found, 471.2
[M+H]+. (500 MHz, Chloroform-^ d 7.16 - 7.12 (m, 1H), 7.09 - 7.07 (m, 1H), 7.03 - 6.94 (m, 3H), 5.84 (br s, 0.37H), 5.16 - 4.59 (m, 3H), 4.01 - 3.70 (m, 3.48H), 3.43 - 3.01 (m,
4H), 2.75 (s, 1H), 2.50 - 2.33 (m, 1H), 1.63 - 1.49 (m, 3H). Example 591 : IY7SV2.7- 8-r(7SV2.7-Dimethyl-3-(3.4.5-trifluorophenylV5.7-dihvdro-4H- pyrazolo G 3.4-clpyridine-6-carbonyll -4-methyl- 1 ,4-benzoxazin-3 -one*TF A salt.
Figure imgf000536_0001
The title compound was prepared in a manner analogous to Example 288, using 4-methyl-3-oxo- 3,4-dihydro-2H-benzo[b][l,4]oxazine-8-carboxylic acid instead of 2-fluoro-6-(2H-l,2,3-triazol- 2-yl)benzoic acid and DMF instead of DCM. MS (ESI): mass calcd. for C24H21F3N4O3, 470.2; m/z found, 471.1 [M+H]+. ¾ NMR (500 MHz, Chlorofornw/) d 7.16 - 6.84 (m, 5H), 5.91 (q, J = 6.7 Hz, 0.53H), 5.00 - 4.56 (m, 2.58H), 4.44 (q, J= 15.1 Hz, 0.54H), 3.86 - 3.74 (m, 3H), 3.63 (dd, J= 13.8, 5.1 Hz, 0.54H), 3.43 - 3.21 (m, 3.59H), 3.14 - 2.99 (m, 0.45H), 2.86 - 2.66 (m, 0.73H), 2.59 - 2.43 (m, 0.75H), 2.36 - 2.27 (m, 0.57H), 1.63 - 1.36 (m, 3H).
Example 592: 3.4-Dihvdro-2H-E4-benzoxazin-8-yl-r(7SV2.7-dimethyl-3-(3A5- trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-c1pyridin-6-yl1methanone.
Figure imgf000536_0002
The title compound was prepared in a manner analogous to Example 288, using 4-methyl-3-oxo- 3,4-dihydro-2H-benzo[b][l,4]oxazine-8-carboxybc acid instead of 2-fluoro-6-(2H-l,2,3-triazol- 2-yl)benzoic acid. MS (ESI): mass calcd. for C23H21F3N4O2, 442.2; m/z found, 443.2
[M+H]+. (500 MHz, Chloroform-r/) d 7.01 - 6.90 (m, 2H), 6.82 - 6.68 (m, 1H), 6.66 - 6.46 (m, 2H), 5.91 (p, J= 6.8 Hz, 0.56H), 5.01 - 4.83 (m, 0.88H), 4.37 - 4.19 (m, 1.66H), 4.13 - 3.99 (m, 0.36H), 3.88 - 3.69 (m, 4.56H), 3.54 - 3.15 (m, 2.56H), 3.08 - 2.93 (m, 0.39H), 2.86 - 2.66 (m, 0.67H), 2.58 - 2.49 (m, 0.28H), 2.48 - 2.39 (m, 0.41H), 2.35 - 2.23 (m,
0.56H), 1.63 - 1.36 (m, 3H).
Example 593: i('7S)-3-[3-('Difluoromethyl)-4-fluoro-phenyll-2.7-dimethyl-5.7-dihvdro-4H- Pyrazolo[3.4-clpyridin-6-yll-('2-methoxy-3-methyl-4-pyridyl)methanone.
Figure imgf000537_0001
Step A: (S)-6-(2-Methoxy-3-methylisonicotinoyl)-2.7-dimethyl-4.5.6.7-tetrahvdro-2H- Pyrazolo[3.4-clpyridin-3-yl trifluoromethanesulfonate. 2,4,6-Tripropyl-l,3,5,2,4,6- trioxatriphosphorinane-2, 4, 6-trioxide (T3P®) (50 % w/w solution in DCM, 1.7 g, 2.6 mmol) was added to a mixture of tert-butyl (S)-2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7- tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 8, 260 mg, 0.9 mmol), 2- methoxy-3-methylisonicotinic acid (166 mg, 1.0 mmol) and DIPEA (0.45 mL, 2.6 mmol) in DMF (3 mL) at room temperature. ETpon completion, saturated aqueous NaHCC (20 mL) was added and the mixture was extracted using EtOAc (3 x 30 mL). The combined organics were dried over MgS04, filtered and concentrated under reduced pressure to afford the title compound (309 mg, 79%). MS (ESI): mass calcd. for C17H19P3N4O5S, 448.1; m/z found, 449.2 [M+H]+. Step B: K7SV3-r3-(DifluoromethylV4-fluoro-phenyl1-2.7-dimethyl-5.7-dihvdro-4H- Pyrazolo[3.4-c1pyridin-6-yl1-('2-methoxy-3-methyl-4-pyridyl)methanone. The title compound was prepared in a manner analogous to Example 106, Step A, using 2-(3-(difluoromethyl)-4- fluorophenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C23H23F3N4O2, 444.2; m/z found, 445.2 Ή NMR (500
Figure imgf000537_0002
MHz, DMSO-r/e) d 8.16 - 8.01 (m, 1H), 7.79 - 7.65 (m, 2H), 7.59 - 7.47 (m, 1H), 7.37 - 7.31 (m, 0.25H), 7.27 - 7.19 (m, 0.50H), 7.16 - 7.09 (m, 0.25H), 6.96 (d, = 5. l Hz, 0.15H), 6.90 (d, J= 5.1 Hz, 0.5 OH), 6.82 (d, J= 5.1 Hz, 0.23H), 6.71 - 6.66 (m, 0.07H), 5.63 (q, J= 6.7 Hz, 0.74H), 4.75 - 4.67 (m, 0.28H), 4.65 - 4.57 (m, 0.12H), 4.46 - 4.38 (m, 0.19H), 3.96 - 3.85 (m, 3H), 3.79 (s, 2.2H), 3.74 (s, 0.8H), 3.11 - 3.01 (m, 0.28H), 2.33 - 2.21 (m, 0.74H), 2.14 - 1.83 (m, 3H). (Fractions of Hs that overlap with DMSO and water are not reported). Example 594: i('7S)-3-[3-(' l .1 -Difluoroethyl)phenyl1-2.7-dimethyl-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('2-methoxy-3-methyl-4-pyridyl)methanone.
Figure imgf000538_0001
The title compound was prepared in a manner analogous to Example 593, using 2-(3-(l,l- difluoroethyl)phenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane instead of 2-(3-(difluoromethyl)- 4-fluorophenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane in Step B. MS (ESI): mass calcd. for C24H26F2N4O2, 440.2; m/z found, 441.3 [M+H]+. Ή NMR (500 MHz, Chloroform-^/) d 8.12 - 7.97 (m, 1H), 7.59 - 7.34 (m, 4H), 6.82 - 6.60 (m, 1H), 5.98 - 5.88 (m, 0.57H), 4.95 (dd, J = 13.1, 5.3 Hz, 0.44H), 4.89 - 4.80 (m, 0.15H), 4.66 (q, J= 6.8 Hz, 0.31H), 4.03 - 3.93 (m, 3H), 3.85 (s, 1.73H), 3.79 (s, 1.27H), 3.60 - 3.46 (m, 0.59H), 3.32 - 3.22 (m, 0.59H), 3.11 - 3.00 (m, 0.44H), 2.88 - 2.76 (m, 0.45H), 2.64 - 2.46 (m, 1H), 2.39 - 2.29 (m, 0.62H), 2.25 - 2.12 (m,
2.17H), 2.04 - 1.89 (m, 3.88H), 1.66 - 1.38 (m, 3H).
Example 595: i('7S)-3-[3-('Difluoromethoxy)-4-fluoro-phenyl1-2.7-dimethyl-5.7-dihvdro-4H- Pyrazoloi3.4-c1pyridin-6-yl1-t2-methoxy-3-methyl-4-pyridyl)methanone.
Figure imgf000538_0002
The title compound was prepared in a manner analogous to Example 593, using 2-(3- (difluoromethoxy)-4-fluorophenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane instead of 2-(3- (difluoromethyl)-4-fluorophenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane in Step B. MS (ESI): mass calcd. for C23H23F3N4O3, 460.2; m/z found, 461.3 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.15 - 8.01 (m, 1H), 7.60 - 7.13 (m, 4H), 6.98 - 6.65 (m, 1H), 5.62 (q, J= 6.7 Hz, 0.75H), 4.75 - 4.67 (m, 0.30H), 4.64 - 4.55 (m, 0.14H), 4.45 - 4.38 (m, 0.20H), 3.95 - 3.87 (m, 3H),
3.82 - 3.71 (m, 3H), 3.11 - 3.00 (m, 0.30H), 2.78 - 2.68 (m, 0.33H), 2.35 - 2.22 (m, 0.76H), 2.13 - 1.83 (m, 3H), 1.51 - 1.25 (m, 3H). (Fractions of Hs that overlap with DMSO and water are not reported).
Example 596: Chroman-7-yl-[('7S)-3-[3-('difluoromethoxy)-5-fluoro-phenyl1-2.7-dimethyl-5.7- dihvdro-4H-pyrazolo[3.4-c1pyridin-6-yl1methanone.
Figure imgf000539_0001
The title compound was prepared in a manner analogous to Example 106, using 2-(3- (difluoromethoxy)-5-fluorophenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane instead of 3,5- difluorophenylboronic acid and (S)-tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)- 2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridine-6-carboxylate (Intermediate 7) in Step A, and chromane-7-carboxylic acid instead of quinoline 6-carboxybc acid in Step C. DMF was used in Step C. MS (ESI): mass calcd. for C25H24F3N3O3, 471.2; m/z found, 472.3 [M+H]+. Ή NMR (400 MHz, Chloroform-^/) d 7.09 - 7.03 (m, 1H), 6.96 - 6.81 (m, 5H), 6.56 (t, J= 72.7 Hz, 1H), 5.82 (br s, 0.49H), 5.17 - 4.65 (m, 1H), 4.24 - 4.14 (m, 2H), 4.00 - 3.69 (m, 3.64H), 3.35 - 2.98 (m, 1H), 2.91 - 2.60 (m, 3H), 2.53 - 2.30 (m, 1H), 2.08 - 1.96 (m, 2H), 1.61 - 1.48 (m, 3H). Example 597: i('7S)-3-[3-('Difluoromethoxy)-5-fluoro-phenyll-2.7-dimethyl-5.7-dihvdro-4H- Pyrazoloi3.4-c1pyridin-6-yl1-('2-methoxy-3-methyl-4-pyridyl)methanone.
Figure imgf000540_0001
The title compound was prepared in a manner analogous to Example 106, using 2-(3- (difluoromethoxy)-5-fluorophenyl)-4,4,5,5-tetramethyl-l ,3,2-dioxaborolane instead of 3,5- difluorophenylboronic acid and (S)-tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)- 2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 2-methoxy-3-methylisonicotinic acid instead of quinoline 6-carboxylic acid in Step C. DMF was used in Step C. MS (ESI): mass calcd. for C23H23F3N4O3, 460.2; m/z found, 461.3 [M+H]+. Ή NMR (600 MHz, Chloroform- ) d 8.11 - 7.98 (m, 1H), 6.97 - 6.87 (m, 3H), 6.81 - 6.42 (m, 2H), 5.96 - 5.87 (m, 0.58H), 4.96 (dd, J= 13.1, 5.3 Hz, 0.41H), 4.87 - 4.79 (m, 0.12H), 4.65 (q, J= 6.7 Hz, 0.25H), 4.02 - 3.93 (m, 3H), 3.86 (s, 1.79H), 3.80 (s, 1.27H), 3.60 - 3.47 (m, 0.55H), 3.30 - 3.21 (m, 0.56H), 3.09 - 3.00 (m, 0.38H), 2.86 - 2.75 (m, 0.38H), 2.62 - 2.49 (m, 1H), 2.39 - 2.30 (m, 0.58H), 2.25 -
2.13 (m, 2.1 OH), 1.99 (s, 0.77H), 1.65 - 1.35 (m, 3H).
Example 598: i('7S)-3-('4-Fluoro-3-methyl-phenyl)-2.7-dimethyl-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-(2-methoxy-3-methyl-4-pyridyl)methanone.
Figure imgf000540_0002
The title compound was prepared in a manner analogous to Example 106, using 2-(4-fluoro-3- methylphenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 7) in Step A, and 2-methoxy-3-methylisonicotinic acid instead of quinoline 6-carboxybc acid in Step C. MS (ESI): mass calcd. for C23H25FN4O2, 408.2; m/z found, 409.3 [M+H]+. ¾ NMR (500 MHz, Chlorofornw/) d 8.11 - 7.97 (m, 1H), 7.19 - 7.05 (m, 3H), 6.82 - 6.59 (m, 1H), 5.95 - 5.87 (m, 0.57H), 4.93 (dd, J= 13.0, 5.3 Hz, 0.43H), 4.87 - 4.80 (m, 0.13H), 4.67 - 4.60 (m, 0.27H), 4.01 - 3.93 (m, 3H), 3.80 (s, 1.71H), 3.75 (s, 1.29H),
3.58 - 3.44 (m, 0.60H), 3.31 - 3.19 (m, 0.58H), 3.10 - 2.99 (m, 0.43H), 2.83 - 2.71 (m, 0.42H),
2.59 - 2.43 (m, 1H), 2.37 - 1.95 (m, 6.84H), 1.66 - 1.35 (m, 3H).
Example 599: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000541_0001
c1pyridin-6-yl1-('3-methoxy-2-methyl-4-pyridyl)methanone.
Figure imgf000541_0002
The title compound was prepared in a manner analogous to Example 106, using 2-(4-fluoro-3- methylphenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 7) in Step A, and 3-methoxy-2-methylisonicotinic acid instead of quinoline 6-carboxybc acid in Step C. MS (ESI): mass calcd. for C22H21F3N4O2, 430.2; m/z found, 431.2 [M+H]+. ¾ NMR (500 MHz, Chlorofornw/) d 8.36 - 8.22 (m, 1H), 7.10 - 6.88 (m, 3H), 5.89 (q, J= 6.8 Hz, 0.64H), 5.00 - 4.89 (m, 0.35H), 4.73 - 4.63 (m, 0.35H), 3.91 - 3.68 (m, 6H), 3.54 - 3.45 (m, 1H), 3.37 - 3.27 (m, 0.38H), 3.25 - 3.17 (m, 0.25H), 3.15 - 2.98 (m, 0.33H), 2.85 - 2.71 (m, 0.60H), 2.62 - 2.45 (m, 3.74H), 2.34 - 2.27 (m, 0.64H), 1.57 (s, 3H).
Example 600: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-n -methyl-4-phenyl-imidazol-2-yl)methanone.
Figure imgf000542_0001
The title compound was prepared in a manner analogous to Example 106, using 3,4,5- trifluorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3-
(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and lithium l-methyl-4-phenyl-lH-imidazole-2-carboxylate instead of quinoline-6-carboxylic acid in Step C. DMF was used instead of DCM in Step C. MS (ESI): mass calcd. for C25H22F3N5O, 465.2; m/z found, 466.2 [M+H]+. Ή NMR (500 MHz, DMSO- e) d 7.86 - 7.74 (m, 3H), 7.60 - 7.51 (m, 2H), 7.44 - 7.34 (m, 2H), 7.28 - 7.21 (m, 1H), 5.90 (q, J = 6.6 Hz, 0.4H), 5.58 (q, J= 6.7 Hz, 0.56H), 4.81 (dd, J= 13.4, 4.9 Hz, 0.59H), 4.65 (dd, J= 12.9, 5.2 Hz, 0.44H), 3.85 - 3.73 (m, 6H), 3.12 - 3.03 (m, 0.42H), 2.99 - 2.89 (m, 0.60H), 2.80 - 2.71 (m, 0.46H), 1.66 (d, J= 6.7 Hz, 1.24H), 1.49 (d, J= 6.8 Hz, 1.73H). (Fractions of Hs that overlap with DMSO and water are not reported).
Example 601 : i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1 -(1 -phenyl imidazol-4-yl)methanone.
Figure imgf000543_0001
The title compound was prepared in a manner analogous to Example 106, using 3,4,5- trifluorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3-
(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 1 -phenyl- lH-imidazole-4-carboxylic acid instead of quinoline-6- carboxylic acid in Step C. DMF was used instead of DCM in Step C. MS (ESI): mass calcd. for C24H20F3N5O, 451.2; m/z found, 452.2 [M+H]+.
Figure imgf000543_0002
NMR (600 MHz, DMSO-r/e) d 8.41 - 8.34 (m, 1H), 8.24 (d, J= 1.5 Hz, 1H), 7.77 - 7.71 (m, 2H), 7.59 - 7.50 (m, 4H), 7.44 - 7.39 (m, 1H),
6.29 (s, 0.40H), 5.57 (s, 0.55H), 5.31 - 5.16 (m, 0.55H), 4.72 - 4.55 (s, 0.39H), 3.87 - 3.71 (m, 3H), 3.09 - 2.65 (m, 1.42H), 2.47 - 2.40 (m, 1H), 1.66 - 1.37 (m, 3H). (Fractions of Hs that overlap with DMSO and water are not reported). Example 602: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-[3-methyl-2-('2-pyridyl)imidazol-4-yl1methanone.
Figure imgf000543_0003
The title compound was prepared in a manner analogous to Example 106, using 3,4,5- trifluorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and l-methyl-2-(pyridin-2-yl)-lH-imidazole-5-carboxylic acid instead of quinoline-6-carboxylic acid in Step C. DMF was used instead of DCM in Step C. MS (ESI): mass calcd. for C24H21F3N6O, 466.2; m/z found, 467.2 [M+H]+. Ή NMR (600 MHz,
DMSO-r/e) 5 8.69 - 8.65 (m, 1H), 8.10 (dt, J= 8.0, 1.1 Hz, 1H), 7.95 (td, J= 7.8, 1.8 Hz, 1H), 7.61 - 7.54 (m, 2H), 7.44 (ddd, J= 7.5, 4.9, 1.2 Hz, 1H), 7.41 (s, 1H), 5.66 - 5.22 (m, 1H), 4.47
- 3.73 (m, 7H), 3.03 - 2.83 (m, 1H), 2.48 - 2.42 (m, 1H), 1.50 (d, J= 6.8 Hz, 3H). (Fractions of Hs that overlap with DMSO and water are not reported).
Example 603: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('2-fluoro-6-pyrazol- l -yl-phenyl)methanone.
Figure imgf000544_0001
The title compound was prepared in a manner analogous to Example 106, using 3,4,5- trifluorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3-
(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 2-fluoro-6-(lH-pyrazol-l-yl)benzoic acid instead of quinoline 6- carboxylic acid in Step C. DMF was used instead of DCM in Step C. MS (ESI): mass calcd. for C24H19F4N5O, 469.2; m/z found, 470.2 [M+H]+.
Example 604: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-spiro[3.4-dihvdro- l .4-benzoxazine-2/l '-cvclopropanel-8-yl-methanone.
Figure imgf000545_0001
The title compound was prepared in a manner analogous to Example 106, using 3,4,5- trifluorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3-
(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 3,4-dihydrospiro[benzo[b][l,4]oxazine-2,l'-cyclopropane]-8- carboxylic acid instead of quinoline 6-carboxybc acid in Step C. DMF was used instead of DCM in Step C. MS (ESI): mass calcd. for C25H23F3N4O2, 468.2; m/z found, 469.1 [M+H]+. ¾ NMR (500 MHz, Chloroform-i/) d 7.00 - 6.89 (m, 2H), 6.85 - 6.71 (m, 1H), 6.69 - 6.46 (m, 2H), 5.92
- 5.81 (m, 0.53H), 5.02 - 4.94 (m, 0.15H), 4.91 (dd, J= 13.1, 5.3 Hz, 0.47H), 4.81 (q, J= 6.8 Hz, 0.31H), 4.02 - 3.86 (m, 1H), 3.85 - 3.65 (m, 3.64H), 3.57 (d, J= 11.5 Hz, 0.30H), 3.50 - 3.37 (m, 0.67H), 3.32 - 3.13 (m, 1.22H), 3.05 - 2.85 (m, 0.76H), 2.80 - 2.65 (m, 0.62H), 2.56 - 2.46 (m, 0.36H), 2.46 - 2.36 (m, 0.46H), 2.33 - 2.22 (m, 0.53H), 1.57 - 1.36 (m, 3H), 1.15 - 1.01 (m, 0.82H), 1.00 - 0.86 (m, 0.59H), 0.75 - 0.53 (m, 2H), 0.41 - 0.32 (m, 0.60H).
Example 605: i('7S)-2.7-Diniethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- clpyridin-6-yll-(3-fluoro- 1 H-pyrrolo[2.3-b1pyridin-4-yl)niethanone.
Figure imgf000545_0002
The title compound was prepared in a manner analogous to Example 371 using 3-fluoro-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[2,3-b]pyridine-4-carboxylic acid (Intermediate 62) instead of 5-trifluoromethyl)-l-((2-(trimethylsilyl)ethoxy)methyl)-lH-pyrrolo[2,3-b]pyridine-4- carboxylic acid (Intermediate 60) in Step A. MS (ESI): mass calcd. for C22H17F4N5O, 443.1; m/z found, 444.2 Ή NMR (500 MHz, Chloroform- ) d 8.79 - 8.62 (m, 1H), 8.43 - 8.34 (m,
Figure imgf000546_0001
1H), 7.17 - 6.89 (m, 4H), 5.99 (q, J= 6.8 Hz, 0.58H), 5.03 (dd, J= 13.0, 5.2 Hz, 0.39H), 4.81 (q, J= 6.7 Hz, 0.39H), 3.84 (s, 1.85H), 3.76 (s, 1.15H), 3.68 - 3.58 (m, 0.59H), 3.39 - 3.27 (m, 0.58H), 3.10 (td, J= 12.7, 3.9 Hz, 0.36H), 2.91 - 2.81 (m, 0.37H), 2.65 - 2.47 (m, 1H), 2.32 - 2.22 (m, 0.56H), 1.71 - 1.39 (m, 3H).
Example 606: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo[3.4- c1pyridin-6-yl1-('9-methylpurin-6-yl)methanone.
Figure imgf000546_0002
The title compound was prepared in a manner analogous to Example 106, using 3,4,5- trifluorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 9-methyl-9H-purine-6-carboxylic acid instead of quinoline 6- carboxylic acid in Step C. DMF was used instead of DCM in Step C. MS (ESI): mass calcd. for C21H18F3N7O, 441.2; m/z found, 442.2 [M+H]+. Ή NMR (500 MHz, Chloroform- ) d 9.06 - 9.01 (m, 1H), 8.15 - 8.09 (m, 1H), 7.00 - 6.92 (m, 2H), 5.99 (q, J= 6.8 Hz, 0.54H), 5.04 (dd, J = 13.1, 5.4 Hz, 0.5 OH), 4.89 (q, J= 6.8 Hz, 0.49H), 3.98 - 3.91 (m, 3H), 3.86 - 3.71 (m, 3H), 3.68 - 3.62 (m, 0.57H), 3.40 - 3.31 (m, 0.55H), 3.17 (td, J= 12.7, 4.0 Hz, 0.43H), 2.98 - 2.85 (m,
1H), 2.54 - 2.48 (m, 0.42H), 2.30 - 2.23 (m, 0.53H), 1.74 - 1.47 (m, 3H). Example 607: i('7S)-2.7-Dimethyl-3-('3.4.5-trifluorophenyl)-5.7-dihvdro-4H-pyrazolo
Figure imgf000547_0001
c1pyridin-6-yl1-('3-fluoro-5-methoxy-4-pyridyl)methanone.
Figure imgf000547_0002
The title compound was prepared in a manner analogous to Example 106, using 3,4,5- trifluorophenylboronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 3-fluoro-5-methoxyisonicotinic acid (Intermediate 107) instead of quinoline 6-carboxybc acid in Step C. DMF was used instead of DCM in Step C. MS (ESI): mass calcd. for C21H18F4N4O2, 434.1 ; m/z found, 435.2 [M+H]+. ¾ NMR (600 MHz,
Chlorofornw/) d 8.29 - 8.16 (m, 2H), 7.02 - 6.91 (m, 2H), 5.91 (p, J= 6.8 Hz, 0.59H), 5.01 - 4.93 (m, 0.40H), 4.70 (q, J= 6.8 Hz, 0.20H), 4.65 (q, J= 6.8 Hz, 0.17H), 4.03 - 3.94 (m, 2.47H), 3.86 - 3.76 (m, 3.62H), 3.55 - 3.47 (m, 0.58H), 3.37 - 3.30 (m, 0.58H), 3.11 - 3.02 (m, 0.37H), 2.82 - 2.75 (m, 0.37H), 2.68 - 2.57 (m, 0.58H), 2.52 - 2.46 (m, 0.38H), 2.39 - 2.31 (m, 0.58H),
1.63 - 1.42 (m, 3H).
Example 608: t3-Chloro-4-methoxy-2-pyridyl)-it7S)-3-[3-tdifluoromethyl)-5-fluoro-phenyl1- 2.7-dimethyl-5.7-dihvdro-4H-pyrazolo c|pyridin-6-yl1methanone.
Figure imgf000547_0003
Figure imgf000547_0004
The title compound was prepared in a manner analogous to Example 106, using 2-(3- (difluoromethyl)-5-fluorophenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane instead of 3,5- difluorophenylboronic acid and (S)-tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)- 2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 3-chloro-4-methoxypicobnic acid instead of quinoline 6-carboxylic acid in Step C. DMF was used instead of DCM in Step C. MS (ESI): mass calcd. for C22H20CIF3N4O2, 464.1; m/z found, 465.2 [M+H]+. Ή NMR (500 MHz, Chlorofornw/) d 8.43 - 8.39 (m, 1H), 7.31 - 7.22 (m, 2H), 7.19 - 7.12 (m, 1H), 6.89 - 6.86 (m, 1H), 6.81 - 6.54 (m, 1H), 5.93 (q, J= 6.8 Hz, 0.59H), 5.01 - 4.94 (m, 0.45H), 4.68 (q, J= 6.8 Hz, 0.44H), 4.01 - 3.97 (m, 3H), 3.87 - 3.77 (m, 3H), 3.46 - 3.38 (m, 0.59H), 3.36 - 3.28 (m, 0.59H), 3.09 (td, J= 12.7, 3.9 Hz, 0.42H), 2.92 - 2.75 (m, 1H), 2.54 - 2.47 (m, 0.42H), 2.33- 2.26 (m, 0.58H), 1.69 - 1.46 (m, 3H).
Example 609: i('7S)-3-[3-('Difluoromethyl)-5-fluoro-phenyl1-2.7-dimethyl-5.7-dihvdro-4H-
Pyrazolo[3.4-c1pyridin-6-yl1-('2-methoxy-3-methyl-4-pyridyl)methanone.
Figure imgf000548_0001
The title compound was prepared in a manner analogous to Example 106, using 2-(3- (difluoromethyl)-5-fluorophenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane instead of 3,5- difluorophenylboronic acid and (S)-tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)- 2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 2-methoxy-3-methylisonicotinic acid instead of quinoline 6-carboxylic acid in Step C. DMF was used instead of DCM in Step C. MS (ESI): mass calcd. for C23H23F3N4O2, 444.2; m/z found, 445.2 [M+H]+. ¾ NMR (500 MHz, Chlorofornw/) d 8.12 - 7.96 (m, 1H), 7.32 - 7.11 (m, 3H), 6.82 - 6.54 (m, 2H), 5.96 - 5.88 (m, 0.55H), 4.96 (dd, J= 13.1, 5.3 Hz, 0.43H), 4.87 - 4.80 (m, 0.14H), 4.69 - 4.61 (m, 0.27H), 4.02 - 3.94 (m, 3H), 3.87 - 3.77 (m, 3H), 3.61 - 3.48 (m, 0.56H), 3.32 - 3.21 (m, 0.55H), 3.10 - 2.99 (m, 0.39H), 2.87 - 2.75 (m, 0.39H), 2.64 - 2.48 (m, 1H), 2.38 - 2.29 (m, 0.57H), 2.25 - 1.96 (m, 3H), 1.66 - 1.36 (m, 3H).
Example 610: Chroman-7-yl-[('7S)-3-[3-('difluoromethyl)-5-fluoro-phenyll-2.7-dimethyl-5.7- dihvdro-4H-pyrazolo[3.4-c|pyridin-6-yl1methanone.
Figure imgf000549_0001
The title compound was prepared in a manner analogous to Example 106, using 2-(3- (difluoromethyl)-5-fluorophenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane instead of 3,5- difluorophenylboronic acid and (S)-tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)- 2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridine-6-carboxylate (Intermediate 7) in Step A, and chromane-7-carboxybc acid instead of quinoline 6-carboxybc acid in Step C. DMF was used instead of DCM in Step C. MS (ESI): mass calcd. for C25H24F3N3O2, 455.2; m/z found, 456.3 [M+H]+. ¾ NMR (500 MHz,
Chloroform-i/) d 7.30 - 7.26 (m, 2H), 7.19 - 7.14 (m, 1H), 7.09 - 7.04 (m, 1H), 6.91 - 6.85 (m, 1H), 6.84 - 6.81 (m, 1H), 6.68 (t, J= 56.1 Hz, 1H), 5.87 (br s, 0.44H), 5.17 - 4.66 (m, 1H), 4.24 - 4.15 (m, 2H), 3.99 - 3.71 (m, 3.55H), 3.34 - 2.97 (m, 1H), 2.91 - 2.63 (m, 3H), 2.51 - 2.29 (m, 1H), 2.06 - 1.96 (m, 2H), 1.69 - 1.43 (m, 3H).
Example 611 : Chroman-7-yl-[('7S)-3-('3-fluoro-5-methoxy-phenyl)-2.7-dimethyl-5.7-dihvdro- 4H-pyrazolo[3.4-c|pyridin-6-yl1methanone.
Figure imgf000549_0002
The title compound was prepared in a manner analogous to Example 106, using (3-fluoro-5- methoxyphenyl)boronic acid instead of 3,5-difluorophenylboronic acid and (S)-tert-butyl 2,7- dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6- carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3- (((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 7) in Step A, and chromane-7-carboxylic acid instead of quinoline 6-carboxybc acid in Step C. DMF was used instead of DCM in Step C. MS (ESI): mass calcd. for
C25H26FN3O3, 435.2; m/z found, 436.3 [M+H]+. 'H NMR (500 MHz, Chloroform- ) d 7.09 - 7.02 (m, 1H), 6.91 - 6.79 (m, 2H), 6.70 - 6.59 (m, 3H), 5.82 (br s, 0.47H), 5.16 - 4.70 (m, 1H), 4.24 - 4.13 (m, 2H), 3.96 - 3.71 (m, 6.44H), 3.35 - 2.96 (m, 1H), 2.90 - 2.61 (m, 3H), 2.53 - 2.31 (m, 1H), 2.06 - 1.96 (m, 2H), 1.67 - 1.44 (m, 3H).
Example 612: (3 -Chloro-4-methoxy-2-pyridyl V G (7S )-3 - G 3 -(difluoromethoxyV 5-fluoro-phenyll -
2.7-dimethyl-5.7-dihvdro-4H-pyrazolo c|pyridin-6-yl1methanone.
Figure imgf000550_0001
Figure imgf000550_0002
The title compound was prepared in a manner analogous to Example 106, using 2-(3- (difluoromethoxy)-5-fluorophenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane instead of 3,5- difluorophenylboronic acid and (S)-tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)- 2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 3-chloro-4-methoxypicolinic acid instead of quinoline 6-carboxylic acid in Step C. DMF was used instead of DCM in Step C. MS (ESI): mass calcd. for C22H20CIF3N4O3, 480.1; m/z found, 481.2 [M+H]+. 'H NMR (600 MHz, Chlorofornw/) d 8.44 - 8.38 (m, 1H), 6.96 - 6.85 (m, 4H), 6.71 - 6.41 (m, 1H), 5.92 (q, J= 6.8 Hz, 0.57H), 5.00 - 4.95 (m, 0.42H), 4.68 (q, J= 6.8 Hz, 0.40H), 4.01 - 3.96 (m, 3H), 3.87 - 3.77 (m, 3H), 3.45 - 3.40 (m, 0.57H), 3.36 - 3.29 (m, 0.58H), 3.08 (td, J= 12.7, 3.9 Hz, 0.41H), 2.91 - 2.83 (m, 0.42H), 2.82 - 2.74 (m, 0.58H), 2.54 - 2.48 (m, 0.41H), 2.34 - 2.28 (m, 0.57H), 1.68 - 1.44 (m, 3H).
Example 613: i('7S)-3-('3-Fluoro-5-methoxy-Dhenyl )-2.7-dimethyl-5.7-dihvdro-4H-Dyrazolo[3.4- clpyridin-6-yll-(2-methoxy-3-methyl-4-pyridyl)methanone.
Figure imgf000551_0001
The title compound was prepared in a manner analogous to Example 106, using (3-fluoro-5- methoxyphenyl)boronic acid and (S)-tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)- 2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 2-methoxy-3-methylisonicotinic acid instead of quinoline 6-carboxylic acid in Step C. DMF was used instead of DCM in Step C. MS (ESI): mass calcd. for C23H25FN4O3, 424.2; m/z found, 425.3 [M+H]+. ¾ NMR (600 MHz, Chloroform-i/) d 8.11 - 7.97 (m, 1H), 6.82 - 6.57 (m, 4H), 5.95 - 5.87 (m, 0.58H), 4.94 (dd, J = 13.1, 5.3 Hz, 0.42H), 4.86 - 4.80 (m, 0.13H), 4.64 (q, J= 6.7 Hz, 0.26H), 4.01 - 3.93 (m, 3H),
3.87 - 3.76 (m, 6H), 3.58 - 3.46 (m, 0.60H), 3.30 - 3.20 (m, 0.58H), 3.10 - 3.00 (m, 0.41H), 2.85 - 2.74 (m, 0.40H), 2.60 - 2.48 (m, 1H), 2.39 - 2.31 (m, 0.58H), 2.24 - 1.96 (m, 3H), 1.65 - 1.36 (m, 3H). Example 614: t3-Chloro-4-methoxy-2-pyridyl)-it7S)-3-t3-fluoro-5-methoxy-phenyl)-2.7- dimethyl-5.7-dihvdro-4H-pyrazolo c|pyridin-6-yl1methanone.
Figure imgf000551_0002
Figure imgf000551_0003
The title compound was prepared in a manner analogous to Example 106, using (3-fluoro-5- methoxyphenyl)boronic acid and (S)-tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)- 2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate (Intermediate 8) instead of racemic tert-butyl 2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridine-6-carboxylate (Intermediate 7) in Step A, and 3-chloro-4-methoxypicolinic acid instead of quinoline 6-carboxylic acid in Step C. DMF was used instead of DCM in Step C. MS (ESI): mass calcd. for C22H22CIFN4O3, 444.1; m/z found, 445.2 [M+H]+. Ή NMR (500 MHz, Chloroform-i/) d 8.43 - 8.39 (m, 1H), 6.89 - 6.85 (m, 1H), 6.69 - 6.60 (m, 3H), 5.92 (q, J= 6.8 Hz, 0.56H), 4.99 - 4.93 (m, 0.44H), 4.68 (q, J= 6.8 Hz, 0.43H), 4.01 - 3.96 (m, 3H), 3.86 - 3.76 (m, 6H), 3.43 - 3.37 (m, 0.56H), 3.36 - 3.28 (m, 0.57H), 3.08 (td, J= 12.7, 3.9 Hz, 0.43H), 2.90 - 2.82 (m, 0.43H), 2.81 - 2.73 (m, 0.56H), 2.56 - 2.49 (m, 0.42H), 2.35 - 2.28 (m, 0.56H), 1.69 - 1.46 (m, 3H).
Example 615: racemic-( 1.1.1 lpentan- 1 -yl)-7-methyl-3-phenyl-2A5.7-tetrahvdro-6H-
Figure imgf000552_0001
Pyrazoloi3.4-c1pyridin-6-yl )t5-cvclopropyl- l -methyl- 1 H-pyrazol-4-yl)methanone.
Figure imgf000552_0002
The title compound was prepared in a manner analogous to Example 288, using 2- (bicyclo[l .1. l]pentan-l -yl)-7-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (Intermediate 51) instead of (S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H- pyrazolo[3,4-c]pyridine (Intermediate 40) and 5-cyclopropyl- 1 -methyl- lH-pyrazole-4-carboxybc acid instead of 2-fluoro-6-(2H- 1,2,3 -triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C26H29N50, 427.2; m/z found, 428.1 [M+H]+. Ή NMR (500 MHz, Chloroform-^/) d 7.45 - 7.36 (m, 4H), 7.33 - 7.29 (m, 2H), 5.91 (brs, 0.41H), 5.16 (brs, 0.39H), 4.82 (brs, 0.42H), 3.98 - 3.82 (m, 3.37H), 3.39 - 2.94 (m, 1H), 2.56 (brs, 1H), 2.43 - 2.20 (m, 2H), 2.06 (s, 6H), 1.73 (s, 1H), 1.55 (brs, 3.16H), 1.07 - 0.54 (m, 4.34H). Example 616: -('2-('Bicvcloi l . 1 . 1 lpentan- 1 -yl)-7-methyl-3-phenyl-2.4.5.7-tetrahydro-6H- pyrazolor3.4-c1pyridin-6-yl 5-cvclopropyl-l-methyl-lH-pyrazol-4-vnmethanone.
Figure imgf000553_0001
The title compound was isolated by SFC purification of race««c-(2-(Bicyclo[l. l . l]pentan-l-yl)- 7-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(5-cyclopropyl-l-methyl- lH-pyrazol-4-yl)methanone (Example 615) (stationary phase: Chiralpak AD, 5pm 250 x 30 mm; mobile phase: 20% MeOH with 0.2% TEA, 80% CCh; flow rate: 85mL/min). MS (ESI):
mass calcd. for C2 H2 N5O, 427.2; m/z found, 428.1 [M+H]+. (R*: single enantiomer, but absolute configuration was not determined).
Example 617: (SV(E6-Dimethyl-lH-pyrazolor3.4-dlpyrimidin-4-yl¥2.7-dimethyl-3-(3.4.5- trifluorophenyl)-2.4.5.7-tetrahvdro-6H-pyrazolol3.4-c1pyridin-6-yl)methanone.
Figure imgf000553_0002
The title compound was prepared in a manner analogous to Example 288, using l,6-dimethyl- lH-pyrazolo[3,4-d]pyrimidine-4-carboxylic acid (Intermediate 110) instead of 2-fluoro-6-(2H- l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C22H20F3N7O, 455.2; m/z found, 456.1 [M+H]+. ¾ NMR (400 MHz, DMSO-r/e) d 8.25 (d, J= 22.1 Hz, 1H), 7.63 - 7.46 (m, 2H), 5.66 (q, J = 6.1 Hz, 1H), 5.03 - 4.66 (m, 1H), 4.15 - 4.00 (m, 3H), 3.92 - 3.64 (m, 4H), 3.20 - 3.09 (m, 1H), 2.81 - 2.74 (m, 3H), 2.37 - 2.21 (m, 1H), 1.50 (dd, J= 32.3, 6.7 Hz, 3H).
Example 618: Cvclopropyl-2-methyl-imidazorE2-al pyridin-3-ylVr(7SV2.7-dimethyl-3-(3.4.5- trifluorophenylV5.7-dihvdro-4H-pyrazolor3.4-cl pyridin-6-yll methanone.
Figure imgf000554_0001
The title compound was prepared in a manner analogous to Example 288, using potassium 6- cyclopropyl-2-methylimidazo[l,2-a]pyridine-3-carboxylate (Intermediate 90) instead of 2- fluoro-6-(2H-l,2,3-triazol-2-yl)benzoic acid. MS (ESI): mass calcd. for C26H24F3N5O, 479.2; m/z found, 480.1 [M+H]+. ¾ NMR (500 MHz, DMSO-r/e) d 8.12 (s, 1H), 7.54 (dd, J= 8.7, 6.6 Hz, 2H), 7.46 (dd, = 9.3, 0.9 Hz, 1H), 7.03 (dd, = 9.3, 1.8 Hz, 1H), 5.65 - 5.46 (m, 1H), 4.19
- 3.96 (m, 1H), 3.82 (s, 3H), 3.47 - 3.34 (m, 1H), 2.84 - 2.68 (m, 1H), 2.45 - 2.39 (m, 1H), 2.37
- 2.29 (m, 3H), 2.08 - 1.92 (m, 1H), 1.48 (d, J= 6.8 Hz, 3H), 1.00 - 0.87 (m, 2H), 0.64 (t, J =
5.1 Hz, 2H).
BIOLOGICAL DATA
The assay used to measure the in vitro activity of MGL is adapted from the assay used for another serine hydrolase (FAAH) described in Wilson et al, 2003 (A high-throughput- compatible assay for determining the activity of fatty acid amide hydrolase. Wilson SJ,
Lovenberg TW, Barbier AJ. Anal Biochem. 2003 Jul 15;318(2):270-5.). The assay consists of combining endogenously expressed MGL from HeLa cells with test compounds, adding
[glycerol-l,3-3H]-oleyl glycerol, incubating for one hour, and then measuring the amount of cleaved [l,3-3H]-glycerol that passes through an activated carbon filter. The amount of cleaved, tritiated glycerol passing through the carbon filter is proportional to the activity of the MGL enzyme in a particular well/test condition.
Standard conditions for this assay combine 300 nM [Glycerol-l,3-3H]-oleyl glycerol with human MGL from HeLa cells and test compounds for one hour, after which the reaction is filtered through activated carbon and tritium is measured in the flow through. The test compound concentration in screening mode is 10 uM, while the highest compound concentration in IC50 assays is determined empirically. MGL is the predominant hydrolase in HeLa cells/cell homogenates.
Table 4
Figure imgf000555_0001
Figure imgf000556_0001
Figure imgf000557_0001
Figure imgf000558_0001
Figure imgf000559_0001
Figure imgf000560_0001
Figure imgf000561_0001
Figure imgf000562_0001
Figure imgf000563_0001
Figure imgf000564_0001
Figure imgf000565_0001
Figure imgf000566_0001
Figure imgf000567_0001
Figure imgf000568_0001
Figure imgf000569_0001
Figure imgf000570_0001
Figure imgf000571_0001
Figure imgf000572_0001
Figure imgf000573_0001
Figure imgf000574_0001
Figure imgf000575_0001
Figure imgf000576_0001
Figure imgf000577_0001
Figure imgf000578_0001
Figure imgf000579_0001
Figure imgf000580_0001
Figure imgf000581_0001
Figure imgf000582_0001
Figure imgf000583_0001
Figure imgf000584_0001
Figure imgf000585_0001
Figure imgf000586_0001
Figure imgf000587_0001
Figure imgf000588_0001
Figure imgf000589_0001
Figure imgf000590_0001
Figure imgf000591_0001
Figure imgf000592_0001
Figure imgf000593_0001
Figure imgf000594_0001
Figure imgf000595_0001
Figure imgf000596_0001
Figure imgf000597_0001
Figure imgf000598_0001
Figure imgf000599_0001
NT means not tested.

Claims

What is claimed
1. A compound of Formula (I),
Figure imgf000600_0001
wherein:
R2 is selected from the group consisting of: (a)
Figure imgf000600_0002
(b) pyridyl substituted with OCi-4haloalkyl;
(c) pyrazole or 1H- 1,2, 4-triazole each substituted with one or two members each independently selected from the group consisting of: H, Cl, Ci-4alkyl, cyclopropyl and phenyl;
(d)
Figure imgf000600_0003
Figure imgf000601_0001
where X is selected from the group consisting of: O, S, NH, and NCH3;
Ra is H or halo;
Rb is selected from the group consisting of: H, halo and CH3;
Rc is H or CF3; and
Rd is H or CH3;
R3 is selected from the group consisting of:
(h) Phenyl; or phenyl independently substituted with one or two members selected from the group consisting of: halo and OCi-4haloalkyl;
Figure imgf000602_0005
R4 is selected from the group consisting of: Ci-4alkyl;
with the proviso that when
Figure imgf000602_0001
, then R3 is cyclopropyl, and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.
2. A compound as claimed in claim 1 , wherein R2 is
Figure imgf000602_0002
3. A compound as claimed in claim 1 , wherein R2 is
Figure imgf000602_0003
4. A compound as claimed in claim 1 , wherein R2 is
Figure imgf000602_0004
5. A compound as claimed in claim 1, wherein
Figure imgf000603_0001
6. A compound as claimed in claim 1 , wherein
Figure imgf000603_0002
7. A compound as claimed in claim 1, wherein
Figure imgf000603_0003
8 A
Figure imgf000603_0004
9. A compound as claimed in claim 1 , wherein R2 is
Figure imgf000603_0005
10. A
Figure imgf000604_0001
11. A compound as claimed in claim 1 , wherein R2 is
Figure imgf000604_0002
12 A compound as claimed in claim 1 , wherein
Figure imgf000604_0003
13. A compound as claimed in claim 1 , wherein R2 is
Figure imgf000604_0004
14. A compound as claimed in claim 1, wherein R2 is
Figure imgf000604_0005
15. A compound as claimed in claim 1, wherein R3 is phenyl, 3,5-difluorophenyl, 3 chlorophenyl, 3 -fluorophenyl, or 3-(difluoromethoxy)phenyl.
16. A compound as claimed in claim 1, wherein R3 is cyclopropyl.
17. A compound as claimed in claim 1, wherein R4 is CH3.
18. A compound as claimed in claim 1, wherein X is O.
19. A compound as claimed in claim 1, wherein X is S.
20. A compound as claimed in claim 1, wherein X is NH or NCH3.
21. A compound selected from the group consisting of:
(2-Methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(naphthalen-l- yl)methanone;
(3-Cyclopropyl-2-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(2,3- dichlorophenyl)methanone;
(3-Cyclopropyl-2-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(naphthalen-l- yl)methanone;
(2-Fluoro-3-(trifluoromethoxy)phenyl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)methanone;
(2-Methoxy-6-(trifluoromethyl)phenyl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)methanone;
(3-Methoxy-5-(trifluoromethyl)phenyl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)methanone;
(2-Methoxy-3-methylphenyl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-
6-yl)methanone;
(2-Ethyl-3-methoxyphenyl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(3,4-Dimethoxyphenyl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(2,6-Dimethoxyphenyl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone; (3,5-Dimethoxyphenyl)-(2-methyl-3-phenyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(2-Chloro-3-hydroxyphenyl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(2-Chloro-3-methoxyphenyl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-
6-yl)methanone;
(3-Chloro-2-methoxy-phenyl)-(2-methyl-3-phenyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(2-Chloro-6-methoxyphenyl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-
6-yl)methanone;
(3-Chloro-5-methoxyphenyl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-
6-yl)methanone;
(2-Amino-3-methylphenyl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(2-(lH-l,2,4-Triazol-l-yl)phenyl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)methanone;
(2-Methyl-3-morpholinophenyl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)methanone;
(5-Chloro-l-methyl-lH-pyrazol-4-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)methanone;
(l,5-Dimethyl-lH-pyrazol-4-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)methanone;
(5-Cyclopropyl-l-methyl-lH-pyrazol-4-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridin-6-yl)methanone;
(2-Methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(l-phenyl-lH-l,2,4- triazol-3-yl)methanone;
(6-(Difluoromethoxy)pyridin-2-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)methanone;
(2-Methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(6-
(trifluoromethoxy)pyridin-2-yl)methanone; 5-(2-Methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-6-carbonyl)-2H- benzo [b] [1,4] oxazin-3 (4H)-one;
(4-Methyl-3,4-dihydro-2H-benzo[b][l,4]oxazin-7-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridin-6-yl)methanone;
Benzo[d][l,3]dioxol-4-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Benzo[d][l,3]dioxol-5-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(2,2-Difluorobenzo[d][l,3]dioxol-4-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)methanone;
(2-Methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(4H-thieno[3,2-b]pyrrol-
2-yl)methanone;
(2-Methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(6-methybmidazo[2,l- b] thiazol- 5 -y l)methanone;
Benzofuran-7-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Benzofuran-4-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Benzofuran-5-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Benzofuran-3-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Benzo[b]thiophen-7-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Benzo[b]thiophen-4-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Benzo[b]thiophen-5-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Benzo[b]thiophen-3-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone; (3-Chlorobenzo[b]thiophen-2-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)methanone;
(lH-Indol-4-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(lH-Indol-5-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(lH-Indol-3-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(lH-Indol-7-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(lH-Indol-6-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(5-Fluoro-lH-indol-4-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(7-Chloro-lH-indol-3-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(4-Chloro-lH-indol-3-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(7-Methyl-lH-indol-2-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(l-Methyl-lH-indol-4-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(l-Methyl-lH-indol-3-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Benzo[d]isoxazol-3-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(6-Chlorobenzo[d]isoxazol-3-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)methanone;
Benzo[c]isoxazol-3-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone; Benzo[d]oxazol-6-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Benzo[d]oxazol-2-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Benzo[d]oxazol-5-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Benzo[d]thiazol-7-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Benzo[d]thiazol-5-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Benzo[d]thiazol-4-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Benzo[d]thiazol-2-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Benzo[d]isothiazol-3-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(lH-Indazol-5-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(lH-Indazol-4-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(lH-Indazol-3-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(lH-Indazol-7-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(lH-Indazol-6-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(7-Chloro-lH-indazol-3-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(l-Methyl-lH-indazol-3-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone; (lH-Benzo[d]imidazol-5-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(2-Methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(2-(trifluoromethyl)-lH- benzo [d] imidazol-4-yl)methanone;
(2-Methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(pyrazolo[l,5-a]pyridin-
5-yl)methanone;
(2-Methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(pyrazolo[l,5-a]pyridin-
3-yl)methanone;
(2-Methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(pyrazolo[l,5-a]pyridin-
7-yl)methanone;
Imidazo[l,5-a]pyridin-l-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Imidazo[l,5-a]pyridin-6-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Imidazo[l,5-a]pyridin-7-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Imidazo[l,5-a]pyridin-5-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Imidazo[l,2-a]pyridin-5-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Imidazo[l,2-a]pyridin-3-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(5-Chloro-2-methylimidazo[l,2-a]pyridin-3-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridin-6-yl)methanone;
(2-Methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(lH-pyrrolo[3,2- c]pyridin-3-yl)methanone;
(l-Methyl-lH-pyrrolo[2,3-b]pyridin-4-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridin-6-yl)methanone;
[l,2,4]Triazolo[l,5-a]pyridin-5-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)methanone; (2-Methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin-4- yl)methanone;
Isoquinolin-4-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
Isoquinolin-l-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(2-Methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin-5- yl)methanone;
(2-Methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin-6- yl)methanone;
(2-Ethyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin-6-yl)methanone;
Isoquinolin-5-yl(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(2-Methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin-8- yl)methanone;
(2-Methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin-2- yl)methanone;
(2-Methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin-3- yl)methanone;
(8-Fluoroquinolin-4-yl)(2-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)methanone;
(2-Methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinoxalin-5- yl)methanone;
(3-(3-(Difluoromethoxy)phenyl)-2-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinolin-6-yl)methanone;
(3-(3-Chlorophenyl)-2-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin-6- yl)methanone;
(3-(3-Fluorophenyl)-2-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin-6- yl)methanone;
(3-(3,5-Difluorophenyl)-2-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin- 6-yl)methanone; Benzo[d]isoxazol-3-yl(2-methyl-3-(5-methylthiophen-2-yl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)methanone;
(2-Methyl-3-(5-(trifluoromethyl)thiophen-2-yl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinolin-6-yl)methanone;
(3-(lH-Indol-2-yl)-2-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin-6- yl)methanone; and
(2-Methyl-3-(l -methyl- lH-indol-2-yl)-2, 4,5, 7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinolin-6-yl)methanone;
and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.
22. A pharmaceutical composition comprising:
(A) a therapeutically effective amount of at least one compound of Formula (I):
Figure imgf000612_0001
wherein: R2 is selected from the group consisting of:
(a)
Figure imgf000612_0002
(b) pyridyl substituted with OCi-4haloalkyl;
(c) pyrazole or 1H- 1,2, 4-triazole each substituted with one or two members each
independently selected from the group consisting of: H, Cl, Ci-4alkyl, cyclopropyl and phenyl;
Figure imgf000613_0001
where X is selected from the group consisting of: O, S, NH, and NCH3;
Ra is H or halo;
Rb is selected from the group consisting of: H, halo and CH3;
Rc is H or CF3; and
Rd is H or CH3;
R3 is selected from the group consisting of:
(h) Phenyl; or phenyl independently substituted with one or two members selected from the
Figure imgf000614_0001
R4 is selected from the group consisting of: Ci-4alkyl;
with the proviso that when
Figure imgf000614_0002
, then R3 is cyclopropyl;
and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers of
compounds of Formula (I);
(B) at least one pharmaceutically acceptable excipient.
23. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 21 and at least one pharmaceutically acceptable excipient. 24. A method of treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by MGL receptor activity, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one compound of Formula (I):
Figure imgf000615_0001
wherein:
R2 is selected from the group consisting of:
(a)
Figure imgf000615_0002
(b) pyridyl substituted with OCi-4haloalkyl;
(c) pyrazole or 1H- 1,2, 4-triazole each substituted with one or two members each
independently selected from the group consisting of: H, Cl, Ci-4alkyl, cyclopropyl and phenyl; (d)
Figure imgf000615_0003
Figure imgf000616_0001
5 (g)
Figure imgf000616_0002
where X is selected from the group consisting of: O, S, NH, and NCH3;
Ra is H or halo;
Rb is selected from the group consisting of: H, halo and CH3;
0 Rc is H or CF3; and
Rd is H or CH3;
R3 is selected from the group consisting of:
(h) Phenyl; or phenyl independently substituted with one or two members selected from the
Figure imgf000616_0003
R4 is selected from the group consisting of: Ci-4alkyl; with the proviso that when
Figure imgf000617_0001
, then R3 is cyclopropyl; and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers of
compounds of Formula (I). 25. The method of claim 24, wherein the MGL receptor mediated disease, disorder, or
condition is selected from the group consisting of: pain, psychiatric conditions, neurological conditions, cancers and eye conditions.
26. The method of claim 25, wherein the MGL receptor mediated disease, disorder or
condition is selected from the group consisting of major depressive disorder, treatment resistant depression, anxious depression and bipolar disorder
27. The method of claim 25, wherein the MGL receptor mediated disease, disorder or condition is inflammatory pain.
28. A compound, having the structure of Formula (II):
Figure imgf000617_0002
wherein
R1 is Ci-4alkyl;
R2a is selected from the group consisting of:
Figure imgf000617_0003
(b) 6-Membered heteroaryl selected from the group consisting of:
Figure imgf000618_0001
(c) 5-Membered heteroaryl selected from the group consisting of:
Figure imgf000618_0002
(d) 5,6-Fused or 6,5-fused heteroaryl selected from the group consisting of:
Figure imgf000618_0003
Figure imgf000619_0001
(e) Fused 6,6 heteroaryl selected from the group consisting of:
Figure imgf000619_0002
(f) Heterocycloalkyl selected from the group consisting of:
Figure imgf000620_0001
R3a is selected from the group consisting of:
(g) Phenyl; or phenyl substituted with one, two, or three members each independently
selected from the group consisting of: halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, and OCi-6haloalkyl;
(h) 5-Membered heteroaryl selected from the group consisting of:
Figure imgf000620_0002
and
Figure imgf000620_0003
(i) 6-Membered heteroaryl selected from the group consisting of:
Figure imgf000620_0004
and
Figure imgf000620_0005
(j) 5,6-Fused or 6,5-fused heteroaryl selected from the group consisting of:
Figure imgf000621_0001
(k) Heterocycloalkyl selected from the group consisting of:
Figure imgf000621_0002
Re is selected from the group consisting of: OCi-4alkyl, OCi-4haloalkyl, (C=0)NHCH3, and 5-membered heteroaryl ring containing two or three nitrogen members, wherein the 5- membered heteroaryl ring is optionally substituted with one Rf member;
Rf is selected from the group consisting of: H, halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, and OCi-4haloalkyl;
Rg is selected from the group consisting of: OCi-4alkyl, OCi-4haloalkyl, CH2OCH3, CH2OH,
Figure imgf000621_0003
Rh is selected from the group consisting of: H, Ci-4alkyl , Ci-4haloalkyl, and C3-6cycloalkyl; R1 is selected from the group consisting of: H, halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, C3-6cycloalkyl, and C3-6cycloalkyl substituted with one or two members independently selected from: F and CH3;
R1 is selected from the group consisting of: H, halo, Ci-4alkyl and Ci-4haloalkyl;
Rk is selected from the group consisting of: H, halo, OH, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, and OCi-4haloalkyl;
Rm is H or Ci-4alkyl;
Rn is selected from the group consisting of: H, halo and OCi-4alkyl;
R° is selected from the group consisting of: H, Ci-4alkyl, and Ci-4haloalkyl;
Rp is selected from the group consisting of: H, Ci-4alkyl, and OCi-4alkyl;
Y is CH or N; and R4a is selected from the group consisting of: CH3, CF2H, CF3, C3-6cycloalkyl, and phenyl; and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.
29. A compound as claimed in claim 28, wherein R1 is CH3.
30. A compound as claimed in claim 28, wherein R1 is CH2CH3.
Figure imgf000622_0001
Figure imgf000622_0002
32. A compound as claimed in claim 28, wherein
Figure imgf000623_0001
Figure imgf000623_0005
33. A compound as claimed in claim 28, wherein
Figure imgf000623_0002
Figure imgf000623_0003
34. A compound as claimed in claim 28, wherein R2a is
Figure imgf000623_0004
35. A compound as claimed in claim 28, wherein R2a is
Figure imgf000624_0001
Figure imgf000624_0002
,
Figure imgf000625_0001
38. A compound as claimed in claim 28, wherein Ria is
Figure imgf000625_0002
39. A
Figure imgf000625_0003
40. A
Figure imgf000626_0001
41. A compound as claimed in claim 28, wherein R2a is
Figure imgf000626_0003
Figure imgf000626_0002
44. A compound as claimed in claim 28, wherein R2a is
Figure imgf000627_0001
45. A compound as claimed in claim 28, wherein R2a is
Figure imgf000627_0002
46. A compound as claimed in claim 28, wherein R2a is
Figure imgf000628_0001
47. A compound as claimed in claim 28, wherein R2a is
Figure imgf000628_0002
48. A compound as claimed in claim 28, wherein R2a
Figure imgf000628_0003
CO or
Figure imgf000628_0004
49. A compound as claimed in claim 28, wherein R2a is
Figure imgf000629_0001
50. A compound as claimed in claim 28, wherein R2a is
Figure imgf000629_0002
A compound as claimed in claim 28, wherein R2a is
Figure imgf000629_0003
52. A
Figure imgf000630_0001
53. A
54. A
Figure imgf000630_0002
,
Figure imgf000630_0003
55. A compound as claimed in claim 28, wherein R2a is
Figure imgf000630_0004
56. A
Figure imgf000630_0005
57. A compound as claimed in claim 28, wherein R2a is
Figure imgf000631_0001
58. A compound as claimed in claim 28, wherein R2a is
Figure imgf000631_0002
59. A compound as claimed in claim 28, wherein R2a is
Figure imgf000631_0003
60. A compound as claimed in claim 28, wherein R2a is
Figure imgf000631_0004
Figure imgf000631_0005
61. A compound as claimed in claim 28, wherein R2a is
Figure imgf000632_0001
62. A compound as claimed in claim 28, wherein R2a is
Figure imgf000632_0002
63. A compound as claimed in claim 28, wherein R2a is
Figure imgf000632_0003
64. A compound as claimed in claim 28, wherein R2a is
Figure imgf000633_0001
65. A compound as claimed in claim 28, wherein R3a is Phenyl; or phenyl substituted with one member selected from the group consisting of: F, Cl, OCFh, OCH2CH3, OCH(CH3)2, OCHF2, CF3, CF2CH3, OCF2H, and OCF3.
66. A compound as claimed in claim 28, wherein R3a is phenyl substituted with two or three members independently selected from the group consisting of: F, Cl, CH3, CF2H, OCF2H and OCH3.
67. A compound as claimed in claim 28, wherein R3a is 3,5-difluorophenyl, 3,5- dichlorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-methoxyphenyl, 3-chloro-4- methoxyphenyl, 3-fluoro-4-methoxyphenyl, or 3,4,5-trifluorophenyl.
68. A compound as claimed in claim 28, wherein R3a is
Figure imgf000633_0002
A compound as claimed in claim 28, wherein R3a is
Figure imgf000634_0001
70. A compound as claimed in claim 28, wherein R4a is CH3.
71. A compound as claimed in claim 28, wherein R4a is CF3.
72. A compound as claimed in claim 28, wherein R4a is CF2H.
73. A compound as claimed in claim 28, wherein R4a is phenyl.
74. The compound of claim 28, and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof , having the structure of Formula (IIA):
Figure imgf000634_0002
wherein
R1 is CH3;
R2a is selected from the group consisting of:
Figure imgf000634_0003
R4a is CH3 or phenyl; and each Rn is independently selected from the group consisting of: H, Cl and F; and m is 1,2, or 3.
75. The compound of claim 28, and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, having the structure of Formula (IIB):
Figure imgf000635_0001
wherein
R1 is CH3 or CH2CH3
Re is selected from the group consisting of: OCi-4alkyl, OCi-4haloalkyl,
(C=0)NHCH3, and 5-membered heteroaryl ring containing two or three nitrogen members, wherein the 5-membered heteroaryl ring is optionally substituted with one Rf member;
Rf is selected from the group consisting of: H, halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, and OCi-4haloalkyl;
R3a is phenyl substituted with one, two, or three members independently selected from halo or Ci-4alkyl; and
R4a is CH3.
76. A compound of claim 75, wherein
R1 is CFF;
Re is selected from the group consisting of: OCi-4alkyl, OCi-4haloalkyl, (C=0)NHCH3, and 5-membered heteroaryl ring containing two or three nitrogen members, wherein the 5-membered heteroaryl ring is optionally substituted with one Rf member;
Rf is selected from the group consisting of: H, halo, Ci-4alkyl, Ci-4haloalkyl,
OCi-4alkyl, and OCi-4haloalkyl;
R3a is 3-chlorophenyl, 3,5-difluorophenyl, 3-fluoro-5-methyl-phenyl, or 3,4,5- trifluorophenyl; and R4a is CH3.
77. The compound of claim 28, and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, having the structure of Formula (IIC):
Figure imgf000636_0001
wherein
R1 is CH3;
R2a is selected from the group consisting of:
Figure imgf000636_0002
Figure imgf000637_0001
R1 is selected from the group consisting of: H, F, CH3, CF3, CF2H, OCH3, and
cyclopropyl;
R1 is selected from the group consisting of: H, Br, F, CH3, and CF3;
Rm is H or CH3;
Rn is selected from the group consisting of: H, halo and OCH3;
R° is selected from the group consisting of: H, CH3, CF3, CF2H, and CH2CH2F;
Y is CH or N;
and
R3a is phenyl substituted with one, two or three members each independently selected from the group consisting of: Cl, F, CH3, and OCH3.
78. A compound of claim 77, wherein
R1 is CH3;
Figure imgf000638_0001
Figure imgf000639_0001
Figure imgf000640_0001
R3a is 3-chlorophenyl, 3,5-difluorophenyl, 3,5-dichlorophenyl, 3-fluoro-5-methylphenyl, 3- chloro-5-methoxy-phenyl, or 3,4,5-trifluorophenyl.
79. The compound of claim 28, and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, having the structure of Formula (IID):
Figure imgf000641_0001
wherein
R2a is selected from the group consisting of:
Figure imgf000641_0002
Rf is selected from the group consisting of: H, F and OCFF;
R1 is selected from the group consisting of: H, Cl, F and CFv
Rk is selected from the group consisting of: H, Br, CFF, CF3, OH, and OCH2CH2F;
Rm is H or CH3; and
Rp is selected from the group consisting of: H, CH3, and OCH3;
R3a is selected from the group consisting of:
(a)Phenyl; or phenyl substituted with one, two or three members each independently selected from the group consisting of: Cl, F, Ci-4alkyl, CF3, OCi-4alkyl, OCF3, and OCF2H; and
Figure imgf000642_0001
Figure imgf000643_0001
R3a is 5-methylfuran-2-yl, 5-(trifluoromethyl)furan-2-yl, pyridin-3-yl, 5-fluoropyridin-3-yl, 5- (trifluoromethyl)pyridin-3-yl, phenyl, 3-chlorophenyl, 3,5-difluorophenyl, 3,5- dichlorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-4-methoxyphenyl, 4- (difluoromethoxy)-3-fluorophenyl, 3-fluoro-5-(trifluoromethyl)phenyl, 3-chloro-4- methoxyphenyl, 3-fluoro-5-methoxyphenyl, 3-chloro-4-methylphenyl, 3,5-difluoro-4- methylphenyl, or 3,4,5-trifluorophenyl; and
R4a is CH3.
81. The compound of claim 28, and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, having the structure of Formula (HE):
Figure imgf000643_0002
wherein
Figure imgf000644_0002
is selected from the group consisting of:
Figure imgf000644_0001
Figure imgf000644_0003
where
Y is CH or N;
Rf is H or F;
Rg is selected from the group consisting of: OCi-4alkyl, CH2OCH3, CH2OH,
Figure imgf000644_0004
Rh is selected from the group consisting of: Ci-4alkyl, CF3, and cyclopropyl;
R1 is selected from the group consisting of: H, halo, Ci-4alkyl, CF2H, CF3, OCH3, cyclopropyl, cyclobutyl, and cyclopropyl substituted with one or two members independently selected from: F and CH3;
R is selected from the group consisting of: H, Cl, F, and CH3;
Rm is H, CH3, or CH2CH3;
R3a is selected from the group consisting of: phenyl, 3, 3-chlorophenyl, 5-difluorophenyl,
3-fluoro-5-methyl-phenyl, 3,4,5-trifluorophenyl; and
R4a is selected from the group consisting of: CH3, C3-6cycloalkyl, and phenyl.
82. The compound of claim 28, and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, having the structure of Formula (IIF):
Figure imgf000645_0001
wherein
Figure imgf000645_0002
is selected from the group consisting of:
Figure imgf000645_0003
where
Rh is CH3;
RJ is H or CF2H;
Rm is H or CH3;
R3a is 3-chlorophenyl or 3,4,5-trifluorophenyl.
83. A compound selected from the group consisting of: (3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinolin-6-yl)methanone;
(S)-(2,7-Dimethyl-3-(5-methylfuran-2-yl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxalin-6-yl)methanone;
(S)-(2,7-Dimethyl-3-(pyridin-3-yl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxalin-6-yl)methanone;
(S)-(3-(5-Fluoropyridin-3-yl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxalin-6-yl)methanone;
(2,7-Dimethyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin-6- yl)methanone;
(R)-(2,7-Dimethyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin-6- yl)methanone;
(S)-(2,7-Dimethyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin-6- yl)methanone;
(7-Methyl-2,3-diphenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin-6- yl)methanone;
(R)-(7-Methyl-2,3-diphenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin-6- yl)methanone;
(S)-(7-Methyl-2,3-diphenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(quinolin-6- yl)methanone;
(S)-(3-Chloro-5-(trifluoromethoxy)phenyl)(3-(3-chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-
6H-pyrazolo[3,4-c]pyridin-6-yl)methanone;
(S)-(3-(3-Chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(l- phenyl- 1 H- 1 ,2,4-triazol-3 -yl)methanone;
(S)-(3-(3-Chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(5- ethyl-l-(2-fluorophenyl)-lH-l,2,4-triazol-3-yl)methanone;
(S)-(3-(3-Chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(4- (hydroxymethyl)pyridin-2-yl)methanone;
(S)-(3-(3-Chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(5- (methoxymethyl)pyridin-3-yl)methanone; (S)-(3-(3-Chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(6- isopropoxypyridin-3-yl)methanone;
(S)-(3-(3-Chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(5- isopropoxypyridin-3-yl)methanone;
(S)-Benzo[d][l,3]dioxol-4-yl(3-(3-chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridin-6-yl)methanone;
(S)-6-(3-(3-Chlorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-6- carbonyl)benzo[d]oxazol-2(3H)-one;
(S)-(3-(3-Chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(2- methylbenzo[d]oxazol-6-yl)methanone;
(3-(3-Chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(furo[3,2- b]pyridin-6-yl)methanone;
(R)-(3-(3-Chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(furo[3,2-b]pyridin-6-yl)methanone;
(S)-(3-(3-Chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(furo[3,2-b]pyridin-6-yl)methanone;
(S)-(3-(3-Chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(furo[3,2-b]pyridin-2-yl)methanone;
(S)-(3-(3-Chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(lH- pyrrolo[2,3-b]pyridin-6-yl)methanone;
(S)-(3-(3-Chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(l,5- naphthyridin-2-yl)methanone;
(3-(3-Chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxalin-6-yl)methanone;
(R)-(3-(3-Chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxalin-6-yl)methanone;
(S)-(3-(3-Chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxalin-6-yl)methanone;
(S)-(8-Bromoquinoxalin-6-yl)(3-(3-chlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridin-6-yl)methanone; (7-Ethyl-3-(3-fluorophenyl)-2-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinolin-6-yl)methanone;
[(7S)-3-(3,5-Difluorophenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[2-(2- fluoroethoxy)phenyl]methanone;
(S)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(4-
(2-fluoroethoxy)phenyl)methanone;
(S)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(3-
(2-fluoroethoxy)phenyl)methanone;
(S)-[3-(3,5-difluorophenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3-(2- fluoranylethoxy)phenyl]methanone;
(S)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(2- fluoro-3-(2-fluoroethoxy)phenyl)methanone;
(S)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(2- fluoro-5-(2-fluoroethoxy)phenyl)methanone;
(S)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(3- fluoro-5-(2-fluoroethoxy)phenyl)methanone;
(S)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(4- fluoro-3-(2-fluoroethoxy)phenyl)methanone;
[2-Chloro-3-(2-fluoroethoxy)phenyl]-[(7S)-3-(3,5-difluorophenyl)-2,7-dimethyl-5,7-dihydro-4H- pyrazolo [3 ,4-c] pyridin-6-yl] methanone;
[2-chloro-5-(2-fluoroethoxy)phenyl]-[(7S)-3-(3,5-difluorophenyl)-2,7-dimethyl-5,7-dihydro-4H- pyrazolo [3 ,4-c] pyridin-6-yl] methanone4-Isopropyl-6-piperazin- 1 -yl-pyrimidin-2- ylamine;
(S)-(2-(2H-l,2,3-Triazol-2-yl)phenyl)(3-(3,5-difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-
6H-pyrazolo[3,4-c]pyridin-6-yl)methanone;
(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(l- phenyl- 1 H- 1 ,2,4-triazol-3 -yl)methanone;
(S)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(5- ethyl- 1 -phenyl- 1 H- 1 ,2,4-triazol-3 -yl)methanone;
(S)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(l-
(2-fluoroethyl)-lH-indol-4-yl)methanone; (S)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(l- (2-(fluoro- 18F)ethyl)- 1 H-indol-5-yl);
(S)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(l-
(2-fluoroethyl)-lH-pyrrolo[2,3-b]pyridin-4-yl)methanone;
(S)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(furo[3,2-b]pyridin-6-yl)methanone;
(R)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(furo[3,2-b]pyridin-6-yl)methanone;
(2-(Difluoromethyl)-3-(3,5-difluorophenyl)-7-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)(quinolin-6-yl)methanone;
(3-(3,5-Difluorophenyl)-7-methyl-2-(trifluoromethyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)(quinolin-6-yl)methanone;
(3-(3,5-Difluorophenyl)-7-methyl-2-(methyl-d3)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-
6-yl)(quinolin-6-yl)methanone;
(R)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinolin-6-yl)methanone;
(S)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinolin-6-yl)methanone;
(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(isoquinolin-3-yl)methanone;
(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(isoquinolin-7-yl)methanone;
(4-Bromoquinolin-6-yl)(3-(3,5-difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridin-6-yl)methanone;
(5-Chloroquinolin-6-yl)(3-(3,5-difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridin-6-yl)methanone;
(S)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(8-
(trifluoromethyl)quinolin-6-yl)methanone;
(S)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(3- (trifluoromethyl)quinolin-6-yl)methanone; (S)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(3-
(2-fluoroethoxy)quinolin-6-yl)methanone;
(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxalin-6-yl)methanone;
(S)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxalin-6-yl)methanone;
(R)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxalin-6-yl)methanone;
(S)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(l,5-naphthyridin-2-yl)methanone;
(S)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(7- fluoroquinoxalin-6-yl)methanone;
(S)-(3-(3,5-Dichlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(2- methylbenzo[d]oxazol-6-yl)methanone;
(S)-(3-(3,5-Dichlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(l- methyl- 1 H-pyrazolo[3 ,4-b]pyridin-3 -yl)methanone;
(S)-(3-(3,5-Dichlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinolin-6-yl)methanone;
(S)-(3-(3,5-Dichlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxalin-6-yl)methanone;
(S)-(3-(3,5-Dichlorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)(2- methylquinoxabn-6-yl)methanone;
(3-(3-Chloro-5-fluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinolin-6-yl)methanone;
(S)-(3-(3-Chloro-5-fluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinolin-6-yl)methanone;
(R)-(3-(3-Chloro-5-fluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinolin-6-yl)methanone;
(3-(3-Chloro-5-fluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxalin-6-yl)methanone; (S)-(3-(3-Chloro-5-fluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxalin-6-yl)methanone;
(R)-(3-(3-Chloro-5-fluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxalin-6-yl)methanone;
(S)-(3-(3-Chloro-4-methylphenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxalin-6-yl)methanone;
(S)-(3-(3-Fluoro-5-(trifluoromethyl)phenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)(quinoxalin-6-yl)methanone;
(S)-(3-(3-Fluoro-4-methoxyphenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-
6-yl)(quinoxalin-6-yl)methanone;
(S)-(3-(3-Fluoro-5-methoxyphenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-
6-yl)(quinoxalin-6-yl)methanone;
(S)-(3-(3-Fluoro-5-methoxyphenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-
6-yl)(7-fluoroquinoxalin-6-yl)methanone;
(S)-(3-(3-Chloro-4-methoxyphenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-
6-yl)(quinoxalin-6-yl)methanone;
(S)-(3-(4-(Difluoromethoxy)-3-fluorophenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)(quinoxalin-6-yl)methanone;
(S)-(3-(3,5-Difluoro-4-methylphenyl)-2,7-dimethyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)(quinoxalin-6-yl)methanone;
(S)-(2-Chloro-3-methoxyphenyl)(2,7-dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridin-6-yl)methanone;
(S)-(3-Chloro-5-methoxyphenyl)(2,7-dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridin-6-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(5-fluoro-2-(lH-pyrazol-l-yl)phenyl)methanone;
(S)-(3-(lH-l,2,4-Triazol-l-yl)phenyl)(2,7-dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-
6H-pyrazolo[3,4-c]pyridin-6-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(3-fluoro-2-(2H-l,2,3-triazol-2-yl)phenyl)methanone; (S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(4-fluoro-2-(2H-l,2,3-triazol-2-yl)phenyl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(5-methyl-2-(2H-l,2,3-triazol-2-yl)phenyl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(l-methyl-5-(trifluoromethyl)-lH-pyrazol-4-yl)methanone;
(S)-(l-(tert-Butyl)-5-(trifluoromethyl)-lH-pyrazol-4-yl)(2,7-dimethyl-3-(3,4,5-trifluorophenyl)-
2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(5-methoxy-l -methyl- lH-pyrazol-3-yl)methanone;
(S)-(5-Cyclopropyl-l-methyl-lH-pyrazol-4-yl)(2,7-dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7- tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(5-ethyl-l -phenyl- 1H-1, 2, 4-triazol-3-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(5-methoxypyridin-3-yl)methanone;
(S)-6-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-6- carbonyl)-4-methyl-2H-benzo[b][l,4]oxazin-3(4H)-one;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(lH-indol-7-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(l-methyl-lH-indol-7-yl)methanone;
(S)-(2,7-dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)( 1 -methyl- 1 H-indol-4-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(lH-indazol-7-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(l-methyl-lH-indazol-7-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(7-methyl-lH-indazol-5-yl)methanone; (S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin· ·6· yl)( 1 -methyl- 1 H-indazol-5 -yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin· 6 y 1) (imidazo [ 1 , 5 -a] pyridin- 8-y l)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin· 6 yl)(imidazo[l,2-a]pyridin-3-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin· 6 yl)(furo[3,2-c]pyridin-4-yl)methanone;
(S)-Benzo[d]isoxazol-3-yl(2,7-dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridin-6-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin· 6 y 1) ( 1 H-pyrrolo [ 3 ,2- c] pyridin-4-y l)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin· 6 yl)(l-methyl-lH-pyrrolo[3,2-c]pyridin-4-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin· 6 yl)(lH-pyrrolo[3,2-c]pyridin-3-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin· 6 yl)(l-methyl-lH-pyrrolo[3,2-c]pyridin-3-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin· 6 yl)(l-methyl-lH-pyrrolo[3,2-b]pyridin-3-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin· 6 yl)( 1 -methyl- 1 H-pyrrolo[2, 3 -c]pyridin-3 -yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin· 6 yl)( 1 -methyl- 1 H-pyrrolo[2, 3 -b]pyridin-2-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin· 6 yl)( 1 -methyl- 1 H-pyrrolo[2, 3 -b]pyri din-3 -yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin· 6 yl)( 1 -methyl- 1 H-pyrrolo[2, 3 -c]pyridin-4-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin· 6 yl)( 1 -methyl- 1 H-pyrrolo[2, 3 -b]pyridin-4-yl)methanone; (S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- y 1) ( 1 -methyl- 1 H-pyrrolo [2, 3 -b] pyridin- 5 -y l)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(pyrazolo[l,5-a]pyridin-4-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- y 1) (pyrazolo [ 1 , 5 -a] pyridin- 5 -y l)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(pyrazolo [ 1 , 5 -a] pyrazin-3 -y l)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(l-methyl-lH-pyrazolo[3,4-b]pyridin-3-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(l-methyl-lH-pyrazolo[3,4-b]pyridin-5-yl)methanone;
(S)-(2-(Difluoromethyl)-7-methyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)(quinolin-6-yl)methanone;
(R)-(2-(Difluoromethyl)-7-methyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)(quinolin-6-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinolin-6-yl)methanone;
(R)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinolin-6-yl)methanone;
(S)-(2,7-dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinolin-8-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(isoquinolin-l-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(8-fluoroquinobn-4-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(2-methylquinolin-4-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(2-methoxyquinobn-4-yl)methanone; (S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(8-fluoro-2-methylquinolin-4-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinoxalin-6-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(2-methylquinoxalin-6-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)( 1 , 5 -naphthyridin-2-yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)( 1 , 5 -naphthyridin-3 -yl)methanone;
(S)-(2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- y 1) ( 1 , 6-naphthyr idin- 8 -y l)methanone;
(S)-(2,7-Dimethyl-3-(5-(trifluoromethyl)furan-2-yl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)(quinoxalin-6-yl)methanone;
(S)-(2,7-Dimethyl-3-(5-(trifluoromethyl)pyridin-3-yl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)(quinoxalin-6-yl)methanone;
(2,7-Dimethyl-3-(l-methyl-lH-indol-4-yl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinolin-6-yl)methanone;
(2,7-Dimethyl-3-(l-methyl-lH-indol-2-yl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinolin-6-yl)methanone;
(2,7-Dimethyl-3-(l-methyl-lH-indol-3-yl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinolin-6-yl)methanone;
(2,7-Dimethyl-3-(l-methyl-lH-indol-5-yl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinolin-6-yl)methanone; and
(2,7-Dimethyl-3-(l-methyl-lH-indol-7-yl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(quinolin-6-yl)methanone;
(S)-(3-(3,5-Difluorophenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3-(2- fluoranylethoxy)-2-fluoro-phenyl]methanone;
[2-Chloro-3-(2-fluoranylethoxy)phenyl]-[(7S)-3-(3,5-difluorophenyl)-2,7-dimethyl-5, 7-dihydro- 4H-pyrazolo[3,4-c]pyridin-6-yl]methanone; (S)-[3-(3,5-Difluorophenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3-(2- fluoranylethoxy)-5-fluoro-phenyl]methanone;
(3-Methoxyphenyl)-[(7S)-7-methyl-2,3-diphenyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl] methanone;
[(7S)-3-(3-Fluoro-5-methyl-phenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-
(4-methoxyphenyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(2- methoxyphenyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(3- methoxyphenyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(4- methoxyphenyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3-
(trifluoromethoxy)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[2-
(trifluoromethoxy)phenyl]methanone;
[4-(Difluoromethoxy)phenyl]-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H- pyrazolo [3 ,4-c] pyridin-6-yl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(2- fluoro-4-methoxy-phenyl)methanone;
3-[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridine-6- carbonyl]-N-methyl-benzamide;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(4- imidazol- 1 -ylphenyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[4- ( 1 H-pyrazol-4-yl)phenyl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[4- ( 1 H-pyrazol-5 -yl)phenyl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3- ( 1 H-pyrazol-3 -yl)phenyl] methanone; [(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[4- methoxy-3-(l-methylpyrazol-3-yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3- ( 1 H-pyrazol-4-yl)phenyl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3-(l- methylpyrazol-4-yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[2- fluoro-5-(l-methylpyrazol-4-yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3-(4- fluoropyrazol- 1 -yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3-(3- methyl- 1 ,2,4-triazol- 1 -yl)phenyl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3- fluoro-5-(l ,2,4-triazol- 1 -yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3- methoxy-5-(l ,2,4-triazol- 1 -yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[2- (1 ,2,4-triazol- 1 -yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[2- fluoro-6-(l ,2,4-triazol- 1 -yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[5- fluoro-2-(l ,2,4-triazol- 1 -yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[2-[3- (trifluoromethyl)-l ,2,4-triazol- 1 -yl]phenyl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3-
(triazol-2-yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3- fluoro-5-(triazol-2-yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[2- fluoro-5-(triazol-2-yl)phenyl]methanone; [(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3- methyl-5-(triazol-2-yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3-
(triazol-2-yl)-5-(trifluoromethyl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[2- fluoro-6-(triazol-2-yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[5- methoxy-2-(triazol-2-yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3-
(l,2,4-triazol-4-yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[4- fluoro-3-(l,2,4-triazol-4-yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3- fluoro-5-(l,2,4-triazol-4-yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3- methyl-5-(l,2,4-triazol-4-yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[4- methyl-3-(l,2,4-triazol-4-yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3-
(l,2,4-triazol-4-yl)-4-(trifluoromethyl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3- (1,2, 4-triazol-4-y 1)- 5 - (tr ifluor omethy l)pheny 1] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[4- methoxy-3-(l,2,4-triazol-4-yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3- methoxy-5-(l,2,4-triazol-4-yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[2-
(l,2,4-triazol-4-yl)phenyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- methoxy- 3 -py ridy l)methanone; [(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- methoxy-2-pyridyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- methoxy-3-methyl-2-pyridyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(3- methoxy-2-pyridyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[5-
(methoxymethyl)-3-pyridyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- isopropoxy-3 -pyridyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- methoxy-2-methyl-3-pyridyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(4- methoxy-3-methyl-2-pyridyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- methoxy-2-methyl-3-pyridyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(4- methoxy-2-pyridyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- methoxy-6-methyl-3-pyridyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(3- methoxy-4-pyridyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(2- methoxy-4-pyridyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- methoxy-4-methyl-3-pyridyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(2- methoxy-3-methyl-4-pyridyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(3- fluoro-2-methoxy-4-pyridyl)methanone; (3-Chloro-2-methoxy-4-pyridyl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H- pyrazolo [3 ,4-c] pyridin-6-yl] methanone;
(3-Chloro-4-methoxy-2-pyridyl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H- pyrazolo [3 ,4-c] pyridin-6-yl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- pyrazol- 1 -yl-3-pyridyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[6- methyl-3-(triazol-2-yl)-2-pyridyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- pyrazol- 1 -yl-2-pyridyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- methyl- 1 -phenyl- 1 ,2,4-triazol-3-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[l-(4- fluorophenyl)-5-methyl-l,2,4-triazol-3-yl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[l-(2- pyridyl)- 1 ,2,4-triazol-3-yl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[l-(3- fluoro-2-pyridyl)-l,2,4-triazol-3-yl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[5-(2- pyridyl)-2-thienyl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- methoxypyrazin-2-yl)methanone;
(l,5-Dimethylpyrazol-4-yl)-[(7S)-3-(3-fluoro-5-methyl-phenyl)-2,7-dimethyl-5,7-dihydro-4H- pyrazolo [3 ,4-c] pyridin-6-yl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- isopropy 1- 1 -methyl-pyrazol-4-y l)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[l-
(trifluoromethyl)pyrazol-4-yl]methanone;
[5-(Difluoromethyl)-l-methyl-pyrazol-4-yl]-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c]pyridin-6-yl] methanone; (l-Cyclopropylpyrazol-4-yl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H- pyrazolo [3 ,4-c] pyridin-6-yl] methanone;
[l-Cyclopropyl-3-(trifluoromethyl)pyrazol-4-yl]-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-
5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]methanone;
(5-Cyclobutyl- l-methyl-pyrazol-4-yl)-[(7S)-2,7-dimethyl-3-(3, 4, 5-trifluorophenyl)-5, 7-dihydro- 4H-pyrazolo[3,4-c]pyridin-6-yl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[l- methyl-5-(l-methylcyclopropyl)pyrazol-4-yl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[5-(l- fluorocyclopropyl)-l-methyl-pyrazol-4-yl]methanone;
(5-(2,2-Difluorocyclopropyl)-l-methyl-lH-pyrazol-4-yl)((S)-2,7-dimethyl-3-(3,4,5- trifluorophenyl)-4,5-dihydro-2H-pyrazolo[3,4-c]pyridin-6-yl)methanone;
(5-((R*)-2,2-difluorocyclopropyl)-l-methyl-lH-pyrazol-4-yl)((S)-2,7-dimethyl-3-(3,4,5- trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)methanone;
(5-((S*)-2,2-Difluorocyclopropyl)-l-methyl-lH-pyrazol-4-yl)((S)-2,7-dimethyl-3-(3,4,5- trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)methanone;
((S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(cis-5-(2-fluorocyclopropyl)-l-methyl-lH-pyrazol-4-yl)methanone;
((S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(trans-5 -(2-fluorocyclopropyl)- 1 -methyl- 1 H-pyrazol-4-yl)methanone;
((S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6- yl)(l-methyl-cis-5-(2-methylcyclopropyl)-lH-pyrazol-4-yl)methanone;
(S*)-(2-(Bicyclo[l. l. l]pentan-l-yl)-7-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)(5-cyclopropyl-l-methyl-lH-pyrazol-4-yl)methanone;
(l,3-Dimethylpyrazol-4-yl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H- pyrazolo [3 ,4-c] pyridin-6-yl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-
(l,3,5-trimethylpyrazol-4-yl)methanone;
(l,5-Dimethylpyrazol-4-yl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H- pyrazolo [3 ,4-c] pyridin-6-yl] methanone; [l-Cyclopropyl-5-(trifluoromethyl)pyrazol-4-yl]-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-
5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[l- methyl-3-(l-methylcyclopropyl)pyrazol-4-yl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3-(l- fluorocyclopropyl)-l-methyl-pyrazol-4-yl]methanone;
(R)-(5-cyclopropyl-l-methyl-lH-pyrazol-4-yl) (7-methyl-2,3-diphenyl-2,4,5,7-tetrahydro-6H- pyrazolo[3,4-c] pyridin-6-yl) methanone;
(S)-(5-cyclopropyl-l -methyl- lH-pyrazol-4-yl) (7-methyl-2,3-diphenyl-2,4,5,7-tetrahydro-6H- pyrazolo [3 ,4-c] pyridin-6-yl)methanone;
(l,2-Dimethylpyrrol-3-yl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H- pyrazolo [3 ,4-c] pyridin-6-yl] methanone;
(4,5-Dimethylisoxazol-3-yl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H- pyrazolo [3 ,4-c] pyridin-6-yl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- fluoro- lH-indol-6-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(7- fluoro- lH-indol-4-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- fluoro- 1 H-indol-3 -yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- fluoro- 1 -methyl-indol-3 -yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(4- fluoro- 1 H-indol-3 -yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- fluoro- 1 H-indol-3 -yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(7- fluoro- 1 H-indol-3 -yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- methy 1- 1 H-indol-3 -yl)methanone; [(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(lH- indazol-3-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(4- fluoro- 1 H-indazol-3 -yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- fluoro- 1 H-indazol-3 -yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- fluoro- 1 H-indazol-3 -yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(2- methylindazol-3-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(l- methylbenzimidazol-4-yl)methanone;
lH-Benzotriazol-4-yl-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H- pyrazolo [3 ,4-c] pyridin-6-yl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(lH- pyrr olo [2, 3 -b] pyridin- 5 -y 1) methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- fluoro- 1 H-pyrrolo[2, 3 -b] pyridin-4-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- fluoro- 1 -methyl-pyrrolo[2,3-b]pyridin-4-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[5- (trifluoromethyl)-lH-pyrrolo[2,3-b]pyridin-4-yl] methanone;
[(7S)-3-(3,5-Difluorophenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[l-(2- fluoranylethyl)pyrrolo[2,3-b]pyridin-4-yl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(lH- pyrrolo[2,3-b]pyridin-3-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- fluoro- 1 H-pyrrolo[2, 3 -b] pyri din-3 -yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(2- methyl-lH-pyrrolo[2,3-b]pyridin-3-yl)methanone; [(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(lH- pyrrolo[2,3-c]pyridin-7-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(3- fluoropyrazolo[ 1 ,5-a]pyridin-4-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(3- fluoropyrazolo[l,5-a]pyridin-5-yl)methanone;
(3-Bromopyrazolo[l,5-a]pyridin-4-yl)-[(7S)-2,7-dimethyl-3-(3, 4, 5-trifluorophenyl)-5, 7-dihydro- 4H-pyrazolo[3,4-c]pyridin-6-yl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(3- methylpyrazolo[ 1 ,5-a]pyridin-4-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- pyrazolo[l,5-a]pyridin-3-yl-methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(2- methylpyrazolo[l,5-a]pyridin-3-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- methylpyrazolo[l,5-a]pyridin-3-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- fluoropyrazolo[l,5-a]pyridin-3-yl)methanone;
(2-Cyclopropyl-7-methyl-pyrazolo[l,5-a]pyridin-3-yl)-[(7S)-2,7-dimethyl-3-(3,4,5- trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl] -(7- methylpyrazolo[l,5-a] pyridin-3-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(7- methoxypyrazolo [ 1 , 5 -a] pyri din-3 -yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- methoxypyrazolo [ 1 , 5 -a] pyri din-3 -yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- methoxypyrazolo [ 1 , 5 -a] pyri din-3 -yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl]-(4- methoxypyrazolo [ 1 , 5 -a] pyri din-3 -yl)methanone; [(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- imidazo [ 1 , 2-a] py ridin- 6-y l-methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- imidazo[l,2-a]pyridin-8-yl-methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(7- fluoroimidazo [ 1 ,2-a] pyri din-3 -yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl] -(2- methy limidazo [ 1 , 2-a] pyr idin- 5 -y l)methanone;
[(7S)-3-(3-Chloro-5-methoxy-phenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6- yl]-(2-methylimidazo[l,2-a] pyridin-3-yl) methanone;
[(7S)-3-(3-Fluoro-5-methyl-phenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl] - (2-methylimidazo[l,2-a] pyridin-3-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(2- methy limidazo [ 1 , 2-a] pyr idin- 3 -y l)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(3- methy limidazo [ 1 , 2-a] pyr idin-2-y l)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(7- methy limidazo [ 1 , 2-a] pyr idin- 3 -y l)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- methy limidazo [ 1 , 2-a] pyr idin- 3 -y l)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- methy limidazo [ 1 , 2-a] pyr idin- 3 -y l)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(7- fluoro-2-methyl-imidazo[ 1 ,2-a]pyridin-3-yl)methanone;
(2,8-Dimethylimidazo[l,2-a] pyridin-3-yl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c] pyridin-6-yl] methanone;
(2,7-Dimethylimidazo[l,2-a]pyridin-3-yl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c] pyri din-6-yl] methanone;
(2,6-Dimethylimidazo[l,2-a]pyridin-3-yl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c] pyri din-6-yl] methanone; [(7S)-3-(3-Chloro-5-methoxy-phenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl] -(6-fluoro-2-methyl-imidazo [ 1 ,2-a]pyridin-3 -yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- fluoro-2-methyl-imidazo[ 1 ,2-a]pyridin-3-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- fluoro-2,8-dimethyl-imidazo[l,2-a]pyridin-3-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- fluoro-2, 7 - dimethy l-imidazo [ 1 , 2-a] py ridin- 3 -y l)methanone;
(6, 8-Difluoro-2-methyl-imidazo [ 1 ,2-a] pyri din-3 -yl)- [(7S)-2,7-dimethyl-3 -(3 ,4, 5 - trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- methoxy-2-methyl-imidazo[l,2-a]pyridin-3-yl)methanone;
[2-(Difluoromethy l)imidazo [ 1 ,2-a]pyridin-3 -yl] - [(7S)-2, 7-dimethyl-3 -(3 ,4, 5 -trifluorophenyl)- 5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl]-[2- (trifluoromethyl) imidazo[l ,2-a]pyridin-3-yl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[5- methyl-2-(trifluoromethyl)imidazo[l,2-a]pyridin-3-yl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl]- pyrrolo [ 1 ,2-a] pyrazin- 1 -yl-methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl]- pyrrolo[l, 2-a] pyrazin- 8-yl-methanone;
(2,4-Dimethylpyrrolo[l,2-a] pyrimidin-8-yl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(3- methy limidazo [ 1 , 5 -a] pyr idin- 6-y l)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl]-(7- methy limidazo [ 1 , 5 -a] pyr idin- 1 -y l)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- imidazo[ 1 , 5 -a] py ridin- 1 -yl-methanone; (3-Cyclopropylimidazo[l,5-a]pyridin-l-yl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c]pyridin-6-yl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(lH- pyrazolo[3,4-b]pyridin-4-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(lH- pyrazolo[3,4-b]pyridin-5-yl)methanone;
(l,6-Dimethylpyrazolo[3,4-b]pyridin-4-yl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c]pyridin-6-yl] methanone;
(l,3-Dimethylpyrazolo[3,4-b]pyridin-4-yl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c]pyridin-6-yl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(lH- pyrazolo[3,4-b]pyridin-3-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(l- methylpyrazolo[3,4-b]pyridin-3-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- fluoro-lH-pyrazolo[3,4-b]pyridin-3-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(2- methylpyrazolo[3,4-c]pyridin-7-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(lH- pyrazolo[3,4-c]pyridin-3-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(l- methylpyrazolo[3,4-c]pyridin-3-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(lH- pyrazolo[3,4-c]pyridin-7-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(l- methylpyrazolo[3,4-c]pyridin-7-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(lH- pyrazolo[4,3-c]pyridin-7-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(lH- pyrazolo[4, 3 -c]pyri din-3 -y l)methanone; [(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl]-(lH- pyrazolo[4,3-b]pyridin-3-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- ([1 ,2,4]triazolo [4,3 -a] pyridin-3 -yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-
([l,2,4]triazolo[4,3-a]pyridin-5-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- ([1 ,2,4]triazolo [4,3 -a] pyridin-6-yl)methanone;
[3-(Difluoromethyl)-[l,2,4]triazolo[4,3-a]pyridin-6-yl]-[(7S)-2,7-dimethyl-3-(3,4,5- trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-
(triazolo[l,5-a]pyridin-3-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl] -(2- methylpyrazolo[l,5-b] pyridazin-3-yl) methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl] -(5- methylpyrazolo[l,5-b] pyridazin-3-yl) methanone;
(2-Cyclopropyl-4-methyl-pyrazolo[l,5-b]pyridazin-3-yl)-[(7S)-2,7-dimethyl-3-(3,4,5- trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]methanone;
(2-Cyclopropyl-5-methyl-pyrazolo[l,5-b]pyridazin-3-yl)-[(7S)-2,7-dimethyl-3-(3,4,5- trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]methanone;
(2,4-Dimethylpyrazolo[l,5-a] pyrazin-3-yl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl] methanone;
(2-Cyclopropyl-4-methyl-pyrazolo[l,5-a]pyrazin-3-yl)-[(7S)-2,7-dimethyl-3-(3,4,5- trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl]- pyrazolo [ 1 , 5 -a] pyrimi din-3 -yl-methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(2- methy lpyrazolo [ 1 , 5 -a] pyr imidin- 3 -y l)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl] -(7- methy lpyrazolo [1,5 -a] pyrimidin-3-yl) methanone; [(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- methy lpyrazolo [ 1 , 5 -a] pyr imidin- 3 -y l)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- imidazo[l,2-b]pyridazin-6-yl-methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl] -(2- methylimidazo[l,2-b]pyridazin-6-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- imidazo[l,2-b]pyridazin-3-yl-methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(2- methylimidazo[l,2-b]pyridazin-3-yl)methanone;
(2,8-Dimethylimidazo[l,2-b] pyridazin-3-yl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c] pyridin-6-yl] methanone;
(2,7-Dimethylimidazo[l,2-b] pyridazin-3-yl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl]-(2- methylimidazo[l,2-a]pyrimidin-3-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- (2, 5 , 8-trimethy limidazo [ 1 ,2-a]pyrazin-3 -y l)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl] -(6- methylimidazo[l,5-a]pyrimidin-8-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl] -(3- methylimidazo[l,5-a]pyrimidin-8-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl] -(3- methylimidazo[l,5-a] pyrazin-l-yl) methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl]-[3- (trifluoromethyl) imidazo[l,5-a] pyrazin-l-yl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)methanone;
[(7S)-3-(3-Fluoro-5-methyl-phenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl] - (7-methylpyrrolo[2,3-d] pyrimidin-4-yl) methanone; [(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(7- methylpyrrolo[2,3-d]pyrimidin-4-yl)methanone;
(5,7-Dimethylpyrrolo[2,3-d] pyrimidin-4-yl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl] methanone;
[(7S)-2,7-Dimethyl-3-[3-(trifluoromethyl) phenyl]-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6- yl] -(6-quinolyl)methanone;
(6,7-Dimethylpyrrolo[2,3-d] pyrimidin-4-yl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c] pyridin-6-yl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(7H- purin-6-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl]-(l- methylpyrazolo[3,4-d]pyrimidin-4-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- methyl- [ 1 ,2,4]triazolo[ 1 , 5-a]pyrimidin-7-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl] -(7- methylquinoxalin-6-yl) methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl] -(2- methy lquinoxalin- 5 -y l)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(3- methy lquinoxalin- 5 -y l)methanone;
(2,3-Dimethylquinoxalin-6-yl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H- pyrazolo [3 ,4-c] pyridin-6-yl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- quinoxalin-2-yl-methanone;
Cinnolin-3-yl-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4- c]pyridin-6-yl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- quinazolin-6-yl-methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- quinazolin-7-yl-methanone; [(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(8- fluoroquinazolin-4-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- quinazolin-4-yl-methanone;
(2-Deuterioquinoxalin-6-yl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H- pyrazolo [3 ,4-c] pyridin-6-yl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- pyrido [4, 3-d] pyrimidin- 5 -y l-methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(l,5- naphthyridin-4-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(l,6- naphthyridin-5-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(2- methyl-l,6-naphthyridin-5-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(l,6- naphthyri din-3 -yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(l,7- naphthyridin-5-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(l,8- naphthyri din-3 -yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(l,8- naphthyridin-4-yl)methanone;
[(7S)-2,7-Dimethyl-3-(o-tolyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone;
[(7S)-2,7-Dimethyl-3-[2-(trifluoromethyl)phenyl]-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-
(6-quinolyl)methanone;
[(7S)-2,7-Dimethyl-3-[4-(trifluoromethyl)phenyl]-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-
(6-quinolyl)methanone;
[(7S)-3-(3-Methoxyphenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone; [(7S)-3-(2-Methoxyphenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone;
[(7S)-3-(4-Ethoxyphenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone;
[(7S)-3-(3-Isopropoxyphenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone;
[(7S)-3-[3-(Difluoromethoxy)phenyl]-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl] -(6-quinolyl)methanone;
[(7S)-2,7-Dimethyl-3-[4-(trifluoromethoxy)phenyl]-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl]-(6-quinolyl)methanone;
[(7S)-2,7-Dimethyl-3-[3-(trifluoromethoxy)phenyl]-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl] -(6-quinolyl)methanone;
[(7S)-3-(2,4-Difluorophenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone;
[(7S)-3-(2,3-Difluorophenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone;
[(7S)-3-(4-Chloro-3-fluoro-phenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-
(6-quinolyl)methanone;
[(7S)-3-(3-Chloro-4-fluoro-phenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- (6-quinolyl)methanone;
[(7S)-3-(2-Chloro-4-fluoro-phenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-
(6-quinolyl)methanone;
[(7S)-3-(3,4-Dichlorophenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone;
[(7S)-3-(5-Fluoro-2-methoxy-phenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl] -(6-quinolyl)methanone;
[(7S)-3-(4-Fluoro-3-methoxy-phenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl] -(6-quinolyl)methanone;
[(7S)-3-(2-Fluoro-3-methoxy-phenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl]-(6-quinolyl)methanone; [(7S)-3-(3-Fluoro-5-methyl-phenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-
(6-quinolyl)methanone;
[(7S)-3-(4-Methoxy-3-methyl-phenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl] -(6-quinolyl)methanone;
[(7S)-3-(3-Chloro-5-methoxy-phenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl] -(6-quinolyl)methanone;
[(7S)-3-(4-Chloro-2,3-difluoro-phenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl] -(6-quinolyl)methanone;
[(7S)-2,7-Dimethyl-3-(2,3,4-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(l- oxidoquinolin- 1 -ium-6-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(2- hydroxy-6-quinolyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(4- hydroxy-6-quinolyl)methanone;
[(7S)-2,7-Dimethyl-3-(6-methyl-3-pyridyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone;
[(7S)-2,7-Dimethyl-3-(2-methyl-4-pyridyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone;
[(7S)-3-[6-(Difluoromethyl)-3-pyridyl]-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl] -(6-quinolyl)methanone;
[(7S)-2,7-Dimethyl-3-[6-(trifluoromethyl)-3-pyridyl]-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl] -(6-quinolyl)methanone;
[(7S)-2,7-Dimethyl-3-[2-(trifluoromethyl)-4-pyridyl]-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl] -(6-quinolyl)methanone;
[(7S)-2,7-Dimethyl-3-[5-(trifluoromethyl)-3-thienyl]-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl] -(6-quinolyl)methanone;
[(7S)-3-(6-Methoxy-3-pyridyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone; [(7S)-3-(2-Methoxy-4-pyridyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone;
[(7S)-3-[6-(Difluoromethoxy)-3-pyridyl]-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-
6-yl]-(6-quinolyl)methanone;
[(7S)-3-[5-(Difluoromethoxy)-3-pyridyl]-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-
6-yl]-(6-quinolyl)methanone;
[(7S)-3-(6-Methoxy-5-methyl-3-pyridyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl] -(6-quinolyl)methanone;
[(7S)-3-[6-Methoxy-5-(trifluoromethyl)-3-pyridyl]-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4- c]pyridin-6-yl]-(6-quinolyl)methanone;
[(7S)-3-(lH-Indol-7-yl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone;
[(7S)-3-(Benzofuran-6-yl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone;
[(7S)-3-(Benzofuran-5-yl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone;
[(7S)-3-(Benzofuran-7-yl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone;
[(7S)-3-(Benzofuran-4-yl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone;
[(7S)-3-(5-Fluorobenzofuran-7-yl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-
(6-quinolyl)methanone;
[(7S)-3-(l,3-Benzothiazol-4-yl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone;
[(7S)-3-(2,l,3-Benzoxadiazol-4-yl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-
(6-quinolyl)methanone;
[(7S)-3-(2,3-Dihydrobenzofuran-7-yl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl] -(6-quinolyl)methanone;
[(7S)-3-(l,3-Benzodioxol-5-yl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone; [(7S)-3-(l,3-Benzodioxol-4-yl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- quinolyl)methanone;
[(7S)-3-(2,2-Difluoro-l,3-benzodioxol-4-yl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4- c]pyridin-6-yl]-(6-quinolyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- isoquinolyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(6- isoquinolyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(5- fluoro-3-quinolyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(8- fluoro-4-isoquinolyl)methanone;
(4-Bromo-6-quinolyl)-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H- pyrazolo [3 ,4-c] pyridin-6-yl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(2- methyl-6-quinolyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(4- methyl-6-quinolyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(8- methoxy-4-quinolyl)methanone;
5.6-Dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c]pyridin-6-yl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-
(4,5,6,7-tetrahydropyrazolo[l,5-a]pyridin-3-yl)methanone;
6.7-Dihydro- 5H-pyrazolo[5,l-b] [1, 3]oxazin-2-yl-[(7S)-2,7-dimethyl-3-(3, 4, 5-trifluorophenyl)-
5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]methanone;
6, 7-Dihydro- 5H-pyrazolo[5,l-b] [1, 3]oxazin-3-yl-[(7S)-2,7-dimethyl-3-(3, 4, 5-trifluorophenyl)-
5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(3- methyl-6,7-dihydro-5H-pyrazolo[5,l-b][l,3]oxazin-2-yl)methanone; [(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- (2,6,6-trimethyl-4,7-dihydropyrazolo[5,l-c][l,4]oxazin-3-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- (3,6,6-trimethyl-4,7-dihydropyrazolo[5,l-c][l,4]oxazin-2-yl)methanone;
((S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-4,5-dihydro-2H-pyrazolo[3,4-c]pyridin-6(7H)-yl)(7- (trifluoromethy l)-4, 5,6,7 -tetrahy dropyrazolo [ 1 , 5 -a] pyr imidin-3 -y l)methanone;
6.7-Dihydro-5H-pyrrolo[l,2-a]imidazol-3-yl-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c]pyridin-6-yl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- (5,6,7,8-tetrahydroimidazo[l,2-a]pyridin-3-yl)methanone;
[2-(Difluoromethyl)-5,6,7,8-tetrahydroimidazo[l,2-a]pyridin-3-yl]-[(7S)-2,7-dimethyl-3-(3,4,5- trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]methanone;
6.8-Dihydro-5H-imidazo[2,l-c][l,4]oxazin-3-yl-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-
5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]methanone;
3.4-Dihydro-2H-pyrano[2,3-b]pyridin-6-yl-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c]pyridin-6-yl] methanone;
3.4-Dihydro-2H-pyrano[2,3-b]pyridin-5-yl-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c]pyridin-6-yl] methanone;
6.8-Dihydro-5H-pyrano[3,4-b]pyridin-4-yl-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c]pyridin-6-yl] methanone;
6.8-Dihydro-5H-pyrano[3,4-b]pyridin-2-yl-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c]pyridin-6-yl] methanone;
7.8-Dihydro-5H-pyrano[4,3-b]pyridin-3-yl-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c]pyridin-6-yl] methanone;
3.4-Dihydro-2H-pyrano[3,2-b]pyridin-8-yl-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c]pyridin-6-yl] methanone;
2.3-Dihydro-[l,4]dioxino[2,3-b]pyridin-8-yl-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c]pyridin-6-yl] methanone;
2.3-Dihydro-[l,4]dioxino[2,3-b]pyridin-7-yl-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c]pyridin-6-yl] methanone;
3.4-Dihydro-2H-pyrido[3,2-b][l,4]oxazin-7-yl-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c]pyridin-6-yl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(4- methyl-2, 3-dihydropyrido[3,2-b][l,4]oxazin-7-yl)methanone;
3.4-Dihydro-2H-pyrano[2,3-c]pyridin-6-yl-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7- dihydro-4H-pyrazolo [3 ,4-c]pyridin-6-yl] methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- (1,2, 3 ,4-tetrahy droisoquinolin- 5-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- (1,2, 3 ,4-tetrahy droisoquinolin- 8-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- isochroman-5-yl-methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- isochroman-7-yl-methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- isochroman-6-yl-methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- isochroman-8-yl-methanone;
Chroman-6-yl-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4- c]pyridin-6-yl]methanone;
Chroman-5-yl-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4- c]pyridin-6-yl]methanone;
Chroman-7-yl-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4- c]pyridin-6-yl]methanone;
Chroman-8-yl-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4- c]pyridin-6-yl]methanone;
4-[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-6- carbonyl]-3H-l,3-benzoxazol-2-one;
4-[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-6- carbonyl]-3-methyl-l,3-benzoxazol-2-one; 5-[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-6- carbonyl]-3H-l,3-benzoxazol-2-one;
7-[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-6- carbonyl]-3H-l,3-benzoxazol-2-one;
6-[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-6- carbonyl]-3H-l,3-benzoxazol-2-one;
7-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-6- carbonyl]-3-methyl-l,3-benzoxazol-2-one;
7-[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-6- carbonyl]-4-methyl-l,4-benzoxazin-3-one;
[(7S)-2,7- 8-[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4- c]pyridine-6-carbonyl]-4-methyl-l,4-benzoxazin-3-one;
3,4-Dihydro-2H-l,4-benzoxazin-8-yl-[(7S)-2,7-dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro- 4H-pyrazolo[3,4-c]pyridin-6-yl]methanone;
[(7S)-3-[3-(Difluoromethyl)-4-fluoro-phenyl]-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4- c]pyridin-6-yl]-(2-methoxy-3-methyl-4-pyridyl)methanone;
[(7S)-3-[3-(l,l-Difluoroethyl)phenyl]-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl]-(2-methoxy-3-methyl-4-pyridyl)methanone;
[(7S)-3-[3-(Difluoromethoxy)-4-fluoro-phenyl]-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4- c]pyridin-6-yl]-(2-methoxy-3-methyl-4-pyridyl)methanone;
Chroman-7-yl-[(7S)-3-[3-(difluoromethoxy)-5-fluoro-phenyl]-2,7-dimethyl-5,7-dihydro-4H- pyrazolo [3 ,4-c]pyridin-6-yl] methanone;
[(7S)-3-[3-(Difluoromethoxy)-5-fluoro-phenyl]-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4- c]pyridin-6-yl]-(2-methoxy-3-methyl-4-pyridyl)methanone;
[(7S)-3-(4-Fluoro-3-methyl-phenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-
(2-methoxy-3-methyl-4-pyridyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(3- methoxy-2-methyl-4-pyridyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(l- methyl-4-phenyl-imidazol-2-yl)methanone; [(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(l- phenylimidazol-4-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-[3- methyl-2-(2-pyridyl)imidazol-4-yl]methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(2- fluoro-6-pyrazol- 1 -yl-phenyl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]- spiro[3,4-dihydro-l,4-benzoxazine-2,l'-cyclopropane]-8-yl-methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(3- fluoro- 1 H-pyrrolo[2, 3 -b] pyridin-4-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(9- methylpurin-6-yl)methanone;
[(7S)-2,7-Dimethyl-3-(3,4,5-trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]-(3- fluoro-5-methoxy-4-pyridyl)methanone;
(3 -Chloro-4-methoxy-2-pyridyl)- [(7S)-3 - [3 -(difluoromethyl)-5 -fluoro-phenyl] -2,7-dimethyl- 5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]methanone;
[(7S)-3-[3-(Difluoromethyl)-5-fluoro-phenyl]-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4- c]pyridin-6-yl]-(2-methoxy-3-methyl-4-pyridyl)methanone;
Chroman-7-yl-[(7S)-3-[3-(difluoromethyl)-5-fluoro-phenyl]-2,7-dimethyl-5,7-dihydro-4H- pyrazolo [3 ,4-c] pyridin-6-yl] methanone;
Chroman-7-yl-[(7S)-3-(3-fluoro-5-methoxy-phenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4- c]pyridin-6-yl]methanone;
(3-Chloro-4-methoxy-2-pyridyl)-[(7S)-3-[3-(difluoromethoxy)-5-fluoro-phenyl]-2,7-dimethyl-
5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6-yl]methanone;
[(7S)-3-(3-Fluoro-5-methoxy-phenyl)-2,7-dimethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-6- yl]-(2-methoxy-3-methyl-4-pyridyl)methanone;
(3-Chloro-4-methoxy-2-pyridyl)-[(7S)-3-(3-fluoro-5-methoxy-phenyl)-2,7-dimethyl-5,7- dihydro-4H-pyrazolo [3 ,4-c]pyridin-6-yl] methanone;
racemic-(2-(Bicyclo[l. l. l]pentan-l-yl)-7-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)(5-cyclopropyl-l-methyl-lH-pyrazol-4-yl)methanone; (R*)-(2-(Bicyclo[l .1.1 ]pentan-l-yl)-7-methyl-3-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4- c]pyridin-6-yl)(5-cyclopropyl-l-methyl-lH-pyrazol-4-yl)methanone;
((S)-(l,6-Dimethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)(2,7-dimethyl-3-(3,4,5-trifluorophenyl)- 2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)methanone; and
Cyclopropyl-2-methyl-imidazo[l,2-a] pyridin-3-yl)-[(7S)-2,7-dimethyl-3-(3,4,5- trifluorophenyl)-5,7-dihydro-4H-pyrazolo[3,4-c] pyridin-6-yl] methanone;
and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.
84. A compound selected from the group consisting of:
Figure imgf000680_0001
and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers.
85. A pharmaceutical composition comprising:
(A) a therapeutically effective amount of at least one compound of Formula (II):
Figure imgf000681_0001
wherein
R1 is Ci-4alkyl;
R2a is selected from the group consisting of:
Figure imgf000681_0002
(b) 6-Membered heteroaryl selected from the group consisting of:
Figure imgf000681_0003
(c) 5-Membered heteroaryl selected from the group consisting of:
Figure imgf000681_0004
(d) 5,6-Fused or 6,5-fused heteroaryl selected from the group consisting of:
Figure imgf000681_0005
Figure imgf000682_0001
(e) Fused 6,6 heteroaryl selected from the group consisting of:
Figure imgf000683_0001
5 (f) Heterocycloalkyl selected from the group consisting of:
Figure imgf000683_0002
R3a is selected from the group consisting of:
(g) Phenyl; or phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, and OCi-6haloalkyl;
(h) 5-Membered heteroaryl selected from the group consisting of:
Figure imgf000684_0001
Figure imgf000684_0002
(i) 6-Membered heteroaryl selected from the group consisting of:
Figure imgf000684_0003
and
Figure imgf000684_0004
(j) 5,6-Fused or 6,5-fused heteroaryl selected from the group consisting of:
Figure imgf000684_0005
(k) Heterocycloalkyl selected from the group consisting of:
Figure imgf000684_0006
Re is selected from the group consisting of: OCi-4alkyl, OCi-4haloalkyl, (C=0)NHCH3, and 5-membered heteroaryl ring containing two or three nitrogen members, wherein the 5-membered heteroaryl ring is optionally substituted with one Rf member;
Rf is selected from the group consisting of: H, halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, and OCi-4haloalkyl; Rg is selected from the group consisting of: OCi-4alkyl, OCi-4haloalkyl, CH2OCH3,
Figure imgf000685_0001
Rh is selected from the group consisting of: H, Ci-4alkyl , Ci-4haloalkyl, and
C3-6cycloalkyl;
R1 is selected from the group consisting of: H, halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, C3-6cycloalkyl, and C3-6cycloalkyl substituted with one or two members
independently selected from: F and CH3;
R1 is selected from the group consisting of: H, halo, Ci-4alkyl and Ci-4haloalkyl;
Rk is selected from the group consisting of: H, halo, OH, Ci-4alkyl, Ci-4haloalkyl, OCi-
4alkyl, and OCi-4haloalkyl;
Rm is H or Ci-4alkyl;
Rn is selected from the group consisting of: H, halo and OCi-4alkyl;
R° is selected from the group consisting of: H, Ci-4alkyl, and Ci-4haloalkyl;
Rp is selected from the group consisting of: H, Ci-4alkyl, and OCi-4alkyl;
Y is CH or N; and
R4a is selected from the group consisting of: CH3, CF2H, CF3, C3-6cycloalkyl, and phenyl; and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers of
compounds of Formula (II); and
(B) at least one pharmaceutically acceptable excipient.
86. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 83 and at least one pharmaceutically acceptable excipient.
87. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 84 and at least one pharmaceutically acceptable excipient.
88. A method of treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by MGL receptor activity, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one compound of Formula (II):
Figure imgf000686_0001
wherein
R1 is Ci-4alkyl;
R2a is selected from the group consisting of:
Figure imgf000686_0002
(b) 6-Membered heteroaryl selected from the group consisting of:
Figure imgf000686_0003
(c) 5-Membered heteroaryl selected from the group consisting of:
Figure imgf000686_0004
(d) 5,6-Fused or 6,5-fused heteroaryl selected from the group consisting of:
Figure imgf000686_0005
Figure imgf000687_0001
(e) Fused 6,6 heteroaryl selected from the group consisting of:
Figure imgf000688_0001
5 (f) Heterocycloalkyl selected from the group consisting of:
Figure imgf000688_0002
10 R3a is selected from the group consisting of: (g) Phenyl; or phenyl substituted with one, two, or three members each independently selected from the group consisting of: halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, and OCi-6haloalkyl;
(h) 5-Membered heteroaryl selected from the group consisting of:
Figure imgf000689_0001
Figure imgf000689_0002
Figure imgf000689_0005
(j) 5,6-Fused or 6,5-fused heteroaryl selected from the group consisting of:
Figure imgf000689_0003
Heterocycloalkyl selected from the group consisting of:
Figure imgf000689_0004
Re is selected from the group consisting of: OCi-4alkyl, OCi-4haloalkyl, (C=0)NHCH3, and 5-membered heteroaryl ring containing two or three nitrogen members, wherein the 5-membered heteroaryl ring is optionally substituted with one Rf member;
Rf is selected from the group consisting of: H, halo, Ci-4alkyl, Ci-4haloalkyl,
OCi-4alkyl, and OCi-4haloalkyl; Rg is selected from the group consisting of: OCi-4alkyl, OCi-4haloalkyl, CH2OCH3,
Figure imgf000690_0001
Rh is selected from the group consisting of: H, Ci-4alkyl , Ci-4haloalkyl, and
C3-6cycloalkyl;
R1 is selected from the group consisting of: H, halo, Ci-4alkyl, Ci-4haloalkyl, OCi-4alkyl, C3-6cycloalkyl, and C3-6cycloalkyl substituted with one or two members independently selected from: F and CH3;
R1 is selected from the group consisting of: H, halo, Ci-4alkyl and Ci-4haloalkyl;
Rk is selected from the group consisting of: H, halo, OH, Ci-4alkyl, Ci-4haloalkyl, OCi- 4alkyl, and OCi-4haloalkyl;
Rm is H or Ci-4alkyl;
Rn is selected from the group consisting of: H, halo and OCi-4alkyl;
R° is selected from the group consisting of: H, Ci-4alkyl, and Ci-4haloalkyl;
Rp is selected from the group consisting of: H, Ci-4alkyl, and OCi-4alkyl;
Y is CH or N; and
R4a is selected from the group consisting of: CH3, CF2H, CF3, C3-6cycloalkyl, and phenyl; and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers of
compounds of Formula (II).
89. The method of claim 88 wherein the MGL receptor mediated disease, disorder, or condition is selected from the group consisting of: pain, psychiatric conditions, neurological conditions, cancers and eye conditions.
90. The method of claim 89, wherein the MGL receptor mediated disease, disorder or condition is selected from the group consisting of major depressive disorder, treatment resistant depression, anxious depression and bipolar disorder.
91. The method of claim 89, wherein the MGL receptor mediated disease, disorder or condition is inflammatory pain.
PCT/IB2019/058240 2018-09-28 2019-09-27 Monoacylglycerol lipase modulators WO2020065613A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CR20210153A CR20210153A (en) 2018-09-28 2019-09-27 Monoacylglycerol lipase modulators
CA3111380A CA3111380A1 (en) 2018-09-28 2019-09-27 Monoacylglycerol lipase modulators
EP19780427.1A EP3856178A1 (en) 2018-09-28 2019-09-27 Monoacylglycerol lipase modulators
MX2021003737A MX2021003737A (en) 2018-09-28 2019-09-27 Monoacylglycerol lipase modulators.
PE2021000405A PE20211773A1 (en) 2018-09-28 2019-09-27 MONACILGLYCEROL LIPASE MODULATORS
JOP/2021/0058A JOP20210058A1 (en) 2018-09-28 2019-09-27 Monoacylglycerol lipase modulators
AU2019350624A AU2019350624A1 (en) 2018-09-28 2019-09-27 Monoacylglycerol lipase modulators
KR1020217012874A KR20210069080A (en) 2018-09-28 2019-09-27 monoacylglycerol lipase modulator
EA202190886A EA202190886A1 (en) 2018-09-28 2019-09-27 MONOACYLGLYCERINE LIPASE MODULATORS
CN201980078969.1A CN113164459A (en) 2018-09-28 2019-09-27 Monoacylglycerol lipase modulators
JP2021517202A JP2022502424A (en) 2018-09-28 2019-09-27 Monoacylglycerol lipase regulator
BR112021005896-6A BR112021005896A2 (en) 2018-09-28 2019-09-27 monoacylglycerol lipase modulators
SG11202102281VA SG11202102281VA (en) 2018-09-28 2019-09-27 Monoacylglycerol lipase modulators
PH12021550659A PH12021550659A1 (en) 2018-09-28 2021-03-22 Monoacylglycerol lipase modulators
IL281812A IL281812A (en) 2018-09-28 2021-03-25 Monoacylglycerol lipase modulators
CONC2021/0003944A CO2021003944A2 (en) 2018-09-28 2021-03-29 Monoacylglycerol lipase modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862738600P 2018-09-28 2018-09-28
US62/738,600 2018-09-28

Publications (1)

Publication Number Publication Date
WO2020065613A1 true WO2020065613A1 (en) 2020-04-02

Family

ID=68109428

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/058240 WO2020065613A1 (en) 2018-09-28 2019-09-27 Monoacylglycerol lipase modulators

Country Status (23)

Country Link
US (3) US20200102303A1 (en)
EP (1) EP3856178A1 (en)
JP (1) JP2022502424A (en)
KR (1) KR20210069080A (en)
CN (1) CN113164459A (en)
AU (1) AU2019350624A1 (en)
BR (1) BR112021005896A2 (en)
CA (1) CA3111380A1 (en)
CL (1) CL2021000757A1 (en)
CO (1) CO2021003944A2 (en)
CR (1) CR20210153A (en)
EA (1) EA202190886A1 (en)
EC (1) ECSP21021381A (en)
IL (1) IL281812A (en)
JO (1) JOP20210058A1 (en)
MA (1) MA53721A (en)
MX (1) MX2021003737A (en)
NI (1) NI202100023A (en)
PE (1) PE20211773A1 (en)
PH (1) PH12021550659A1 (en)
SG (1) SG11202102281VA (en)
TW (1) TW202028198A (en)
WO (1) WO2020065613A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021064569A1 (en) * 2019-09-30 2021-04-08 Janssen Pharmaceutica Nv Radiolabelled mgl pet ligands
CN113072497A (en) * 2021-01-12 2021-07-06 西湖大学 Protease inhibitors, their preparation and use
US11225478B2 (en) 2013-03-14 2022-01-18 Janssen Pharmaceutica Nv P2X7 modulators
US11597728B2 (en) 2018-09-28 2023-03-07 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
WO2023110958A1 (en) 2021-12-16 2023-06-22 F. Hoffmann-La Roche Ag Bicyclic heterocyclic compounds useful as monoacylglycerol lipase inhibitors
US11820766B2 (en) 2018-09-28 2023-11-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
US11891387B2 (en) 2020-03-26 2024-02-06 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140275015A1 (en) * 2013-03-14 2014-09-18 Janssen Pharmaceutica Nv P2x7 modulators
WO2015025026A1 (en) 2013-08-22 2015-02-26 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
WO2016040789A1 (en) 2014-09-11 2016-03-17 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
US4816463A (en) 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
JP3208139B2 (en) 1990-10-02 2001-09-10 ワーナー−ランバート・コンパニー Angiotensin II antagonist
WO2004014374A1 (en) 2002-07-25 2004-02-19 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
MXPA05000945A (en) 2002-07-25 2005-05-16 Pharmacia Italia Spa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
FR2857363B1 (en) 2003-07-10 2007-09-07 Aventis Pharma Sa SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO [3,4-C] PYRIDINES COMPOSITIONS CONTAINING SAME AND USE THEREOF
AR045037A1 (en) 2003-07-10 2005-10-12 Aventis Pharma Sa TETRAHIDRO-1H-PIRAZOLO [3,4-C] SUBSTITUTED PYRIDINS, COMPOSITIONS THAT CONTAIN THEM AND ITS USE.
WO2006023750A2 (en) 2004-08-23 2006-03-02 Merck & Co., Inc. Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP1844003A4 (en) 2005-01-27 2010-09-22 Astrazeneca Ab Novel biaromatic compounds, inhibitors of the p2x7-receptor
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
MX2010000098A (en) 2007-06-21 2010-04-21 Schering Corp Polycyclic guanine derivatives and use thereof.
NZ582056A (en) 2007-08-10 2012-08-31 Lundbeck & Co As H Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation
FR2921342B1 (en) 2007-09-20 2010-03-12 Airbus France LOWER REAR AERODYNAMIC FAIRING FOR AN AIRCRAFT ENGINE CLAMPING DEVICE
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
US8431704B2 (en) 2008-04-22 2013-04-30 Janssen Pharmaceutica Nv Quinoline or isoquinoline substituted P2X7 antagonists
EP2370437B1 (en) 2008-11-25 2013-09-04 Nerviano Medical Sciences S.r.l. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
WO2010066629A2 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
WO2010124122A1 (en) * 2009-04-22 2010-10-28 Janssen Pharmaceutica Nv Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
WO2010125102A1 (en) 2009-04-29 2010-11-04 Glaxo Group Limited 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS
GB0907515D0 (en) 2009-04-30 2009-06-10 Glaxo Group Ltd Compounds
US8871760B2 (en) 2009-09-21 2014-10-28 Roche Palo Alto Llc [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
EP2491031B1 (en) 2009-10-23 2013-08-07 Janssen Pharmaceutica N.V. Fused heterocyclic compounds as orexin receptor modulators
WO2011103715A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
CN102906093B (en) 2010-04-02 2016-01-13 欧洲筛选有限公司 NK-3 receptor selective antagonists compound, pharmaceutical composition and the using method in the receptor-mediated disease of NK-3
MX2011004046A (en) 2010-04-16 2011-10-17 Rodrigo Graf Fernandez Foldable structures for a construction.
EP2619204A4 (en) 2010-09-21 2014-08-27 Merck Sharp & Dohme Triazolopyrazinones as p2x7 receptor antagonists
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
US9273947B2 (en) 2012-02-07 2016-03-01 Lg Innotek Co., Ltd. Sensing magnet apparatus for motor
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
AU2013266398A1 (en) 2012-05-22 2015-01-22 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (en) 2012-09-09 2020-07-05 H Lundbeck As Pharmaceutical compositions for treating alzheimer's disease
KR102057365B1 (en) 2012-10-15 2019-12-18 에피자임, 인코포레이티드 Substituted benzene compounds
AU2013331496B2 (en) 2012-10-16 2017-07-27 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ROR-gamma-t
WO2014071031A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
WO2014100620A2 (en) 2012-12-21 2014-06-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EA028774B1 (en) 2012-12-21 2017-12-29 Квонтисел Фармасьютикалс, Инк. Histone demethylase inhibitors
CN105188371A (en) 2013-02-08 2015-12-23 西建阿维拉米斯研究公司 Erk inhibitors and uses thereof
TWI617554B (en) 2013-03-06 2018-03-11 健生藥品公司 Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
NO335177B1 (en) 2013-03-06 2014-10-13 Cambi Technology As Process and apparatus for thermal biodegradation and dewatering of biomass
SG10201707545XA (en) 2013-03-14 2017-10-30 Newlink Genetics Corp Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
SG11201506245QA (en) 2013-03-14 2015-09-29 Glaxosmithkline Ip No 2 Ltd 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
ES2845473T3 (en) 2013-03-14 2021-07-26 Boehringer Ingelheim Int (Benzyl-cyano-methyl) -substituted amides of 2-aza-bicyclo [2.2.1] heptane-3-carboxylic acid cathepsin-C inhibitors
JO3383B1 (en) 2013-03-14 2019-03-13 Lilly Co Eli CDC7 Inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
JO3509B1 (en) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv P2x7 modulators
WO2014186035A1 (en) 2013-03-14 2014-11-20 Curadev Pharma Private Ltd. Inhibitors of the kynurenine pathway
EP3321266A1 (en) 2013-03-14 2018-05-16 Janssen Pharmaceutica NV P2x7 modulators
AU2014242908B2 (en) 2013-03-29 2018-07-19 Ogeda Sa Novel N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
US10150766B2 (en) 2014-09-12 2018-12-11 Janssen Pharmaceutica Nv P2X7 modulators
US20180118749A1 (en) 2014-09-12 2018-05-03 Janssen Pharmaceutica Nv P2x7 modulators
WO2017087858A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
TW202035409A (en) 2018-09-28 2020-10-01 比利時商健生藥品公司 Monoacylglycerol lipase modulators
US20200102303A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol Lipase Modulators
CN112272670B (en) 2019-04-16 2023-12-12 上海翰森生物医药科技有限公司 Di-ring derivative-containing inhibitor, preparation method and application thereof
JP2022550767A (en) 2019-09-30 2022-12-05 ヤンセン ファーマシューティカ エヌ．ベー． Radiolabeled MGL PET ligand
WO2021191359A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140275015A1 (en) * 2013-03-14 2014-09-18 Janssen Pharmaceutica Nv P2x7 modulators
WO2015025026A1 (en) 2013-08-22 2015-02-26 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
WO2016040789A1 (en) 2014-09-11 2016-03-17 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators

Non-Patent Citations (66)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Salts, Properties, Selection, and Use", 2002, WILEY-VCH AND VHCA
AHN ET AL., CHEM REV., vol. 108, no. 5, 2008, pages 1687 - 707
ALHOUAYEK ET AL., FASEB J., vol. 25, no. 8, August 2011 (2011-08-01), pages 2711 - 21
BEDSE ET AL., BIOL PSYCHIATRY, vol. 82, no. 7, 1 October 2017 (2017-10-01), pages 488 - 499
BENITO ET AL., BRIT J PHARMACOL, vol. 153, 2008, pages 277 - 285
BERNAL-CHICO ET AL., GLIA, vol. 3, no. 1, 6 January 2015 (2015-01-06), pages 163 - 76
BETSE ET AL., TRANSL PSYCHIATRY, vol. 8, no. 1, 26 April 2018 (2018-04-26), pages 92
BUCZYNSKIPARSONS, BRIT J PHARMACOL, vol. 160, no. 3, 2010, pages 423 - 42
CAVUOTO, BIOCHEM BIOPHYS RES COMMUN, vol. 364, 2007, pages 105 - 110
CHEN ET AL., CELL REP., vol. 2, no. 5, 29 November 2012 (2012-11-29), pages 1329 - 39
CHINNADURAI ET AL., MED HYPOTHESES, vol. 131, October 2019 (2019-10-01), pages 109321
CHRISTENSEN ET AL., THE LANCET, vol. 370, 2007, pages 1706 - 1713
COVEY ET AL., NEUROPSYCHOPHARMACOLOGY, vol. 43, 2018, pages 2056 - 2063
CURRY ET AL., J PHARMACOL EXP THER., vol. 366, no. 1, July 2018 (2018-07-01), pages 169 - 18
DEVANE ET AL., SCIENCE, vol. 258, 1992, pages 1946 - 9
DI MARZO ET AL., ANNU REV MED.,, vol. 57, 2006, pages 553 - 74
DI MARZO ET AL., CURR OPIN LIPIDOL, vol. 18, 2007, pages 129 - 140
DINH ET AL., PROC NATL ACAD SCI U SA., vol. 99, no. 16, 6 August 2002 (2002-08-06), pages 10819 - 24
GUINDON ET AL., BR JPHARMACOL., vol. 163, no. 7, August 2011 (2011-08-01), pages 1464 - 78
HAJRASOULIHA ET AL., EUR J PHARMACOL, vol. 579, 2008, pages 246 - 252
HAUER ET AL., REV NEUROSCI., vol. 23, no. 5-6, 2012, pages 681 - 90
HERKENAM ET AL., PROC. NAT. ACAD. SCI., vol. 87, no. 5, 1990, pages 1932 - 1936
HERNADEZ-TORRES ET AL., ANGEW CHEM INT ED ENGL., vol. 53, no. 50, 8 December 2014 (2014-12-08), pages 13765 - 70
HILL ET AL., PHARMACOPSYCHIATRY, vol. 41, no. 2, March 2008 (2008-03-01), pages 48 - 53
HILL ET AL., PSYCHONEUROENDOCRINOLOGY, vol. 34, no. 8, September 2009 (2009-09-01), pages 1257 - 1262
HILL ET AL., PSYCHONEUROENDOCRINOLOGY, vol. 38, no. 12, 2013, pages 2952 - 2961
KATZ ET AL., J NEUROTRAUMA., vol. 32, no. 5, 1 March 2015 (2015-03-01), pages 297 - 306
KINSEY ET AL., J PHARMACOL EXP THER., vol. 330, no. 3, September 2009 (2009-09-01), pages 902 - 10
LIGRESTI ET AL., CURR OPIN CHEM BIOL., vol. 13, no. 3, June 2009 (2009-06-01), pages 321 - 31
LONG ET AL., CHEM BIOI., vol. 16, no. 7, 31 July 2009 (2009-07-31), pages 744 - 53
LONG ET AL., NAT CHEM BIOL., vol. 5, no. 1, January 2009 (2009-01-01), pages 37 - 44
MATSUDA ET AL., NATURE, vol. 346, 1990, pages 561 - 4
MECHOULAM ET AL., BIOCHEM PHARMACOL, vol. 50, 1995, pages 83 - 90
MILLER ET AL., PHARMACEUTICALS, vol. 11, 2018, pages 50
MULVIHILL ET AL., LIFE SCI., vol. 92, no. 8-9, 19 March 2013 (2013-03-19), pages 492 - 505
MUNRO ET AL., NATURE, vol. 365, 1993, pages 61 - 5
NIKITENKO, A.A. ET AL., ORG. PROCESS RES. DEV., vol. 10, no. 4, 2006, pages 712 - 716
NITHIPATIKOM ET AL., BIOCHEM BIOPHYS RES COMMUN., vol. 332, no. 4, 15 July 2005 (2005-07-15), pages 1028 - 33
NITHIPATIKOM ET AL., CANCER RES., vol. 64, no. 24, 15 December 2004 (2004-12-15), pages 8826 - 30
NITHIPATIKOM ET AL., PROSTAGLANDINS OTHER LIPID MEDIAT., vol. 4, no. 1-2, 9 February 2011 (2011-02-09), pages 34 - 43
NOMURA ET AL., SCIENCE, vol. 334, no. 6057, 11 November 2011 (2011-11-11), pages 809 - 13
PACHER ET AL., AMER J PHYSIOL, vol. 294, 2008, pages HI 133 - H1134
PASQUARELLI ET AL., NEUROCHEM INT., vol. 0, 11 November 2017 (2017-11-11), pages 14 - 24
PASQUARELLI ET AL., NEUROPHARMACOLOGY, vol. 124, 15 September 2017 (2017-09-15), pages 157 - 169
PATEL ET AL., NEUROSCI BIOBEHAV REV., vol. 6, 7 May 2017 (2017-05-07), pages 56 - 66
PIOMELLI, NAT REV NEUROSCI, vol. 4, 2003, pages 873 - 884
PIRO ET AL., CELL REP., vol. 1, no. 6, 28 June 2012 (2012-06-28), pages 617 - 23
R.H.F. MANSKEM.KULKA: "The Skraup Synthesis of Quinolines", ORG. REACTION, vol. 7, 1953, pages 59 - 98
RAMESH ET AL., J PHARMACOL EXP THER., vol. 39, no. 1, 3 October 2011 (2011-10-03), pages 173 - 85
S.M. BERGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19, XP002675560, doi:10.1002/jps.2600660104
SCHLOSBURG ET AL., NAT NEUROSCI., vol. 13, no. 9, September 2010 (2010-09-01), pages 1113 - 9
STICHT ET AL., BR JPHARMACOL., vol. 5, no. 8, 16 April 2012 (2012-04-16), pages 2425 - 35
STRAIKER ET AL., MOL PHARMACOL., vol. 76, no. 6, December 2009 (2009-12-01), pages 1220 - 7
SUGIURA ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 215, 1995, pages 89 - 97
SUGIURA ET AL., PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS., vol. 66, no. 2-3, February 2002 (2002-02-01), pages 173 - 92
SUGUIRA ET AL., PROG LIPID RES, vol. 45, no. 5, 2006, pages 405 - 46
T. W. GREENEP. G. M. WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS, pages: 518 - 525
TERRONE ET AL., EPILEPSIA, vol. 9, no. 1, 5 January 2018 (2018-01-05), pages 79 - 91
TETRAHEDRON, vol. 45, no. 19, 1989, pages 6211 - 20
TUO ET AL., J MED CHEM., vol. 60, no. 1, 12 January 2017 (2017-01-12), pages 4 - 46
VON RUDEN ET AL., NEUROBIOL DIS., vol. 77, May 2015 (2015-05-01), pages 238 - 45
WALTER ET AL., J NEUROSCI., vol. 24, no. 37, 15 September 2004 (2004-09-15), pages 8068 - 74
WENZEL ET AL., LIFE SCI., vol. 207, 15 August 2018 (2018-08-15), pages 314 - 322
WILKERSON ET AL., J PHARMACOL EXP THER., vol. 357, no. l, April 2016 (2016-04-01), pages 145 - 56
YI ET AL., PROGRESS IN NEURO-PSYCHOPHARMACOLOGY AND BIOLOGICAL PSYCHIATRY, vol. 67, no. 3, 2016, pages 92 - 97
ZHANG ET AL., J CEREB BLOOD FLOW METAB., vol. 35, no. 4, 31 March 2015 (2015-03-31), pages 706

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11225478B2 (en) 2013-03-14 2022-01-18 Janssen Pharmaceutica Nv P2X7 modulators
US11820770B2 (en) 2013-03-14 2023-11-21 Janssen Pharmaceutica Nv P2X7 modulators
US11597728B2 (en) 2018-09-28 2023-03-07 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
US11820766B2 (en) 2018-09-28 2023-11-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
WO2021064569A1 (en) * 2019-09-30 2021-04-08 Janssen Pharmaceutica Nv Radiolabelled mgl pet ligands
CN114555596A (en) * 2019-09-30 2022-05-27 詹森药业有限公司 Radiolabeled MGL PET ligands
US11839663B2 (en) 2019-09-30 2023-12-12 Janssen Pharmaceutica Nv Radiolabelled MGL pet ligands
US11891387B2 (en) 2020-03-26 2024-02-06 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
CN113072497A (en) * 2021-01-12 2021-07-06 西湖大学 Protease inhibitors, their preparation and use
US11958830B2 (en) 2021-01-12 2024-04-16 Westlake Pharmaceuticals (Hangzhou) Co., Ltd. Protease inhibitors, preparation, and uses thereof
WO2023110958A1 (en) 2021-12-16 2023-06-22 F. Hoffmann-La Roche Ag Bicyclic heterocyclic compounds useful as monoacylglycerol lipase inhibitors

Also Published As

Publication number Publication date
SG11202102281VA (en) 2021-04-29
CL2021000757A1 (en) 2021-08-27
PH12021550659A1 (en) 2022-02-21
ECSP21021381A (en) 2021-04-29
CA3111380A1 (en) 2020-04-02
BR112021005896A2 (en) 2021-07-27
US11820766B2 (en) 2023-11-21
CN113164459A (en) 2021-07-23
CR20210153A (en) 2021-05-11
MA53721A (en) 2021-09-15
PE20211773A1 (en) 2021-09-08
US20220332713A1 (en) 2022-10-20
IL281812A (en) 2021-05-31
EA202190886A1 (en) 2021-09-07
CO2021003944A2 (en) 2021-04-19
NI202100023A (en) 2021-09-07
US20200102303A1 (en) 2020-04-02
JOP20210058A1 (en) 2021-03-24
KR20210069080A (en) 2021-06-10
TW202028198A (en) 2020-08-01
MX2021003737A (en) 2021-05-14
EP3856178A1 (en) 2021-08-04
JP2022502424A (en) 2022-01-11
US20230145249A1 (en) 2023-05-11
AU2019350624A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
US11820766B2 (en) Monoacylglycerol lipase modulators
KR102516711B1 (en) P2x7 modulators
US11597728B2 (en) Monoacylglycerol lipase modulators
WO2014113388A1 (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
CA3198809A1 (en) Heterocyclic spiro compounds and methods of use
WO2021191359A1 (en) Monoacylglycerol lipase modulators
CN117836297A (en) (S) -1- (5- ((pyridin-3-yl) thio) pyrazin-2-yl) -4&#39;H,6&#39; H-spiro [ piperidine-4, 5 &#39;-pyrrolo [1,2-B ] pyrazol ] -4&#39; -amine derivatives and similar compounds as SHP2 inhibitors for the treatment of, for example, cancer
TW202216720A (en) Indole compounds as androgen receptor modulators
US20230339970A1 (en) Casein kinase 1 delta modulators
RU2797323C2 (en) Monoacylglycerol lipase modulators
WO2024086809A1 (en) Methods for treating cancer
CA3189703A1 (en) Casein kinase 1 delta modulators

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19780427

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3111380

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019350624

Country of ref document: AU

Date of ref document: 20190927

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2021517202

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2101001828

Country of ref document: TH

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021005896

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20217012874

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019780427

Country of ref document: EP

Effective date: 20210428

ENP Entry into the national phase

Ref document number: 112021005896

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210326

WWE Wipo information: entry into national phase

Ref document number: 522441561

Country of ref document: SA